#CLS_PREDICTION_ENTITY|MASK_PREDICTION_ENTITY|ACTUAL_ENTITY|CLS_PREDICTIONS|MASKED_PREDICTIONS|MASKED_WORD|SENTENCE
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|lithium sodium potassium agents agent|lithium valproate carbamazepine lamotrigine phenytoin|lithium|is being evaluated as a monotherapy and in the iti-007-402 trial , lumateperone is being evaluated as an adjunctive therapy with entity or valproate .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|lithium sodium potassium agents agent|antidepressants benzodiazepines opioids antipsychotics medications|lithium|current drug therapy for bipolar disorder includes the use of entity and anti-depressants .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|lithium sodium potassium agents agent|antidepressants antipsychotics benzodiazepines steroids medications|lithium|mood-stabilizing drugs can treat bipolar symptoms when they are present , including entity and anticonvulsants , such as valproic acid and lamotrigine .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|lithium sodium potassium agents agent|dispensed containing sales sold purchased|lithium|retail sales of energizers entity and rechargeable products increased 22% in the quarter while our price-oriented product sales declined 12% .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|lithium sodium potassium agents agent|inactive unknown safe cytotoxic anticonvulsant|lithium|to date , the only drug that interacted with zs-9 is entity .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|lithium sodium potassium agents agent|commercial alternative popular national whose|lithium|mr . friess and mr . schwartz sold most of their shares of pisv for $275 , 000 and pisv became china entity technologies inc . listed on the otcbb symbol ( cltt ) .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|lithium sodium potassium agents agent|adequately mechanically electrically poorly externally|lithium|chairman of cardiac pacemakers , inc . , a company founded by mr . villafana to develop , manufacture and market a new generation of entity powered pacemakers .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|lithium sodium potassium agents agent|battery ion lithium electrochemical potassium|lithium|the e-go is an all-electric vehicle powered by advanced entity batteries .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|lithium sodium potassium agents agent|lithium ion inorganic organic metallic|lithium|inc . , a company that is engaged in the manufacture , commercialization and distribution of a wide variety of standard and customized entity ion rechargeable batteries .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|lithium sodium potassium agents agent|aripiprazole quetiapine olanzapine risperidone haloperidol|lithium|these adjunctive agents may include atypical antipsychotics , like aripiprazole and quetiapine , or other agents such as buproprion and entity .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 2)])|drug|lithium sodium potassium agents agent|placebo etanercept azithromycin bupropion ketoconazole|lithium|in the last few years several academic research initiatives were conducted to explore the efficacy of approved drugs such as entity , varenicline ( chantix ® ) , riluzol and dalfampridine .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|lithium sodium potassium agents agent|lithium valproate carbamazepine lamotrigine topiramate|lithium|for the treatment of patients with depressive episodes associated with bipolar i disorder as monotherapy and as adjunctive therapy with entity or valproate , which expires in june 2016 .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|lithium sodium potassium agents agent|mechanically adequately electrically easily poorly|lithium|( now a division of guidant corporation ) , a company founded by mr . villafaña to develop , manufacture and market a new generation of entity powered pacemakers .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|lithium sodium potassium agents agent|lithium antidepressant medication antidepressants lamotrigine|lithium|in the iti-007-402 trial , patients receive lumateperone or placebo adjunctive to their existing mood stabilizer entity or valproate .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|lithium sodium potassium agents agent|lithium potassium sodium carbon metallic|lithium|and as director to aug 2015 where he led a team of scientists and entrepreneurs for the development of solid-state entity ion battery for electric vehicles and smart grid applications .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|lithium sodium potassium agents agent|lithium battery ion potassium carbon|lithium|the car is all-electric and powered by advanced entity ion batteries .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|lithium sodium potassium agents agent|lipids electrolytes metabolites vitamins pharmaceuticals|lithium|· with further investment , other patches can be developed which are able to measure alternative analytes , including lactates , uric acid , entity and drugs .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|lithium sodium potassium agents agent|batteries devices battery anode lithium|lithium|recently , higher power , higher priced entity and rechargeable batteries have grown in response to more demanding power needs of more advanced devices .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lithium sodium potassium agents agent|valproate lithium carbamazepine sodium lamotrigine|lithium|abilify®  in february , the fda approved abilify as an adjunct to mood stabilizers entity or valproate for the maintenance treatment of bipolar i disorder .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|lithium sodium potassium agents agent|phosphorus inorganic phosphate magnesium lithium|lithium|the u . s . retail battery category is defined as alkaline , carbon zinc , entity , rechargeable and specialty batteries .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|anesthesia administered propofol infusion during|atropine salbutamol endotracheal ethidium sevoflurane|vecuronium|( sugammadex ) injection 100 mg / ml was approved by the fda for the reversal of neuromuscular blockade induced by rocuronium bromide and entity bromide in adults undergoing surgery .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|anesthesia administered propofol infusion during|atropine salbutamol ethidium ketamine propofol|vecuronium|is specifically designed to reverse the effects of certain muscle relaxants , marketed in the united states as zemuron ( r ) ( rocuronium bromide ) and entity bromide .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|anesthesia administered propofol infusion during|ethidium sodium ethyl benzyl ammonium|vecuronium|we initiated a recall of a batch of entity bromide , a product we 43 market on behalf of a third party , in february 2001 due to concerns with filtration-testing
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|anesthesia administered propofol infusion during|cisplatin bleomycin etoposide carboplatin paclitaxel|vecuronium|the first u . s . regulatory approvals on products that are difficult to produce , such as etoposide ( with gll ) , bleomycin , pancuronium and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|anesthesia administered propofol infusion during|ethidium benzyl polyvinyl vinyl ethyl|vecuronium|the company is manufacturing and marketing entity bromide prior to expiration of the patent covering this product pursuant to a licensing arrangement .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|anesthesia administered propofol infusion during|phosphate creatine magnesium methylprednisolone methotrexate|vecuronium|nevzat ilac sanayii a . s . , a subsidiary of amgen , inc . , ( mn ) to acquire the rights to three products : methylprednsilone sodium succinate , entity and pamidronate disodium .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|anesthesia administered propofol infusion during|atropine salbutamol ethidium ketamine endotracheal|vecuronium|in december 2015 , the fda approved bridion for the reversal of neuromuscular blockade induced by rocuronium bromide and entity bromide in adults undergoing surgery .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|anesthesia administered propofol infusion during|propofol midazolam fentanyl lidocaine ketamine|vecuronium|of a clinical trial site for sugammadex , mercks investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|anesthesia administered propofol infusion during|atropine ethidium endotracheal salbutamol sevoflurane|vecuronium|demand of bridion ( sugammadex ) injection 100 mg / ml , a medicine for the reversal of neuromuscular blockade induced by rocuronium bromide or entity bromide in adults undergoing surgery .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|anesthesia administered propofol infusion during|paclitaxel docetaxel doxorubicin gemcitabine cisplatin|vecuronium|in addition , we have been able to help alleviate market shortages through the launches of entity and paclitaxel .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|anesthesia administered propofol infusion during|ethidium ethyl benzyl sodium diphenyl|vecuronium|in march 2000 , the company resumed the manufacture and commercial distribution of entity bromide under the expedited certification procedures provided in the consent agreement .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|anesthesia administered propofol infusion during|ethidium diphenyl midazolam sodium ethyl|vecuronium|for purposes of this paragraph , the term " krypton products " refers to glipizide , glyburide , ismn , midazolam hcl and entity bromide .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|anesthesia administered propofol infusion during|propofol fentanyl midazolam lidocaine ketamine|vecuronium|sugammadex sodium injection is mercks investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|anesthesia administered propofol infusion during|ethidium sodium benzyl methyl dimethyl|vecuronium|dosage product portfolio are 45 products for which the company is currently the sole generic source , one of which is entity bromide .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|anesthesia administered propofol infusion during|ethidium ethyl polyvinyl sodium benzyl|vecuronium|due to deviations from the fda  s manufacturing regulations , we are conducting voluntary product recalls of entity bromide and pte-4 products .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|anesthesia administered propofol infusion during|consent medicines materials standards physicians|vecuronium|in march 2000 , the company resumed the manufacture and commercial distribution of entity under the expedited certification procedures provided in the consent agreement .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|anesthesia administered propofol infusion during|ethidium sodium ethyl benzyl ammonium|vecuronium|we initiated a recall of a batch of entity bromide , a product we market on behalf of a third party , in february 2001 due to concerns with filtration- testing
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|anesthesia administered propofol infusion during|ethidium midazolam diphenyl lithium sodium|vecuronium|for purposes of this paragraph , the term krypton products refers to glipizide , glyburide , ismn , midazolam hcl and entity bromide .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|anesthesia administered propofol infusion during|placebo midazolam propofol fentanyl phenytoin|vecuronium|for odanacatib for osteoporosis , suvorexant for insomnia and sugammadex sodium injection for reversal of neuromuscular blockade induced by rocuronium or entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|anesthesia administered propofol infusion during|consent medicines standards materials physicians|vecuronium|in march 2000 , schein resumed the manufacture and commercial distribution of entity under the expedited certification procedures provided in the consent agreement .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|surg avi ve iv te|ceftazidime piperacillin amikacin imipenem cefotaxime|avibactam|the ceftazidime / entity combination product forest expects will receive three years of hatch-waxman exclusivity upon approval .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|drug|surg avi ve iv te|ceftazidime amikacin gentamicin vancomycin meropenem|avibactam|for cre infections , physicians have resorted to older drugs such as colistin or more recently drugs such as tigecycline and ceftazidime / entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 1)])|drug|surg avi ve iv te|ciprofloxacin there linezolid vancomycin penicillin|avibactam|entity is a novel , non beta-lactam , beta lactamase inhibitor , quite a mouthful , itself as a molecule does not possess intrinsic antibacterial
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('DIS', 2), ('OTHER', 2)])|drug|surg avi ve iv te|vancomycin linezolid chemotherapy ceftazidime ciprofloxacin|avibactam|entity is currently being developed in combination with ceftazidime , a cephalosporin antibiotic .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('DIS', 1), ('OTHER', 1)])|drug|surg avi ve iv te|gentamicin ceftazidime vancomycin ciprofloxacin amikacin|avibactam|the addition of entity to ceftazidime protects ceftazidime from breakdown by β-lactamases .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('DIS', 1), ('OTHER', 1)])|drug|surg avi ve iv te|ceftazidime ciprofloxacin amikacin ceftriaxone ampicillin|avibactam|it consists of a combination of entity and ceftazidime - a third generation antipseudomonal cephalosporin with a well-established efficacy and safety profile .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('DIS', 2), ('OTHER', 2)])|drug|surg avi ve iv te|ceftazidime vancomycin antibiotics gentamicin imipenem|avibactam|the addition of entity protects ceftazidime from being broken down by beta-lactamases that are produced by resistant bacteria .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 2)])|drug|surg avi ve iv te|ceftazidime imipenem amikacin meropenem ciprofloxacin|avibactam|it has structural similarities to entity , a bli recently approved in combination with ceftazidime ( avycaz ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 2)])|drug|surg avi ve iv te|ceftazidime amikacin imipenem ciprofloxacin meropenem|avibactam|almirall for las100977   0 . 25 licensing payment to astrazeneca for entity and ceftazidime / entity   0 . 75 rounding  
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|drug|surg avi ve iv te|amikacin vancomycin gentamicin ceftazidime taz|avibactam|actavis and astrazeneca are developing ceftazidime / entity and ceftaroline / entity for pneumonia and complicated urinary and intra-abdominal infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|surg avi ve iv te|she fda there industry australia|avibactam|entity is also protected by an issued united states patent directed to combinations with an antibiotic that expires in 2026 .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 2)])|drug|surg avi ve iv te|ceftazidime meropenem piperacillin imipenem amikacin|avibactam|entity is a first-in-class broad-spectrum β-lactamase inhibitor , which protects ceftazidime against degradation by class a , c and some d , β-lactamases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|surg avi ve iv te|pte australia canada cdc swine|avibactam|in addition , entity is protected by a united states composition-of-matter patent that expires in 2022 , without pte .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|surg avi ve iv te|amikacin ceftazidime gentamicin meropenem cefotaxime|avibactam|based on the results of these studies , we and astrazeneca initiated phase iii studies for ceftazidime / entity in patients with ciai in december 2011 and in patients with cuti in july 2012 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|surg avi ve iv te|valsartan sirolimus ribavirin meropenem ritonavir|avibactam|in fiscal 2013 , these costs were largely related to clinical trials for nebivolol / valsartan , aclidinium / formoterol , vilazodone , memantine , and ceftazidime / entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 1)])|drug|surg avi ve iv te|vancomycin taz gentamicin amikacin cephalosporin|avibactam|actavis plc and astrazeneca plc are developing ceftazidime / entity and ceftaroline / entity for pneumonia and complicated urinary and intra-abdominal infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|surg avi ve iv te|you today too next here|avibactam|so we are very excited to introduce to you entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|drug|surg avi ve iv te|amikacin vancomycin taz gentamicin ceftazidime|avibactam|forest laboratories and astrazeneca are developing ceftazidime / entity and ceftaroline / entity for pneumonia and complicated urinary and intra-abdominal infections .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|oxaliplatin gemcitabine paclitaxel docetaxel platinum|irinotecan|erbitux product labeling to include overall survival data as a single agent in egfr-expressing mcrc patients after failure of both entity- and oxaliplatin-based regimens .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|cpt mph cga tp max|irinotecan|sn38 is the active metabolite of cpt-11 ( entity ) , which is approved for the treatment of colorectal cancer .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|docetaxel capecitabine chemotherapy approval oxaliplatin|irinotecan|the fda approved entity as camptosar in 1994 for use in colorectal cancer .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|chemotherapy gemcitabine capecitabine oxaliplatin cetuximab|irinotecan|erbitux ( r ) is approved in united states , austria , canada , germany and switzerland for metastatic colorectal in combination with entity in entity-refractory patients .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|fu irinotecan paclitaxel oxaliplatin gemcitabine|irinotecan|we did observe statistically significant improvements in progression free survival , or pfs , and other efficacy endpoints for ha-entity compared with irinotecan alone .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|cisplatin paclitaxel gemcitabine docetaxel doxorubicin|irinotecan|entity and cisplatin are two established anticancer drugs which together constitute an active combination for treating sclc .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 3)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|temozolomide cisplatin chemotherapy bevacizumab radiotherapy|irinotecan|note : chemotherapy regimens included temozolomide and entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|cetuximab bevacizumab cisplatin oxaliplatin gemcitabine|irinotecan|is to assess the safety and pharmacokinetics of mm-121 in combination with cetuximab and mm-121 in combination with cetuximab and entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 3), ('DRUG', 3), ('DIS', 1)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|chemotherapy bevacizumab immunotherapy stent monotherapy|irinotecan|one of our clinical development strategies is to replace the use of entity with mm-398 by demonstrating that mm-398 has favorable efficacy and safety characteristics compared to entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|worldwide covered elsewhere funded today|irinotecan|that are currently conducted by aventis , together with certain patents and other assets relating to territories where pfizer currently markets entity , including the united states .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|paclitaxel docetaxel gemcitabine cetuximab bevacizumab|irinotecan|” the study was initiated following the demonstration of synergy between nimotuzumab and entity in the laboratories of daiichi sankyo in gastric cancer cell lines .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|oxaliplatin irinotecan doxorubicin gemcitabine capecitabine|irinotecan|advanced colorectal cancer in which nuc-3373 will be combined with many of the agents typically combined with 5-fu , including leucovorin , entity , oxaliplatin and monoclonal antibodies .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|chemotherapy trial myeloma pancreatectomy trials|irinotecan|clinical development of mm-398 we are pursuing two approaches in the ongoing clinical development of mm-398 : replace entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|oxaliplatin cisplatin irinotecan paclitaxel docetaxel|irinotecan|two camptothecin derivatives , topotecan and entity , have been approved by the fda for the treatment of small-cell lung , ovarian , and colorectal cancers .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|oxaliplatin capecitabine gemcitabine irinotecan carboplatin|irinotecan|most systemic therapies for colorectal cancer include 5-fu , either as monotherapy or in combination with another chemotherapeutic , typically oxaliplatin or entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|oxaliplatin platinum gemcitabine paclitaxel cisplatin|irinotecan|this study enrolled 463 patients with metastatic colorectal cancer who had failed standard entity- and oxaliplatin-containing chemotherapy .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|doxorubicin paclitaxel curcumin oxaliplatin rapamycin|irinotecan|these two adcs facilitate targeted delivery of sn-38 , the active metabolite of entity , an effective , yet toxic chemotherapeutic , directly to tumor cells .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|paclitaxel cisplatin docetaxel gemcitabine doxorubicin|irinotecan|entity and cisplatin combinations were evaluated systematically for drug ratio-dependent synergy in vitro using a panel of 20 tumor cell lines .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|methotrexate infliximab azathioprine etanercept placebo|irinotecan|our clinical strategy is to administer birinapant with therapies ( for example , azacitidine or entity ) that induce the production of tnf or related molecules .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|irinotecan pharmacokinetics oxaliplatin trial evaluate|medicine physicians tuberculosis malaria researchers|irinotecan|since that time he has had increasing responsibility for overseeing the global research plans and teams for entity and dalteparin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|inhibitor inhibited minocycline upon inhibitors|kind entity remains becomes purely|minocycline|“its quite unique in that its a entity topical ; i dont like a lot of the entity oral [ products ] , but entity topical – i can certainly get excited about .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|inhibitor inhibited minocycline upon inhibitors|corticosteroids contraceptives antibiotics steroids medications|minocycline|reported novel imaging techniques , suggesting that bpx-01 effectively targets p . acnes in the skin without the systemic side effects of oral entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|inhibitor inhibited minocycline upon inhibitors|topical dosage injectable formulation ointment|minocycline|in october , they received approval for their first product , amzeeq , a topical entity formulation for the treatment of acne .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|drug|inhibitor inhibited minocycline upon inhibitors|placebo laser lidocaine chlorhexidine cream|minocycline|in this study , no serious adverse events were observed and the treatment-related adverse events were related to dermal irritation in the 2% entity treatment arm .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|inhibitor inhibited minocycline upon inhibitors|formulation regimen antibiotic antibiotics derivative|minocycline|our lead product candidate , fmx101 for moderate-to-severe acne , is a novel topical foam formulation of the antibiotic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|inhibitor inhibited minocycline upon inhibitors|hcl phosphate gel containing citrate|minocycline|in september 1999 we recognized a gain of $2 . 7 million on the sale of our vectrin ( r ) entity hcl product line .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|inhibitor inhibited minocycline upon inhibitors|market price industry pill company|minocycline|solodyn , a branded oral entity , the current standard of care for moderate-to-severe acne , accounted for nearly one half of the total branded oral market for
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|inhibitor inhibited minocycline upon inhibitors|albumin choline gentamicin chloride sodium|minocycline|thus , it has been demonstrated that the amount of either entity or edetate that leaks into the serum is very low or none at all .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|inhibitor inhibited minocycline upon inhibitors|antibiotics formulation vancomycin probiotics chitosan|minocycline|limitations of use : this formulation of entity has not been evaluated in the treatment of infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|inhibitor inhibited minocycline upon inhibitors|another marketed respectively removed introduced|minocycline|are marketed outside the u . s . during 1998 , the company filed anda  s for two products previously selected , from which one product , entity , received approval in march 1999 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|drug|inhibitor inhibited minocycline upon inhibitors|erythema hair epidermis penetration edema|minocycline|dose a resulted in 5 mg / cm2 of entity , which translates to approximately about 1 mg / g of skin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|inhibitor inhibited minocycline upon inhibitors|hygiene candidiasis contraceptives mucositis acne|minocycline|limitations of current standard of care for acne : oral entity , such as solodyn , is the current standard of care for moderate-to-severe acne .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|inhibitor inhibited minocycline upon inhibitors|multidrug antimicrobial antibiotic pharmacological gentamicin|minocycline|mpts in blood serum and saliva in order to observe the drug release profile , and to assess the development of entity resistance .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|inhibitor inhibited minocycline upon inhibitors|inactive passive hydrophilic biodegradable loaded|minocycline|bpx-04 is designed to deliver the active , entity , into the skin without further irritating the skin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|inhibitor inhibited minocycline upon inhibitors|sales retail annual pharmacy market|minocycline|the prior year sales included $6 , 373 of entity sales which the company stopped selling in late 1999 because of deteriorating market conditions .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|inhibitor inhibited minocycline upon inhibitors|prednisolone acne minocycline corticosteroids hygiene|minocycline|oral entity has been a commonly used treatment for acne for years .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|inhibitor inhibited minocycline upon inhibitors|peptides substituents lysine residues flavonoids|minocycline|this approach was via structure-activity relationship chemistry-based modifications of the seven and nine positions of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|inhibitor inhibited minocycline upon inhibitors|tetracycline antibiotic original fungal entire|minocycline|used its expertise in biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the entity core structure .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|inhibitor inhibited minocycline upon inhibitors|gel coated foam versus sol|minocycline|success in iga @ week 12 difference from vehicle fmx103 entity foam , 1 . 5% 10-week study epsolay® ( † ) sol-gel did not conduct a head-to-head comparison trial or study .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|inhibitor inhibited minocycline upon inhibitors|containing contains between contained into|minocycline|or the cipan agreement , which provides the terms and conditions under which cipan will manufacture and supply to the company entity starting material and crude omadacycline .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|chemotherapy trial approved rats al|gdnf bevacizumab vegf rapamycin etanercept|rasagiline|that are intended to alter the course of the disease , including the investigational drugs known as cep-1347 , gdnf , tch-346 and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|chemotherapy trial approved rats al|herbal 200 40 50 tablets|rasagiline|azilect® ( entity tablets ) , tevas once-daily treatment for parkinsons disease , continued to establish itself in the u . s . and europe .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|chemotherapy trial approved rats al|sim dbs das tev pan|rasagiline|a number of mao inhibitors are approved for pd therapy , including zelapar ( selegiline / valeant ) and azilect ( entity ; teva / lundbeck ) .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|chemotherapy trial approved rats al|european national international fda scientific|rasagiline|teva and its strategic partner h . lundbeck a / s recently submitted the entity regulatory file to the european agency for evaluation of medicinal products .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|chemotherapy trial approved rats al|tablets herbal tablet injectable pharmaceutical|rasagiline|about azilect® ( united states ) indication azilect® ( entity tablets ) is indicated for the treatment of the signs and symptoms of parkinsons disease ( pd ) both as initial therapy alone and
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|chemotherapy trial approved rats al|vitamin glutathione cathepsin adenosine alzheimer|rasagiline|youdim has published numerous articles describing entity  s neuroprotective and neurorescue activities in various laboratory models .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|chemotherapy trial approved rats al|herbal 50 200 tablets sodium|rasagiline|our once-daily treatment for parkinsons disease , azilect® ( entity tablets ) , continued to grow .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|chemotherapy trial approved rats al|levodopa dbs acupuncture pharmacotherapy parkinsonism|rasagiline|completion of the two phase iii clinical trials in march , teva submitted to the fda a new drug application for entity for the treatment of parkinsons disease .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|chemotherapy trial approved rats al|ibuprofen herbal pharmaceutical tablet levodopa|rasagiline|developed by teva , entity tablets are approved in over 40 countries for the treatment of parkinsons disease .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|chemotherapy trial approved rats al|herbal tablets 200 50 sodium|rasagiline|our once-daily treatment for parkinsons disease , azilect® ( entity tablets ) , continued to grow in the u . s . and europe .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|chemotherapy trial approved rats al|serotonin dopamine tyramine catecholamines histamine|rasagiline|selectivity was tested by evaluating the interaction between tyramine and entity in healthy subjects .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|chemotherapy trial approved rats al|tablets herbal 200 50 tablet|rasagiline|our once-daily treatment for parkinsons disease , azilect® ( entity tablets ) , continued to establish itself in the u . s . and europe .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|chemotherapy trial approved rats al|herbal 200 sodium 40 injectable|rasagiline|azilect® ( entity tablets ) , tevas once-daily treatment for parkinsons disease and its second innovative drug , is now available in 29 countries .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|chemotherapy trial approved rats al|them medicines ltd vaccines protocols|rasagiline| teva pharmaceutical industries ltd . ( israel ) : we are in collaboration with teva pharmaceutical industries ltd . to develop and commercialize entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|chemotherapy trial approved rats al|reg tp cy sum dep|rasagiline|about azilect&reg azilect&reg tablets ( entity ) 1 mg / day are indicated for the treatment of the signs and symptoms of parkinson  s disease both as initial therapy alone
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|chemotherapy trial approved rats al|competition market companies cooperation partnerships|rasagiline|teva expects to market entity in europe with h . lundbeck a / s , and in the united states with its new strategic partner eisai inc . teva
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|chemotherapy trial approved rats al|200 40 iv placebo 50|rasagiline|about azilect &reg azilect&reg 1 mg tablets ( entity tablets ) are indicated for the treatment of the signs and symptoms of parkinson  s disease both as initial therapy alone and
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|chemotherapy trial approved rats al|levodopa iv sodium 40 50|rasagiline|azilect® ( entity tablets ) is indicated as initial monotherapy and as an adjunct to levodopa for the treatment of the signs and symptoms
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|chemotherapy trial approved rats al|40 tablets placebo herbal 50|rasagiline|about azilect® azilect® tablets ( entity tablets ) are indicated for the treatment of the signs and symptoms of parkinsons disease both as initial therapy alone and
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|chemotherapy trial approved rats al|levodopa iv 40 tablets sodium|rasagiline|azilect® ( entity tablets ) is indicated as an initial monotherapy and as an adjunct to levodopa for the treatment of the signs and
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|appl ophthalmic medicine sleep university|generic lithium potassium sodium magnesium|bethanechol|according to wolters kluwer , total sales of generic entity chloride 5mg , 10mg and 25mg tablets at awp were $56 million in 2007 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|placebo amitriptyline mood venlafaxine absolute|budesonide corticosteroids prednisolone steroids corticosteroid|nortriptyline|crx-170 is a novel synergistic combination drug candidate containing low dose budesonide and low dose entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|placebo amitriptyline mood venlafaxine absolute|gabapentin amitriptyline carbamazepine pregabalin clonidine|nortriptyline|clinical trials of the antiepileptic agents gabapentin and lamotrigine and the antidepressants entity and amitriptyline have all been negative .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|placebo amitriptyline mood venlafaxine absolute|placebo etanercept adalimumab mtx prednisone|nortriptyline|on multiple measures such as psoriatic infiltrate thickness , erythema and clinical skin condition and produced greater improvements than mometasone and entity alone .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|placebo amitriptyline mood venlafaxine absolute|chemotherapy placebo medications corticosteroids analgesics|nortriptyline|the 2 most common adverse events related to crx-170 were dry mouth , drowsiness , constipation and headache ; known effects of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|placebo amitriptyline mood venlafaxine absolute|placebo carbamazepine antidepressants levodopa topiramate|nortriptyline|procom , u . s . patent no . 6 , 344 , 487 , claims a method of treating insomnia with low dosage forms ( 0 . 5 mg to 10 mg ) of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|placebo amitriptyline mood venlafaxine absolute|levodopa placebo carbamazepine gabapentin antidepressants|nortriptyline|license from procom , u . s . patent no . 6 , 344 , 487 , claims a method of treating insomnia with low dosage forms ( 0 . 5mg to 10mg ) of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|placebo amitriptyline mood venlafaxine absolute|they there placebo neither csa|nortriptyline|crx-170 did not show a modulation of the inflammatory marker cd163 from the treatment baseline , although entity clearly did decrease cd163 on its own .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|placebo amitriptyline mood venlafaxine absolute|respectively antidepressants morphine fluoxetine amitriptyline|nortriptyline|crx-191 contains a mid- potency glucocorticosteroid , mometasone , and a low dose of the tricyclic anti-depressant , entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|placebo amitriptyline mood venlafaxine absolute|respectively antidepressants morphine fluoxetine amitriptyline|nortriptyline|crx-191 contains a mid-potency glucocorticosteroid , mometasone , and a very low dose of the tricyclic anti-depressant , entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|placebo amitriptyline mood venlafaxine absolute|chemotherapy corticosteroids placebo analgesics medications|nortriptyline|the most common adverse events related to crx-170 were dry mouth , drowsiness , constipation and headache ; known effects of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|placebo amitriptyline mood venlafaxine absolute|carbamazepine antidepressants placebo lamotrigine topiramate|nortriptyline|license from procom one , u . s . patent no . 6 , 344 , 487 , claims a method of treating insomnia with low dosage forms ( 0 . 5 mg to 10 mg ) of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|placebo amitriptyline mood venlafaxine absolute|agent agents potency steroids efficacy|nortriptyline|about crx-170 crx-170 is an oral synergistic combination drug candidate containing low doses of the steroid prednisolone and the anti-depressant entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|ter ophthalmic sodium bis alkaloid|medicines formulations tablets ingredients medications|terbinafine|we believe the usage of branded and generic entity has been limited due to safety concerns related to liver toxicity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|ter ophthalmic sodium bis alkaloid|adalimumab ibuprofen minocycline vancomycin curcumin|terbinafine|mycova™ combines an existing , approved drug for nail fungus , entity , with the nexact® technology that enhances the absorption of the drug through the skin .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|ter ophthalmic sodium bis alkaloid|medicines pharmaceuticals medications antibiotics cigarettes|terbinafine|consistent with this strategy , during fiscal 2006 we commenced sales of generic entity in certain european markets through an out-licensing arrangement .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|ter ophthalmic sodium bis alkaloid|bevacizumab ibuprofen tacrolimus curcumin formulation|terbinafine|“novartis formulation”means any topical formulation of entity ( other than the nexmed formulation ) developed by or on behalf of novartis .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 1)])|drug|ter ophthalmic sodium bis alkaloid|minocycline voriconazole doxycycline vancomycin curcumin|terbinafine|nm100060 is topically applied , and incorporates entity , a currently marketed oral anti-fungal drug , with the nexact® technology , which facilitates the permeation of the drug through the nail
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ter ophthalmic sodium bis alkaloid|hydrochloride powder hcl bis 40|terbinafine|aerosol no protection lamisil entity ( entity hydrochloride ) fungal infection of the skin and nails caused by dermatophyte fungi tinea capitis fungal infections of the skin
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ter ophthalmic sodium bis alkaloid|medicinal commercial tobacco pharmaceutical herbal|terbinafine|worldwide sales of the branded entity product lamisil , the most prescribed systemic drug for onychomycosis , were $1 . 2 billion in 2004 and $978 million in 2006 , when
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ter ophthalmic sodium bis alkaloid|ongoing randomized remaining largest original|terbinafine|umang vohra though the entity trials are ongoing , we have not got an early read kind of a methodology for that trial and we hope
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ter ophthalmic sodium bis alkaloid|placebo tablets tablet ibuprofen marketed|terbinafine|significant product launches in fiscal 2006 included glimepiride tablets and zonisamide tablets in the united states and entity tablets in the united kingdom .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|ter ophthalmic sodium bis alkaloid|antibiotics corticosteroids topical bisphosphonates steroids|terbinafine|treatments are segmented into two approaches , either oral therapies , such as entity , or topical products , such as jublia , an azole , and kerydin , an oxaborole .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ter ophthalmic sodium bis alkaloid|final own pharmaceutical original next|terbinafine|evolved for promius pharma as a whole and how do you see that going forward and some update on your entity product for which you had phase three already enrolled?
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|ter ophthalmic sodium bis alkaloid|sertraline paroxetine aripiprazole venlafaxine fluoxetine|terbinafine|new product launches in fiscal 2006 included the generic versions of glimepiride , lansoprazole , lisinopril , sertraline and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|ter ophthalmic sodium bis alkaloid|omeprazole clarithromycin ciprofloxacin amoxicillin levofloxacin|terbinafine|during fiscal 2008 , we launched carvedilol tablets , meprobamate tablets , omeprazole , finasteride , ceterizine otc , ranitidine otc , zolpidem tablets , entity and ciprofloxacin er tablets .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|ter ophthalmic sodium bis alkaloid|formulations medicines ingredients tablets analogues|terbinafine|despite its high labeled efficacy ( 38% ) , we believe the usage of branded and generic entity has been limited due to safety concerns related to liver toxicity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ter ophthalmic sodium bis alkaloid|lam bd vi csa mpa|terbinafine|lamisil ( entity ) , a systemic drug approved for onychomycosis , had worldwide peak sales of $1 . 2 billion in 2004 , before generic entry .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|ter ophthalmic sodium bis alkaloid|itraconazole fluconazole voriconazole ketoconazole ciprofloxacin|terbinafine|preclinical studies have shown that itraconazole , the antifungal agent in hyphanox , has a broader spectrum of activity than entity , the antifungal agent in lamisil .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|ter ophthalmic sodium bis alkaloid|sertraline paroxetine venlafaxine fluoxetine ssris|terbinafine|however , this was offset to some extent by a decrease in sales of entity and sertraline .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|ter ophthalmic sodium bis alkaloid|medicines prescriptions medication pharmacy medications|terbinafine|period ending june 30 , 2010 , 1 . 4 million new prescriptions were filled in the united states for both branded and generic versions of entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ter ophthalmic sodium bis alkaloid|df ta mpa lam tm|terbinafine|lamisil ( entity ) is a treatment for fungal nail infection ( onychomycosis ) .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ter ophthalmic sodium bis alkaloid|germany recently revised who canada|terbinafine|a generic version of lamisil , entity , recently became available .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|antiviral hepatitis diarrhea clinic sof|ribavirin lamivudine monotherapy regimen ritonavir|ledipasvir|harvoni combines the ns5a inhibitor entity with sofosbuvir and is indicated for an eight , 12 or 24 week treatment duration depending on prior treatment history , cirrhosis
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|antiviral hepatitis diarrhea clinic sof|pegylated ribavirin lamivudine capecitabine interferon|ledipasvir|in october 2014 the fda approved gileads interferon-free harvoni , a entity / sofosbuvir combination for patients with genotype 1 .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|antiviral hepatitis diarrhea clinic sof|ribavirin lamivudine tenofovir efavirenz interferon|ledipasvir|pending patent applications directed to the use of combinations for the treatment of hcv , and , specifically , to the combination of entity and sofosbuvir .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|antiviral hepatitis diarrhea clinic sof|ribavirin lamivudine ritonavir efavirenz azathioprine|ledipasvir|gilead sciences markets harvoni as a  cure  for hepatitis c . it combines two drugs : sovaldi ( sofosbuvir ) and entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|antiviral hepatitis diarrhea clinic sof|oil them cholesterol silica lipids|ledipasvir|additionally , abbvie has obtained canadian patent no . 2 , 857 , 339 ( the 339 patent ) which purports to cover a solid composition that contains entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|antiviral hepatitis diarrhea clinic sof|ribavirin lamivudine antiviral rifampicin inhibitor|ledipasvir|classes of compounds that provide better safety and efficacy such as nucleotide polymerase inhibitors sofosbuvir ( sovaldi ) and the sofosbuvir and entity combination ( harvoni ) .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|antiviral hepatitis diarrhea clinic sof|ribavirin lamivudine tenofovir ritonavir efavirenz|ledipasvir|in october 2014 , we also received approval of the fixed-dose combination of entity and sofosbuvir , now known commercially as harvoni .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|antiviral hepatitis diarrhea clinic sof|ribavirin lamivudine ritonavir gemcitabine infliximab|ledipasvir|in october 2014 the fda approved gileads interferon-free harvoni® , a fixed-dose combination of sofosbuvir and entity ( a ns5a inhibitor ) for patients with genotype 1 hcv .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|antiviral hepatitis diarrhea clinic sof|hcv lamivudine ribavirin efavirenz ritonavir|ledipasvir|the hcv ns5a drug resistance assay assesses resistance to entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|antiviral hepatitis diarrhea clinic sof|started occurred approved introduced ribavirin|ledipasvir|resistance to sofosbuvir , which was approved as a single daa in 2013 and as a co-formulation with the ns5a inhibitor , entity , in 2014 .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|antiviral hepatitis diarrhea clinic sof|sof lamivudine ribavirin peg ritonavir|ledipasvir|separately , results from a phase 2 study demonstrated the safety and efficacy of entity / sofosbuvir in patients with genotypes 4 or 5 infection .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|antiviral hepatitis diarrhea clinic sof|ribavirin antiviral lamivudine rifampicin antibiotic|ledipasvir|classes of compounds that provide better safety and efficacy such as nucleotide polymerase inhibitors sofosbuvir ( sovaldi® ) and the sofosbuvir and entity combination ( harvoni ) .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|antiviral hepatitis diarrhea clinic sof|ribavirin resveratrol lovastatin rapamycin interferon|ledipasvir|entity inhibits the ns5a hcv viral protein .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|rats fluoxetine antagonist depressed antidepressant|cured placebo another them cure|fluoxetine|as cured ( with a ham-d score lower than 8 ) , we had between 37% and 39% , of a similar order to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|rats fluoxetine antagonist depressed antidepressant|serotonin placebo amphetamine fluoxetine benzodiazepines|fluoxetine|vilazodone has greater in vitro potency and selectivity for serotonin reuptake than compounds such as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|rats fluoxetine antagonist depressed antidepressant|paroxetine fluoxetine citalopram ssris amitriptyline|fluoxetine|compete with newer generation anti-depressants used to treat hot 17 table of contents flash frequency , such as venlafaxine by wyeth , entity by eli lilly and paroxetine by glaxo smith kline .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|rats fluoxetine antagonist depressed antidepressant|buprenorphine there aripiprazole quetiapine chlorpromazine|fluoxetine|entity is the generic equivalent of eli lilly  s prozac antidepressant , which is patent protected and had annual sales of $1 . 7 billion for the twelve months ended september 30 , 1997 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|rats fluoxetine antagonist depressed antidepressant|regimen monotherapy antagonist formulation itself|fluoxetine|in the same preclinical studies , the ssri entity did not induce rapid onset antidepressant-like responses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|rats fluoxetine antagonist depressed antidepressant|schizophrenia there dopamine rats anti|fluoxetine|entity capsules central nervous system anti-psychotic rs .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('DIS', 3), ('OTHER', 2)])|drug|rats fluoxetine antagonist depressed antidepressant|tamoxifen methotrexate docetaxel metformin estrogen|fluoxetine|product sales , excluding entity and tamoxifen , were approximately $122 million during the third quarter .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|rats fluoxetine antagonist depressed antidepressant|amitriptyline venlafaxine antidepressants fluoxetine citalopram|fluoxetine|commonly prescribed drugs for other symptoms include ditropan or detrol for bladder dysfunction , provigil for fatigue , entity for depression , and amitriptyline for pain .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|rats fluoxetine antagonist depressed antidepressant|example reasons people medicine women|fluoxetine|you can see that the adverse effects are relatively traditional for entity : essentially digestive , gastrointestinal orders and nausea and disappear in function of time .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|rats fluoxetine antagonist depressed antidepressant|paroxetine fluoxetine imipramine sertraline citalopram|fluoxetine|major marketed brands include tofranil ( imipramine ) , prozac ( entity ) , paxil ( paroxetine ) , luvox ( fluoxamine ) and zoloft ( sertaline ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|rats fluoxetine antagonist depressed antidepressant|api fda formulation industry molecule|fluoxetine|the api entity has been the subject of multiple studies in humans and has been approved for use in humans for decades .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|drug|rats fluoxetine antagonist depressed antidepressant|patent malaria manufacturers decades medicines|fluoxetine|the company filed its application for entity in january 1996 , and has been sued for patent infringement by eli lilly , initiating the patent challenge process .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|rats fluoxetine antagonist depressed antidepressant|matter europe australia market canada|fluoxetine|based on a recent federal court of appeals ruling , lilly  s composition of matter patent on entity will expire in the summer of 2001 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|placebo antagonist trial metabolite methylphenidate|placebo paracetamol midazolam atropine ibuprofen|bupropion|/ mecamylamine tablets formulation and method of making tablets containing entity and mecamylamine issued march 9 , 2010 expires july 25 , 2027 us appl .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|placebo antagonist trial metabolite methylphenidate|bupropion nicotine placebo fluoxetine citalopram|bupropion|neuropsychiatric reactions in patients taking entity for smoking cessation serious neuropsychiatric reactions have occurred in patients taking bupropion for smoking cessation .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|placebo antagonist trial metabolite methylphenidate|topical placebo transdermal ibuprofen diclofenac|bupropion|adverse events and laboratory findings appeared to be consistent with the individual components of empatic , entity and zonisamide .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|placebo antagonist trial metabolite methylphenidate|naltrexone buprenorphine morphine nicotine methadone|bupropion|however , we could be exposed to potential patent infringement liability from other third parties who hold patents on various formulations of entity and naltrexone .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|placebo antagonist trial metabolite methylphenidate|placebo nicotine saline aspirin sham|bupropion|approximately 60 smokers interested in quitting will be randomized in a 1 : 1 ratio to receive either axs-05 or entity for 4 weeks .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 2)])|drug|placebo antagonist trial metabolite methylphenidate|placebo metformin atorvastatin mtx cisplatin|bupropion|for all doses tested , administration of dm in combination with entity resulted in substantial increases in auc0‑12 and cmax values of dm on day 8 as compared to day 1 of dosing .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|placebo antagonist trial metabolite methylphenidate|resveratrol curcumin berberine derivatives 16|bupropion|in addition , empatic contains entity , the same active ingredient that gave rise to the fdas concerns regarding the cardiovascular safety profile of nb32 , which depending
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 2)])|drug|placebo antagonist trial metabolite methylphenidate|sodium inhaled strontium lithium diclofenac|bupropion|aplenzin is a once-daily formulation of entity hydrobromide and has been approved in 174mg , 348mg , and 522mg extended-release tablets .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|placebo antagonist trial metabolite methylphenidate|placebo nonresponders responders longer responding|bupropion|we are very encouraged by the magnitude of superiority in responders over entity , the active control .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|placebo antagonist trial metabolite methylphenidate|adding racemic liposomal administering hcl|bupropion|in 2001 , we licensed our once-daily formulation of entity hcl to gsk and have been collaborating with them to seek regulatory approval of wellbutrin xl .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|placebo antagonist trial metabolite methylphenidate|hcl diclofenac sodium bismuth paracetamol|bupropion|for this period also includes a $3 . 0 million bond received from glaxo to settle all patent infringement litigation relating to entity hcl , er 100 mg and 150 mg tablets .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|placebo antagonist trial metabolite methylphenidate|oc dm mtx dha zn|bupropion|that we are pursuing ; however , generic forms of the active ingredients of our product candidates , including zoledronic acid , dm , and entity , are available and could be used off‑label .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|placebo antagonist trial metabolite methylphenidate|api naltrexone transdermal another opioid|bupropion|we have entered into long-term supply agreements for the supply of naltrexone and entity api .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|placebo antagonist trial metabolite methylphenidate|hcl sodium diclofenac intravenous ibuprofen|bupropion|biovail also acquired the right to market its once-daily formulation of entity hcl in canada under the trade name wellbutrin® xl if regulatory approval is received .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|placebo antagonist trial metabolite methylphenidate|formulations formulation pharmaceuticals patents agents|bupropion|for example , we have in-licensed from glaxosmithkline certain formulation patents related to entity that expand our formulation options as we develop our commercial formulation of contrave .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|placebo antagonist trial metabolite methylphenidate|placebo sodium naltrexone transdermal twice|bupropion|the basis of the pet results , we added a second set of patients randomized either to 32mg naltrexone plus 400mg entity sr or a double placebo .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|placebo antagonist trial metabolite methylphenidate|via nicotine placebo bupropion fractional|bupropion|forfivo xl® ( entity extended-release ) is the first 450 mg bupropion hcl tablet indicated for major depressive disorder , approved by the fda .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|placebo antagonist trial metabolite methylphenidate|antidepressant agent sodium than ingredient|bupropion|cpi-300 is a higher strength of the antidepressant entity hcl , the active ingredient in wellbutrin xl® .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|placebo antagonist trial metabolite methylphenidate|agent than antidepressant sodium ingredient|bupropion|: cpi-300 is a higher strength of the antidepressant entity hcl , the active ingredient in wellbutrin xl® .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|nebul aerosol sodium kg sublingual|vaccines ribavirin vaccine bcg pbs|albuterol|for which we provide sterile manufacturing services include several influenza 2 table of contents vaccines , xopenex® , and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|drug|nebul aerosol sodium kg sublingual|antibiotics influenza nicotine pathogens respiration|albuterol|in the respiratory market , we compete primarily against entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 2)])|drug|nebul aerosol sodium kg sublingual|entity erlotinib placebo bevacizumab monotherapy|albuterol|we also evaluated rpl554 administered as an add-on therapy to either entity or ipratropium , in each case as compared to entity or ipratropium alone .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|nebul aerosol sodium kg sublingual|placebo nonusers monotherapy azithromycin ciprofloxacin|albuterol|symbicort demonstrated a 51% reduction in the rate of annual asthma exacerbations , compared to entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|nebul aerosol sodium kg sublingual|agonist nicotine generic antagonist inhaled|albuterol|xopenex inhalation solution and generic entity inhalation solution currently account for the majority of beta-agonist inhalation solution prescriptions in the market .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|nebul aerosol sodium kg sublingual|hcl saline ibuprofen powder phenobarbital|albuterol|the second quarter 2007 to institute a new , bundled payment amount for xopenexò brand leventity hcl inhalation solution and generic entity inhalation solution products .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|nebul aerosol sodium kg sublingual|salbutamol theophylline midazolam nicotine budesonide|albuterol|effective january 1 , 2007 , cms established new billing codes and payment methodologies for other compounded inhalation drugs , including entity and ipratropium .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|nebul aerosol sodium kg sublingual|sodium sulfate magnesium inhaled sublingual|albuterol| proair digihaler ( entity sulfate 117 mcg ) inhalation powder is the first and only digital inhaler with built-in sensors which connects to a companion
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|nebul aerosol sodium kg sublingual|alternative cfc identical ideal adequate|albuterol|in 1998 , ivax also applied for approval to market an entity non-cfc formulation in various european countries .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|nebul aerosol sodium kg sublingual|mdi budesonide inhaler salbutamol theophylline|albuterol|entity is the most widely used mdi product approved for the treatment of asthma , accounting for nearly $680 million in sales
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|nebul aerosol sodium kg sublingual|plc ht peg she what|albuterol|entity is marketed by glaxowellcome plc ( " glaxowellcome " ) , schering-plough and others .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|nebul aerosol sodium kg sublingual|generic flexible inhaler powder fluorescent|albuterol|with xopenex hfa , we compete with generic chlorofluorocarbon-based entity metered-dose inhalers and brand-name hfa entity metered-dose inhalers .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|nebul aerosol sodium kg sublingual|2d consecutive hf iv 1d|albuterol|cfc-containing entity mdis are required to be phased-out before the end of 2008 , with patients increasingly transitioning to hfa 2 mdis .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|nebul aerosol sodium kg sublingual|budesonide placebo corticosteroids prednisolone corticosteroid|albuterol|there was no difference in the exacerbation rate between symbicort and twice-daily maintenance budesonide plus entity , despite a 52% reduction in the mean steroid dose with symbicort .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|nebul aerosol sodium kg sublingual|example medicare medicaid england adults|albuterol|upon commercialization , zambon will be entitled to certain royalties on payments received by us for entity , ipratropium and cromolyn sales for specified periods .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|nebul aerosol sodium kg sublingual|inhalation ibuprofen budesonide acetaminophen what|albuterol|entity has been marketed for many years , is well established and sells at prices substantially lower than xopenex inhalation solution .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|nebul aerosol sodium kg sublingual|into containing versus than during|albuterol|this increase was principally due to the continued transition of patients previously using chlorofluorocarbon ( cfc ) entity mdis .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|nebul aerosol sodium kg sublingual|commercial market synthetic generic largest|albuterol|almost one-half of the market is still comprised of cfc entity mdis , representing a sizeable remaining market opportunity for the xopenex hfa product .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|nebul aerosol sodium kg sublingual|national settlement government private civil|albuterol|non-refundable $65 million cash deposit and issuance of letters of credit for the remaining balance , to be held by the entity settlement trust fund as security for potential future payments .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|nebul aerosol sodium kg sublingual|allergy taste allergen pharmaceutical milk|albuterol|this reflected the impact of generic entity substitutes on ventolin in the us , the impact of covid-19 pandemic related destocking in europe and allergy market contraction in
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|hydrochloride intravenous inhalation sodium iv|items prescription example article paper|tromethamine|pursuant to the sprix purchase agreement , the company acquired specified assets and liabilities associated with sprix ( ketorolac entity )
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride intravenous inhalation sodium iv|aqueous containing topical into via|tromethamine|entities acting in concert with them , are enjoined from making any preparations to make , sell , or offer for sale ketorolac entity ophthalmic solution 0 . 5% in the united states .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|hydrochloride intravenous inhalation sodium iv|dosage tablet formulation hydrochloride analgesic|tromethamine|district court for the eastern district of texas alleging patent infringement claims against the company relating to the 0 . 4% ketorolac entity formulation .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride intravenous inhalation sodium iv|spray hydrochloride tablets tablet sulfate|tromethamine|egalet has two approved products : oxaydo® ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|hydrochloride intravenous inhalation sodium iv|monotherapy hydrochloride placebo acetate 2b|tromethamine|the company has two vda drug candidates currently being tested in clinical trials , fosbretabulin entity , or fosbretabulin , and oxi4503 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride intravenous inhalation sodium iv|database guideline protocol review format|tromethamine|the fosbretabulin entity is being provided to ctep under a cooperative research and development agreement ( crada ) with oxigene and the bevacizumab is being
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|hydrochloride intravenous inhalation sodium iv|hydrochloride ibuprofen overdose ketorolac sulfate|tromethamine|for example , ketorolac entity is an injectable nsaid that had significant sales prior to the fdas imposing a black box warning limiting the combined
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride intravenous inhalation sodium iv|hydrochloride spray tablet tablets hcl|tromethamine|the company has two approved products : oxaydo ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride intravenous inhalation sodium iv|hydrochloride spray tablet tablets hcl|tromethamine|the company has two approved products : oxaydo ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|hydrochloride intravenous inhalation sodium iv|hydrochloride sulfate sulphate chloride acetate|tromethamine|drug substances the api used in sprix nasal spray is ketorolac entity , in oxaydo is oxycodone hydrochloride , in arymo er is morphine sulfate , and in egalet‑002 is oxycodone hydrochloride .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride intravenous inhalation sodium iv|months paper article weeks days|tromethamine|pursuant to which the company engaged jhs to provide certain services related to the manufacture and supply of sprix® ( ketorolac entity )
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride intravenous inhalation sodium iv|spray hydrochloride sulfate hc tablets|tromethamine|use only cii , developed using egalets proprietary guardian technology , oxaydo® ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride intravenous inhalation sodium iv|spray hydrochloride tablets tablet sulfate|tromethamine|we are marketing two innovative pain products , sprix® ( ketorolac entity ) nasal spray and oxaydotm ( oxycodone hci , usp ) tablets for oral use onlycii .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|hydrochloride intravenous inhalation sodium iv|phosphate kinase acetate tartrate pyrophosphate|tromethamine|our lead compound is ca4p , which is also known as combretastatin a4-phosphate , fosbretabulin entity , fosbretabulin and zybrestat® .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|hydrochloride intravenous inhalation sodium iv|days prescriptions article medication prescription|tromethamine|pursuant to the purchase agreement , the company acquired specified assets and liabilities associated with sprix® ( ketorolac entity )
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|hydrochloride intravenous inhalation sodium iv|spray di hc hydrochloride midazolam|tromethamine|the company is currently marketing sprix® ( ketorolac entity ) nasal spray ( “sprix nasal spray” ) and oxaydo® ( oxycodone hci , usp ) tablets for oral use only—cii ( “oxaydo” ) .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|ceftriaxone administered prophylaxis penicillin rates|methotrexate allopurinol tacrolimus cyclophosphamide cyclosporine|ceftriaxone|the increase in other u . s . sales was primarily due to increased sales of new products ( entity and deferoxamine ) to alternate site healthcare customers .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|ceftriaxone administered prophylaxis penicillin rates|amoxicillin ciprofloxacin doxycycline azithromycin penicillin|ceftriaxone|the current standard of treatment for bacterial urethritis / gonorrhea requires combination therapy including both an intramuscular injection of entity and oral azithromycin ( 1000 mg ) .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|ceftriaxone administered prophylaxis penicillin rates|antibiotics chemotherapy prophylaxis iv vancomycin|ceftriaxone|cdi , c . difficile associated diarrhea ( cdad ) and aad in patients hospitalized for a lower respiratory tract infection and receiving iv entity .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|drug|ceftriaxone administered prophylaxis penicillin rates|chemotherapy antibiotics medicine medicines art|ceftriaxone|to utilize ihma  s expertise and experience in " bridge " oral drug delivery techniques to research , develop and commercialize oral forms of entity .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|ceftriaxone administered prophylaxis penicillin rates|raw fresh original finished commercial|ceftriaxone|included in the amount pending approval at june 30 , 2005 was $7 . 4 million of entity raw material and finished product .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|ceftriaxone administered prophylaxis penicillin rates|dollars approval participants citations people|ceftriaxone|included in the amount pending approval at december 31 , 2005 was $7 . 4 million of entity , which was approved by the fda in february 2006 .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|ceftriaxone administered prophylaxis penicillin rates|azithromycin metronidazole erythromycin ciprofloxacin clarithromycin|ceftriaxone|study with a single oral dose of 1000 mg of solithromycin compared with the standard of care , 500 mg of entity administered intramuscularly and 1000 mg of oral azithromycin .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|ceftriaxone administered prophylaxis penicillin rates|orally once azithromycin metronidazole intravenously|ceftriaxone|current treatment of bacterial urethritis includes two drugs : entity administered intramuscularly and oral azithromycin , which is added to treat co-infections with chlamydia .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|ceftriaxone administered prophylaxis penicillin rates|placebo clopidogrel chemotherapy nac celecoxib|ceftriaxone|there was one treatment-related serious adverse event in the entity group .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 1)])|drug|ceftriaxone administered prophylaxis penicillin rates|levofloxacin ciprofloxacin moxifloxacin gentamicin amikacin|ceftriaxone|in a recent survey , 95% and 76% of the esbl isolates of escherichia coli found in utis were resistant to entity and levofloxacin , respectively .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|ceftriaxone administered prophylaxis penicillin rates|tetracycline metronidazole doxycycline erythromycin antibiotics|ceftriaxone|intramuscular entity now represents the last-resort treatment option for gonorrhea , although resistant strains are beginning to emerge .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5)])|drug|ceftriaxone administered prophylaxis penicillin rates|vancomycin gentamicin linezolid daptomycin ciprofloxacin|ceftriaxone|of the most common treatments for serious bacterial infections , vancomycin , daptomycin , entity and tigecycline are only available as injectable or iv formulations .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|ceftriaxone administered prophylaxis penicillin rates|sul placebo ampicillin ceftriaxone amoxicillin|ceftriaxone|treatment related diarrhea was reported by one subject following sulopenem single dose iv , and by a further two subjects following entity .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|ceftriaxone administered prophylaxis penicillin rates|sul iv placebo bismuth ampicillin|ceftriaxone|itt patients were similar on each regimen ( 9 / 10 , 9 / 11 and 7 / 12 , on sulopenem single iv dose , sulopenem multidose iv and entity , respectively ) .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|ceftriaxone administered prophylaxis penicillin rates|azithromycin amoxicillin metronidazole erythromycin intramuscular|ceftriaxone|of a single 1000 mg dose of oral solithromycin in patients with uncomplicated gonorrhea and chlamydia infections compared with intramuscular entity plus oral azithromycin .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|ceftriaxone administered prophylaxis penicillin rates|placebo sul tmp ampicillin azt|ceftriaxone|treatment-emergent adverse events were reported in six subjects each in the sulopenem groups and eight subjects in the entity group .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ceftriaxone administered prophylaxis penicillin rates|tacrolimus ibuprofen paclitaxel sirolimus methotrexate|ceftriaxone|entity is currently only marketed in an intravenous formulation .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5)])|drug|ceftriaxone administered prophylaxis penicillin rates|tetracycline penicillin methotrexate clindamycin gentamicin|ceftriaxone|the current standard of treatment for gonorrhea is a single intramuscular injection of entity .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ceftriaxone administered prophylaxis penicillin rates|ibuprofen curcumin dexamethasone paclitaxel steroids|ceftriaxone|there is no oral formulation of entity .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ceftriaxone administered prophylaxis penicillin rates|cab aripiprazole art trastuzumab scs|ceftriaxone|develop existing pre-clinical and clinical candidates , including cab-175 and an oral version of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|vi iii iv il gut|vi iv iii vii iiia|vilanterol|for the treatment of copd , the collaboration is developing combination products , relovair and the lama / laba ( gsk573719 / entity or 719 / vi ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|vi iii iv il gut|vi iv iii citrate ml|vilanterol|anoro™ ellipta® ( umeclidinium bromide / entity , umec / vi ) on april 28 , 2014 , gsk and theravance announced that anoro™ ellipta® , the first once-daily product approved in the u . s .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|vi iii iv il gut|placebo ibuprofen theophylline lactose gentamicin|vilanterol|are required and in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to either fluticasone furoate , entity , or any of the excipients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|vi iii iv il gut|named termed namely designated indole|vilanterol|the lead laba candidate , entity trifenatate ( or vi ) , is a gsk-discovered laba and gsk and we have jointly determined to focus the collaborations laba development
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|vi iii iv il gut|placebo valsartan budesonide ibuprofen aspirin|vilanterol|therefore fluticasone furoate / entity should be used with caution in patients with severe cardiovascular disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|vi iii iv il gut|monotherapy triple egfr gefitinib everolimus|vilanterol|our economic interest will not include any payments associated with relvar® ellipta® / breo® ellipta® , anoro® ellipta® or entity monotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|vi iii iv il gut|sodium inhaled budesonide bismuth dimethyl|vilanterol|· fluticasone furoate ( ff ) and entity trifenatate ( vi ) are promising agents for a combined , long-acting , once-daily treatment of asthma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|vi iii iv il gut|gsk egfr akt mtor gefitinib|vilanterol|our economic interest does not include any payments by gsk associated with relvar® ellipta® / breo® ellipta® , anoro® ellipta® or entity monotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|vi iii iv il gut|inhaler placebo budesonide m2 ibuprofen|vilanterol|anoro® ellipta® ( umeclidinium / entity ) to be reimbursed in australia for chronic obstructive pulmonary disease - administered using a new dry powder inhaler called
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|vi iii iv il gut|placebo budesonide salbutamol valsartan metronidazole|vilanterol|donohue october 26 , 2014 , 1 : 30 pm - 3 : 00 pm cdt efficacy and safety of once-daily umeclidinium added to fluticasone furoate / entity in chronic obstructive pulmonary disease :
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|vi iii iv il gut|vi iv iii vii ic|vilanterol|lama / laba combination ( gsk573719 / entity or 719 / vi ) the phase 3a program for the once-daily lama / laba dual bronchodilator 719 / vi is progressing well .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|vi iii iv il gut|monotherapy concomitant steroid triple methadone|vilanterol|our economic interest will not include any payments associated with relvar ellipta / breo ellipta , anoro ellipta or entity monotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|vi iii iv il gut|monotherapy concomitant steroid triple methadone|vilanterol|our economic interest does not include any payments associated with relvar ellipta / breo ellipta , anoro ellipta or entity monotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|vi iii iv il gut|vi iv bromide acetate ff|vilanterol|closed triple or ff / umec / vi ( fluticasone furoate / umeclidinium bromide / entity )
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|vi iii iv il gut|sodium inhaled lithium administered potassium|vilanterol|at 24h being developed for use as a monotherapy for asthma and in combination with a once-daily long-acting beta2 agonist ( laba ) , entity trifenatate ( vi , gw642444m ) , for asthma and copd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|vi iii iv il gut|placebo budesonide ibuprofen salbutamol propionate|vilanterol|had , or were at high-risk for , cardiovascular disease ; the primary objective was to evaluate the impact of fluticasone furoate ( ff ) / entity ( vi ) on all-cause mortality .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|vi iii iv il gut|agonist antagonist corticosteroid budesonide ics|vilanterol|breo is a fixed-dose combination of the inhaled corticosteroid ( ics ) fluticasone furoate ( ff ) and the long-acting beta2-agonist ( laba ) entity ( vi ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|vi iii iv il gut|placebo ibuprofen lactose indomethacin theophylline|vilanterol|ellipta is contraindicated in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to either fluticasone furoate , entity , or any of the excipients .
OrderedDict([('OTHER', 3), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|chemotherapy adjuvant bevacizumab capecitabine lymphoma|cea tc cas inh fda|arcitumomab|we continue to strengthen our u . s . and european sales and marketing effort for cea-scan ( r ) ( entity ) as well as our european effort for leukoscan ( r ) ( sulesomab ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|safety potency equivalence efficacy valent|ganciclovir|cell / bone marrow and solid organ transplant patients at risk for cmv infection or with active cmv disease receive entity or valentity ( both marketed by f . hoffmann-la roche ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|cmv mtx art ci tm|ganciclovir|valcyte , the oral pro-drug of cytovene ( entity ) , is the most widely prescribed anti-cmv medication in the united states .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|ribavirin antibiotics interferon vaccines chemotherapy|ganciclovir|demonstrated activity in cell culture against both clinical isolates and viruses which have become resistant to current therapies , such as entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|costs rates market antibiotics prices|ganciclovir|in 2008 , the market for cmv drugs was $600 million with entity controlling over 90% of the market .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|placebo etanercept tenofovir rifampicin diclofenac|ganciclovir|development of products that have achieved cumulative sales of close to $2 , 000 , 000 , 000 , including monistat ; delfen cream , for herpes virus infection ; entity ; solaraze ; and maci .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|methotrexate ganciclovir cyclophosphamide thalidomide rituximab|ganciclovir|currently approved drugs for cmv retinitis are entity , foscarnet , cidofovir and fomivirsen , or vitravene .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|antibiotics prophylaxis steroids haart aspirin|ganciclovir|the company is aware that a number of physicians have prescribed cytogam in combination with entity for the prevention of cmv disease in certain patients .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|australia dermatologists france canada tenofovir|ganciclovir|products that have achieved cumulative sales of close to two billion dollars including , monistat , delfen cream for herpes virus infectons , entity , solaraze , and maci .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|methotrexate dexamethasone antibiotics bevacizumab steroids|ganciclovir|the hytk gene was used to mark the cells and allow for ablation of the cells by administration of entity if undesirable side effects resulted from the therapy .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|vivo situ detail elisa suspension|ganciclovir|cells will be stimulated with anti-ig antibodies , and selected in entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|ribavirin cyclophosphamide methotrexate lamivudine rifampicin|ganciclovir|drug therapies approved or commonly used for cmv infection include antiviral compounds such as entity , valentity , cidofovir and foscarnet .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|inhibitor inhibitors sirna plasmid protease|ganciclovir|cells containing the tk reporter will be killed by the entity unless a peptide inhibitor is present which inhibits the gene  s expression ( appendix h ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|methotrexate dexamethasone bevacizumab heparin ketamine|ganciclovir|entity is available in intravenous and oral doses , as well as in an intraocular implant form .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|thymidine glutathione methionine tyrosine interferon|ganciclovir|in vivo activity for a bacterial strain which expresses the herpes simplex virus thymidine kinase gene for the conversion of entity to its toxic phosphorylated forms .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|hct guidelines imatinib fda caution|ganciclovir|in spite of trials conducted with entity for cmv prevention , entity is approved for use only as a preemptive therapy or treatment for cmv in hct .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|there attention literature knowledge emphasis|ganciclovir|entity was limited in its ability to be used as a preventive therapy by the risk of significant neutropenia , which has
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|methotrexate ibuprofen infliximab thalidomide everolimus|ganciclovir|dr . martin is the co-inventor of entity , a pharmaceutical now used for treatment of cytomegalovirus infection .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|corticosteroids steroids prednisolone methotrexate cyclosporine|ganciclovir|the company believes that , with the exception of oral entity , none of the drugs described above are currently administered prophylactically prior to manifestation of cmv retinitis .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|corticosteroids tacrolimus bevacizumab antibiotics paclitaxel|ganciclovir|our one commercial product , vitrasert , primarily competes with treatments involving the systemic delivery of entity , a roche holdings ag product , and other drugs .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|ganciclovir acyclovir cmv pharmacokinetics prophylaxis|rapamycin tk ganciclovir zidovudine lamivudine|ganciclovir|such as tumor cells , the tk gene renders these cells sensitive to the toxic effect of the fda-approved antiviral drug , entity ( " gcv " ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|inhibitor iv agent osteosarcoma stent|placebo curcumin diclofenac coumarin paclitaxel|talazoparib|bmn-673 means sellers proprietary compound known as bmn-673 or entity , having the chemical structure set forth in schedule 1 ( d ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|inhibitor iv agent osteosarcoma stent|business infrastructure innovation users resources|talazoparib|good presentation , and i agree that the offer from sanofi really substantially undervalued the business and the pipeline and especially entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|inhibitor iv agent osteosarcoma stent|rituximab methotrexate etanercept mtx azathioprine|talazoparib|we are excited about entity and pidilizumab .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|inhibitor iv agent osteosarcoma stent|gemcitabine capecitabine cetuximab oxaliplatin bevacizumab|talazoparib|for a select group of patients with hr-d breast cancer , entity , an oral parp inhibitor , was approved by the fda in 2018 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|inhibitor iv agent osteosarcoma stent|rights respect respond belong refer|talazoparib|and twelve months ended december 31 , 2015 , represents the net gain on the sale of the companys world-wide rights to entity to medivation inc . ### 11
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|inhibitor iv agent osteosarcoma stent|independently continuously substantially automatically exclusively|talazoparib|through acquisition of medivation in aug , 2016 , medivation acquired entity from biomarin in 2015 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|inhibitor iv agent osteosarcoma stent|rituximab etanercept adalimumab ribavirin placebo|talazoparib|trials , and our future drug development activities , including those with respect to pidilizumab ( which is referred to as mdv9300 ) and entity ( which is referred to as mdv3800 ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|inhibitor iv agent osteosarcoma stent|200 fda usa uk iii|talazoparib|business development at medivation , identified and led the acquisition of a compound that was subsequently developed and approved as talzenna ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|inhibitor iv agent osteosarcoma stent|parp chemotherapy apoptosis efficacy inhibitors|talazoparib|to start potential registrational trials  many of which will be the first initiated for a parp inhibitor  for entity in multiple other tumor types by the end of 2016 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|inhibitor iv agent osteosarcoma stent|move come reach travel learn|talazoparib|similarly , the company acquired the worldwide rights to entity just seven months ago from biomarin , again demonstrating an ability to move quickly and boldly by 9 table of
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|inhibitor iv agent osteosarcoma stent|here our they herein how|talazoparib|entity would complement our solid tumor pipeline with potential in a variety of cancers , both in our current pipeline such as
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|inhibitor iv agent osteosarcoma stent|bevacizumab paclitaxel cetuximab trastuzumab docetaxel|talazoparib|based on these data , we initiated a phase 1 / 2 clinical trial of the combination of telaglenastat plus entity in patients with rcc and tnbc in march 2019 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|inhibitor iv agent osteosarcoma stent|rights respect belong refer respond|talazoparib|and twelve months ended december 31 , 2015 , represents the net gain on the sale of the companys world-wide rights to entity to medivation inc .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|inhibitor iv agent osteosarcoma stent|rituximab adalimumab etanercept cetuximab infliximab|talazoparib|xtandi , we are well positioned for long-term sustainable growth with a promising pipeline that includes two late-stage wholly owned assets : entity and pidilizumab .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|inhibitor iv agent osteosarcoma stent|knowledge them insight insights text|talazoparib|bofa merrill lynch - analyst can you talk a little bit about the process that you went through to acquire entity from biomarin?
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|inhibitor iv agent osteosarcoma stent|parp bevacizumab oxaliplatin cetuximab gemcitabine|talazoparib|approved parp inhibitors include olaparib , entity and niraparib .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|bis rop iron analogue analogues|own sole gel original herbal|ropinirole|partner for jzp-4 , its potential treatment for epilepsy and bipolar , disorder and will no longer pursue development of jzp-7 , its entity gel product candidate for restless legs syndrome .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|bis rop iron analogue analogues|commercial original final tobacco own|ropinirole|we were previously targeting an nda submission for our entity product candidate in calendar 2008 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|bis rop iron analogue analogues|here platform herein technology recently|ropinirole|staccato entity we have identified two new preclinical product candidates for development based on the single-dose staccato platform currently being manufactured in
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|bis rop iron analogue analogues|sublingual although topical whether chewing|ropinirole|entity oral spray is ideal for the geriatric population who may be suffering from dysphagia ( difficulty swallowing ) ; 85% of sufferers of
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|bis rop iron analogue analogues|topical our nasal spray sublingual|ropinirole|our formulation of entity oral spray may represent a more convenient way for the patient or healthcare provider to deliver entity to patients suffering stiffness and / or tremors .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|bis rop iron analogue analogues|acupuncture caution psychotherapy radiotherapy attention|ropinirole|entity is indicated for the treatment of the signs and symptoms of idiopathic parkinson  s disease .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|bis rop iron analogue analogues|agent implant biomaterial option formulation|ropinirole|we completed a non-clinical study with long-term delivery of dopamine agonists which supports the potential to develop an implant delivering entity for treating parkinsons disease .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|bis rop iron analogue analogues|lithium olanzapine levodopa amphetamine topiramate|ropinirole|commonly prescribed dopamine agonists that directly activate dopamine receptors include agents such as mirapex ( pramipexole / bi ) and requip ( entity / glaxosmithkline ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|bis rop iron analogue analogues|bromocriptine haloperidol levodopa risperidone amphetamine|ropinirole|japan , and in 2006 in the u . s . the competition for parkinson  s disease drugs includes l-dopa , cabergoline , bromocriptine , pergolide , lisuride and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|bis rop iron analogue analogues|ibuprofen levodopa donepezil paracetamol lidocaine|ropinirole|the new prolonged release tablet of entity is taken once daily , and is indicated for the treatment of parkinson  s disease ( pd ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|bis rop iron analogue analogues|dopamine levodopa morphine haloperidol naltrexone|ropinirole|we have performed the preclinical development work on a transdermal formulation of entity , a proven and fda-approved dopamine agonist for treating parkinsons disease .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|bis rop iron analogue analogues|technology software arrays assembly instrumentation|ropinirole|our proprietary pipeline also includes corplex entity for the treatment of parkinsons disease .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|bis rop iron analogue analogues|dopamine levodopa topiramate clozapine aripiprazole|ropinirole|entity is a dopamine agonist currently available in daily or more frequently dosed oral formulations for the treatment of parkinson  s disease
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|kg antagonist propranolol antihypertensive metoprolol|guidelines date publication hospitals germany|nebivolol|the decrease in research and development expenses is the result of the completion of clinical studies related to entity , for which a nda was filed on april 30 , 2004 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|kg antagonist propranolol antihypertensive metoprolol|hydrochloride guanidine sulfon lidocaine sodium|nebivolol|the u . s . composition of matter patent covering entity hydrochloride is licensed from mylan inc . ( mylan ) and expires in 2020 and we submitted a patent term extension application to
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|drug|kg antagonist propranolol antihypertensive metoprolol|treating diagnosing predicting idiopathic suspected|nebivolol|could you give us a little bit more color on the timing of the nda filing for entity congestive heart failure?
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|kg antagonist propranolol antihypertensive metoprolol|50 200 oh max 21|nebivolol|bystolic® ( entity ) , a beta-blocker for the treatment of hypertension , recorded sales of $142 . 9 millionin in the fourth quarter 2014 , an increase of
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|kg antagonist propranolol antihypertensive metoprolol|hydrochloride guanidine lidocaine ketamine sodium|nebivolol|the u . s . composition of matter patent covering entity hydrochloride is licensed from mylan laboratories inc . and expires in 2020 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|kg antagonist propranolol antihypertensive metoprolol|who whether once placebo never|nebivolol|* trial 305 ( general population ) trial 202 ( african-american patients ) add-on therapy vs . placebo trial 321 ( entity added to current antihypertensive treatment )
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|drug|kg antagonist propranolol antihypertensive metoprolol|asthma schizophrenia copd psoriasis ibs|nebivolol|brand segment r&d is primarily the result of the completion , during fiscal 2004 , of the phase iii clinical studies for entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|kg antagonist propranolol antihypertensive metoprolol|due according next leading alternatives|nebivolol|today , we are announcing that the best available option is to out license entity to a major brand pharmaceutical company , which will co develop and commercialize this product .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|kg antagonist propranolol antihypertensive metoprolol|recurring continuing occasional temporary escalating|nebivolol|eps to gaap diluted eps : adjusted diluted eps $ 0 . 26 mylan bertek and entity expenses ( $0 . 05 ) restructuring charges and other non-recurring expenses ( $0 . 02 ) contingent legal liability
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|kg antagonist propranolol antihypertensive metoprolol|existing national uk original german|nebivolol|we expect to experience increased research and development expenses in support of the entity clinical program , as well as milestone payments under our license agreement .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|kg antagonist propranolol antihypertensive metoprolol|safety prevention costs women mortality|nebivolol|the restructuring , while r&d expense increased as a result of an increase in ongoing studies , including those with respect to entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|kg antagonist propranolol antihypertensive metoprolol|deaths falls residents hospitals injuries|nebivolol|the overall decrease is primarily the result of the outlicensing of entity , which occurred late in fiscal 2006 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|kg antagonist propranolol antihypertensive metoprolol|connection relation cooperation germany denmark|nebivolol|the irs regarding whether the proceeds received by the company in connection with the 2008 sale of its rights in entity constituted a capital gain or ordinary income .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|kg antagonist propranolol antihypertensive metoprolol|aging obesity dementia ageing ethnicity|nebivolol|the increase was primarily attributable to research and development expense due to ongoing clinical studies related to entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|kg antagonist propranolol antihypertensive metoprolol|price public medicare law market|nebivolol|number one , ed , can you walk me through the five-cent charge in entity and bertek expenses and point me to where i can find it on the p&l?
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|kg antagonist propranolol antihypertensive metoprolol|technology scientists physicians knowledge them|nebivolol|the opportunity to launch entity will significantly expand our existing cardiovascular franchise .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|kg antagonist propranolol antihypertensive metoprolol|students teaching comparison acquisition example|nebivolol|changes of the king business and the lack of appropriate other acquisition alternatives we have chosen a different course for entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|kg antagonist propranolol antihypertensive metoprolol|amlodipine sildenafil warfarin everolimus digoxin|nebivolol|our flagship product , altaceò . this is a perfect fit with mylan because of its growing pipeline of proprietary products , including entity , a hypertension product .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|kg antagonist propranolol antihypertensive metoprolol|200 max fr 111 rct|nebivolol|bystolic ( entity ) , our beta-blocker indicated for the treatment of hypertension launched in january 2008 , achieved sales of $59 , 522 , an increase of $21 , 857
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|kg antagonist propranolol antihypertensive metoprolol|acl acetaminophen theophylline ibuprofen morphine|nebivolol|for the same period last year , third party development costs were largely related to clinical trials for entity , aclidinium / formoterol , vilazodone and roflumilast .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|tin ophthalmic 25 cream itraconazole|ciprofloxacin trimethoprim metronidazole tetracycline voriconazole|tinidazole|nitroimidazoles for use in the invention include metronidizole , ornidazole , secnidazole , and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|tin ophthalmic 25 cream itraconazole|entity within although unlike named|tinidazole|entity vaginal effervescent tablet the key component of entity vaginal effervescent tablet is entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|tin ophthalmic 25 cream itraconazole|ciprofloxacin amoxicillin aspirin methotrexate metronidazole|tinidazole|six ulcerative colits patients with ipaa ( 3 refractory pouchitis , 2 crohns disease , 1 irritable pouch syndrome ) received entity plus xifaxan or ciprofloxacin for 2-4 weeks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|drug|lif al ga mit implantation|everolimus abcg2 cyp3a4 shp imatinib|lifitegrast|( “r&d” ) was up 6% particularly due to investment in new uses for ldx ( the active ingredient in vyvanse ) , shp602 and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|drug|lif al ga mit implantation|psoriasis asthma ich copd schizophrenia|lifitegrast|the new drug application for entity included data from four randomized , controlled clinical trials with more than 1 , 800 patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|lif al ga mit implantation|topical aqueous ophthalmic sodium intravenous|lifitegrast|novartis entered into an agreement with takeda pharmaceutical company limited ( takeda ) to acquire the assets associated with xiidra ( entity ophthalmic solution ) 5% worldwide .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|lif al ga mit implantation|celecoxib paclitaxel indomethacin curcumin rgd|lifitegrast| shire plc has a small molecule integrin antagonist , entity , which is formulated for topical , ophthalmic delivery and is currently in phase 3 clinical development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|lif al ga mit implantation|guidelines art medications recommendations therapeutics|lifitegrast| if approved , shire would benefit from the launch of entity for dry eye disease in 2016 , and hopes to increase awareness , diagnosis and treatment of this condition .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|lif al ga mit implantation|40 bis 23 ic 28|lifitegrast|leukocytes [ ] selected based on its properties for further development as a candidate to treat dry eye disease [ graphic omitted ] entity ( formerly sar 1118 ) mw 610 g / mol 1 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|lif al ga mit implantation|aqueous topical ophthalmic rabbit sodium|lifitegrast|these relate to the xiidra ( entity ophthalmic solution ) product which takeda had subsequently announced a sale agreement for .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|lif al ga mit implantation|moving forward knowledge going medicine|lifitegrast|“our commitment to moving entity forward reflects our intent to grow in the ophthalmics therapeutic category in areas of unmet patient need .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|lif al ga mit implantation|guidelines companies manufacturers approval standards|lifitegrast|shire plc recently received fda approval to market entity for the treatment of dry eye and will be launching the product in the u . s . restasis , and other products , have
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|lif al ga mit implantation|approved safe named candidate feasible|lifitegrast|shire plc is developing its product candidate , entity , and is in pivotal phase 3 clinical trials in the u . s . shire has said it plans to resubmit an nda for entity in 2016 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|lif al ga mit implantation|prevention prophylaxis immunotherapy pharmacotherapy treatments|lifitegrast|press release www . shire . com shire plans to submit a new drug application to fda for entity for dry eye disease in adults · fda submission planned for 1st quarter 2015 · shire forms business
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|lif al ga mit implantation|aqueous topical ophthalmic sodium dissolved|lifitegrast|these relate to the xiidra® ( entity ophthalmic solution ) product which takeda has subsequently announced a sale agreement for , as included in note 33 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|lif al ga mit implantation|example publication instance reasons approval|lifitegrast|of any of our product candidates , such as our planned submission of a new drug application to the fda for entity , may be delayed for any number of reasons and , once submitted ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|lif al ga mit implantation|canada england india japan europe|lifitegrast|on shp602 ( formerly known as spd602 ) for iron overload and on development programs acquired through business development in 2013 , including entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|lif al ga mit implantation|topical ophthalmic herbal percutaneous synthetic|lifitegrast|novartis entered into an agreement with takeda pharmaceutical company limited ( takeda ) to acquire the assets associated with xiidra&#xae ; ( entity ophthalmic solution ) 5% worldwide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|lif al ga mit implantation|example request what date another|lifitegrast|maybe to refresh the topic , on entity , obviously the other key near-term event with the october 25 pdufa date .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|lif al ga mit implantation|infliximab bevacizumab adalimumab etanercept pregabalin|lifitegrast|opus-3 , a randomized , double-masked , 12-week phase 3 study enrolled 711 patients to evaluate the efficacy and safety of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|drug|lif al ga mit implantation|ranibizumab bevacizumab pdt nac tacrolimus|lifitegrast|in addition , patients treated with entity showed a statistically significant improvement in ocular discomfort and eye dryness , symptoms of dry eye disease , as reported by patients
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|lif al ga mit implantation|placebo another con what sham|lifitegrast|when i look at restasis relative to entity , in terms of efficacy measures , sustaining tear production and goblet cell density , i think restasis is a great option .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|lif al ga mit implantation|cyclosporine tacrolimus cyclosporin azathioprine sirolimus|lifitegrast|in the united states , yet only two drugs are approved for dry eye disease treatment , restasis® ( cyclosporine 0 . 05% ) and xiidra® ( entity 5% ) .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|thymidine 60 sodium hydrochloride 90|irinotecan oxaliplatin paclitaxel cisplatin gemcitabine|floxuridine|the 1 : 1 molar ratio of irinotecan : entity was frequently synergistic and avoided antagonism whereas other ratios exhibited a loss of synergy and in some cases the appearance
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|thymidine 60 sodium hydrochloride 90|irinotecan oxaliplatin gemcitabine paclitaxel capecitabine|floxuridine|range of preclinical solid tumor models , cpx-1 consistently provided dramatic improvements in therapeutic efficacy over the unencapsulated free-drug cocktail of irinotecan : entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|thymidine 60 sodium hydrochloride 90|paclitaxel docetaxel irinotecan gemcitabine oxaliplatin|floxuridine| cpx-1 is a liposomal formulation of irinotecan : entity , which is a clinical stage product candidate ;  cpx-8 is a hydrophobic docetaxel prodrug nanoparticle which is a preclinical stage
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|thymidine 60 sodium hydrochloride 90|oxaliplatin irinotecan paclitaxel gemcitabine cisplatin|floxuridine|scientific rationale of cpx-1 the combination of irinotecan and entity was screened for drug ratio dependent synergy in vitro in a panel of tumor cell lines .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|thymidine 60 sodium hydrochloride 90|paclitaxel cisplatin carboplatin fluorouracil gemcitabine|floxuridine|from 7 . 8 months to 12 . 0 months ( p = 0 . 05 ) for patients with advanced , unresectable colorectal liver metastases receiving sir-spheres and entity ( fudr ) vs fudr alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|bis cns 24 ol alkaloid|nd vi 200 nc cg|eszopiclone|additionally , in early 2003 , sepracor filed an nda for estorra ( entity ) for the treatment of insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|bis cns 24 ol alkaloid|cigarettes tobacco medicines sales heroin|eszopiclone|in exchange , sepracor permitted aventis to assign sepracors obligation to pay a royalty on sales of entity in the u . s . to a third party .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|bis cns 24 ol alkaloid|crt cbt hemodialysis ppi levodopa|eszopiclone|in addition , patients on entity reported improved daytime alertness ( p less than 0 . 005 ) and improved daytime ability to function ( p less than 0 . 001 ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|bis cns 24 ol alkaloid|celecoxib haloperidol pregabalin atorvastatin ondansetron|eszopiclone|furthermore , patients treated with entity 2 mg reported significant improvements in daytime alertness ( p<0 . 03 ) and sense of physical well-being ( p<0 . 05 ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|bis cns 24 ol alkaloid|pesticides chemicals pharmaceuticals substances alkaloids|eszopiclone|we have entered into out-licensing arrangements with respect to the sale of entity outside of the united states , canada and mexico and with respect to several other compounds .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|bis cns 24 ol alkaloid|pharmaceutical final original intended commercial|eszopiclone|our entity product will be marketed by gsk in its territory primarily as lunivia® brand entity for the treatment of insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|drug|bis cns 24 ol alkaloid|placebo chemotherapy medication she radiotherapy|eszopiclone|no decline in therapeutic effect was observed on any outcome parameter over the course of the trial , and entity was well tolerated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|bis cns 24 ol alkaloid|ibuprofen paracetamol placebo acetaminophen theophylline|eszopiclone|upon approval of estorra , during which the fda would not approve an abbreviated new drug application for any product containing entity , the active ingredient of estorra .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|bis cns 24 ol alkaloid|generic tablet pharmaceutical tablets marketed|eszopiclone|has filed an abbreviated new drug application ( anda ) with the u . s . food and drug administration ( fda ) for generic versions of entity tablets ( 1 mg , 2 mg and 3 mg ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 2)])|drug|bis cns 24 ol alkaloid|fenofibrate statin eze pharmaceuticals rosiglitazone|eszopiclone|products that we launched in the united states during the year ended march 31 , 2015 : product innovatorsbrand innovator entity lunesta® seprocor fenofibrate capsules
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|bis cns 24 ol alkaloid|vi 50 h1n1 oh nd|eszopiclone|other branded prescription sleep aids include lunesta® ( entity ) , which was approved in december 2004 by the fda and launched in the first quarter of 2005 , and rozerem® ( ramelteon ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|bis cns 24 ol alkaloid|placebo paracetamol overdose acetaminophen aspirin|eszopiclone|in clinical trials with entity , one case of overdose with up to 36 mg of entity was reported in which the subject fully recovered .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|bis cns 24 ol alkaloid|brand name manufacturers users discovery|eszopiclone|the fda is currently reviewing our nda for estorra brand entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|bis cns 24 ol alkaloid|brand name price consumption choice|eszopiclone|as a result of this policy , we capitalized $1 , 735 , 000 of lunesta brand entity inventory during the first quarter of 2005 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|bis cns 24 ol alkaloid|pesticides pharmaceuticals alkaloids medicines chemicals|eszopiclone|we have entered into out-licensing arrangements with respect to the sale of entity in japan and with respect to several other compounds .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|bis cns 24 ol alkaloid|fda approved original updated recommended|eszopiclone|we cannot assure you that we adequately responded to the fdas concerns or that the entity nda will be approved .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|bis cns 24 ol alkaloid|50 oh 200 vi 111|eszopiclone|other branded prescription sleep aids include lunesta® ( entity ) , marketed by sepracor , inc . , which was approved in december 2004 by the fda and launched in the first quarter of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|bis cns 24 ol alkaloid|approval fda publication marketing users|eszopiclone|assuming favorable results from the ongoing studies , we anticipate submitting an nda for entity to the fda , in 2002 , which , if approved , we would market under the name estorra .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|bis cns 24 ol alkaloid|contained containing took comprised covered|eszopiclone|other events on april 4 , 2005 , sepracor commercially launched lunesta brand entity 1 mg , 2 mg and 3 mg tablets for the treatment of insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|bis cns 24 ol alkaloid|paracetamol acetaminophen morphine methadone buprenorphine|eszopiclone|individuals have fully recovered from racemic zopiclone overdoses up to 340 mg ( 56 times the maximum recommended dose of entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|atropine antagonist administered inhibits analogue|saline epinephrine morphine fentanyl bupivacaine|atropine|between august and october , 2010 , we reintroduced entity , morphine , dextrose , and epinephrine prefilled syringes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|atropine antagonist administered inhibits analogue|magnesium sodium chondroitin sulfate dextran|atropine|in november 2000 , we received our first fda approval to manufacture and sell diphenoxylate with entity sulfate tablets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|atropine antagonist administered inhibits analogue|magnesium chondroitin dehydroepiandrosterone protamine sulfate|atropine|for propranolol er driven by price , tempered by the impact of the second quarter 2017 launch of diphenoxylate hydrochloride and entity sulfate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|atropine antagonist administered inhibits analogue|approximately cream almost nearly inhibitor|atropine|while macrodose entity 1% is currently fda-approved for pupil dilation in the united states , its significant side effect profile has impeded clinical utility
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|atropine antagonist administered inhibits analogue|magnesium dextran chondroitin protamine sodium|atropine|trobigard is designed for intramuscular self- or buddy-administration of entity sulfate and obidoxime chloride for pre-hospital intervention .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|atropine antagonist administered inhibits analogue|topical aqueous sodium ophthalmic artificial|atropine|anticipated milestone : initiate and complete phase iii vision trials in 2020 about micropine for progressive myopia micropine ( entity ophthalmic solution )
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|atropine antagonist administered inhibits analogue|sodium ammonium magnesium dextran sulfate|atropine|“micropine product” means entity sulfate , as the sole active pharmaceutical ingredient , formulated and loaded into a cartridge for delivery using , and delivered by means
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|atropine antagonist administered inhibits analogue|iol bevacizumab myopia silicone lens|atropine|for example , our micropine program which is a micro-formulation of entity , is intended to slow myopia progression in the pediatric population .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|atropine antagonist administered inhibits analogue|pam dexamethasone diazepam nimodipine lidocaine|atropine|exposed to approximately 75% less nerve agent and then treated immediately with the current standard therapy , a three-drug cocktail of entity , 2-pam and diazepam .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|atropine antagonist administered inhibits analogue|fentanyl d4 buprenorphine dopamine methotrexate|atropine|contract by dod valued at up to approximately $23 million to develop a multi-drug auto-injector for nerve agent antidote delivery ( entity and pralidoxime chloride ) , which we refer to as d4 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|atropine antagonist administered inhibits analogue|therapies medications treatments perimetry medication|atropine|despite activity , safety concerns such as pupil dilation , photosensitivity and accommodation difficulties associated with standard entity , 1% have tempered initial clinical adoption .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|atropine antagonist administered inhibits analogue|bevacizumab antibiotics rapamycin ranibizumab curcumin|atropine|the first pipeline opportunity is micropine , which is a micro-therapeutic formulation of entity to target myopia ( or near sightedness ) progression .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|atropine antagonist administered inhibits analogue|bevacizumab antibiotics ranibizumab rapamycin medications|atropine|the first pipeline 4 table of contents opportunity is micropine , which is a micro-therapeutic formulation of entity to target myopia ( or near sightedness ) progression .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|atropine antagonist administered inhibits analogue|benzodiazepines steroids antidepressants corticosteroids theophylline|atropine|the standard of care for post-exposure treatment involves repeated doses of a cocktail of drugs including entity , oxime reactivators ( " 2-pam " ) and anti-convulsants .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|atropine antagonist administered inhibits analogue|iii physician who where medicine|atropine|the director ( nih od ) , and the ninds competition the current standard of care for nerve agent exposure is entity® and benzodiazepines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ophthalmic 24 trial 36 med|oh 50 bd fr 200|naldemedine| acquired rights to commercialize symproic® ( entity ) tablets 0 . 2 mg in the u . s . on april 4 , with bdsis sales force fully trained and actively promoting symproic as of may
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ophthalmic 24 trial 36 med|opioid naloxone morphine naltrexone efficacious|naldemedine|shionogi & co . is developing entity , another mu-opioid receptor antagonist , for patients with oic .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|methacholine airways inhaled inhalation asthma|50 60 90 max poc|methacholine|the only fda-approved direct test is provocholine® ( entity ) , marketed by methapharm inc .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|methacholine airways inhaled inhalation asthma|formaldehyde smoke mercury toluene vapour|methacholine|entity is inhaled as a vapour and causes bronchial constriction in asthmatic patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|methacholine airways inhaled inhalation asthma|histamine methacholine salbutamol nicotine acetylcholine|methacholine|the first category , known as direct challenge tests , use either histamine or entity to directly cause airway narrowing .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 3)])|drug|methacholine airways inhaled inhalation asthma|histamine aspirin zymosan lps acetylcholine|methacholine|the response from the direct tests ( entity and histamine ) are not dependent on the presence of inflammatory cells and their mediators and have a poor sensitivity for
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|drug|methacholine airways inhaled inhalation asthma|methacholine forced bronchial nasal bronchodilator|methacholine|volume in 1 second ( fev1 ) > 65% ;  increase in fev1 of at least 12% with bronchodilator use over baseline fev1 ;  entity challenge test with a pc20 £ 8mg / ml .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|methacholine airways inhaled inhalation asthma|allergen inhaled methacholine asthma airway|methacholine|entity challenge treatment differences ( pc20 ) performed 25h post-dose and 24h following an inhaled allergen challenge table 1 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|drug|methacholine airways inhaled inhalation asthma|allergen methacholine bronchial nasal allergic|methacholine|the primary phenotypes for analysis include lifetime history of asthma , age of asthma onset , entity challenge response , smoking history , and skin prick tests for twelve common allergens .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|methacholine airways inhaled inhalation asthma|methacholine placebo feno bronchodilator histamine|methacholine|aridol also had similar specificity to entity , ( 66% versus 70% respectively ) in subjects without exercise induced bronchoconstriction .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|methacholine airways inhaled inhalation asthma|methacholine nasal pulmonary bronchial forced|methacholine|efficacy will be evaluated using standard measures of respiratory function , e . g . , fev1 , entity challenge , serial spirometry .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|methacholine airways inhaled inhalation asthma|mannitol histamine saline dopamine epinephrine|methacholine|s . spector et al . , mannitol inhalational challenge : will it replace entity or histamine?
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|methacholine airways inhaled inhalation asthma|than into tracheal electrically smooth|methacholine|moreover , ck-2018571 relaxed entity pre-constricted tracheal rings in a concentration-dependent manner , suggesting its potential utility as a bronchodilator .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|methacholine airways inhaled inhalation asthma|methacholine forced nasal bronchial breath|methacholine|the 500 mg tid treatment group , including serial spirometry , morning and evening peak flow rates and pc20 values in a entity challenge test ( common measures of respiratory function ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|drug|methacholine airways inhaled inhalation asthma|airway bronchial allergen methacholine nasal|methacholine|· adding vi to ff also provided further reduction of ahr as measured by entity responsiveness 24h after the allergen provocation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|methacholine airways inhaled inhalation asthma|include includes requires require receive|methacholine|provocholine diagnosis of bronchial airway hyperactivity in subjects who do not have clinically apparent asthma entity chloride immunoglobulins ivig 5% treatment
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|methacholine airways inhaled inhalation asthma|cohort trials cohorts analyses purposes|methacholine|in comparison entity , an approved lung function test in the u . s . , identified 54% of cases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|methacholine airways inhaled inhalation asthma|histamine nicotine morphine dopamine oxytocin|methacholine|examples include entity and histamine .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|methacholine airways inhaled inhalation asthma|involving evaluating comparing assessing investigating|methacholine|to an individual or company to sell a product meta-analysis pooling and examining data from a number of studies entity inhalation test a test used in the diagnosis of asthma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|methacholine airways inhaled inhalation asthma|respectively placebo etc kit anova|methacholine|of 501 patients , and the study showed that aridol performed as well or better than the only currently approved test , entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|cytarabine chemotherapy agents administered infusion|morphine bupivacaine fentanyl lidocaine opioids|cytarabine|for safety reasons , continuous intrathecal infusion of entity is not a viable option .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|cytarabine chemotherapy agents administered infusion|doxorubicin cisplatin anthracycline paclitaxel gemcitabine|cytarabine|these patients typically receive frontline therapy , usually chemotherapy , including entity and an anthracycline , a therapy that has not changed in over 40 years .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|cytarabine chemotherapy agents administered infusion|liposomal iv liposome intravenous subcutaneous|cytarabine|products the products prepared for enzon by skyepharma are defined in the supply agreement including depocyt® , ( entity liposome injection , sky0101 ) formulation 1 . 5 ( us ) iii .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|cytarabine chemotherapy agents administered infusion|methotrexate cytarabine cyclophosphamide chemotherapy dexamethasone|cytarabine|% can be achieved , and patients with good-risk or standard-risk chromosomal changes will typically receive post-remission therapy with high dose entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|cytarabine chemotherapy agents administered infusion|methotrexate tacrolimus amiodarone metformin topiramate|cytarabine|entity is one of several drugs most commonly used for this therapy .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|cytarabine chemotherapy agents administered infusion|rituximab imatinib chemotherapy cetuximab paclitaxel|cytarabine|in may 2007 , our phase iii trial of onrigintm in combination with entity in relapsed aml was put on clinical hold by the fda after accrual of 268 patients .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|cytarabine chemotherapy agents administered infusion|methotrexate ara interferon cytarabine cyclophosphamide|cytarabine|from the trial showed positive safety and response rate data for subjects treated with a combination of motixafortide and high-dose entity ( ara-c ) , or hidac .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 2)])|drug|cytarabine chemotherapy agents administered infusion|rituximab chemotherapy imatinib crt cetuximab|cytarabine|an investigator-sponsored phase i / ii trial in combination with entity for elderly patients with previously untreated aml was initiated in may 2008 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|cytarabine chemotherapy agents administered infusion|gemcitabine oxaliplatin cisplatin doxorubicin paclitaxel|cytarabine|a number of nucleoside drugs , such as gemcitabine and entity , also known as ara-c , both generic drugs , are in wide use as conventional chemotherapies .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|cytarabine chemotherapy agents administered infusion|cytarabine chemotherapy methotrexate rituximab cyclophosphamide|cytarabine|is in the efficacy portion of a phase 2 clinical trial for acute myeloid leukemia ( “aml” ) in combination with low-dose entity ( “ldac” ) and in combination with decitabine .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|cytarabine chemotherapy agents administered infusion|corticosteroids mtx steroids prp methotrexate|cytarabine|because the therapeutic half-life of entity in the csf is relatively short , frequent and repeated injections are necessary for effective treatment .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|cytarabine chemotherapy agents administered infusion|placebo aspirin ibuprofen indomethacin diclofenac|cytarabine|certain compositions containing vosaroxin , with expiry in 2030 ; and · u . s . patent no . 7 , 968 , 565 claims a combination of vosaroxin and entity , with expiry in 2026 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 3), ('DIS', 2), ('OTHER', 2)])|drug|cytarabine chemotherapy agents administered infusion|placebo monotherapy comparator atorvastatin simvastatin|cytarabine|the rate of serious adverse events was 55 . 5% in the vosaroxin combination arm compared to 35 . 7% in the placebo and entity arm .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|cytarabine chemotherapy agents administered infusion|formulations immunotherapy dosing biologics therapies|cytarabine|clinical trials have demonstrated , however , that depocyt provides certain clinical advantages versus generic entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|cytarabine chemotherapy agents administered infusion|methotrexate cyclophosphamide dexamethasone cytarabine methylprednisolone|cytarabine|patients who achieve a cr after induction will go on to receive consolidation therapy with high dose entity ( hidac ) with ento or placebo as per their randomization assignment .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|cytarabine chemotherapy agents administered infusion|gemcitabine ribavirin paclitaxel everolimus thalidomide|cytarabine|a number of nucleoside drugs , such as gemcitabine , or gemzar® , from eli lilly , and entity , also known as ara-c , a generic drug , are in wide use as conventional chemotherapies .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|cytarabine chemotherapy agents administered infusion|doxorubicin cytarabine daunorubicin methotrexate paclitaxel|cytarabine|our lead product is vyxeostm , a nano-scale liposomal formulation of entity : daunorubicin , completed a phase 3 clinical trial for the treatment of acute myeloid leukemia ( aml ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|cytarabine chemotherapy agents administered infusion|administered started planned recommended conducted|cytarabine|high-intensity induction chemotherapy is typically entity plus an anthracycline ( so called 7+3 ) administered over a 28-day cycle .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|cytarabine chemotherapy agents administered infusion|rituximab imatinib chemotherapy cetuximab thalidomide|cytarabine|our phase iii trial of onrigintm in combination with entity in relapsed aml was put on clinical hold by the fda in may 2007 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|cytarabine chemotherapy agents administered infusion|rapamycin cisplatin p53 chloroquine testosterone|cytarabine|entity acts by inhibiting a vital enzyme in dna synthesis , resulting in death of a dividing cell .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|al mom fur cad vitamin|topical intravenous inhaled prophylactic intralesional|mometasone|three of the patients who responded received entity steroids tapered to zero by day 21 .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|al mom fur cad vitamin|dexamethasone steroids corticosteroids tacrolimus budesonide|mometasone|we are also developing a topical water-based hydrogel formulation of entity , a medium-potency steroid , primarily for the treatment of atopic dermatitis .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|al mom fur cad vitamin|sodium methyl vinyl potassium tenofovir|mometasone|to $160 million in the first six months of 2013 compared with the same periods of 2012 . global sales of dulera ( entity furoate / formoterol fumarate dihydrate )
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|al mom fur cad vitamin|budesonide placebo dexamethasone azithromycin mmf|mometasone|^ nasonex and entity are currently the only other intranasal steroids approved for the treatment of nasal polyps .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|al mom fur cad vitamin|synthetic injectable another biodegradable commercial|mometasone|we are currently in formulation development with entity hydrogel and expect to file an investigational new drug application , or ind , in 2006 .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|al mom fur cad vitamin|ics 50 111 ic iv|mometasone|indacaterol as a single agent and in combination with an ics ( entity ) , is being developed by novartis and schering-plough .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|al mom fur cad vitamin|sodium methyl ethyl potassium vinyl|mometasone|respiratory global sales of nasonex ( entity furoate monohydrate ) , an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms , increased 3% in the first quarter of
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|al mom fur cad vitamin|inhaled sodium budesonide triamcinolone chlorhexidine|mometasone|sc loading dose followed by q8w 150mg sc and ( iii ) placebo , in each case concomitant with 400 micrograms daily of entity furoate nasal spray .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|al mom fur cad vitamin|dexamethasone antidepressants morphine fluoxetine glucocorticoid|mometasone|crx-191 contains a mid-potency glucocorticoid , entity , and a very low dose of the tricyclic anti-depressant , nortriptyline .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|al mom fur cad vitamin|sodium acetate potassium ammonium ester|mometasone|a decision issued in june 2013 held that the merck patent covering entity furoate monohydrate was valid , but that it was not infringed by apotex corp . s proposed product .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|al mom fur cad vitamin|antidepressants steroids antidepressant amitriptyline morphine|mometasone|crx-191 contains a mid-potency glucocorticosteroid , entity , and a very low dose of the tricyclic anti-depressant , nortriptyline .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|al mom fur cad vitamin|inhaled nasal sodium topical intravenous|mometasone|patients are being treated with two multi-dosing frequencies of subcutaneously-administered etokimab or placebo , each in combination with entity furoate nasal spray as background therapy .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|al mom fur cad vitamin|budesonide salbutamol placebo dexamethasone aspirin|mometasone|sch 418131 , mff , is a combination of two previously approved drugs for the treatment of asthma : entity ( asmanex ) and formoterol ( foradil ) .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|al mom fur cad vitamin|topical cream herbal psoriasis ointment|mometasone|ovixan® is an improved prescription entity cream for the treatment of psoriasis and eczema , and oviderm® is a moisturizer for the treatment of dry skin .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|al mom fur cad vitamin|sodium budesonide methyl ethyl salbutamol|mometasone| qmf149 ( indacaterol acetate / entity furoate ) is a once daily fixed-dose combination being investigated in asthmatic patients who are uncontrolled on an inhaled corticosteroid .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|al mom fur cad vitamin|budesonide nicotine histamine cholesterol ige|mometasone|novartiss qvm-149 ( entity / glycopyrronium / indacaterol ) is under review by the ema for asthma .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|al mom fur cad vitamin|florida cotton lettuce california wood|mometasone|during the first quarter of 2004 is primarily due to the purchase of raw materials related to the eligard , atrisone , entity and fluticasone products .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|al mom fur cad vitamin|corticosteroids ics mmf adalimumab infliximab|mometasone|prior to treatment with nomacopan ( coversin ) , two out of the three patients were already on topical corticosteroids ( entity ) while a third was naïve to steroid treatment .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|al mom fur cad vitamin|placebo tacrolimus ribavirin budesonide abbott|mometasone|new combinations of formoterol with ciclesonide , fluticasone or entity are being developed by sanofi-aventis , abbott ( with skyepharma ) , and novartis ( with schering-plough ) respectively .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|al mom fur cad vitamin|nasal sodium budesonide topical chlorhexidine|mometasone|nasonex , or entity furoate nasal spray , is currently the only other branded ins approved by the fda for the treatment of nasal polyps .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|iv analogue metabolite hydrochloride alkaloid|lidocaine bupivacaine saline placebo ropivacaine|prilocaine|phn to receive the qutenza patch application after a 60-minute pretreatment with an fda-approved topical anesthetic ( 2 . 5% lidocaine / 2 . 5% entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|iv analogue metabolite hydrochloride alkaloid|lidocaine bupivacaine fentanyl ketamine paracetamol|prilocaine|psd502 is a unique , proprietary , rapidly absorbed formulation of two , well-established local anesthetics , lidocaine and entity , dispensed in a metered dose spray .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|iv analogue metabolite hydrochloride alkaloid|lidocaine saline bupivacaine placebo ketamine|prilocaine|emla ( lidocaine + entity ) is a local anaesthetic for topical application .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|iv analogue metabolite hydrochloride alkaloid|lidocaine bupivacaine fentanyl ketamine paracetamol|prilocaine|psd502 is a unique , proprietary , rapidly absorbed formulation of two well-established local anesthetics , lidocaine and entity , dispensed in a metered dose spray .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|iv analogue metabolite hydrochloride alkaloid|lidocaine bupivacaine diclofenac saline fentanyl|prilocaine|> emla ( lidocaine and entity ) is used as a local anaesthetic for topical application to prevent pain associated with injections and superficial surgical procedures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|iv analogue metabolite hydrochloride alkaloid|lidocaine bupivacaine saline placebo chlorhexidine|prilocaine|the skin permeation data compares a 2 . 5% lidocaine gel and the emla cream , which contains 2 . 5% lidocaine and 2 . 5% entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|iv analogue metabolite hydrochloride alkaloid|lidocaine cream placebo oil topical|prilocaine|this product in the third quarter of 2018 . on july 2 , 2018 , we announced approval of an anda for lidocaine and entity cream usp , 2 . 5% / 2 . 5% .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|iv analogue metabolite hydrochloride alkaloid|50 iv iii 111 max|prilocaine|local intracervical anesthetic block is achieved using 8 . 8 ml citanest ( entity ) with octapressin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|iv analogue metabolite hydrochloride alkaloid|lidocaine digoxin epinephrine paracetamol bupivacaine|prilocaine|in particular , the dojs subpoena to impax focused on four generic medications : digoxin tablets , terbutaline sulfate tablets , entity / lidocaine cream , and calcipotriene topical solution .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|iv analogue metabolite hydrochloride alkaloid|versus cream topical containing lidocaine|prilocaine|number of products marketed under lidocaine entity topical cream 1 number of product
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|iv analogue metabolite hydrochloride alkaloid|lidocaine bupivacaine saline placebo fentanyl|prilocaine|> emla ( lidocaine + entity ) is used as a local anaesthetic for topical application .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|iv analogue metabolite hydrochloride alkaloid|coated artificial topical subsurface hydrophilic|prilocaine|for example , one non-injectable , subsurface local anesthetic commercially available today is oraqix® ( lidocaine and entity periodontal gel ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|od bis iv ol 24|hcl iv containing sodium meth|dexrazoxane|totect&#xa0 ; &#xae ; &#xa0 ; ( entity hcl ) is a marketed , injectable treatment for anthracycline extravasation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|od bis iv ol 24|cyclosporine tacrolimus cyclosporin sirolimus methotrexate|dexrazoxane|bulk drug substances the muscle relaxants atracurium besylate , pancuronium bromide and vecuronium bromide , the immunosuppressant drug cyclosporine and the prodrug entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|od bis iv ol 24|sodium iv anthracycline platinum vinyl|dexrazoxane|totect® ( entity hcl ) is a marketed , injectable treatment for anthracycline extravasation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|od bis iv ol 24|intracellular iron anthracycline purine pyrimidine|dexrazoxane|entity metabolites trap the iron ions involved in the process which leads to myocardial damage caused by anthracycline oncolytic agents such as doxorubicin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|od bis iv ol 24|medicines farmers pharmaceuticals employees consumers|dexrazoxane|we launched totect during a national shortage of entity in late 2017 , resulting in strong initial demand for the product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|od bis iv ol 24|medline pubmed fda technology internet|dexrazoxane|entity is manufactured using a proprietary process covered by patents filed in several countries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|od bis iv ol 24|substances cannabinoids amphetamine cocaine caffeine|dexrazoxane|( f ) " cardioxane-trademark- " means the substance known by the chemical name of entity , and any analogues or derivatives thereof .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|od bis iv ol 24|prepared classified designed come published|dexrazoxane|sicor s . p . a . manufactures entity according to a proprietary process covered by process patents filed in many countries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|od bis iv ol 24|ibuprofen ketamine guanidine diclofenac hydrochloride|dexrazoxane|the companys entry into the oncology specialty includes two initial supportive care medications : ethyol® ( amifostine ) injection and totect® ( entity hydrochloride ) injection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|od bis iv ol 24|approved suitable recommended choice designed|dexrazoxane|zinecard ( r ) ( entity for injection ) sold in the u . s . and canada , is a preparation for reducing cardiac side effects in women with metastatic
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|od bis iv ol 24|companies company brand manufacturers employees|dexrazoxane|he oversaw the distribution of our new totect brand during a national shortage of entity resulting in many new customer relationships for the company .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|od bis iv ol 24|iv sodium anthracycline bismuth doxorubicin|dexrazoxane|apricus bio currently markets totect® ( entity hcl ) , the only drug approved in the us for the treatment of anthracycline extravasation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|od bis iv ol 24|formulations countries medicines formulation pharmaceuticals|dexrazoxane|sicor s . p . a . developed entity with chiron bv , including performing clinical trials , developing dosage form manufacturing , marketing and sales .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|od bis iv ol 24|original own market entire traditional|dexrazoxane|totect was acquired by clinigen in march 2016 to expand its entity portfolio and enter the u . s . market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|od bis iv ol 24|99m oh 111 50 200|dexrazoxane|” about totect® ( entity ) totect is an anthracycline extravasation agent approved by the united states food and drug administration .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|od bis iv ol 24|sodium iv doxorubicin cisplatin hcl|dexrazoxane|totect® ( entity hcl ) was approved by the fda in 2007 for the treatment of anthracycline extravasation , which is the leaking of chemotherapy
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|od bis iv ol 24|chemotherapy agents liposomes sirna adenovirus|dexrazoxane|administration of entity with such oncolytic agents protects tissues of the heart and allows for higher dosages of the oncolytic agent .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|od bis iv ol 24|99m 111 iv 125 oh|dexrazoxane|about totect® ( entity ) injectiontotect is an anthracycline extravasation agent approved by the fda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|od bis iv ol 24|original own market national entire|dexrazoxane|totect was acquired by clinigens specialty pharmaceuticals ( sp ) division in march 2016 to expand its entity portfolio for the u . s . market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|od bis iv ol 24|guanidine ketamine hydrochloride ibuprofen lidocaine|dexrazoxane|totect® cumberland announced fda approval of new labeling of totect® ( entity hydrochloride ) .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|phenylephrine receptors stimulated contracted endothelium|api substance pharmaceuticals metabolite metabolites|phenylephrine|each 5ml dose contains the api entity hci , pyrilamine maleate and dextromethorphan hbr .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|phenylephrine receptors stimulated contracted endothelium|ketorolac lidocaine ibuprofen acetaminophen methotrexate|phenylephrine|european medicines agencys committee for medicinal products for human use had adopted a positive opinion for omeros drug product omidria® ( entity and ketorolac injection ) 1% / 0 . 3% .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|phenylephrine receptors stimulated contracted endothelium|placebo theophylline paracetamol midazolam caffeine|phenylephrine|pse also competes against entity , an alternate nasal decongestant available in non-prescription products .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|phenylephrine receptors stimulated contracted endothelium|sodium iv hcl intravenous hypertonic|phenylephrine|biorphen ( entity hcl injection ) is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|phenylephrine receptors stimulated contracted endothelium|ketorolac diclofenac lidocaine topical paracetamol|phenylephrine|the companys drug product omidria® ( entity and ketorolac injection ) 1% / 0 . 3% is marketed for use during cataract surgery or intraocular lens ( iol ) replacement to maintain
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|phenylephrine receptors stimulated contracted endothelium|fuel market supply public pharmaceutical|phenylephrine|ongoing entity supply disruptions from 503b compounding facilities , including the announced shutdown of compounding industry leader pharmedium in january , have highlighted the
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|phenylephrine receptors stimulated contracted endothelium|paracetamol ibuprofen diclofenac phenytoin lidocaine|phenylephrine|otc products contain any one of several active ingredients including glycerin , entity , pramoxine , white petrolatum , shark liver oil and / or witch hazel , for symptomatic relief .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|phenylephrine receptors stimulated contracted endothelium|ketorolac topical bevacizumab lidocaine intravitreal|phenylephrine|our marketed drug product omidria® ( entity and ketorolac injection ) 1% / 0 . 3% was broadly launched in the u . s . in april 2015 for use during cataract surgery or intraocular
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|phenylephrine receptors stimulated contracted endothelium|diltiazem verapamil nifedipine digoxin ibuprofen|phenylephrine|ventrus is also required to reimburse s . l . a . for clinical development costs associated with the technology development of both diltiazem and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|phenylephrine receptors stimulated contracted endothelium|diltiazem verapamil nifedipine ibuprofen clopidogrel|phenylephrine|is also required to reimburse s . l . a . pharma for clinical development costs associated with the technology development of both diltiazem and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|phenylephrine receptors stimulated contracted endothelium|paracetamol acetaminophen ibuprofen morphine lidocaine|phenylephrine|these products generally contain active ingredients such as acetaminophen , dextromethorphan , diphenhydramine , guaifenesin , loratadine , entity , and pseudoephedrine .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|phenylephrine receptors stimulated contracted endothelium|zinc sodium silicone sol chlorhexidine|phenylephrine|: 267  270 , 1999 normal subjects , entity gel ( 5% , 10% , 20% , 30% ) applied once to anal verge resting anal pressure increased by 8% to 33% , effect
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|phenylephrine receptors stimulated contracted endothelium|hcl paracetamol diclofenac ibuprofen guanidine|phenylephrine|aldex ct is an antihistamine / decongestant combination administered orally in a chewable tablet form containing the api diphenhydramine hcl and entity hcl .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|phenylephrine receptors stimulated contracted endothelium|ketorolac lidocaine diclofenac ibuprofen topical|phenylephrine|our marketed drug product omidria™ ( entity and ketorolac injection ) 1% / 0 . 3% is approved in the u . s . for use during cataract surgery or intraocular lens , or iol , replacement
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|phenylephrine receptors stimulated contracted endothelium|aqueous diluted nacl peg ce|phenylephrine|microdose delivery of entity 10% ( pe - µd ) was associated with significantly less systemic exposure than traditional eye drops ( pe 10% ) .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|phenylephrine receptors stimulated contracted endothelium|ketorolac acetaminophen paracetamol ibuprofen morphine|phenylephrine|application seeking approval from the u . s . food and drug administration to market a generic version of the companys drug omidria® ( entity and ketorolac injection ) 1% / 0 . 3% .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|phenylephrine receptors stimulated contracted endothelium|hydrochloride guanidine lidocaine ketamine diclofenac|phenylephrine|on june 28 , 2013 , the group filed an nda for vazculep ( entity hydrochloride injection ) .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|phenylephrine receptors stimulated contracted endothelium|zinc transdermal gelatin silicone topical|phenylephrine|entity gel ( ven 308 ) for the treatment of fecal incontinence associated with ileal pouch anal anastomosis , an fda orphan indication .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 1)])|drug|phenylephrine receptors stimulated contracted endothelium|bevacizumab curcumin minocycline antibiotics vancomycin|phenylephrine|because of the extensive patient exposure to entity , we intend to develop ven 308 as a topical formulation through a section 505 ( b ) nda .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|phenylephrine receptors stimulated contracted endothelium|zinc sodium silicone sol gel|phenylephrine|: 267 - 270 , 1999 normal subjects , entity gel ( 5% , 10% , 20% , 30% ) applied once to anal verge resting anal pressure increased by 8% to 33% , effect
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|placebo sham empty alternating triple|pemetrexed|in the th-302 plus entity arm , th-302 is administered intravenously on days 1 and 8 of a 21 day cycle .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|usa placebo france uk fda|pemetrexed|obtain approval for talotrexin , we will compete with existing antifolate therapies currently being sold by pfizer ( trimetrexate ) , eli lilly & co . ( entity ) and novartis ( edatrexate ) .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|m2 wt dt al min|pemetrexed|pth-305 : nsclc ( w / entity ) 2 / 2006 to 6 / 2007 400 , 600 136 138 os was lower in talabostat vs placebo .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|ep paclitaxel ibuprofen liposomes chitosan|pemetrexed|eagle  s solution : ep-5101 ( pemfexy™ ) ep-5101 is an rtd liquid formulation of entity .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|carboplatin gemcitabine paclitaxel rituximab cyclophosphamide|pemetrexed|interim data conducted on a small number of patients showed encouraging response rates with the combination of carboplatin , entity and bavituximab .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|docetaxel paclitaxel gemcitabine cisplatin doxorubicin|pemetrexed|administered as monotherapies , these include entity ( alimta® ) , docetaxel ( taxotere® ) , or erlotinib ( tarceva® ) .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|carboplatin paclitaxel cisplatin platinum etoposide|pemetrexed|the addition of apatorsen to carboplatin and entity therapy did not demonstrate an overall survival benefit in the study ( hr= 1 . 067 ; 80% ci : 0 . 838-1 . 359 ) .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|finally furthermore here additionally next|pemetrexed|entity , supply agreement term sheet in december 2016 , we entered into a binding term sheet with nang-kuang pharmaceutical co . , ltd and
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|docetaxel gemcitabine cisplatin paclitaxel carboplatin|pemetrexed|of the thirty-two patients with relapsed or refractory nsclc treated with th-302 in combination with either docetaxel or entity , eight patients achieved prs and fourteen patients achieved sd .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|carboplatin paclitaxel gemcitabine cisplatin docetaxel|pemetrexed|·a phase ib ist evaluating bavituximab in combination with carboplatin and entity in up to 25 patients with previously untreated stage iv nsclc .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|docetaxel cisplatin paclitaxel gemcitabine doxorubicin|pemetrexed|with docetaxel in metastatic squamous nsclc that has progressed after previous therapy ( arm b ) ; or · in combination with entity and cisplatin in mesothelioma ( arm c ) .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|ibuprofen methotrexate she tacrolimus vancomycin|pemetrexed|entity is dosed according to its package insert .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|medicine medicines market marketing technology|pemetrexed|which we allege infringement against apotex inc . ( apotex ) in response to its application to market products using alternative forms of entity .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|carboplatin paclitaxel neoadjuvant cisplatin salvage|pemetrexed|the aim of the trial is to determine if adding apatorsen to carboplatin and entity therapy could extend pfs outcome .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|placebo aspirin adalimumab bevacizumab tacrolimus|pemetrexed|the second 400-patient trial , evaluating the combination of talabostat with entity versus placebo and entity opened to enrollment in february 2006 .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|erlotinib bevacizumab everolimus gefitinib cetuximab|pemetrexed|each study will combine pf-3512676 with either avastin® ( bevacizumab ) , erbitux® ( erlotinib ) or alimta® ( entity ) .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|weekly concurrently chemotherapy continuously sequentially|pemetrexed|patients continued entity with weekly apatorsen or placebo infusions as maintenance treatment until disease progression if they completed a minimum of 3 cycles of chemotherapy treatment .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|usa placebo uk france germany|pemetrexed|some of our competitors include pfizer ( trimetrexate ) , eli lilly & co . ( entity ) , novartis ( edatrexate ) , and allos ( pdx ) , respectively .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|chemotherapy monotherapy hemodialysis egfr remission|pemetrexed|strata 1 and 3 also had maintenance entity or continued egfr-tki therapy , respectively .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|chemotherapy carboplatin irinotecan pharmacokinetics cisplatin|carboplatin paclitaxel gemcitabine cisplatin docetaxel|pemetrexed|the denali trial is testing demcizumab with entity and carboplatin versus entity and carboplatin alone in first-line advanced non-small cell lung cancer patients .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|antibiotics inhibitor analogue antagonist hormone|nor versus containing formulation except|moxidectin|both products  entity formulations offer numerous advantages over traditional deworming agents .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|antibiotics inhibitor analogue antagonist hormone|promising synthetic medicinal suitable pharmaceutical|moxidectin|cydectin , a entity product to control parasites in animals , will have patent protection until at least 2011 .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|antibiotics inhibitor analogue antagonist hormone|formulation gel topical subcutaneous tablet|moxidectin|the first entity formulation for horses , equest gel , was launched in new zealand .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|placebo upper original older closed|oxaliplatin|this data represents a five-fold improvement to results seen from the entity arm of the study .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|mortality future added predicting incremental|oxaliplatin|also performed a gene identification study which analyzed over 700 new genes , and identified 16 genes as being predictive of entity benefit for use in patients with stage iii disease .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|generic medicines pharmaceuticals them brand|oxaliplatin|in 2010 ) , following a court ruling barring manufacturers of generics in the u . s . from selling their unapproved generic versions of entity from june 30 , 2010 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|capecitabine oxaliplatin docetaxel gemcitabine cisplatin|oxaliplatin|currently in clinical trials , including trials for hormone refractory prostate cancer , inoperable liver cancer , and in combination with capecitabine or entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|chemotherapy docetaxel oxaliplatin anthracycline cisplatin|oxaliplatin|the company began offering the oncotype dx colon cancer test for use in patients with stage iii disease treated with entity containing adjuvant therapy .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|capecitabine oxaliplatin fluorouracil gemcitabine irinotecan|oxaliplatin|other chemotherapies include capecitabine ( xeloda® ) , entity ( eloxatin® ) , fluorouracil or leucovorin .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|medicines manufacturers pharmaceuticals them medications|oxaliplatin|in the first half of 2010 ) after a court ruling barred generics manufacturers from selling their unauthorized generic versions of entity in the united states from june 30 , 2010 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|neoadjuvant chemotherapy sequential triple adjuvant|oxaliplatin|two weeks in patients with advanced non-small cell lung cancer ; and ø a u . s . phase iii trial in patients undergoing treatment with entity regimens for advanced colorectal cancer .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|paclitaxel saline mtx ptx dox|oxaliplatin|marketed products in oncology include padexol injection ( paclitaxel ) , didox capsule ( doxifluridine ) , oxp injection ( entity ) and crabcan injection ( irrinotecan ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|paclitaxel cisplatin everolimus docetaxel doxorubicin|oxaliplatin|entity , a formulation of dach platinum , is a chemotherapeutic which was initially approved in france and in europe in 1999 for
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|company fuel safety oil tobacco|oxaliplatin|on june 30 , 2010 , the company ceased selling sun pharmas entity product in the united states market , pending the appeal .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|carboplatin paclitaxel cisplatin docetaxel gemcitabine|oxaliplatin|the originator of the drug , and several generic manufacturers ; ▪ carboplatin , marketed by bristol-myers squibb in the us ; and ▪ entity , marketed exclusively by sanofi-aventis .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|intravenous between subcutaneous intramuscular ip|oxaliplatin|entity injection 50mg / 10ml and 100mg / 20ml are the ab-rated generic versions of eloxatin® , which had annual sales of approximately $1 . 4 billion for
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|gemcitabine oxaliplatin cisplatin paclitaxel docetaxel|oxaliplatin|other combinations of gemcitabine with cisplatin , entity , irinotecan or docetaxel tested in phase 3 trials have not been of superior benefit to gemcitabine alone .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|oxaliplatin irinotecan gemcitabine capecitabine doxorubicin|oxaliplatin|for most patients , initial chemotherapy is based on folfox ( 5-fu , leucovorin and entity ) , or similar agents .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|pharmaceuticals medicines medications materials tablets|oxaliplatin|the growth was driven by an increase in specialty injectable pharmaceuticals , primarily a result of the third-quarter launch of entity in solution form in the united states .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|50 gemcitabine cisplatin 25 40|oxaliplatin|demonstrated preliminary evidence of efficacy but grade 2 innate immune adverse effects were seen with standard doses of gemcitabine and entity and 10 µg / kg doses of mt-3724 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|paclitaxel cisplatin gemcitabine platinum docetaxel|oxaliplatin|aroplatin aroplatin is a novel liposomal formulation of a third-generation platinum chemotherapeutic structurally similar to entity , a recently approved treatment for colorectal cancer .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|into commercial intravenous syringe subcutaneous|oxaliplatin|on august 11 , 2009 , teva commenced sales of its 50mg / 10ml and 100mg / 20ml entity injection products .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|oxaliplatin pharmacokinetics evaluate anticancer administered|paclitaxel cisplatin docetaxel everolimus doxorubicin|oxaliplatin|entity , a compound of dach platinum , is a chemotherapeutic which was initially approved in europe in 1999 for the treatment of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|drug|infusion administered levo than analogue|hormone renal thyroid steroid glucocorticoid|levothyroxine|skin reactions , hypothyroidism in patients taking entity replacement , gi perforation , in some cases fatal and tumor lysis syndrome , which can be life threatening , have also been reported
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|infusion administered levo than analogue|sodium containing prescription commercial regular|levothyroxine|levoxylò ( entity sodium tablets , usp ) net sales decreased to $26 million during the second quarter ended june 30 , 2007 from $29 million during the second
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|infusion administered levo than analogue|marketed generic commercial pharmaceutical synthetic|levothyroxine|if the fda were to determine that another entity sodium product is bioequivalent to levoxyl® , generic substitution for levoxyl® may become possible which could result in a decrease in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|infusion administered levo than analogue|commercial fda pharmaceutical safe european|levothyroxine|could be affected by future actions of the fda and by uncertainty in the entity sodium product market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|infusion administered levo than analogue|colleagues physicians medicare guidelines hospitals|levothyroxine|of upfront payment represents the amortization of the upfront payment made to lannett in connection with our transition agreement with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|infusion administered levo than analogue|sodium containing weekly prescription regular|levothyroxine|levoxylò ( entity sodium tablets , usp ) net sales totaled $32 million during the fourth quarter and $100 million for the year ended december 31 , 2007 , compared
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|infusion administered levo than analogue|original commercial final tablet placebo|levothyroxine|in december 2004 , the entity sodium tablet product received the ab rating to synthroid® .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|infusion administered levo than analogue|intravenous sodium injectable parenteral commercial|levothyroxine|on august 14 , 1997 , the fda announced in the federal register ( 62 fr 43535 ) that orally administered entity sodium drug products are new drugs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|infusion administered levo than analogue|sodium containing intravenous regular injectable|levothyroxine|net sales of levoxyl ( r ) ( entity sodium tablets , usp ) equaled $28 . 7 million during the first quarter ended march 31 , 2004 , a decrease of 14% from $33 . 2
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|infusion administered levo than analogue|medicines tobacco sugar drinks cigarettes|levothyroxine|volumes were favorably impacted due to increased sales of entity as customer demand increased in anticipation of the transition of the product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|infusion administered levo than analogue|plans art success transitions leadership|levothyroxine|complementing our second quarter performance was a well-executed plan associated with the transition of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|infusion administered levo than analogue|fentanyl intravenous propofol diclofenac sodium|levothyroxine|nitrofurantoin during our 180-day exclusivity period ; the delay in the launch of our fentanyl product and the regulatory actions surrounding entity sodium .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|infusion administered levo than analogue|intravenous sodium potassium parenteral injectable|levothyroxine|worldwide agreement with jerome stevens pharmaceuticals , inc . to market and distribute jerome stevens  nda ( new drug application ) approved form of entity sodium , usp tablets .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|infusion administered levo than analogue|sodium injectable prescription regular potassium|levothyroxine|of $2 , 220 , 931 due to an improvement in timely collections , and the launch of the company  s new product sales campaign for entity sodium tablets in april 2003 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|infusion administered levo than analogue|intravenous sodium injectable parenteral commercial|levothyroxine|drug administration , which we refer to as the fda ,  announced in the federal register ( 62 fr 43535 ) that orally administered entity sodium drug products are new drugs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|infusion administered levo than analogue|sodium regular generic commercial intravenous|levothyroxine|this dual approval will now allow pharmacists to substitute entity sodium tablets for both dominant brands .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|infusion administered levo than analogue|sodium potassium magnesium vitamin thyroxine|levothyroxine|thyromed chewable tablets contain the active ingredient entity sodium , which is a clinically proven replacement for the naturally occurring hormone secreted by the thyroid gland .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|infusion administered levo than analogue|adequate intravenous sodium supplemental sufficient|levothyroxine|these chewable tablets , which are administered daily for the life of the dog , provide entity sodium , a replacement therapy for the hormone normally produced by the dog .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|infusion administered levo than analogue|medicare physicians hospitals medicaid reimbursement|levothyroxine|of upfront payment represents the amortization of the upfront payment made to lannett in connection with our transition agreement for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|infusion administered levo than analogue|generic commercial synthetic pharmaceutical fluorinated|levothyroxine|application for an equivalent product after august 14 , 2001 must submit an anda seeking approval of a generic substitute for a entity sodium product with an approved nda .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|neomycin resistant antibiotic plasmid mutants|placebo cream triamcinolone corticosteroid ointment|neomycin|triamcinolone acetonide and entity paste used for neurodermatitis circumscripta and chronic eczema .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|neomycin resistant antibiotic plasmid mutants|tobramycin gentamicin amikacin ciprofloxacin doxycycline|neomycin|existing drugs , such as tobramycin , entity , zithromax® and zyvox® , demonstrate that successful medicines can modulate rna function .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5)])|drug|neomycin resistant antibiotic plasmid mutants|tetracycline chloramphenicol streptomycin erythromycin ampicillin|neomycin|our products that contain virginiamycin , oxytetracycline or entity are classified by the fda as medically important antimicrobials .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5)])|drug|neomycin resistant antibiotic plasmid mutants|tetracycline erythromycin streptomycin gentamicin ampicillin|neomycin|our products that contain virginiamycin , oxytetracycline or entity have previously been classified by the fda as medically important antibacterials .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|neomycin resistant antibiotic plasmid mutants|magnesium chondroitin dextran ammonium polymyxin|neomycin|neoflo is a dressing that incorporates the triple antibiotic , polymyxin b sulfate , bacitracin zinc and entity sulfate .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|neomycin resistant antibiotic plasmid mutants|ciprofloxacin metronidazole amoxicillin vancomycin tetracycline|neomycin|the company believes that current antibiotic therapies , including entity and metronidazole , are inadequate treatments , however , due to their limited antibacterial spectrum and side effects .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|drug|neomycin resistant antibiotic plasmid mutants|aaa placebo normals glutamine hc|neomycin|the abnormal plasma amino acid pattern characterized by decreased levels of bcaas and elevated levels of aaas , as compared to entity , which was used as an active control .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|neomycin resistant antibiotic plasmid mutants|steroids corticosteroids prednisolone dexamethasone mtx|neomycin|nexavar exposure decreases when coadministered with oral entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5)])|drug|neomycin resistant antibiotic plasmid mutants|tetracycline erythromycin streptomycin gentamicin chloramphenicol|neomycin|our products that contain virginiamycin , oxytetracycline or entity have previously been classified by the fda as medically important antimicrobials .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|neomycin resistant antibiotic plasmid mutants|magnesium chondroitin ammonium dextran sulfate|neomycin|neoflo is a dressing that incorporates the triple antibiotic , polymyxin b sulfate , bacitracin zinc and entity sulfate ( neosporin-registered trademark- ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|ade mcr df rv rr|tenofovir|the later stages of the phase iii clinical trials for adefovir dipivoxil will not arise in the clinical trials for entity df or that we will achieve adequate treatment benefits .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|hcv tt art vire hbv|tenofovir|initiate in 2017 the phase 2b clinical trial to evaluate sb 9200 as a monotherapy and in combination with viread ( entity ) targeting approximately 200 patients with chronic hbv .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('DIS', 1), ('OTHER', 1)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|curcumin ketoconazole etanercept ciprofloxacin infliximab|tenofovir|entity has potent activity against chronic hepatitis b . it is particularly useful in patients who have developed drug resistance to other
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|tenofovir fumarate sodium dimethyl methyl|tenofovir|unenforceable and / or will not be infringed by teva  s manufacture , use or sale of a generic fixed-dose combination of emtricitabine and entity disoproxil fumarate .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|lamivudine tenofovir ribavirin efavirenz zidovudine|tenofovir|the most commonly used therapy for chronic hbv is life-long suppressive therapy with nrtis , like entity or entecavir .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|tenofovir sodium fumarate methyl containing|tenofovir| viread sales of viread® ( entity disoproxil fumarate ) were $189 . 4 million in the third quarter of 2005 , a two percent decrease from $193 . 9 million in the
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|haart art infections hcv relapse|tenofovir|use of viread should be considered for treating adult patients with hiv-1 strains that are expected to be susceptible to entity as assessed by laboratory testing or treatment history .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|ftc tdf azt nt art|tenofovir|nrtis , such as epivir ( 3tc ) , emtriva ( ftc ) , viread ( entity ) , retrovir ( azt ) and zerit ( d4t ) , have become the predominant class of drugs in hiv therapy .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|das derivative named thym cyclosporin|tenofovir|txl is a highly potent analog of the antiviral drug entity df ( viread® ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|intravenous iv sodium m2 liposomal|tenofovir|which gilead is funding and conducting a phase 2 clinical trial examining the co-administration of inarigivir and vemlidy® 25 mg ( entity alafenamide ) in patients infected with chronic hbv .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|our what national how international|tenofovir|addendum to entity disoproxil fumarate manufacturing supply agreement the parties hereby acknowledge and agree to the following :
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|doxorubicin rapamycin respectively ribavirin hcv|tenofovir|nucleotide compound , uses the same proprietary lipid technology as cmx001 to deliver high intracellular concentrations of another potent antiviral drug , entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|fumarate synthetic methyl sodium tenofovir|tenofovir|and in april 2013 , gilead and teva reached an agreement in principle to settle the lawsuit on the patents covering entity disoproxil fumarate contained in the atripla*
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|basis previous own rule opinion|tenofovir|we cannot predict the outcome of these proceedings on our entity df patent application .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|medicines services resources formulations pharmaceuticals|tenofovir|in addition , in late 2011 , generic entity also became available in turkey , which resulted in an increase in the rebate for viread in turkey .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|although while nucleoside whereas iv|tenofovir|entity df is in the same class of drugs as adefovir dipivoxil .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|tdf tenofovir placebo healthy ftc|tenofovir|of cmx157 in healthy volunteers and are on track to complete the ongoing phase 2a head-to-head study of cmx157 vs . entity df ( tdf , gileads viread® ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|tenofovir lamivudine efavirenz ritonavir zidovudine|tenofovir|entity and entecavir have emerged as the standard of care in this disease with very low rates of resistance over five
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|interferon ribavirin ifn pegylated peg|tenofovir|the replicor 401 study , a study of naps in combination with entity and pegylated interferon , reported a 39% functional cure rate .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|tenofovir fumarate efavirenz ritonavir lamivudine|tenofovir fumarate sodium nucleoside ornithine|tenofovir|in the notice related to teva  s anda for a generic version of truvada , teva challenged four patents related to entity disoproxil fumarate and two additional patents related to emtricitabine .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|m2 ami cisplatin trial agent|methotrexate dexamethasone radiotherapy glucocorticoids steroids|amifostine|we are also aware of research relating to the use of high doses of entity ( a drug used to control some of the side effects of chemotherapy and radiation therapy ) for the protection of hearing
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|m2 ami cisplatin trial agent|docetaxel paclitaxel doxorubicin gemcitabine cisplatin|amifostine|he played key consulting roles in registration strategy and post-registration development of recent products such as entity , docetaxel , cpt-11 and irofulven .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|m2 ami cisplatin trial agent|ci dd tc dv gm|amifostine|we anticipate that ethyolregistered trademark ( entity ) will be a meaningful product for medimmune following our merger .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|m2 ami cisplatin trial agent|cds ts bt ci fda|amifostine|sales of ethyol-registered trademark- ( entity ) increased 48% and 23% for the quarter and six months ended june 30 , 1999 , respectively , compared to the same periods
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|m2 ami cisplatin trial agent|111 50 200 60 iii|amifostine|medical applications the arsenal of medical radiation-protectors is limited to ethyol™ ( entity ) , sold by medimmune , and acquired by astrazeneca international .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|m2 ami cisplatin trial agent|fda aca isa uk pan|amifostine|mycelex-registered trademark- ( clotrimazole ) troche , which alza began marketing in the second half of 1997 , and increased sales of ethyol-registered trademark- ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|m2 ami cisplatin trial agent|cisplatin paclitaxel gemcitabine bortezomib doxorubicin|amifostine|entity ( ethyolâ ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity associated with repeated administration of cisplatin
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|drug|m2 ami cisplatin trial agent|chemotherapy radiotherapy cisplatin methotrexate platinum|amifostine|we are also aware of research relating to the use of high dose entity for the protection of hearing in connection with platinum-based chemotherapy .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|m2 ami cisplatin trial agent|intranasal intravenous rabbit equine bovine|amifostine|we market synagis ( palivizumab ) , flumist ( influenza virus vaccine live , intranasal ) , ethyol ( entity ) and cytogam ( cytomegalovirus immune globulin intravenous ( human ) ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|m2 ami cisplatin trial agent|eth inh vi oc bz|amifostine|sun pharmaceutical industries limited has submitted an abbreviated new drug application to the fda for a generic version of ethyol ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|m2 ami cisplatin trial agent|cisplatin paclitaxel gemcitabine bortezomib doxorubicin|amifostine|entity ( ethyol® ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity associated with repeated administration of cisplatin
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|m2 ami cisplatin trial agent|rabbit bovine eth intravenous murine|amifostine|the company markets synagis ( palivizumab ) , ethyol ( entity ) , and cytogam ( cytomegalovirus immune globulin intravenous ( human ) ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|m2 ami cisplatin trial agent|respectively etc tacrolimus cyclophosphamide fda|amifostine|neupogen ( r ) currently faces market competition from a competing csf product , granulocyte macrophage colony stimulating factor ( " gm-csf " ) and from the chemoprotectant , entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|m2 ami cisplatin trial agent|paclitaxel gemcitabine doxorubicin cisplatin docetaxel|amifostine|entity ( ethyol® ) is approved by the fda as a radioprotector .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|m2 ami cisplatin trial agent|fda cds cdc cps who|amifostine|in december 1995 , alza entered into a marketing and distribution agreement with u . s . bioscience , inc . ( " u . s . bioscience " ) for ethyol-registered trademark- ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|m2 ami cisplatin trial agent|resveratrol curcumin bortezomib paclitaxel aluminum|amifostine|entity ( ethyol® ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity and radiation-induced xerostomia ( damage to the
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|m2 ami cisplatin trial agent|cisplatin paclitaxel doxorubicin gemcitabine docetaxel|amifostine|entity ( ethyol ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity associated with repeated administration of cisplatin
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|m2 ami cisplatin trial agent|fda approved everolimus presently sirolimus|amifostine|there is one drug , entity , approved for use in reducing side effects from radiation therapy .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|m2 ami cisplatin trial agent|docetaxel paclitaxel doxorubicin gemcitabine cisplatin|amifostine|he played key consulting roles in registration strategy and post-registration development of recent products such as entity , docetaxel , cpt-11 , and irofulven .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|m2 ami cisplatin trial agent|50 200 60 90 21|amifostine|product sales of $66 million , including $33 million in worldwide sales of synagis and $25 million in sales of ethyol® ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|hydrocortisone administered rats steroids analogue|lidocaine bupivacaine morphine paracetamol propofol|hydrocortisone|· igi will formulate four combination products of entity and lidocaine at different strengths : 1 .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 3), ('DIS', 1), ('DRUG', 1)])|drug|hydrocortisone administered rats steroids analogue|ic50 incubation curcumin sirna pdt|hydrocortisone|at 4 µm , 42% at 8 µm and 52% at 16 µm . therefore , the ic50 was 16 µm . by comparison , entity at 10 µm caused a 54% reduction in il-8 expression .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|hydrocortisone administered rats steroids analogue|hydrocortisone dexamethasone placebo tacrolimus budesonide|hydrocortisone|in canada , 0 . 5% entity , a common anti-inflammatory product , described in the monograph , hydrocortisone topical published by health canada on january 22 , 2007 , can be
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|hydrocortisone administered rats steroids analogue|placebo tablet ie eg original|hydrocortisone|on november 15 , 2011 , we acquired rights to plenadren® ( entity , modified release tablet ) for treatment of ai .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|hydrocortisone administered rats steroids analogue|topical cream sodium sublingual subcutaneous|hydrocortisone|entity rectal cream is used for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|hydrocortisone administered rats steroids analogue|ketoconazole amphotericin itraconazole prednisone cyclosporine|hydrocortisone|discuss how fda views our package of the us experience with ketoconazole and entity combination and discuss how much value in the historical experience will be accepted .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|hydrocortisone administered rats steroids analogue|sodium methyl ethyl potassium dietary|hydrocortisone|this was partially offset by the product launch of entity butyrate lotion .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|hydrocortisone administered rats steroids analogue|sulfamethoxazole trimethoprim antibiotics ciprofloxacin rifampicin|hydrocortisone|the launch of entity with acetic acid along with strong sales of sulfamethoxazole with trimethoprim and fluticasone propionate nasal spray also contributed to the
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|hydrocortisone administered rats steroids analogue|topical ointment cream ophthalmic placebo|hydrocortisone|-jun-11 t36® 0 . 5% entity ointment 80026139 30-jun-11 pedia-safe polyvitamin drops1 80001571 05-apr-06 ferroheme2 1 licensed to the company by canagen in an agreement dated
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|drug|hydrocortisone administered rats steroids analogue|placebo indomethacin celecoxib lps tac|hydrocortisone|cbn was similar to entity with respect to anti-inflammatory activity in this model .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|hydrocortisone administered rats steroids analogue|analgesic anesthetic placebo analgesics lidocaine|hydrocortisone|anamantlehc , launched in january 2003 , is a prescription cream containing a topical anesthetic and entity , which treats hemorrhoids and anal fissures .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|hydrocortisone administered rats steroids analogue|diclofenac tacrolimus ibuprofen placebo psoriasis|hydrocortisone|the combination of aloe vera and entity offers therapeutic benefits for skin irritations such as minor burns , allergic itch , insect bite itch , sun burn itch , eczema in
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|hydrocortisone administered rats steroids analogue|intravenous intrathecal intra injections morphine|hydrocortisone|entity injection toxic symptom caused by various infections , hypocorticoidism caused by various infections , anaphylactic shock .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|hydrocortisone administered rats steroids analogue|tablet tablets sodium placebo pharmaceutical|hydrocortisone|cma issued a statement of objections to a third party and the company in relation to the supply of 10mg entity tablets in the u . k . between 2013 and 2016 .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|hydrocortisone administered rats steroids analogue|nacl dextrose methanol starch glycerol|hydrocortisone|both products are formulated with aloe vera and cortiveraä contains 0 . 5% entity and cortivera plusä contains 1% entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|hydrocortisone administered rats steroids analogue|commercial topical suitable cream promising|hydrocortisone|formulation design up to 8 78 , 600 · igi will formulate a entity cream product .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|hydrocortisone administered rats steroids analogue|cytokines antioxidants peptides flavonoids antioxidant|hydrocortisone|lidamantle®hc also contains entity , which helps to reduce inflammation .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 4)])|drug|rosiglitazone hepatic renal diabetic antagonist|metformin pioglitazone aspirin clopidogrel sulfonyl|rosiglitazone|commonly prescribed drugs include diabetic medicines such as metformin , entity and sulfonylurea .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|rosiglitazone hepatic renal diabetic antagonist|av hh vi bd eu|rosiglitazone|for the district of colorado into the group  s us sales and promotional practices and for product liability cases regarding avandia ( entity ) .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|rosiglitazone hepatic renal diabetic antagonist|docetaxel paclitaxel everolimus placebo sirolimus|rosiglitazone|a fixed combination product of starlix and entity was approved by fda in 2003 .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 2)])|drug|rosiglitazone hepatic renal diabetic antagonist|pioglitazone metformin rosiglitazone sirolimus placebo|rosiglitazone|will compete with cs-917 include the insulin sensitizers actos , or pioglitazone , co-marketed by takeda and eli lilly , and avandia , or entity , marketed by glaxosmithkline .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('DIS', 3), ('OTHER', 3)])|drug|rosiglitazone hepatic renal diabetic antagonist|metformin pioglitazone placebo rosiglitazone rosuvastatin|rosiglitazone|cvr number : 24256790 the three lead® studies showed that liraglutide in combination with either glimepiride or metformin or metformin and entity is well tolerated .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('DIS', 3), ('OTHER', 2)])|drug|rosiglitazone hepatic renal diabetic antagonist|metformin placebo pioglitazone rosiglitazone atorvastatin|rosiglitazone|the study investigated the effect of different doses of liraglutide in combination with metformin and entity , and included 533 patients with type 2 diabetes .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|rosiglitazone hepatic renal diabetic antagonist|garlic sodium choice arginine hydrochlorothiazide|rosiglitazone|june 2007 the group voluntarily dismissed its infringement claims in respect of the patent covering the maleate salt form of entity ( the active ingredient in avandia ) .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('DIS', 3), ('OTHER', 3)])|drug|rosiglitazone hepatic renal diabetic antagonist|metformin pioglitazone rosiglitazone tacrolimus statins|rosiglitazone|starlix ( diabetes ) was also filed in the us in december for use in combination with entity , a commonly used oral antidiabetic .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|rosiglitazone hepatic renal diabetic antagonist|sodium methyl racemic transdermal intravenous|rosiglitazone|with respect to avandamet ( entity maleate / metformin hydrochloride ) tablets , the company anticipates resupplying the distribution channels within two weeks .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 3), ('DIS', 2)])|drug|rosiglitazone hepatic renal diabetic antagonist|placebo metformin usual hydrochlorothiazide monotherapy|rosiglitazone|this weight loss was achieved with blood sugar-lowering efficacy comparable to entity .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|rosiglitazone hepatic renal diabetic antagonist|paroxetine fluoxetine citalopram sertraline ssri|rosiglitazone|site at cidra , puerto rico ; product liability and anti-trust litigation relating to paxil ( paroxetine ) , and product liability cases regarding avandia ( entity ) and other products .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|rosiglitazone hepatic renal diabetic antagonist|sodium versus methyl diethyl transdermal|rosiglitazone|for example , recent studies have suggested an increased cardiovascular risk in patients using avandia® ( entity maleate ) .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|drug|rosiglitazone hepatic renal diabetic antagonist|aging bph cvd luts chemotherapy|rosiglitazone|there also have been concerns of other cardiovascular issues with entity and also concerns raised regarding bladder cancer associated with treatment with tzds .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('DIS', 2), ('OTHER', 2)])|drug|rosiglitazone hepatic renal diabetic antagonist|pioglitazone rosiglitazone metformin resveratrol rapamycin|rosiglitazone|insulin sensitizing agents approved to treat t2d are the ppar gamma agonists pioglitazone and entity .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('DIS', 3), ('OTHER', 1)])|drug|rosiglitazone hepatic renal diabetic antagonist|metformin rosiglitazone pioglitazone medication atorvastatin|rosiglitazone|of starlix® ( nateglinide ) improves glycemic control and is well-tolerated in patients whose type 2 diabetes is inadequately controlled by taking entity alone .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('DIS', 3), ('OTHER', 2)])|drug|rosiglitazone hepatic renal diabetic antagonist|placebo metformin pioglitazone rosiglitazone atorvastatin|rosiglitazone|after a run-in period of metformin and entity , patients in the study were randomised to add-on treatment with either liraglutide or placebo .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('DIS', 3), ('OTHER', 2)])|drug|rosiglitazone hepatic renal diabetic antagonist|pioglitazone metformin rosiglitazone atorvastatin resveratrol|rosiglitazone|entity ( avandia® ) and pioglitazone ( actos® ) fall into this category of anti-diabetic agent .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('DIS', 2), ('OTHER', 2)])|drug|rosiglitazone hepatic renal diabetic antagonist|pioglitazone metformin rosiglitazone everolimus placebo|rosiglitazone|tzds include pioglitazone , marketed by eli lilly & company and takeda pharmaceutical company limited as actos , and entity , marketed by glaxosmithkline plc as avandia .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|rosiglitazone hepatic renal diabetic antagonist|celecoxib placebo paracetamol adalimumab nsaids|rosiglitazone|a comparator with entity , which has been shown to have some efficacy in humans , indicates the mgl-3196 performs better than entity in this study .
OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('DIS', 3), ('OTHER', 2)])|drug|rosiglitazone hepatic renal diabetic antagonist|pioglitazone rosiglitazone metformin clopidogrel rapamycin|rosiglitazone|insulin sensitizing agents approved to treat type 2 diabetes are the ppar gamma agonists pioglitazone and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|tetra bis chloride hexa into|lidocaine bupivacaine epinephrine placebo ketorolac|tetracaine|we entered into a license agreement with zars pharma for the north american rights to syneratm ( lidocaine 70 mg and entity 70 mg ) topical patch ( zars agreement ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|tetra bis chloride hexa into|lidocaine bupivacaine epinephrine placebo dexamethasone|tetracaine|license agreement with zars pharma that will give it the exclusive north american rights to syneratm ( lidocaine 70 mg and entity 70 mg ) topical patch .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|tetra bis chloride hexa into|lidocaine bupivacaine epinephrine ibuprofen propranolol|tetracaine|the drug formulation is a eutectic mixture of lidocaine 70 mg and entity 70 mg .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|tetra bis chloride hexa into|lidocaine bupivacaine epinephrine ketorolac dexamethasone|tetracaine|this product combines our peel technology with a proprietary formulation of lidocaine and entity to safely and efficiently anesthetize contoured areas of the body .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|tetra bis chloride hexa into|lidocaine bupivacaine ketorolac epinephrine placebo|tetracaine|we entered into a license agreement with zars pharma for the north american rights to synera® ( lidocaine 70 mg and entity 70 mg ) topical patch , referred to as the zars agreement .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|tetra bis chloride hexa into|lidocaine cream silicone placebo topical|tetracaine|allergy u . s . rx lidocaine ointment xylocaine™ dermatologics and topicals u . s . rx lidocaine / entity gel pliaglis® dermatologics and topicals u . s . rx loratadine solution claritin® allergy
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|tetra bis chloride hexa into|bupivacaine lidocaine fentanyl ketamine epinephrine|tetracaine|it uses our chadd technology and a proprietary formulation of lidocaine and entity to provide more convenient and faster anesthetic effect compared to the most commonly used product .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|tetra bis chloride hexa into|our another commercial comet placebo|tetracaine|the fda has specified a limit of 1 . 5% tetra acid relative to entity assay .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|tetra bis chloride hexa into|while during whereas via unlike|tetracaine|must demonstrate an acceptable level of tetra acid , which is a compound that is formed as the active product ingredients , entity assay , degrade over time .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|tetra bis chloride hexa into|lidocaine bupivacaine epinephrine placebo ketorolac|tetracaine|we entered into an agreement with zars pharma for the north american rights to syneratm ( lidocaine 70 mg and entity 70 mg ) topical patch .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|months clinic antimalarial anaemia pyrim|capsaicin lidocaine morphine paracetamol diclofenac|pramoxine|current phn treatments are symptomatic , affecting the pain signaling circuit ( such as novocaine , entity , capsaicin , etc . ) , and do not produce lasting control .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|months clinic antimalarial anaemia pyrim|sulfate acetate chloride sulphate sodium|pramoxine|manufacture had to be obtained by copley before it shipped in interstate commerce and distributed for human use , brompheril , hydrocortisone entity , potassium chloride or procainamide .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|months clinic antimalarial anaemia pyrim|phenylephrine nitroglycerin lidocaine saline placebo|pramoxine|preparation h® or similar products for symptomatic relief ( active ingredients can vary by country but generally include glycerin , phenylephrine hcl , entity hcl , and white petrolatum ) .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|months clinic antimalarial anaemia pyrim|phenylephrine lidocaine theophylline phenytoin diclofenac|pramoxine|otc products contain any one of several active ingredients including glycerin , phenylephrine , entity , white petrolatum , shark liver oil and / or witch hazel , for symptomatic relief .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|li sodium chloride potassium iodine|finally subsequently furthermore additionally here|liothyronine|entity , a concordia product , was included in the initial draft .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|li sodium chloride potassium iodine|example humans instance them pharmaceuticals|liothyronine|we believe that due to the fact that the market for entity is small , the manufacture and sale of generic forms of this compound are not economically attractive to potential competitors .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|li sodium chloride potassium iodine|sodium potassium supplemental inorganic elemental|liothyronine|entity sodium , one of the company  s products , was included in the initial draft .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|li sodium chloride potassium iodine|sodium urinary potassium fecal urine|liothyronine|the company recorded a total impairment charge of $301 , 538 , primarily related to entity sodium - $128 , 191 , fusidic acid -
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|li sodium chloride potassium iodine|remove produce replace reduce maintain|liothyronine|during the second quarter of 2017 , the company also became aware of the anticipated launch of a competitive product to entity sodium .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|li sodium chloride potassium iodine|ibuprofen aspirin paracetamol dexamethasone progesterone|liothyronine|amcos product portfolio in the united kingdom is its largest and is predominantly comprised of products such as levothyroxine , entity and nitrofurantoin .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|li sodium chloride potassium iodine|generic sodium bioactive marine pharmaceutical|liothyronine|generic entity sodium tablets are also available from coastal pharmaceuticals , mylan , and sigma pharmaceuticals .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|li sodium chloride potassium iodine|sodium intravenous methylprednisolone prednisolone diclofenac|liothyronine|the remaining decrease of 13% is due to volume declines on key products including entity sodium , prednisolone and nefopam .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|li sodium chloride potassium iodine|nine placebo tablet twelve 40|liothyronine|the cma pricing investigation , which commenced in october 2016 , relates to three products , including entity tablets .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|li sodium chloride potassium iodine|aspirin ibuprofen placebo paracetamol indomethacin|liothyronine|concordia international sells products such as entity , nitrofurantoin and levothyroxine within this category of the pharmaceutical market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|uro urology surg trial oncology|e2 t3 fsh hcg ml|urofollitropin|entity - this is fsh derived from the urine of postmenopausal women .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|uro urology surg trial oncology|technology progesterone proteomics tamoxifen testosterone|urofollitropin|entity is used in research to develop fertility drugs and in basic endocrinology research .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|uro urology surg trial oncology|antibiotics urine salmonella peptides analytes|urofollitropin|sicor currently expects to file a process patent covering purification of entity in early 1997 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|uro urology surg trial oncology|medicines pharmaceuticals foods tobacco milk|urofollitropin|sicor currently expects to file a process patent covering purification of entity in 1997 and is in discussions with potential partners about marketing the product in the u . s . and europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|uro urology surg trial oncology|marketed successful approved safe introduced|urofollitropin|in order to commercialize therapeutics , initially entity , the company must outsource the manufacturing to a fda-regulated facility .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|uro urology surg trial oncology|tm testosterone liposomes inhibitors protease|urofollitropin|the company  s present product candidates targeted to treat infertility include purified entity ( " vitropin ( tm ) " ) for injection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|uro urology surg trial oncology|glycoprotein respectively here glycosylated designated|urofollitropin|in addition , at its facility outside of turin , sicor is developing a glycoprotein , entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|uro urology surg trial oncology|testosterone metabolites estrogens antibiotics urine|urofollitropin|sicor is developing a process for the isolation of entity from the urine of post- menopausal women .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|uro urology surg trial oncology|progesterone melatonin oxytocin testosterone estrogen|urofollitropin|entity is involved in the stimulation of ovulation and is used in the treatment of certain types of infertility .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|uro urology surg trial oncology|testosterone metabolites estrogens antibiotics urine|urofollitropin|sicor is developing a process for the isolation of entity from the urine of post-menopausal women .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|uro urology surg trial oncology|glycoprotein glycosylated respectively here designated|urofollitropin|in addition , at its santhia facility outside of turin , sicor is developing a glycoprotein , entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|uro urology surg trial oncology|testosterone tm liposomes vesicles protease|urofollitropin|the company  s present products envisioned to treat infertility include purified entity ( " vitropin ( tm ) " ) for injection .
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|iv antibiotics vi pneumonia antibiotic|another them our commercial there|eravacycline|we may be unable to develop and commercialize entity or any other product candidate and , even if we do , may never achieve profitability .
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|iv antibiotics vi pneumonia antibiotic|hospitals pharmaceuticals manufacturers technology programs|eravacycline|our operations to date have been limited to financing and staffing our company , developing our technology and developing entity and other product candidates .
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|iv antibiotics vi pneumonia antibiotic|ga ds cq bt nd|eravacycline|the companys commercial product , xerava ( entity ) , a fully synthetic fluorocycline , is an intravenous ( iv ) antibiotic that is approved for use as a first-line empiric monotherapy for
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|iv antibiotics vi pneumonia antibiotic|organizations medicines pharmacists researchers clinicians|eravacycline|our current plan is to commercialize entity outside the united states with collaborators .
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|iv antibiotics vi pneumonia antibiotic|antibiotics chlorhexidine ciprofloxacin vancomycin metronidazole|eravacycline|xerava was investigated for the treatment of ciai as part of the companys ignite ( investigating gram-negative infections treated with entity )
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|iv antibiotics vi pneumonia antibiotic|namely inc france respectively company|eravacycline|the companys lead product candidate , entity , is a fully synthetic tetracycline derivative that the company is developing as a broad-spectrum intravenous and oral antibiotic for use
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|iv antibiotics vi pneumonia antibiotic|agents therapeutics technology routes pharmaceuticals|eravacycline|tetraphase pharmaceuticals is developing entity for complicated urinary and intra-abdominal infections , as well as pneumonia .
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|iv antibiotics vi pneumonia antibiotic|they participants she trials our|eravacycline|for example , although entity achieved favorable results in the lead-in part of our phase 3 clinical trial in cuti , the pivotal portion of the
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|iv antibiotics vi pneumonia antibiotic|them physicians researchers consumers plants|eravacycline|this may make it difficult for entity to compete with these products .
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|drug|iv antibiotics vi pneumonia antibiotic|psoriasis adalimumab dermatology infliximab etanercept|eravacycline|its phase 3 clinical trials ( ignite1 and ignite4 ) would be sufficient to support submission of a new drug application for entity for the treatment of ciai .
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|iv antibiotics vi pneumonia antibiotic|antibiotics vancomycin ciprofloxacin metronidazole placebo|eravacycline|approval of xerava was based on our ignite ( investigating gram-negative infections treated with entity ) phase 3 program .
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|iv antibiotics vi pneumonia antibiotic|article there they she actually|eravacycline|moreover , the company does not believe that the statement indicates in any respect that entity covers any or all of these infections .
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|drug|iv antibiotics vi pneumonia antibiotic|tacrolimus rapamycin placebo curcumin simvastatin|eravacycline|if clinical trials of entity or of any other product candidate that we advance to clinical trials fail to demonstrate safety and efficacy to the
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|iv antibiotics vi pneumonia antibiotic|placebo price fda prescription pharmacy|eravacycline|if entity is approved , it may be priced at a significant premium over other competitive products .
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|iv antibiotics vi pneumonia antibiotic|them activities purposes actions decisions|eravacycline|prior written notice if any governmental agency takes any action that prevents the company from importing , exporting , purchasing or selling entity .
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|iv antibiotics vi pneumonia antibiotic|ds rd nps ga vc|eravacycline|tetraphase is currently selling xeravatm ( entity ) in the united states .
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|iv antibiotics vi pneumonia antibiotic|another whether fluoroquinolones warfarin none|eravacycline|however , we do not believe these limitations would apply to entity or any of our other investigational antibiotics .
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|iv antibiotics vi pneumonia antibiotic|finally here scientists furthermore today|eravacycline|entity , along with the companys proprietary drug discovery platform technology , make tetraphase an exceptional opportunity that i look forward to being
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|iv antibiotics vi pneumonia antibiotic|pharmaceuticals antibiotics ibuprofen nicotine medicines|eravacycline|case based on our achievement of company goals with respect to the development of the intravenous and oral formulations of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|bis complexes analogue derivatives hydrochloride|lidocaine sevoflurane propofol bupivacaine fentanyl|dyclonine|a bema ( tm ) product containing entity as a local anesthetic prior to dental procedures and for the treatment of canker sores has been consumer tested .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|bis complexes analogue derivatives hydrochloride|pharmaceutical ce eg dip herbal|dyclonine|mucosal surfaces single claim  layered bioerodable pharmaceutical ( entity only ) carrier device .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|concentrations trial kg antagonist bioavailability|require underwent intravenous during receive|atosiban|the safety and pharmacokinetics of obe022 administered to pregnant women , who are receiving standard of care therapy for preterm labor , entity infusion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|concentrations trial kg antagonist bioavailability|naloxone oxytocin vasopressin propranolol antagonist|atosiban|these effects were blocked by the oxytocin receptor antagonist , entity , indicating the effects of intranasal oxytocin were mediated by oxytocin receptors .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|concentrations trial kg antagonist bioavailability|placebo misoprostol aspirin dexamethasone prednisone|atosiban|in singleton pregnancies , 12 . 5% of women receiving ebopiprant plus entity delivered within 48 hours compared to 26 . 8% receiving entity only ( or 90% ci : 0 . 39 ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|concentrations trial kg antagonist bioavailability|oxytocin hydrochloride misoprostol fentanyl morphine|atosiban|ferring pharmaceuticals entity , an oxytocin receptor antagonist , has been used in investigator initiated trials in connection with ivf outside the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|concentrations trial kg antagonist bioavailability|ci tm ta mrsa psi|atosiban|with respect to obe022 , tractocile ( entity ) is approved to delay preterm birth outside of the united states , and we anticipate potential competition as a single agent ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|concentrations trial kg antagonist bioavailability|oxytocin mifepristone naloxone misoprostol naltrexone|atosiban|entity , an oxytocin antagonist , is available in europe , but was denied regulatory approval in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|concentrations trial kg antagonist bioavailability|oxytocin naloxone propranolol saline naltrexone|atosiban|to exacerbate behavioral changes , entity , an oxytocin antagonist , was administered to the pups by slow intravenous push .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|concentrations trial kg antagonist bioavailability|placebo acupuncture anaesthesia anesthesia randomization|atosiban|two groups were given placebo in place of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|concentrations trial kg antagonist bioavailability|underwent during intravenous require took|atosiban|the safety and pharmacokinetics of obe022 in pregnant women , who were already receiving standard of care therapy for preterm labor , entity infusion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|concentrations trial kg antagonist bioavailability|oxytocin mifepristone fentanyl naltrexone naloxone|atosiban|entity , an oxytocin antagonist , is available in europe , but was denied regulatory approval in the u . s . the usefulness of these ß2-adrenergic
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|suv doses tracer fdg trial|vi iv ic tio v3|suvorexant|franchises grew · fda approved grastek and ragwitek sublingual allergen extract immunotherapy tablets and accepted filings for v503 and entity
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|suv doses tracer fdg trial|orexin ghrelin melatonin dopamine naltrexone|suvorexant|these may include the following :  entity , an orexin receptor antagonist , is being developed by merck & co . , inc . for the treatment of insomnia .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 2)])|drug|suv doses tracer fdg trial|pharmacotherapy guidelines prescription approved medication|suvorexant|three of these medicines were filed in the u . s . ( entity for insomnia ; sugammadex for neuromuscular blockade and a combination of ezetimibe and atorvastatin for atherosclerosis ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|suv doses tracer fdg trial|medicines approval pharmaceuticals physicians tobacco|suvorexant|the company is continuing with plans to seek approval for entity in other countries around the world .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|drug|suv doses tracer fdg trial|insomnia migraine narcolepsy schizophrenia sleep|suvorexant|· received a complete response letter from the fda regarding the new drug application for entity , mercks investigational medicine for the treatment of insomnia .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|suv doses tracer fdg trial|they there orexin gabapentin dopamine|suvorexant|if approved , entity would be the first in a new class of medicines , called orexin receptor antagonists , for use in patients with insomnia .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|suv doses tracer fdg trial|orexin naloxone naltrexone topiramate fluoxetine|suvorexant|in august 2014 , merck & co . s dual orexin receptor antagonist , entity , was approved by the fda and is currently marketed under the name belsomra® .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|suv doses tracer fdg trial|placebo haloperidol sleep propofol caution|suvorexant|the effects produced by doras on rem sleep explain the motor effects and other side effects seen with entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|suv doses tracer fdg trial|efficacy safety effectiveness they prescriptions|suvorexant|entity will be evaluated by the controlled substance staff of the fda during nda review .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|suv doses tracer fdg trial|200 nac 50 germany iii|suvorexant|for the treatment of advanced melanoma and metastatic nsclc in patients whose disease has progressed after other therapies , and belsomra ( entity ) for the treatment of insomnia .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|suv doses tracer fdg trial|medicines biotechnology pharmaceuticals researchers countries|suvorexant|merck has announced that it plans to file regulatory applications for entity in 2012 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|suv doses tracer fdg trial|orexin trp bmi 50 vi|suvorexant|merck is marketing belsomra® ( entity ) , which is a dual orexin receptor anatomist indicated for insomnia .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|suv doses tracer fdg trial|fda eu rct who irb|suvorexant|in august 2014 , merck announced that the fda approved belsomra ( entity ) for the treatment of adults with insomnia who have difficulty falling asleep and / or staying asleep .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|suv doses tracer fdg trial|pharmacotherapy medications searching indications treatments|suvorexant|seeing significant progress in the pipeline this year , and we expect six major filings over the next 18 months , including entity for insomnia and odanacatib for osteoporosis .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|suv doses tracer fdg trial|nac trp vpa orexin rct|suvorexant|neurosciencebelsomra ( entity ) , an orexin receptor antagonist indicated for the treatment of insomnia , characterized by difficulties with sleep onset and / or sleep maintenance .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|suv doses tracer fdg trial|them fda approval errors safety|suvorexant|both fda approval and a separate scheduling determination by the u . s . drug enforcement administration are required before merck can introduce entity in the united states .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|suv doses tracer fdg trial|ibuprofen acetaminophen carbamazepine methamphetamine tablets|suvorexant|on may 22 , 2013 , the fdas peripheral and central nervous system drugs advisory committee will meet to discuss the nda for entity ( mk-4305 ) tablets .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|suv doses tracer fdg trial|respectively usa here org ltd|suvorexant|mk-4305 , entity , is an investigational insomnia medicine in a new class of medicines called orexin receptor antagonists for use in patients with
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 2)])|drug|biologics bevacizumab il infliximab approval|psoriasis etanercept adalimumab infliximab methotrexate|guselkumab|entity is currently being investigated in clinical studies in several indications , including plaque psoriasis , pediatric psoriasis , psoriatic arthritis , crohns disease , hidradenitis
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|biologics bevacizumab il infliximab approval|interleukin interferon rituximab dexamethasone cytomegalovirus|guselkumab|entity ( tremfya® ) is the first approved antibody binding the p19 subunit of il-23 .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|biologics bevacizumab il infliximab approval|50 200 60 90 111|guselkumab|in july , subsequent to the quarter , the fda approved tremfya™ ( entity ) for the treatment of adults living with moderate to severe plaque psoriasis .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|biologics bevacizumab il infliximab approval|infliximab methotrexate azathioprine rituximab corticosteroids|guselkumab|next-generation ibd antibody drugs , such as entity , target the p19 subunit of the il-23 ligand and are specific to the il-23 pathway , which is believed to be
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|drug|biologics bevacizumab il infliximab approval|immunotherapy uc probiotics antibiotics ibd|guselkumab|of morphosys ag , said : we are very pleased that our licensee janssen has further expanded the clinical development program of entity by initiating a clinical study in ulcerative colitis .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|biologics bevacizumab il infliximab approval|50 200 111 60 80|guselkumab|in 2017 , tremfya® ( entity ) , marketed by janssen , became the first therapeutic antibody based on morphosyss proprietary technology to receive marketing approval for the treatment
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|biologics bevacizumab il infliximab approval|200 fda everolimus adalimumab cxcr4|guselkumab|to the same period a year ago driven by strong uptake of stelara® ( ustekinumab ) and the u . s . launch of tremfya® ( entity ) .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|biologics bevacizumab il infliximab approval|larger randomized published randomised ongoing|guselkumab|more information about entity clinical studies is available on clinicaltrials . gov .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|biologics bevacizumab il infliximab approval|etanercept infliximab adalimumab efficacy mtx|guselkumab|moreover , entity is currently being investigated in two phase 3 trials in psoriatic arthritis and also in a phase 2 / 3 clinical study program in crohns disease .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|biologics bevacizumab il infliximab approval|bevacizumab pegylated rituximab etanercept adalimumab|guselkumab|entity ( tremfya ® ) overview guselkumab ( tremfya ® ) is a human hucal antibody targeting the p 19 subunit of il - 23 that is being
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|biologics bevacizumab il infliximab approval|50 60 200 90 111|guselkumab|in july 2018 , morphosys announced that its licensee , janssen , initiated a clinical development program with tremfya® ( entity ) in crohns disease .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|biologics bevacizumab il infliximab approval|infliximab methotrexate azathioprine nsaids rituximab|guselkumab|next-generation ibd antibody drugs , such as entity , target the p19 subunit of the il‑23 ligand and are specific to the il‑23 pathway , which is believed to be
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|biologics bevacizumab il infliximab approval|fda 200 50 vi eu|guselkumab|the european commission approved tremfya® ( entity ) for the treatment of adults with moderate to severe plaque psoriasis and granted approval to broaden the existing marketing authorization
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|biologics bevacizumab il infliximab approval|adalimumab infliximab etanercept tacrolimus bevacizumab|guselkumab|entity is currently approved in the eu for the treatment of moderate to severe plaque psoriasis in adults who are candidates
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|biologics bevacizumab il infliximab approval|adalimumab infliximab etanercept rituximab immunotherapy|guselkumab|in november 2017 , the eu commission granted european approval of entity ( tremfya® ) for the treatment of patients with moderate-to-severe plaque psoriasis .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|biologics bevacizumab il infliximab approval|50 200 111 60 80|guselkumab|in 2017 , tremfya® ( entity ) , marketed by janssen , became the first therapeutic antibody based on morphosys  s proprietary technology to receive marketing approval for the treatment
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 2)])|drug|biologics bevacizumab il infliximab approval|etanercept psoriasis adalimumab infliximab vegf|guselkumab|entity is currently being investigated in clinical studies in several indications , including additional studies in plaque psoriasis , pediatric psoriasis , psoriatic arthritis ,
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|biologics bevacizumab il infliximab approval|infliximab methotrexate azathioprine rituximab nsaids|guselkumab|next-generation ibd antibody drugs , such as entity , target the p19 subunit of the il-23 ligand to confer specificity for the il-23 pathway that is believed to be
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|medicine university hormone pharmacology al|registration there participation agreement what|triptorelin|entity is in pre-registration in the united states .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|medicine university hormone pharmacology al|pregabalin everolimus budesonide sirolimus placebo|triptorelin|two additional agents are also currently marketed , trelstar by watson , delivers entity , and zoladex marketed by astrazeneca , a biodegradable rod , that contains goserelin .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|medicine university hormone pharmacology al|bisphosphonates docetaxel everolimus trastuzumab thalidomide|triptorelin|in addition , in europe or certain other parts of the world , entity ( debiopharm s . a . ) and buserelin ( hoechst marion roussel , inc . ) are also approved and being marketed .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|medicine university hormone pharmacology al|placebo saline aspirin dexamethasone celecoxib|triptorelin|women were randomized to one of four mvt-602 dose groups ( 0 . 1 µg , 0 . 3 µg , 1 µg or 3 µg ) , to entity , 0 . 2 mg , or to placebo .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|medicine university hormone pharmacology al|orally originally newly formerly presently|triptorelin|entity marketed as trelstar® ( watson pharmaceuticals ) and marketed as decapeptyl® ( ipsen ) is also a lhrh agonist .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|pharmaceuticals pas god medicine iii|docetaxel oxaliplatin gemcitabine cisplatin doxorubicin|rasburicase|in that role , he had key product sales responsibility for eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) , anzemet® ( dolasetron mesylate ) , and elitek® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|pharmaceuticals pas god medicine iii|cisplatin docetaxel oxaliplatin paclitaxel carboplatin|rasburicase|dr . bizzari was the vice president , clinical oncology development for sanofi-aventis where he oversaw the approval of oxaliplatin , docetaxel and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|pharmaceuticals pas god medicine iii|200 50 111 60 21|rasburicase|a specific r&d effort has already culminated in the launch of fasturtec® ( entity ) in 2001 , for prevention of the increase in blood uric acid levels during chemotherapy of acute leukemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|pharmaceuticals pas god medicine iii|docetaxel oxaliplatin cisplatin gemcitabine paclitaxel|rasburicase|the vice president , clinical oncology development for sanofi-aventis where he oversaw the approval of eloxatin ( oxaliplatin ) , taxotere® ( docetaxel ) and elitek ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|pharmaceuticals pas god medicine iii|docetaxel oxaliplatin cisplatin gemcitabine paclitaxel|rasburicase|for sanofi-aventis ( formerly rhône-poulenc , rhône-poulenc rorer and aventis ) where he oversaw the approval of eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) and elitek® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|pharmaceuticals pas god medicine iii|docetaxel cisplatin oxaliplatin gemcitabine paclitaxel|rasburicase|the vice president , clinical oncology development for sanofi-aventis where he oversaw the approval of eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) and elitek® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|pharmaceuticals pas god medicine iii|docetaxel oxaliplatin gemcitabine cisplatin doxorubicin|rasburicase|in that role , he had key product sales responsibility for eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) , anzemet® ( dolasetron mesylate ) , and elitek® ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|drug|clopidogrel randomized antiplatelet aspirin tic|pra suc tra aca pri|clopidogrel|to $5 . 3 billion in 2007 compared to 2006 due to loss of exclusivity of pravachol and the impact of generic entity bisulfate , partially offset by growth in other key products .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|drug|clopidogrel randomized antiplatelet aspirin tic|san el un reb una|clopidogrel|filed a revocation action before the scottish court of session seeking to invalidate the sanofi-aventis patent in the uk claiming entity bisulfate .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|clopidogrel randomized antiplatelet aspirin tic|nucleoside sodium salts analogs methyl|clopidogrel|apotex filed a notice of appeal appealing the holding of validity of the entity bisulfate , hydrochloride , hydrobromide , and taurocholate claims .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|drug|clopidogrel randomized antiplatelet aspirin tic|contents top nearly approximately raw|clopidogrel|growth in total prescriptions ( trx ) of entity 82 table of contents bisulfate remained strong , at 11 . 8% ( ims npa 3 channels  q4 2006 ) in the fourth
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|drug|clopidogrel randomized antiplatelet aspirin tic|statin antihypertensive ppi warfarin antidepressant|clopidogrel|however , the presence of less common cyp2c10 non-functional alleles or variation in other genes may negatively impact the efficacy of entity therapy .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|drug|clopidogrel randomized antiplatelet aspirin tic|article statement agency project initiative|clopidogrel|drug interactions medco health solutions inc . robert epstein , said it is an example of the " law of unintended consequences " entity ( plavix ( r ) )
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|drug|clopidogrel randomized antiplatelet aspirin tic|participants versus include cohort protocol|clopidogrel|medco outcomes study entity alone 0 . 18 entity+ppi 0 . 25 relative risk 1 . 50 ( 1 . 39-1 . 62 ) podium-presented at american heart association 11 / 11 / 08 *
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|clopidogrel randomized antiplatelet aspirin tic|omeprazole ppis oxaliplatin aspirin ibuprofen|clopidogrel|however , this is confounded by the fda warning against the use of certain ppis , such as omeprazole , with entity ( plavix ) .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|clopidogrel randomized antiplatelet aspirin tic|cyp3a4 dha warfarin carnitine cyp2d6|clopidogrel|o comment : entity is expected to be converted efficiently to its active metabolite in patients with this genotype .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|clopidogrel randomized antiplatelet aspirin tic|hydro dimethyl diethyl penta mono|clopidogrel|on august 12 , 2008 , the federal court of australia held that claims of patent no . 597784 covering entity bisulfate , hydrochloride , hydrobromide , and taurocholate salts were valid .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|clopidogrel randomized antiplatelet aspirin tic|infusion formulation medication tablet route|clopidogrel|captisol-enabled intravenous entity is an intravenous formulation of the anti-platelet medication designed for situations where the administration of oral platelet inhibitors is not
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DRUG', 1)])|drug|clopidogrel randomized antiplatelet aspirin tic|ko a2 platelets a1 adp|clopidogrel|plavix® / iscover® plavix® ( entity ) , a platelet adenosine diphosphate ( adp ) receptor antagonist with a rapid onset of action that selectively inhibits platelet aggregation induced by
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|clopidogrel randomized antiplatelet aspirin tic|nucleoside methyl sodium biliary aca|clopidogrel|genrx-apotex appealed the holding of validity of the entity bisulfate , hydrochloride , hydrobromide , and taurocholate claims .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|drug|clopidogrel randomized antiplatelet aspirin tic|statin ppi triple eradication warfarin|clopidogrel|the presence of less common cyp2c19 alleles or variations in other genes may additionally enhance or reduce the efficacy of entity therapy .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|clopidogrel randomized antiplatelet aspirin tic|placebo clopidogrel stenting stent pci|clopidogrel|stent thrombosis at 48 hours had been met , as cangrelor demonstrated statistically significant improvement for this endpoint as compared to entity .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|clopidogrel randomized antiplatelet aspirin tic|hcl acetaminophen salts ciprofloxacin pharmaceuticals|clopidogrel|the federal court also held that the process claims , pharmaceutical composition claims , and claim directed to entity and its pharmaceutically acceptable salts were invalid .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|clopidogrel randomized antiplatelet aspirin tic|placebo saline docetaxel mtx ibuprofen|clopidogrel|when pa32540 and entity were dosed 10 hours apart , data from the study indicate no ex-vivo drug-drug interaction based on the study  s pre-specified primary analysis .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|drug|clopidogrel randomized antiplatelet aspirin tic|apo und une un ind|clopidogrel|and the minister of health in response to a notice of allegation from apotex directed against canadian patent 1 , 336 , 777 covering entity bisulfate .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|clopidogrel randomized antiplatelet aspirin tic|tacrolimus sirolimus cyclosporine everolimus voriconazole|clopidogrel|us launch of tacrolimus ( prograf® ) ; and the launches in various european countries of pantoprazole ( marketed in the us as protonix® ) , entity ( plavix® ) , and esomeprazole ( nexium® ) .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|drug|clopidogrel randomized antiplatelet aspirin tic|aspirin heparin clopidogrel warfarin anticoagulants|clopidogrel|according to present plans , all patients will receive background treatment including heparin , aspirin and entity ( plavix® ) , if not contraindicated .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|cef administered amikacin tobramycin sul|derivatives agents antibiotics inhibitors substances|cefadroxil|crude bulk drugs of the cephalosporin division and cefalexin and entity of the penicillin division were new products the company introduced during the six-month period of 2008 .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5)])|drug|cef administered amikacin tobramycin sul|vancomycin ciprofloxacin clindamycin penicillin ampicillin|cefadroxil|cefalexin and entity are penicillin g downstream products that are widely used to treat urinary tract infections , respiratory tract , skin and soft tissue
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|cef administered amikacin tobramycin sul|naltrexone heroin methadone placebo morphine|cefadroxil|the increase was lead by increases in market share for medroxyprogesterone , naltrexone , danazol and sales of entity , which the company launched in june 1999 .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 2)])|drug|cef administered amikacin tobramycin sul|warfarin hydroxyurea methotrexate aspirin cyclophosphamide|cefadroxil|the increase was led by higher sales of warfarin sodium , naltrexone , medroxyprogesterone , danazol , entity and hydroxyurea .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|cef administered amikacin tobramycin sul|sodium potassium zinc ibuprofen bismuth|cefadroxil|for sake of clarity and avoidance of doubt , " product " does not include any non-oral suspension forms or formulations of duricef ( r ) ( entity monohydrate ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|cef administered amikacin tobramycin sul|ciprofloxacin 50 2b 60 vancomycin|cefadroxil|cefzil* cefprozil , an oral cephalosporin used in the treatment of respiratory infections and sinusitis duricef* entity , an oral cephalosporin .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|cef administered amikacin tobramycin sul|cephalosporin antibiotic piperacillin aminoglycoside vancomycin|cefadroxil|offset by the decrease in gross margins in cephalosporin crude bulk drugs , cephalosporin formulation drugs as well as cefalexin and entity divisional revenues and gross margin analysis
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 3), ('OTHER', 2)])|drug|cef administered amikacin tobramycin sul|chlorhexidine clindamycin azithromycin ketamine there|cefadroxil|entity is for use to treat strep throat , skin and urinaru tract infections .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|cef administered amikacin tobramycin sul|cef liquid preserv chlor ciprofloxacin|cefadroxil|% 9 . 94 % cefalexin / entity sterilized bulk drug / bulk cephalexin is used in treating urinary tract infections , repiratory tract infections , skin and soft tissue infections .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 3), ('OTHER', 2)])|drug|cef administered amikacin tobramycin sul|chlorhexidine clindamycin azithromycin ketamine there|cefadroxil|entity is for use to treat strep throat , skin and urinaru tract infections .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|cef administered amikacin tobramycin sul|fda choice approval name pharmaceuticals|cefadroxil|although ivax remains the only fda approved generic manufacturer of entity , the company marketing the brand name version of this drug is marketing its own generic form of this product .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|cef administered amikacin tobramycin sul|cigarettes tobacco medicines sales marijuana|cefadroxil|net revenues attributable to sales of entity , approved in march 1996 , were $17 . 1 million in the 1996 second quarter .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|cef administered amikacin tobramycin sul|cef liquid preserv chlor ciprofloxacin|cefadroxil|% 9 . 94% cefalexin / entity sterilized bulk drug / bulk cephalexin is used in treating urinary tract infections , repiratory tract infections , skin and soft tissue infections .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 3), ('OTHER', 2)])|drug|cef administered amikacin tobramycin sul|sales cephalosporins ciprofloxacin prices vancomycin|cefadroxil|sales for the cefalexin and entity for the first quarter of 2010 were approximately 3% lower than the same period in 2009 , because of a 4%
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5)])|drug|cef administered amikacin tobramycin sul|penicillin ampicillin gentamicin ciprofloxacin clindamycin|cefadroxil|the penicillin division currently operates the production and sales of clavulanic acid , cefalexin and entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|cef administered amikacin tobramycin sul|ciprofloxacin vancomycin amikacin gentamicin tobramycin|cefadroxil|cefalexin and entity were launched and included in the companys product portfolio only at the beginning of 2008 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|alp radix iii al ta|oxaliplatin capecitabine placebo paclitaxel dox|alpelisib|qd : once daily 111 table of contents we also assessed the anti-tumor activity of zn-c5 , alongside fulvestrant and entity , in each case as monotherapy , in preclinical models .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|alp radix iii al ta|fda everolimus eg ie approved|alpelisib|• byl719 ( entity , approved in the us as piqray ) is an orally bioavailable , alpha-specific pi3k inhibitor approved in combination with fulvestrant for the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|alp radix iii al ta|pivotal 111 200 prospective oh|alpelisib|· byl719 ( entity ) phase iii solar-1 trial data presented at esmo showed byl719 plus fulvestrant nearly doubles median progression free survival in patients with
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|alp radix iii al ta|rct oh h1n1 fda 200|alpelisib|· byl719 ( entity ) solar-1 trial of the investigational alpha-specific inhibitor byl719 in combination with fulvestrant met its primary endpoint showing an improvement in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alp radix iii al ta|ptx egcg dox ko ts|alpelisib| byl719 ( entity ) is an orally bioavailable , alpha isoform-specific pi3k inhibitor .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|drug|alp radix iii al ta|gov braf pik3ca kras grant|alpelisib|·entity ( byl719 ) is on track for a us submission in pik3ca-related overgrowth spectrum ( pros ) in 2021 .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|alp radix iii al ta|bevacizumab gemcitabine imatinib paclitaxel everolimus|alpelisib|% of pi3k mutated late stage breast cancer patients achieved an objective response in a phase iii clinical trial with entity , a recently approved pi3k inhibitor .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 2)])|drug|alp radix iii al ta|rituximab nsclc imatinib melanoma aml|alpelisib|therapy in this population , including ibrance , kisqali , afinitor , verzenio , and other therapies currently in phase 3 clinical development such as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|alp radix iii al ta|gemcitabine metformin paclitaxel resveratrol celecoxib|alpelisib|biomedical research , inc . , or novartis , to evaluate the combination of op-1250 and novartis ribociclib , a cdk4 / 6 inhibitor , as well as entity , their pi3kα inhibitor .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|alp radix iii al ta|oxaliplatin etanercept curcumin dox cisplatin|alpelisib|we also observed that the combination of zn-c5 and entity had more potent anti-tumor activity than the combination therapy using 3 mg / dose of fulvestrant and 50 mg / kg of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|alp radix iii al ta|placebo zinc celecoxib hrt curcumin|alpelisib|zn-c5 and fulvestrant were also assessed in combination with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|alp radix iii al ta|wt dox ptx 50 ko|alpelisib|more recently piqray® ( entity ) , an inhibitor of the alpha isoform phosphatidylinositol-3-kinase , became the first agent approved for use in a specific subpopulation of hr+
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|alp radix iii al ta|oh 125 50 99m 123|alpelisib|about piqray® ( entity ) piqray is a kinase inhibitor approved in combination with fulvestrant for the treatment of postmenopausal women , and men , with hr+ / her2- ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|alp radix iii al ta|zn zinc curcumin nac gsh|alpelisib|even greater anti-tumor activity was observed with the combination of 1 mg / kg of zn-c5 and 50 mg / kg of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|alp radix iii al ta|metformin gemcitabine curcumin rapamycin celecoxib|alpelisib|fulvestrant used in combination with entity , an oral pi3k inhibitor marketed as piqray® by novartis approved by the fda in may 2019 , has demonstrated improved clinical
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alp radix iii al ta|fda bbb 200 nc mtx|alpelisib|approved may 2019 ( breast cancer ) [ accelerated approval ] limited toxicities to date does not cross blood-brain barrier ü û ü piqray ( entity )
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|alp radix iii al ta|everolimus bortezomib paclitaxel erlotinib resveratrol|alpelisib|entity , marketed as piqray® by novartis , is the only fda-approved inhibitor for cancers with mutated pi3kα .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|alp radix iii al ta|there despite oxaliplatin chemotherapy adding|alpelisib|the study showed that entity added toxicity with only marginal additional activity , therefore the beacon crc trial will replace it with binimetinib in the triplet
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|alp radix iii al ta|curcumin resveratrol rapamycin tsa ly294002|alpelisib|in contrast , entity and gdc-0077 ( an orthosteric pi3kα inhibitor currently in development ) biochemically inhibited the mutant and wild-type proteins with approximately equivalent potency .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|alp radix iii al ta|chemotherapy immunotherapy paclitaxel everolimus therapeutics|alpelisib|while these factors limit the clinical utility of entity , these data nonetheless establish mutant pi3kα as a clinically validated target in breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('DIS', 3), ('OTHER', 3)])|drug|ol bis oxide alkaloid iv|bevacizumab adalimumab etanercept imatinib statins|omadacycline|to depend on independent clinical investigators and cros to conduct our clinical trials , including our planned phase 3 trials of entity in absssi .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|drug|ol bis oxide alkaloid iv|she chemotherapy imatinib fda immunotherapy|omadacycline|entity is ready to advance into phase 3 , the final stage of clinical development .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|ol bis oxide alkaloid iv|thalidomide methotrexate voriconazole bortezomib paclitaxel|omadacycline|entity ( paratek pharmaceuticals ) and lefamulin ( nabriva therapeutics ) , and dalafloxcacin ( melinta ) all are expected to be pursued as a possible treatment for
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|drug|ol bis oxide alkaloid iv|tuberculosis stroke malaria thrombosis antibiotics|omadacycline|in hong kong and three pending patent applications in taiwan , respectively that relate to different methods of treatment related to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ol bis oxide alkaloid iv|example employees workers employers industry|omadacycline|under the novartis agreement , novartis was to have led development activities for entity , and the company was to have co-developed and contributed a share of the development expense .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|ol bis oxide alkaloid iv|they antibiotics antimicrobials penicillin fluoroquinolones|omadacycline|if approved by the fda , entity will also compete with other antibiotics in the community-acquired pneumonia market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|ol bis oxide alkaloid iv|registration inclusion example stroke women|omadacycline|payment of $50 , 000 to tufts for achieving the first milestone following commencement of the phase 3 non-registration clinical trial for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|ol bis oxide alkaloid iv|fda medicines pharmaceuticals experts art|omadacycline|this prsu was awarded under the 2015 plan and vests upon fda approval of entity , and shall , upon achievement of the milestone , be eligible to vest as to 100% of the prsus subject to the
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|drug|ol bis oxide alkaloid iv|ciprofloxacin vancomycin namely meropenem ceftazidime|omadacycline|our success is currently dependent on the successful development and commercialization of our most advanced product candidates , entity and sarecycline .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ol bis oxide alkaloid iv|recent latest numerous existing recommended|omadacycline|to working with the fda as it considers the comments from the committee members and completes its review of the entity new drug applications .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|ol bis oxide alkaloid iv|she fda ibuprofen celecoxib paclitaxel|omadacycline|in all three studies , entity met all primary and secondary efficacy outcomes designated by the fda and was generally safe and well-tolerated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|ol bis oxide alkaloid iv|pharmaceuticals humans antibiotics fluoroquinolones example|omadacycline|in addition , achaogen , inc . developed and gained approval for plazomicin and paratek pharmaceuticals , inc . developed and gained approval for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ol bis oxide alkaloid iv|them pharmaceuticals partners manufacturers consumers|omadacycline|to obtain a return on the investments we have made in our or any of our partners product candidates , including entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ol bis oxide alkaloid iv|fear anxiety consciousness entropy text|omadacycline|“crude entity” has the meaning set forth in the recitals hereto .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|ol bis oxide alkaloid iv|they caution antibiotics opioids corticosteroids|omadacycline|we believe entity , if approved , will be used in the emergency room , hospital and community care settings .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 1)])|drug|ol bis oxide alkaloid iv|ciprofloxacin vancomycin voriconazole meropenem linezolid|omadacycline|if entity and sarecycline are not successfully developed and commercialized , we will not have any product candidates under development from which we
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|ol bis oxide alkaloid iv|adalimumab infliximab acupuncture rituximab radiotherapy|omadacycline|under our spa agreement , we plan to commence a pivotal registration program including two phase 3 registration trials of entity for the treatment of absssi in the second half of 2012 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ol bis oxide alkaloid iv|discussed inc recommended emerged viz|omadacycline|substantial additional funding in connection with the companys continuing operations to support commercial activities associated with its lead product candidate , entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|drug|ol bis oxide alkaloid iv|imipenem ciprofloxacin vancomycin meropenem antibacterial|omadacycline|our two lead antibacterial product candidates are entity and sarecycline .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|ol bis oxide alkaloid iv|placebo receive iv chemotherapy randomization|omadacycline|for oral therapy , patients randomized to entity received 200 mg of entity ( dosed as two 100 mg capsules ) every 24 hours .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|receptors analogue tamoxifen antagonist endocrine|fluoxetine antidepressants ssris benzodiazepines heroin|tamoxifen|increased product sales were due mainly to the introduction of fluoxetine in august 2001 , as well as , increased sales of entity and other products .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|receptors analogue tamoxifen antagonist endocrine|sodium citrate potassium magnesium ammonium|tamoxifen|soltamox ( entity citrate ) oral solution , our first proprietary , fda approved product , is a drug primarily used to treat breast cancer .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|drug|receptors analogue tamoxifen antagonist endocrine|radiotherapy chemotherapy brachytherapy cryotherapy curettage|tamoxifen|external beam radiation and entity are both used to treat gynecomastia .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|receptors analogue tamoxifen antagonist endocrine|citrate iv magnesium intravenous sodium|tamoxifen|the company acquired exclusive u . s . marketing rights to its &#160 ; first commercial , fda-approved proprietary product license &#160 ; soltamox&#174 ; ( entity citrate ) oral solution .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|receptors analogue tamoxifen antagonist endocrine|placebo saline diclofenac celecoxib ibuprofen|tamoxifen|femara is generally well tolerated and adverse reactions rates in the first-line study in which femara was compared to entity were similar with those seen in second-line studies .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|receptors analogue tamoxifen antagonist endocrine|sodium citrate potassium ammonium magnesium|tamoxifen|the alamo sales team , in addition to promoting our products soltamox ( entity citrate ) and gelclair , also promotes two mission products : ferralet® 90 , and aquoral® .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|receptors analogue tamoxifen antagonist endocrine|adjuvant photodynamic hormone neoadjuvant trastuzumab|tamoxifen|entity therapy is currently indicated by the fda for breast cancer patients for five years .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|receptors analogue tamoxifen antagonist endocrine|choice liquid carbon oil antibiotics|tamoxifen|nevertheless , we believe that soltamox being the first and only liquid form of entity to successfully make some in roads in to that market .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 2)])|drug|receptors analogue tamoxifen antagonist endocrine|tamoxifen estrogen estrogens placebo progesterone|tamoxifen|during 2001 , we announced the issuance of an u . s . patent on the use of our anti-estrogen compound in combination with entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|drug|receptors analogue tamoxifen antagonist endocrine|excision mastectomy recurrence resection radiotherapy|tamoxifen|a dcis score result , to help guide treatment decision-making in women with dcis treated by local excision , with or without entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|receptors analogue tamoxifen antagonist endocrine|own national private european medicare|tamoxifen|we maintain $20 million of product liability insurance and have an indemnification provision in our entity agreement .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|receptors analogue tamoxifen antagonist endocrine|commercial own market pharmacy retail|tamoxifen|us revenues for nolvadex fell 27% to $337 million , as sales of our entity products fell as a result of the expiry of our distribution agreement with barr laboratories .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|receptors analogue tamoxifen antagonist endocrine|methotrexate colchicine azathioprine etanercept vincristine|tamoxifen|however , a number of medical therapies have been used to treat peyronies including vitamin e , colchicine , potassium aminobenzoate ( potaba ) , entity , interferon a2a and corticosteroids .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|drug|receptors analogue tamoxifen antagonist endocrine|hormonal hormone adjuvant tamoxifen antiretroviral|tamoxifen|women were assessed for risk of developing breast cancer using the brevagen test to determine eligibility for five years of entity therapy .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|receptors analogue tamoxifen antagonist endocrine|cigarette tobacco sales pharmacy retail|tamoxifen|entity sales increased 56% from $145 , 161 to $226 , 749 .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|receptors analogue tamoxifen antagonist endocrine|europe switzerland australia germany canada|tamoxifen|due to its proven superiority over entity , it has won category leadership in france , spain , belgium , mexico , switzerland and australia .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|receptors analogue tamoxifen antagonist endocrine|everolimus monotherapy chemotherapy sirolimus paclitaxel|tamoxifen|treatment was stopped due to toxicities in three patients in the everolimus plus entity arm and in four patients in the entity-only arm .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|receptors analogue tamoxifen antagonist endocrine|mortality curative oncologic cosmetic prognostic|tamoxifen|oncotype dx predicts likelihood of recurrence because it predicts both prognosis and entity benefit .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|receptors analogue tamoxifen antagonist endocrine|plans claims harm costs who|tamoxifen|the plaintiff in this action , however , asserts that the companys alleged misclassification of entity improperly denied plan benefits and breached an alleged fiduciary duty under erisa .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|receptors analogue tamoxifen antagonist endocrine|estradiol tamoxifen progesterone estrogen testosterone|tamoxifen|entity , the most commonly used serm treatment for breast cancer , also inhibits this action by estradiol , but with less affinity for
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 2)])|drug|les par pas ans du|uric allopurinol urate hyperuricemia amiodarone|lesinurad|entity is a selective inhibitor of urat1 , a transporter in the proximal tubule cells of the kidney that regulates uric acid
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|les par pas ans du|bd oh om vi nd|lesinurad|about zurampic ( entity ) 200mg tablets zurampic ( entity ) works in combination with xanthine oxidase inhibitors ( xois ) to treat hyperuricemia associated with uncontrolled gout .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|les par pas ans du|original final waiting legal entire|lesinurad|closing of the entity transaction is subject to the expiration or termination of the waiting period under the hart-scott-rodino antitrust improvements act of 1976 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|les par pas ans du|every his original final top|lesinurad|the write-down was recorded as write-down of entity commercial supply to net realizable value in the companys condensed consolidated statement of operations .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|les par pas ans du|medicaid national federal annual government|lesinurad|to $140 million ) , and · amortization of intangible assets to be $8 million ( not applicable prior to the u . s . entity license ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('DIS', 3), ('OTHER', 3)])|drug|les par pas ans du|allopurinol warfarin aspirin methotrexate phenytoin|lesinurad|astrazeneca entered into a licensing agreement with ironwood pharmaceuticals for the exclusive us rights to zurampic and the fixed-dose combination of entity and allopurinol .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|les par pas ans du|methotrexate infliximab mtx etanercept ibuprofen|lesinurad|however , entity , like all other ults , has been shown to increase flares upon initiation of treatment .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|les par pas ans du|allopurinol amiodarone fenofibrate metformin ibuprofen|lesinurad|entity is an oral inhibitor of urat1 , which is the transporter that mediates reuptake of uric acid from the proximal tubules of the kidney and drives renal elimination of uric acid .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|les par pas ans du|doxorubicin oxaliplatin plc curcumin gemcitabine|lesinurad|entity is a drug in phase 3 development by astrazeneca plc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|les par pas ans du|strategies approaches guidelines trials protocols|lesinurad|we are developing entity to be used as both monotherapy and in combination with drugs like allopurinol and febuxostat to treat the large number
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 3)])|drug|les par pas ans du|allopurinol clopidogrel ibuprofen enalapril warfarin|lesinurad|for patients who require more control or who are contraindicated , the uricosuric agent , entity , may be prescribed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|les par pas ans du|our ur another rd dl|lesinurad|entity entity , our most advanced product candidate , previously called rdea594 , is an inhibitor of urat1 , a transporter in the kidney that regulates uric acid excretion from the body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|les par pas ans du|commercial original gross final remaining|lesinurad|we calculated gross product revenue based on the wholesale acquisition cost that we charged our distributors for the entity products .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|drug|les par pas ans du|hemodialysis allopurinol ibuprofen paracetamol indomethacin|lesinurad|entity has been shown to normalize the amount of uric acid excreted by gout patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|les par pas ans du|rituximab etanercept methotrexate biologics cyclophosphamide|lesinurad|these drugs are entity , sifalimumab , anifrolumab , mavrilimumab and brodalumab .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 3)])|drug|les par pas ans du|colonoscopy aspirin warfarin hemodialysis allopurinol|lesinurad|entity carries a black box warning associated with renal toxicity and is contraindicated in patients with renal impairment .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|les par pas ans du|federal national medicare european official|lesinurad|january 2007 , as amended , for our cambridge , massachusetts corporate headquarters and a reduction in reimbursement obligations to astrazeneca under the entity license .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 3), ('DRUG', 2), ('OTHER', 2)])|drug|les par pas ans du|allopurinol gout hyperuricemia hemodialysis urate|lesinurad|entity normalizes the amount of uric acid excreted by gout patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('DRUG', 4), ('OTHER', 3)])|drug|les par pas ans du|allopurinol sua hyperuricemia clopidogrel warfarin|lesinurad|entity is being studied as an add-on treatment to allopurinol patients not reaching target sua levels , as an add-on to febuxostat
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 4)])|drug|les par pas ans du|allopurinol aspirin clopidogrel statins celecoxib|lesinurad|the combination of entity and allopurinol has been generally well tolerated in the ongoing extension portion of study 203 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|antagonist kg sodium iv antagonists|placebo paracetamol infliximab ibuprofen midazolam|prucalopride|compared to the group receiving entity ( an fda approved drug for the treatment of chronic idiopathic constipation ) , the pcs12852 dose groups showed higher stool frequency for
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|drug|antagonist kg sodium iv antagonists|fda tamoxifen infliximab naloxone buprenorphine|prucalopride|entity has been approved for commercialization in certain european countries for the treatment of chronic constipation in women but has not yet been launched .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|antagonist kg sodium iv antagonists|adults women example inclusion individuals|prucalopride|shire has discussed with the fda the requirements for filing an nda for entity and is currently working towards fulfilling those requirements in anticipation of an nda submission .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|antagonist kg sodium iv antagonists|tenofovir nanotechnology telemedicine ritonavir influenza|prucalopride|entity was launched in several european markets .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|antagonist kg sodium iv antagonists|females males eu women italy|prucalopride|phase 3 globally global ( excluding italy and latin america ) resolor ( entity ) chronic constipation ( males ) phase 3 in eu europe spd 556 ( m0002 )
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|antagonist kg sodium iv antagonists|guidelines recommendations standards programs trends|prucalopride|shire intends to develop entity in the united states for cc .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|antagonist kg sodium iv antagonists|peg paracetamol acetaminophen h2 ribavirin|prucalopride|alan has played a major role in development of gastroenterology products such as motilium® and entity and has considerable experience and knowledge of the gastrointestinal ( gi ) space .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|antagonist kg sodium iv antagonists|competition market markets exist humans|prucalopride|johnson & johnson has rights to entity in north american and certain european countries and we expect entity to provide competition in markets around the world .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|antagonist kg sodium iv antagonists|50 200 111 60 40|prucalopride|shire plc obtained approval of motegrity™ ( entity ) in the u . s . for the treatment of cic in adults in december 2018 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|antagonist kg sodium iv antagonists|opioids acupuncture nsaids pregabalin dexmedetomidine|prucalopride|sloots ej , et al . efficacy and safety of entity in patients with chronic non-cancer pain suffering from oic .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|antagonist kg sodium iv antagonists|trends mutations challenges mrsa infections|prucalopride|movetis was acquired by shire in september 2010 , which intends to develop entity in the u . s . for cc .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|antagonist kg sodium iv antagonists|emerging withdrawn released absent coming|prucalopride|another prokinetic compound in development in europe , with the potential for commercialization in the united states and asia , is entity from movetis .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|antagonist kg sodium iv antagonists|rights them medicines standards themselves|prucalopride|shire has recently announced it acquired rights to develop and commercialize entity in the u . s . for the cc indication .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|antagonist kg sodium iv antagonists|tenofovir launched lamivudine ritonavir telemedicine|prucalopride|entity was launched in germany in january 2010 , in the u . k . in march 2010 and in belgium in september 2010 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|antagonist kg sodium iv antagonists|placebo ibuprofen paracetamol midazolam celecoxib|prucalopride|pcs12852 increased stool frequency with faster onset when compared to entity , an fda approved drug for the treatment of chronic idiopathic constipation .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|antagonist kg sodium iv antagonists|colleagues ve atm nf phb|prucalopride|a number of leadership positions within johnson & johnson focusing on development of gastroenterology products including propulsid® , motilium® , aciphex® and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|antagonist kg sodium iv antagonists|colleagues atm ve nf phb|prucalopride|held a number of leadership positions within johnson & johnson focusing on development of gastroenterology products including propulsid® , motilium® , aciphex® and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|antagonist kg sodium iv antagonists|guidelines acupuncture constipation naltrexone medicines|prucalopride|janssen belgium exclusive license agreement to develop and market entity as a treatment for chronic constipation in the u . s . motegrity , approved in december 2018 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|antagonist kg sodium iv antagonists|efficacy placebo agents effectiveness probiotics|prucalopride|trials are on-going in europe testing entity in the treatment of chronic constipation in men .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|antagonist kg sodium iv antagonists|200 uk iv usa iii|prucalopride|the most recent entrant to the cc marketplace , solely in europe , is resolor ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|24 med surg article 90|fda marketing approved updated original|polidocanol|additional manufacturing information and documentation is also being prepared by kreussler for submission to the fda to support the entity nda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|24 med surg article 90|alkaloids antioxidant volatile surfactant lidocaine|polidocanol|in contrast , aethoxysklerol contains entity , a chemical with anesthetic properties , which we believe may be one of the key advantages of aethoxysklerol .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|24 med surg article 90|during january november october medline|polidocanol|entity nda submission and review  in july 2009 , bioform medicals partner , chemische fabrik kreussler & co . gmbh ( kreussler ) , submitted
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|24 med surg article 90|physicians canada australia germany america|polidocanol|the $0 . 7 million milestone payment pursuant to our agreement with kreussler for exclusive united states licensing and distribution rights of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|24 med surg article 90|final commercial raw added alternative|polidocanol|the definition of product ( s ) may be amended from time to time to include additional entity product ( s ) in accordance with article ii ( b ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|24 med surg article 90|sclerotherapy literature pubmed medline papers|polidocanol|our partner , kreussler , is also making good progress in the nda review of entity , our future sclerotherapy product .  31 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|university medicine clinic 25 surg|sodium potassium mannitol diclofenac intravenous|nedocromil|brannan jd , anderson sd , freed r , leuppi jd , koskela h , chan h-k . entity sodium inhibits responsiveness to inhaled mannitol in asthmatic subjects .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|university medicine clinic 25 surg|treating sodium intravenous managing obtaining|nedocromil|the basic chemical patents for sodium cromoglycate have already expired , and such patents for entity sodium expire principally between 1998 and 2006 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|university medicine clinic 25 surg|traditional formula updated ordinary cubic|nedocromil|“bulk form” means cromolyn sodium micronized stage 9 ( the “intal bulk form” ) and entity sodium dried stage 11 ( the “tilade bulk form” ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|approval pharmacokinetics approved efficacy isr|tm fda who poc art|etravirine|during 2008 , the company received regulatory approval in the u . s . , canada and european union for intelencetm ( entity ) for hiv combination therapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|approval pharmacokinetics approved efficacy isr|infliximab adalimumab etanercept azathioprine tenofovir|etravirine|while at johnson & johnson , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|approval pharmacokinetics approved efficacy isr|japan usa china namely everolimus|etravirine|tibotecs drug , entity , received fda marketing approval in early 2008 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|approval pharmacokinetics approved efficacy isr|sm ga ts tc sf|etravirine|in january 2008 , the company received accelerated approval from the u . s . food and drug administration ( fda ) for intelence ( entity ) tablets , an anti-hiv medication .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|approval pharmacokinetics approved efficacy isr|infliximab adalimumab etanercept azathioprine mtx|etravirine|in this role , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|approval pharmacokinetics approved efficacy isr|infliximab adalimumab etanercept azathioprine tenofovir|etravirine|while at j&j , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|approval pharmacokinetics approved efficacy isr|art ortho azt ada lamivudine|etravirine|two new drugs , intelence ( entity ) and prezista ( darunavir ) from tibotec therapeutics , a division of ortho biotech products , l . p . , are included in the revised drug resistance
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|approval pharmacokinetics approved efficacy isr|infliximab adalimumab etanercept azathioprine mtx|etravirine|in this role , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|approval pharmacokinetics approved efficacy isr|infliximab adalimumab etanercept azathioprine methotrexate|etravirine|the development and launches of several products , including page 1 of 3 remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|approval pharmacokinetics approved efficacy isr|tenofovir hcv lamivudine ribavirin ritonavir|etravirine|company group chairman for johnson & johnsons worldwide virology business unit , where she oversaw the launches of prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|dimer polymer polymerization sodium agents|intravenous subcutaneous intramuscular saline needle|dimercaprol|bal in oil is a therapeutic entity injection used to treat arsenic , gold and mercury poisoning .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|amine hydrochloride amino agent diethyl|metabolites peptides ingredients extracts volatiles|galantamine|reminyl was launched using natural entity extracted from daffodil bulbs .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|amine hydrochloride amino agent diethyl|donepezil memantine levodopa haloperidol scopolamine|galantamine|related to ad , patients with ad are prescribed drugs for enhancing their cognition , and include acetylcholinesterase inhibitors such as , donepezil , entity , rivastigmine and memantine .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|amine hydrochloride amino agent diethyl|generic our iv marketed original|galantamine|entity ir tablets are the ab-rated generic versions of ortho-mcneil and janssen&#8217 ; s razadyne &#174 ; , which had annual sales of approximately
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|amine hydrochloride amino agent diethyl|own original constituent respective pure|galantamine|successful in their allegations of patent infringement , barr could be required to pay damages relating to the sale of its entity ir tablets .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|amine hydrochloride amino agent diethyl|dementia neurodegeneration epilepsy parkinsonism donepezil|galantamine|he contributed to the clinical development of currently marketed drugs in epilepsy ( topiramate and levetiracetam ) and entity in alzheimers .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|amine hydrochloride amino agent diethyl|incentives guidelines antioxidants spc artemisinin|galantamine|seeking a declaration to nullify the supplementary protection certificate ( " spc " ) for ep 236684 ( the patent that claims the use of entity for the treatment of alzheimer  s disease ) .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|amine hydrochloride amino agent diethyl|combinations derivatives respectively conjugates derivative|galantamine|the new drugs were new drug types such as the antimalarial arteether , echinocandin- derived antifungal caspofungin and the anti-alzheimers drug entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|amine hydrochloride amino agent diethyl|medications antibiotics medicines antidepressants opioids|galantamine|deemed to include all parents licensed to shire or its affiliates in the territory in respect of the use of entity for cfs ) .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|amine hydrochloride amino agent diethyl|into orally weekly via bid|galantamine|in october 2008 , barr commenced sales of its 8 mg , 16 mg and 24 mg entity extended release ( er ) capsules .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|amine hydrochloride amino agent diethyl|donepezil memantine levodopa scopolamine haloperidol|galantamine|other drugs commonly used to treat ad , such as donepezil and entity , inhibit acetylcholinesterase but not butyrylcholinesterase .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|amine hydrochloride amino agent diethyl|donepezil memantine levodopa haloperidol risperidone|galantamine|treatments for ad patients are only indicated for enhancing cognition in ad patients , and include acetylcholinesterase inhibitors such as donepezil , entity , rivastigmine and memantine .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|amine hydrochloride amino agent diethyl|medicines tobacco marketing cigarettes fda|galantamine|the first european application for marketing of entity was submitted in march 1999 ; subsequently , various other applications have been made .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|amine hydrochloride amino agent diethyl|derivatives combinations respectively conjugates activities|galantamine|the new drugs were new drug types such as the antimalarial arteether , echinocandin- derived antifungal caspofungin and the anti-alzheimer  s drug entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|amine hydrochloride amino agent diethyl|sodium intravenous radioactive potassium lithium|galantamine|infringed u . s . patent no . 4 , 663 , 318 ( the 318 patent ) by submitting a paragraph iv certification to the fda for approval of tablets containing entity hydrobromide .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|amine hydrochloride amino agent diethyl|generic our preferred promising recommended|galantamine|entity er capsules are the ab-rated generic versions of ortho-mcneil and janssens razadyne er® , which had annual sales of approximately $110
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|amine hydrochloride amino agent diethyl|donepezil memantine scopolamine haloperidol fluoxetine|galantamine|in a pre-clinical animal model of cognition , prx-03140 demonstrated synergistic activity when combined with the acetylcholinesterase inhibitor entity ( razadyne ) .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|amine hydrochloride amino agent diethyl|donepezil memantine carbamazepine levodopa placebo|galantamine|namzaricin the market for alzheimers disease treatments , namzaric competes or will compete with branded and generic products such as entity , rivastigmine , memantine , and donepezil .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|amine hydrochloride amino agent diethyl|sodium intravenous radioactive potassium lithium|galantamine|infringed u . s . patent no . 4 , 663 , 318 ( the 318 patent ) by submitting a paragraph iv certification to the fda for approval of tablets containing entity hydrobromide .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|amine hydrochloride amino agent diethyl|into tablets containing via tablet|galantamine|in august 2008 , barr commenced sales of its 4 mg , 8 mg and 12 mg entity immediate release ( ir ) tablets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|drug|protamine heparin sulfate iv iii|heparin enoxaparin aspirin clopidogrel warfarin|protamine|entity , a drug that reverses the anticoagulant effect of heparin , is rarely used in pci due to its unpredictable effect and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 2), ('DRUG', 2)])|drug|protamine heparin sulfate iv iii|smoking obesity hyperglycemia hyperlipidemia migraine|protamine|in medical studies , entity has been associated with adverse side effects , such as abnormal changes in blood pressure , depression of heart function and acute
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|protamine heparin sulfate iv iii|heparin warfarin anticoagulant lmwh enoxaparin|protamine|phase ii clinical trials indicate that neutralase can reverse heparin anticoagulation without the adverse changes in blood pressure associated with entity usage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|protamine heparin sulfate iv iii|newly subcutaneously recently orally chemically|protamine|our preclinical data demonstrated improved antigen expression at the site of injection if the entity formulated vaccine was injected via a needle free jet device .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|protamine heparin sulfate iv iii|antibiotics penicillin protease substrates antibiotic|protamine|one patient that died was found to have used entity and not neutralase .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|drug|protamine heparin sulfate iv iii|heparin lmwh enoxaparin warfarin aspirin|protamine|although entity is available as an antidote for heparin , it does not work with lmwh and there currently are no antidotes for
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|protamine heparin sulfate iv iii|heparin enoxaparin methotrexate dexamethasone aspirin|protamine|arc183 has shown potential in preclinical studies to be equally effective , with fewer side effects than heparin and entity in combination .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|protamine heparin sulfate iv iii|newly recently orally widely commonly|protamine|bi1361849 was administered via conventional needle based intradermal injection , later shown to be a suboptimal mode of injection for the entity formulated rabies vaccine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|protamine heparin sulfate iv iii|there aspirin rituximab fda enoxaparin|protamine|in the ufh antagonist market , entity is the only available antidote for and antagonist to ufh and , as such , entity currently dominates this market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|protamine heparin sulfate iv iii|market our demand pri licens|protamine|because of entitys virtual monopoly of the ufh antidote / antagonist market , we believe that it may be
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|drug|protamine heparin sulfate iv iii|heparin balloon warfarin catheter aspirin|protamine|be safely used in the general cardiac surgery patient population by demonstrating similar results to a regimen of heparin plus entity reversal .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|protamine heparin sulfate iv iii|our overcoming there barrier flaw|protamine|because of entitys potentially problematic side effect profile , we believe that our heptagonist products may penetrate into
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|drug|protamine heparin sulfate iv iii|heparin aspirin caution warfarin clopidogrel|protamine|in addition , the effects of heparin are routinely reversed with entity , the use of which has been associated with an allergic reaction and a subsequent increase in the risk of death
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|drug|protamine heparin sulfate iv iii|heparin lmwh aspirin enoxaparin warfarin|protamine|reversed at the end of the procedure and which does not have the significant side effects associated with heparin and entity would result in improved outcomes for patients undergoing ohs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|drug|protamine heparin sulfate iv iii|ffp rfvi concentrates platelets lmwh|protamine|that directly or indirectly support clotting , such as vitamin k ; fresh frozen plasma , or ffp ; prothrombin complex concentrates , or pccs ; entity ; and recombinant factor viia , or rfviia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|protamine heparin sulfate iv iii|heparin enoxaparin warfarin lmwh there|protamine|currently , entity is the only product commercially available for the reversal of heparin anticoagulation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|drug|protamine heparin sulfate iv iii|placebo heparin warfarin normals clopidogrel|protamine|the efficacy of rpf4 for the reversal of the anticoagulant effects of heparin in cardiac catheterization patients in comparison to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|protamine heparin sulfate iv iii|infusion prophylaxis monotherapy medication now|protamine|market opportunity unfractionated heparin ( ufh ) entity is the only available reversing agent for ufh .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|protamine heparin sulfate iv iii|mrna mrnas laminin glycoproteins cdna|protamine|an antigenic protein that is expressible in human cells as well as the same mrna formed as a complex with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|protamine heparin sulfate iv iii|heparin enoxaparin lmwh warfarin pcc|protamine|k , ffp and , more recently , pccs , while low molecular weight heparin patients needing reversal are often managed with ffp or entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|esc placebo during min ssri|placebo medication olanzapine aspirin risperidone|escitalopram|( n=301 ) for the first eight weeks , followed by a two-week period in which patients discontinued study drug but continued receiving entity and placebo .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|esc placebo during min ssri|paroxetine sertraline fluoxetine venlafaxine ssris|escitalopram|major marketed brands include lexapro ( entity ) , paxil ( paroxetine ) , zoloft ( sertraline ) , effexor xr ( venlafaxine ) and wellbutrin® .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|esc placebo during min ssri|antidepressant antidepressants medication fluoxetine regimen|escitalopram|these results showed an increase of serotonin and dopamine after a single dose of min-117 , unlike the reference antidepressant entity which only induced a modest and transient increase .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|esc placebo during min ssri|dul meth dma ana cer|escitalopram|to approximately 195 legal actions asserting product liability claims relating to the use of celexa® ( citalopram hbr ) ( celexa ) or lexapro® ( entity oxalate ) ( lexapro ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|esc placebo during min ssri|sodium vitamin 200 var piper|escitalopram|sales of lexapro® ( entity oxalate ) , an ssri indicated for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder in adults ,
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|esc placebo during min ssri|placebo amitriptyline fluoxetine antidepressants donepezil|escitalopram|is a significant predictor of patient response and remission from depression when utilized one week following initiation of treatment with entity , an anti-depressant drug .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|esc placebo during min ssri|original prototype resulting own thin|escitalopram|our entity thin film is currently in pre-clinical development .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|esc placebo during min ssri|cns schizophrenia epilepsy als autism|escitalopram|cns clinical research division ; and forest laboratories , as director , cns clinical development , where he was involved in the development of entity ( lexapro ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|esc placebo during min ssri|while versus 23 mol bismuth|escitalopram|ranitidine 170 152 gemcitabine 153 143 entity oxalate 128 227 others 2 , 246 3 , 105
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|esc placebo during min ssri|prototype resulting thin original designed|escitalopram|our entity thin film is currently in pre-clinical development and we expect to conduct pilot bioavailability / bioequivalence clinical trials during the first half
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|esc placebo during min ssri|fluoxetine paroxetine ssris ssri citalopram|escitalopram|that affect the serotonin system , as 176 table of contents shown recently in generalized anxiety disorder trials with the ssris entity and paroxetine .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|esc placebo during min ssri|paroxetine fluoxetine sertraline venlafaxine citalopram|escitalopram|major brands include prozac ( fluoxetine ) , lexapro ( entity ) , paxil ( paroxetine ) , zoloft ( sertraline ) and effexor xr ( venlafaxine ) and wellbutrin® .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|esc placebo during min ssri|includes uses remains exists contains|escitalopram|patent infringement based on tevas filing of an abbreviated new drug application for a generic equivalent to our lexapro brand entity oxalate .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|esc placebo during min ssri|manufacturers industry sales medicines technology|escitalopram|this reduction was principally due to the launch of entity in the first quarter of 2012 , our most significant product launch with shared exclusivity in the prior year .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|esc placebo during min ssri|income poverty residence medicaid race|escitalopram|excluding the impact of entity in both periods , third party net revenues in north america were essentially flat on a year-over-year basis .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|esc placebo during min ssri|vitamin cn pyrid phen var|escitalopram|· lexapro® ( entity oxalate ) , an ssri for the initial and maintenance treatment of mdd in adults and adolescents and generalized anxiety disorder in
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|esc placebo during min ssri|marijuana nicotine tobacco cannabis fda|escitalopram|entity is marketed by forest laboratories , inc . under the brand name lexapro® and generated sales of $2 . 0 billion in 2006 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|esc placebo during min ssri|serotonin another renal monoamine sodium|escitalopram|entity oxalate entity is in a class of drugs called selective serotonin reuptake inhibitors .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|esc placebo during min ssri|hb ada ll vi dma|escitalopram|lexapro® : lexapro ( entity oxalate ) , our single isomer version of citalopram hbr , for the treatment of mdd in adults and adolescents and generalized anxiety
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|esc placebo during min ssri|paroxetine fluoxetine venlafaxine sertraline ssris|escitalopram|major marketed brands include lexapro ( entity ) , paxil ( paroxetine ) , zoloft ( sertaline ) and effexor xr ( venlafaxine ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|tio oxide nanoparticles alloy nanoparticle|paclitaxel aspirin cisplatin theophylline corticosteroids|tiotropium|boehringer-ingelheim is developing a combination product with entity and the long-acting beta agonist bi-1744 for the treatment of copd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|tio oxide nanoparticles alloy nanoparticle|placebo bid usual saline weekly|tiotropium|explore efficacy and safety at doses of 15 . 6 to 125mcg od and 15 . 6mcg and 31 . 25mcg twice daily ( bid ) compared with entity od or placebo in subjects with copd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|tio oxide nanoparticles alloy nanoparticle|placebo ibuprofen salbutamol budesonide atorvastatin|tiotropium|significantly greater than placebo and similar in magnitude to a combination therapy active control of salmeterol dosed twice daily plus entity dosed once daily .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 2)])|drug|tio oxide nanoparticles alloy nanoparticle|placebo simvastatin celecoxib monotherapy aspirin|tiotropium|separately , a phase iii study showed that once-daily nva237 is superior to placebo and similar to entity in improving lung function in patients with moderate-to-severe copd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|tio oxide nanoparticles alloy nanoparticle|placebo fev1 fvc pef fev|tiotropium|% of the patients in the study , yupelri demonstrated nominally statistically significant and clinically relevant improvements in trough fev1 versus entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|tio oxide nanoparticles alloy nanoparticle|celecoxib placebo aspirin nsaids gemcitabine|tiotropium|the studies showed that when used in conjunction with entity , indacaterol produces a significantly greater improvement in lung function than entity alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|tio oxide nanoparticles alloy nanoparticle|budesonide salbutamol asthma placebo bronchodilator|tiotropium|this trial is evaluating rpl554 as an add-on therapy to entity , a commonly used long-acting bronchodilator , in approximately 30 patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 3)])|drug|tio oxide nanoparticles alloy nanoparticle|tamoxifen warfarin placebo osteoporosis chemotherapy|tiotropium|this trial is evaluating rpl554 as an add-on therapy to entity in approximately 30 patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|tio oxide nanoparticles alloy nanoparticle|placebo budesonide bronchodilator inhaled copd|tiotropium|phase 2a clinical trial in the united kingdom evaluating rpl554 in approximately 30 patients with copd as an add-on therapy to entity , a commonly used bronchodilator .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|tio oxide nanoparticles alloy nanoparticle|copd placebo exacerbations smokers adults|tiotropium|no : p27 ( a6797 ) umec / vi as step-up therapy from entity in moderate symptomatic copd : a randomized , 12-week study exhibit 99 . 4 press release issued : wednesday 18th may 2016
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|tio oxide nanoparticles alloy nanoparticle|placebo spirometry inhalation earlier monotherapy|tiotropium|early post-dose spirometry data suggested a more rapid onset of action than entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|tio oxide nanoparticles alloy nanoparticle|placebo aspirin theophylline budesonide salbutamol|tiotropium|mg and 6 mg , or placebo , dosed twice-daily for three days , in addition to a dual bronchodilator therapy comprising entity and olodaterol , a commonly used lama / laba , dosed once daily .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|tio oxide nanoparticles alloy nanoparticle|placebo paclitaxel cisplatin chemotherapy docetaxel|tiotropium|the primary analysis was to determine non-inferiority ( based on a margin of -50ml ) or superiority of umeclidinium to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|tio oxide nanoparticles alloy nanoparticle|trials rcts trial arms placebo|tiotropium|showed that nva237 was well-tolerated with a similar incidence of adverse events for patients treated with nva237 , placebo and open-label entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|tio oxide nanoparticles alloy nanoparticle|receiving od placebo versus receive|tiotropium|· in both studies , placebo and open-label od entity 18mcg were comparators .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|tio oxide nanoparticles alloy nanoparticle|triple inhaled usual previous corticosteroid|tiotropium|•verona pharma announced positive data in a 4-week phase 2b copd trial with nebulized ensifentrine on top of entity therapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|tio oxide nanoparticles alloy nanoparticle|ethidium diphenyl salbutamol piper ethyl|tiotropium|table of contents  braltus® ( entity bromide ) , a long-acting muscarinic antagonist , indicated for adult patients with copd , delivered via the zonda® inhaler , was launched in europe
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|tio oxide nanoparticles alloy nanoparticle|placebo benzoate ondansetron salbutamol meth|tiotropium|when compared to placebo , glycopyrronium 50 mcg was also numerically higher than ol entity 18 mcg versus placebo at all-time points for trough fev1 ( day 1 and weeks 12 , 26 and 52 ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|tio oxide nanoparticles alloy nanoparticle|ethidium mycophenolate inhaled dimethyl diphenyl|tiotropium|been playing a central role in the management of copd , and are currently the most common therapy in copd ( e . g . , entity bromide ; a long-acting bronchodilator ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|tio oxide nanoparticles alloy nanoparticle|placebo peg saline receive sham|tiotropium|patients were randomised 1 : 1 to umeclidinium 62 . 5mcg inhalation powder or entity 18mcg .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|pharmacokinetics administered sodium inhibitor dogs|fda donepezil approved rituximab memantine|flutemetamol|in october 2013 , the fda approved entity , under the name vizamyltm , for adults being evaluated for ad and dementia with pet brain imaging .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|pharmacokinetics administered sodium inhibitor dogs|emerging introduction pharmacy teaching coming|flutemetamol|in addition to fluorbetapir , there are two other beta-amyloid imaging agents available : florbetaben from piramal enterprises , imaging division , and entity from ge healthcare .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|pharmacokinetics administered sodium inhibitor dogs|fdg fluorodeoxyglucose 18f positron fluoro|flutemetamol|the filing also includes data from a recently completed [ 18f ] entity pet image reader training validation study , results of which will be presented at a scientific forum in coming months .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|pharmacokinetics administered sodium inhibitor dogs|placebo dha mph val pan|flutemetamol|as an aid to the evaluation of patients with signs of alzheimers disease : amyvid® ( florbetapir ) , marketed by lilly , and vizamyl® ( entity ) , marketed by ge healthcare .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|pharmacokinetics administered sodium inhibitor dogs|chinese another amyloid cocaine gold|flutemetamol|in addition to fluorbetipir , there are two other beta-amyloid imaging agents in late stage development : florbetaben from bayer schering and entity from general electric .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|gos trial university trials months|gnrh lhrh progesterone estradiol fsh|goserelin|among the different classes of peptides , gnrh / lhrh agonists ( leuprorelin , entity ) account for almost 50 percent of the market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|gos trial university trials months|them dexamethasone calcitonin saline placebo|goserelin|formulations such as lupron and eligard , which deliver leuprolide , trelstar , which delivers triptorelin , and zoladex , a biodegradable rod , which delivers entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|gos trial university trials months|triamcinolone methylprednisolone prednisolone cyclosporine prostaglandin|goserelin|patients in the second arm will receive bnt112 combined with entity acetate and cemiplimab , and patients in the third arm will receive bnt112 combined with entity acetate alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|gos trial university trials months|acetate methylprednisolone magnesium estradiol triamcinolone|goserelin|primary objective of this study will be to establish the safety and tolerability of bnt112 alone , or in combination with entity acetate with or without cemiplimab .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|gos trial university trials months|acetate ethyl sodium lithium estradiol|goserelin|zoladex ( entity acetate implant ) is a lhrh agonist for treating prostate and breast cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|gos trial university trials months|acetate ethyl vinyl sodium lithium|goserelin|for all classes , the only astrazeneca drug at issue is zoladex™ ( entity acetate implant ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|gos trial university trials months|acetate ethyl lithium vinyl sodium|goserelin|astrazeneca announced that it had entered into an agreement with tersera therapeutics llc ( tersera ) for the commercial rights to zoladex ( entity acetate implant ) in the u . s . and canada .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|gos trial university trials months|ingredients medicines formulations pharmaceuticals tablets|goserelin|launches of generic entity ( the active ingredient in zoladex ) are expected in europe during 2012 .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|gos trial university trials months|acetate estradiol lithium ethyl testosterone|goserelin|zoladex ( entity acetate implant ) , available in one month and three month depots , is the worlds second largest lhrh agonist by value .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|gos trial university trials months|ethyl acetate vinyl lithium sodium|goserelin|in the us , the us department of justice has been conducting an investigation into the sales and marketing of zoladex ( entity acetate implant ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|gos trial university trials months|ingredients medicines formulations manufacturers excipients|goserelin|competition in the lhrh agonist market is expected to increase in europe during 2011 , with further launches of generic entity ( the active ingredient in zoladex ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|gos trial university trials months|estradiol acetate cyclic testosterone lhrh|goserelin|examples of commercially marketed lhrh agonists are lupron® ( leuprolide acetate ) , zoladex® ( entity acetate ) , viadur® ( leuprolide acetate ) and eligard® ( leuprolide acetate ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|drug|gos trial university trials months|tamoxifen trastuzumab her2 docetaxel estrogen|goserelin|lee011 + tamoxifen + entity or nsai + entity hr+ / her2- premenopausal abc 1st line 2018 iii - fully enrolled lee011 + fulvestrant hr+ / her2- postmenopausal abc 1st / 2nd line 2018 iii
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|gos trial university trials months|acetate ethyl lithium sodium vinyl|goserelin|for all classes , the only astrazeneca drug at issue is zoladex ( entity acetate implant ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|mit bis bip macular fur|codeine paracetamol morphine tramadol ibuprofen|biperiden|increases over the same quarter in the prior year in certain molecules including cyclizine hydrochloride , codeine phosphate + paracetomol and entity hydrochloride .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|somatostatin octreotide analog gastrointestinal analogue|bioactive depot placebo larger synthetic|lanreotide|we do not have patent composition coverage on the entity molecule ( the active pharmaceutical ingredient of somatuline® depot ) alone .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|somatostatin octreotide analog gastrointestinal analogue|somatostatin analog alfa octreotide kinase|lanreotide|somatuline entity ( " somatuline " ) is another long- acting somatostatin analog .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|somatostatin octreotide analog gastrointestinal analogue|injectable somatostatin newer subcutaneous octreotide|lanreotide|we look forward to advancing mycapssa as a preferred treatment option for patients with acromegaly treated with octreotide and entity injectables ,  mr . kannan concluded .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|somatostatin octreotide analog gastrointestinal analogue|octreotide placebo somatostatin dexamethasone bevacizumab|lanreotide|on june 26 , 2020 , chiasma received fda approval of mycapssa for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|somatostatin octreotide analog gastrointestinal analogue|bioactive depot placebo larger synthetic|lanreotide|we do not have composition of matter patent coverage on the entity molecule ( the active pharmaceutical ingredient of somatuline® depot ) alone .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|somatostatin octreotide analog gastrointestinal analogue|depot somatostatin octreotide subcutaneous placebo|lanreotide|receptor type 2 ( sst2 ) biased agonist , in patients with acromegaly whose disease is not biochemically controlled by octreotide lar or entity depot alone .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|somatostatin octreotide analog gastrointestinal analogue|bioactive recombinant synthetic larger inhibitor|lanreotide|we do not have patent composition coverage on the entity molecule ( the active pharmaceutical ingredient of somatuline® autogel® ) alone .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|somatostatin octreotide analog gastrointestinal analogue|octreotide somatostatin intravenous subcutaneous placebo|lanreotide|hormone levels used to measure disease at 24 weeks versus continued treatment with the long acting release form of octreotide , or entity autogel , meeting the primary endpoint .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|somatostatin octreotide analog gastrointestinal analogue|octreotide placebo somatostatin dexamethasone gh|lanreotide|week 13 in acromegaly patients who were switched from an injected somatostatin receptor ligand ( srl ) depot of either octreotide or entity monotherapy .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|somatostatin octreotide analog gastrointestinal analogue|them tablets oil formulation pharmaceuticals|lanreotide|the somatuline® autogel® formulation requires no excipient other than water and releases entity over a period of at least 28 days and up to 56 days .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|somatostatin octreotide analog gastrointestinal analogue|octreotide placebo somatostatin dexamethasone rituximab|lanreotide|approval of mycapssa for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|somatostatin octreotide analog gastrointestinal analogue|bevacizumab curcumin paclitaxel imatinib rituximab|lanreotide|a pilot trial involving six children with neuroblastoma cancer and seven adults with neuroendocrine cancer has been completed using entity as the targeting agent .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|somatostatin octreotide analog gastrointestinal analogue|octreotide acetate hydrocortisone lar ethyl|lanreotide|these products include sandostatin lar depot ( octreotide / im injection ) by novartis a . g . , and somatuline depot ( entity acetate ) by tercica inc .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|somatostatin octreotide analog gastrointestinal analogue|synthesized secreted inactive biocompatible soluble|lanreotide|active substance the active substance in somatuline® depot is entity , which inhibits the growth and secretion of several endocrine , exocrine and paracrine functions .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|somatostatin octreotide analog gastrointestinal analogue|somatostatin octreotide dexamethasone ghrelin paclitaxel|lanreotide|somatuline® depot is an injectable sustained-release formulation containing entity , a somatostatin analogue .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|somatostatin octreotide analog gastrointestinal analogue|octreotide somatostatin placebo dexamethasone propranolol|lanreotide|surgical removal of the pituitary tumor consists of lifelong , once-monthly injections of an extended release somatostatin analog , primarily octreotide or entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|somatostatin octreotide analog gastrointestinal analogue|octreotide somatostatin placebo dexamethasone metoclopramide|lanreotide|care for patients diagnosed with acromegaly consists of lifelong , once-monthly injections of an extended release somatostatin analog , primarily octreotide or entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|somatostatin octreotide analog gastrointestinal analogue|somatostatin octreotide progesterone dexamethasone metoclopramide|lanreotide|long-acting analogues of the hormone somatostatin , such as octreotide and entity have established themselves as a primary treatment of neuroendocrine tumors , although with limited efficacy .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|somatostatin octreotide analog gastrointestinal analogue|octreotide somatostatin dexamethasone glucagon metoclopramide|lanreotide|somatostatin analogs octreotide ( marketed as sandostatin ) and entity ( marketed as somatuline ) are selective for sst2 receptors and are the preferred first-line pharmacologic treatments .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|somatostatin octreotide analog gastrointestinal analogue|lar octreotide gh acromegaly sst|lanreotide|acromegaly in the united states : sandostatin lar ( octreotide ) marketed by novartis ; signifor lar ( pasireotide ) marketed by novartis ; and somatuline depot ( entity ) marketed by ipsen .
OrderedDict([('DRUG', 5), ('OTHER', 1)])|OrderedDict([('OTHER', 5)])|drug|cef cephalosporin penicillin ciprofloxacin cephalosporins|topical injectable intravenous intramuscular commercial|cefotetan|entity disodium injectable ( vial ) 1gr , 2gr , 10gr vials entity ® nda / anda indicated for the treatment of various bacterial infections .
OrderedDict([('DRUG', 5), ('OTHER', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|drug|cef cephalosporin penicillin ciprofloxacin cephalosporins|linezolid meropenem ceftazidime ciprofloxacin levofloxacin|cefotetan|entity is a second-generation cephalosporin with a broad range of anti-microbial activity .
OrderedDict([('DRUG', 5), ('OTHER', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|cef cephalosporin penicillin ciprofloxacin cephalosporins|sodium topical intravenous injectable intramuscular|cefotetan|entity disodium 20mg / ml injectable ( bag ) 50ml bags entity ® nda indicated for the treatment of various bacterial infections .
OrderedDict([('DRUG', 5), ('OTHER', 1)])|OrderedDict([('OTHER', 5)])|drug|cef cephalosporin penicillin ciprofloxacin cephalosporins|approved indications fda recommended except|cefotetan|we received fda approval for and launched our first injectable product , cefotan® ( entity for injection ) , in the first quarter of 2016 .
OrderedDict([('DRUG', 5), ('OTHER', 1)])|OrderedDict([('OTHER', 5)])|drug|cef cephalosporin penicillin ciprofloxacin cephalosporins|them companies europe legislation industry|cefotetan|we launched entity in september 2007 and are currently the only company to market entity in the united states .
OrderedDict([('DRUG', 5), ('OTHER', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|cef cephalosporin penicillin ciprofloxacin cephalosporins|paclitaxel gemcitabine docetaxel doxorubicin everolimus|cefotetan|march 31 , 2007 were $23 . 6 million of paclitaxel ( whole plant ) , $3 . 9 million in other abraxane® related materials and $3 . 0 million of entity .
OrderedDict([('DRUG', 5), ('OTHER', 1)])|OrderedDict([('OTHER', 5)])|drug|cef cephalosporin penicillin ciprofloxacin cephalosporins|approved fda indications approval indication|cefotetan|and ·in december 2015 , the company received approval of its supplemental new drug application from the fda for cefotan® ( entity for injection ) .
OrderedDict([('DRUG', 5), ('OTHER', 1)])|OrderedDict([('OTHER', 5)])|drug|cef cephalosporin penicillin ciprofloxacin cephalosporins|fda approved indications approval indication|cefotetan|received approval of the company  s supplemental new drug application ( snda ) from the u . s . food and drug administration ( fda ) for cefotan® ( entity for injection ) .
OrderedDict([('DRUG', 5), ('OTHER', 1)])|OrderedDict([('OTHER', 5)])|drug|cef cephalosporin penicillin ciprofloxacin cephalosporins|them companies fda legislation markets|cefotetan|we launched entity in september 2007 and are currently the only company to market entity vials in the united states .
OrderedDict([('DRUG', 5), ('OTHER', 1)])|OrderedDict([('OTHER', 5)])|drug|cef cephalosporin penicillin ciprofloxacin cephalosporins|approved indications fda approval licensed|cefotetan|we have received fda approval for our first product in this portfolio , cefotan® ( entity for injection ) , which we launched in the first quarter of 2016 .
OrderedDict([('DRUG', 5), ('OTHER', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|cef cephalosporin penicillin ciprofloxacin cephalosporins|sodium topical chlorhexidine aqueous potassium|cefotetan|·the company launched cefotan® ( entity disodium for injection ) and lidocaine 5% ointment in march of 2016 .
OrderedDict([('DRUG', 5), ('OTHER', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|cef cephalosporin penicillin ciprofloxacin cephalosporins|lidocaine clindamycin doxycycline morphine bupivacaine|cefotetan|entity is often used for surgical prophylaxis and offers the longest half-life of any cephalopsorin .
OrderedDict([('DRUG', 5), ('OTHER', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|cef cephalosporin penicillin ciprofloxacin cephalosporins|sodium aluminum injectable intravenous injecting|cefotetan|in the third quarter , app launched entity disodium for injection .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|topiramate anticonvulsant efficacy analog analogue|placebo paracetamol amitriptyline caffeine carbamazepine|topiramate|an overactive thyroid ; by patients taking a type of anti-depressant called maoi ; or by patients who are allergic to phentermine , entity , or any of the ingredients in qsymia .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|drug|topiramate anticonvulsant efficacy analog analogue|placebo levodopa metformin biofeedback statin|topiramate|controlled-release phentermine / entity therapy improves glycaemic status and prevents progression to type 2 diabetes mellitus :
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|topiramate anticonvulsant efficacy analog analogue|original placebo fda alternative suicide|topiramate|we anticipate that the label for qnexa , if approved , will contain the similar suicidality warnings to those contained in the entity label .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|topiramate anticonvulsant efficacy analog analogue|cocaine shs pesticides nicotine smoking|topiramate|the exercise primarily includes identifying these mother-infant pairs exposed to entity at the doses that the fda has recommended .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|topiramate anticonvulsant efficacy analog analogue|topiramate placebo naltrexone methamphetamine lamotrigine|topiramate|marketed in the united states under the name belviq and in september 2012 , vivus , inc . commercially launched its combination product , phentermine / entity , under the trade name qsymia .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|topiramate anticonvulsant efficacy analog analogue|carbamazepine phenytoin lamotrigine valproate gabapentin|topiramate|immediate release formulations of entity and oxcarbazepine are available in generic form and are marketed under the brand names of topamax and trileptal , respectively .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|topiramate anticonvulsant efficacy analog analogue|lamotrigine valproate phenytoin lithium vpa|topiramate|et-104 is one of etons three neurology-focused liquid product candidates , along with et-105 ( lamotrigine oral suspension ) and et-101 ( entity oral solution ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|topiramate anticonvulsant efficacy analog analogue|carbamazepine lamotrigine phenytoin valproate methylphenidate|topiramate|the company has two marketed products for epilepsy , oxtellar xr ( extended-release oxcarbazepine ) and trokendi xr ( extended-release entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|topiramate anticonvulsant efficacy analog analogue|placebo cocaine saline tenofovir aspirin|topiramate|in the qnexa studies , which included 15 offspring from women exposed to qnexa or entity , there were no reports of congenital malformations .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|topiramate anticonvulsant efficacy analog analogue|placebo levodopa biofeedback metformin antipsychotic|topiramate|controlled-release phentermine / entity therapy improves glycaemic status and prevents progression to type 2 diabetes mellitus : authors : w . timothy garvey , md ( a ) ; craig a .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|topiramate anticonvulsant efficacy analog analogue|melatonin dopamine serotonin caffeine what|topiramate|entity is believed to work in epilepsy through various mechanisms .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|topiramate anticonvulsant efficacy analog analogue|chlorpromazine morphine carbamazepine placebo topiramate|topiramate|in addition , we currently do not have manufacturing agreements in place for entity or phentermine .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|topiramate anticonvulsant efficacy analog analogue|placebo naltrexone topiramate methamphetamine amphetamine|topiramate|in july 2012 , vivus , inc . obtained fda approval for its combination product , phentermine / entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|topiramate anticonvulsant efficacy analog analogue|carbamazepine lamotrigine valproate phenytoin placebo|topiramate|the company has two marketed products for epilepsy , oxtellar xr® ( extended-release oxcarbazepine ) and trokendi xr® ( extended-release entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|topiramate anticonvulsant efficacy analog analogue|amphetamine naltrexone placebo methylphenidate naloxone|topiramate|and patient market research to assess potential growth of the obesity therapeutics market as well as preference shares between nb32 , phentermine / entity and lorcaserin .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|topiramate anticonvulsant efficacy analog analogue|antibiotics formulation pharmaceuticals formulations pharmacokinetics|topiramate|the pharmaceutical company performing research of entity alone announced they had discontinued development of a time-release formulation due to side effects at high doses .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|topiramate anticonvulsant efficacy analog analogue|placebo caffeine yes amphetamine topiramate|topiramate|<a  leland wilson> : we typically characterize our product as the low-dose combination of phentermine and entity , so thats what thats referring to , yes .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|topiramate anticonvulsant efficacy analog analogue|fda 200 60 uk h1n1|topiramate|u . s . attorneys office in boston , massachusetts seeking documents relating to the marketing , including alleged off-label marketing , of the drug topamax® ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|topiramate anticonvulsant efficacy analog analogue|placebo morphine bupropion dopamine methylphenidate|topiramate|qsymia® ( phentermine and entity extended release ) is approved by fda for chronic weight management .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|topiramate anticonvulsant efficacy analog analogue|carbamazepine valproate phenytoin lamotrigine phenobarbital|topiramate|or aeds , available in the united states and worldwide , including the generic products levetiracetam , lamotrigine , carbamazepine , oxcarbazepine , valproic acid and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|theophylline analogue analog analogues metabolite|aspirin doxorubicin corticosteroids cisplatin placebo|theophylline|fully funds a 36 patient phase 1 / 2 investigator-sponsored phase 1 / 2 study for use of hs-110 as a combination therapy with entity and oxygen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|theophylline analogue analog analogues metabolite|midazolam omeprazole cyp3a4 celecoxib cyp1a2|theophylline|therapeutic monitoring of cyp1a2 substrates with a narrow therapeutic index ( e . g . entity and tizanidine ) is recommended when coadministered with ocaliva .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|theophylline analogue analog analogues metabolite|trough cortisol opioid morphine dosing|theophylline|monitor entity levels if concurrent administration cannot be avoided .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|theophylline analogue analog analogues metabolite|salbutamol nicotine theophylline histamine acetylcholine|theophylline|entity relaxes the smooth muscle of the bronchial airways and thus acts mainly as a bronchodilator .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|drug|theophylline analogue analog analogues metabolite|warfarin anticoagulation stroke prescription heparin|theophylline|when taking zyflo , entity dose should be reduced by 50% and appropriately monitored ; patients taking propranolol or warfarin should be monitored and doses adjusted
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|theophylline analogue analog analogues metabolite|strategy phenomenon event habit task|theophylline|respiratory sales growth was moderated in 1995 by lower sales of theo-dur , a sustained-action entity , due to increased generic competition .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|theophylline analogue analog analogues metabolite|tobacco pharmaceutical herbal oil medicinal|theophylline|the company noted that it discontinued marketing its u . s . entity products in june 2001 and that proventil repetabs have not been available since july 2001 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|theophylline analogue analog analogues metabolite|salbutamol theophylline bronchodilator budesonide amiodarone|theophylline|the most commonly used oral bronchodilator is entity , a drug with good efficacy but which is capable of producing certain undesirable side effects such as disturbances in heart
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|theophylline analogue analog analogues metabolite|corticosteroids steroids antihistamines antidepressants salbutamol|theophylline|the bronchodilator agents most often used are ß2 agonists , anticholinergics , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|theophylline analogue analog analogues metabolite|placebo ibuprofen cannabis paracetamol amphetamine|theophylline|euphyllin , a drug based on a substance called entity , is used for the treatment of asthma and copd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|theophylline analogue analog analogues metabolite|ratios emissions ratio consumption concentrations|theophylline|[ * * * ] entity ( including product sold under the theochron ( r ) trademark )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|theophylline analogue analog analogues metabolite|salbutamol ibuprofen budesonide paracetamol aspirin|theophylline|entity and albuterol are frequently prescribed to produce dilation of bronchioles for both emphysema and chronic bronchitis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|theophylline analogue analog analogues metabolite|crt ga placebo chemotherapy te|theophylline|patients taking zyflo cr and entity should reduce the entity dose by 50% .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|theophylline analogue analog analogues metabolite|tablets usp pharmaceuticals paracetamol medicines|theophylline|decree also includes a recall , initiated in early may 2002 and directed to u . s . trade accounts , of all lots of entity , usp tablets and proventil ( albuterol sulfate , usp ) repetabs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|theophylline analogue analog analogues metabolite|placebo salbutamol theophylline nicotine indomethacin|theophylline|antihistamines , antiemetics , histamine h-2 receptor antagonists , barbiturates , prostoglandins , and bronchial dilators selected from the group consisting of terbutaline , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|theophylline analogue analog analogues metabolite|choline phosphatidylcholine bile cholesterol phospholipids|theophylline|other products choledyl ( r ) choledyl ( r ) ( oxtriphylline ) is the choline salt of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|theophylline analogue analog analogues metabolite|sold occur exists occurs occurred|theophylline|[ * * * ] entity in elixir form sold under the elixophyllin ( r ) trademark [
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|theophylline analogue analog analogues metabolite|asthma ics copd rhinitis asthmatic|theophylline|offices and central labs to measure patient blood drug levels for the most commonly prescribed therapeutic drugs to control asthma ( entity ) and epilepsy ( carbamazepine , and phenytoin ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|theophylline analogue analog analogues metabolite|theophylline salbutamol xanthine caffeine histamine|theophylline|bronchodilators dilate the airways and include beta agonists ( such as albuterol and bitolterol ) , xanthines ( such as entity ) and anticholinergics ( such as ipratropium ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|theophylline analogue analog analogues metabolite|ciprofloxacin gentamicin amikacin clindamycin metronidazole|theophylline|serious and fatal reactions have been reported in patients receiving concur-rent administration of ciprofloxacin and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ino resuscitation asthma trials intubation|50 200 60 111 80|inotersen|the company holds the rights for the commercialization of tegsedi™ ( entity ) and waylivra™ ( volanesorsen ) for the treatment of rare diseases in countries in latin america and the caribbean .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ino resuscitation asthma trials intubation|during spend save continue shorten|inotersen|slower rate than revenue with the increase primarily due to higher sg&a expenses as ionis prepares to commercialize volanesorsen and entity this year .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ino resuscitation asthma trials intubation|user technology economic utility computer|inotersen|commercial entity inventory acquired from ionis commercial inventory acquired clinical material acquired from ionis clinical material acquired liability for costs incurred and
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ino resuscitation asthma trials intubation|his pdf viii ix vii|inotersen|that the defendants breached their fiduciary duties in connection with the licensing transaction that we and ionis entered into regarding entity and akcea-ttr-lrx .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ino resuscitation asthma trials intubation|another originally recently now approved|inotersen|akcea has received marketing approval for an antisense drug , entity that was developed by ionis , in the u . s . , the eu and canada , for the treatment of hattr amyloidosis .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ino resuscitation asthma trials intubation|ttr tat fap cta tmp|inotersen|the parties agree to maintain books and records for entity and ionis-ttr-lrx that will allow each party to provide the other party with net revenues , expenses ( including each cost category
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|ino resuscitation asthma trials intubation|das aripiprazole colleagues tablets ritonavir|inotersen|tafamidis , patisiran and entity are currently marketed for attr-pn in various geographies our product concept  potentially best-in-class oral small molecule ttr stabilizer
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ino resuscitation asthma trials intubation|ptc smo usa cbz art|inotersen|today announced a collaboration under which ptc will commercialize two of akceas rare disease drugs in latin america ( latam ) : tegsedi™ ( entity ) and waylivra™ ( volanesorsen ) .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ino resuscitation asthma trials intubation|companies industry manufacturers scientists physicians|inotersen|both entity and volanesorsen are progressing toward regulatory filings for marketing authorization .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|ino resuscitation asthma trials intubation|placebo ketamine colleagues paracetamol carbamazepine|inotersen|icon clinical research limited , inc research toronto , inc . and medpace for the clinical studies for our drugs , including volanesorsen and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|drug|ino resuscitation asthma trials intubation|who everolimus imatinib biologics ribavirin|inotersen|ag10 also will not be the first treatment on the market for attr-pn as tafamidis , patisiran , and entity are approved for the treatment of attr-pn in a variety of countries globally .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ino resuscitation asthma trials intubation|200 40 50 fda nc|inotersen|we created tegsedi™ ( entity ) the worlds first rna-targeted therapeutic approved for the treatment of polyneuropathy of hereditary transthyretin ( ttr ) amyloidosis ( attr ) in adult patients
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ino resuscitation asthma trials intubation|das aripiprazole tablets placebo colleagues|inotersen|tafamidis , patisiran and entity are currently marketed for attr-pn in various geographies our product concept  oral small molecule ttr stabilizer
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ino resuscitation asthma trials intubation|implementation transaction simulation collaborative validation|inotersen|for ionis , this transaction achieves all the goals we laid out at the outset of our entity process .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|trial iv nep antiarrhythmic randomized|topical ophthalmic percutaneous intravenous aqueous|nepafenac|ilevro ( entity ophthalmic suspension ) , 0 . 3%fda approval received for the treatment of pain and inflammation associated with cataract surgery .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|trial iv nep antiarrhythmic randomized|topical percutaneous ophthalmic intravenous nasal|nepafenac|ilevro ( entity ophthalmic suspension ) , 0 . 3%launched in the us , received ema approval and launched in europe , and received health canada approval for the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|trial iv nep antiarrhythmic randomized|finally recently furthermore additionally here|nepafenac|entity , new formulation anti-inflammatory us 2011 eu 2012 approved approved - ilevro approved in q4 2012 - ilevro approved q2 2013
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|trial iv nep antiarrhythmic randomized|topical aqueous ophthalmic liposomal timolol|nepafenac|· alcon received approval to market ilevro , a new formulation of entity ophthalmic suspension ( 0 . 3% ) , in the us .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|trial iv nep antiarrhythmic randomized|topical ophthalmic aqueous percutaneous nasal|nepafenac|in august 2005 , the fda approved nevanac ( entity ophthalmic suspension ) 0 . 1% for the treatment of pain and inflammation associated with cataract surgery .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alkaloids analogue alkaloid metabolite derivatives|civil social legal criminal historical|phentermine|sus has been named as a defendant in a total of 4 , 196 such entity lawsuits , in respect of which sus has been dismissed as a defendant in 3 , 936 cases .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|alkaloids analogue alkaloid metabolite derivatives|topiramate lamotrigine valproate carbamazepine lithium|phentermine|marketed in the united states under the name belviq and in september 2012 , vivus , inc . commercially launched its combination product , entity / topiramate , under the trade name qsymia .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|alkaloids analogue alkaloid metabolite derivatives|topiramate lamotrigine lithium carbamazepine valproate|phentermine|qnexa is our investigational drug candidate involving low doses of entity and topiramate .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|alkaloids analogue alkaloid metabolite derivatives|methylphenidate amphetamine bupropion placebo nicotine|phentermine|in addition , a number of generic pharmaceutical products are prescribed for obesity , including entity , phendimetrazine , mazindol , benzphetamine and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alkaloids analogue alkaloid metabolite derivatives|200 during among although since|phentermine|entity hcl , usp sales in the year ended december 31 , 2001 reflected an increase in unit volume from the refilling of distribution
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|alkaloids analogue alkaloid metabolite derivatives|topiramate olanzapine quetiapine risperidone aripiprazole|phentermine|in particular , it is possible that patients will seek to acquire entity and topiramate , the generic components of qsymia .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|alkaloids analogue alkaloid metabolite derivatives|amphetamine benzodiazepines nicotine methylphenidate quinine|phentermine|a defendant in more than two thousand five hundred multi-defendant lawsuits involving the manufacture and sale of dexfenfluramine , fenfluramine , and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|alkaloids analogue alkaloid metabolite derivatives|medicines medicine law marijuana manufacturers|phentermine|the lawsuits allege that the manufacturers of entity knew that its use could cause serious side effects , but failed to warn against those dangers .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|alkaloids analogue alkaloid metabolite derivatives|market industry list prescription overdose|phentermine|to fisons ) and 585 ( as to rugby ) personal injury lawsuits in the u . s . ( including class actions ) concerning the weight-loss drug entity ( fisons brand name ionamin ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|alkaloids analogue alkaloid metabolite derivatives|topiramate placebo lamotrigine valproate quetiapine|phentermine|the equate study also contained a mid-dose of qnexa containing 46 mg of topiramate cr and 7 . 5 mg of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|alkaloids analogue alkaloid metabolite derivatives|topiramate valproate lamotrigine aripiprazole carbamazepine|phentermine|drug candidate for the treatment of obesity , incorporating low doses of active ingredients from two previously approved products , topiramate and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|alkaloids analogue alkaloid metabolite derivatives|medication together concurrently medications regularly|phentermine|contrary to the approved labelling of these products , physicians in the us co-prescribed entity with fenfluramine or dexfenfluramine for management of obesity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|alkaloids analogue alkaloid metabolite derivatives|topiramate quetiapine aripiprazole olanzapine pregabalin|phentermine|qsymia ( entity and topiramate extended release ) is approved by the u . s . food and drug administration ( &#x201c ; fda&#x201d ; ) for chronic weight management .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|alkaloids analogue alkaloid metabolite derivatives|rituximab methotrexate octreotide imatinib infliximab|phentermine|entity is the largest selling antiobesity therapeutic and is available in several generic forms .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|alkaloids analogue alkaloid metabolite derivatives|hydrochloride guanidine lidocaine meth ketamine|phentermine|&#160 ; the company had one approved and marketed product , suprenza ( entity hydrochloride ) , which it had out licensed for promotion in the united states , canada and mexico .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|alkaloids analogue alkaloid metabolite derivatives|sodium meth hen dimethyl diethyl|phentermine|to a decline in both unit volume and selling prices of fluvoxamine maleate and a decline in unit volume of entity hcl , usp .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|alkaloids analogue alkaloid metabolite derivatives|topiramate nicotine naltrexone dox sirolimus|phentermine|as expected , the chmp recommended against approval of the marketing authorization application ( maa ) for qsiva ( entity / topiramate er ) for the treatment of obesity in the european union .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alkaloids analogue alkaloid metabolite derivatives|nicotine artemisinin money internet she|phentermine|entity is sold at much lower prices than we charge for qsymia .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|drug|alkaloids analogue alkaloid metabolite derivatives|obesity dyslipidemia obese overweight osteoporosis|phentermine|there are a number of generic pharmaceutical drugs that are prescribed for obesity , predominantly entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|alkaloids analogue alkaloid metabolite derivatives|topiramate quetiapine aripiprazole pregabalin olanzapine|phentermine|qsymia ( entity and topiramate extended release ) is approved by the u . s . food and drug administration ( “fda” ) for chronic weight management .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|paracetamol placebo ibuprofen formulation tablets|carvedilol|which is available as both an oral and an iv formulation , and querto® , a therapeutic based on a substance called entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|metoprolol amlodipine placebo propranolol carvedilol|carvedilol|toprol-xl and coreg have generic equivalents commercially available in the u . s . ( metoprolol succinate and entity , respectively ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|pde mpa dox ptx iv|carvedilol|coreg ( entity ) is a beta-blocker indicated for the treatment of congestive heart failure and flomax ( tamsulosin ) is indicated for the treatment of
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|sodium potassium phosphate inorganic zinc|carvedilol|flamel technologies has collaborations with a number of leading pharmaceutical and biotechnology companies , including glaxosmithkline ( coreg cr® , entity phosphate ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|sodium magnesium creatine dietary inorganic|carvedilol|entity phosphate is indicated for the treatment of hypertension and heart failure .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|own original generic pharmaceutical tablets|carvedilol|teva and numerous other generic producers began selling their entity tablets ( the generic version of coreg® ) in september of 2007 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|industry approved formulation marketed sirolimus|carvedilol|european marketing application submitted in october 2014 ; and ( ix ) rhb-101 - a once-daily oral pill formulation of the cardio drug entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|own original generic tablets respective|carvedilol|teva and eight other generic producers began selling their entity tablets ( the generic version of gsks coreg® ) in september 2007 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|inorganic sodium potassium magnesium phosphate|carvedilol|this technology has successfully transitioned to commercial stage with coreg cr® , a micropump-based controlled-release formulation of entity phosphate , sold in the us since 2007 by gsk .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|ibuprofen paracetamol placebo theophylline paclitaxel|carvedilol|first part of the market includes generic drugs based on the immediate release of the generic active ingredient known as entity ( such as coreg® produced by glaxosmithkline ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|sodium inorganic potassium magnesium phosphate|carvedilol|when we entered into a license agreement for use of our micropump platform for an extended release formulation of entity phosphate .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|formulation approved sirolimus marketed etc|carvedilol|planned for the third quarter of 2014 ; and ( viii ) rhb-101 - a once-daily oral pill formulation of the cardio drug entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|industry approved marketed formulation sirolimus|carvedilol|european marketing application submitted in october 2014 ; and ( viii ) rhb-101 - a once-daily oral pill formulation of the cardio drug entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|triple otc eu bismuth azithromycin|carvedilol|during fiscal 2008 , we launched entity tablets , meprobamate tablets , omeprazole , finasteride , ceterizine otc , ranitidine otc , zolpidem tablets , terbinafine and ciprofloxacin er tablets .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|patent own original commercial final|carvedilol|teva would be permitted to continue selling its entity products , given that gsk  s patent has expired .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|sildenafil she everolimus infliximab pioglitazone|carvedilol|since 1991 , entity has been approved as a treatment for hypertension in several european countries , and in september 1995 , it was approved by
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|metoprolol placebo propranolol monotherapy atenolol|carvedilol|bucindolol in sort of all comers , what you see is a data set that compares favorably to metoprolol or a entity , at least on the data that are available .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|own patent commercial medicinal market|carvedilol|successful in its allegations of patent infringement , teva could be required to pay damages relating to past sales of its entity products .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|own original generic tablets respective|carvedilol|teva and eight other generic producers began selling their entity tablets ( the generic version of gsks coreg® ) in september 2007 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|drug|carvedilol metoprolol antagonist pharmacokinetics chf|metoprolol amlodipine placebo propranolol carvedilol|carvedilol|toprol-xl and coreg have generic equivalents commercially available in the u . s . ( metoprolol succinate and entity , respectively ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ol channel pollen oliv vol|max thc 50 mph oh|lemborexant|merck is marketing belsomra® ( suvorexant ) and eisai is marketing dayvigo® ( entity ) which are dual orexin receptor antagonists indicated for insomnia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ol channel pollen oliv vol|50 ptx 21 ox max|lemborexant|in december 2019 , eisai announced u . s . fda approval of dayvigo™ ( entity ) , a dual orexin receptor antagonist for the treatment of insomnia in adult patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ol channel pollen oliv vol|worldwide countries slowly naturally here|lemborexant|purdue and eisai are developing entity and glaxosmithkline is developing sb-649868 which are also dual orexin receptor antagonists .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|inhibitor than sodium efficacy potency|enoxaparin gemcitabine carboplatin paclitaxel cisplatin|lansoprazole|volume was flat as a result of competition on us sales of enoxaparin , lost us authorized generics of gemcitabine and entity in the prior year , and lower sales in germany .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|inhibitor than sodium efficacy potency|ppi pep ds tp asp|lansoprazole|the principal indications for prevacid ( entity ) , a proton pump inhibitor , are for short-term treatment of duodenal ulcers , gastric ulcers and erosive esophagitis .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|inhibitor than sodium efficacy potency|tablet generic herbal injectable pharmaceutical|lansoprazole|in september 2008 , abbott and takeda settled that patent infringement lawsuit against apotex and apotex was allowed to begin selling generic entity capsules in canada on may 1 , 2009 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|inhibitor than sodium efficacy potency|pharmaceuticals technology medicines service fda|lansoprazole|the original united states compound patent covering entity is licensed by tap from takeda and will expire in 2009 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|inhibitor than sodium efficacy potency|own original generic pure respective|lansoprazole|with tap pharmaceutical products inc . , or tap , granting tap the right to develop one or more products based on its entity ppi product and derivatives of entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|inhibitor than sodium efficacy potency|omeprazole ranitidine cimetidine placebo ppis|lansoprazole|in the treatment of reflux oesophagitis , it provides healing and symptom relief in more patients than losec / prilosec , entity or pantoprazole .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|inhibitor than sodium efficacy potency|derivatives analogues examples materials analogs|lansoprazole|to tap the north american rights to develop , manufacture and sell products resulting from the use of our technology with entity and derivatives of entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|inhibitor than sodium efficacy potency|pharmaceuticals tablets ibuprofen antibiotics curcumin|lansoprazole|our ongoing work with tap pharmaceuticals on an improved formulation of entity continues to progress smoothly .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|inhibitor than sodium efficacy potency|newly recently commonly fewer poorly|lansoprazole|million ) , which caused pricing to decline , as well as nearly usd 100 million of prior-year sales of sandozs gemcitabine and entity authorized generics .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|inhibitor than sodium efficacy potency|omeprazole ibuprofen paracetamol acetaminophen cimetidine|lansoprazole|dosage forms of acetaminophen , and an improved method of manufacturing for drugs requiring protection from stomach acid , such omeprazole and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|inhibitor than sodium efficacy potency|omeprazole metronidazole cimetidine ibuprofen ranitidine|lansoprazole|with respect to omeprazole and entity , we believe that we have created an improved method of manufacture , requiring less time and producing higher purity amid better
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|inhibitor than sodium efficacy potency|derivatives analogues peptides pharmaceuticals formulations|lansoprazole|the north american rights to develop , manufacture and sell products resulting from the use of our immediate-release ppi technology with entity and derivatives of entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|inhibitor than sodium efficacy potency|omeprazole ppis clarithromycin amoxicillin cimetidine|lansoprazole|nexium ( esomeprazole ) is the first proton pump inhibitor ( ppi ) to offer significant clinical improvements over losec / prilosec and its main competitors , entity and pantoprazole .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|inhibitor than sodium efficacy potency|bt gb sm fr ci|lansoprazole|tap also markets prevacid-registered trademark- ( entity ) , a proton pump inhibitor , and has a co-promotion arrangement with the company for prevacid-registered trademark- .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|inhibitor than sodium efficacy potency|everolimus infliximab adalimumab celecoxib respectively|lansoprazole|prevonco™ for the treatment of solid tumors , contains a currently third-party marketed anti-ulcer compound , entity , for the treatment of solid tumors .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|inhibitor than sodium efficacy potency|medicines pharmaceuticals pharmacists cigarettes pharmacy|lansoprazole|sales of entity , which was launched in december 2004 , accounted for 8% of our branded pharmaceutical revenues during the six months ended june 30 , 2005
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|inhibitor than sodium efficacy potency|omeprazole ppis ppi clarithromycin tablets|lansoprazole|pantoprazole faces competition from various other branded ppis , including takedas entity and astrazenecas esomeprazole .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|inhibitor than sodium efficacy potency|curcumin gemcitabine oxaliplatin celecoxib doxorubicin|lansoprazole|prevonco™ for the treatment of solid tumors , contains a marketed anti-ulcer compound , entity , that could be used alone or in combination with other chemotherapeutic agents .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|inhibitor than sodium efficacy potency|max dox oh wt 50|lansoprazole|tap also markets prevacid® ( entity ) , a proton pump inhibitor .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|drug|inhibitor than sodium efficacy potency|antibiotics them endoscopy inhibitors now|lansoprazole|preceding these notable launches , takeda pioneered gastroenterological breakthroughs in proton pump inhibitors beginning in the 1990s with entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|sodium benz azo benzo than|itraconazole fluconazole ketoconazole voriconazole nitrate|terconazole|prescription drugs in the antifungal field include nizoral ( ketoconazole ) , sporanox ( itraconazole ) , terazol ( entity ) and daktarin ( miconazole nitrate ) antifungal products .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|sodium benz azo benzo than|fluconazole itraconazole ketoconazole gentamicin tetracycline|terconazole|product in this category which does not contain a fungicide such as 95 table of contents clotrimazole , miconazole , entity or nystatin .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|sodium benz azo benzo than|fluconazole itraconazole voriconazole ketoconazole oxaliplatin|terconazole|the approved prescription therapies for vvc are diflucan ( fluconazole ) and terazol ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|sodium benz azo benzo than|fluconazole ketoconazole itraconazole gentamicin erythromycin|terconazole|a probiotic , purfem is the only product in this category which does not contain a fungicide such as clotrimazole , miconazole , entity or nystatin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|agent teg agents fibrin thromboxane|iv iii 50 dox max|azelastine|the astelin ( entity ) tablet nda for asthma will be withdrawn as soon as it is no longer needed to support the other two
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|agent teg agents fibrin thromboxane|iv iii ta ga dox|azelastine|the astelin ( entity ) tablet nda for rhinitis is pending at the fda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|agent teg agents fibrin thromboxane|iv dox ptx oc hy|azelastine|division the division had a successful year highlighted by the first full year of marketing a new antihistamine , 2 astelin ( entity ) nasal spray .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|agent teg agents fibrin thromboxane|hcl sodium topical iv diclofenac|azelastine|in august 2002 , we entered into an agreement with medpointe inc . to co-promote medpointe  s nasal-spray antihistamine , astelin® ( entity hcl ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|agent teg agents fibrin thromboxane|hcl sodium topical aqueous iv|azelastine|in august 2002 , we signed an agreement with medpointe , inc . for the co-promotion of astelin® ( entity hcl ) , a nasal-spray antihistamine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|agent teg agents fibrin thromboxane|hcl containing formulation hydrochloride sodium|azelastine|on october 1 , 2004 , we terminated our co-promotion agreement with medpointe , inc . , or medpointe , for the co-promotion of astelin brand entity hcl for the treatment of allergic rhinitis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|pas mit al ol med|50 60 200 90 111|patiromer|new patient starts , outpatient prescriptions and units sold to hospitals / other institutions for the full month of april 2016 for veltassa® ( entity ) for oral suspension ( veltassa ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|pas mit al ol med|50 60 40 16 max|patiromer|on october 21 , 2015 , the u . s . food and drug administration , or fda , approved our first drug , veltassa® ( entity ) for oral suspension , or veltassa , for the treatment of hyperkalemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|pas mit al ol med|candidate marketed designed promising synthesized|patiromer|relypsas lead product candidate is entity , which is also known as rly5016 , is a non-absorbed potassium binder that is currently being evaluated for the treatment of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|pas mit al ol med|ranging originating apart resulting prepared|patiromer|also aware of two products for which regulatory approval in the united states has been sought for treatment of hyperkalemia , entity from relypsa and zs-9 from zs pharma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|pas mit al ol med|physicians them providers eds specialists|patiromer|veitinger , a member of our board of directors , under which dr . veitinger provides certain consulting services to us in connection with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|pas mit al ol med|vi iv 200 50 pf|patiromer|to hospitals / other institutions for the full month of march and the three month period ended march 31 , 2016 for veltassa ® ( entity ) for oral suspension ( veltassa ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|pas mit al ol med|example instance pharmaceuticals industry chemicals|patiromer|the agreement , dsm fine chemicals has agreed to manufacture and supply for commercial sale the active pharmaceutical ingredient ( api ) for entity , the companys lead product candidate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|pas mit al ol med|recombinant synthetic mammalian exogenous another|patiromer|drug discovery technology or by selectively pursuing the in-licensing or acquisition of additional compounds that would be commercially synergistic with entity fos .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|drug|pas mit al ol med|psoriasis schizophrenia asthma medicines tuberculosis|patiromer|if the companys new drug application for entity is not accepted by the fda on or before december 31 , 2013 , 25% of the shares subject to the option shall
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|pas mit al ol med|50 max 60 16 40|patiromer|we are substantially dependent on the success of our first and only drug , veltassa® ( entity ) for oral suspension , or veltassa .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|pas mit al ol med|pay advocate compete society substitute|patiromer|relypsa has global royalty-free commercialization rights to entity for oral suspension , which has intellectual property protection in the u . s . until at least 2030 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|pas mit al ol med|our commercial another existing approved|patiromer|we are not permitted to market entity fos in the u . s . until we receive approval of our nda from the fda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|pas mit al ol med|pharmaceutical commercial gal art medicine|patiromer|in this offer to purchase ) with vifor fresenius medical care renal pharma ltd . ( vfmcrp ) , an affiliate of galenica , to commercialize entity fos outside of the united states and japan .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|pas mit al ol med|50 60 200 90 111|patiromer|new patient starts , outpatient prescriptions and units sold to hospitals / other institutions for the full month of february 2016 for veltassa® ( entity ) for oral suspension ( veltassa ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|pas mit al ol med|pay advocate prepare compete substitute|patiromer|relypsa has global royalty-free commercialization rights to entity for oral suspension , which has intellectual property protection in the united states until at least 2030 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|pas mit al ol med|medicines retail commercial purchase market|patiromer|relypsa intends to commercialize entity fos , if approved , with its own dedicated u . s . -based commercial team and specialty sales force of approximately 120 sales representatives .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|pas mit al ol med|potassium sodium phosphate prednisone diuretics|patiromer|the challenge all potassium binders ( e . g . entity ) have limited efficacy on per gram basis therapeutic dose for kayexelate , entity or zs-9 substantially the same ( 15-30 g / day )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|pas mit al ol med|your national structured business collaborative|patiromer|business entity clinical development program—pivotal phase 3 trial , page 101 please expand your discussion of your results to identify the serious adverse
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|pas mit al ol med|potassium sodium lithium magnesium caffeine|patiromer|entity is a non-absorbed , potassium binding polymer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|pas mit al ol med|vel iv bt vi av|patiromer|veltassa ( entity fos ) , an oral , polymer-based potassium binder , was approved for marketing by the fda in october 2015 and was commercially launched
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|benz bis hydrochloride derivatives sodium|amphetamine methylphenidate methamphetamine topiramate scopolamine|benzphetamine|several older agents , indicated for short-term administration , are amphetamine-like compounds including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|benz bis hydrochloride derivatives sodium|methylphenidate topiramate bupropion naltrexone amphetamine|benzphetamine|in the united states for the treatment of obesity , and several older agents , indicated for short-term administration , including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|benz bis hydrochloride derivatives sodium|methylphenidate topiramate bupropion amphetamine venlafaxine|benzphetamine|in addition , a number of generic pharmaceutical products are prescribed for obesity , including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|benz bis hydrochloride derivatives sodium|topiramate carbamazepine amphetamine lamotrigine methylphenidate|benzphetamine|several older drugs , indicated for short-term administration , include phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|benz bis hydrochloride derivatives sodium|amphetamine memantine antidepressants methylphenidate valproate|benzphetamine|the treatment of obesity , and several older agents , indicated for short-term administration , including phentermine , phendimetrazine , 33 table of contents entity and diethylpropion .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|benz bis hydrochloride derivatives sodium|methylphenidate topiramate placebo bupropion naltrexone|benzphetamine|products in the united states for the treatment of obesity , and several older agents , indicated for short-term administration , phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|benz bis hydrochloride derivatives sodium|amphetamine methylphenidate methamphetamine topiramate diazepam|benzphetamine|several older drugs , indicated for short-term administration , have an amphetamine-like profile , including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|benz bis hydrochloride derivatives sodium|versus fenofibrate nor placebo while|benzphetamine|mg tab mysoline® promethazine 12 . 5 , 25 , 50mg tab ( 2 separate andas ) phenergan® fenofibrate 54 , 160mg tab lofibra® entity 50mg tab didrex® not currently marketed .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|benz bis hydrochloride derivatives sodium|methylphenidate amphetamine propranolol bupropion topiramate|benzphetamine|in addition , a number of generic pharmaceutical products are prescribed for obesity , including phentermine , phendimetrazine , mazindol , entity and diethylpropion .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5)])|drug|ciprofloxacin resistant inhibited mic administered|gentamicin ciprofloxacin tetracycline amikacin vancomycin|ciprofloxacin|infecton® is the proprietary combination of the widely used antibiotic , entity , with technetium ( 99mtc ) , the most commonly used radioisotope in nuclear medical imaging .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|ciprofloxacin resistant inhibited mic administered|antidepressants benzodiazepines opioids medications antipsychotics|ciprofloxacin|should inform their physician if they are taking , or planning to take , any prescription or over-the-counter drugs , especially antidepressants and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|ciprofloxacin resistant inhibited mic administered|topical sodium synthetic aqueous named|ciprofloxacin|about otiprio® otiprio ( entity otic suspension ) is a fluoroquinolone antibacterial indicated for the treatment of pediatric patients with bilateral otitis media with effusion undergoing
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|ciprofloxacin resistant inhibited mic administered|pharmaceutical safety dosage medicinal antimicrobial|ciprofloxacin|bayer corporation has developed a once-daily entity product for the treatment of urinary tract infections , which is currently marketed by schering-plough corporation .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|ciprofloxacin resistant inhibited mic administered|agent against reagent amine substance|ciprofloxacin|and we agreed to settle the then pending litigation regarding bayer  s patent protecting entity hydrochloride .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin resistant inhibited mic administered|patent own remains recently been|ciprofloxacin|carlsbad has withdrawn all other defenses it had originally raised challenging the validity and enforceability of bayer ag  s entity patent .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|ciprofloxacin resistant inhibited mic administered|tablets tablet ibuprofen medicines pharmaceuticals|ciprofloxacin|we intend to begin marketing and selling the tablet dosage form of entity through our alliance with lannett if and when anda approval is given by the fda and following the expiration of
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|ciprofloxacin resistant inhibited mic administered|topical intravenous sodium nasal synthetic|ciprofloxacin|otiprio ( entity otic suspension ) is the first drug approved in the united states for use during tympanostomy tube placement ( ttp ) surgery and
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|ciprofloxacin resistant inhibited mic administered|rituximab infliximab linezolid daptomycin capecitabine|ciprofloxacin|entity is approved as therapy for infectious diarrhea with a dosing regimen of twice daily administrations for five to seven days .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin resistant inhibited mic administered|them adults patent hospitals decades|ciprofloxacin|if we lost our patent protection for entity , or if the expiration of the patent were accelerated to october 2002 , we believe that we would forego significant revenue .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin resistant inhibited mic administered|another every his our her|ciprofloxacin|if we are not already distributing the product , we , along with our partner , will have the right to begin distributing entity product manufactured by bayer .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin resistant inhibited mic administered|own final pharmaceutical safety commercial|ciprofloxacin|the decrease in the quarter reflects the launch of the company  s entity product on june 9 , 2003 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|ciprofloxacin resistant inhibited mic administered|ciprofloxacin azithromycin antibiotics metronidazole rif|ciprofloxacin|limitations of entity , rifaximin and tmp / smx , three of the most commonly prescribed treatments for infectious diarrhea , include one or more of the following :
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|ciprofloxacin resistant inhibited mic administered|cigarettes tobacco marijuana medicines nicotine|ciprofloxacin|based on the plaintiffs expert testimony in the california case , estimated sales of entity in california were approximately $500 million during the alleged damages period .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin resistant inhibited mic administered|them agreement consensus questionnaires surveys|ciprofloxacin|pursuant to the terms of the agreement , we began distributing entity on june 9 , 2003 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ciprofloxacin resistant inhibited mic administered|registered completed prescribed incident diagnosed|ciprofloxacin|year ended march 31 , 2002 2003 entity hcl rs .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 1)])|drug|ciprofloxacin resistant inhibited mic administered|ciprofloxacin fluoroquinolones levofloxacin erythromycin tetracycline|ciprofloxacin|gyra and parc are the targets of the fluoroquinolone class of antibacterial agents , such as entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|ciprofloxacin resistant inhibited mic administered|ml sf m2 rfa dx|ciprofloxacin|the fda placed the valortim® / entity study on partial clinical hold pending the outcome of the investigation .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|ciprofloxacin resistant inhibited mic administered|xr diclofenac hydrochloride ciprofloxacin ibuprofen|ciprofloxacin|proquin® xr ( entity hydrochloride ) is a once-daily treatment for uncomplicated urinary tract infections that the company no longer manufactures or markets .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin resistant inhibited mic administered|own national original existing international|ciprofloxacin|we intend to continue taking vigorous action to maintain our entity patent rights in the united states through their normal expiry in december 2003 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sulf derivatives bis derivative sodium|silver sulfate nitrate sulphate oxide|sulfadiazine|the most common topical antimicrobial agent used is silver entity cream .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|sulf derivatives bis derivative sodium|cream nitrate sulfate silver ointment|sulfadiazine|wound epithelialization was 11 days for patients treated with transcyte as compared to 18 days for patients treated with silver entity cream .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sulf derivatives bis derivative sodium|cream ointment gel dressings sulphate|sulfadiazine|as compared to silver entity , dermagraft-tc may reduce the pain , time and cost associated with once or twice daily dressing changes and excision .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sulf derivatives bis derivative sodium|gel cream sulfate ointment sulphate|sulfadiazine|a number of studies have been conducted which compared the efficacy of collagenase santyl ( r ) to standard treatment ( silver entity ) for deep second degree burns .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sulf derivatives bis derivative sodium|sulfate staining silver nitrate oxide|sulfadiazine|intended for delivery through the skin ) for the treatment of burns that is expected to not only reduce infection ( silver entity ) , but also enhance tissue growth .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|sulf derivatives bis derivative sodium|aeruginosa clearance aminotransferase relief dosage|sulfadiazine|in this same model , d2a21 demonstrated significant improvement in percent survival ( 85% versus 0% in the control group , p entity ( ssd ) and sulfamylon .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|sulf derivatives bis derivative sodium|nitrate sulfate cream dioxide chloride|sulfadiazine|in a clinical trial under a physician  s ide , transcyte was evaluated as an alternative to silver entity in the treatment of patients with limited to moderate partial-thickness burns .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|sulf derivatives bis derivative sodium|gel dressings cream dressing nanoparticles|sulfadiazine|transcyte was compared to silver entity which had twice daily dressing changes and wound debridement as per the burn center  s standard practice .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sulf derivatives bis derivative sodium|sulfate nanoparticles silver ointment microm|sulfadiazine|sildaflo is a dressing that incorporates silver 6 entity , the most widely-used topical antimicrobial for the treatment of burns .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sulf derivatives bis derivative sodium|silver nitrate oxide gel cream|sulfadiazine|in partial-thickness burns , dermagraft-tc , as compared to silver entity , has been shown to significantly reduce pain and to heal burns faster and with less scarring .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|sulf derivatives bis derivative sodium|topical evaluate commercial inhaled antimicrobial|sulfadiazine|entity silver ointment health product designed to assist in the prevention of infections related to burns .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|sulf derivatives bis derivative sodium|gel sulfate chloride nitrate silver|sulfadiazine|transcyte , as compared to silver entity in treating second degree burns , has been shown to heal burns faster .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sulf derivatives bis derivative sodium|sulfate nanoparticles nitrate silver sulphate|sulfadiazine|sildaflo is a dressing that incorporates silver entity , the most widely-used topical antimicrobial for the treatment of burns .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|sulf derivatives bis derivative sodium|topical compare evaluate inhaled randomised|sulfadiazine|entity silver ointment designed to the treatment or the prevention of infections related to burns .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|sulf derivatives bis derivative sodium|topical ointment silver sodium intravenous|sulfadiazine|banlangen tablets , dansheng tablets and entity silver ointment remain listed in the updated state insurance catalogue .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|sulf derivatives bis derivative sodium|topical silver ointment intralesional sodium|sulfadiazine|at present , xuesaitong soft capsules and entity silver ointment have already been listed in the insurance catalogue .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|al con iv ot vi|aripiprazole lithium quetiapine dexamethasone risperidone|conivaptan|the study evaluated both 20 and 40 mg / day doses of entity in hyponatremic patients and was conducted at 26 u . s . and 2 international centers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|drug|al con iv ot vi|iv vap lps iii vi|conivaptan|of an open label multicenter study adding to the growing body of literature supporting the efficacy and use of vaprisol ( entity ) injection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|al con iv ot vi|ketamine guanidine hydrochloride ibuprofen acetaminophen|conivaptan|about vaprisol® ( entity hydrochloride ) injectionvaprisol an intravenous treatment for hyponatremia used in the critical care setting .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|al con iv ot vi|ketamine guanidine hydrochloride ibuprofen acetaminophen|conivaptan|about vaprisol® ( entity hydrochloride ) injectionvaprisol is an intravenous treatment for hyponatremia used in the critical care setting .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ro 90 36 60 ol|hcl vi iv tmp mmc|roflumilast|two of our newest products , daliresp ( entity ) and viibryd ( vilazodone hcl ) became available to patients during the june 2011 quarter and were formally launched in late august
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|ro 90 36 60 ol|propranolol verapamil ibuprofen diltiazem clopidogrel|roflumilast|and these products were nebivolol , milnacipran , ceftaroline , entity , aclidinium , linaclotide , levomilnacipran and cariprazine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ro 90 36 60 ol|cream foam herbal topical silicone|roflumilast|pending of which we are unaware and which may later result in issued patents that we may infringe by commercializing entity cream , entity foam , arq-252 or arq-255 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ro 90 36 60 ol|pde ptx hdac tp ap|roflumilast|one such treatment is an oral formulation of a pde4 inhibitor ( entity ) with anti-inflammatory properties , although frequency of adverse events has limited its use in copd patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ro 90 36 60 ol|fda nps aas 200 pos|roflumilast|this year in addition to teflaro . in addition , we are hopeful to obtain fda approval later this quarter for daxas ( entity ) , for the treatment of copd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ro 90 36 60 ol|mtx pos iv ada nt|roflumilast|q31 ) what is the status of daxas ( entity ) ?
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ro 90 36 60 ol|m2 ml weeks gy kg|roflumilast|* forced expiratory volume in 1 second , primary endpoint of the ratio trial table of contents pharmaceuticals 9 entity , administered at a daily dose of 500 µg , is an effective product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ro 90 36 60 ol|pde 200 iii vi ics|roflumilast|daliresp ( entity ) , our selective phosphodiesterase 4 ( pde4 ) enzyme inhibitor indicated for the treatment to reduce risk of exacerbations in patients with severe
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ro 90 36 60 ol|adults pharmaceuticals asthma adolescents humans|roflumilast|as oral administration ariflo® ( cilomilast ) of glaxosmithkline pharmaceuticals , recently found approvable for maintenance of lung function in certain patients , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ro 90 36 60 ol|iii vi iv 111 fda|roflumilast|daliresp ( entity ) us patent proceedings in 2015 and subsequently , in response to paragraph iv notices from multiple anda filers , astrazeneca filed patent
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|ro 90 36 60 ol|corticosteroids steroids antibiotics agents medications|roflumilast|each of these areas present a variety of treatment challenges which may be well suited to treatment with topical entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|drug|ro 90 36 60 ol|copd aspirin celecoxib sildenafil statins|roflumilast|in addition , we did not observe the gastrointestinal or other side effects associated with entity , the only pde4 inhibitor currently on the market approved for the treatment of copd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 2)])|drug|ro 90 36 60 ol|metformin budesonide simvastatin theophylline levofloxacin|roflumilast|entity was generally well tolerated in the treatment of patients with copd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ro 90 36 60 ol|iii iv vi 111 fda|roflumilast|daliresp ( entity ) patent proceedings in the us in april 2015 , astrazeneca received several paragraph iv notices challenging certain patents listed in the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ro 90 36 60 ol|iv pos mtx ada iii|roflumilast|q34 ) what is the status of daxas ( entity ) ?
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 3)])|drug|ro 90 36 60 ol|aspirin statins metformin celecoxib nsaids|roflumilast|our clinical trials , and has not been observed to result in the gastrointestinal or other side effects commonly associated with entity , the only pde4 inhibitor currently on the market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ro 90 36 60 ol|mtx pos iv ada iii|roflumilast|q33 ) what is the status of daxas ( entity ) ?
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ro 90 36 60 ol|cer cds nc dma pos|roflumilast|daliresp / daxas ( entity ) copd $215m , up 14% ( 15% at cer ) growth driven by favourable affordability-programme changes and inventory movements in the us .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|ro 90 36 60 ol|nacl hg dextran glycerol dmso|roflumilast|we therefore elected to reduce the maximum concentration from 0 . 5% entity to 0 . 3% entity for subsequent development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|ro 90 36 60 ol|injectable commercial pharmaceutical tablet inexpensive|roflumilast|page 4 investment projects 2003 altana pharma will establish an ultra-modern entity tablet-producing factory in cork , ireland .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('DIS', 4), ('OTHER', 3)])|drug|renal pharmacokinetics sodium bis weeks|rosuvastatin simvastatin atorvastatin eze combinations|levamlodipine|simceres strategic cardiovascular portfolio also continues to grow with our recently launched cholesterol lowering drug rosuvastatin and hypertension drug entity both performing well .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|trial unknown antibiotics article trials|sodium nitrate methyl ammonium potassium|butoconazole|the caption immediately below the picture of gynazole-1 ( r ) reads : " gynazole-1 ( r ) ( entity nitrate ) vaginal cream 2% only one dose .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|trial unknown antibiotics article trials|nitrate ammonium sodium potassium nitrite|butoconazole|the product combines roche  s proprietary entity nitrate with kv  s proprietary site release ( r ) drug delivery technology .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|trial unknown antibiotics article trials|nitrate topical sodium nitrite chlorhexidine|butoconazole|its licensing partner , ferring , inc . of canada has received approval from the canadian regulatory agency , hpb to market kv  s gynazole-1 ( r ) ( entity nitrate 2% vaginal cream ) .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|trial unknown antibiotics article trials|nitrate nitrite sodium silver ammonium|butoconazole|important safety information for gynazole-1 ( entity nitrate vaginal cream usp , 2% ) 5 . 7% of patients enrolled in the gynazole●1 clinical trials reported complaints such as vulvar / vaginal
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|trial unknown antibiotics article trials|nitrate sodium ammonium topical methyl|butoconazole|gynazole-1 ( r ) ( entity nitrate 2% ) is a rapidly growing branded prescription vaginal antifungal product indicated for the local treatment of vulvovaginal candidiasis in butoconazole 
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|dysplasia carcinoma congenital degeneration ossification|asthma schizophrenia psoriasis epilepsy jia|achondroplasia|january 2014 , we announced the initiation of a phase 2 clinical trial for vosoritide for the treatment of children with entity .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|dysplasia carcinoma congenital degeneration ossification|asthma cah adhd child jia|achondroplasia|the phase 3 study is a randomized , placebo-controlled study of vosoritide in approximately 110 children with entity ages 5-14 for 52 weeks .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|dysplasia carcinoma congenital degeneration ossification|crc hcc nsclc psoriasis epilepsy|achondroplasia|currently , there are no medical therapies for entity approved by the fda .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|dysplasia carcinoma congenital degeneration ossification|osteoporosis osteoarthritis arthritis osteosarcoma osteopenia|achondroplasia|in animal models of entity , administration of synthetic cnp and cnp analogues rescued the impaired bone growth phenotype without significant adverse effects .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|dysplasia carcinoma congenital degeneration ossification|asthma jia epilepsy adhd schizophrenia|achondroplasia|we announced the initiation of a phase 2 clinical trial for bmn 111 for the treatment of children with entity .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|dysplasia carcinoma congenital degeneration ossification|dementia schizophrenia asthma copd disabilities|achondroplasia|this is approximately 25 percent of people with entity .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|dysplasia carcinoma congenital degeneration ossification|dementia schizophrenia asthma copd epilepsy|achondroplasia|this is approximately 25% of people with entity .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|dysplasia carcinoma congenital degeneration ossification|example comparison safety inclusion registration|achondroplasia| bmn-111 for entity : the company expects to initiate a phase 2 trial in patients in mid 2013 .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|dysplasia carcinoma congenital degeneration ossification|allergy antibodies anaphylaxis cirrhosis contraindications|achondroplasia|on july 23 , 2020 , the company announced that it had submitted the maa for vosoritide for the treatment of children with entity to the ema .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|dysplasia carcinoma congenital degeneration ossification|asthma hf copd hcc osteoporosis|achondroplasia|the goal is to provide a safer and more efficacious therapy for entity , than daily administration of short-acting cnp analogues .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|dysplasia carcinoma congenital degeneration ossification|asthma adhd epilepsy schizophrenia jia|achondroplasia|global phase 2 multiple dose , randomized study to assess the safety , tolerability , pharmacokinetics and efficacy of recifercept in children with entity .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|dysplasia carcinoma congenital degeneration ossification|diarrhea kd epilepsy asthma adhd|achondroplasia|continuing studies include our phase 3 study of vosoritide in approximately 110 children with entity for 52 weeks and a long-term open-label phase 2 study of approximately 23 children .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|dysplasia carcinoma congenital degeneration ossification|dwarf vitiligo obesity epilepsy osteoporosis|achondroplasia|transcon cnp is being developed for the treatment of entity , the most common form of dwarfism .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|dysplasia carcinoma congenital degeneration ossification|nsclc hcc osteoporosis chf cancers|achondroplasia|genetically-defined cancers , and bmn-111 , a modified c-natriuretic peptide , which is currently in phase i clinical development for the treatment of entity .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|dysplasia carcinoma congenital degeneration ossification|osteoporosis defects osteopenia fractures osteogenesis|achondroplasia|natriuretic peptide , or cnp , is a regulator of bone growth and can rescue defects in fibroblast growth factor 3 that cause entity resulting in dwarfism .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|dysplasia carcinoma congenital degeneration ossification|psoriasis acne asthma osteoporosis epilepsy|achondroplasia|rapid clinical development and ( iv ) the possible approval and commercialization of biomarins product candidates , including vosoritide for the treatment of entity .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|dysplasia carcinoma congenital degeneration ossification|gestational infants child pediatric ages|achondroplasia|the phase 2 study is a randomized , placebo-controlled study of vosoritide in approximately 70 infants and young children with entity ages zero to less than 60 months for 52 weeks .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|renal syndromes polyneuropathy anemia ataxia|glaucoma ald tuberculosis pediatrics obesity|adrenoleukodystrophy|we will also regain control of the preclinical programs in entity ( ald ) and two ophthalmic programs .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|renal syndromes polyneuropathy anemia ataxia|palsy infarction malaria hemorrhage vasospasm|adrenoleukodystrophy|european medicines agency ( ema ) granted an accelerated assessment to elivaldogene autotemcel ( eli-cel , lenti-d gene therapy ) for the treatment of cerebral entity ( cald ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|renal syndromes polyneuropathy anemia ataxia|immunoassay immunosorbent pharmacokinetics immunoassays pharmacokinetic|adrenoleukodystrophy|trb : x-linked entity , plans current status evaluation of vk0214 ongoing , encouraging in vitro results in vivo model in progress poc results expected 2016
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|renal syndromes polyneuropathy anemia ataxia|perfusion angiography palsy autoregulation infarction|adrenoleukodystrophy|cerebral entity ( cald ) the cald platform includes three patent portfolios , described below .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|renal syndromes polyneuropathy anemia ataxia|epilepsy schizophrenia asthma psoriasis hcc|adrenoleukodystrophy|our lenti-d product candidate has been granted orphan drug status by the fda and the ema for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('DRUG', 1), ('OTHER', 1)])|disease|renal syndromes polyneuropathy anemia ataxia|ald amyloidosis dyslipidemia hypothyroidism arthritis|adrenoleukodystrophy|our second trß agonist is vk0214 , which we are evaluating in the orphan disease known as x-linked entity , or x-ald .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|renal syndromes polyneuropathy anemia ataxia|palsy ischemia infarction edema hemorrhage|adrenoleukodystrophy|our lenti-d product candidate to treat cerebral entity ( cald ) •
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|renal syndromes polyneuropathy anemia ataxia|infarction cortex palsy malaria encephalopathy|adrenoleukodystrophy|on our two most advanced programs in tdt and cerebral entity , these data will dictate the timing and path for future regulatory submissions in the us and europe .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2), ('DRUG', 1)])|disease|renal syndromes polyneuropathy anemia ataxia|ald diseases dyslipidemia hepatitis myopathy|adrenoleukodystrophy|vk0214 is being evaluated as a potential treatment for x-linked entity ( x-ald ) , a devastating disease caused by a defect in a peroxisomal transporter called abcd1 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|renal syndromes polyneuropathy anemia ataxia|ophthalmic ophthalmologists glaucoma pharmaceuticals herbs|adrenoleukodystrophy|in february 2016 , the company announced biogens selection of entity as the non-ophthalmic indication of the three discovery programs .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|renal syndromes polyneuropathy anemia ataxia|metastases angiography metastasis transplantation infarction|adrenoleukodystrophy|clinical study of our bb2121 product candidate in relapsed / refractory multiple myeloma and updates on our lenti-d program in cerebral entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|renal syndromes polyneuropathy anemia ataxia|epilepsy leukemia dementia dermatomyositis thrombocytopenia|adrenoleukodystrophy|diseases treatable with hematopoietic stem cell transplants include inherited metabolic diseases , such as krabbe syndrome , metachromatic leukodystrophy , hurler syndrome and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|renal syndromes polyneuropathy anemia ataxia|ophthalmic ophthalmologists glaucoma pharmaceuticals herbs|adrenoleukodystrophy|in february 2016 , the company announced biogens selection of entity as the non-ophthalmic indication of the three discovery programs .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|renal syndromes polyneuropathy anemia ataxia|palsy infarction stroke hemorrhage encephalopathy|adrenoleukodystrophy|bio intends to use the net proceeds of this offering primarily to advance its clinical studies in ccald ( childhood cerebral entity ) , beta-thalassemia major and sickle cell disease .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|renal syndromes polyneuropathy anemia ataxia|ald bpd chd rd ihd|adrenoleukodystrophy|the worldwide incidence rate for entity , or ald , the superset of ccald , is approximately one in 20 , 000 newborn males .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|renal syndromes polyneuropathy anemia ataxia|ald ataxia encephalopathy dementia obesity|adrenoleukodystrophy|entity , or ald , is a genetically determined neurological disorder that affects 1 in every 17 , 900 boys worldwide or 1 in 50 , 000
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|renal syndromes polyneuropathy anemia ataxia|ophthalmic ophthalmologists pharmaceuticals herbs pesticides|adrenoleukodystrophy|in february 2016 , the company announced biogens selection of entity as the non-ophthalmic indication of the discovery programs .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|renal syndromes polyneuropathy anemia ataxia|pneumothorax preeclampsia sepsis stroke eclampsia|adrenoleukodystrophy|entity is a rare , often fatal condition believed to occur with an incidence of approximately one in 17 , 000 births .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2), ('DRUG', 1)])|disease|renal syndromes polyneuropathy anemia ataxia|ald dyslipidemia hepatitis diseases amyloidosis|adrenoleukodystrophy|▪ evaluation of vk0214 in an in vivo model of x-linked entity ( x-ald ) recently completed .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|renal syndromes polyneuropathy anemia ataxia|ald diseases glomerulonephritis amyloidosis tuberculosis|adrenoleukodystrophy|▪ advancing ind-enabling work for vk0214 in x-linked entity ( x-ald ) ; ind filing planned in 2h19 .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|utero cerebral encephalopathy encephal hydrocephalus|epilepsy microcephaly autism obesity ataxia|anencephaly|ntds include often devastating abnormalities such as spina bifida and entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|renal arginine insufficiency aminotransferase rats|spasticity dystonia ataxia neuropathy dyskinesia|argininemia|own decreased spasticity adapted from sakiyama et al “a successful trial of enzyme replacement therapy in a case of entity” j exp med .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|renal arginine insufficiency aminotransferase rats|psoriasis alcoholism obesity diseases al|argininemia|enzyme activity adapted from sakiyama et al “a successful trial of enzyme replacement therapy in a case of entity” j exp med .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|asthma prevalence airways adults rhinitis|psoriasis arthritis asthma tuberculosis osteoarthritis|asthma|acute inflammatory disease , as well as an oral anti-cytokine therapy that could be directed at chronic inflammatory diseases such as entity , rheumatoid arthritis and crohns disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|asthma prevalence airways adults rhinitis|allergy asthma obesity autoimmunity psoriasis|asthma|we currently have programs in entity / allergy , autoimmunity , transplant rejection , rheumatoid arthritis / inflammatory bowel disease , and tumor growth .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|asthma prevalence airways adults rhinitis|aml hcc nsclc isr crc|asthma|we remain on track to initiate a phase 1a single ascending dose clinical trial for entity in the second quarter with preliminary data anticipated by the end of 2014 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|asthma prevalence airways adults rhinitis|atopic psoriasis inclusion allergic final|asthma|•we reported positive , pivotal , phase 2b data for dupilumab in the entity indication and completed enrollment of three phase 3 studies of dupilumab in atopic dermatitis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|asthma prevalence airways adults rhinitis|oncology cardiology gastroenterology neurosurgery pharmacy|asthma|acuspheres three initial product candidates are designed to address large unmet clinical needs within cardiology , oncology and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|asthma prevalence airways adults rhinitis|atherosclerosis psoriasis asthma arthritis melanoma|asthma|vla-4 antagonists represent a new class of compounds that has shown promise in multiple preclinical animal models of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|asthma prevalence airways adults rhinitis|psoriasis asthma osteoporosis uc ibd|asthma|the primary focus of the collaboration will be to discover orally available vla-4 antagonists as treatments for entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|asthma prevalence airways adults rhinitis|asthma cough copd rhinitis bronchitis|asthma|cromolyn is considered first line therapy in mild persistent entity and is frequently prescribed for children .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|asthma prevalence airways adults rhinitis|diseases rhinitis disorders asthma reactions|asthma|is designed to mediate the suppression of ige and ige-producing cells and originally was developed for the treatment of allergic entity and other ige-mediated diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|asthma prevalence airways adults rhinitis|cirrhosis asthma copd hepatitis chb|asthma|development program to date for prv-300 included studies in healthy adult volunteers and adult patients with stable ( mild to moderate ) entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|asthma prevalence airways adults rhinitis|allergy allergies asthma cancers allergic|asthma|are engaged in the discovery , development and commercialization of novel therapeutics based on synthetic dna for the treatment of cancer , entity / allergies and infectious diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|disease|asthma prevalence airways adults rhinitis|asthma pneumonia esophagitis eosinophilic dermatitis|asthma|glaxosmithklines , or gsk  s , mepolizumab ( nucala ) which targets il-5 was approved for severe eosinophilic entity in adults and children older than 12 in 2015 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|asthma prevalence airways adults rhinitis|copd asthma airways exacerbations lungs|asthma|beclomethasone is a steroid used to treat the inflammatory component of entity and certain symptoms of copd .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|asthma prevalence airways adults rhinitis|pediatric elderly certain older obese|asthma|receptor subtypes , it can cause unwanted side effects including flushing , dyspnea and headache , and it should not be used in entity patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|asthma prevalence airways adults rhinitis|asthma psoriasis sle jia schizophrenia|asthma|the first human proof-of-concept data being obtained in a phase 2 study of genentechs anti-il-13 antibody lebrikizumab for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|asthma prevalence airways adults rhinitis|ischemic ischaemic migraine attack coronary|asthma|however , in certain instances , the process may be overly active , such as during an acute entity attack where an immediate inflammatory reaction occurs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|asthma prevalence airways adults rhinitis|asthma allergy allergic psoriasis influenza|asthma|xmab7195 were developing for entity and allergic disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|disease|asthma prevalence airways adults rhinitis|asthma spasm hyperresponsiveness obstruction stenosis|asthma|it is a prophylactic agent indicated for the management of bronchial entity and exercise-induced bronchospasm .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|asthma prevalence airways adults rhinitis|psoriasis stroke copd ckd ibd|asthma|clinical development program for zyflo consisted of 21 safety and efficacy trials in an aggregate of approximately 3 , 000 patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|asthma prevalence airways adults rhinitis|psoriasis acne asthma hcc copd|asthma|and sales infrastructure to promote zyflo and the controlled-release formulation of zileuton that we are developing for the treatment of entity upon regulatory approval from the fda .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|chord chondrosarcoma malignant benign cystic|melanoma sarcoma rhabdomyosarcoma lymphoma sarcomas|chordoma|we are conducting a multi-cohort , global phase 2 trial of tazemetostat in adults with ini1-negative tumors , including epithelioid sarcoma or entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|disease|chord chondrosarcoma malignant benign cystic|healthy unrelated elderly asymptomatic older|chordoma|the other three entity subjects in the study have been diagnosed with progressive disease .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|disease|chord chondrosarcoma malignant benign cystic|melanoma lymphoma metastases metastasis adenocarcinoma|chordoma|the trial was an open-label , phase 1 trial and enrolled 38 patients with metastatic cancer or entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|chord chondrosarcoma malignant benign cystic|nci rats humans vivo nsclc|chordoma| a phase 2 study in entity is being prepared for initiation at the nci .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|chord chondrosarcoma malignant benign cystic|crc nsclc hcc melanoma osteosarcoma|chordoma|clinical trial designed to investigate the safety and efficacy of evaluating gi-6301 in combination with radiation therapy in patients with entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|disease|chord chondrosarcoma malignant benign cystic|eligible evaluable enrolled consecutive japanese|chordoma|the company believes that the summary results from the 11 entity patients enrolled in this trial compare favorably with historically published data .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|chord chondrosarcoma malignant benign cystic|melanoma cancers sarcomas neoplasms cirrhosis|chordoma|additional phase ib / ii clinical trials in various indications are newly opened , including for colorectal and hepatocellular cancers and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|chord chondrosarcoma malignant benign cystic|mrt metastases sarcomas meningioma rhabdomyosarcoma|chordoma|trial of tazemetostat in adults with ini1-negative tumors , including epithelioid sarcoma , malignant rhabdoid tumors , or mrt , other ini1-negative tumors , and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|chord chondrosarcoma malignant benign cystic|nsclc crc copd melanoma hcc|chordoma|we are excited about the recent initiation of the phase 2 trial of gi-6301 at the nci for patients with entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|disease|chord chondrosarcoma malignant benign cystic|recombinant validated pegylated named hence|chordoma|mva-bn brachyury for the treatment of metastatic cancer and entity mva-bn brachyury is a cancer immunotherapy developed using our proprietary validated mva-bn platform .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|chord chondrosarcoma malignant benign cystic|aml sts mcl mrt mds|chordoma|we have obtained orphan drug designations for tazemetostat for the treatment of patients with fl , entity , malignant rhabdoid tumors , or mrt , soft tissue sarcoma , or sts , and mesothelioma .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|chord chondrosarcoma malignant benign cystic|nsclc hcc crc melanoma who|chordoma|clinical trial designed to investigate the safety and efficacy of evaluating gi-6301 in combination with radiation therapy in patients with entity is still enrolling patients .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|disease|chord chondrosarcoma malignant benign cystic|validation original entire remaining larger|chordoma|we added the entity cohort due to the high rate of enrollment of these patients in the other ini1-negative cohort and the observed clinical
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|chord chondrosarcoma malignant benign cystic|mtc cirrhosis lymphoma hepatitis colorectal|chordoma|the clinical and commercial landscape for pancreas cancer , non-small cell lung cancer , colorectal cancer , mtc , entity and chronic hepatitis b infection is rapidly changing .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|chord chondrosarcoma malignant benign cystic|mrt rhabdomyosarcoma rms sarcomas meningioma|chordoma|which we collectively refer to as ini1-negative tumors , including epithelioid sarcoma , malignant rhabdoid tumors , or mrt , other ini1-negative tumors , and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|disease|chord chondrosarcoma malignant benign cystic|our scientific his my civil|chordoma|dr . mahony also serves on the board of entity foundation , a nonprofit organization dedicated to improving the lives of those affected by chordoma .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|disease|chord chondrosarcoma malignant benign cystic|melanoma carcinoma melanomas adenocarcinoma sarcoma|chordoma|are conducting a multi-cohort global phase 2 trial of tazemetostat in adults with ini1-negative tumors , including epithelioid sarcoma or metastatic entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|chord chondrosarcoma malignant benign cystic|elderly older younger crc hcc|chordoma|it is believed that radiation therapy can reduce the risk of recurrence after surgery and prolong survival for entity patients .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|chord chondrosarcoma malignant benign cystic|hcc crc nsclc ibd melanoma|chordoma|the company believes that the gi-6301 tarmogen® , exclusively licensed to celgene corporation , has demonstrated promising initial results in entity patients evaluated in a recent phase 1 study .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|disease|chord chondrosarcoma malignant benign cystic|pediatric paediatric hospitalized our adolescent|chordoma|the cohort of patients in the phase 2 study of entity patients is ongoing , and we are evaluating tazemetostat in the dose-expansion portion of a phase 1 study in pediatric patients
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|macular pigment choroid carcinoma disorder|psoriasis aml osteoporosis leukemia asthma|choroideremia|the company&#8217 ; s lead product candidate , nsr-rep1 , for the treatment of entity is in phase 3 clinical development .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|macular pigment choroid carcinoma disorder|fabry dermatomyositis dmd gout adpkd|choroideremia|products for the treatment of the indications for which we have product candidates , including fabry disease , cystic fibrosis , xlrp and entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|macular pigment choroid carcinoma disorder|aav hcc melanoma epilepsy ibd|choroideremia|we are aware that biogen inc . , or biogen , is developing an aav-based gene therapy for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|macular pigment choroid carcinoma disorder|pharmaceuticals references france pharmacists classes|choroideremia|the designation of the first [ *** ] such roche product classes under section 2 . 2 ( including entity ) is included in the initiation payment set forth in section 12 . 1 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|macular pigment choroid carcinoma disorder|nsclc hcc aml isr crc|choroideremia|the pipeline also includes spk-7001 in an ongoing phase 1 / 2 clinical trial for entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|macular pigment choroid carcinoma disorder|psoriasis asthma acne endometriosis copd|choroideremia|spk-rpe65 to address a broad spectrum of blinding conditions , starting with the development of spk-chm for the potential treatment of entity , currently in a phase 1 / 2 clinical trial .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|macular pigment choroid carcinoma disorder|retinopathy glaucoma cataract cataracts neuropathy|choroideremia|these diseases include entity , diabetic retinopathy , glaucoma , lebers congenital amaurosis ( lca ) , macular telangiectasia , retinitis pigmentosa , wet amd and xlrs , among others .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|macular pigment choroid carcinoma disorder|schizophrenia epilepsy addiction asthma osteoporosis|choroideremia|spk-7001 has been granted orphan drug designation by fda and the european commission for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|macular pigment choroid carcinoma disorder|asthma psoriasis osteoporosis leukemia epilepsy|choroideremia|has been granted orphan product designation by the european commission and fda for its product candidate for the treatment of entity that is in a phase 1 / 2 clinical trial .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|macular pigment choroid carcinoma disorder|fviii tfpi prp haemophilia tf|choroideremia|our pipeline includes : a product candidate targeting entity , or chm , currently in a phase 1 / 2 clinical trial ; a product candidate for hemophilia a , currently in a phase 1 / 2
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|macular pigment choroid carcinoma disorder|cataract glaucoma retinitis blindness neurofibromatosis|choroideremia|some irds , such as retinitis pigmentosa ( rp ) , usher syndrome , or entity ( chm ) are associated with a gradual loss of vision , eventually leading to complete blindness .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|macular pigment choroid carcinoma disorder|france europe germany japan canada|choroideremia|in addition , roche currently holds a license to 4d-110 in entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|macular pigment choroid carcinoma disorder|hcc melanoma aav vitiligo epilepsy|choroideremia|we are aware that nightstarx is developing an aav-based gene therapy for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|macular pigment choroid carcinoma disorder|schizophrenia epilepsy addiction asthma psychosis|choroideremia|spk-chm has also been granted orphan drug designation by fda and the european commission for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|macular pigment choroid carcinoma disorder|objectives summary conclusions aim here|choroideremia|entity : spark therapeutics is enrolling patients in its first phase 1 / 2 clinical trial of spk-chm , an aav-based gene therapy for the
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|macular pigment choroid carcinoma disorder|asthma psoriasis bph crc hcc|choroideremia|our first such follow-on product candidate is spk-chm for the treatment of entity , or chm .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|macular pigment choroid carcinoma disorder|aml npc hcc psoriasis crc|choroideremia|our lead product candidate , nsr-rep1 , for the treatment of entity , or chm , is entering phase 3 clinical development in the first half of 2018 and represents the most clinically advanced
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|macular pigment choroid carcinoma disorder|schizophrenia epilepsy asthma addiction osteoporosis|choroideremia|spk-chm has been granted orphan drug designation by fda and the european commission for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|macular pigment choroid carcinoma disorder|malaria asthma psoriasis stroke tuberculosis|choroideremia|as a result , we have not sought , and may be unable to seek , patent protection for spk-chm to treat entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|macular pigment choroid carcinoma disorder|aav hcc psoriasis ibd epilepsy|choroideremia|we are aware that nightstar therapeutics plc , or nightstar , is developing an aav-based gene therapy for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|renal insufficiency disturbances follows during|neurofibromatosis colorectal hepatitis hcv pancreatic|citrullinemia|current therapy for entity type 1 is considered difficult for patients and generally ineffective , including diet restriction and nitrogen scavengers , and the only curative
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|renal insufficiency disturbances follows during|neurofibromatosis schizophrenia alzheimer dengue ckd|citrullinemia|individuals with entity type i can build-up excessive levels of ammonia and citrulline in their blood , potentially resulting in neurological deficits and other toxicities .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|renal insufficiency disturbances follows during|pku ch hba adhd cip|citrullinemia|*** revision to work plans for pku and entity
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|renal insufficiency disturbances follows during|hepatic pulmonary intestinal pediatric renal|citrullinemia|to evaluate the therapeutic response to dtx601 , we plan to measure ammonia levels , which is a well-established measure of entity type i disease status .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|renal insufficiency disturbances follows during|pku wilson encephalopathy dementia parkinsonism|citrullinemia|you know , wilson , or pku or entity?
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|renal insufficiency disturbances follows during|neurofibromatosis rotavirus diabetic hsv sporadic|citrullinemia|the incidence of entity type 1 is estimated at approximately 1 per 250 , 000 live births , affecting more than 2 , 000 individuals worldwide .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|cardiomyopathy renin hem renal mutations|finally furthermore moreover here conversely|afibrinogenemia|entity , the condition where the factor i is completely absent , is estimated to afflict one in one million , or 300 patients
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|renal cystic ureter nephropathy hyperparathyroidism|tm endometriosis uc bph ibd|homocystinuria|the company is orphan medical  s exclusive direct-to-patient distributor for cystadane ( tm ) , indicated for patients with entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|renal cystic ureter nephropathy hyperparathyroidism|europe cta japan germany canada|homocystinuria|acn00177 in entity in the second quarter of 2020 , we announced the approval of our clinical trial application , or cta , by the united
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|renal cystic ureter nephropathy hyperparathyroidism|dementia epilepsy stroke asthma copd|homocystinuria|there are approximately 1 , 000 patients with entity in the united states .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|renal cystic ureter nephropathy hyperparathyroidism|example humans instance adults alcoholism|homocystinuria|humans and an antidote for methanol or suspected methanol ingestion in humans ; and cystadane® ( betaine anhydrous for oral solution ) , for entity , a genetic disease .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|renal cystic ureter nephropathy hyperparathyroidism|endometriosis bph osteoporosis acne epilepsy|homocystinuria|cystadane is a known compound which has already been used to treat entity and is , therefore , not patentable for this indication .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|renal cystic ureter nephropathy hyperparathyroidism|epilepsy tuberculosis endometriosis osteoporosis schistosomiasis|homocystinuria|the company has obtained orphan drug status for cystadane for the treatment of entity , which provides marketing exclusivity to the company through october 2003 .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|renal cystic ureter nephropathy hyperparathyroidism|thalassemia etiology dermatomyositis obesity epilepsy|homocystinuria|elevated blood levels of this amino acid arise in the rare genetic disease of classical entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|renal cystic ureter nephropathy hyperparathyroidism|schizophrenia psoriasis atherosclerosis ckd ibd|homocystinuria|for aeb4104 demonstrating decreases in plasma homocysteine levels that improved important disease-related abnormalities and survival in a preclinical model of entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|renal cystic ureter nephropathy hyperparathyroidism|diseases malignancies psoriasis asthma cancers|homocystinuria|( “orphan” ) , a privately held , clinical-stage biopharmaceutical company focused on the development of product candidate ot-58 for the treatment of classical entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|renal cystic ureter nephropathy hyperparathyroidism|abortion stillbirth mortality birth infertility|homocystinuria|it has been estimated that entity occurs about once in every 200 , 000 live births worldwide .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|renal cystic ureter nephropathy hyperparathyroidism|our another what whose every|homocystinuria|understanding entity entity is an inherited disorder of methionine metabolism that results in elevated homocysteine and homocystine , or thcy , in plasma and urine .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|renal cystic ureter nephropathy hyperparathyroidism|epilepsy tuberculosis endometriosis osteoporosis schizophrenia|homocystinuria|the company obtained orphan drug status for cystadane for the treatment of entity , which provided marketing exclusivity to the company through october 2003 .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|renal cystic ureter nephropathy hyperparathyroidism|special our brief summary literature|homocystinuria|acn00177 in entity overview : our product candidate , acn00177 , is a novel pegylated , or polyethylene glycol modified , human enzyme engineered to degrade free homocysteine and
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|renal cystic ureter nephropathy hyperparathyroidism|technology nanotechnology biology medicine innovation|homocystinuria|we believe classical entity represents a viable market opportunity with significant unmet medical need , which we plan to address by continuing our preclinical development
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|renal cystic ureter nephropathy hyperparathyroidism|obesity schizophrenia hypercholesterolemia osteoporosis acromegaly|homocystinuria|it is the first agent approved by the fda for the treatment of entity , an inherited metabolic disease .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|renal cystic ureter nephropathy hyperparathyroidism|worldwide syndromes entity burden itself|homocystinuria|the board of hcu network america , a non-profit which provides advocacy and support for patients affected by the rare disease entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|renal cystic ureter nephropathy hyperparathyroidism|tuberculosis epilepsy endometriosis osteoporosis schistosomiasis|homocystinuria|the company has obtained orphan drug status for cystadane for the treatment of entity , which provides marketing exclusivity to the company through october 24 , 2003 .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|renal cystic ureter nephropathy hyperparathyroidism|obesity acromegaly osteoporosis hypercholesterolemia schizophrenia|homocystinuria|cystadane is approved by the fda for the treatment of entity , an inherited metabolic disease .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|renal cystic ureter nephropathy hyperparathyroidism|our als dmd diabetic schizophrenia|homocystinuria|the majority of entity patients suffer mutations of a gene that regulates the production of the enzyme known as cystathionine beta-synthase , or cbs , which
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|renal cystic ureter nephropathy hyperparathyroidism|hospitals japan germany france canada|homocystinuria|trial in patients with arginase 1 deficiency and closing cancer trials ; offset by a ramp-up in manufacturing for acn00177 in entity and higher personnel-related expenses .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|renal urinary urine ureter proteinuria|nephropathy ckd proteinuria urolithiasis anemia|cystinuria|tablets ) is approved in the united states for the prevention of cystine ( kidney ) stone formation in patients with severe homozygous entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|renal urinary urine ureter proteinuria|discovery medicine genomics crc biotechnology|cystinuria|aeglea has an active discovery platform , with the most advanced program for entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 2)])|disease|renal urinary urine ureter proteinuria|urolithiasis adpkd hyperparathyroidism nephropathy hematuria|cystinuria|entity is an inherited disease that causes stones made of the amino acid cystine to form in the kidneys , bladder and / or
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|renal urinary urine ureter proteinuria|elderly pediatric older hemodialysis asthmatic|cystinuria|our patent-pending customizable delayed-release tiopronin medications that may be prescribed by physicians as a lower-cost alternative to fda-approved thiola® for entity patients .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|renal urinary urine ureter proteinuria|worldwide iii duplication modular urology|cystinuria|aeglea has two programs in ind-enabling studies for homoentity and cystinuria and an active discovery pipeline .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|renal urinary urine ureter proteinuria|crc psoriasis hcc asthma melanoma|cystinuria|additionally , we have commenced ind-enabling studies for our aeb5100 program for the treatment of entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|renal urinary urine ureter proteinuria|nephropathy urolithiasis proteinuria stones ckd|cystinuria|( tiopronin ) is approved in the united states for the prevention of cystine ( kidney ) stone formation in patients with severe homozygous entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|renal urinary urine ureter proteinuria|fsgs igan nephropathy glomerulosclerosis proteinuria|cystinuria|evaluating sparsentan for fsgs and iga nephropathy , and the recent approval and launch of thiola ec for the treatment of entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|renal urinary urine ureter proteinuria|dm nephropathy cad schizophrenia ckd|cystinuria|captopril is not fda approved for the treatment of entity but has been prescribed for patients with entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 1)])|disease|renal urinary urine ureter proteinuria|proteinuria adpkd osteoporosis nephropathy schizophrenia|cystinuria|evaluating the suitability of our ersg library for development in additional renal disorders , including autosomal dominant polycystic kidney disease , and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|renal urinary urine ureter proteinuria|ckd urolithiasis adpkd nephropathy hemodialysis|cystinuria|and cysteine , decreased the amount of cystine in the urine and reduced kidney stone formation in a preclinical model of entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|renal urinary urine ureter proteinuria|familial idiopathic sporadic cirrhosis mutated|cystinuria|aeb5100 in patients with entity aeb5100 is a novel recombinant human enzyme that degrades plasma cystine and cysteine .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|renal urinary urine ureter proteinuria|pediatric elderly older asthmatic obese|cystinuria|our patent-pending tiopronin delayed-release compounded formulations that may be prescribed by physicians as a lower-cost alternative to fda-approved thiola® for entity patients .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|renal urinary urine ureter proteinuria|osteoporosis hyperparathyroidism hypercalcemia rhabdomyolysis nephrotoxicity|cystinuria|entity occurs due to genetic mutations in amino acid transporters that lead to increased amounts of cystine in the urine .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|renal urinary urine ureter proteinuria|psoriasis acne asthma copd osteoporosis|cystinuria|thiola•in 2018 , the company expects an nda to be filed for its new formulation of thiola for the treatment of entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|renal urinary urine ureter proteinuria|urolithiasis adpkd hematuria nephropathy ckd|cystinuria|entity is a chronic genetic disease that causes stones made of the amino acid cystine to form in the kidneys , bladder
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|renal urinary urine ureter proteinuria|nephropathy proteinuria urolithiasis stones ckd|cystinuria|( tiopronin ) is approved in the united states for the prevention of cysteine ( kidney ) stone formation in patients with severe homozygous entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|renal urinary urine ureter proteinuria|adpkd nephropathy ckd fsgs rcc|cystinuria|clinical development programs and evaluating the suitability of our ersg library for development in additional renal disorders , including adpkd and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|renal urinary urine ureter proteinuria|elderly hemodialysis obese pediatric older|cystinuria|citrate delayed release compounded formulations that may be prescribed by physicians as a lower-cost therapeutic alternative to fda-approved thiola® for entity patients .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|renal urinary urine ureter proteinuria|psoriasis epilepsy dementia asthma ibd|cystinuria|the company believes there are 10 , 000-12 , 000 patients with entity in the united states , of which 4 , 000-5 , 000 patients may be appropriate candidates for treatment .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|renal galactose diabetic disturbances follows|eligible thirty nine enrolled twenty|galactosemia|entity patients will be eligible for treatment up to 28 days total ( single dose followed by 27 consecutive days of dosing ) .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|disease|renal galactose diabetic disturbances follows|obesity dyslipidemia atherosclerosis hypercholesterolemia nafld|galactosemia|therapeutics plans to leverage recent fda guidance permitting biomarker-based development in low prevalence , slowly progressing rare metabolic diseases , such as entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 2)])|disease|renal galactose diabetic disturbances follows|cardiovascular obesity stroke dyslipidemia hyperlipidemia|galactosemia|in particular , the company is currently targeting treatments for cardiovascular disease , entity and diabetic complications .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|renal galactose diabetic disturbances follows|expert scientific nurse academic international|galactosemia|we also hosted an educational symposium featuring a panel of entity experts .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|renal galactose diabetic disturbances follows|pediatric stroke transplant asthma hf|galactosemia|we will continue to characterize at-007 long-term safety in adult entity patients and intend to initiate a pediatric study .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|renal galactose diabetic disturbances follows|diabetic uc ibd crc pcos|galactosemia|the key biomarker outcome of the study was reduction in galactitol , an aberrant toxic metabolite of galactose , formed by ar in entity patients .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|renal galactose diabetic disturbances follows|diabetic hypertensive t2dm pcos dm|galactosemia|at-007 treatment resulted in a statistically significant and robust reduction in plasma galactitol versus placebo in adult entity patients .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|renal galactose diabetic disturbances follows|schizophrenia epilepsy glioblastoma melanoma psoriasis|galactosemia|” recent highlights ·presented data on at-007 for treatment of entity at the entity foundation 2020 virtual conference .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|renal galactose diabetic disturbances follows|29 24 16 28 nine|galactosemia|at-007 was well tolerated , with no drug-related adverse events noted to date in entity patients or in the 72 healthy volunteers treated in part 1 of the trial .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|renal galactose diabetic disturbances follows|china canada korea france japan|galactosemia|· received fda orphan drug designation for at-007 in entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|renal galactose diabetic disturbances follows|psoriasis osteoporosis epilepsy asthma schizophrenia|galactosemia|· presented data highlighting at-007 for the treatment of entity at the ashg annual meeting .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|renal galactose diabetic disturbances follows|cohort retrospective pk cardiomyopathy entity|galactosemia|·announced start of at-007 pediatric entity study ; released additional 40mg / kg data from adult entity study .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|renal galactose diabetic disturbances follows|adults humans women hcc neonates|galactosemia|june 2020 , we announced additional supportive biomarker efficacy and safety data for at-007 in entity at 40 mg / kg .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|renal galactose diabetic disturbances follows|japan france korea china europe|galactosemia|in may 2019 , we received orphan drug designation for at-007 in entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|renal galactose diabetic disturbances follows|ibd jia fmf hcc sle|galactosemia|in june 2019 we initiated a pivotal phase 1 / 2 study in healthy volunteers and adults with entity to evaluate safety , pharmacokinetics , and biomarker endpoints in adults with entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|renal galactose diabetic disturbances follows|japan china beijing france korea|galactosemia|we initiated a phase 1 / 2 study of at-007 in entity in june 2019 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|disorder diseases congenital gaucher cystic|conclusion fact yeast summary vivo|galactosialidosis|in entity , the missing protease , cathepsin a , is a lysosomal stabilizing agent for the two other enzymes : sialidase and beta-galactosidase .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|disorder diseases congenital gaucher cystic|psoriasis cml adults dermatomyositis dmd|galactosialidosis|rhppca is in preclinical development as an enzyme replacement therapy for entity , a rare lysosomal storage disease for which there are no currently approved drug therapies .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|disorder diseases congenital gaucher cystic|gel there tolerated today transplantation|galactosialidosis|emil : well entity is another small enzyme therapy program like our mps7 program .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|disorder diseases congenital gaucher cystic|colleagues drosophila kim smith martin|galactosialidosis|how the opportunities at dimension compared to those in your own pipeline at a similar stage such as arcturus and entity?
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|disorder diseases congenital gaucher cystic|schizophrenia epilepsy dementia stroke malaria|galactosialidosis|currently no issued patents that cover the rhppca composition of matter or the use of rhppca for the treatment of entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|glioma glioblastoma malignant melanoma gliomas|schizophrenia epilepsy asthma addiction psychosis|glioma|in january 2013 , the ema also granted orphan drug protection to val-083 for the treatment of entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|glioma glioblastoma malignant melanoma gliomas|gliomas epilepsy glioma neuroblastoma astrocytomas|glioma|in february 2018 , an investigator-sponsored trial was initiated evaluating day101 in pediatric low-grade entity ( plgg ) , for which sunesis believes the scientific rationale is compelling .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|glioma glioblastoma malignant melanoma gliomas|psoriasis schizophrenia acne asthma epilepsy|glioma|california , san francisco , which is conducting phase 2 clinical trials of prophage series g-100 and g-200 for the treatment of entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|glioma glioblastoma malignant melanoma gliomas|colorectal cirrhosis hcc melanoma lymphoma|glioma|research our primary business focus is the clinical development of litx for the treatment of hepatoma , metastatic colorectal cancer , entity and one or more possible follow-on indications .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|glioma glioblastoma malignant melanoma gliomas|japan europe china korea taiwan|glioma|rcc tumors received and approximately 85% of the tumors received from patients in our ongoing phase 2 clinical trials in entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|glioma glioblastoma malignant melanoma gliomas|melanoma mesothelioma gliomas glioma neoplasms|glioma|by nih , a third party might be able to develop a cintredekin besudotox based drug for the treatment of malignant entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|glioma glioblastoma malignant melanoma gliomas|melanoma lymphoma glioma gliomas neoplasms|glioma|the company has completed a phase ii clinical trial for use of su101 as a treatment for refractory malignant entity and has recently initiated a phase iii clinical trial in first relapse entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|glioma glioblastoma malignant melanoma gliomas|japan oncology adults korea women|glioma|investigator sponsored trials include a phase 2 clinical trial in colorectal cancer and a phase 1 clinical trial in entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|glioma glioblastoma malignant melanoma gliomas|melanoma glioma breast mesothelioma lymphoma|glioma|the median survival time was over 609 days ( approximately 21 months ) , which compares favorably to the survival historically recorded for malignant entity patients ( approximately 12 months ) .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|glioma glioblastoma malignant melanoma gliomas|glioblastoma gliomas glioma melanoma hcc|glioma|in vivo studies that cannabinoids have a synergistic effect with temozolomide , the standard chemotherapeutic agent used in the treatment of entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|glioma glioblastoma malignant melanoma gliomas|schizophrenia epilepsy asthma osteoporosis hcc|glioma|sl-701 was awarded orphan drug designation from the fda for the treatment of entity in january 2015 .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|glioma glioblastoma malignant melanoma gliomas|retroviral neoplastic infectious leukemia tuberculosis|glioma|hypericin compounds to inactivate viruses and retroviruses , as a therapeutic or preventative for viral or retroviral diseases , and for anti- entity ( brain tumor ) indications .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|glioma glioblastoma malignant melanoma gliomas|epilepsy osteoporosis schizophrenia obesity asthma|glioma|ca4p has been granted orphan drug designation for the treatment of entity in the united states .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|glioma glioblastoma malignant melanoma gliomas|melanoma glioma neoplasms gliomas tumours|glioma|orphan drug act , gliadel® wafer became entitled to seven years of market exclusivity for the treatment of patients with malignant entity undergoing primary surgical resection .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|glioma glioblastoma malignant melanoma gliomas|gliomas glioblastoma epilepsy melanoma glioma|glioma|phase 2 clinical trials in a range of indications and is currently in a phase 2 clinical trial in recurrent entity , a type of brain cancer .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|glioma glioblastoma malignant melanoma gliomas|melanoma glioma malignant metastatic lymphoma|glioma|the first of these trials was a phase i / ii recurrent malignant entity clinical trial .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|glioma glioblastoma malignant melanoma gliomas|pancreatic pancreas breast prostate bladder|glioma|is overexpressed in numerous difficult to treat tumors including lung , breast , bladder , gastric , ovarian , endometrial , cervical , melanoma , esophageal , pancreatic , and entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|glioma glioblastoma malignant melanoma gliomas|psoriasis asthma schizophrenia melanoma tuberculosis|glioma|our product pipeline also includes compounds in phase 1 and 2 clinical development for entity , ulcerative colitis type 2 diabetes and schizophrenia .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|glioma glioblastoma malignant melanoma gliomas|hcc nsclc crc gbm melanoma|glioma|the crada also covers research to determine whether expression of a component of this pathway correlates with prognosis in entity patients .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|glioma glioblastoma malignant melanoma gliomas|cancers gbm diseases malignancies glioblastoma|glioma|granted protection under the orphan drug act by the united states food and drug administration ( “fda” ) for the treatment of entity , including gbm .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|vir infect sea nad rodents|benign familial idiopathic infantile neurofibromatosis|progeria|we are also developing lonafarnib monotherapy for treatment of entity and progeroid laminopathies .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|vir infect sea nad rodents|topic updated conference world nhs|progeria|( a ) the parties acknowledge that a priority review voucher may be available and awarded to eiger as the sponsor of the entity nda ( “entity prv” ) .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|vir infect sea nad rodents|ataxia fever johnson chiari shock|progeria|eiger has initiated a rolling new drug application ( nda ) submission process for lonafarnib to treat hutchinson-gilford entity syndrome ( hgps or entity ) and progeroid laminopathies .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|vir infect sea nad rodents|shock fever encephalitis withdrawal johnson|progeria|licensed field of use under the merck agreement to include all uses of lonafarnib related to the treatment of hutchinson-gilford entity syndrome ( entity ) in humans .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|vir infect sea nad rodents|ei ideal notion theoretical null|progeria|eiger agrees not to retain the entity prv for itself or any of its affiliates .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|vir infect sea nad rodents|benign infantile neurofibromatosis familial idiopathic|progeria|with prf any proceeds from the monetization of any prv that we may receive for lonafarnib for the treatment of entity and progeroid laminopathies to support future entity research .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|vir infect sea nad rodents|ataxia chiari neurological fever johnson|progeria|eiger is preparing an nda and maa for lonafarnib to treat hutchinson-gilford entity syndrome ( hgps or entity ) and progeroid laminopathies with plans to file in q4 2019 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|vir infect sea nad rodents|benign neurofibromatosis familial autoimmune dermatomyositis|progeria|the u . s . food and drug administration ( fda ) accepted the new drug application ( nda ) for accelerated review of zokinvytm ( lonafarnib ) for treatment of entity and progeroid laminopathies .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|vir infect sea nad rodents|benign infantile familial idiopathic hereditary|progeria|and data controlled by prf to prepare and file any new drug application ( “nda” ) for a product containing lonafarnib for entity and progeroid laminopathies .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|vir infect sea nad rodents|vivo humans mammals rats adulthood|progeria|that progerin may make the nucleus unstable , and that cellular instability may lead to the process of premature aging in entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|vir infect sea nad rodents|ataxia cardiomyopathy encephalopathy johnson special|progeria|hutchinson-gilford entity syndrome ( entity ) overview ultra-rare , fatal , premature aging pediatric disease point mutation in the lamin a gene results in a farnesylated aberrant protein ,
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 2)])|disease|vir infect sea nad rodents|atherosclerosis arteriosclerosis chd dementia hyperlipidemia|progeria|children with entity die of the same heart disease that affects millions of normally aging adults ( arteriosclerosis ) , but at an average age of
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|vir infect sea nad rodents|example adults overdose inclusion instance|progeria|as a result we may not successfully obtain approval by the fda of an nda for lonafarnib for entity in the near term , or at all .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hydrocephalus shunt malformation encephalopathy congenital|headache vomiting dizziness nausea fever|hydrocephalus|two events occurred in one patient , these were headache and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|hydrocephalus shunt malformation encephalopathy congenital|mild idiopathic hypoxic hydrocephalus hypertensive|hydrocephalus|prevents obstruction in the cerebrospinal fluid ( csf ) catheters implanted in the ventricle of the brain of patients who suffer from entity or normal pressure hydrocephalus ( nph ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|hydrocephalus shunt malformation encephalopathy congenital|shunt arteriovenous venous shunting arterial|hydrocephalus|we believe that our cerebral spinal fluid ( csf ) pressure management product line , including the advanced orbis sigma ii entity shunt , is unsurpassed in the industry .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|hydrocephalus shunt malformation encephalopathy congenital|existing modern contemporary newer pulmonary|hydrocephalus|entity shunt designs have changed little since their introduction in the 1950s .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|hydrocephalus shunt malformation encephalopathy congenital|blindness deafness epilepsy headache microcephaly|hydrocephalus|bone sclerosis impinges cranial nerve and spinal foramina with resulting neurologic abnormalities , including entity , progressive blindness and auditory impairment .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|hydrocephalus shunt malformation encephalopathy congenital|thrombocytopenia thrombosis hyperhomocysteinemia calcification fibrin|hydrocephalus|entity has also been reported in children with severe hypoplasminogenemia , apparently related to the deposition of fibrin in the cerebral ventricular
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|hydrocephalus shunt malformation encephalopathy congenital|ulcers mellitus disorder retinopathy nephropathy|hydrocephalus|the same condition , known as normal pressure entity ( nph ) , presented mostly in the elderly population , causing thinking and reasoning problems , difficulty walking , etc .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|hydrocephalus shunt malformation encephalopathy congenital|french german english spanish north|hydrocephalus|implantable drainage valve for treatment of entity - french patent application no . 9306356 filed june 27 , 1993 ( docket 91087 ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|hydrocephalus shunt malformation encephalopathy congenital|valves fluids stones organisms membranes|hydrocephalus|this slow accumulation means that the fluid pressure may not be as high as in other types of entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hydrocephalus shunt malformation encephalopathy congenital|hydrocephalus shunts aneurysms avms shunt|hydrocephalus|wayne state university , which supports the scstms potential as a viable technology for preventing occlusion in shunts used to treat entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|hydrocephalus shunt malformation encephalopathy congenital|hydrocephalus them hemorrhage meningitis stroke|hydrocephalus|shunts in the brain to help drain excess csf either externally or into the body for reabsorption to help treat entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|hydrocephalus shunt malformation encephalopathy congenital|abortion stillbirth birth obesity births|hydrocephalus|entity occurs in about 1 in every 500 births in the u . s . alone1 , 2 over 1 , 000 , 000 people in the united states currently
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|hydrocephalus shunt malformation encephalopathy congenital|nph ibs bph dm pop|hydrocephalus|microbot is developing scs as a device for the treatment of entity and nph and is developing tipcat as an endoscopic tool , with colonoscopy as the most immediate application of the tipcat
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|hydrocephalus shunt malformation encephalopathy congenital|hydrocephalus mild idiopathic benign intracranial|hydrocephalus|virob platform , microbot is currently developing its first product candidate : the self cleaning shunt , or scstm , for the treatment of entity and normal pressure hydrocephalus , or nph .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|hydrocephalus shunt malformation encephalopathy congenital|cns bbb gm csf cerebellum|hydrocephalus|tuberous sclerosis complex is also associated with a variety of resulting disorders including seizures , swelling in the brain ( entity ) , developmental delays and skin lesions , , .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hydrocephalus shunt malformation encephalopathy congenital|hydrocephalus stroke pneumothorax shunt meningitis|hydrocephalus|entity is most often treated by the surgical insertion of a shunt system .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|hydrocephalus shunt malformation encephalopathy congenital|hemorrhage occurred retinopathy glaucoma edema|hydrocephalus|mannitol injection entity , glaucoma , edema caused by deep burning or scald , acute renal failure and ascites .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|hydrocephalus shunt malformation encephalopathy congenital|scoliosis osteoporosis osteoarthritis myelopathy headache|hydrocephalus|silicone products , state of the art implanted application systems for spinal opiates and market leading valve systems for treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|hydrocephalus shunt malformation encephalopathy congenital|mild hydrocephalus idiopathic benign borderline|hydrocephalus|using the virob platform , microbot is currently developing the self cleaning shunt , or scstm , for the treatment of entity and normal pressure hydrocephalus , or nph .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hydrocephalus shunt malformation encephalopathy congenital|hydrocephalus epilepsy seizures avms ich|hydrocephalus|the proposed indication for use of the scs device would be for the treatment of entity as a component of a shunt system when draining or shunting of csf is indicated .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hyperprolactin prolactin endocrin secretion thyrotoxic|infertility obesity amenorrhea osteoporosis endometriosis|hyperprolactinemia|both sgas and fgas can cause entity , a hormonal imbalance resulting from d2 receptor blockade , which can lead to enlargement of breast tissue in males and infertility .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|hyperprolactin prolactin endocrin secretion thyrotoxic|adenomas malignancy pheochromocytoma tumours osteoporosis|hyperprolactinemia|x213 could be developed to treat entity in prolactinomas , a condition of benign tumors on the pituitary gland that leads to sexual dysfunction , infertility , and osteoporosis .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|hyperprolactin prolactin endocrin secretion thyrotoxic|category week regimen protocol table|hyperprolactinemia|treated for potential oncology indications for up to 48 weeks ; doses up to 20x higher than expected clinical dose for entity 1 .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 1)])|disease|hyperprolactin prolactin endocrin secretion thyrotoxic|acromegaly pheochromocytoma osteoporosis hypothyroidism epilepsy|hyperprolactinemia|by fda for use in humans for more than 15 years for several indications , including treating parkinson  s disease , acromegaly , and entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|hyperprolactin prolactin endocrin secretion thyrotoxic|society choice mind america humans|hyperprolactinemia|corporation ) , and we exercised our right to bring the product back into our portfolio to develop it for diseases of entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|hyperprolactin prolactin endocrin secretion thyrotoxic|acromegaly epilepsy osteoporosis pheochromocytoma dermatomyositis|hyperprolactinemia|respect to the other approved indications , and bromocriptine remains on the market for the treatment of parkinson  s disease , acromegaly , and entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hyperprolactin prolactin endocrin secretion thyrotoxic|pah ssc psoriasis epilepsy schizophrenia|hyperprolactinemia|finalized the design of a proof-of-concept study for xoma 213 , which may offer a new therapeutic option for patients with entity , and anticipate initiating the study midyear .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|hyperprolactin prolactin endocrin secretion thyrotoxic|radiotherapy melanoma chemotherapy bladder oncology|hyperprolactinemia|upjohn announced nda submissions to the fda for pramipexole for parkinson  s disease , remisar ( r ) for bladder cancer and dostinex ( r ) ( cabergoline ) for entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hyperprolactin prolactin endocrin secretion thyrotoxic|headache epilepsy insomnia schizophrenia nausea|hyperprolactinemia|this mechanism likely contributes to the favorable safety profile of iti-007 , with reduced risk for entity , akathisia , extrapyramidal symptoms , and other motoric side effects .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hyperprolactin prolactin endocrin secretion thyrotoxic|tolerability mortality safety anxiety delirium|hyperprolactinemia|the favorable safety profile of iti-007 with reduced risk for akathisia , extrapyramidal side effects and other motoric side effects , and entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hyperprolactin prolactin endocrin secretion thyrotoxic|osteoporosis psoriasis epilepsy schizophrenia asthma|hyperprolactinemia|cabergoline was recently launched in certain european countries for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|disease|hyperprolactin prolactin endocrin secretion thyrotoxic|placebo celecoxib medication pregabalin acupuncture|hyperprolactinemia|iti- 2 007 likely contributes to its favorable clinical profile with motoric tolerability similar to placebo and without entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|hyperprolactin prolactin endocrin secretion thyrotoxic|acromegaly pheochromocytoma osteoporosis dermatomyositis melanoma|hyperprolactinemia|approved by fda for use in humans for approximately 20 years for several indications , including treating parkinson  s disease , acromegaly , and entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 2)])|disease|hyperprolactin prolactin endocrin secretion thyrotoxic|prolactin progesterone tamoxifen aromatase dopamine|hyperprolactinemia|our endocrine portfolio also includes a phase 2-ready product candidate , xoma 213 , targeting the prolactin receptor , and entity , and multiple research-stage programs .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|hyperprolactin prolactin endocrin secretion thyrotoxic|acromegaly schizophrenia women prolactin humans|hyperprolactinemia|inhibit prolactin secretion with no reported effect on other pituitary hormones and are therefore generally the drugs of choice for entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|hyperprolactin prolactin endocrin secretion thyrotoxic|conclusion conclusions summary finally furthermore|hyperprolactinemia|entity : as with other drugs that antagonize dopamine d2 receptors , fanapttm elevates prolactin levels .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hypophosph rick renal include oste|asthma schizophrenia epilepsy diarrhea sepsis|hypophosphatasia|asfotase alfa has shown very compelling phase ii clinical data in infants and juveniles with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|hypophosph rick renal include oste|osteoporosis osteoarthritis arthritis osteopenia psoriasis|hypophosphatasia|we note that other examples of animal models of bone disease such as osteoporosis and entity have previously translated in vivo findings into the clinic .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|hypophosph rick renal include oste|tuberculosis pancreatitis acne diarrhea psoriasis|hypophosphatasia|time investing in preparations for the anticipated 2015 launch of our second commercial product , asfotase alfa for the treatment of entity ( hpp ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|kur al hu gm science|bill symbol stock el wa|kuru|and related stockholder matters market information our common stock is traded on the nasd  s over-the-counter bulletin board under the symbol " entity ob " since november 6 , 2008 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|macular lepr retinopathy ga clinic|versus than familial atypical homozygous|leprechaunism| type a and type b syndrome  rabson-mendenhall syndrome  entity type a syndrome patients have high circulating concentrations of insulin with impaired glucose tolerance or diabetes .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|macular lepr retinopathy ga clinic|obesity epilepsy schizophrenia autism hypoglycemia|leprechaunism|defects in the insulin receptor or insulin signaling pathways and include type a and type b syndromes , rabson-mendenhall syndrome and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|macular lepr retinopathy ga clinic|epilepsy schizophrenia autism migraine dermatomyositis|leprechaunism|these conditions include :  type a and type b syndrome ,  rabson-mendenhall syndrome , and  entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|includes cystic pulmonary describe benign|polyposis neurofibromatosis lam hemangioma neoplasia|lymphangioleiomyomatosis|the exist-2 study will evaluate everolimus in patients with angiomyolipoma associated with either ts or sporadic entity ( lam ) 9 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|disease|medulloblastoma malignant kind encompasses uncommon|meningioma glioblastoma glioma neuroblastoma melanoma|medulloblastoma|the following tumor types were treated thus far : high-grade glioma , entity , neuroblastoma , and ependymoma .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|medulloblastoma malignant kind encompasses uncommon|neuroblastoma osteosarcoma rhabdomyosarcoma lymphoma melanoma|medulloblastoma|of five childhood cancers typically treated with intensive cisplatin therapy , including newly diagnosed hepatoblastoma , germ cell tumor , osteosarcoma , neuroblastoma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|disease|medulloblastoma malignant kind encompasses uncommon|adolescents adults infants neuroblastoma lymphoma|medulloblastoma|the work at nih has now extended to the most common brain tumor of children , entity , and to the most common cancer of children , neuroblastoma .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|medulloblastoma malignant kind encompasses uncommon|adolescents adults infants neuroblastoma parents|medulloblastoma|the work at nih was then extended to the most common brain tumor of children , entity , and to the most common extracranial solid tumor of children , neuroblastoma .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|medulloblastoma malignant kind encompasses uncommon|melanoma glioblastoma neuroblastoma lymphoma rhabdomyosarcoma|medulloblastoma|in addition , compounds from both series have anti-cancer activity in animal models of glioblastoma multiforme , neuroblastoma , and entity , all cancers of neural tissue .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|medulloblastoma malignant kind encompasses uncommon|glioblastoma meningioma astrocytoma glioma melanoma|medulloblastoma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , astrocytoma , oligodendroglioma , mixed glioma , entity , and malignant meningioma .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|medulloblastoma malignant kind encompasses uncommon|glioblastoma melanoma glioma meningioma gliomas|medulloblastoma|joint patent applications with nih have been filed for the treatment of glioblastoma multiforme , entity , and neuroblastoma .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|medulloblastoma malignant kind encompasses uncommon|neuroblastoma osteosarcoma melanoma rhabdomyosarcoma lymphoma|medulloblastoma|of one of five childhood cancers typically treated with intensive cisplatin therapy , including hepatoblastoma , germ cell tumor , osteosarcoma , neuroblastoma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|medulloblastoma malignant kind encompasses uncommon|breast colorectal prostate ovarian gastric|medulloblastoma|in 2016 , the fda also granted orphan drug protection to val-083 for the treatment of entity and ovarian cancer .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|medulloblastoma malignant kind encompasses uncommon|cancers versus iii metastasis metastases|medulloblastoma|ii - paragon-hf to start aug . 2014 29 lde225 solid tumors ≥ 2018 i entity ≥ 2018 iii lee011 breast cancer 2016 iii - phase iii registration study enrolling solid tumors ≥
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|disease|medulloblastoma malignant kind encompasses uncommon|pancreatic pancreas gastric colorectal breast|medulloblastoma|sl-301 has demonstrated activity against brain and pancreatic cscs and tumor bulk in vitro , and against glioblastoma and entity cscs in in vivo animal models .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|medulloblastoma malignant kind encompasses uncommon|gliomas glioma medulloblastoma tumours neuroblastoma|medulloblastoma|have presented data indicating that val-083 offers potential therapeutic alternatives for the treatment of pediatric brain tumors including shh-p53 mutated entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|medulloblastoma malignant kind encompasses uncommon|hcc psoriasis epilepsy ibd nsclc|medulloblastoma|phase i clinical trials that are designed to evaluate dose and safety of gdc-0449 in pediatric and adult patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DRUG', 1), ('DIS', 1)])|disease|medulloblastoma malignant kind encompasses uncommon|they plants smokers macrophages humans|medulloblastoma|emory studies so far have indicated that entity may be particularly vulnerable to the ability of wp1066 to block the activated form of stat3 , a key signaling protein
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|medulloblastoma malignant kind encompasses uncommon|melanoma osteosarcoma lymphoma neuroblastoma rhabdomyosarcoma|medulloblastoma|treated with intensive cisplatin therapy for localized and disseminated disease , including newly diagnosed hepatoblastoma , germ cell tumor , osteosarcoma , neuroblastoma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|medulloblastoma malignant kind encompasses uncommon|neuroblastoma melanoma glioblastoma meningioma rhabdomyosarcoma|medulloblastoma|no conventional therapy exists , or a relapsed brain tumor with a predilection for lm dissemination ( primitive neuroectodermal tumor , rhabdoid tumor , entity ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|medulloblastoma malignant kind encompasses uncommon|breast prostate colorectal ovarian melanoma|medulloblastoma|the fda has also granted orphan drug protection to val-083 for the treatment of entity and ovarian cancer .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|medulloblastoma malignant kind encompasses uncommon|benign melanoma glioblastoma glioma malignant|medulloblastoma|pre-clinical studies of lb-100 that showed anti-cancer activity in models of a variety of human brain tumors , including glioblastomamultiforme ( gbm ) , entity and malignant meningioma .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|medulloblastoma malignant kind encompasses uncommon|melanoma lymphoma ovarian mesothelioma neuroblastoma|medulloblastoma|we have been granted orphan drug designation in the united states for gbm , ovarian cancer , and entity , and in europe for gbm .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|meningioma malignant meningiomas mimic benign|glioma melanoma gliomas neoplasms tumours|meningioma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , astrocytoma , oligodendroglioma , mixed glioma , medulloblastoma , and malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 2)])|disease|meningioma malignant meningiomas mimic benign|schwannoma schwannomas melanoma meningioma neurofibromatosis|meningioma|in february 2012 , the fda granted two orphan drug designations for ar-42 for the treatment of entity and the treatment of schwannoma of the central nervous system .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 2)])|disease|meningioma malignant meningiomas mimic benign|schwannoma schwannomas meningioma melanoma neurofibromatosis|meningioma|the fda has granted two orphan drug designations for ar-42 for the treatment of entity and the treatment of schwannoma of the central nervous system .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('DRUG', 1), ('OTHER', 1)])|disease|meningioma malignant meningiomas mimic benign|melanoma glioblastoma schwannoma meningioma glioma|meningioma|in addition , preclinical models have demonstrated anti-tumor activity in tumor types ( schwannoma and entity ) that are associated with the genetic illness , neurofibromatosis type 2 ( nf2 ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('DRUG', 1), ('OTHER', 1)])|disease|meningioma malignant meningiomas mimic benign|melanoma schwannoma meningioma glioblastoma glioma|meningioma|in addition , pre-clinical models have demonstrated anti-tumor activity in tumor types ( schwannoma and entity ) that are associated with the genetic illness neurofibromatosis type 2 ( nf2 ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 3)])|disease|meningioma malignant meningiomas mimic benign|schwannoma meningioma schwannomas rhabdomyosarcoma neurofibromatosis|meningioma|entity and schwannoma are rare , benign tumors that can present in different locations within the brain and the spinal cord and
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 1), ('DRUG', 1)])|disease|meningioma malignant meningiomas mimic benign|melanoma schwannoma lymphoma meningioma glioblastoma|meningioma|intend to collaborate with ohio state to conduct a phase 0 investigator-initiated study of ar-42 in patients with schwannoma and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|meningioma malignant meningiomas mimic benign|disorder stroke complication arthritis malignancy|meningioma|this patient was a 61-year-old female that was subsequently diagnosed with a non-treatment related entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|meningioma malignant meningiomas mimic benign|glioma melanoma gliomas neoplasms glioblastoma|meningioma|lb-100 that showed anti-cancer activity in models of a variety of human brain tumors , including glioblastomamultiforme ( gbm ) , medulloblastoma and malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|meningioma malignant meningiomas mimic benign|melanoma schwannoma glioblastoma glioma gbm|meningioma|in preclinical studies , ar-42 has demonstrated anti-tumor activity in both entity and schwannoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|prevalence obesity affect worldwide among|obesity disorders comorbidities diseases osteoporosis|obesity|in the majority of these men , often with co-morbid entity , t replacement is not optimal and indeed may be counterproductive .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|prevalence obesity affect worldwide among|tax financial budget incremental pay|obesity|eps growth  restating 2012 to exclude the 2012 entity impact of $0 . 10 and including the 2012 r&d tax credit impact of $0 . 06 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|prevalence obesity affect worldwide among|academic endocrine updated fda approved|obesity|development of the pyy compound and has recently announced that it expects to file an ind on pyy for an entity indication in 2003 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|prevalence obesity affect worldwide among|randomized iii randomised multicenter ongoing|obesity|exhibit 99 . 01 regeneron initiate phase ii entity clinical trial tarrytown , new york ( march 28 , 2000 ) - regeneron pharmaceuticals , inc . ( nasdaq : regn ) announced that it has initiated a
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|prevalence obesity affect worldwide among|disorder syndromes disorders respectively who|obesity|with open-label one year extensions , and was planned to include approximately four to six patients with genetically confirmed pomc deficiency entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|prevalence obesity affect worldwide among|sexual reproductive sexuality infertility fertility|obesity|-k . about vivus vivus , inc . is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing entity and sexual health .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|prevalence obesity affect worldwide among|osteoporosis psoriasis asthma infertility diseases|obesity|the company also has drug candidates or development programs for entity , erectile dysfunction , cardiovascular diseases , pulmonary diseases , inflammatory diseases and dermatologic diseases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|prevalence obesity affect worldwide among|future successful national suitable recommended|obesity|strong business momentum continues to accelerate sales & eps growth * sales growth in local currency retrospectively adjusted to exclude entity intervention business .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|disease|prevalence obesity affect worldwide among|led leads grant prescription safety|obesity|in addition , outsourced clinical expenses in the companys entity program increased by $0 . 3 million in 2007 for phase 1 clinical trials on the companys lead compound , ngd-4715 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|prevalence obesity affect worldwide among|schizophrenia epilepsy insomnia anxiety delirium|obesity|tolerability of topiramate , which was the scientific rationale for combining these two agents at low doses for the treatment of entity and related co-morbidities .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|prevalence obesity affect worldwide among|stroke obesity dementia hepatitis lymphoma|obesity|dr . amatruda was the senior vice president and franchise head , diabetes and entity at merck research laboratories .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|prevalence obesity affect worldwide among|eps productivity annual ef cumulative|obesity|* 2012 eps growth includes the 2012 entity impact of $0 . 10 and the 2012 r&d tax credit impact of $0 . 06 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|prevalence obesity affect worldwide among|obesity diseases atherosclerosis hyperglycemia morbidity|obesity|axokine is being developed for the treatment of entity and complications of entity such as type ii diabetes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|disease|prevalence obesity affect worldwide among|medications antibiotics chemotherapy radiotherapy analgesics|obesity|incontinence may be caused by a wide range of factors , including childbirth , menopause , surgery , entity , drugs and neurological damage .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 1)])|disease|prevalence obesity affect worldwide among|hyperglycemia obesity hypoxia pancreatitis chemically|obesity|academic researchers have increasingly linked chronic entity induced inflammation with type 2 diabetes and the potential role of inflammation in promoting insulin resistance in type 2 diabetes
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|prevalence obesity affect worldwide among|circumference height waist obesity skinfold|obesity|● increased waist circumference ( central or apple-shaped entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|prevalence obesity affect worldwide among|obesity osteoporosis asthma schizophrenia epilepsy|obesity|about orexigen therapeutics orexigen therapeutics , inc . is a biopharmaceutical company focused on the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|prevalence obesity affect worldwide among|asthma obesity schizophrenia atherosclerosis psoriasis|obesity|we believe that this discovery indicates that overactivity of this gpcr may be associated with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|prevalence obesity affect worldwide among|osteoporosis isr psoriasis chemotherapy leukemia|obesity|the companys lead combination product candidates targeted for entity are contrave , which is in phase 3 clinical trials , and empatic , which is in the later stages of phase 2
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|prevalence obesity affect worldwide among|obesity atherosclerosis nafld hypertriglyceridemia fibrosis|obesity|conversely , transgenic mice that overexpress dgat-1 in adipose tissue are predisposed to entity when fed a high-fat diet and have elevated levels of circulating free fatty acids .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|osteoporosis among prevalence prevention affect|stroke tuberculosis asthma psoriasis dementia|osteoporosis|the revenue decline in the second quarter largely reflects lower sales of fosamax for the treatment and prevention of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|osteoporosis among prevalence prevention affect|oncology psychiatric treating hospitalized nursing|osteoporosis|ystps trademarks xiangbala jidan and zangyu in particular are well recognized in china among physicians and hospital administrators , pharmacists and entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|osteoporosis among prevalence prevention affect|promising newer emerging biologic alternative|osteoporosis|other entity therapies include estrogen replacement therapy , selective estrogen receptor modulators , bisphosphonates and several new biologics that are under development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|osteoporosis among prevalence prevention affect|stroke cardiomyopathy osteoporosis arrhythmia pneumonia|osteoporosis|and outcomes management programs targeted at major categories of disease commonly found in the elderly , such as congestive heart failure , entity and atrial fibrillation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|osteoporosis among prevalence prevention affect|osteoporosis bmd pth osteopenia bmc|osteoporosis|a key set of parameters in the monitoring of entity , both before and after therapy , are biochemical markers of bone metabolism .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|osteoporosis among prevalence prevention affect|comparison women par safety analgesia|osteoporosis|under the asset purchase agreement , par acquired certain assets pertaining to calcitonin nasal spray for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|osteoporosis among prevalence prevention affect|osteoporosis menopause infertility amenorrhea relapse|osteoporosis|and estraderm mx ( estradiol ) transdermal patches are treatments for symptoms of estrogen deficiency in post-menopausal women , and prevention of post-menopausal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|osteoporosis among prevalence prevention affect|osteoporosis arthritis diseases osteoarthritis fractures|osteoporosis|▪ approved for treatment of adult entity ▪ synthetic analogues of pyrophosphate ▪ inhibit bone resorption ▪ can be given orally or intravenously , depending on compound ▪
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|osteoporosis among prevalence prevention affect|obesity hypercholesterolemia infertility anemia dyslipidemia|osteoporosis|portfolio will include two drug candidates in advanced clinical trials for the treatment of types 1 and 2 diabetes , severe entity and polycystic ovary syndrome .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|osteoporosis among prevalence prevention affect|cachexia obesity sarcopenia osteoporosis frailty|osteoporosis|currently in preclinical development as a potential treatment for age-related muscle loss , frailty , weight loss associated with cancer cachexia and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|osteoporosis among prevalence prevention affect|nutrition medicine immunology biochemistry oncology|osteoporosis|since 1990 , he has been the organizer and chairman of the international symposia on nutrition and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|osteoporosis among prevalence prevention affect|medicine immunology science psychiatry urology|osteoporosis|he is treasurer of the international foundation of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|osteoporosis among prevalence prevention affect|communities organizations hospitals families resources|osteoporosis|also organize free community healthcare activities , such as arranging for bone density tests and organizing seminars on our products and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|osteoporosis among prevalence prevention affect|asthma tbi burn copd stroke|osteoporosis|we believe this study population contains a patient population reflective of the type of severe entity patients that specialists will treat in their practices .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 2)])|disease|osteoporosis among prevalence prevention affect|anxiety obesity hyperlipidemia smoking dyslipidemia|osteoporosis|we also anticipate using our sales force to promote pharmaceutical products that address other midlife conditions such as hypertension , entity , depression and incontinence .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|osteoporosis among prevalence prevention affect|infections mortality sepsis falls stroke|osteoporosis|is also associated with a wide range of adverse events , including high blood pressure , weight gain , diabetes , serious infections and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|osteoporosis among prevalence prevention affect|osteoporosis psoriasis fractures aml diseases|osteoporosis|company and sb will continue to work together to develop one or more novel therapeutic approaches to the treatment of entity utilizing the company  s calcium receptor technology .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|osteoporosis among prevalence prevention affect|allergy osteoporosis refractory responders resistant|osteoporosis|we have licensed worldwide rights to our manufacturing and delivery technologies for pth for the treatment of entity to gsk .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|osteoporosis among prevalence prevention affect|schizophrenia epilepsy tuberculosis choice osteoporosis|osteoporosis|pursuant to a tenth amendment , we have been granted the exclusive right to negotiate an expansion of the field of use to include treatment of entity ( the &#8220 ; option&#8221 ; ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|osteoporosis among prevalence prevention affect|hcv tuberculosis cytomegalovirus syphilis hepatitis|osteoporosis|hepatitis c , and multiple sclerosis business categories , as well as other lower margin business categories , including human immunodeficiency virus and entity , versus the prior year .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2), ('BIO', 1)])|disease|paragangli malignant pheochromocytoma benign uncommon|pheochromocytoma melanoma prostate lymphoma adenocarcinoma|paraganglioma|we will make a difference in how patients with prostate cancer , pheochromocytoma , and entity are diagnosed and treated .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|paragangli malignant pheochromocytoma benign uncommon|pheochromocytoma carcinoma melanoma cholangiocarcinoma lymphoma|paraganglioma|administration ( fda ) has designated azedra as a breakthrough therapy for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|paragangli malignant pheochromocytoma benign uncommon|underwent completed randomized entered enrolled|paraganglioma|agent for prostate cancer phase 2 testing completed azedra™ treatment of pheochromocytoma and entity phase 2b registrational trial under special protocol assessment ( spa ) relistor®
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|disease|paragangli malignant pheochromocytoma benign uncommon|pheochromocytoma melanoma glioblastoma lymphoma neuroblastoma|paraganglioma|study of azedra demonstrating a positive safety profile and durable objective tumor responses in patients with neuroendocrine cancers , pheochromocytoma and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|disease|paragangli malignant pheochromocytoma benign uncommon|pheochromocytoma lymphoma neuroblastoma melanoma glioblastoma|paraganglioma|first patient had been dosed in the resumed pivotal phase 2 study of azedra™ in patients with malignant pheochromocytoma and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|paragangli malignant pheochromocytoma benign uncommon|pheochromocytoma melanoma lymphoma osteosarcoma prostate|paraganglioma|a preeminent , patient-centric oncology company and we intend to make a difference in how patients with prostate cancer , pheochromocytoma , and entity are diagnosed and treated .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 1), ('DRUG', 1)])|disease|paragangli malignant pheochromocytoma benign uncommon|pheochromocytoma carcinoma lymphoma adenoma adrenal|paraganglioma|to evaluate the efficacy and safety of the administration of two therapeutic doses of azedra in patients with pheochromocytoma / entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|paragangli malignant pheochromocytoma benign uncommon|colorectal neuroendocrine ovarian breast pancreatic|paraganglioma|twenty-four subjects were enrolled ( 11 female , 13 male ) , and seven subjects experienced stable disease in breast , neuroendocrine , entity , head / neck or colorectal cancer .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|paragangli malignant pheochromocytoma benign uncommon|malignant benign between among concerning|paraganglioma|about pheochromocytoma and entity pheochromocytomas and paragangliomas are rare neuroendocrine tumors that arise from cells of the sympathetic nervous system .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|disease|paragangli malignant pheochromocytoma benign uncommon|pheochromocytoma lymphoma neuroblastoma melanoma glioblastoma|paraganglioma|first patient had been dosed in the resumed pivotal phase 2 study of azedra™ in patients with malignant pheochromocytoma and entity , an ultra-orphan indication .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|paragangli malignant pheochromocytoma benign uncommon|pheochromocytoma lymphoma neuroblastoma melanoma epilepsy|paraganglioma|under compassionate use and named patient programs in 10 european countries in almost 1 , 300 patients , including those with pheochromocytoma and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|paragangli malignant pheochromocytoma benign uncommon|pancreas prostate pancreatic breast bladder|paraganglioma|or disease stabilization was observed in several cancer types , including parotid gland adenocarcinoma , colon , kaposi  s sarcoma , melanoma , ovarian , pancreatic and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|paragangli malignant pheochromocytoma benign uncommon|pah hcc metastasis cirrhosis sarcoidosis|paraganglioma|dysregulation of hif-2α under pseudohypoxia is thought to contribute to pah and entity , a neuroendocrine tumor .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5)])|disease|paragangli malignant pheochromocytoma benign uncommon|pheochromocytoma neuroblastoma lymphoma carcinoma glioblastoma|paraganglioma|in addition to potentially treating pheochromocytoma and entity , azedra may also have utility in treating neuroblastoma and other neuroendocrine tumors .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 1)])|disease|paragangli malignant pheochromocytoma benign uncommon|neuroblastoma pheochromocytoma lymphoma epilepsy carcinoma|paraganglioma|in addition to potentially treating pheochromocytoma and entity , azedra may also have utility in treating neuroblastoma and other neuroendocrine diseases .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|disease|paragangli malignant pheochromocytoma benign uncommon|pheochromocytoma melanoma carcinoma adenocarcinoma osteosarcoma|paraganglioma|candidates for prostate cancer , and resumed a pivotal phase 2 trial of an ultra-orphan radiotherapy candidate for malignant pheochromocytoma and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|disease|paragangli malignant pheochromocytoma benign uncommon|pheochromocytoma adenocarcinoma neuroblastoma adenomas cholangiocarcinoma|paraganglioma|we are developing azedra as a treatment for patients with malignant , recurrent , and / or unresectable pheochromocytoma and entity , which are rare neuroendocrine tumors .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|paragangli malignant pheochromocytoma benign uncommon|pheochromocytoma melanoma neuroblastoma cholangiocarcinoma carcinoma|paraganglioma|other than azedra , there are currently no approved anticancer treatments in the u . s . for malignant , recurrent , and / or unresectable pheochromocytoma and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|disease|paragangli malignant pheochromocytoma benign uncommon|pancreas pancreatic colorectal prostate breast|paraganglioma|stable disease was observed in several cancer types , including melanoma , ovarian , kaposi  s sarcoma , angiosarcoma , parotid gland adenocarcinoma , colorectal , pancreatic and entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|renal disorder mutations nephropathy pku|national international american uk university|phenylketonuria|camp km , et al . entity scientific review conference : state of the science and future research needs .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|renal disorder mutations nephropathy pku|pku schizophrenia adhd narcolepsy hypothyroidism|phenylketonuria|table of contents until march 2020 , we had been developing rtx-134 for the treatment of entity , or pku .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|renal disorder mutations nephropathy pku|hydroxylase pku heterozygous sporadic 25|phenylketonuria|page 2 of 3 about entity ( pku ) pku , a genetic disorder affecting at least 50 , 000 diagnosed patients under the age of 40 in the developed
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|disease|renal disorder mutations nephropathy pku|pku schizophrenia phenylalanine hydroxylase disorder|phenylketonuria|kuvan is a commercialized product for the treatment of patients with entity ( pku ) and / or for primary bh4 deficiency in certain countries .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|renal disorder mutations nephropathy pku|pku schizophrenia obesity psychosis epilepsy|phenylketonuria|privately held biotechnology company focused on developing therapies for orphan metabolic diseases , to evaluate sepiapterin ( " cnsa-001 " ) for the treatment of entity ( " pku " ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|renal disorder mutations nephropathy pku|pku schizophrenia hydroxylase ataxia disorder|phenylketonuria|company will use intrexons technology relating to the development and commercialization of novel biotherapeutics for the treatment of patients with entity ( pku ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|renal disorder mutations nephropathy pku|psoriasis migraine itp cll epilepsy|phenylketonuria|or in-license are currently pending patent applications except that we own one issued u . s . patent directed to methods of treating entity with rtx-134 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|renal disorder mutations nephropathy pku|pku schizophrenia obesity epilepsy hypothyroidism|phenylketonuria|privately held biotechnology company focused on developing therapies for the orphan metabolic diseases , is developing cnsa-001 for the treatment of entity ( " pku " ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|disease|renal disorder mutations nephropathy pku|pku phenylalanine develop potassium alanine|phenylketonuria|· october 1 , 2015 , biomarin to acquire rights to entity ( pku ) franchise from merck serono : the company announced that it has entered into a definitive agreement to acquire all
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|renal disorder mutations nephropathy pku|pku schizophrenia ketoacidosis narcolepsy psychosis|phenylketonuria|• pegvaliase for entity ( pku ) : pivotal results for the phase 3 prism-2 study ( formerly referred to as 165-302 ) that pegvaliase met the primary endpoint
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|renal disorder mutations nephropathy pku|pku schizophrenia ketoacidosis narcolepsy hypoglycaemia|phenylketonuria|investigational product candidates include phenoptin ( sapropterin hydrochloride ) , a phase 3 product candidate for the treatment of entity ( pku ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|renal disorder mutations nephropathy pku|sales example comparison france prices|phenylketonuria|and in the third quarter of 2017 , both france and germany had their first commercial sales . • kuvan® for entity :
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|renal disorder mutations nephropathy pku|25 hydroxylase pku 23 21|phenylketonuria|about entity ( pku ) pku , a genetic disorder affecting at least 50 , 000 diagnosed patients under the age of 40 in the developed
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|renal disorder mutations nephropathy pku|iv iii 1a genotype 2b|phenylketonuria|mucopolysaccharidosis iv type a , or mps iva mucopolysaccharidosis vi , or mps vi entity , or pku 6 kuvan has been granted orphan drug status in the eu , which together with pediatric
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|disease|renal disorder mutations nephropathy pku|obesity smoking cholesterol asthma tobacco|phenylketonuria|substantial progress has been made over the past six decades , beginning with the first report of dietary control of entity in the early 1950s .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|renal disorder mutations nephropathy pku|cirrhosis malnutrition alcoholism encephalopathy malabsorption|phenylketonuria|nutritional management of individuals with rare , inborn errors of metabolism such as maple syrup urine disease ( mead johnson bcad ) and entity ( mead johnson phenyl-free ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|renal disorder mutations nephropathy pku|obesity rhabdomyolysis encephalopathy malnutrition acidosis|phenylketonuria|nutritional management of individuals with rare , inborn errors of metabolism such as maple syrup urine disease ( mead johnson bcad® ) and entity ( mead johnson phenyl-free® ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|disease|renal disorder mutations nephropathy pku|hydroxylase tyrosine pku phenylalanine heterozygous|phenylketonuria|about entity ( pku ) pku is caused by a defect in the gene encoding phenylalanine hydroxylase ( pah ) , a liver enzyme that metabolizes phe .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2), ('BIO', 1)])|disease|pheochromocytoma malignant paragangli carcinoma shows|prostate melanoma pheochromocytoma meningioma adenocarcinoma|pheochromocytoma|we will make a difference in how patients with prostate cancer , entity , and paraganglioma are diagnosed and treated .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|pheochromocytoma malignant paragangli carcinoma shows|neoplasms melanoma neuroblastoma tumours gliomas|pheochromocytoma|azedra program " means the company  s therapeutic program for the treatment of malignant entity , pediatric neuroblastoma and carcinoid cancers with ultratrace iobenguane i 131 .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 3)])|disease|pheochromocytoma malignant paragangli carcinoma shows|pheochromocytoma paragangli adrenal thyroid carcinoid|pheochromocytoma|trial to evaluate the efficacy and safety of the administration of two therapeutic doses of azedra in patients with entity / paraganglioma .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|pheochromocytoma malignant paragangli carcinoma shows|pheochromocytoma adenomas hemangiomas meningiomas neoplasms|pheochromocytoma|although the majority of entity and paragangliomas are benign , approximately 10-25% of these tumors present with metastasis , and up to 35% of these cases are
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|pheochromocytoma malignant paragangli carcinoma shows|pediatric paediatric adults neonatal adolescent|pheochromocytoma|we are currently pursuing adult clinical trials for entity and pediatric clinical trials for neuroblastoma , which are detailed below .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|pheochromocytoma malignant paragangli carcinoma shows|pediatric neuroblastoma paediatric pancreatic rhabdomyosarcoma|pheochromocytoma|the company is conducting azedra pivotal trials for both adult entity and pediatric neuroblastoma neuroendocrine tumor indications .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|pheochromocytoma malignant paragangli carcinoma shows|neuroblastoma melanoma glioblastoma breast rhabdomyosarcoma|pheochromocytoma|azedra clinical development plan azedra is under development for the systemic treatment of the metastatic neuroendocrine cancers entity and neuroblastoma .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|pheochromocytoma malignant paragangli carcinoma shows|melanoma prostate meningioma lymphoma pheochromocytoma|pheochromocytoma|to become a preeminent , patient-centric oncology company and we intend to make a difference in how patients with prostate cancer , entity , and paraganglioma are diagnosed and treated .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|pheochromocytoma malignant paragangli carcinoma shows|melanoma pheochromocytoma glioma mesothelioma gliomas|pheochromocytoma|that the first patient had been dosed in the resumed pivotal phase 2 study of azedra™ in patients with malignant entity and paraganglioma .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|pheochromocytoma malignant paragangli carcinoma shows|melanoma prostate mesothelioma pheochromocytoma neoplasms|pheochromocytoma|two product candidates for prostate cancer , and resumed a pivotal phase 2 trial of an ultra-orphan radiotherapy candidate for malignant entity and paraganglioma .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|pheochromocytoma malignant paragangli carcinoma shows|breast carcinoid colorectal pancreatic ovarian|pheochromocytoma|azedra is currently in a phase 1 trial for entity or carcinoid tumors , and has received orphan drug status and a fast track designation by the united states food and
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|pheochromocytoma malignant paragangli carcinoma shows|pheochromocytoma neuroendocrine tumours neoplasms adrenal|pheochromocytoma|we are developing azedra as a treatment for patients with malignant , recurrent , and / or unresectable entity and paraganglioma , which are rare neuroendocrine tumors .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 2)])|disease|pheochromocytoma malignant paragangli carcinoma shows|pheochromocytoma hemangiomas adenomas neoplasms schwannomas|pheochromocytoma|about entity and paragangliomas entitys and paragangliomas are rare neuroendocrine tumors that arise from cells of the sympathetic nervous system .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|pheochromocytoma malignant paragangli carcinoma shows|pheochromocytoma paragangli adrenal melanoma neoplasms|pheochromocytoma|perelman school of medicine presented preliminary dosimetry data from the phase 2 study in patients with iobenguane-avid metastatic and / or recurrent entity / paraganglioma .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|pheochromocytoma malignant paragangli carcinoma shows|hippocampal neuroblastoma c6 pc12 pheochromocytoma|pheochromocytoma|pharmacology 2005 ; 74 : 65-78 . " local anesthetic procaine protects rat entity pc12 cells against beta-amyloid-induced neurotoxicity " .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|pheochromocytoma malignant paragangli carcinoma shows|neuroblastoma pheochromocytoma medulloblastoma rhabdomyosarcoma meningioma|pheochromocytoma|in addition to potentially treating entity and paraganglioma , azedra may also have utility in treating neuroblastoma and other neuroendocrine diseases .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1), ('DRUG', 1)])|disease|pheochromocytoma malignant paragangli carcinoma shows|rcc pheochromocytoma melanoma neuroblastoma adenocarcinoma|pheochromocytoma|patients harboring a rare head and neck cancer , known as paraganglioma , and a rare adrenal or extra-adrenal cancer , known as entity , and rare subset clear cell rcc .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|glands prolactin gland malignant benign|pheochromocytoma acromegaly there malignancy hyperthyroidism|prolactinoma|entity is a condition in which a non-cancerous tumor of the pituitary gland overproduces prolactin .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|disease|glands prolactin gland malignant benign|schizophrenia efficacy preclinical humans monotherapy|prolactinoma|study for xoma 213 , which , if successful , will allow us to advance the compound into a phase 2 study for entity and potentially into anti-psychotic medication-induced hyperprolactinemia .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|glands prolactin gland malignant benign|elderly stroke psoriasis hospitalized medicare|prolactinoma|for ten percent of the 140 , 000 entity patients in the united states , existing therapies are poorly tolerated or not effective .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|glands prolactin gland malignant benign|there acromegaly neurofibromatosis pheochromocytoma malignancy|prolactinoma|entity is a condition of benign tumors on the pituitary gland .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|glands prolactin gland malignant benign|episodes relief hypothyroidism disorders remission|prolactinoma|we intend to move xoma 213 into clinical development , initially for symptomatic entity potentially followed by medication-induced hyperprolactinemia .
OrderedDict([('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hepatic cholesterol anaemia anemia severity|mayo framingham prospective cohort original|sitosterolemia|treatment experience with zetia in the pediatric population is limited to 4 patients ( 9 to 17 years ) in the entity study and 5 patients ( 11 to 17 years ) in the hofh study .
OrderedDict([('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|hepatic cholesterol anaemia anemia severity|syphilis sarcoidosis tuberculosis sle sepsis|sitosterolemia|doctors ruled out a diagnosis of a disease called entity , based on certain blood test results .
OrderedDict([('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|hepatic cholesterol anaemia anemia severity|occurred been died failed disappeared|sitosterolemia|this finding indicated that the infant definitely has entity , despite the prior contradictory test results .
OrderedDict([('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hepatic cholesterol anaemia anemia severity|sarcoidosis asthma syphilis tuberculosis psoriasis|sitosterolemia|doctors ruled out a diagnosis of a disease called entity , based on certain test results .
OrderedDict([('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|hepatic cholesterol anaemia anemia severity|nafld hypercholesterolemia ldlr ldl nephropathy|sitosterolemia|treatment experience with ezetimibe in the pediatric population is limited to 4 patients ( 9 to 17 years ) with homozygous entity and 5 patients ( 11 to 17 years ) with hofh .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|disease|trich pigment rub rhiz ver|opioids buprenorphine naloxone placebo methadone|trichotillomania|patent claims the use of opioid antagonists , including nalmefene , for the treatment of impulse control disorders with the exception of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|trich pigment rub rhiz ver|ocd adhd schizophrenia ptsd asd|trichotillomania|dr . blochs research interests focus on studying tourette syndrome , ocd , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|trich pigment rub rhiz ver|disorders psychiatric disorder diseases autoimmune|trichotillomania|yale school of medicine - n oted researcher on the study of tourette syndrome , obsessive - compulsive disorder and entity prof . daniele piomelli
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|trich pigment rub rhiz ver|ocd adhd bd asd ptsd|trichotillomania|dr . blochs research interests focus on studying ts , ocd , and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|disease|vitiligo cutaneous melanoma psoriasis clinic|psoriasis eczema arthritis dermatitis vitiligo|vitiligo|has registered a variety of domain names and established an initial website to include in depth information regarding psoriasis , eczema , entity , and the psoria-light device .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|vitiligo cutaneous melanoma psoriasis clinic|melanoma relapse psoriasis ptld vitiligo|vitiligo|two prior clinical trials of immunotherapies conducted by others suggest that the development of entity was correlated with a favorable response to therapy in melanoma patients .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|vitiligo cutaneous melanoma psoriasis clinic|psoriasis acne hc uc amd|vitiligo|the enrollment and / or results for a number of phase 2 studies with ati-502 for the topical treatment of aa and entity , including results from its auatb-201 study .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|vitiligo cutaneous melanoma psoriasis clinic|psoriasis atopic vitiligo eczema dermatitis|vitiligo|specified dermatological conditions , including alopecia areata , or aa , androgenetic alopecia , or aga , also known as male or female pattern baldness , entity and atopic dermatitis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|vitiligo cutaneous melanoma psoriasis clinic|psoriasis alopecia melanoma vitiligo warts|vitiligo|raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts , alopecia areata , and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|vitiligo cutaneous melanoma psoriasis clinic|psoriasis eczema vitiligo melanoma dermatitis|vitiligo|psoriasis , eczema , and entity , are common skin conditions that can be challenging to treat , and often cause the patient significant psychosocial stress .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|vitiligo cutaneous melanoma psoriasis clinic|psoriasis eczema vitiligo melanoma dermatitis|vitiligo|psoriasis , eczema , and entity , are common skin conditions that can be challenging to treat , and often cause the client significant psychosocial stress .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|vitiligo cutaneous melanoma psoriasis clinic|nausea psoriasis neutropenia rejection rash|vitiligo|to date , some patients have experienced entity and uveitis , but there has been no other evidence of off-target effects associated with til therapy .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|disease|vitiligo cutaneous melanoma psoriasis clinic|psoriasis vitiligo dermatitis arthritis eczema|vitiligo|pharos 2 excimer laser system is fda-cleared and is used as a tool in the treatment of psoriasis , entity , atopic dermatitis , and leukoderma .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|vitiligo cutaneous melanoma psoriasis clinic|melanoma psoriasis sle vitiligo crc|vitiligo|we have demonstrated that plasma from individuals with entity contains anti-melanoma activities , and we are attempting to develop vitigam for the treatment of stage iii and stage iv melanoma .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|disease|vitiligo cutaneous melanoma psoriasis clinic|psoriasis dermatitis arthritis eczema vitiligo|vitiligo|pharos was granted ce mark clearance in september of 2016 for use in the treatment of psoriasis , entity , atopic dermatitis and leukoderma by the application of uvb ultraviolet light .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|vitiligo cutaneous melanoma psoriasis clinic|psoriasis vitiligo melanoma acne asthma|vitiligo|vitigam is an igg-based product manufactured from the plasma of donors with entity , a benign skin condition affecting up to 2% of the general population .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|disease|vitiligo cutaneous melanoma psoriasis clinic|psoriasis alopecia scalp eczema vitiligo|vitiligo|the continued development of arq-151 for atopic dermatitis , arq-154 for seborrheic dermatitis and scalp psoriasis , arq-252 for hand eczema and entity , and arq-255 for alopecia areata .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|vitiligo cutaneous melanoma psoriasis clinic|psoriasis asthma osteoporosis acne copd|vitiligo|we plan to commence a phase 2 clinical trial for ati-50002 , for the treatment of entity , in the second half of 2017 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|disease|vitiligo cutaneous melanoma psoriasis clinic|psoriasis arthritis asthma melanoma eczema|vitiligo|the fda has granted 510 ( k ) clearance to market pharos in the u . s . for psoriasis , entity , atopic dermatitis , and leukoderma .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|vitiligo cutaneous melanoma psoriasis clinic|neutropenia recurrence fever relapse diarrhea|vitiligo|as of september 8 , 2011 , entity was observed in four out of 25 ( 16% ) patients .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|vitiligo cutaneous melanoma psoriasis clinic|psoriasis vitiligo acne melanoma migraine|vitiligo|we also plan to develop ati-50001 and ati-50002 as potential treatments for entity , a disorder in which white patches of skin appear on different parts of the body .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|disease|vitiligo cutaneous melanoma psoriasis clinic|psoriasis arthritis eczema asthma dermatitis|vitiligo|otc aoxing ointment walnut meat and camphor used to treat psoriasis , entity and various dermatitis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|vitiligo cutaneous melanoma psoriasis clinic|melanoma psoriasis vitiligo acne scleroderma|vitiligo|entity is an autoimmune condition in which the patient  s immune system attacks melanoctyes , the cells responsible for skin pigmentation and potential melanoma cancer cells .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|disease|vitiligo cutaneous melanoma psoriasis clinic|psoriasis dermatitis vitiligo eczema erythema|vitiligo|developing the xtrac laser system to be the standard of care for psoriasis , and expanded its utilization to include dermatitis , entity and leukoderma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|angio lymphangi hemangi renal artery|melanoma psoriasis malignancy glioblastoma malignancies|angiosarcoma|first quarter highlights , we recently announced the fda has granted us orphan drug designation for oraxol for the treatment of entity , a rare form of malignant blood vessel cancer .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|angio lymphangi hemangi renal artery|oncology sarcoma japan vivo humans|angiosarcoma|a phase 3 study in entity is planned , and stratification of pfs in the phase 2 trial by tumor endoglin expression may identify other sarcoma histologies
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|angio lymphangi hemangi renal artery|sepsis ards uc ibd neutropenia|angiosarcoma|¡ in addition , one patient with entity who had a dramatic initial response on skin lesions was not evaluable for response due to death from sepsis ( not
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|angio lymphangi hemangi renal artery|nsclc hcc melanoma psoriasis crc|angiosarcoma|we are also evaluating oral paclitaxel in the treatment of entity and in combination with other therapies , including anti-vegf and anti-pd-1 therapies .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|angio lymphangi hemangi renal artery|prolonging improving reducing predicting prolonged|angiosarcoma|cr cr trc105 + votrient is active in entity pfs in 13 vegf inhibitor-naïve patients of 7 . 8 months vs . 3 month pfs expected with votrient most vegf inhibitor patients
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|angio lymphangi hemangi renal artery|melanoma malignancies melanomas cancers scc|angiosarcoma|in may 2019 , we announced early and complete response data from a clinical study of oral paclitaxel in cutaneous entity , and the study is continuing to enroll .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|angio lymphangi hemangi renal artery|japan germany china france switzerland|angiosarcoma|• announcement of the results of the interim analysis from the phase 3 pivotal tappas trial of trc105 in entity is expected in the second half of 2018 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|angio lymphangi hemangi renal artery|melanoma hcc tumours gliomas cancers|angiosarcoma|we are initially focused on entity which is a tumor that highly expresses endoglin , the target of trc105 , and therefore may be more responsive to treatment
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|angio lymphangi hemangi renal artery|randomized multicenter preclinical prospective randomised|angiosarcoma|trc105 is currently being studied in a pivotal phase 3 trial in entity and multiple phase 2 clinical trials , in combination with vegf inhibitors .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|angio lymphangi hemangi renal artery|nsclc melanoma rcc crc hcc|angiosarcoma|efficacy in the phase 3 tappas trial evaluating trc105 in combination with votrient® ( pazopanib ) in patients with advanced or metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|angio lymphangi hemangi renal artery|melanoma leishmaniasis cancers melanomas psoriasis|angiosarcoma|xiangxue life sciences ( xlifesc )  reported promising clinical results from a clinical study of oraxol in cutaneous entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|disease|angio lymphangi hemangi renal artery|sarcoma osteosarcoma melanoma sarcomas adenocarcinoma|angiosarcoma|a total of five patients with entity , a sarcoma subtype known to express high levels of endoglin , have been evaluated for response in the phase 1b / 2 study .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|angio lymphangi hemangi renal artery|relapse rituximab recurrence lymphoma neutropenia|angiosarcoma|one of these patients , with entity , has an ongoing complete response at month 4 of treatment .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|angio lymphangi hemangi renal artery|pubmed sarcomas fda capecitabine osteosarcoma|angiosarcoma|received orphan drug designation from the fda and the ema for trc105 for the treatment of soft tissue sarcoma , including entity , in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|angio lymphangi hemangi renal artery|japan europe korea china germany|angiosarcoma|we have leveraged this platform in all of our ongoing clinical trials including our international phase 3 tappas trial in entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 1)])|disease|angio lymphangi hemangi renal artery|humans vivo melanoma glioblastoma adenocarcinoma|angiosarcoma|we are particularly excited by the ongoing complete responses seen in entity , a tumor type known to express high levels of endoglin , and expect to initiate a phase 3 trial in this
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|angio lymphangi hemangi renal artery|melanoma cancers nsclc crc hcc|angiosarcoma| presented preclinical data on oraxol in the treatment of entity at the american association for cancer research ( aacr ) annual meeting on april 3 , 2019  announced acceptance of
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|angio lymphangi hemangi renal artery|japan china beijing korea france|angiosarcoma|we plan to initiate a phase 3 study in entity in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|angio lymphangi hemangi renal artery|gtn stemi japan cea humans|angiosarcoma|we have seen complete ongoing responses in these tumor types and plan to initiate initial phase 3 development in entity and an international multicenter phase 2 trial in gtn in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|angio lymphangi hemangi renal artery|nsclc crc hcc npc pca|angiosarcoma|phase 3 tappas trial ( a randomized phase 3 trial of trc105 and pazopanib versus pazopanib alone in patients with advanced entity ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|chik diseases fever encephalitis hepatitis|influenza vaccinia newcastle ebola jc|chikungunya|the interim analysis has shown that with a single dose administered , up to 98% of study participants produced a neutralizing antibody response against the entity virus by day 7 .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|chik diseases fever encephalitis hepatitis|dengue sle wnv malaria syphilis|chikungunya|is vector test systems , inc . , vector test systems , inc . markets and sells a product for the rapid detection of wnv , entity , malaria , dengue , sle , eee and wee among other tests .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|chik diseases fever encephalitis hepatitis|tuberculosis asthma malaria syphilis influenza|chikungunya|to manufacture virus-like particle based vaccines for third parties for indications other than respiratory viruses , certain allergies , hiv , malaria and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|chik diseases fever encephalitis hepatitis|dengue rubella fever malaria mumps|chikungunya|hds is also in the process of developing the platform for the qualitative testing for other infectious diseases including typhoid , entity , zika and other diseases .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|chik diseases fever encephalitis hepatitis|burkholderia aspergillus leptospirosis pseudomonas rickettsia|chikungunya|there are also a number of emerging markets for lateral flow tests for infectious diseases such as burkholderia , entity , lassa , leptospirosis , marburg , rickettsia and zika .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|chik diseases fever encephalitis hepatitis|influenza vaccinia hepatitis ebola dengue|chikungunya|•antibody against entity virus ( mrna-1944 ) : we announced positive interim data in the first analysis of safety and activity in a phase 1 clinical
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|chik diseases fever encephalitis hepatitis|influenza dengue measles ebola cytomegalovirus|chikungunya|vaxart may consider developing vaccines targeting other infectious diseases including entity , ebola , hepatitis b , herpes simplex virus 2 , or hsv-2 , and venezuelan equine encephalitis .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|chik diseases fever encephalitis hepatitis|dengue ebola malaria fever denv|chikungunya|chembio to fund the 12-month development of a dpp® fever panel assay to simultaneously detect malaria , dengue , ebola , lassa , marburg , and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|chik diseases fever encephalitis hepatitis|influenza vaccine bcg pneumococcal pertussis|chikungunya|solicited aes after each study vaccination for the safety set in the phase 1 trial for entity vaccine ( mrna-1388 ) 25 µg 50 µg 100 µg placebo % ( no . with
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|chik diseases fever encephalitis hepatitis|dengue wnv malaria sle syphilis|chikungunya|is vector test systems inc . vector test systems inc markets and sells a product for the rapid detection of wnv , entity , malaria , dengue , sle , eee and wee among other tests . .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|chik diseases fever encephalitis hepatitis|cmv monoclonal neutralizing hcv chimeric|chikungunya|specifically , the positive phase 1 results from our cmv vaccine and entity antibody programs provide important validation for our approach as we move ahead .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|chik diseases fever encephalitis hepatitis|dengue zika malaria rubella fever|chikungunya|today announced the signing of a long-term agreement with bio-manguinhos to commercialize chembios poc diagnostic tests for dengue , zika and entity in brazil .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|chik diseases fever encephalitis hepatitis|dengue rubella zika influenza syphilis|chikungunya|expanding beyond sexually transmitted disease , to include future poc tests for fever and tropical diseases such as malaria , dengue , zika , entity , ebola , lassa and marburg .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|chik diseases fever encephalitis hepatitis|vaccination influenza rabies vaccine booster|chikungunya|all subjects reported full resolution by day 4 post vaccination , and thereby distinct from the persistent type observed in post entity virus infection arthralgias .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|chik diseases fever encephalitis hepatitis|influenza pneumococcal pertussis measles vaccine|chikungunya|unsolicited aes reported for the safety set in the phase 1 trial for entity vaccine ( mrna-1388 ) 25 µg 50 µg 100 µg placebo no . , % of
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|chik diseases fever encephalitis hepatitis|brucellosis influenza malaria cholera tuberculosis|chikungunya|zydus cadilaindiapartnership agreement to address the global threat of entity and develop a entity vaccine an emerging infectious disease in africa , asia and the indian subcontinent .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|chik diseases fever encephalitis hepatitis|influenza ebola dengue vaccinia rabies|chikungunya|the antibody against entity virus is our first systemic secreted therapeutic for which we have filed an ind .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|chik diseases fever encephalitis hepatitis|ebola influenza vaccinia dengue hepatitis|chikungunya|cepis priority diseases include ebola virus , lassa virus , middle east respiratory syndrome coronavirus , nipah virus , rift valley fever and entity virus .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|chik diseases fever encephalitis hepatitis|influenza viruses vaccine adenovirus h1n1|chikungunya|vaccine pre-clinical phase i hiv-1 x rsv on hold hsv on hold malaria x influenza x entity x 5 hiv-1 and aids hiv-1 ( human immunodeficiency virus type 1 ) is a retrovirus
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|disease|chik diseases fever encephalitis hepatitis|elisa pcr mtb eia commercial|chikungunya|of vaccines , diagnostics and biopharmaceuticals , primarily to meet the demands of brazil  s national public health system , related to the dpp® entity assay .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|bot toxin symptom kind clinic|viruses diarrhea infections antibodies gastroenteritis|botulism|in addition , our botvax® b vaccine has successfully protected hundreds of thousands of horses and foals against type b entity ( commonly known as shaker foal syndrome ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|bot toxin symptom kind clinic|organophosphate poisoning accidental pesticide paraquat|botulism|of the national institutes of health ( contract no . hhsn272200800028c ) , to support ongoing development of drug candidates for the treatment of entity poisoning .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|bot toxin symptom kind clinic|anthrax dengue rabies tuberculosis influenza|botulism|the department of homeland security has identified 13 such threats , including anthrax , smallpox , ebola / marburg , tularemia , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|bot toxin symptom kind clinic|botulinum osteomyelitis meningitis sepsis fasciitis|botulism|entity is a frequently fatal disease caused by botulinum toxins produced by the bacterium clostridium botulinum .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|disease|bot toxin symptom kind clinic|shellfish formaldehyde mussels poisoning copper|botulism|zebra mussels are also believed to be the source of deadly avian entity poisoning that has killed tens of thousands of birds in the great lakes since the late 1990s .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|bot toxin symptom kind clinic|organophosphate accidental acetaminophen poisoning benzodiazepine|botulism|an additional contract with niaid to support our on-going development of drug candidates toward clinical trials in the treatment of entity poisoning .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|bot toxin symptom kind clinic|rabies anthrax dengue cholera encephalitis|botulism|we evaluated the use of mrna for passive immunization in two indications , rabies and entity , that can be considered prototypes for anti-pathogen and anti-toxin therapies , respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|bot toxin symptom kind clinic|medicine equine veterinary pharmaceuticals diseases|botulism|sales of neogens vaccine for equine entity and amvet veterinary pharmaceuticals experienced strong increases as they continued to gain market acceptance .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|bot toxin symptom kind clinic|viruses infections diarrhea fever streptococci|botulism|in addition , the companys botvax b vaccine has successfully protected thousands of high-value horses and foals against type b entity , commonly known as shaker foal syndrome .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|bot toxin symptom kind clinic|vaccine salmonella transgenic commercial wheat|botulism|the companys boxvax b vaccine is also produced in the tampa , facility , utilizing type b entity seed cultures and a traditional fermentation process .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|bot toxin symptom kind clinic|poisoning mortality fever infections diarrhea|botulism|supply of 200 , 000 doses of bat that are intended for treating individuals who have been exposed to the toxins that cause entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|bot toxin symptom kind clinic|infections nephropathy diarrhea gastroenteritis arthritis|botulism|our botvax® b product is the only usda-approved vaccine for the prevention of type b entity in horses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|bot toxin symptom kind clinic|them away cough violence him|botulism|david scarlett a complaint was filed on july 16 , 2008 by counsel representing mr . scarlett in ohio who alleges to have contracted entity from a castleberrys product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|bot toxin symptom kind clinic|they infants wounds infections cats|botulism|entity can also be contracted if botulinum bacteria contaminate wounds or colonize in the intestine of infants , which is referred to as infant botulism .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|bot toxin symptom kind clinic|anthrax dengue rabies tuberculosis viruses|botulism|expands our capabilities in biological warfare defense research and allows for the development of vaccines for smallpox , anthrax and plague , entity and other biological pathogens .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|bot toxin symptom kind clinic|poisoning organophosphate cyanide paraquat pesticide|botulism|other companies are developing other products targeting entity poisoning , and these products may prove more effective than xoma 3ab .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|bot toxin symptom kind clinic|wheat salmonella vaccine commercial seed|botulism|the companys botvax ®b vaccine is also produced in the lansing facility utilizing type b entity seed cultures and a traditional fermentation process .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|bot toxin symptom kind clinic|poisoning organophosphate pesticide paraquat cyanide|botulism|other companies are developing other products targeting entity poisoning and these products may prove more effective than xoma 3ab .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|bot toxin symptom kind clinic|arthritis seizures migraine infections dystonia|botulism|bat is indicated for the treatment of symptomatic entity following documented or suspected exposure to botulinum neurotoxin serotypes a , b , c , d , e , f , or g in adults and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|bot toxin symptom kind clinic|wild meningococcal neurofibromatosis canine hepatitis|botulism|in the veterinary market , neogen markets botvax b , the only usda approved vaccine for the prevention of entity type b in horses .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|bart purpura caused shows describe|intravenous measles recombinant intrathecal rabbit|bartonellosis|entity ( cat scratch fever ) vaccine bartonella henselae is the causative agent of cat scratch fever .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|pon vari pter transposition malformation|neck ap closed supine anterior|torticollis|the patient  s head may turn to the right or left ( entity ) , may tilt to one side ( laterocollis ) , or may tilt upwards ( retrocollis ) or downwards ( anterocollis ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|pon vari pter transposition malformation|dystonia symptom tremor spasm severity|torticollis|primary efficacy measurement was the improvement in dystonia symptoms as determined by reduction from baseline on the toronto western spasmodic entity rating scale ( “twstrs” ) total score .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|pon vari pter transposition malformation|dystonia disorder dyskinesia tremor headache|torticollis|also known as spasmodic entity , cervical dystonia is a painful and debilitating neurological movement disorder .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|pon vari pter transposition malformation|dystonia disorder disorders spasm tremor|torticollis|cervical dystonia ( also referred to as spasmodic entity ) may be primary ( meaning that it is the only apparent neurological disorder , with or without a family history ) or may
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|pon vari pter transposition malformation|symptom spasm anxiety agitation disorder|torticollis|units or 250 units showed a statistically significant greater change from baseline as measured on the toronto western spasmodic entity rating scale ( twstrs ) total score .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|pon vari pter transposition malformation|dystonia spasm neuromuscular tremor headache|torticollis|cervical dystonia affects approximately three in every 10 , 000 people , or about 90 , 000 people in the united states , according to the national spasmodic entity association .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|pon vari pter transposition malformation|symptom dystonia tremor spasm epilepsy|torticollis|primary efficacy measurement was the improvement in dystonia symptoms as determined by reduction from baseline on the toronto western spasmodic entity rating scale ( twstrs ) -total score .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|pon vari pter transposition malformation|symptom dystonia tremor spasm epilepsy|torticollis|primary efficacy measurement was the improvement in dystonia symptoms as determined by reduction from baseline on the toronto western spasmodic entity rating scale ( twstrs ) total score .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|pon vari pter transposition malformation|symptom spasm severity agitation anxiety|torticollis|treatment until the return of signs and symptoms that warrant retreatment , based on subjects reaching their target toronto western spasmodic entity rating scale ( twstrs ) score .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|disease|lymphoma cutaneous lymphomas uncommon malignant|them lymphocytes antibodies clones subsets|lymphoma|first , the cd19 antigen is used in the clinic to distinguish entity derived from b cells from those derived from t cells .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|disease|lymphoma cutaneous lymphomas uncommon malignant|lymphoma lymphomas nhl sarcoma leukemia|lymphoma|plan to file an ind and initiate our own clinical trial for mb-106 for the treatment of patients with non-hodgkin entity and chronic lymphocytic leukemia .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|lymphoma cutaneous lymphomas uncommon malignant|lymphoma lymphomas nhl leukemia diseases|lymphoma|for which a u . s . marketing application is currently being reviewed by the fda for the treatment of relapsed aggressive non-hodgkin  s entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|lymphoma cutaneous lymphomas uncommon malignant|lymphoma lymphomas leukemia neoplasms tumours|lymphoma|inc . yeah , so invariably we want to look for drugs which are active in diffuse large b-cell entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|lymphoma cutaneous lymphomas uncommon malignant|epilepsy asthma diarrhea seizures diarrhoea|lymphoma|we currently have two products ( at-004 and at-005 ) for treatment of entity in dogs which have received a conditional license from the u . s . department of agriculture , or the usda .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|lymphoma cutaneous lymphomas uncommon malignant|specificity immunogenicity safety antibodies efficacy|lymphoma|the treatment of generalized lipodystrophy , and carries a boxed warning for the risks of anti-metreleptin antibodies with neutralizing activities and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 3), ('OTHER', 2)])|disease|lymphoma cutaneous lymphomas uncommon malignant|oncology leukemia leukaemia hematology lymphoma|lymphoma|type : debit period type : duration x - definitionrepresents the maximum amount of grants to be received from the leukemia and entity society ( lls ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|lymphoma cutaneous lymphomas uncommon malignant|lymphoma tumours tumour lymphomas dlbcl|lymphoma|approximately 50% to 60% of dlbcl patients are cured with first-line therapy and do not have recurrence of their entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|lymphoma cutaneous lymphomas uncommon malignant|lymphoma lymphomas oncology leukemia nhl|lymphoma|to finance the analysis of unblinded data on biovaxidtm , an active immunotherapeutic in a pivotal phase 3 study of non-hodgkins entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|lymphoma cutaneous lymphomas uncommon malignant|lymphoma carcinoma lymphomas melanoma leukemia|lymphoma|phase ii clinical trials to assess the oms electroimmunotherapy technology in patients with melanoma , merkel cell carcinoma and cutaneous t-cell entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|disease|lymphoma cutaneous lymphomas uncommon malignant|lymphoma lymphomas sarcoma nhl carcinoma|lymphoma|we are also aware of other potentially competitive biologic therapies for non-hodgkin  s entity in development .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|lymphoma cutaneous lymphomas uncommon malignant|lymphoma lymphomas leukemia nhl relapsed|lymphoma|this trial will seek to treat both non-hodgkins entity and chronic lymphocytic leukemia patients that have failed venetoclax .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|disease|lymphoma cutaneous lymphomas uncommon malignant|lymphoma lymphomas nhl leukemia carcinoma|lymphoma|morphosys will continue to be responsible for its ongoing clinical studies with tafasitamab in non-hodgkins entity ( nhl ) , cll , r / r dlbcl and first-line dlbcl .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|lymphoma cutaneous lymphomas uncommon malignant|lymphoma metastases malignancies melanoma sarcomas|lymphoma|an open-labeled , uncontrolled , dose-escalation , phase i clinical trial of cudc-427 ( nct01226277 ; iam4914g ) began in patients with refractory solid tumors or entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|lymphoma cutaneous lymphomas uncommon malignant|lymphomas lymphoma neoplasms tumours carcinomas|lymphoma|one of the issues is even in the novel space there are a limited number of agents which have significant activity in diffuse large b-cell entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|lymphoma cutaneous lymphomas uncommon malignant|leukemia lymphoma leukaemia lymphomas leukemias|lymphoma|cancers because the therapy can deplete all b cells or t cells including normal and cancer cells in leukemia and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|lymphoma cutaneous lymphomas uncommon malignant|lymphoma lymphomas malignancies nhl leukemia|lymphoma|designed to assess the safety and tolerability of vegf trap in patients with solid tumor malignancies and subjects with non-hodgkins entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2), ('DRUG', 1)])|disease|lymphoma cutaneous lymphomas uncommon malignant|leukemia lymphoma myeloma cll refractory|lymphoma|a large proportion of t-cell entity patients are refractory to or relapse following treatment with standard therapies and there remains a need to develop an effective
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|lymphoma cutaneous lymphomas uncommon malignant|lymphoma lymphomas leukemia carcinoma dlbcl|lymphoma|in february 2013 , we received clia approval for matba®-dlbcl , our proprietary microarray for diagnosis , prognosis and patient monitoring in diffuse large b cell entity ( dlbcl ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|lymphoma cutaneous lymphomas uncommon malignant|lymphoma nhl leukemia lymphomas who|lymphoma|process for review of inds , initiate a clinical trial of adi-001 targeting cd20 for the treatment of patients with non-hodgkins entity and treat the first patient in the first half of 2021 .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|congenital myel malformation idiopathic hydrocephalus|infants neonates newborns malformations fetuses|myelomeningocele|dr . moise is also actively involved in the open fetal surgical repair program for entity ( spina bifida ) at the fetal center .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|multifocal leuk polyneuropathy degeneration dementia|pml myelopathy sclerosis leukemia meningitis|leukoencephalopathy|this decision was based on reports of progressive multifocal entity ( pml ) , a rare and potentially fatal , demyelinating disease of the central nervous system .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|multifocal leuk polyneuropathy degeneration dementia|leukemia sclerosis fibrosis lymphoma pml|leukoencephalopathy|these include : fatal infusion reactions , tumor lysis syndrome ( tls ) with associated acute renal failure , severe mucocutaneous reactions and progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|multifocal leuk polyneuropathy degeneration dementia|myelopathy sclerosis pml demyelination encephalitis|leukoencephalopathy|in immunosuppressed individuals , jc virus is responsible for a life-threatening infection of the brain and spinal cord called progressive multifocal entity , or pml .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|multifocal leuk polyneuropathy degeneration dementia|pml sclerosis leukemia myelopathy fibrosis|leukoencephalopathy|tysabri increases the risk of progressive multifocal entity ( pml ) , an opportunistic viral infection of the brain which usually leads to death or severe disability .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|multifocal leuk polyneuropathy degeneration dementia|sclerosis fibrosis emphysema exacerbations dyspnea|leukoencephalopathy|dyspnea and bronchospasm have been reported , and due to the mechanism of action , increased risk for infections and progressive multifocal entity must be advised and monitored .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|multifocal leuk polyneuropathy degeneration dementia|pml sclerosis myelopathy leukemia meningitis|leukoencephalopathy|identifies anti-jcv antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|multifocal leuk polyneuropathy degeneration dementia|encephalitis sclerosis encephalomyelitis myelopathy meningitis|leukoencephalopathy|identifies anti-jcv antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|multifocal leuk polyneuropathy degeneration dementia|sclerosis pml myelopathy leukemia encephalomyelitis|leukoencephalopathy| progressive multifocal entity ( pml ) : jc virus infection resulting in pml and death has been reported in adcetris-treated patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|multifocal leuk polyneuropathy degeneration dementia|pml sclerosis myelopathy leukemia meningitis|leukoencephalopathy|these events involved two cases of progressive multifocal entity ( pml ) , a rare and potentially fatal , demyelinating disease of the central nervous system .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|multifocal leuk polyneuropathy degeneration dementia|pml sclerosis myelopathy leukemia fibrosis|leukoencephalopathy|shown a reduction in arr of 67% , but it may cause serious side effects including increased risk of progressive multifocal entity ( pml ) , a rare and potentially fatal viral disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|multifocal leuk polyneuropathy degeneration dementia|pml sclerosis leukemia myelopathy fibrosis|leukoencephalopathy|tysabri increases the risk of progressive multifocal entity ( pml ) , an opportunistic viral infection of the brain that usually leads to death or severe disability .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|multifocal leuk polyneuropathy degeneration dementia|sclerosis pml myelopathy leukemia fibrosis|leukoencephalopathy|the new label identifies anti-jc virus ( jcv ) antibody status as a risk factor for progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 1)])|disease|multifocal leuk polyneuropathy degeneration dementia|pml sclerosis myeloma lymphoma myelopathy|leukoencephalopathy|however , tysabri  s association with progressive multifocal 69 table of contents entity , " pml , " has limited its usage to patients for whom other treatment has failed .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 1)])|disease|multifocal leuk polyneuropathy degeneration dementia|pml sclerosis leukemia myelopathy myeloma|leukoencephalopathy|several initiatives under way that may lead to defi ning patients who are at greater risk of developing progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 1)])|disease|multifocal leuk polyneuropathy degeneration dementia|sclerosis pml leukemia myelopathy myeloma|leukoencephalopathy|inclusion of anti-jcv antibody status as an additional factor to aid in stratifying patients at risk for developing progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|multifocal leuk polyneuropathy degeneration dementia|sclerosis pml myelopathy leukemia fibrosis|leukoencephalopathy|we have also begun animal studies related to two orphan diseases , multiple system atrophy ( msa ) and progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 1)])|disease|multifocal leuk polyneuropathy degeneration dementia|pml leukemia sclerosis myelopathy myeloma|leukoencephalopathy|collaboration will focus on the discovery and development of therapeutics based on rnai for the potential treatment of progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 1)])|disease|multifocal leuk polyneuropathy degeneration dementia|sclerosis pml myelopathy leukemia myeloma|leukoencephalopathy|progressive multifocal entity ( pml )  a rare and potentially fatal demyelinating disease of the central nervous system .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|multifocal leuk polyneuropathy degeneration dementia|sclerosis multifocal cataracts glomerulosclerosis fibrosis|leukoencephalopathy|biologics used for multiple sclerosis increased the risk of infections and progressive multifocal entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 1)])|disease|multifocal leuk polyneuropathy degeneration dementia|pml sclerosis leukemia myelopathy myeloma|leukoencephalopathy|to inform physicians and patients of the benefits and risks of tysabri treatment and minimize potential risk of progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|keratoconus corneal corneas cornea keratocon|cataract cataracts keratoconus phacoemulsification endophthalmitis|keratoconus|in 2000 , this patient underwent corneal transplantation caused by entity , simultaneously with extraction of a cataract and implantation of an artificial lens .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|disease|keratoconus corneal corneas cornea keratocon|blindness neovascularization keratitis glaucoma vision|keratoconus|are the only fda-approved riboflavin ophthalmic formulations used with our kxl system to treat progressive 122 table of contents entity and corneal ectasia following refractive surgery .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|keratoconus corneal corneas cornea keratocon|our diabetic pediatric transplant eligible|keratoconus|literature estimates that as many as 20% of entity patients ultimately require a corneal transplant , a costly and invasive procedure with high failure rates .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|keratoconus corneal corneas cornea keratocon|vision tka ta blindness cataract|keratoconus|trial underway ; us clinical trial planned • 38 globally issued patents with 59 pending patent applications vision correction pipeline $3b entity $15b presbyopia $8b low myopia
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|keratoconus corneal corneas cornea keratocon|glaucoma myopia blindness cataract vision|keratoconus|typically diagnosed in a patients teenage years , entity is characterized by progressive thinning and weakening of the cornea , resulting in vision loss .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|keratoconus corneal corneas cornea keratocon|edema glaucoma retinopathy cataracts neovascularization|keratoconus|purified formulations of the enzyme hyaluronidase to treat diseases and conditions such as vitreous hemorrhage , diabetic retinopathy , corneal opacification and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|keratoconus corneal corneas cornea keratocon|keratoconus fibrosis glaucoma amd corneal|keratoconus|ten patients with advanced entity , or severe corneal scarring , were implanted with the recombinant collagen implants and have been followed for more than five years .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|keratoconus corneal corneas cornea keratocon|keratoconus myopia cataract glaucoma retinopathy|keratoconus|entity is a degenerative corneal disease that impairs vision and is characterized by progressive thinning of the cornea and the development
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|keratoconus corneal corneas cornea keratocon|myopia glaucoma cataract deafness cataracts|keratoconus|one significant cause of night myopia is entity , an orphan disease that starts at a young age with progressive thinning of the cornea usually due to genetic and
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|keratoconus corneal corneas cornea keratocon|vision eyes glaucoma been blindness|keratoconus|i  d say there  s  if you look at the prevalence now , there  s 1 . 1 million eyes that are available that have entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|keratoconus corneal corneas cornea keratocon|immunosuppressive anticancer immunomodulatory cytotoxic antiviral|keratoconus|unlike conventional entity treatments , studies have found that avedros photrexa® actually slows or halts disease progression .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|keratoconus corneal corneas cornea keratocon|glaucoma cataracts retinopathy cataract edema|keratoconus|of the enzyme hyaluronidase 7 8 to treat diseases and conditions such as vitreous hemorrhage , diabetic retinopathy , corneal opacification and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|keratoconus corneal corneas cornea keratocon|stroke dementia died disabilities asthma|keratoconus|we believe that there are approximately 400 , 000 people in the united states , western europe and japan who currently have entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|keratoconus corneal corneas cornea keratocon|own successful future alternative optimal|keratoconus|avedro estimates the total u . s . opportunity for its entity therapy to be approximately $3 billion .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|keratoconus corneal corneas cornea keratocon|glaucoma retinopathy neovascularization cataracts cataract|keratoconus|to digest proteoglycans to treat a variety of eye diseases and conditions , including vitreous hemorrhage , diabetic retinopathy , corneal opacification and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|keratoconus corneal corneas cornea keratocon|tuberculosis dementia what his illness|keratoconus|know were going to probably get bogged down in migs shortly but just when you think a little bit about entity , arguably an undiagnosed or under diagnosed , i should say , disease state .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|keratoconus corneal corneas cornea keratocon|glaucoma cataracts retinopathy hemorrhage cataract|keratoconus|purified formulations of the enzyme hyaluronidase to treat diseases and conditions such as vitreous hemorrhage , diabetic retinopathy , corneal opacification , and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|keratoconus corneal corneas cornea keratocon|glomerulosclerosis fibrosis sclerosis arthritis dementia|keratoconus|for our latest-generation kxl system , its associated investigational drug formulations and our investigational boost goggles for the treatment of progressive entity in an epi-on procedure .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|keratoconus corneal corneas cornea keratocon|epilepsy psoriasis acne osteoporosis endometriosis|keratoconus|keraform we are developing keraform , our proprietary system for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|osteonecrosis jaw renal cutaneous occur|osteoporosis osteoarthritis arthritis fractures psoriasis|osteonecrosis|thus , we expect that new clinical indications may include orthopedics , secondary osteoporosis ( including glucocorticoid induced osteoporosis ) , entity , and osteoarthritis .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|osteonecrosis jaw renal cutaneous occur|osteonecrosis fractures osteoarthritis aneurysms osteoporosis|osteonecrosis|in march 2006 , our proprietary trcs received an orphan drug designation from the fda for use in the treatment of entity of the femoral head .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|osteonecrosis jaw renal cutaneous occur|injuries harm fractures obstruction discomfort|osteonecrosis|plaintiffs allege aredia causes entity to the jaw .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|osteonecrosis jaw renal cutaneous occur|hipp den international vo pdc|osteonecrosis|“entity” means the death of bone cells due to decreased blood flow .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|osteonecrosis jaw renal cutaneous occur|regeneration necrosis carcinoma apoptosis degeneration|osteonecrosis|entity of the femoral head involves the death of cells in the bone and marrow within the femur head and in
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|osteonecrosis jaw renal cutaneous occur|apoptosis nephrotoxicity neurotoxicity cytotoxicity cardiotoxicity|osteonecrosis|in our original ind submission , we described a finding of entity ( microscopic evidence of bone and bone marrow death ) in a toxicity study of gen-003 conducted in mice .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|osteonecrosis jaw renal cutaneous occur|fractures osteonecrosis dislocation rupture collapse|osteonecrosis|there have been no cases of entity of the jaw or atypical femoral fracture in the entire tymlos development program .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|osteonecrosis jaw renal cutaneous occur|osteonecrosis fractures osteoporosis osteoarthritis carcinoma|osteonecrosis|describing changes to the label for zometa and aredia , another intravenous bisphosphonate used to treat metastatic bone disease , relating to entity of the jaw .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|osteonecrosis jaw renal cutaneous occur|osteoporosis stones urolithiasis aneurysms diseases|osteonecrosis|additional patent applications are for specific methods of manufacturing strontium salts and for other clinical indications , such as treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|osteonecrosis jaw renal cutaneous occur|rejection mortality hemorrhage efficacy aes|osteonecrosis|there were no events of entity observed in the trial .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|osteonecrosis jaw renal cutaneous occur|potentially serious limb sight sudden|osteonecrosis|more severe complications can occur , such as deep tissue infections and entity threatening life of the limb .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|osteonecrosis jaw renal cutaneous occur|osteonecrosis fractures cancers carcinoma swelling|osteonecrosis|plaintiffs claim to have experienced entity of the jaw after having been treated with zometa or aredia , which are used to treat patients whose cancer has
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|osteonecrosis jaw renal cutaneous occur|fractures osteoarthritis osteonecrosis injuries compression|osteonecrosis|the orthopaedic institute , könig-ludwig-haus , university of würzburg , germany , involving the first use of our brcs to treat patients suffering from entity of the femoral head .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|osteonecrosis jaw renal cutaneous occur|osteonecrosis carcinoma dysfunction metastasis dysplasia|osteonecrosis|entity of the jaw ( onj ) : onj has been reported in patients with cancer receiving treatment including bisphosphonates , chemotherapy and / or corticosteroids .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|osteonecrosis jaw renal cutaneous occur|diseases cardiomyopathy disorders osteoarthritis osteonecrosis|osteonecrosis|aastrom product candidates to treat entity of the femoral head and dilated cardiomyopathy have been designated for orphan drug status by the fda .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|osteonecrosis jaw renal cutaneous occur|osteonecrosis headache fever swelling edema|osteonecrosis|the most frequent serious adverse reactions were entity of the jaw , bone giant cell tumor , anemia , pneumonia , and back pain .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|osteonecrosis jaw renal cutaneous occur|fractures nonunion osteoarthritis injuries dislocations|osteonecrosis|other potential orthopedic applications include wrist fractures , poor-healing fractures , and entity , or conditions of bone degeneration .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|disease|osteonecrosis jaw renal cutaneous occur|osteonecrosis swelling irritation fatigue eruption|osteonecrosis|the most frequent adverse reaction resulting in discontinuation of xgeva® was entity of the jaw .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|osteomyelitis cutaneous occur includes uncommon|bacteremia sepsis infections neutropenia pneumonia|osteomyelitis|that torezolid phosphate may offer a safer alternative to linezolid for infections requiring longer term dosing , such as bacteremia and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|osteomyelitis cutaneous occur includes uncommon|immunocompromised hospitalized diabetic pediatric elderly|osteomyelitis|most entity patients currently use chemical drugs such as antibiotics for treatment which may develop drug resistance if the chemical drugs are
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|osteomyelitis cutaneous occur includes uncommon|market tobacco pharmaceutical cigarette marketing|osteomyelitis|increase in marketing expenses , which increased from $43 , 000 to $95 , 000 as a result of a commissioned research study on the entity market .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|osteomyelitis cutaneous occur includes uncommon|sepsis psoriasis arthritis ibd pancreatitis|osteomyelitis|lefamulin has shown substantial tissue penetration and activity against the most common causative organism in all forms of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|osteomyelitis cutaneous occur includes uncommon|meningitis pneumonia sepsis tuberculosis septicemia|osteomyelitis|invasive pneumococcal disease includes bacteremic pneumonia , bacteremia , sepsis , meningitis and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|osteomyelitis cutaneous occur includes uncommon|infections osteomyelitis pneumonia meningitis candidiasis|osteomyelitis|up to 90% of cases of hematogenous entity , most frequently in children , are caused by s . aureus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|osteomyelitis cutaneous occur includes uncommon|endocarditis sepsis infections bacteremia meningitis|osteomyelitis|these data indicate that s . aureus bloodstream infections including infective endocarditis and entity may be a potentially promising area of clinical development with ceftobiprole .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|osteomyelitis cutaneous occur includes uncommon|pneumonia bacteremia sepsis meningitis osteomyelitis|osteomyelitis|is exebacase , a lysin which targets staph aureus , including methicillin-resistant strains , which causes serious infections such as bacteremia , pneumonia and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|osteomyelitis cutaneous occur includes uncommon|pneumonia bacteremia sepsis meningitis infections|osteomyelitis|organisms , such as methicillin-resistant staph aureus ( mrsa ) and p . aeruginosa , which can cause serious infections such as bacteremia , pneumonia and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|osteomyelitis cutaneous occur includes uncommon|osteoporosis fractures osteoarthritis osteomyelitis infections|osteomyelitis|are currently one of the few resorbable bone void fillers available in international markets for the prevention and treatment of entity , an acute or chronic infection of the bone .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|osteomyelitis cutaneous occur includes uncommon|infections osteomyelitis arthritis fractures osteoarthritis|osteomyelitis|could fulfill the need for a safe , long-term oral therapy to treat chronic infections such as prosthetic joint infections and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|osteomyelitis cutaneous occur includes uncommon|placebo herbal once orthodontic usual|osteomyelitis|sui yan pian kang gu sui yan pian ( entity treatment tablets ) is used to treat bone and bone marrow inflammations .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|osteomyelitis cutaneous occur includes uncommon|infections bacteremia pneumonia sepsis hospitals|osteomyelitis|gram-positive bacteria can also cause other serious illnesses , including pediatric and adult entity , community- and habp , including vabp , bacteremia and diabetic foot infection .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|osteomyelitis cutaneous occur includes uncommon|osteoporosis osteoarthritis psoriasis arthritis fractures|osteomyelitis|medicated pellets are currently the only synthetic resorbable bone void filler available on the international market for the treatment of entity , an acute or chronic inflammation of bone .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|osteomyelitis cutaneous occur includes uncommon|osteoporosis osteoarthritis arthritis psoriasis osteosarcoma|osteomyelitis|for example , applications of mdp-25 include metastatic bone disease , pagets disease , arthritic disease and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|osteomyelitis cutaneous occur includes uncommon|osteoarthritis arthritis osteomyelitis infections haemophilia|osteomyelitis|mtf-101 , a diaminopyrimidine that may be suitable for testing in clinical trials to demonstrate safety and efficacy in patients with entity and patients with prosthetic joint infections .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|osteomyelitis cutaneous occur includes uncommon|bacteremia sepsis neutropenia infections septicemia|osteomyelitis|that torezolid phosphate may offer a safer alternative to linezolid for infections requiring longer term dosing such as bacteremia and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|osteomyelitis cutaneous occur includes uncommon|infections arthritis osteoporosis osteomyelitis tuberculosis|osteomyelitis|the need for a safe , long-term oral therapy to treat chronic infections such as refractory bone and joint infections and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|osteomyelitis cutaneous occur includes uncommon|psoriasis schizophrenia migraine epilepsy asthma|osteomyelitis|our goal is to develop an effective therapy for entity that permits infrequent dosing .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|osteomyelitis cutaneous occur includes uncommon|uc psoriasis melanoma vitiligo aml|osteomyelitis|we believe that lefamulin has the potential to be an effective treatment option for entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|dermatomyositis cutaneous includes comprises follows|our international although another every|dermatomyositis|entity clinical program update corbus is currently evaluating anabasum in an on-going phase 2 study for the treatment of skin-predominant dermatomyositis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|dermatomyositis cutaneous includes comprises follows|ache ulcer psoriasis cutaneous mpo|dermatomyositis|change in the cutaneous entity activity and severity index ( “cdasi” ) activity score is a secondary efficacy outcome .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|dermatomyositis cutaneous includes comprises follows|psoriasis erythematosus arthritis vulgaris autoimmune|dermatomyositis|above disease programs , we performed phase i pilot clinical trials with eculizumab in patients afflicted with the chronic autoimmune disorders entity , psoriasis , and bullous pemphigoid .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|dermatomyositis cutaneous includes comprises follows|dermatomyositis polymy myositis scleroderma arthritis|dermatomyositis|servier also began testing gevokizumab in a variety of small clinical studies , including polymyositis / entity and schnitzler syndrome .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|dermatomyositis cutaneous includes comprises follows|dermatomyositis sle polymy sarcoidosis scleroderma|dermatomyositis|in patients with any one of the following six different autoimmune diseases : cle , sle , sjögrens syndrome , systemic sclerosis , polymyositis and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|dermatomyositis cutaneous includes comprises follows|psoriasis melanoma sclerosis arthritis lymphoma|dermatomyositis|resunab is currently in phase 2 studies for the treatment of diffuse cutaneous systemic sclerosis and skin-predominant entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|dermatomyositis cutaneous includes comprises follows|dermatomyositis polymy myositis scleroderma sarcoidosis|dermatomyositis|two rare autoimmune connective tissue conditions , polymyositis and entity , have been alleged to occur with increased frequency in patients who have received cosmetic collagen treatments .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|dermatomyositis cutaneous includes comprises follows|osteoarthritis fibromyalgia psoriasis dermatomyositis asthma|dermatomyositis|new drug application with the fda to commence a phase ib pilot clinical study trial with 5g1 . 1 in patients with entity , a severe inflammatory muscle disorder .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|dermatomyositis cutaneous includes comprises follows|psoriasis myositis als osteoarthritis sarcopenia|dermatomyositis|based on these ongoing efforts , we have focused our development strategy on entity , a form of the disease in which there is muscle and skin involvement .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|dermatomyositis cutaneous includes comprises follows|cutaneous sle psoriasis lupus peripheral|dermatomyositis|lenabasum is currently being evaluated in entity and systemic lupus erythematosus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|dermatomyositis cutaneous includes comprises follows|dermatomyositis myositis polymy polyneuropathy erythematosus|dermatomyositis|age , and the treatment of certain rheumatology related conditions , including the treatment of the rare and closely related neuromuscular disorders entity and polymyositis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|dermatomyositis cutaneous includes comprises follows|melanoma sarcoidosis tuberculosis psoriasis lymphoma|dermatomyositis|continue to increase as we advance to clinical trials for indications for the treatment of cystic fibrosis , systemic sclerosis and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|dermatomyositis cutaneous includes comprises follows|dermatomyositis sarcoidosis myositis polymy arthritis|dermatomyositis|forms of b-cell lymphoma , including waldenströms macroglobulinemia and diffuse large b-cell lymphoma , and in orphan autoimmune diseases , including polymyositis and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('DRUG', 2), ('OTHER', 2)])|disease|dermatomyositis cutaneous includes comprises follows|psoriasis rituximab sarcoidosis myeloma imatinib|dermatomyositis|we are developing imo-8400 for the treatment of a rare disease called entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|dermatomyositis cutaneous includes comprises follows|psoriasis vasculitis arthritis melanoma sarcoidosis|dermatomyositis|lenabasum is currently being evaluated in systemic sclerosis , cystic fibrosis , entity , and systemic lupus erythematosus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|dermatomyositis cutaneous includes comprises follows|psoriasis arthritis melanoma sarcoidosis stroke|dermatomyositis|lenabasum is not approved for the treatment of systemic sclerosis , entity , cystic fibrosis or systemic lupus erythematosus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|dermatomyositis cutaneous includes comprises follows|dermatomyositis polymy arthritis myositis sarcoidosis|dermatomyositis|in 2013 , servier also began testing gevokizumab in a variety of poc studies , including polymyositis / entity , schnitzler syndrome , and giant cell arteritis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|dermatomyositis cutaneous includes comprises follows|melanoma sarcoidosis lymphoma psoriasis fibrosis|dermatomyositis|dose in the phase 2 clinical trials currently underway and recently completed with jbt-101 in cystic fibrosis , systemic sclerosis and entity , respectively .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|disease|dermatomyositis cutaneous includes comprises follows|psoriasis vitiligo urticaria scleroderma dermatitis|dermatomyositis|entity is an autoimmune disorder in which the immune system attacks the patients muscles and skin , which may cause extensive rash
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|dermatomyositis cutaneous includes comprises follows|dermatomyositis idiopathic polyneuropathy nephritis syndromes|dermatomyositis|by therapeutic area paid prescriptions multiple sclerosis ( ms ) nephrotic syndrome ( ns ) infantile spasms ( is ) entity / polymyositis ( dm / pm ) ** jan-10 67 6 26 feb-10 72
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|leprosy endemic people clinic diseases|ibd sepsis cdi om vap|leprosy|enl , a complication of entity , is a chronic bacterial disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|leprosy endemic people clinic diseases|ibd sepsis psoriasis periodontitis tuberculosis|leprosy|enl , an inflammatory complication of entity , is a chronic bacterial disease associated with excess tumor necrosis factor alpha , or tnf ( alpha ) production .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|disease|leprosy endemic people clinic diseases|pharmaceuticals medicines artemisinin malaria schizophrenia|leprosy|novartis as the pharmaceutical partner in the global alliance set up by the who for the elimination of entity takes great pride in having been able to contribute to this achievement .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|leprosy endemic people clinic diseases|malaria tuberculosis leukemia fever asthma|leprosy|we expanded our programs designed to facilitate the supply of drugs to indigent patients suffering from entity , malaria , tuberculosis and chronic myeloid leukemia ( cml ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|disease|leprosy endemic people clinic diseases|enl il tnf infliximab mda|leprosy|from the fda which allowed us to market thalomid® for the treatment and suppression of enl , an inflammatory complication of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|leprosy endemic people clinic diseases|hospitalized our infected ibd immunocompromised|leprosy|enl occurs in about 30% of entity patients , and is characterized by cutaneous lesions , acute inflammation , fever , and anorexia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|leprosy endemic people clinic diseases|arthritis tnf ibd pancreatitis sepsis|leprosy|enl is an inflammatory complication of entity associated with excess tnf ( alpha ) production .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|leprosy endemic people clinic diseases|psoriasis psoriatic diabetic elderly pediatric|leprosy|approval from the fda to market thalidomide for the treatment of erythema nodosum leprosum , an inflammatory skin condition of some entity patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|leprosy endemic people clinic diseases|antimalarial antiepileptic psychotropic existing malaria|leprosy|the group provided further support for patients in developing countries by supplying entity drugs free of charge and by selling coartem , our new antimalarial treatment , to the who at cost .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|leprosy endemic people clinic diseases|enl psoriasis warts vitiligo om|leprosy|market and sell thalomid ( thalidomide ) for the treatment of erythema nodosum leprosum ( enl ) , a severe and debilitating condition associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|disease|leprosy endemic people clinic diseases|prescription intravenous another our psychotropic|leprosy|we have given entity medication free of charge since the year 2000  again to 3 million patients and on an ongoing basis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|leprosy endemic people clinic diseases|malaria tuberculosis schistosomiasis dengue leprosy|leprosy|this approval reinforces the company  s commitment to reduce the burden of neglected tropical diseases including fascioliasis , entity and malaria .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|leprosy endemic people clinic diseases|psoriasis vitiligo asthma malaria dermatitis|leprosy|when given orally , dapsone is used for the treatment of such diseases as entity , malaria and dermatitis herpetiformis , an autoimmune skin disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|leprosy endemic people clinic diseases|dementia tuberculosis obesity psoriasis copd|leprosy|entity afflicts millions worldwide , although the disease is relatively rare in the united states .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|leprosy endemic people clinic diseases|hospitalized our ibd allergic infected|leprosy|enl occurs in about 30% of entity patients and is characterized by skin lesions , acute inflammation , fever and anorexia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|leprosy endemic people clinic diseases|humans infections them diseases tuberculosis|leprosy|infection caused by a protozoal parasite that affects the skin and abdominal organs , causing ulcers or skin disorders that resemble entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|leprosy endemic people clinic diseases|hospitalized our ibd infected allergic|leprosy|enl occurs in about 30% of entity patients and is characterized by cutaneous lesions , acute inflammation , fever and anorexia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|leprosy endemic people clinic diseases|melanoma myeloma arthritis leukemia hematologic|leprosy|approved for sale in the u . s . , thalidomide has been used as an investigational agent to treat thousands of patients for entity and other diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|leprosy endemic people clinic diseases|tuberculosis psoriasis stroke dengue dementia|leprosy|although entity is relatively rare in the united states , the disease afflicts millions worldwide .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|leprosy endemic people clinic diseases|pmr hcv alcoholism art enl|leprosy|the fda an approvable letter for its nda for thalomid for the treatment of enl , a disease state associated with entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|ehrlich diseases tumour agent carcinoma|infectious veterinary gastrointestinal zoonotic pulmonary|ehrlichiosis|entity diseases quilvax-l ( tm ) 10 million licensing schering- product to prevent dogs at risk efficacy and plough .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|ehrlich diseases tumour agent carcinoma|toxoplasmosis brucellosis syphilis tuberculosis malaria|ehrlichiosis|the most prevalent and well known tick-borne disease is lyme disease , but there are others such as anaplasmosis , entity , and babesiosis .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|disease|ehrlich diseases tumour agent carcinoma|leukemia leukaemia lymphoma sarcoma diseases|ehrlichiosis|aquila also has several issued and pending patents in the field of lyme disease and human granulocytic entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|ehrlich diseases tumour agent carcinoma|abs igg log antibodies igm|ehrlichiosis|x2 ehrlichia equi igg & igm ( hge ) abs each [ *** ] * 7846 86609x2 ; 86618x2 entity ( granulocytic ) & lyme disease evaluation each
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|disease|mumps measles rubella meningitis encephalitis|mumps rubella measles typhoid rabies|mumps|other diseases such as rubella , polio , measles , entity , chickenpox , and typhoid are nowhere near as common as they were a hundred years ago .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|mumps measles rubella meningitis encephalitis|mumps rubella measles tuberculosis influenza|mumps|polio , measles , entity and many other viral illnesses are now controllable and smallpox has been eradicated from nature .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|mumps measles rubella meningitis encephalitis|mumps rubella measles influenza cytomegalovirus|mumps|the company recently applied for regulatory clearance in canada to market episcreen for the detection of measles , entity and rubella .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|mumps measles rubella meningitis encephalitis|canine swine murine porcine feline|mumps|product portfolio includes vaccines against hepatitis a and b , seasonal influenza , h5n1 pandemic influenza ( avian flu ) , h1n1 influenza ( swine flu ) , entity and canine rabies .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|mumps measles rubella meningitis encephalitis|own conjugate commercial inactivated original|mumps|in december 2011 , sinovac dalian , an operating subsidiary of the company obtained the production license from the sfda for its entity vaccine .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|mumps measles rubella meningitis encephalitis|mumps rubella measles varicella influenza|mumps|legionella and influenza ,  epstein barr virus , and  other viral pathogens , including measles , entity , rubella and varicella .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|mumps measles rubella meningitis encephalitis|measles mumps rubella influenza varicella|mumps|mercks sales of m‑m‑r ii , a vaccine to help protect against measles , entity and rubella , were $103 million for the third quarter of 2015 compared with $86 million for the third quarter of
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|mumps measles rubella meningitis encephalitis|mumps measles rubella varicella influenza|mumps|these viruses include measles , entity , rubella , varicella , and epstein-barr and may be involved in the pathogenesis of ms in several ways : transient or persistent
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|mumps measles rubella meningitis encephalitis|tuberculosis measles mumps influenza rubella|mumps|( e ) annual medical report indicating satisfactory health status , including immunization for communicable disease such as hepatitis b , entity , measles , rubeola and tuberculosis .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|mumps measles rubella meningitis encephalitis|rubella mumps hib measles pertussis|mumps|conjugate , enterovirus 71 ( ev71 ) ( against hand , foot & mouth disease ) , japanese encephalitis , animal and human rabies , hib and epidemic meningitis , chickenpox , entity and rubella .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|mumps measles rubella meningitis encephalitis|stroke dementia pneumonia tuberculosis childhood|mumps|while death from entity is rare , it can be associated with a number of serious complications , such as meningitis and encephalitis , especially in older
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|mumps measles rubella meningitis encephalitis|mumps rubella measles polio varicella|mumps|live virus vaccines , including those for smallpox , polio , measles , entity , rubella and chicken pox , have had a long record of preventing disease .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|mumps measles rubella meningitis encephalitis|mumps rubella measles influenza varicella|mumps|examples include the measles , entity , rubella ( mmr ) , yellow fever ( a flavivirus ) , varicella , influenza , smallpox and the oral vaccine against polio , which has been widely deployed
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|mumps measles rubella meningitis encephalitis|rabies influenza rubella vaccine measles|mumps|company overview china bio-immunity corporation ( the “company” or “we” ) , a nevada corporation , is a leading provider of rabies and entity vaccines in the peoples republic of china ( “prc” ) .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|mumps measles rubella meningitis encephalitis|vaccine antigenic immunogenic mobile fourth|mumps|things , that the company defrauded the u . s . government by falsifying data in connection with a clinical study conducted on the entity component of the companys m-m-r ii vaccine .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|mumps measles rubella meningitis encephalitis|herpes vaccinia influenza hepatitis immunodeficiency|mumps|dth skin tests have been commonly used to detect t cell responses to tuberculosis , fungal pathogens , and entity virus .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|mumps measles rubella meningitis encephalitis|rubella mumps measles diphtheria pertussis|mumps|claim to suffer from autism or autism spectrum disorder as a result of receiving thimerosal-containing childhood vaccines and / or the measles , entity and rubella ( mmr ) vaccine .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|mumps measles rubella meningitis encephalitis|vaccine commercial child veterinary chicken|mumps|&nbsp ; revenue for animal and entity vaccines without a right of return provided to customers is recognized when delivery has occurred .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|mumps measles rubella meningitis encephalitis|vaccines vaccine measles influenza varicella|mumps|priorix tetra , which builds on gsks existing entity , measles and rubella vaccine with the addition of varicella protection , will be filed in european and international markets .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|mumps measles rubella meningitis encephalitis|mumps rubella measles cytomegalovirus rabies|mumps|these cell lines have been successfully used to produce a number of human vaccines ( rubella , entity , measles , rabies and hepatitis a ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|asbestos mesothelioma chrys dust workers|cancers asbestos smoking mesothelioma smoke|asbestosis|that entity , lung cancer , and other rare types of cancer have been associated with exposure primarily in asbestos-related industries where
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|disease|asbestos mesothelioma chrys dust workers|mesothelioma melanoma asthma asbestos adenocarcinoma|asbestosis|when inhaled , asbestos fibers can cause certain diseases , including entity , mesothelioma and lung cancer ( and risks for smokers are dramatically compounded ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|asbestos mesothelioma chrys dust workers|asthma emphysema mesothelioma melanoma bronchitis|asbestosis|if inhaled , asbestos fibers can accumulate in the lungs and , as exposure increases , the risk of disease ( such as entity and cancer ) increases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|asbestos mesothelioma chrys dust workers|asthma mesothelioma melanoma bronchitis emphysema|asbestosis|if inhaled , asbestos fibers can accumulate in the lungs and , as exposure increases , the risk of disease ( such as entity or cancer ) increases .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|diseases nosocomial pneumonia outbreak caused|pneumonia tuberculosis them malaria legionella|legionellosis|of contents serotypes of legionella pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are commonly used to treat entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|diseases nosocomial pneumonia outbreak caused|tuberculosis pneumonia asthma leishmaniasis malaria|legionellosis|pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are 73 table of contents commonly used to treat entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|diseases nosocomial pneumonia outbreak caused|pneumonia tuberculosis them legionella malaria|legionellosis|against several serotypes of legionella pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are commonly used to treat entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|diseases nosocomial pneumonia outbreak caused|tuberculosis pneumonia asthma malaria leishmaniasis|legionellosis|pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are 75 table of contents commonly used to treat entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|occurs include occur oste consists|psoriasis prognosis improvement grading agreement|osteomalacia|entity was characterized by the pathologist as improving from severe to mild disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|occurs include occur oste consists|diseases anemia malnutrition neurotoxicity nephrotoxicity|osteomalacia|used because aluminum absorbed from the intestinal tract accumulates in the tissues of patients with chronic kidney failure , causing aluminum-related entity , anemia and dementia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|occurs include occur oste consists|anemia diseases nephrotoxicity nephropathy malnutrition|osteomalacia|used because aluminum absorbed from the intestinal tract accumulates in the tissues of patients with chronic kidney failure , causing aluminum-related entity , anemia and dialysis dementia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|occurs include occur oste consists|mortality transplant metastatic safety rejection|osteomalacia|with respect to the tumor-induced entity indication , this goal measured completion of enrollment for our phase 2 study , generation of data to support proof of concept
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|occurs include occur oste consists|osteoporosis hypercalcemia fractures weakness hypocalcemia|osteomalacia|tio results from typically benign tumors that produce excess levels of fgf23 , which can lead to severe entity , bone fractures , bone and muscle pain , and muscle weakness .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|occurs include occur oste consists|hyperthermia apoptosis necrosis melanoma ali|osteomalacia| krn23 is also intended for the treatment of tumor-induced entity , or tio .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|occurs include occur oste consists|osteoporosis osteogenesis arthritis hypercalcemia osteosarcoma|osteomalacia|crysvita is being studied for the treatment of tumor induced entity ( tio ) , a rare disease that impairs bone mineralization .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|occurs include occur oste consists|bmd progression scores healing psa|osteomalacia|the bone biopsy data demonstrated substantial improvement in entity from severe to mild disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|occurs include occur oste consists|osteoporosis obesity osteoarthritis aging arthritis|osteomalacia|entity leads to severe bone pain , fatigue , muscle weakness and risk of recurring bone fractures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|occurs include occur oste consists|osteoporosis hypercalcemia osteopenia calcification obesity|osteomalacia|bone growth plates at the end of adolescence , in addition to continuing vascular and organ calcification , enpp1 deficiency manifests as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|occurs include occur oste consists|qol hrqol cognition knowledge efficacy|osteomalacia|in our past discussions with fda , they emphasized that improvement in entity could also be considered an important outcome for adults with xlh .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|occurs include occur oste consists|osteoporosis osteopenia hypercalcemia osteoarthritis arthritis|osteomalacia|of pth lead to excessive release of calcium and phosphorus from bones , causing debilitating metabolic bone diseases , such as osteoporosis , entity , rickets and renal osteodystrophy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|occurs include occur oste consists|hyperthermia apoptosis necrosis cytotoxicity angiogenesis|osteomalacia|krn23 ( ux023 ) for the treatment of tio krn23 is also intended for the treatment of tumor-induced entity , or tio .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|occurs include occur oste consists|osteoporosis fractures falls hypercalcemia weakness|osteomalacia|for tio , a disease characterized by typically benign tumors that produce excess levels of fgf23 , which can lead to severe entity , fractures , bone and muscle pain , and muscle weakness .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|occurs include occur oste consists|osteoporosis hypercalcemia cardiomyopathy osteosarcoma arthritis|osteomalacia|crysvita is being developed to treat xlh and tumor-induced entity ( tio ) , diseases characterized by excess levels of fgf23 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|occurs include occur oste consists|tio hyperthermia necrosis apoptosis angiogenesis|osteomalacia|krn23 ( ux023 ) for the treatment of tio we are also developing krn23 for the treatment of tumor-induced entity , or tio .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|leuk renal polyneuropathy gaucher progressive|polyneuropathy sclerosis encephalopathy degeneration inclusions|leukodystrophy|trauma has a neurosteroid compound intended to treat rare brain disorders , such as als , niemann picks disease , krabbes disease , metachromatic entity and other leukodystrophies .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|leuk renal polyneuropathy gaucher progressive|disorder neurodegenerative complication dementia symptom|leukodystrophy|the disease is a entity , caused by degradation of white matter in the brain , which prevents proper synaptic communication of neurons .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|leuk renal polyneuropathy gaucher progressive|disorder symptom complication dementia stroke|leukodystrophy|the disease is a entity , caused by degradation of white matter in the brain .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 1), ('BIO', 1)])|disease|leuk renal polyneuropathy gaucher progressive|purpura glomerulonephritis erythrocytes nephritis nephropathy|leukodystrophy|with regard to our biomarker for metachromatic entity , we own two separate patent families .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|disease|pertussis toxin diphtheria guinea vaccine|antibodies pathogens measles vaccines ige|pertussis|and one of the ways of blocking the transmission of entity to newborns is to create an immunized cocoon around them so that all of the adults that are in contact
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|pertussis toxin diphtheria guinea vaccine|diphtheria vaccine polysaccharide polymer dermal|pertussis|accordingly , the company has been selling its acellular entity toxoid to ssi for formulation into dtap and dtap-ipv for sale in sweden and 12 denmark , respectively .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 2)])|disease|pertussis toxin diphtheria guinea vaccine|acinetobacter pseudomonas mrsa enterobacteriaceae baumannii|pertussis|to date , we have initiated development of a mab therapy for the treatment of entity and acinetobacter infections .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|pertussis toxin diphtheria guinea vaccine|influenza asthma measles vap wheezing|pertussis|the incidence of entity is increasing in association with exposure of unvaccinated and under-vaccinated individuals including infants who are not yet fully vaccinated , exposure
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|pertussis toxin diphtheria guinea vaccine|chagas autoimmune infectious lyme huntington|pertussis|certiva [ trademark ] is the company  s investigational vaccine against diphtheria , tetanus and entity disease .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|pertussis toxin diphtheria guinea vaccine|tuberculosis malaria influenza dengue rabies|pertussis|entity is an endemic disease , but epidemics occur every 3 - 5 years .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|pertussis toxin diphtheria guinea vaccine|diphtheria tetanus pertussis rubella polio|pertussis|quadracel® , a quadrivalent booster vaccine ( fifth dose ) including diphtheria , tetanus , accelular entity and ipv is being developed for the u . s . market .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|pertussis toxin diphtheria guinea vaccine|botulinum toxin cholera anthrax certain|pertussis|the validity of the italian counterpart of connaught  s european patent 0 322 115 ( the "  115 patent " ) which allegedly relates to entity toxin mutants .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 1)])|disease|pertussis toxin diphtheria guinea vaccine|hib polio mumps tetanus measles|pertussis|full-year polio / entity / hib vaccines sales were down 0 . 7% to 1 , 749 million .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|pertussis toxin diphtheria guinea vaccine|ards pneumonia sepsis hf asthma|pertussis|infants with entity often require hospitalization in pediatric intensive care units , frequently requiring mechanical ventilation .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|pertussis toxin diphtheria guinea vaccine|polio hib mumps tetanus rubella|pertussis|reported 2013 reported change on a reported basis change at constantexchange rates polio / entity / hib vaccines ( including pentacel® and pentaxim® ) 1 , 154 1 , 148 +0 . 5% +1 . 9%
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|pertussis toxin diphtheria guinea vaccine|acellular pneumococcal dermal polysaccharide pertussis|pertussis|the company  s manufacturing operations for neisvac-c ( tm ) , certiva ( r ) and its acellular entity vaccine are located principally in one facility .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|pertussis toxin diphtheria guinea vaccine|tuberculosis syphilis asthma dementia leukemia|pertussis|worldwide , nearly 50 million cases of entity are diagnosed annually and about 350 , 000 people die of the disease .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|pertussis toxin diphtheria guinea vaccine|pertussis fever pneumonia cough diphtheria|pertussis|illumigene® bordetella entity ( whooping cough )  commercialized in march 2014 6 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2), ('DRUG', 1)])|disease|pertussis toxin diphtheria guinea vaccine|hib mumps polio tetanus diphtheria|pertussis|+33 . 3 % total vaccines 1 , 800 1 , 422 +26 . 6 % +24 . 5 % polio / entity / hib vaccines posted 2017 first-half net sales of 901 million , up 41 . 3% cer .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|synd congenital anomaly defects dysplasia|scarring erythema atrophy generalized mild|syndactyly|however , the severity of the condition does increase with age due to scarring , entity and generalized skin atrophy .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|synd congenital anomaly defects dysplasia|generalized superficial mild erythema atrophic|syndactyly|however , the severity of the condition does increase with age due to scarring , entity and generalized skin 82 table of contents atrophy .
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|osteoporosis ckd hyperparathyroidism esrd pth|hypoparathyroidism|we believe transcon pth may provide patients suffering from entity with a pth replacement therapy that is designed to fully address all aspects of the disease more than standard of
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|osteoporosis osteoarthritis obesity arthritis osteopenia|hypoparathyroidism|we now have the financial resources to fund the continued u . s . development of preos in a variety of indications , including entity and osteoporosis .
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|asthma sepsis psoriasis illness copd|hypoparathyroidism|treatment , even with the less frequent regimens , may be an effective treatment option for those patients suffering from less severe entity .
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|psoriasis acne asthma copd hcc|hypoparathyroidism|eb612 for the treatment of entity we believe eb612 may offer several advantages over natpara for the following reasons : • eb612 is designed to be dosed
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|psoriasis asthma schizophrenia copd crc|hypoparathyroidism|would enable us to seek u . s . marketing approval of npsp558 as a new standard of care for the treatment of entity .
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|osteoporosis example pth hyperparathyroidism osteoarthritis|hypoparathyroidism|our lead oral pth product candidate , eb612 , has successfully completed a phase 2a trial for entity , a rare condition in which the body fails to produce sufficient amounts of pth .
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|sbs mbc bms rct rcts|hypoparathyroidism|we believe positive results from steps and replace will enable us to seek u . s . marketing approval of gattex for sbs and npsp558 for entity .
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|osteoporosis acromegaly women endometriosis infertility|hypoparathyroidism|origin ] injection ) is being evaluated in a phase 3 registration study known as replace as a hormone replacement therapy for entity .
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|osteoporosis example pth hyperparathyroidism osteoarthritis|hypoparathyroidism|our lead oral pth product candidate , eb612 , has successfully completed a phase 2a trial for entity , a rare condition in which the body fails to produce sufficient amounts of pth .
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|ckd schizophrenia dm bph uc|hypoparathyroidism|showed the predicted pharmacokinetic and pharmacodynamic response , suggesting the ability to normalize serum and urinary calcium levels in patients with entity .
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|osteoporosis fractures osteopenia osteoarthritis nonunion|hypoparathyroidism|candidate we chose to pursue was pth , which has the potential for therapeutic use in a number of indications including entity , osteoporosis and non-union fractures .
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|women rats males volunteers females|hypoparathyroidism|( sbs ) and a phase 3 registration study has been completed for natpara ( recombinant human parathyroid hormone ( rhpth [ 1-84 ] ) in adult entity .
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|bd pdd tmd ocd adhd|hypoparathyroidism|while sbs and entity are relatively rare disorders , we believe they represent a substantial commercial opportunity to us due to the significant unmet need
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|hemodialysis pediatric hypertensive ckd uremic|hypoparathyroidism|replace , a phase 3 registration study of npsp558 , the companys bioengineered replica of human parathyroid hormone ( rhpth 1-84 ) , in adult entity patients .
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|ibs osteoporosis psoriasis acne asthma|hypoparathyroidism|the symptoms of entity are typically managed with large doses of oral calcium supplementation and active vitamin d therapy to reduce the severity of
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 2)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|phosphorus hypocalcemia magnesium pth phosphate|hypoparathyroidism|short bowel syndrome ) and our study of npsp558 is known as replace ( recombinant parathyroid hormone to normalize calcium and treat entity ) .
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|psoriasis acne epilepsy osteoporosis endometriosis|hypoparathyroidism|criteria for 20 , 250 of these options was satisfied when the fda accepted the bla for natpara for the treatment of entity .
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|china brazil africa india humans|hypoparathyroidism|we are committed to advancing the development of preos in entity .
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|asthma epilepsy obesity psoriasis acne|hypoparathyroidism|we are also developing natpara® ( rhpth [ 1-84 ] ) for the treatment of adult entity .
OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|insufficiency thyroid hypothyroidism hormone hyperparathyroidism|php ckd osteoporosis hyperparathyroidism hypocalcemia|hypoparathyroidism|reported the fdas approval of natpara as an adjunct to calcium and vitamin d to control hypocalcemia in patients with entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|typh fever rickettsia scrub deer|pneumonia fever meningitis anthrax septicemia|typhus|doxycycline is an antibiotic used to treat anthrax , rocky mountain spotted fever , entity and mycoplasma pneumonia .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|typh fever rickettsia scrub deer|syphilis chlamydia rubella mumps tetanus|typhus|diseases that can be acquired from such accidents include hiv / aids , hbv , hcv , diphtheria , gonorrhea , entity , herpes simplex virus , malaria , syphilis and tuberculosis .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|typh fever rickettsia scrub deer|pneumonia fever septicemia sepsis meningitis|typhus|doxycycline is an antibiotic used to treat rocky mountain spotted fever , entity and mycoplasma pneumonia .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|rabies viruses vaccine zoonotic rodent|dengue influenza viruses tuberculosis hcv|rabies|these efforts , we will continue the development of these drugs , as well as our other drug development endeavors that include entity , dengue viruses , and ebola / marburg viruses .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|rabies viruses vaccine zoonotic rodent|tetanus pertussis diphtheria rubella influenza|rabies|talecris also has a line of hyperimmune therapies that provide treatment for tetanus , entity , hepatitis b , hepatitis a and rh factor control during pregnancy and at birth .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|rabies viruses vaccine zoonotic rodent|influenza vaccinia infectious recombinant introduced|rabies|the candidate ligands for this nanoviricide were designed by the company using publicly available information regarding the interaction of the entity virus with cells .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|rabies viruses vaccine zoonotic rodent|meningococcal booster vaccine commercial conjugate|rabies| an additional phase ii study in healthy adults evaluating crucells monoclonal antibody in combination with a entity vaccine is scheduled to start in india in the second quarter of 2009 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|rabies viruses vaccine zoonotic rodent|cytomegalovirus syphilis influenza tuberculosis hepatitis|rabies|seasonal influenza , hiv , oral and genital herpes ( hsv ) , viral diseases of the eye including ekc and herpes keratitis , hepatitis c , entity , dengue fever , and ebola virus , among others .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|rabies viruses vaccine zoonotic rodent|vaccinia infectious influenza vesicular ebola|rabies|cv7202 is an mrna that encodes the entity virus glycoprotein , rabv-g , formulated with lnps .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|rabies viruses vaccine zoonotic rodent|intravenous albumin igg immunoglobulin urinary|rabies|sales volume for human albumin and human immunoglobulin for intravenous decreased by 19 . 4% and 24 . 3% , respectively , while human entity immunoglobulin recorded an increase of 94 . 9% .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|rabies viruses vaccine zoonotic rodent|example instance comparison choice overdose|rabies|nihe thereafter requested that we develop a drug for entity , a request to which we agreed .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|rabies viruses vaccine zoonotic rodent|encephalitis ebola asia hepatitis hcv|rabies|types i , ii , iii , & iv ; · hepatitis b virus ( hbv ) ; · hepatitis c virus ( hcv ) ; · entity ; · ebola and marburg viruses ; · japanese encephalitis ; and · west nile virus .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|rabies viruses vaccine zoonotic rodent|influenza hbv mrsa dengue tuberculosis|rabies|our lead vaccine program , cv7202 , is being developed for prophylactic vaccination against entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|rabies viruses vaccine zoonotic rodent|malaria dengue influenza rabies humans|rabies|rabicide , a nanoviricide against entity finished its first set of animal studies in the first quarter of 2007 in vietnam .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|rabies viruses vaccine zoonotic rodent|pneumonia infections tuberculosis elsewhere bronchiolitis|rabies|[ **** ] against rsv , para influenza , cmv pneumo ( including s . pneumoniae , branhamalla , non-typable haemophilus influenza and otitis media ) and entity in the field in the territory .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|rabies viruses vaccine zoonotic rodent|allergy cholera tuberculosis diarrhea anthrax|rabies|we evaluated the use of mrna for passive immunization in two indications , entity and botulism , that can be considered prototypes for anti-pathogen and anti-toxin therapies , respectively .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|rabies viruses vaccine zoonotic rodent|hcv influenza bovine rabbit hbe|rabies|anti-entity immune globulin therapy is prescribed for individuals suspected of recent exposure to the entity virus .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|rabies viruses vaccine zoonotic rodent|saliva rabies syphilis malaria cholera|rabies|entity is commonly transmitted by infectious saliva from the bite of a rabid animal .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|rabies viruses vaccine zoonotic rodent|conjugate candidate vaccine influenza alternative|rabies|since 2010 , isconova and vetbiochem have collaborated on the development of entity vaccines for dogs and cats .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|rabies viruses vaccine zoonotic rodent|japan adults china korea taiwan|rabies|in january 2020 , we reported preliminary data from our phase 1 trial of cv7202 in entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|rabies viruses vaccine zoonotic rodent|yellow influenza vaccinia dengue swine|rabies|have entered into work orders for the preclinical development of a lassa virus vaccine , a yellow fever vaccine and our entity virus vaccine .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|rabies viruses vaccine zoonotic rodent|influenza hcv adenovirus cytomegalovirus viruses|rabies|licenses in perpetuity for technologies developed by theracour for the virus types : hiv , hcv , herpes , asian ( bird ) flu , influenza and entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|rabies viruses vaccine zoonotic rodent|ebola dengue sars them tuberculosis|rabies|further , the company has identified highly active nanoviricide drug candidates against ebola / marburg , and against entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|nov var vari psi al|tuberculosis malaria encephalitis hepatitis pneumonia|psittacosis|dr . moore has conducted clinical research on infectious diseases such as venezuelan equine encephalitis , tuberculosis , listeriosis , entity , human orf , malaria , and hiv / aids .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|trach cystic pigment cysts epithelial|trachomatis gonorrh vagin rhin chlamydial|trachoma|chlamydia entitytis also causes the ocular disease entity , which is a form of vesicular conjunctivitis .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|trach cystic pigment cysts epithelial|diseases infections disorders errors arthritis|trachoma|through the iti , we donate the antibiotic zithromax to combat blinding entity in developing countries .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|trach cystic pigment cysts epithelial|errors bias blinding error diseases|trachoma|we intend to help the world health organization achieve its goal of eliminating blinding entity by the year 2020 .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|trach cystic pigment cysts epithelial|blindness malaria tuberculosis cataract melanoma|trachoma|increase in annual dividends to $1 . 36 from $0 . 80•since 2010 , donated more than 580 million doses of zithromax ( azithromycin ) to treat entity , the leading cause of infectious blindness .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|trach cystic pigment cysts epithelial|partnership collaboration collaborative partnerships cooperation|trachoma|internationally , we have two innovative access programs : the international entity initiative ( iti ) and the diflucan partnership program ( dpp ) .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|trach cystic pigment cysts epithelial|national consensus collaborative collaboration scientific|trachoma|dr . feczko is a member of the technical expert committee for the international entity initiative of the task force for global health .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|trach cystic pigment cysts epithelial|gonorrh genital haemat vir trachomatis|trachoma|because c . entitytis also causes entity , the world  s most common form of preventable blindness , the who estimates chlamydia is responsible for at least 15 percent of
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|trach cystic pigment cysts epithelial|blindness sudden incident retinal permanent|trachoma|in response , the number of people at risk of entity blindness worldwide has been reduced to 158 million from more than 300 million in 2010 . shantanu narayen , lead independent director of
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|trach cystic pigment cysts epithelial|entity entities algorithm nomenclature category|trachoma|because c . entitytis also causes entity , the worlds most common form of preventable blindness , the who estimates c . entitytis is responsible for at least 15 percent of the
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|trach cystic pigment cysts epithelial|blindness glaucoma cataract prematurity obesity|trachoma|entity is the leading cause of preventable blindness worldwide .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|trach cystic pigment cysts epithelial|pneumonia infections tuberculosis sepsis meningitis|trachoma|medicine for human diseases to treat a host of bacterial infections , including acute otitis media infection , pharyngitis , pneumonia , skin infection , entity , and etc .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|trach cystic pigment cysts epithelial|pilot nine academic partnership draft|trachoma|the iti , in which pfizer is a partner , has initiated entity programs in nine developing countries to date and plans to launch programs in an additional 10 countries .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|trach cystic pigment cysts epithelial|gonorrh genital haemat vir vagin|trachoma|because c . entitytis also causes entity , the worlds most common form of 4 preventable blindness , the who estimates chlamydia is responsible for at least 15 percent
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|ery peptidoglycan comprises iii antibiotics|cellulitis abscesses abscess sepsis osteomyelitis|erysipelas|in this trial , patients with wound infections , major abscesses , and entity / cellulitis were enrolled in equal numbers .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|ery peptidoglycan comprises iii antibiotics|cellulitis abscess abscesses edema erythema|erysipelas|a lesion size of at least 75 cm2 ( lesion size measured by the area of redness , edema or induration ) , and includes cellulitis / entity , wound infections and major cutaneous abscesses .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|ery peptidoglycan comprises iii antibiotics|cellulitis abscess abscesses osteomyelitis gangrene|erysipelas|is defined as a bacterial infection of the skin with a lesion size area of at least 75 cm and includes cellulitis / entity , wound infections , and major cutanenous abscesses .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|ery peptidoglycan comprises iii antibiotics|pneumonia cellulitis sepsis abscess fever|erysipelas|were more than 4 . 8 million hospital admissions of adults with absssi from 2005 through 2011 , which included patients with cellulitis , entity , wound infection and major cutaneous abscess .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|ery peptidoglycan comprises iii antibiotics|cellulitis abscess abscesses edema erythema|erysipelas|lesion size of at least 75 cm2 ( lesion size measured by the area of redness , edema or induration ) , and includes cellulitis / entity , wound infections and major cutaneous abscesses .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|ery peptidoglycan comprises iii antibiotics|concussion falls stroke sport injuries|erysipelas|reported for at least 0 . 1% of subjects and for which p<0 . 01 included concussion ( denosumab <0 . 1% , n=1 ; placebo 0 . 3% , n=11 ) and entity ( denosumab 0 . 2% , n=7 ; placebo 0% , n=0 ) .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|ery peptidoglycan comprises iii antibiotics|abscess cellulitis sepsis pneumonia gangrene|erysipelas|examples of absssi are cellulitis / entity , wound infection , major cutaneous abscess and burn infections .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|ery peptidoglycan comprises iii antibiotics|fever sepsis septicemia tuberculosis pneumonia|erysipelas|in pairs or chains , many species of which destroy red blood cells and cause various diseases in human beings , including entity , scarlet fever , and septic sore throat .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|ery peptidoglycan comprises iii antibiotics|pneumonia sepsis cellulitis abscess fever|erysipelas|were more than 4 . 8 million hospital admissions of adults with absssi from 2005 through 2011 , which included patients with cellulitis , entity , wound infection , and major cutaneous abscess .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|sarcoidosis pulmonary presents pathogenesis unknown|asthma gerd achalasia ibs psoriasis|sarcoidosis|the primary treatment for entity is corticosteroids ; however , the outcome of this treatment on the ph is unclear .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|disease|sarcoidosis pulmonary presents pathogenesis unknown|apoptosis aging cholesterol phospholipids surfactant|sarcoidosis|there are a number of different mechanisms linking ph with entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|sarcoidosis pulmonary presents pathogenesis unknown|sarcoidosis ild nodules metastases fibrosis|sarcoidosis|we selected pulmonary entity as our first ild indication and we are currently enrolling a proof-of-concept phase 1b / 2a clinical trial .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|sarcoidosis pulmonary presents pathogenesis unknown|acidosis sepsis cholestasis epilepsy hydrocephalus|sarcoidosis|in 2018 , we also initiated development of inopulse for the treatment of ph associated with entity ( ph-sarc ) .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|sarcoidosis pulmonary presents pathogenesis unknown|our every another final prospective|sarcoidosis|entity initial phase ii trial completed .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|disease|sarcoidosis pulmonary presents pathogenesis unknown|pah ntm mrsa tuberculosis sarcoidosis|sarcoidosis|that we are exploring in multiple rare diseases of unmet medical need , including methicillin-resistant staph aureus ( mrsa ) , ntm , pah , and entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|sarcoidosis pulmonary presents pathogenesis unknown|tuberculosis transplantation metastases aspergillosis fibrosis|sarcoidosis|phase 1b / 2a clinical trial and , if that trial is successful , we believe we can expedite development of atyr1923 for pulmonary entity towards regulatory approval .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|sarcoidosis pulmonary presents pathogenesis unknown|sarcoidosis ild biopsies nodules fibrosis|sarcoidosis|we selected pulmonary entity as our first ild indication and initiated a phase 1b / 2a proof-of-concept clinical trial in december 2018 .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|sarcoidosis pulmonary presents pathogenesis unknown|sarcoidosis tuberculosis psoriasis leprosy dermatomyositis|sarcoidosis|entity is a multi-system disease which is characterized by the growth of granulomas ( inflammatory cells ) in one or more organs .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|sarcoidosis pulmonary presents pathogenesis unknown|fibrosis asthma pneumonia sepsis emphysema|sarcoidosis|by mondobiotech and the ema has designated aviptadil an orphan medicinal product for the treatment of acute lung injury and entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|sarcoidosis pulmonary presents pathogenesis unknown|copd asthma rhinosinusitis outpatients exacerbations|sarcoidosis|for example , we are just now beginning to explore the potential for acthar in symptomatic entity with a small pilot selling effort to pulmonologists .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|disease|sarcoidosis pulmonary presents pathogenesis unknown|pah ntm tuberculosis mrsa sarcoidosis|sarcoidosis|that we are evaluating in multiple rare diseases of unmet medical need , including methicillin-resistant staph aureus ( mrsa ) , ntm , pah and entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|sarcoidosis pulmonary presents pathogenesis unknown|neonates hcc sle cirrhosis sepsis|sarcoidosis|the presence of ph in entity is associated with a poor prognosis .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|disease|sarcoidosis pulmonary presents pathogenesis unknown|sarc sarcoidosis hydrocephalus pss adh|sarcoidosis|inopulse for ph-sarc we are also developing inopulse for the treatment of ph associated with entity , or ph-sarc .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|sarcoidosis pulmonary presents pathogenesis unknown|sepsis malignancy pph epilepsy cholestasis|sarcoidosis|there is no approved therapy for ph associated with entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|sarcoidosis pulmonary presents pathogenesis unknown|ild copd pah ards sarcoidosis|sarcoidosis|who group v consists of ph with multifactorial mechanisms , of which we are focusing on a subset of patients with entity that has caused ild .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|sarcoidosis pulmonary presents pathogenesis unknown|epilepsy sepsis hypoglycemia acidosis hypothermia|sarcoidosis|in 2018 , we initiated development of inopulse for the treatment of ph associated with entity ( “ph-sarc” ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|tetanus toxin diphtheria toxoid pertussis|tetanus diphtheria pertussis toxoid varicella|tetanus|the same participants when stimulated with 85 table of contents cytomegalovirus ( cmv ) , epstein barr virus ( ebv ) , influenza virus and entity toxoid-derived immuno- dominant peptide panels .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|tetanus toxin diphtheria toxoid pertussis|toxoid diphtheria tetanus toxin pertussis|tetanus|and is manufacturing and marketing , a line of vaccines including whole virus and split virus influenza vaccines , a combined diphtheria entity vaccine and a vaccine to prevent tuberculosis .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|tetanus toxin diphtheria toxoid pertussis|botulinum tetanus toxin diphtheria pertussis|tetanus|particularly applied to patients who have allergic reactions to entity antitoxin .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|tetanus toxin diphtheria toxoid pertussis|tetanus diphtheria pertussis mumps rubella|tetanus|response facilitates the use of preventative vaccines that protect against viral and bacterial infections such as measles , polio , diphtheria and entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|tetanus toxin diphtheria toxoid pertussis|cytomegalovirus rabies hbv hcv rubella|tetanus|hyperimmune products currently available include hepatitis b , entity , rabies cytomegalovirus and rhod immune globulins .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|disease|tetanus toxin diphtheria toxoid pertussis|influenza polio mucosal vaccine conjugate|tetanus|during 2000 , we anticipate that innovaccines will begin to scale up an oral entity vaccine to take into human clinical trials .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|tetanus toxin diphtheria toxoid pertussis|leukocyte intravenous monoclonal recombinant immunoglobulin|tetanus|human entity immunoglobulin – 250iu mainly used for the prevention and therapy of entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|tetanus toxin diphtheria toxoid pertussis|tetanus diphtheria pertussis toxoid cholera|tetanus|if ssi fails to continue to supply the company with these components , the company has a royalty-bearing license to produce diphtheria and entity toxoids for this purpose .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|tetanus toxin diphtheria toxoid pertussis|tetanus diphtheria pertussis cholera toxoid|tetanus|then the antigenic proteins , entity toxoid and candida albicans were applied topically to the treated skin sites .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|tetanus toxin diphtheria toxoid pertussis|botulinum tetanus toxin diphtheria pertussis|tetanus|particularly applied to patients who have allergic reactions to entity antitoxin .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|tetanus toxin diphtheria toxoid pertussis|recombinant urinary namely soluble purified|tetanus|for our plasma products , entity immunoglobulin , factor viii and pcc are included on the life-saving essential drug list in most chinese provinces , for which drug
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|disease|tetanus toxin diphtheria toxoid pertussis|rabies recombinant measles canine parvovirus|tetanus|three of our approved products , human albumin , human rabies immunoglobulin and human entity immunoglobulin are affected by the 2013 adjustments .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|tetanus toxin diphtheria toxoid pertussis|diphtheria tetanus pertussis cholera mumps|tetanus|vaccines against two life-threatening bacterial diseases , diphtheria and entity , came into use early in this century .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|tetanus toxin diphtheria toxoid pertussis|cd20 cd3 idi cd8 igm|tetanus|xmab5871 inhibited anti-entity antibody responses in mice engrafted with human b cells and immunized with entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|tetanus toxin diphtheria toxoid pertussis|recombinant leukocyte monoclonal igg intravenous|tetanus|human entity immunoglobulin  250iu mainly used for the prevention and therapy of tetanus .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|tetanus toxin diphtheria toxoid pertussis|measles mumps cytomegalovirus rubella influenza|tetanus|ivig product enriched with naturally occurring polyclonal anti-pathogen antibodies , such as streptococcus pneumonia , h . influenza type b , cytomegalovirus , measles and entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|tetanus toxin diphtheria toxoid pertussis|diphtheria tetanus pertussis cholera measles|tetanus|sales of adacel ( adult entity / diphtheria / whooping cough booster ) , launched in the united states in july 2005 , reached 154 million in 2006 .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|tetanus toxin diphtheria toxoid pertussis|tetanus diphtheria pertussis toxoid cholera|tetanus|sp0173 : the current adacel® ( tdap booster vaccine containing entity toxoid , diphtheria toxoid , and 5-component acellular pertussis ) is not indicated in the us for persons aged over 64 .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|tetanus toxin diphtheria toxoid pertussis|mumps cytomegalovirus measles rubella influenza|tetanus|streptococcus pneumoniae , h . influenza type b , cmv , measles , entity etc . ) as well as high levels of antibodies targeted to respiratory syncytial virus , or rsv .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|tetanus toxin diphtheria toxoid pertussis|tetanus pertussis diphtheria mumps influenza|tetanus|food and drug administration ( " fda " ) to market its dtap vaccine ( certiva ( registered ) ) in the united states for the prevention of diphtheria , entity , and pertussis ( whooping cough ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|diphtheria toxin tetanus toxins enterotoxin|toxoid tetanus diphtheria toxin pertussis|diphtheria|vaccines business segment :  march 27 , 2007 : akorn announced the signing of a three-year exclusive distribution agreement for tetanus entity vaccine .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|diphtheria toxin tetanus toxins enterotoxin|measles mumps tuberculosis influenza varicella|diphtheria|they have eradicated smallpox and dramatically reduced the mortality and morbidity associated with many other infectious diseases , such as entity , measles , polio and tetanus .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|diphtheria toxin tetanus toxins enterotoxin|tetanus mumps diphtheria pertussis rubella|diphtheria|adaptive immune response is the basis for preventative vaccines that protect against viral and bacterial infections such as measles , polio , entity and tetanus .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|diphtheria toxin tetanus toxins enterotoxin|mumps tetanus pertussis rubella diphtheria|diphtheria|adaptive immune response facilitates the use of preventative vaccines that protect against viral and bacterial infections such as measles , polio , entity , and tetanus .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|diphtheria toxin tetanus toxins enterotoxin|tetanus diphtheria pertussis dengue measles|diphtheria|vaccines against two life-threatening bacterial diseases , entity and tetanus , came into use early in this century .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 2)])|disease|diphtheria toxin tetanus toxins enterotoxin|diphtheria tetanus pertussis pneumococcal hib|diphtheria|under supply agreements , the company manufactures the acellular pertussis component , and ssi manufactures the entity , tetanus and ipv components for the dtap and dtap-ipv vaccines .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|diphtheria toxin tetanus toxins enterotoxin|pneumonia influenza cough diarrhoea fever|diphtheria|total sales of rotarix , for rotavirus , boostrix , for prevention of entity , tetanus and whooping cough , and influenza vaccines , fluarix / flulaval , reached £274 million , up 91% .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|diphtheria toxin tetanus toxins enterotoxin|botulinum cholera pertussis tetanus diphtheria|diphtheria|according to the world health organization , the majority of the western world  s population is immunized to entity toxin .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|diphtheria toxin tetanus toxins enterotoxin|diphtheria tetanus pertussis measles toxoid|diphtheria|the company produces the monocomponent acellular pertussis toxoid and formulates the final product with entity and tetanus toxoids manufactured and supplied by ssi .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|diphtheria toxin tetanus toxins enterotoxin|tetanus diphtheria pertussis cholera toxoid|diphtheria|the peptide is joined to a carrier , entity toxoid , to enhance the immune response .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|diphtheria toxin tetanus toxins enterotoxin|pertussis diphtheria tetanus measles influenza|diphtheria|vaccination against entity , tetanus and pertussis is mandated by most states for all children with a total of five doses administered at two ,
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|diphtheria toxin tetanus toxins enterotoxin|toxin recombinant cholera anthrax botulinum|diphtheria|using a plasmid with an expression cassette of the entity toxin , no immune response will be encountered as happens when using a virus ; moreover , people born in western countries are routinely
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|diphtheria toxin tetanus toxins enterotoxin|cholera botulinum diphtheria anthrax pertussis|diphtheria| crm197  we have several development and commercial partnerships in place for crm197 , which is a non-toxic mutant of entity toxin .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|diphtheria toxin tetanus toxins enterotoxin|tetanus diphtheria pertussis cholera toxoid|diphtheria|we obtain some of the key components , including entity toxoid ( dt ) and tetanus toxoid ( tt ) , through a supply contract with aventis pasteur , one of our strategic collaborators .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|diphtheria toxin tetanus toxins enterotoxin|against toxin than into tetanus|diphtheria|gtb-1550 binds to cancer cells , the cancer cells internalize gtb-1550 , and are killed due to the action of drugs cytotoxic entity toxin payload .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|diphtheria toxin tetanus toxins enterotoxin|chlamydia syphilis chlamydial influenza hpv|diphtheria|expanded its internal research and development efforts with emphasis on a mucosal vaccine against chlamydia and a mucosal vaccine against entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|diphtheria toxin tetanus toxins enterotoxin|diphtheria pertussis botulinum cholera tetanus|diphtheria|biocancell  s leading drug , bc-819 , is a double stranded dna plasmid construct that incorporates the gene for entity toxin ( dta ) under the regulation of the promoter sequence for h19 gene .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|diphtheria toxin tetanus toxins enterotoxin|pertussis tetanus diphtheria mumps influenza|diphtheria|daptacel® , a trivalent vaccine against pertussis , entity and tetanus , was launched in the united states in 2002 and has become a strong sales contributor due to its
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|diphtheria toxin tetanus toxins enterotoxin|tetanus diphtheria pertussis cholera toxoid|diphtheria|the supply commitment of materials suitable for human use consists of entity toxoid and / or tetanus toxoid .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|diphtheria toxin tetanus toxins enterotoxin|diphtheria tetanus pertussis measles influenza|diphtheria|also launched in 1995 was infanrix , the combined acellular vaccine for entity , tetanus and pertussis ( whooping cough ) in switzerland .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|macular choroid edema macula ophthalmic|his learn her him another|choroiditis|as a student during the 1950s he had lost much of the sight in his right eye to entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|macular choroid edema macula ophthalmic|vasculitis sepsis uveitis meningitis thrombosis|choroiditis|no vasculitis , retinitis , or entity were observed .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|macular choroid edema macula ophthalmic|uveitis idiopathic sarcoidosis benign autoimmune|choroiditis|this type of uveitis is called entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|polyd congenital anomaly anomalies malformation|epilepsy obesity cataracts neuropathy headache|polydactyly|early onset obesity and hyperphagia often associated with bbs , a rare genetic disorder that is also characterized by vision loss , entity , kidney abnormalities , and other symptoms .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|polyd congenital anomaly anomalies malformation|epilepsy obesity neuropathy cataracts headache|polydactyly|it is a rare monogenic disorder that causes severe obesity and hyperphagia as well as vision loss , entity , kidney abnormalities , and other signs and symptoms .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|polyd congenital anomaly anomalies malformation|obesity epilepsy cataracts neuropathy headache|polydactyly|bardet-biedl syndrome is a monogenic disorder that causes severe obesity and hyperphagia as well as vision loss , entity , kidney abnormalities , and other signs and symptoms .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|polyd congenital anomaly anomalies malformation|reached comprised achieved underwent covered|polydactyly|acrania / turner syndrome / prader willi syndrom / left ventricular hypoplasia entity 112 table of contents in the trial , ongoing pregnancies were followed up to 28 days post-delivery .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|polyd congenital anomaly anomalies malformation|obesity epilepsy cataracts neuropathy headache|polydactyly|bardet‑biedl syndrome is a monogenic disorder that causes severe obesity and hyperphagia as well as vision loss , entity , kidney abnormalities , and other signs and symptoms .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|disease|lister diseases tick pathogen listeria|ae she sarcoidosis eosinophilia there|listeriosis|entity has also been reported as a grade 3 ae .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|lister diseases tick pathogen listeria|vomiting headache dizziness fatigue nausea|listeriosis|examples of the aes experienced include , fevers , chills , nausea , vomiting , fatigue , headaches , hypotension and entity among others .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|lister diseases tick pathogen listeria|vomiting headache dizziness fever nausea|listeriosis|examples of the aes experienced include among others , fevers , chills , nausea , vomiting , fatigue , headaches , hypotension and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|lister diseases tick pathogen listeria|suicide anaphylaxis anxiety poisoning stroke|listeriosis|the event was diagnosed by the treating investigator as being a case of entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|lister diseases tick pathogen listeria|infections diarrhoea diarrhea thrombocytopenia fever|listeriosis|when ingested , some strains of listeria can cause entity , which affects primarily the elderly , pregnant women , newborns and adults with weakened immune systems .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|lister diseases tick pathogen listeria|ae aes asthma pneumothorax headache|listeriosis|one grade 3 serious ae of entity was reported .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|lister diseases tick pathogen listeria|goats sheep goat cattle cow|listeriosis|the overhalla facility was purchased by the aahd in november 1994 and presently manufactures ringworm vaccines for cattle and entity vaccines for sheep and goats .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|lister diseases tick pathogen listeria|beings rights biology medicine immunology|listeriosis|dr . lorbers major interest in infectious diseases is in human entity , an area in which he is regarded as an international authority .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|lister diseases tick pathogen listeria|escape benefit isolates extrapolation pathogens|listeriosis|the attenuation of the listeria strains used in advaxis immunotherapies , these listeria are nonpathogenic and therefore limit the potential for entity from our immunotherapies .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|lister diseases tick pathogen listeria|escape killing isolates replication viruses|listeriosis|advaxis immunotherapies , the listeria do not replicate and spread from cell to cell at this point , limiting the potential for entity from our immunotherapies .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|onchocerc endemic schistosomiasis ver helminth|tobacco malaria pest parasite endemic|onchocerciasis|apply outside the disease endemic countries , or in relation to sales of the product for purposes other than filariasis or entity control .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|club foot ankle shoe knee|ankle neck trunk forehead mandible|clubfoot|hips at birth , prominent chin and forehead , flat feet , soft skin , floppy heart valve ( mitral valve prolapse ) , curved spine and entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|gastro endoscopic esophag duoden obstruction|phenomenon behaviour disorder polymorphism alteration|gastroparesis|dr . aurora reported that this entity can result in up to an 80% slower rate of digestion , or gastric motility , in migraineurs .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|gastro endoscopic esophag duoden obstruction|ketoacidosis nephropathy retinopathy neuropathy pancreatitis|gastroparesis|this protein may have utility in the treatment of post-operative ileus and gastrointestinal motility disorders , such as diabetic entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|gastro endoscopic esophag duoden obstruction|gerd gastritis cardiomyopathy nephropathy esophagitis|gastroparesis|agonist of the motilin receptor that enhances esophageal motility in gerd patients and accelerates gastric emptying in patients with diabetic entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|disease|gastro endoscopic esophag duoden obstruction|asthma atopic eczema dermatitis arthritis|gastroparesis| the results of the recent atopic dermatitis ( epione ) , entity ( vly686-2301 ) and motion sickness ( motion sifnos ) studies have all been submitted to peer-review publications .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|gastro endoscopic esophag duoden obstruction|gastritis pancreatitis reflux ileus colitis|gastroparesis|post-surgical entity is often associated with peptic ulcer surgery , bariatric procedures or esophageal procedures and is thought to result from damage / desensitization of
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|gastro endoscopic esophag duoden obstruction|nephropathy neuropathy retinopathy ketoacidosis episodes|gastroparesis|results from a phase 3 clinical trial of gimoti in female patients with symptoms associated with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|gastro endoscopic esophag duoden obstruction|asthma copd ibs ibd allergy|gastroparesis|we believe our novel intranasal delivery formulation will address a significant unmet market need for patients with the symptoms of entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gastro endoscopic esophag duoden obstruction|asthma schizophrenia dyspepsia gerd ibs|gastroparesis|in march 2015 , we initiated a phase 2b study of velusetrag for the treatment of patients with entity and other gastrointestinal motility disorders .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|gastro endoscopic esophag duoden obstruction|neuropathy nephropathy ketoacidosis retinopathy syndromes|gastroparesis|are the only products currently approved in the united states to treat the symptoms associated with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|gastro endoscopic esophag duoden obstruction|ibs constipation gerd dyspepsia ibd|gastroparesis|ati-7505 has potential use in five indications : chronic constipation , functional dyspepsia , gerd , entity and ibs with constipation .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|gastro endoscopic esophag duoden obstruction|neuropathy nephropathy retinopathy ketoacidosis polyneuropathy|gastroparesis|spray , the first and only nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|gastro endoscopic esophag duoden obstruction|psoriasis asthma eczema vitiligo dermatitis|gastroparesis|neurokinin-1 receptor ( nk-1r ) antagonist , which is presently in clinical development for the treatment of chronic pruritus in atopic dermatitis and entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|gastro endoscopic esophag duoden obstruction|nephropathy retinopathy neuropathy ketoacidosis cardiomyopathy|gastroparesis|the results of these clinical trials support our belief that relamorelin has the potential to be a safe and effective treatment for diabetic entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|gastro endoscopic esophag duoden obstruction|nephropathy neuropathy retinopathy ketoacidosis episodes|gastroparesis|in april 2014 , we commenced a phase 3 clinical trial of evk-001 in female patients with symptoms associated with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|gastro endoscopic esophag duoden obstruction|paralysis vomiting dysphagia headache weakness|gastroparesis|subjects with no history of migraine , migraineurs experienced , to varying degrees , paralysis of the muscles of the stomach , or entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|gastro endoscopic esophag duoden obstruction|nephropathy neuropathy retinopathy ketoacidosis disorders|gastroparesis|motus has the worldwide rights to rm-131 ( relamorelin ) , a peptide ghrelin agonist being developed for the treatment of diabetic entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|gastro endoscopic esophag duoden obstruction|ketoacidosis nausea neuropathy emesis ulcers|gastroparesis|the company believes that emitasol ( r ) , when given intranasally , may be effective in treating diabetic entity and in preventing delayed onset emesis .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|gastro endoscopic esophag duoden obstruction|epilepsy constipation asthma pancreatitis obesity|gastroparesis|metoclopramide is the only product currently approved in the united states to treat entity , and is currently available only in oral and intravenous forms .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|gastro endoscopic esophag duoden obstruction|copd schizophrenia asthma adhd ibs|gastroparesis|the primary endpoint will be the effect of velusetrag on symptoms in subjects with entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|gastro endoscopic esophag duoden obstruction|neuropathy hyperglycemia tolerance ketoacidosis glycemia|gastroparesis|emitasol ( r ) is proposed as a method to control diabetic entity and to prevent delayed emesis associated with cancer chemotherapy .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|cystic pulmonary crypt presents cysts|schizophrenia epilepsy asthma osteoporosis obesity|cryptococcosis|in addition , the fda has granted orphan drug designation to mat2203 for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|cystic pulmonary crypt presents cysts|national descriptive our published international|cryptococcosis|according to entity statistics maintained on the centers for disease control and preventions website from february 2014 , the greatest burden of this disease
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|cystic pulmonary crypt presents cysts|tuberculosis there africa malaria much|cryptococcosis|cryptococcal meningitis has become the most common cause of adult meningitis in many parts of africa , where entity now rivals tuberculosis in all-case mortality .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|cystic pulmonary crypt presents cysts|schizophrenia epilepsy asthma psoriasis psychosis|cryptococcosis|●as previously reported , during the fourth quarter of 2019 , fda granted mat2203 orphan drug designation for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|cystic pulmonary crypt presents cysts|aspergillosis candidiasis tuberculosis sepsis lymphoma|cryptococcosis|the three major types of these infections are candidiasis , aspergillosis and entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|cystic pulmonary crypt presents cysts|tuberculosis pneumonia sepsis sarcoidosis meningitis|cryptococcosis|entity is an infectious disease of the lungs caused by the fungus cryptococcus neoformans and is one of the most common
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|cystic pulmonary crypt presents cysts|aspergillosis candidiasis candida osteomyelitis aspergillus|cryptococcosis|examples of such infections include aspergillosis , blastomycosis , candidiasis , coccidioidomycosis , entity and zycomycosis .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|cystic pulmonary crypt presents cysts|tuberculosis sepsis pneumonia aspergillosis candidiasis|cryptococcosis|entity is an infectious disease of the lungs caused by the fungus cryptococcus neoformans and is one of the most common life-threatening fungal
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cystic pulmonary crypt presents cysts|asthma brucellosis fever diarrhea gastroenteritis|cryptococcosis|in april 2015 , the ema granted two orphan drug designations for ar-12 for the treatment of entity and tularaemia .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|cysts arachnoid ganglion meningitis granuloma|poisoning reactions intoxication rejection hypersensitivity|arachnoiditis|if left untreated , chemical entity may be fatal .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|cysts arachnoid ganglion meningitis granuloma|poisoning reactions allergy intolerance intoxication|arachnoiditis|the incidence and severity of chemical entity can be reduced by coadministration of dexamethasone .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|cysts arachnoid ganglion meningitis granuloma|allergy poisoning intolerance sensitization reactions|arachnoiditis|patients receiving depocyt should be treated concurrently with dexamethasone to mitigate the symptoms of chemical entity .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|cysts arachnoid ganglion meningitis granuloma|allergy poisoning abuse intolerance addiction|arachnoiditis|in all clinical studies , chemical entity , a syndrome manifested primarily by nausea , vomiting , headache and fever , was a common adverse event .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|bacterium pathogen genus polyp vir|innovative promising alternative numerous newer|aniridia|entity therapeutic interventions , such as artificial iris implantation , are being developed by humanoptics ag . •emflaza for dmd .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|bacterium pathogen genus polyp vir|our sporadic chd familial sca|aniridia|we estimate that approximately one-third of all entity cases are due to a nonsense mutation .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|bacterium pathogen genus polyp vir|glaucoma cataract myopia blindness deafness|aniridia|entity is a genetic disorder due to mutations in the pax6 gene associated with loss of eyesight and other symptoms .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|bacterium pathogen genus polyp vir|humans vivo china india oncology|aniridia|· translarna pipeline will expand with a proof of concept study in entity .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|bacterium pathogen genus polyp vir|glaucoma cataract myopia vitiligo retinoblastoma|aniridia|entity is a rare genetic disorder that results in disruption in the development of the eye .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|bacterium pathogen genus polyp vir|glaucoma cataract myopia strabismus blindness|aniridia|for example , investigators studying entity , a genetic disorder due to mutations in the pax6 gene associated with loss of eyesight and other symptoms in which
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|bacterium pathogen genus polyp vir|prevention published rates epidemiology registry|aniridia|ptc plans to initiate a phase 2 proof of concept study in nonsense mutation entity by year end 2015 .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|bacterium pathogen genus polyp vir|iii iv vi hf ds|aniridia|in addition to its advanced dmd and cf programs , ptc is now pursuing two additional indications , mps i and entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|malaria plasmodium vivax falciparum endemic|immunodeficiency diseases infections immunity malaria|malaria|other pox virus vectors are being evaluated in experimental models of human entity and , in a hybrid regimen combining doses of a modified live virus , with a subunit hiv vaccine to protect high
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|malaria plasmodium vivax falciparum endemic|against include includes recognizes requires|malaria|ema regulatory decision on glaxosmithklines entity vaccine candidate rts , s , which contains agenuss qs-21 stimulon® adjuvant .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|malaria plasmodium vivax falciparum endemic|influenza vaccine pneumococcal candidate conjugate|malaria| entity vaccine based on advac® / per . c6® technologies : crucell and its collaborator , the us national institute of allergy and infectious diseases ( niaid ) , part
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|malaria plasmodium vivax falciparum endemic|malaria mosquito insecticide dengue pest|malaria|the global plan for insecticide resistance management in entity vectors , released in 2012 , contains a five-pillar strategy on managing the threat of insecticide resistance .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|malaria plasmodium vivax falciparum endemic|national malaria world european scientific|malaria|as per the entity foundation international , malaria now kills more people than it did 3 decades ago .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|malaria plasmodium vivax falciparum endemic|quinine malaria humans adults chloroquine|malaria|quinine , a natural product from the bark of the cinchona tree , was one of the first treatments for entity and appeared in the 17 ( th ) century .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|malaria plasmodium vivax falciparum endemic|breeding resulting largest final national|malaria|in 2004 , the entity program revenue was limited to breeding activities to create a new founder line .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|malaria plasmodium vivax falciparum endemic|malaria dengue schistosomiasis mosquitoes rabies|malaria|currently pursuing our negotiation with several countries in africa to introduce our larvicide product , greenex™ as a prevention agent for entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|malaria plasmodium vivax falciparum endemic|every safety future vent sick|malaria|dr . rosenberg also serves on the boards of directors of lovelace respiratory research institute , karo bio ab , and medicines for entity venture .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|malaria plasmodium vivax falciparum endemic|hsv syphilis cytomegalovirus hpv chlamydia|malaria|we expect similarly to advance our novel non-clinical prophylactic vaccine and immunotherapy programs against chlamydia , hsv-2 and entity through human 3 table of contents proof of concept .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|malaria plasmodium vivax falciparum endemic|mosquito malaria pest insecticide insect|malaria|mosquito resistance to at least one insecticide used for entity control has been identified in 64 countries around the world .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|malaria plasmodium vivax falciparum endemic|entity define between classify definition|malaria|currently , both our cassette entity pf and entity pf / pv have been listed under the who procurement process .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|malaria plasmodium vivax falciparum endemic|influenza vaccine meningococcal pneumococcal malaria|malaria|we are collaborating with the bill & melinda gates foundation on entity vaccine research .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|malaria plasmodium vivax falciparum endemic|germany china india medicine canada|malaria|the who has made the roll back of entity , by 50% during the decade ending 2011 , one of its 4 major objectives of the current decade .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|malaria plasmodium vivax falciparum endemic|original final alternative own optimized|malaria|in the case of our entity product candidate , we may encounter difficulties in finding potential patients because our initial regimen requires patients to first fail other
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|malaria plasmodium vivax falciparum endemic|tuberculosis mrsa infections sepsis candidiasis|malaria|as well as an extended spectrum of activity against ca-mrsa , streptococci , haemophilus , enterococci , mycobacterium avium and in animal models of entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|malaria plasmodium vivax falciparum endemic|malaria infections vivax diseases falciparum|malaria|who currently recommends chloroquine for the treatment of p . vivax entity where the drug remains effective .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|malaria plasmodium vivax falciparum endemic|laboratories hospitals hematology countries cardiology|malaria|the kemri / cdc research and public health collaboration has well-developed entity , hiv , microbiology , and tuberculosis laboratories that perform a range of standard diagnostic procedures .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|malaria plasmodium vivax falciparum endemic|malaria infections vivax falciparum plasmodium|malaria|who recommends acts for the treatment of chloroquine-resistant p . vivax entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|malaria plasmodium vivax falciparum endemic|dengue influenza tuberculosis hbv measles|malaria|u . s . naval medical research center ( nmrc ) allowing them to use our proprietary adenovector technology for the development of vaccines against entity and dengue virus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|cutaneous dermat disseminated includes characterized|tuberculosis histoplasm aspergillosis fungi candidiasis|blastomycosis|endemic mycoses are caused by coccidiomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto " ) found in the soil of certain regions of the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|cutaneous dermat disseminated includes characterized|tuberculosis histoplasm aspergillosis lymphoma candidiasis|blastomycosis|there are three basic forms of endemic mycoses : coccidioidomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|cutaneous dermat disseminated includes characterized|aspergillosis tuberculosis candidiasis meningitis pneumonia|blastomycosis|examples of such infections include aspergillosis , entity , candidiasis , coccidioidomycosis , cryptococcosis and zycomycosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|cutaneous dermat disseminated includes characterized|tuberculosis histoplasm aspergillosis candidiasis lymphoma|blastomycosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto , " respectively ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|cutaneous dermat disseminated includes characterized|tuberculosis histoplasm aspergillosis candidiasis lymphoma|blastomycosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|lysosomal gaucher muco disorder comprises|mps angiotensin glycoprotein calpain cathepsin|mucopolysaccharidosis|if approved , this would be the first human enzyme replacement therapy for the treatment of hunter syndrome , also known as entity ii ( mps ii ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|lysosomal gaucher muco disorder comprises|mps troponin aps calpain das|mucopolysaccharidosis|entity i , or mps i lambert eaton myasthenic syndrome , or lems firdapse has not received
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|lysosomal gaucher muco disorder comprises|mps bipolar calpain topoisomerase haemophilia|mucopolysaccharidosis|the u . s . patent and trademark office issued to us the u . s . patent no . 6 , 426 , 208 covering aldurazyme for the treatment of entity i ( or mps i ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|lysosomal gaucher muco disorder comprises|mps chromosome genotype bipolar keratin|mucopolysaccharidosis|alpha-n-acetylglucosaminidase ( naglu ) with a peptide derived from insulin-like growth factor 2 ( igf2 ) for the treatment of sanfilippo b syndrome or entity iiib ( mps iiib ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|lysosomal gaucher muco disorder comprises|iiia iv subgroup subtype iii|mucopolysaccharidosis|hgt- 1410 for sanfilippo a syndrome ( entity iiia ) hgt- 1410 is in development as an ert delivered intrathecally for the treatment of sanfilippo a syndrome ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|lysosomal gaucher muco disorder comprises|subtype subgroup category axis zone|mucopolysaccharidosis|shp610 for sanfilippo a syndrome ( entity iiia ) shp610 is in development as an ert delivered intrathecally for the treatment of sanfilippo a syndrome , a lysosomal
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|lysosomal gaucher muco disorder comprises|mps neurofibromatosis hypercholesterolemia fibrosis amyloid|mucopolysaccharidosis|our most advanced programs are for the treatment of two severe genetic diseases , homozygous familial hypercholesterolemia ( hofh ) and entity type i ( mps i ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|lysosomal gaucher muco disorder comprises|mps chromosome bipolar cms aps|mucopolysaccharidosis|entity i , or mps i , is a rare genetic disorder that affects many body systems and that leads to organ damage .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|lysosomal gaucher muco disorder comprises|mps neurofibromatosis myopathy haemophilia psoriasis|mucopolysaccharidosis|elaprase elaprase is a treatment for hunter syndrome ( also known as entity type ii or mps ii ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|lysosomal gaucher muco disorder comprises|mps aps cda cms hit|mucopolysaccharidosis|alexion decided to reduce its investment in sbc-103 , a recombinant form of the naglu enzyme being evaluated in patients with entity iiib , or mps iiib .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|lysosomal gaucher muco disorder comprises|mps fragile haemophilia iga lysosomal|mucopolysaccharidosis|naglazyme is a recombinant form of n-acetylgalactosamine 4-sulfatase ( arylsulfatase b ) indicated for patients with entity vi ( mps vi ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|lysosomal gaucher muco disorder comprises|mps haemophilia troponin calpain glycoprotein|mucopolysaccharidosis|agreement with genzyme to establish a joint venture ( biomarin / genzyme llc ) for the worldwide development and commercialization of aldurazyme to treat entity i ( mps i ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|lysosomal gaucher muco disorder comprises|mps glycoprotein collagens prp myeloma|mucopolysaccharidosis|our initial programs are focused on lsds such as entity ( mps ) iiia and iiib .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|lysosomal gaucher muco disorder comprises|gaucher fabry alzheimer parkinson neurofibromatosis|mucopolysaccharidosis|this model , initially focused on gaucher disease , has extended to fabry disease , entity type i , and pompe disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|lysosomal gaucher muco disorder comprises|mps apolipoprotein genotype lysosomal iga|mucopolysaccharidosis|decreased levels of the alpha-l-iduronidase enzyme result in -------------- individuals having entity i ( " mps i " ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|uveitis macular macul ocular intraocular|uveitis rhinosinusitis tuberculosis arthritis infections|uveitis|we believe that reproxalap and certain of our other product candidates may qualify as an orphan drug for noninfectious anterior entity , and possibly other diseases that we may test .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|uveitis macular macul ocular intraocular|uveitis cataracts cataract glaucoma sclerosis|uveitis|patients with noninfectious anterior entity generally experience severe pain , sensitivity to light , and vision loss .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|uveitis macular macul ocular intraocular|uveitis periodontitis arthritis rhinosinusitis osteomyelitis|uveitis| clinical trials in 2015 , pending successful ind submissions , we intend to initiate clinical trials in sls and noninfectious anterior entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|disease|uveitis macular macul ocular intraocular|amd bevacizumab ranibizumab glaucoma dme|uveitis|in december 2018 for xipere , and , if approved , xipere will be the first therapy indicated for macular edema associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|uveitis macular macul ocular intraocular|colitis fibrosis sepsis nephritis atherosclerosis|uveitis|we have conducted with our mc1r peptide drug candidates have shown positive results in experimental models of inflammatory bowel disease , entity and nephritis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|uveitis macular macul ocular intraocular|retinopathy glaucoma uveitis detachment nephropathy|uveitis|the company is planning phase ii studies for age-related macular degeneration ( later diabetic macular edema , proliferative vitreoretinopathy and entity ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|disease|uveitis macular macul ocular intraocular|dme bevacizumab amd glaucoma retinopathy|uveitis|value . ”about ebi-031 eleven biotherapeutics  most advanced preclinical product candidate is ebi-031 for treatment of diabetic macular edema , or dme , and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|uveitis macular macul ocular intraocular|onset progression prevention hoc trial|uveitis|and drug administration ( fda ) to review the phase 3 eyeguard-b data together with the data from the two behçets disease entity phase 2 studies conducted independently by xoma and servier .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|disease|uveitis macular macul ocular intraocular|glaucoma amd bevacizumab sildenafil pdt|uveitis|also demonstrate comparability of the proposed drug , which we believe may require a clinical trial in macular edema associated with entity , against our product , unless a biowaiver is obtained .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|uveitis macular macul ocular intraocular|uveitis discectomy chamber anterior decompression|uveitis|both the sjögren-larsson syndrome ( sls ) trial and noninfectious anterior entity trial have begun enrollment and we expect to begin to provide preliminary data for these indications by the end of
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|uveitis macular macul ocular intraocular|uveitis cataract glaucoma cataracts vitrectomy|uveitis|lombs ) product retisert ( a surgically implanted intravitreal drug delivery device containing fa approved for the treatment of chronic non-infectious posterior entity ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|uveitis macular macul ocular intraocular|diseases arthritis disorders uveitis hepatitis|uveitis|due to its th17 activity , we believe vtp-43742 will be most effective in psoriasis , ms , behcet  s disease and autoimmune entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|uveitis macular macul ocular intraocular|glaucoma blindness cataract melanoma diseases|uveitis|develop and sell psividas proprietary delivery device for indications for diseases outside of the eye or for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|uveitis macular macul ocular intraocular|asthma copd tuberculosis nsclc psoriasis|uveitis|the second quarter of 2016 ; and ( ii ) planning on initiating a phase ii study of cf101 for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|uveitis macular macul ocular intraocular|uveitis keratitis diseases retinopathy endophthalmitis|uveitis|bausch + lomb markets retisert , an intravitreal implant of the corticosteroid fluocinolone acetonide , for the treatment of non-infectious entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|uveitis macular macul ocular intraocular|dry cataract glaucoma arthritis psoriasis|uveitis|diseases , including inflammatory bowel disease , nephritis , which is inflammation of the kidneys , and rheumatoid arthritis , and ocular indications such as entity and dry eye .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|uveitis macular macul ocular intraocular|uveitis cataract glaucoma vitrectomy cataracts|uveitis|trial of the ns2 eye drop formulation in a serious and , we believe , poorly treated ocular disease called noninfectious anterior entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|uveitis macular macul ocular intraocular|uveitis periodontitis arthritis rhinosinusitis infections|uveitis|in noninfectious anterior entity , aldehydes may mediate , at least in part , inflammation , pain , fibrotic changes , and lipid destruction leading to dryness and surface irritation .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uveitis macular macul ocular intraocular|uveitis glaucoma amd vitrectomy cataract|uveitis|novartis ( esba105 ) and eyegate pharmaceuticals , inc . ( egp-437 ) have conducted or are conducting clinical trials in anterior entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|uveitis macular macul ocular intraocular|amd glaucoma cataract blindness nc|uveitis|in addition to entity , rvo and wet amd , there are a number of ophthalmic conditions affecting the retina and choroid with unmet medical need
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|fever typhoid diarrhea epidemic virulence|dengue typhoid haemorrhagic reduce treat|typhoid|these vaccines , which currently include vaccines to prevent urinary tract infections and entity fever , are all in basic research or preclinical stage of development .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|fever typhoid diarrhea epidemic virulence|anthrax conjugate inactivated influenza recombinant|typhoid|company also anticipates continued investment in its advanced product development pipeline , including an anthrax ig therapeutic , hepatitis b therapeutic and entity vaccine , among others .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|fever typhoid diarrhea epidemic virulence|dengue typhoid hemorrhagic haemorrhagic infectious|typhoid|innovative vector vaccine delivery , manufacturing and preservation technologiesthe technology behind our single dose , oral , rapidly protecting vaccines for cholera and entity fever .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|disease|fever typhoid diarrhea epidemic virulence|mucosal influenza hygiene polio conjugate|typhoid|establishing a travel vaccines franchise through its us-based subsidiary berna products corporation , which markets vivotif® , the worlds only licensed oral entity vaccine , in north america .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|fever typhoid diarrhea epidemic virulence|conjugate meningococcal vaccine recombinant universal|typhoid|a two-year extension of the development program with brookwood pharmaceuticals and a commercial evaluation license with nih for developing a entity vaccine with gelsiteò polymer .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|fever typhoid diarrhea epidemic virulence|fever yellow typhoid spotted swine|typhoid|avant is also developing an oral entity fever vaccine , ty800 , for global health needs .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|fever typhoid diarrhea epidemic virulence|entity meningococcal influenza polysaccharide conjugate|typhoid|one oral entity vaccine and one injectable entity vaccine are currently approved and administered in the united states and europe .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|fever typhoid diarrhea epidemic virulence|swine fever yellow dengue typhoid|typhoid|of health ( nih ) initiated a phase 1 / 2 in-patient dose-ranging clinical trial aimed at demonstrating the safety and immunogenicity of the ty800 entity fever vaccine .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|disease|fever typhoid diarrhea epidemic virulence|mucosal influenza mucositis polio vaccine|typhoid|acambis  us-based subsidiary berna products corporation markets vivotif ( r ) , the world  s only licensed oral entity vaccine , in north america .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|fever typhoid diarrhea epidemic virulence|fever epidemic hemorrhagic infectious shock|typhoid|status bacterial vaccines global health choleragarde® ty800 cholera entity fever ivi nih phase 2b phase 2 travelers  etec enterotoxigenic e coli infection  pre-clinical
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|fever typhoid diarrhea epidemic virulence|cholera pertussis influenza rubella tetanus|typhoid|patents for the technology used in the cholera and entity vaccines expire between 2013 and 2016 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|fever typhoid diarrhea epidemic virulence|murine recombinant adjuvant hepatic vaccine|typhoid|entity phase 2 medeva tolerising peptide ( rye grass ) . . . . .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|fever typhoid diarrhea epidemic virulence|tuberculosis influenza anthrax cholera pertussis|typhoid|emergent biosolutions program pipeline currently includes programs focused on anthrax , tuberculosis , entity , influenza and chlamydia .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|fever typhoid diarrhea epidemic virulence|typhoid dengue haemorrhagic hemorrhagic rheumatic|typhoid|a broad portfolio of vaccines against viral and bacterial diseases , including single-dose oral vaccines aimed at protecting travelers from cholera , entity fever and other illnesses .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|fever typhoid diarrhea epidemic virulence|fever hemorrhagic infectious epidemic shock|typhoid|pre-clinical infectious disease choleragarde® ty800 cholera entity fever ivi nih phase 2b phase 2 etec enterotoxigenic e coli infection nih pre-clinical
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|fever typhoid diarrhea epidemic virulence|tuberculosis anthrax influenza meningitis hepatitis|typhoid|emergents clinical pipeline includes programs focused on anthrax , botulism , entity , tuberculosis , hepatitis b and chlamydia .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|fever typhoid diarrhea epidemic virulence|swine fever yellow dengue typhoid|typhoid|to conduct a phase i in-patient dose ranging clinical trial aimed at demonstrating the safety and immunogenicity of the ty800 entity fever vaccine .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|fever typhoid diarrhea epidemic virulence|swine fever dengue typhoid yellow|typhoid|niaid to conduct a phase i in-patient dose-ranging clinical trial aimed at demonstrating the safety and immunogenicity of the ty800 entity fever vaccine .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|fever typhoid diarrhea epidemic virulence|dengue typhoid hemorrhagic fever yellow|typhoid|thus immunity to an intestinal disease such as entity fever , is best induced by giving the vaccine orally , so that the antigens are presented directly to the lining of
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|fever typhoid diarrhea epidemic virulence|influenza tuberculosis leukemia syphilis hcv|typhoid|including rheumatoid arthritis , or ra , and systemic lupus erythematosus , or sle ; and other infectious diseases such as tuberculosis , influenza and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|porphyr iii hepatic locus nerve|dementia schizophrenia epilepsy stroke migraine|porphyria|people with entity should not be treated with visudyne .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|porphyr iii hepatic locus nerve|claudication intermittent episodes headache fatigue|porphyria|the most advanced of these programs are the following : amt-021 for acute intermittent entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|porphyr iii hepatic locus nerve|dementia schizophrenia psoriasis asthma epilepsy|porphyria|people with entity should not be treated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|porphyr iii hepatic locus nerve|migraine attacks attack ischemic hemorrhagic|porphyria|doses of aln-as1 resulted in lowering of aminolevulinic acid ( ala ) and porphobilinogen ( pbg ) , the toxic heme synthesis intermediates that mediate entity attacks .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 1)])|disease|porphyr iii hepatic locus nerve|claudication intermittent pancreatitis urticaria hemodialysis|porphyria|or pnh ;  filed a cta to initiate a phase 1 trial with aln-as1 in acute intermittent entity , or aip patients ;  initiated a phase 1 trial with aln-pcssc in normal human volunteers with elevated
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 2), ('BIO', 1)])|disease|porphyr iii hepatic locus nerve|claudication pancreatitis urticaria cholecystitis attacks|porphyria|this trial are encouraging , the data are preliminary in nature , based on a limited number of patients with acute intermittent entity , or aip .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|porphyr iii hepatic locus nerve|pancreatitis claudication cholangitis hepatitis cholecystitis|porphyria|we and our collaborator digna biotech are developing amt-021 as a gene therapy for acute intermittent entity , or aip , a severe liver disorder .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|porphyr iii hepatic locus nerve|hemorrhagic ischemic migraine fatal transient|porphyria|excluding entity attacks , three patients had four saes , including one previously reported fatal episode of hemorrhagic pancreatitis ; none of these saes were
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|porphyr iii hepatic locus nerve|migraine headache panic depressive psychotic|porphyria| present data from the ongoing phase 1 study  including initial data in patients that experience recurring entity attacks  in late 2016 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|porphyr iii hepatic locus nerve|intermittent onset progressive hepatic incident|porphyria|acute intermittent entity aip disease and market background aip is a rare metabolic liver disorder resulting from mutations in the pbgd gene .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|porphyr iii hepatic locus nerve|encephalopathy cirrhosis steatosis fibrosis insufficiency|porphyria|advanced investigational rnai therapeutic , givosiran , targets aminolevulinic acid synthase 1 , or alas1 , for the treatment of patients with acute hepatic entity , or ahp .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|porphyr iii hepatic locus nerve|encephalopathy insufficiency cirrhosis pancreatitis fibrosis|porphyria|food and drug administration ( fda ) approved givlaari ( givosiran ) injection for subcutaneous use for the treatment of adults with acute hepatic entity ( ahp ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|porphyr iii hepatic locus nerve|migraine headache attacks smoking psychiatric|porphyria|defined mutation in the pbgd gene and elevated urinary levels of ala and pbg , but no current entity attacks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|porphyr iii hepatic locus nerve|porphyr claudication hepatic poisoning hyperlipidemia|porphyria|amt-021 for acute intermittent entity we are developing amt-021 as a gene therapy for acute intermittent porphyria , or aip , a severe liver disorder .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|cutaneous dermat disseminated describe includes|meningitis tuberculosis fever pneumonia sepsis|coccidioidomycosis|status in the united states for vt-1129 for the treatment of cryptococcal meningitis and for vt-1598 for the treatment of entity , also known as valley fever .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cutaneous dermat disseminated describe includes|dengue fever leptospirosis malaria tuberculosis|coccidioidomycosis|our third program , vt-1598 for the treatment of entity , a fungal infection in the southwestern united states also known as valley fever , is in ind-enabling studies targeting an ind
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|cutaneous dermat disseminated describe includes|fever dengue viruses influenza leptospirosis|coccidioidomycosis|these diseases include entity , commonly known as valley fever .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|cutaneous dermat disseminated describe includes|aspergillosis candidiasis tuberculosis lymphoma melanoma|coccidioidomycosis|examples of such infections include aspergillosis , blastomycosis , candidiasis , entity , cryptococcosis and zycomycosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|cutaneous dermat disseminated describe includes|dengue example japanese fungal tropical|coccidioidomycosis|vt-1598 for entity ( valley fever ) vt-1598 is an orally available inhibitor of fungal cyp51 that has shown high potency and selectivity in in vitro studies .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|oste dysplasia idiopathic osteop al|polyneuropathy leukemia melanoma neuropathy disorder|osteopetrosis|infantile malignant entity ( imo ) : imo is a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|oste dysplasia idiopathic osteop al|illness dementia asthma pneumonia epilepsy|osteopetrosis|imo is a severe form of entity that typically presents in the first year of life and is associated with severe manifestations leading to death within the
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|oste dysplasia idiopathic osteop al|melanoma lymphoma colitis mesothelioma hepatitis|osteopetrosis|hcv collaboration with roche and sales of actimmune® , which is approved for two indications , chronic granulomatous disease ( cgd ) and severe , malignant entity .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|oste dysplasia idiopathic osteop al|melanoma mesothelioma arthritis colitis lymphoma|osteopetrosis|actimmune is currently approved in the united states for the treatment of chronic granulomatous disease ( cgd ) and severe , malignant entity .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|oste dysplasia idiopathic osteop al|polyneuropathy leukemia melanoma glioma mesothelioma|osteopetrosis|infantile malignant entity ( “imo” ) imo is a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|oste dysplasia idiopathic osteop al|melanoma mesothelioma diseases lymphoma neoplasms|osteopetrosis|is approved in the united states and numerous other countries for the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|oste dysplasia idiopathic osteop al|melanoma mesothelioma lymphoma arthritis colitis|osteopetrosis|actimmune has been approved by the fda f16 for use in the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|oste dysplasia idiopathic osteop al|melanoma lymphoma mesothelioma retinopathy anemia|osteopetrosis|frequency and severity of serious infections associated with chronic granulomatous disease ( cgd ) and to slow the worsening of severe malignant entity ( smo ) .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|oste dysplasia idiopathic osteop al|melanoma glioma lymphoma gliomas mesothelioma|osteopetrosis|the fda approved actimmune as a treatment to delay the time to disease progression in patients with severe , malignant entity .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|oste dysplasia idiopathic osteop al|melanoma glioma diseases ascites neoplasms|osteopetrosis|in the united states , the company estimates that there are approximately 1 , 200 patients with cgd and less than 500 patients with severe , malignant entity .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|oste dysplasia idiopathic osteop al|melanoma glioma mesothelioma lymphoma neoplasms|osteopetrosis|is also targeting research in other diseases such as pyruvate kinase deficiency ( pkd ) , leukocyte adhesion deficiency-i ( lad-i ) , and infantile malignant entity .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|oste dysplasia idiopathic osteop al|melanoma mesothelioma diseases lymphoma neoplasms|osteopetrosis|actimmune we currently market our lead product , actimmune , for the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|oste dysplasia idiopathic osteop al|melanoma lymphoma mesothelioma arthritis colitis|osteopetrosis|actimmune is approved by the fda for use in children and adults with chronic granulomatous disease ( cgd ) and severe , malignant entity ( smo ) .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|oste dysplasia idiopathic osteop al|conclusion fact vivo humans mammals|osteopetrosis|in entity , the cells that break down bone ( osteoclasts ) do not work properly , which leads to the bones becoming thicker and not as healthy .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|oste dysplasia idiopathic osteop al|psoriasis schizophrenia asthma tuberculosis epilepsy|osteopetrosis|for example , we have ongoing phase 4 post-marketing commitments to the fda relating to actimmune for the treatment of entity , including a registry and drug interaction study .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|oste dysplasia idiopathic osteop al|melanoma mesothelioma arthritis lymphoma colitis|osteopetrosis|we currently market actimmune in the united states for the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|oste dysplasia idiopathic osteop al|osteoporosis hyperparathyroidism calcification aging osteoarthritis|osteopetrosis|entity is a disorder of bone development in which the bones become thickened .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|oste dysplasia idiopathic osteop al|osteoporosis dementia osteoarthritis schizophrenia arthritis|osteopetrosis|in people with entity , this balance is not maintained and the resorption of old bone material decreases while the formation of new bone continues .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|oste dysplasia idiopathic osteop al|melanoma glioma mesothelioma lymphoma cardiomyopathy|osteopetrosis|severe , malignant entity is a life-threatening , congenital disorder that primarily affects children .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|oste dysplasia idiopathic osteop al|melanoma mesothelioma lymphoma arthritis neoplasms|osteopetrosis|actimmune has been approved by the fda for use in the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|disseminated cutaneous aspergillosis pulmonary candida|aspergillus additionally aspergillosis furthermore subsequently|aspergillosis|entity , a fungal infection caused by aspergillus , begins as an upper airway infection and can become a systemic fungal infection in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|disseminated cutaneous aspergillosis pulmonary candida|candidiasis aspergillosis fungal sinusitis carcinoma|aspergillosis|astellas commercially launched isavuconazole in the united states in april 2015 for the treatment of invasive entity and invasive mucormycosis in adults .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|disseminated cutaneous aspergillosis pulmonary candida|candidiasis aspergillosis infections melanoma malignancies|aspergillosis|overview until recently , we were focused on developing our novel antifungal vl-2397 , for the treatment of patients with invasive entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|disseminated cutaneous aspergillosis pulmonary candida|aspergillosis diseases candidiasis infections tuberculosis|aspergillosis|the fda has also granted vical qualified infectious disease product ( qidp ) , orphan drug and fast track designations for vl‑2397 for the treatment of invasive entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|disseminated cutaneous aspergillosis pulmonary candida|humans dogs japan europe korea|aspergillosis|compound , cancidastm ( caspofungintm ) or mk-0991 , in the same class as our v-echinocandin , recently received fda approval for salvage therapy in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|disseminated cutaneous aspergillosis pulmonary candida|tuberculosis candidiasis melanoma leishmaniasis psoriasis|aspergillosis|indications currently being explored for mat2203 include resistant candidiasis , cryptococcal meningoencephalitis , entity and leishmaniasis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|disseminated cutaneous aspergillosis pulmonary candida|aspergillosis candidiasis infections wounds leukemia|aspergillosis|it is indicated for primary treatment of acute invasive entity and salvage therapy for rare but serious fungal infections caused by the pathogens scedosporium apiospermum and fusarium spp .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|disseminated cutaneous aspergillosis pulmonary candida|aspergillosis candidiasis cancers carcinoma melanoma|aspergillosis|fda has advised that vl‑2397 would be eligible for a limited use indication ( lui ) approval for the treatment of invasive entity for patients with limited treatment options .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|disease|disseminated cutaneous aspergillosis pulmonary candida|aspergillosis candidiasis carcinoma scc uc|aspergillosis|with soc vs . aspergillus spp . , we plan to initiate a phase 2 study of oral scy-078 in patients with invasive entity in the third quarter of 2018 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|disseminated cutaneous aspergillosis pulmonary candida|aspergillosis candidiasis fungal infections fungi|aspergillosis|we market amphotec® worldwide for the treatment of invasive entity , a life-threatening systemic fungal infection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|disseminated cutaneous aspergillosis pulmonary candida|aspergillosis cancers purposes diseases medicine|aspergillosis|although we market amphotec for invasive entity , we do not believe that it will provide sufficient revenue to us in the near future , if ever , and , consequently ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|disseminated cutaneous aspergillosis pulmonary candida|candidiasis aspergillosis melanoma gastrointestinal cutaneous|aspergillosis|development history of mat2203 mat2203 was extensively studied in animal model studies of various fungal infections including invasive candidiasis , entity , and visceral leichmaniasis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|disseminated cutaneous aspergillosis pulmonary candida|aspergillosis candidiasis fungal infections fungi|aspergillosis|amphotec is an fda-approved lipid-complexed form of amphotericin b indicated for the treatment of invasive entity , a life-threatening systemic fungal infection .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 1)])|disease|disseminated cutaneous aspergillosis pulmonary candida|aspergillosis carcinoma candidiasis melanoma adenocarcinoma|aspergillosis|an estimated 200 , 000 cases of invasive entity are diagnosed annually worldwide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|disseminated cutaneous aspergillosis pulmonary candida|fungal bloodstream cutaneous gastrointestinal wound|aspergillosis|sequus is conducting a phase iii double-blind , randomized study comparing amphotec with amphotericin b in treating patients with first-line entity infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|disseminated cutaneous aspergillosis pulmonary candida|aspergillus candida penicillium cryptococcus fusarium|aspergillosis|the amphotericin b cochleate demonstrated reasonable activity against at least one strain of entity fumigatus and one strain of candida albicans in vitro .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|disseminated cutaneous aspergillosis pulmonary candida|dysplasia aspergillosis carcinoma bronchopulmonary fibrosis|aspergillosis| received a second qidp status for pulmazole to treat fungal infections in the airways of allergic bronchopulmonary entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|disseminated cutaneous aspergillosis pulmonary candida|aspergillosis candidiasis carcinoma melanoma malignancies|aspergillosis|cancidas  has not been studied as an initial therapy for invasive entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|disseminated cutaneous aspergillosis pulmonary candida|aspergillosis candidiasis infections carcinoma cancers|aspergillosis|hepatitis c virus ( hcv ) , infections , and amphotec® ( amphotericin b cholesteryl sulfate complex for injection ) , approved for the treatment of invasive entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|disseminated cutaneous aspergillosis pulmonary candida|candidiasis aspergillosis cancers carcinoma carcinomas|aspergillosis|we have world-wide marketing rights to amphotec for the treatment of invasive entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|schistosomiasis schistosoma mansoni endemic parasite|them diarrhea diarrhoea malaria adults|schistosomiasis|three months ended march 31 , 2012 , approximately 60% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|schistosomiasis schistosoma mansoni endemic parasite|malaria schistosomiasis dengue diseases tuberculosis|schistosomiasis|deuterated praziquantel in collaboration with the therapeutics for rare and neglected diseases division of the nih for the treatment of entity and other parasitic diseases .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|schistosomiasis schistosoma mansoni endemic parasite|them diarrhoea malaria diarrhea tuberculosis|schistosomiasis|three months ended june 30 , 2009 , approximately $943 , 137 or 15 . 52% of total revenue resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|schistosomiasis schistosoma mansoni endemic parasite|psoriasis acne vitiligo asthma epilepsy|schistosomiasis|lucanthone was originally used as an antiparasitic agent for the treatment of entity in the 1950s and 1960s , and has a demonstrated safety profile .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|schistosomiasis schistosoma mansoni endemic parasite|them diarrhoea malaria diarrhea adults|schistosomiasis|three months ended june 30 , 2011 , approximately 22% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|schistosomiasis schistosoma mansoni endemic parasite|them malaria diarrhoea diarrhea schistosomiasis|schistosomiasis|the three months march 31 , 2010 , approximately $830 , 600 , or 17% of total revenues , resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|schistosomiasis schistosoma mansoni endemic parasite|them malaria diarrhoea diarrhea schistosomiasis|schistosomiasis|ended december 31 , 2010 , approximately $12 , 198 , 522 or 25 . 7% of total revenue resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|schistosomiasis schistosoma mansoni endemic parasite|them malaria diarrhoea diarrhea schistosomiasis|schistosomiasis|three months ended september 30 , 2009 , approximately $3 , 330 , 000 or 26% of total revenue resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|schistosomiasis schistosoma mansoni endemic parasite|malaria schistosomiasis tuberculosis leishmaniasis candidiasis|schistosomiasis|it is an anthelmintic effective against entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|schistosomiasis schistosoma mansoni endemic parasite|schistosomiasis malaria leishmaniasis tuberculosis diarrhoea|schistosomiasis|entity is a parasitic disease that affects both animals and humans .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|schistosomiasis schistosoma mansoni endemic parasite|diarrhea them diarrhoea malaria asthma|schistosomiasis|during the three months ended june 30 , 2010 , approximately $1 , 864 , 203 or 33 . 7% resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|disease|schistosomiasis schistosoma mansoni endemic parasite|urbanization china leptospirosis malaria arsenic|schistosomiasis|entity is prevalent in southern china where there are a lot of fresh water lakes and rivers .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|schistosomiasis schistosoma mansoni endemic parasite|them diarrhoea diarrhea malaria adults|schistosomiasis|nine months ended september 30 , 2012 , approximately 44% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|schistosomiasis schistosoma mansoni endemic parasite|them diarrhea diarrhoea malaria schistosomiasis|schistosomiasis|during the three months ended september 30 , 2010 , approximately $5 , 104 , 961 or 41% resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|schistosomiasis schistosoma mansoni endemic parasite|psoriasis acne asthma vitiligo epilepsy|schistosomiasis|table of contents lucanthone was originally used as an antiparasitic agent for the treatment of entity in the 1950s and 1960s , and has a demonstrated safety profile .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|schistosomiasis schistosoma mansoni endemic parasite|them diarrhoea diarrhea malaria adults|schistosomiasis|during year ended december 31 , 2011 , approximately 36% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|schistosomiasis schistosoma mansoni endemic parasite|them diarrhea diarrhoea malaria schistosomiasis|schistosomiasis|during the three months ended march 31 , 2011 , approximately 1 , 058 , 132 or 15% resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|schistosomiasis schistosoma mansoni endemic parasite|malaria diarrhoea diarrhea infections schistosomiasis|schistosomiasis|praziquantel is a compound of pyrazine and isoquinolin designed to treat and prevent entity in livestock .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|schistosomiasis schistosoma mansoni endemic parasite|them diarrhoea malaria diarrhea adults|schistosomiasis|three months ended september 30 , 2011 , approximately 26% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|schistosomiasis schistosoma mansoni endemic parasite|giardia cryptosporidium parasites leishmania schistosomiasis|schistosomiasis|examples of analytes in this field are : aspergillus , candida , markers or antibodies associated with entity , giardia lamblia , leishmaniasis , lyme disease , chagas , toxoplasmosis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|lymphangi benign cystic uncommon malignant|hemangioma melanoma pheochromocytoma prostate testis|lymphangioma|aortic body and other paraganglia coccygeal body glomus jugulare para-aortic body 227 . 8 other 227 . 9 endocrine gland , site unspecified 228 hemangioma and entity , any site includes :
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|lymphangi benign cystic uncommon malignant|hemangioma pheochromocytoma melanoma meningioma neurofibromatosis|lymphangioma|paraganglia coccygeal body glomus jugulare para-aortic body 227 . 8 other 227 . 9 endocrine gland , site unspecified 228 hemangioma and entity , any site includes :
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|cholera toxin enterotoxin toxins glycoprotein|outbreak influenza epidemic measles entire|cholera|during the entity outbreak we responded to a further specific request for antibiotics and donated £250 , 000 to the british red cross to support
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|cholera toxin enterotoxin toxins glycoprotein|viruses ndv pathogens vaccines antigens|cholera|quarter of 2000 , will test the safety , immunogenecity and protective capacity of the vaccine against a challenge with live virulent entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|cholera toxin enterotoxin toxins glycoprotein|fever hepatitis encephalitis attack nephropathy|cholera|qilian shan® oxytetracycline api used for treating following diseases : rickettsia , mycoplasma infection , chlamydia infection , regression fever , brucellosis entity , rabbit fever and plague .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|cholera toxin enterotoxin toxins glycoprotein|diarrhea fever diarrhoea gastroenteritis cough|cholera|( the causative agent of entity ) are often confused with travelers diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|cholera toxin enterotoxin toxins glycoprotein|diarrhea diarrhoea fever pneumonia tuberculosis|cholera|in human patients with various types of watery diarrhea , including traveler  s diarrhea , hiv-related diarrhea and other acute infectious diarrheas , including entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|cholera toxin enterotoxin toxins glycoprotein|diarrhea asthma ibd ibs constipation|cholera|in addition , an early stage cftr inhibitor program is planned for the treatment of secretory diarrhea disorders , including entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|cholera toxin enterotoxin toxins glycoprotein|diarrhea diarrhoea gastroenteritis dengue rotavirus|cholera|entity is an acute diarrheal illness that kills thousands of people worldwide each year due to rapid dehydration in the first 2 -18 hours after infection .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|cholera toxin enterotoxin toxins glycoprotein|vaccine influenza malaria vaccination measles|cholera|and supported the start of phase ii trials in december 2002 with the international vaccine institute ( ivi ) in bangladesh where entity is endemic .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|cholera toxin enterotoxin toxins glycoprotein|malaria peru rabies diarrhea africa|cholera|investigation , peru-15 may be an excellent candidate as a potential single dose , oral vaccine for travelers going to areas where entity is endemic .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|cholera toxin enterotoxin toxins glycoprotein|cholera infectious typhoid toxin pertussis|cholera|entity / general watery diarrhea we are investigating lechlemer for the indication of cholera / general watery diarrhea in adults and children .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|disease|cholera toxin enterotoxin toxins glycoprotein|pneumococcal meningococcal antibacterial microbial probiotic|cholera|development of a safe , effective entity vaccine is the first step in establishing avants single-dose , oral bacterial vaccine franchise .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|disease|cholera toxin enterotoxin toxins glycoprotein|diarrhea diarrhoea mucosal rotavirus polysaccharide|cholera|ctb has already been administered to hundreds of thousands of patients worldwide and is a major component of an existing oral entity vaccine and traveler  s diarrhea vaccine .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|cholera toxin enterotoxin toxins glycoprotein|causative infecting pathogenic killed susceptible|cholera|published results have shown the vaccine to be well tolerated and immunogenic against the entity organism in the adult portion of this trial .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|cholera toxin enterotoxin toxins glycoprotein|botulinum toxin cholera diphtheria anthrax|cholera|maxvax mucosal vaccine carrier / adjuvant platform maxvax is a mucosal vaccine carrier / adjuvant platform based on the entity toxin b subunit ( ctb ) .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|cholera toxin enterotoxin toxins glycoprotein|influenza conjugate hepatitis typhoid polysaccharide|cholera|crucell also markets travel vaccines , such as the only oral anti-typhoid vaccine , an oral entity vaccine and the only aluminium-free hepatitis a vaccine on the market .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|cholera toxin enterotoxin toxins glycoprotein|influenza hepatitis typhoid rotavirus conjugate|cholera|crucell also markets travel vaccines , such as an oral anti-typhoid vaccine , an oral entity vaccine and the only aluminum-free hepatitis a vaccine on the market .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cholera toxin enterotoxin toxins glycoprotein|malaria vaccine influenza rotavirus india|cholera|this vaccine and supported the start of phase 2 trials in december 2002 with the international vaccine institute ( ivi ) in bangladesh where entity is endemic .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|cholera toxin enterotoxin toxins glycoprotein|influenza vaccine rv conjugate original|cholera|we will then determine our commercialization strategy with respect to the entity vaccine based on clinical data from the trial .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|cholera toxin enterotoxin toxins glycoprotein|influenza hepatitis conjugate vaccine typhoid|cholera|crucell also markets travel vaccines , such as the only oral anti-typhoid vaccine , an oral entity vaccine and the only aluminum-free hepatitis a vaccine on the market .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|cholera toxin enterotoxin toxins glycoprotein|decades immunotherapy humans centuries infants|cholera|in addition , a second-generation proprietary anti-secretory agent is in development for entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|ichthy pigment eruption dermat seb|neuropathy disorder recessive malformation arthritis|ichthyosis|the loss of tgm-1-activity results in the severe genetic skin disease autosomal recessive congenital entity ( arci ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|ichthy pigment eruption dermat seb|malformations anomalies defects hypothyroidism malformation|ichthyosis|there is no prescription drug currently approved in the united states that is indicated for the treatment of congenital entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|ichthy pigment eruption dermat seb|malformations anomalies defects hypothyroidism malformation|ichthyosis|announced that the united states food and drug administration ( fda ) granted adx-102 orphan drug designation for the treatment of congenital entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|ichthy pigment eruption dermat seb|acne pemphigus psoriasis ichthy erythema|ichthyosis|entity vulgaris is the most common form of ichthyosis affecting around one in 250 people worldwide .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|disease|ichthy pigment eruption dermat seb|psoriasis eczema dermatitis arthritis vitiligo|ichthyosis|moisturizers that are used for the treatment of dry skin or certain inflammatory skin conditions , such as psoriasis , eczema or entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|ichthy pigment eruption dermat seb|hypothyroidism malformations defects anomalies cataracts|ichthyosis| liarozolean oral therapeutic for the treatment of congenital entity , a rare genetic disease characterized by dryness and scaling of the skin .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 3), ('OTHER', 2)])|disease|ichthy pigment eruption dermat seb|hypothyroidism defects disorder syphilis dysplasia|ichthyosis|kb105 , delivers functional human transglutaminase-1 , or tgm1 genes using our gene therapy platform to patients with tgm1-deficient autosomal recessive congenital entity , or arci .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ichthy pigment eruption dermat seb|psoriasis acne epilepsy vitiligo asthma|ichthyosis|a dermatologic form of adx-102 is in late-stage clinical development for the treatment of entity due to sjögren-larsson syndrome , an inborn error of aldehyde metabolism .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|disease|ichthy pigment eruption dermat seb|psoriasis acne eczema erythema itch|ichthyosis|thus , ns2 may be partially or wholly effective in preventing and treating entity or other dermal symptoms , signs , or pathologies in sls .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|ichthy pigment eruption dermat seb|illness anemia complication fever morbidity|ichthyosis|sls patients are generally diagnosed as neonates given the severe entity that presents at birth .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|ichthy pigment eruption dermat seb|hypothyroidism malformations retardation malformation disorder|ichthyosis|- dosing of the 4th patient in the phase 1 / 2 study of kb105 in patients with tgm1 deficient autosomal recessive congenital entity ( arci ) has completed .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|ichthy pigment eruption dermat seb|cysts keratitis keratoplasty cataracts fractures|ichthyosis|compared to the same periods 2006 due to the completion of our phase 2 / 3 trial for the treatment of lamellar entity in april 2007 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|ichthy pigment eruption dermat seb|malformations hypothyroidism defects anomalies epilepsy|ichthyosis|in june , barrier therapeutics announced that liarozole was granted orphan drug status from the fda for the treatment of congenital entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|ichthy pigment eruption dermat seb|acne pemphigus psoriasis erythema alopecia|ichthyosis|frequently results in lethargy and reduced libido in men above the age of 40 , and glylorin ( tm ) , a novel treatment for entity vulgaris , a debilitating skin disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|ichthy pigment eruption dermat seb|generalized called erythema pars macaca|ichthyosis|“primary indication” means the netherton syndrome , also known as comel-netherton syndrome , ns , bamboo hair syndrome , and entity linearis cirumflexa .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|ichthy pigment eruption dermat seb|dermatitis candidiasis acne osteomyelitis keratitis|ichthyosis|barrier has other product candidates in various stages of clinical development for the treatment of onychomycosis , lamellar entity , acne , psoriasis and fungal infections .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|ichthy pigment eruption dermat seb|ataxia blindness retinopathy cataracts cataract|ichthyosis|of fatty aldehydes in sjögren-larsson syndrome , an orphan disease caused by mutations in fatty acid aldehyde dehydrogenase , lead to severe entity , retinal disease and neurological disorders .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|ichthy pigment eruption dermat seb|acne pemphigus erythema psoriasis vulgaris|ichthyosis|table of contents was licensed to ohr cosmetics for dermatological uses was evaluated in a moisturizer formulation in subjects with entity vulgaris at a non-us testing site .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|ichthy pigment eruption dermat seb|cataracts malformations defects anomalies sls|ichthyosis|in april 2017 , we announced that the fda granted reproxalap orphan drug designation for the treatment of congenital entity , a severe skin disease characteristic of sls .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|ichthy pigment eruption dermat seb|malformations anomalies defects toxoplasmosis infections|ichthyosis|in or entering phase 3 clinical trials for the treatment of seborrheic dermatitis , fungal infections , including vaginal candidiasis , and congenital entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|histoplasm capsul disseminated describe uncommon|meningitis aspergillosis pneumonia tuberculosis candidiasis|histoplasmosis|among the most common systemic fungal infections that may infect these patients include candidiasis , aspergillosis , entity , and cryptococcal meningitis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|histoplasm capsul disseminated describe uncommon|diseases anomalies pathologies dysfunction disorders|histoplasmosis|visudyne is also used for the treatment of subfoveal cnv due to pathologic myopia , or severe near-sightedness , and presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|histoplasm capsul disseminated describe uncommon|leprosy tuberculosis osteomyelitis septicemia aspergillus|histoplasmosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto , " respectively ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|histoplasm capsul disseminated describe uncommon|cryptococcus neoformans candida aspergillus fungi|histoplasmosis|in conjunction with fujisawa , is conducting two phase iii clinical trials of ambisome in the u . s . for the treatment of entity and for the treatment of cryptococcus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|histoplasm capsul disseminated describe uncommon|blindness glaucoma degeneration pathologies neovascularization|histoplasmosis|other macular neovascular conditions such as minimally classic and occult with no classic amd lesions , pathologic myopia and presumed ocular entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|histoplasm capsul disseminated describe uncommon|diseases pathologies disorders sarcoidosis blindness|histoplasmosis|in some countries , including the u . s . and canada , visudyne is also approved for presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|histoplasm capsul disseminated describe uncommon|meningitis aspergillosis pneumonia tuberculosis candidiasis|histoplasmosis|among the most common 5 8 systemic fungal infections that may infect these patients include candidiasis , aspergillosis , entity , and cryptococcal meningitis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|histoplasm capsul disseminated describe uncommon|fungi infections penicillium osteomyelitis aspergillus|histoplasmosis|endemic mycoses are caused by coccidiomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto " ) found in the soil of certain regions of the united states .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|histoplasm capsul disseminated describe uncommon|melanoma psoriasis tuberculosis acne leukemia|histoplasmosis|the trial for entity is being monitored and analyzed by the mycology study group of the national institutes of health .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|histoplasm capsul disseminated describe uncommon|hepatitis tuberculosis cirrhosis leukemia lymphoma|histoplasmosis|many antibody drugs are immunosuppressive , which may lead to increased risk of serious or opportunistic infection , such as tuberculosis , entity and hepatitis b , or malignancy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|histoplasm capsul disseminated describe uncommon|leprosy osteomyelitis tuberculosis fungi aspergillus|histoplasmosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|histoplasm capsul disseminated describe uncommon|distress refractive detachment cataract myopia|histoplasmosis|visudyne has recently been launched for two new indications , pathologic myopia ( in the united states and europe ) and ocular entity syndrome ( in the united states ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|histoplasm capsul disseminated describe uncommon|diseases pathologies disorders sarcoidosis blindness|histoplasmosis|in some countries ( including the u . s . and canada ) visudyne is also approved for presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|histoplasm capsul disseminated describe uncommon|osteomyelitis leprosy tuberculosis fungi aspergillus|histoplasmosis|there are three basic forms of endemic mycoses : coccidioidomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|disease|histoplasm capsul disseminated describe uncommon|distress infections congestion vasculitis irritation|histoplasmosis|presumed ocular entity syndrome ( ohs ) is a condition caused by a fungal infection endemic to certain areas in the central and eastern u . s .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|histoplasm capsul disseminated describe uncommon|diseases disorders pathologies dysfunction irritation|histoplasmosis|in some countries visudyne is also approved for presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|histoplasm capsul disseminated describe uncommon|pediatric thirty multicenter fifty eastern|histoplasmosis|entity phase iii cryptococcal meningitis phase iii daunoxome advanced kaposi  s sarcoma approved for marketing in the u . s . , canada and 12 western
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|histoplasm capsul disseminated describe uncommon|dysfunction anomalies diseases pathologies irritation|histoplasmosis|in the us , visudyne has received an additional approval for cnv due to presumed ocular entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|histoplasm capsul disseminated describe uncommon|neovascular neovascularization hypertensive detachment pigment|histoplasmosis|due to pathologic myopia in the united states , canada and the european union and for cnv due to presumed ocular entity syndrome ( " ohs " ) in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|disease|epilepsy epileptic seizure onset subtypes|epilepsy dementia seizures seizure medication|epilepsy|mothers exposed to other antiepileptic drugs , or aeds , and a purported prevalence of 0 . 07% in infants born to mothers without entity or treatment with other aeds .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|epilepsy epileptic seizure onset subtypes|asthma copd psoriasis allergy rhinitis|epilepsy|the company has clinical stage programs in entity and asthma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|epilepsy epileptic seizure onset subtypes|psoriasis fever arthritis fatigue asthma|epilepsy|the company is conducting research and development activities in a number of disease areas , including entity , pain and inflammation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|epilepsy epileptic seizure onset subtypes|epilepsy seizures schizophrenia adhd autism|epilepsy|we are also preparing for the potential commercial launch of diazepam nasal spray , a treatment for people with entity who experience cluster seizures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 3), ('DRUG', 1)])|disease|epilepsy epileptic seizure onset subtypes|hyperlipidemia migraine arthritis epilepsy stroke|epilepsy|the products are intended to treat a variety of disorders including the following : hypertension , arthritis , seizures , entity , diabetes and pain management .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|epilepsy epileptic seizure onset subtypes|poor improve fair improving maintain|epilepsy|continue making payments to parteq of c$108 , 000 each quarter as a result of the renewal of the alzheimers agreement and entity agreement with parteq .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|epilepsy epileptic seizure onset subtypes|psychotropic antiepileptic antipsychotic psychoactive antidepressant|epilepsy|in 2005 , the fda requested that all makers of entity drugs analyze their clinical trial data to determine whether these drugs increase the risk of suicide in patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|epilepsy epileptic seizure onset subtypes|seizures epilepsy aes episodes fever|epilepsy|myoclonic entity 0 1 ( 3 . 4% ) 2 ( 6 . 9% ) serious aes , or saes , of seizure were reported
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|epilepsy epileptic seizure onset subtypes|humans rats dbs microdialysis propofol|epilepsy|to evaluate cbd and cbdvhs ( and possibly additional cbd-derivatives ) in a human in vitro neural model with an application to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|epilepsy epileptic seizure onset subtypes|birth perinatal infant stillbirth neonatal|epilepsy|the uk entity and pregnancy register reported a similarly increased prevalence of oral clefts ( 3 . 2% ) among infants born to mothers exposed to topiramate
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|epilepsy epileptic seizure onset subtypes|cognition schizophrenia dementia cognitive neurodegeneration|epilepsy|amarins cns development pipeline includes two programs in parkinsons disease , one in entity and one in memory and cognition .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|epilepsy epileptic seizure onset subtypes|homeobox mutant promoter reporter coding|epilepsy|a patent application relating to the epm1 entity gene is pending in the uspto .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|epilepsy epileptic seizure onset subtypes|epilepsy seizures schizophrenia seizure choice|epilepsy|patients with refractory focal seizures , which we refer to as the star 1 ( synthetic transdermal cannabidiol for the treatment of entity ) trial .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|epilepsy epileptic seizure onset subtypes|epilepsy schizophrenia migraine stroke dementia|epilepsy|in chronic use for the treatment of entity , vigabatrin has been generally well tolerated with lower than average neurological side effects compared to other approved entity therapies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|epilepsy epileptic seizure onset subtypes|asthma schizophrenia copd psoriasis tuberculosis|epilepsy|sales of drugs for the treatment of entity decreased by approximately $967 , 000 in the second quarter of fiscal 2008 compared to the second quarter of fiscal 2007 because
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|epilepsy epileptic seizure onset subtypes|epilepsy tremor stroke migraine fibromyalgia|epilepsy|electrical neurostimulation technology has seen growing use in recent years for numerous applications– such as chronic pain , parkinsons , essential tremor , entity , and others .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|epilepsy epileptic seizure onset subtypes|scientific european nci national pharmaceutical|epilepsy|this study was sponsored by the entity foundation , and conducted in 2013 in the laboratory of dr . annamaria vezzani at the mario negri institute for pharmacological research
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|epilepsy epileptic seizure onset subtypes|psoriasis cml aml asthma epilepsy|epilepsy|we are developing sage-217 so that it will have what we believe is an optimal profile as a monotherapy for entity in many forms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|epilepsy epileptic seizure onset subtypes|psoriasis asthma acne osteoporosis hcc|epilepsy|with janssen pharmaceuticals , inc . , is scheduled to enter a phase 2a proof of concept clinical study for the treatment of entity in h1 2021 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|epilepsy epileptic seizure onset subtypes|promising alternative approved final commercial|epilepsy|our two entity product candidates are spn-538 ( extended release topiramate ) , for which we submitted a new drug application , or nda , that was accepted
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|headache fever migraine jaundice dyspepsia|cholecystitis|these include entity ( gallbladder inflammation ) , seizure , palpitations , paresthesia and vertigo .
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|mortality efficacy improvement relapse recurrence|cholecystitis|there was one report of entity in a phase 1 clinical trial of lum001 and one report of elevated levels of alanine aminotransferase and aspartate aminotransferase ,
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|diverticulitis perforation appendicitis abscess peritonitis|cholecystitis|ciai diagnoses include intra-abdominal abscess , stomach or intestinal perforation , peritonitis , appendicitis , entity , or diverticulitis .
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|pancreatitis cholecystitis appendicitis peritonitis cholelithiasis|cholecystitis|a single patient during the extension study developed acute entity and cholelithiasis later treated with cholecystectomy .
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|pancreatitis rejection bronchitis hepatitis exacerbation|cholecystitis|one subject had a baseline pro-c3 of 9 . 9 ng / ml , experienced a serious ae of acute entity , stopped taking axa1125 at the end of week 1 and then discontinued from the study on week 5 .
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|vomiting diarrhea fatigue nausea fever|cholecystitis|serious adverse events reported in the trial included disease progression , pyrexia , mastitis , pneumonia , nausea , entity and pain in extremity , each of which was reported only once .
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|rejection pancreatitis fatigue exacerbation toxicities|cholecystitis|a single patient during the extension study experienced acute entity classified as a serious adverse event but deemed unlikely related to sbc-102 by the investigator .
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|vomiting diarrhea nausea withdrawal illness|cholecystitis|the one subject who received akr-001 70mg iv had a serious adverse event of entity initially reported as abdominal pain beginning on day 11 .
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|cellulitis abdomen diarrhea infections neutropenia|cholecystitis|two study group subjects experienced saes , severe acute entity and moderate cellulitis , with the latter subject discontinuing treatment prior to end of treatment .
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|uc gall cdi uti rectum|cholecystitis|serious adverse events included skin infection ( cellulitis , two cases ) , abdominal pain and inflammation of the gall bladder ( entity ) .
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 2)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|pancreatitis cholecystitis cholecystectomy appendicitis cholelithiasis|cholecystitis|findings from a subsequent cholecystectomy were consistent with chronic entity .
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|gallstones stones cirrhosis cholangitis cholelithiasis|cholecystitis|with respect to hepatobiliary events , more patients ( 3% ) on oca 25 mg experienced gallstones or entity compared to <1% on placebo and 1% on oca 10 mg .
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|hepatotoxicity toxicities infections morbidity mortality|cholecystitis|the biliary system is a significant target for many conditions , including drug toxicities , entity , and liver-related abnormal function associated with the cystic fibrosis mutation .
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|obesity cholelithiasis cirrhosis atherosclerosis gallstone|cholecystitis|this potentially represents a previously unrecognized factor in the development of entity and cholelithiasis disease .
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|uc calc arthritis cad ibd|cholecystitis|the project seeks to determine if human cell derived nanoparticles are pathogenic and induce inflammatory ( entity ) and calcific pathologic ( cholelithiasis ) disease .
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|foot stroke abdomen wound rejection|cholecystitis|there were two serious aes reported , acute entity and right toe infection , which were deemed not reasonably associated with the study product , and more likely due to subject  s
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|exacerbation rejection pancreatitis exacerbations clearance|cholecystitis|the subject  s end-of-study pro-c3 level was 31 . 9 ng / ml , reflecting both the acute inflammatory state ( i . e . , acute entity ) and also likely a washout effect of axa1125 .
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|ae sepsis pneumonia aes cough|cholecystitis|one patient was hospitalized for entity , a serious ae , two days after receiving seven days of treatment with torezolid phosphate , which the clinical investigator determined to
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|bladder obesity diarrhea constipation cystitis|cholecystitis|both consisted of entity , or gall bladder inflammation , which is common in people who experience rapid or significant weight loss .
OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 2)])|disease|cholecystitis gallbladder cholelithiasis cholecyst follows|etc hyperlipidemia peritonitis hematuria jaundice|cholecystitis|lidan paishi pian clear heat and promote diuresis , cholagogue and remove calculi , biliary tract infection , entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|tular describe pulmonary prevalence dogs|fever dengue meningitis anthrax mumps|tularemia|category is category a . the six agents that the cdc has classified as category a are anthrax , botulism , plague , smallpox , entity and viral hemorrhagic fevers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|tular describe pulmonary prevalence dogs|anthrax tuberculosis salmonella influenza dengue|tularemia|barda is funding studies to test the efficacy of solithromycin in treating bioterror pathogens such as entity and anthrax .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|tular describe pulmonary prevalence dogs|anthrax plague tuberculosis influenza salmonella|tularemia|equally compelling , restanza has shown effectiveness against several lethal pathogens , including anthrax , plague , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|tular describe pulmonary prevalence dogs|plague anthrax tuberculosis meningitis fever|tularemia|cethromycin is also being developed as a biodefense agent for use in the treatment of anthrax , plague and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|tular describe pulmonary prevalence dogs|plague tuberculosis pneumonia malaria humans|tularemia|these two bacteria species are considered potential bioweapons and are the causative agents for plague and entity , respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|tular describe pulmonary prevalence dogs|vaccinia norway germany bcg newcastle|tularemia|the company has been in contractual negotiations for the first two products , entity and vaccinia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|tular describe pulmonary prevalence dogs|anthrax plague meningitis pneumonia tuberculosis|tularemia|preliminary data from our preclinical experiments indicates that our product candidates have potent activity against biowarfare agents that cause anthrax , entity and plague .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|tular describe pulmonary prevalence dogs|anthrax meningitis fever pertussis rabies|tularemia|these tests have been completed in non-human primates and have shown that solithromycin is effective in treating anthrax and entity when the infection was initiated by the pulmonary route .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|tular describe pulmonary prevalence dogs|anthrax fever mumps influenza dengue|tularemia|the department of homeland security has identified 13 such threats , including anthrax , smallpox , ebola / marburg , entity , and botulism .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|tular describe pulmonary prevalence dogs|plague anthrax tuberculosis humans dengue|tularemia|the bicyclolides are to be used as medical countermeasures against multiple biodefense bacteria found in anthrax , plague and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|tular describe pulmonary prevalence dogs|anthrax plague tuberculosis meningitis rabies|tularemia|the fda has granted cethromycin an orphan drug designation for the prophylactic treatment of inhalation anthrax , plague and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|tular describe pulmonary prevalence dogs|fever encephalitis tuberculosis dengue malaria|tularemia|other tick-borne diseases include rocky mountain spotted fever , babesiosis , erlichiosis , anaplasmosis , powassan disease , tick-borne relapsing fever and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|tular describe pulmonary prevalence dogs|plague humans vietnam swine europe|tularemia|· received fda orphan drug designation for restanza in plague and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|tular describe pulmonary prevalence dogs|infectious dengue fever influenza hemorrhagic|tularemia|a non-exclusive , royalty-bearing license to use certain of our patents and related know how for the prevention or treatment of entity and viral hemorrhagic fever indications .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|tular describe pulmonary prevalence dogs|anthrax tuberculosis salmonella influenza fever|tularemia|barda funded studies to test the efficacy of solithromycin in treating bioterror pathogens such as entity and anthrax .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|tular describe pulmonary prevalence dogs|plague tuberculosis fever meningitis anthrax|tularemia|for the treatment of serious hospital infections as well as the treatment of bioterror pathogens , such as anthrax , plague and entity after signs and symptoms are present .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|tular describe pulmonary prevalence dogs|anthrax plague tuberculosis meningitis pneumonia|tularemia|is focused on the development of antibiotic compounds to treat biowarfare agents , including the highly infectious bacteria that cause anthrax , entity and plague .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|tular describe pulmonary prevalence dogs|anthrax tuberculosis influenza rabies meningitis|tularemia|solithromycin for the treatment of bacterial infections in pediatric populations and infections caused by bioterror threat pathogens , specifically anthrax and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|tular describe pulmonary prevalence dogs|anthrax tuberculosis influenza salmonella dengue|tularemia|barda also is funding studies to test the efficacy of solithromycin in treating bioterror pathogens such as entity and anthrax .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|tular describe pulmonary prevalence dogs|plague humans adults cattle dogs|tularemia|after symptoms developed ; · pivotal primate study showing protective efficacy in plague ; · pivotal animal study showing 100% survival in entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|hemophilia iii include includes possess|hepatitis haemophilia hemophilia amphotericin mps|hemophilia|used in the trial consistently led to long-term expression of the hfix transgene at therapeutic levels in patients with severe entity b , without acute or long-lasting toxicity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 2)])|disease|hemophilia iii include includes possess|hepatitis amphotericin hemophilia haemophilia vitamin|hemophilia|we further note that you cite uniqure and spark therapeutics as competitors with treatments for entity b in phase 3 clinical trials .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|hemophilia iii include includes possess|hemophilia hepatitis haemophilia amphotericin fulminant|hemophilia|human coagulation factor ix prevention and control of bleeding in patients who suffer from entity b . completed the clinical trial and preparing documentation for the registration purpose .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hemophilia iii include includes possess|anemia infants obesity sepsis neonates|hemophilia|kedrion markets therapies globally for entity , hemolytic disease of the newborn , immune and neurological disorders .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hemophilia iii include includes possess|decades centuries publication adolescents example|hemophilia|he has served as baxters global franchise head for entity since june 2012 and is expected to continue in that role until the separation is completed .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hemophilia iii include includes possess|collection distance dating publication registration|hemophilia|he served as baxters global franchise head for entity from 2012 until the separation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|hemophilia iii include includes possess|them fibrosis spleen eae rejection|hemophilia|for example : · porcine spleen tissue was successfully implanted into a mouse , effectively treating entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hemophilia iii include includes possess|hcc cirrhosis nafld nash cholangiocarcinoma|hemophilia| continue to build a liver-directed gene therapy platform , with an initial focus on the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hemophilia iii include includes possess|previous setting future original formal|hemophilia|spark hereby grants pfizer the exclusive right to negotiate an agreement with spark with respect to the entity a program subject to the terms of this section 2 . 9 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|hemophilia iii include includes possess|what literature another his warfarin|hemophilia|the treatment concept is similar to entity , in which a patient is treated regularly with the particular clotting factor in which he is deficient .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hemophilia iii include includes possess|vw vte scd hemophilia dvt|hemophilia|vwd may experience mild symptoms , but some patients can experience severe bleeding events similar to bleeding experienced by patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|hemophilia iii include includes possess|hemophilia haemophilia hepatitis mps thrombocytopenia|hemophilia|an improved next-generation coagulation factor viia variant , cb 813d , that has successfully completed a phase 1 clinical trial in severe entity a and b patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|hemophilia iii include includes possess|hemophilia haemophilia immunoglobulin hepatitis cyclosporin|hemophilia|therapeutic proteins are increasingly used to treat diseases , including interferon beta for multiple sclerosis , factor viii for entity a , and monoclonal antibodies for various disorders .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 2)])|disease|hemophilia iii include includes possess|hepatitis amphotericin hemophilia haemophilia polymyxin|hemophilia|of our collaboration agreement for the development of coagulin-b , our product candidate that we were developing for the treatment of entity b , involving administration to the liver .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|hemophilia iii include includes possess|entity subtype entities amphotericin haemophilia|hemophilia| entity b . entity b patients typically are treated by a variety of plasma-derived , recombinant or long-acting products that are produced by a number of companies , including pfizer .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|hemophilia iii include includes possess|immunoglobulin albumin globulin tacrolimus immunoglobulins|hemophilia|in june 2014 , we acquired medpro , a specialty pharmacy focused on specialty infusion including entity and immune globulin .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|hemophilia iii include includes possess|hepatitis haemophilia hemophilia amphotericin subtype|hemophilia|many other companies are developing gene therapies to treat entity b , including baxter , uniqure and dimension .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 2)])|disease|hemophilia iii include includes possess|hepatitis hemophilia haemophilia balb amphotericin|hemophilia|preliminary data in entity b mice indicate that treatment with amt-060 induces normalization of fix levels as well as clotting time .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|hemophilia iii include includes possess|psoriasis vte opioids physicians thromboembolism|hemophilia|in december 2013 , we acquired ahf , which provides specialty drugs and infusion services for bleeding disorders , principally entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|disease|hemophilia iii include includes possess|vitamin amphotericin tier aurora rnase|hemophilia|outlook 2017 in 2017 we plan to : · drive our entity b program towards late stage clinical development ; · continue non-clinical and preclinical studies that are expected to support an ind
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|leptospirosis outbreak pathogen zoonotic during|original final desired commercial approved|leptospirosis|we are completing the manufacture of the entity product so that we can provide evaluation lots and documentation to fiocruz for their regulatory approval submission of this product
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|disease|leptospirosis outbreak pathogen zoonotic during|elisa mtb taqman tat rif|leptospirosis|similar increases in both clinical and analytical sensitivity were observed for our human tb and entity assays .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|leptospirosis outbreak pathogen zoonotic during|leishmaniasis tuberculosis serology malaria vl|leptospirosis|agreements are for the following rapid test products : i ) dpp® hiv 1 / 2 screen , ii ) dpp® hiv 1 / 2 confirmatory , iii ) dpp® entity and iv ) dpp® leishmaniasis .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|leptospirosis outbreak pathogen zoonotic during|tuberculosis syphilis leishmaniasis hepatitis malaria|leptospirosis|we also have licensed the antigens used in other tests including our syphilis , tuberculosis , entity , leishmaniasis and chagas tests , and we may enter other license agreements .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|leptospirosis outbreak pathogen zoonotic during|200 march grant april graduate|leptospirosis|dpp® entity – in june 2009 , as we previously reported , we were awarded a three-year $3 million small business innovative research ( sbir )
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|leptospirosis outbreak pathogen zoonotic during|collaboration consensus agreements disagreement agreement|leptospirosis|entity [ member ] refers to agreements relates to research and development arrangements .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|leptospirosis outbreak pathogen zoonotic during|tuberculosis infections influenza pneumonia viruses|leptospirosis|in addition to viral vaccines , diamond also manufactures vaccines against bacterial infections , such as entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|leptospirosis outbreak pathogen zoonotic during|syphilis tuberculosis leishmaniasis hepatitis malaria|leptospirosis|the five products under agreement with fiocruz are for dpp® products for hiv screening , hiv confirmatory , leishmaniasis , entity and syphilis .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|leptospirosis outbreak pathogen zoonotic during|syphilis std cmv psa serology|leptospirosis|believe fiocruz will receive during 2011 the required approvals from anvisa for the second dpp® syphilis test and the dpp® entity test , although there can be no assurance of this .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|leptospirosis outbreak pathogen zoonotic during|proficiency validation tolerance commercial fixation|leptospirosis|with respect to chembio  s dpp® entity test , bio-manguinhos had not qualified to request the technology transfer .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|leptospirosis outbreak pathogen zoonotic during|grant com implement here see|leptospirosis|dpp® entity – we have approximately nine months left of the three-year $3 million small business innovative research ( sbir ) phase ii grant
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|leptospirosis outbreak pathogen zoonotic during|syphilis leishmaniasis tuberculosis malaria melanoma|leptospirosis|separate right to request a technology transfer for that product only are : dpp® products for hiv screening , hiv confirmatory , leishmaniasis , entity and syphilis .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|leptospirosis outbreak pathogen zoonotic during|fever foot throat cough calf|leptospirosis|bacterial vaccines are bacterial products that are used on a routine basis to prevent diseases such as black leg , entity , red water and shipping fever .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|leptospirosis outbreak pathogen zoonotic during|syphilis tuberculosis physicians psoriasis asthma|leptospirosis|from the united states national institutes of health ( nih ) to fully develop , validate , and commercialize a rapid diagnostic test for entity for general use worldwide .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|leptospirosis outbreak pathogen zoonotic during|annual national implementation grant eu|leptospirosis|· dpp® entity phase ii grant – in 2009 we were awarded a three year , $1 . 9 million small business innovative research ( sbir ) phase
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|leptospirosis outbreak pathogen zoonotic during|leishmaniasis syphilis leishmania serological malaria|leptospirosis|three of these products ( leishmaniasis and the hiv screening and confirmation tests ) , and we have substantially completed development of the entity test .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|leptospirosis outbreak pathogen zoonotic during|tuberculosis hcv tat syphilis mtb|leptospirosis|this new patent-pending platform , including the testing of our current hiv test strip ( as well as our human tb and entity assays ) that was recently approved in this new platform .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|leptospirosis outbreak pathogen zoonotic during|validity hpv reliability syphilis asthma|leptospirosis|to be completed three-year grant from the united states national institutes of health to complete development of a test for entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|leptospirosis outbreak pathogen zoonotic during|rights beings diseases safety ethics|leptospirosis|a press release entitled “chembio awarded three year $3mm nih sbir phase ii grant to complete dpp® test for human entity ” .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|leptospirosis outbreak pathogen zoonotic during|nih grant leukemia award students|leptospirosis|three year , $3mm phase ii nih grant for entity awarded june 2009 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|crani deformities skull congenital correction|myelodysplastic osteoporosis dwarf turner marfan|craniosynostosis|of limb and lungs and unregulated fgf signaling leads to a variety of human bone morphogenic disorders , including dwarfism and entity syndromes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|disease|crani deformities skull congenital correction|ossification osteogenesis regeneration healing rupture|craniosynostosis|his research interests include the molecular mechanism of entity , which is the premature fusion of calvarial suture line in infants and tissue engineering of bone .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|iron anemia hereditary hem hemoglobin|anemia etc osteoporosis cirrhosis hemodialysis|hemochromatosis|u . s . safety information for auryxia® ( ferric citrate ) contraindication auryxia® ( ferric citrate ) is contraindicated in patients with iron overload syndromes , e . g . , entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|iron anemia hereditary hem hemoglobin|fda who prothrombin international anticoagulant|hemochromatosis|prontotm prothrombin ( factor ii ) approved f9923 prontotm thromborisktm approved f9949 prontotm entity approved f9904 prontotm fmf basic approved f9946 prontotm cf euro i
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|iron anemia hereditary hem hemoglobin|anemia anaemia thalassemia neuropathy diseases|hemochromatosis|beta thalassemia patients suffering from iron overload and the initiation of a phase 2 study for ljpc-401in patients with hereditary entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|iron anemia hereditary hem hemoglobin|diseases disorders neuropathy dementia mutations|hemochromatosis|it is also estimated that one million americans are afflicted with hereditary entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 3)])|disease|iron anemia hereditary hem hemoglobin|thalassemia anemia sepsis hypercholesterolemia iron|hemochromatosis|we are developing ljpc-401 for the treatment of conditions characterized by iron overload , such as entity and beta thalassemia .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|iron anemia hereditary hem hemoglobin|hereditary familial inherited idiopathic heterozygous|hemochromatosis|hereditary entity hereditary hemochromatosis is an iron overload disease that can lead to life-threatening conditions such as cirrhosis , liver cancer , diabetes , heart failure and
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|iron anemia hereditary hem hemoglobin|diseases syndromes disorders malignancies leukemias|hemochromatosis|treatment of patients with polycythemia vera , myelodysplastic syndromes and hereditary entity may represent additional opportunities for future development of ptg-300 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|iron anemia hereditary hem hemoglobin|thrombosis thromboembolism lymphoma melanoma cirrhosis|hemochromatosis|in addition , savyon  s products are used in clinical laboratories performing pre-disposition testing ( thrombosis , entity , certain cancers and several other diseases and conditions ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|iron anemia hereditary hem hemoglobin|france europe china canada germany|hemochromatosis|and chief executive officer of bond biosciences , inc . , a private start-up biotechnology company focused on addressing the iron overload in entity , from july 2016 to may 2018 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|iron anemia hereditary hem hemoglobin|uremic anemia thalassemia hemophilia haemophilia|hemochromatosis|ferisk ( tm ) is intended to become a standard in the screening , diagnosis and follow-up of hereditary entity patients , as well as others who suffer from iron overload .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|disease|iron anemia hereditary hem hemoglobin|anemia hemodialysis adults warfarin iron|hemochromatosis|important safety information contraindication : patients with iron overload syndrome , e . g . entity , should not take auryxia ( ferric citrate ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|iron anemia hereditary hem hemoglobin|anemia hepatitis diseases hfe anaemia|hemochromatosis|in addition , hereditary entity and the more severe form , juvenile hemochromatosis , are both inherited disorders of reduced hepcidin production and consequently iron overload .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|iron anemia hereditary hem hemoglobin|anemia anaemia epilepsy thrombocytopenia thalassemia|hemochromatosis|iron levels can be found in disorders such as cooley  s anemia , sickle cell anemia and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|iron anemia hereditary hem hemoglobin|diseases disorders anemia deafness neuropathy|hemochromatosis|iron overload is also associated with hereditary entity where a genetic defect in a protein involved in iron absorption leads to excess absorption of iron and iron overload
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|iron anemia hereditary hem hemoglobin|telangiectasia neuropathy anemia hh anaemia|hemochromatosis|evaluate the safety and efficacy of ljpc-401 , la jollas proprietary formulation of synthetic human hepcidin , as a treatment for hereditary entity ( hh ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|vol al channel asbestos 24|hyperbilirubinemia bilirubin jaundice encephalopathy prematurity|kernicterus|in june 2001 , the center for disease control  s morbidity and mortality weekly report published four case studies of entity , a form of hyperbilirubinemia which is preventable .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|vol al channel asbestos 24|just here themselves twice never|kernicterus|the national quality forum has in the past described entity as a “never event , ” one which physicians should ensure never occurs in their practice .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|vol al channel asbestos 24|cirrhosis relapse malignancy hcc anemia|kernicterus|however , phototherapy rapidly becomes less effective following puberty , increasing the risk for entity , resulting in the need for liver transplantation to control the disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|vol al channel asbestos 24|relapse recurrence thromboembolism mortality cirrhosis|kernicterus|use : atazanavir is not recommended for use in pediatric patients below the age of 3 months due to the risk of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|vol al channel asbestos 24|articles literature reviewed books records|kernicterus|the center for disease controls morbidity and mortality weekly report published four case studies of 7 table of contents entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|vol al channel asbestos 24|poisoning sepsis stroke malaria leukemia|kernicterus|entity is a completely preventable condition that often results in permanent neurological damage brought on by the known toxic effects of
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 2)])|disease|vol al channel asbestos 24|hyperbilirubinemia bilirubin antibiotics phototherapy hypothermia|kernicterus|the center for disease controls report stated that early detection of hyperbilirubinemia is critical to prevent the irreversible effects of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|vol al channel asbestos 24|hyperbilirubinemia bilirubin jaundice encephalopathy prematurity|kernicterus|in june 2001 , the center for disease controls morbidity and mortality weekly report published four case studies of entity , a form of hyperbilirubinemia which is preventable .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|vol al channel asbestos 24|bilirubin hyperbilirubinemia jaundice cirrhosis sepsis|kernicterus|bilirubin toxicity can ultimately result in a chronic , severe , and disabling condition called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|vol al channel asbestos 24|tbi aes ich tr tia|kernicterus|the total loss of ugt1a1 activity and the resulting severe jaundice and risk of neurological sequelae ( entity ) are associated with cn type 1 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|vol al channel asbestos 24|anemia thrombocytopenia preeclampsia sepsis hyperbilirubinemia|kernicterus|its effects on the fetus or newborn include hemolytic anemia , hyperbilrubinemia , entity , or intrauterine deaths due to hydrous fetalis .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 2)])|disease|vol al channel asbestos 24|hyperbilirubinemia bilirubin antibiotics phototherapy hypothermia|kernicterus|the center for disease control  s report stated that early detection of hyperbilirubinemia is critical to prevent the irreversible effects of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|vol al channel asbestos 24|stroke there palsy epilepsy aphasia|kernicterus|entity is a cerebral palsy-like condition in which the patient lacks muscle tone and motor control , cannot operate self-sufficiently , and typically requires long-term care .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|proliferation cultures hyperplasia cultured precursors|lymphocytes macrophages leukocytes platelets monocytes|cytotrophoblasts|high complexity probes according to claim 28 wherein said fetal cells are leukocytes and entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|oligodendrocytes myelin degeneration labeled neurons|myelin oligodendrocytes axons nerves macrophages|oligodendrocytes|the pathology of spinal cord injury involves extensive loss of the myelin sheath produced by entity at the site of injury .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|oligodendrocytes myelin degeneration labeled neurons|astrocytes neurons microglia macrophages oligodendrocytes|oligodendrocytes|was studied in rat brain 3d microtissues , a 3d cell model containing a mix of neurons , astrocytes , microglial cells and entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|oligodendrocytes myelin degeneration labeled neurons|neurons anesthetics stimuli astrocytes axons|oligodendrocytes|occurs in a diffuse fashion throughout the adult brain and appears to reflect a loss of axonal support by local entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|oligodendrocytes myelin degeneration labeled neurons|oligodendrocytes neurons macrophages astrocytes them|oligodendrocytes|in our preclinical research , we have shown that hucns-sc cells differentiate into entity , the myelin producing cells , and produce myelin .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DRUG', 1)])|cell|oligodendrocytes myelin degeneration labeled neurons|oligodendrocytes neurons mscs astrocytes microglia|oligodendrocytes|mechanism of action underlying the enhanced remyelination in vivo and shown that multistem cells and secreted factors increase differentiation of entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|oligodendrocytes myelin degeneration labeled neurons|aggregates axons oligodendrocytes myelin neurons|oligodendrocytes|remyelination remyelination is the process propagating oligodendrocyte precursor cells to form entity to create new myelin sheaths on demyelinated axons in the cns .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|oligodendrocytes myelin degeneration labeled neurons|they astrocytes microglia neurons there|oligodendrocytes|entity are natures neuronal insulating cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|oligodendrocytes myelin degeneration labeled neurons|oligodendrocytes neurons astrocytes lysosomes macrophages|oligodendrocytes|deficient in myelin production , transplantation of hcns-sc into the brain resulted in widespread engraftment of human cells that matured into entity , the myelin producing cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|oligodendrocytes myelin degeneration labeled neurons|astrocytes neurons glia microglia macrophages|oligodendrocytes|q-cells produce astrocytes and entity , the support cells that enable the normal function of neurons .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|oligodendrocytes myelin degeneration labeled neurons|they there neurons astrocytes microglia|oligodendrocytes|entity are natures neural insulating cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1)])|cell|oligodendrocytes myelin degeneration labeled neurons|peptides mscs molecules derivatives nsc|oligodendrocytes|japan patent 2011-047716 – entity derived from human embryonic stem cells for remyelination and treatment of spinal cord injury are described .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|oligodendrocytes myelin degeneration labeled neurons|myelin nerve sheath periphery retina|oligodendrocytes|myelin sheath that insulates nerve fibres , or axons , in the central nervous system and the cells that make myelin , the entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|oligodendrocytes myelin degeneration labeled neurons|they fibers neurons electrodes axons|oligodendrocytes|like the insulation covering an electrical wire , entity enable the conduction of electrical impulses along nerve fibers throughout the central and peripheral nervous system .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 3)])|cell|oligodendrocytes myelin degeneration labeled neurons|astrocytes cultures neurons fibroblasts glia|oligodendrocytes|$ 4 , 000 tissue culture - culture of primary entity derived from mixed glial cultures .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1), ('DIS', 1)])|cell|oligodendrocytes myelin degeneration labeled neurons|neurons precursors oligodendrocytes progenitors macrophages|oligodendrocytes|financial statements gpc program our gpc program aims to deliver healthy allogeneic gpcs , the precursors to both astroglia and myelin-producing entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|oligodendrocytes myelin degeneration labeled neurons|decisions them conclusions inferences consent|oligodendrocytes|the patent relates to methods of making entity from human embryonic stem cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|oligodendrocytes myelin degeneration labeled neurons|astrocytes neurons macrophages glia microglia|oligodendrocytes|the resulting differentiated cells ( astrocytes and entity , shown in figure 2 ) then can perform the support functions of these glial cells in vivo as described above .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|oste osteoblasts proliferation characterized epithelium|osteoblasts osteoclasts vivo humans mammals|osteocytes|sclerostin is produced in entity , which are mature bone cells that are thought to be the mechanoreceptor cells that regulate the activity of bone-building osteoblasts
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('BIO', 5), ('DRUG', 2), ('DIS', 2), ('OTHER', 2)])|cell|oste osteoblasts proliferation characterized epithelium|adipocytes fibroblasts macrophages monocytes osteoblasts|osteocytes|the presence and absence of particular biological markers , and the ability of the cell to differentiate into at least adipocytes , entity , endothelial cells and smooth muscle cells .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 1)])|cell|oste osteoblasts proliferation characterized epithelium|osteoblasts osteoclasts chondrocytes fibroblasts mscs|osteocytes|merits bone formation involves the migration of undifferentiated mesenchymal cells , differentiation into cartilage , and subsequent bone replacement by osteoblasts and entity .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DRUG', 1)])|cell|osteoclasts affect upon epithelial osteoblasts|osteoblasts osteoclasts mscs bmscs platelets|osteoclasts|in addition , unlike currently marketed ra 1 table of contents drugs , fpa008 directly inhibits bone-destroying cells called entity .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|osteoclasts affect upon epithelial osteoblasts|osteoblasts osteoclasts resorption osteoclastogenesis mineralization|osteoclasts|gallium acts upon bone by enhancing the formation of osteoblasts and inhibiting entity , thereby increasing bone deposition and reducing bone turnover .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DRUG', 2), ('DIS', 1)])|cell|osteoclasts affect upon epithelial osteoblasts|osteoclasts bisphosphonates osteoblasts glucocorticoids cytokines|osteoclasts|up to now , bisphosphonates have been most effective in tumors where bone destruction is caused primarily by overstimulation of entity , which abnormally accelerate the breakdown of bone .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|osteoclasts affect upon epithelial osteoblasts|osteoblasts osteoclasts macrophages fibroblasts chondrocytes|osteoclasts|two main types of cells are responsible for this process : entity , which break down bone tissue , and osteoblasts , which secrete new bone tissue .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|osteoclasts affect upon epithelial osteoblasts|osteoclasts osteoblasts bisphosphonates osteoblast osteoclast|osteoclasts|bisphosphonates are compounds that bind with high affinity to bone mineral and inhibit the bone‑resorbing cells called entity .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|osteoclasts affect upon epithelial osteoblasts|osteoblasts osteoclasts they implants rats|osteoclasts|entity resorb bone by secreting protons and generating an acidic extracellular microenvironment .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|osteoclasts affect upon epithelial osteoblasts|sct mscs osteoblasts osteoclasts bm|osteoclasts|sct is a hormone that inhibits the bone-tissue resorbing activity of specialized bone cells called entity , enabling the bone to retain more of its mass and functionality .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DRUG', 1)])|cell|osteoclasts affect upon epithelial osteoblasts|osteoclasts osteoblasts mscs ocs bmscs|osteoclasts|bone health is maintained through regulation of the competing activities of bone forming cells ( osteoblasts ) and bone resorbing cells ( entity ) .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|osteoclasts affect upon epithelial osteoblasts|macrophages monocytes neutrophils eosinophils lymphocytes|osteoclasts|treatment of ra in which it reversibly blocks signaling in multiple cell types involved in inflammation and tissue degradation ( e . g . macrophages , entity , mast cells and b cells ) .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('BIO', 3), ('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|cell|osteoclasts affect upon epithelial osteoblasts|cytokines macrophages macrophage ratios mscs|osteoclasts|( osteopenia ) • ( a ) when bone marrow derived macrophages ( bmdm ) from nomid mice are stimulated with rankl ( rank ligand ) , they differentiate into entity • : 1315-1325 .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|cell|osteoclasts affect upon epithelial osteoblasts|into against between produce generate|osteoclasts|rankl stimulation macrophages entity nomid bmdm nomid bmdm plus ati-450 ( a ) ( b ) bone marrow derived macrophages ( bmdm ) from nomid mice 19© copyright 2020 aclaris
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|osteoclasts affect upon epithelial osteoblasts|osteoclastogenesis osteoblasts osteoclasts proliferation apoptosis|osteoclasts|zoledronic acid is the most potent bisphosphonate , a class of drugs known to inhibit entity , which are key cells involved in the maintenance , repair and remodeling of bone .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|osteoclasts affect upon epithelial osteoblasts|osteoblasts osteoclasts osteoclast they mscs|osteoclasts|cells called osteoblasts cause new bone formation while other cells called entity remove old bone through a process called resorption .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|osteoclasts affect upon epithelial osteoblasts|osteoclastogenesis osteoblasts angiogenesis apoptosis osteoclasts|osteoclasts|axs‑02 is a potent inhibitor of entity , which are bone remodeling cells that break down bone tissue .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|osteoclasts affect upon epithelial osteoblasts|osteoclasts rates osteoblasts stresses they|osteoclasts|bisphosphonate drugs slow down the rate at which entity , which are cells which resorb or take away bone , reduce the bones mass .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|osteoclasts affect upon epithelial osteoblasts|functions joints muscles activities teeth|osteoclasts|in people with osteopetrosis , this balance is not maintained because their entity do not function properly .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|osteoclasts affect upon epithelial osteoblasts|osteoclasts osteoblasts bisphosphonates osteoclast osteoblast|osteoclasts|bisphosphonates are compounds that bind with high affinity to bone mineral and inhibit the bone-resorbing cells called entity .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|osteoclasts affect upon epithelial osteoblasts|osteoblasts osteoclasts platelets osteoclast neurons|osteoclasts|calcitonin , a peptide , inhibits bone resorption by acting on specific receptors on entity .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|cell|osteoclasts affect upon epithelial osteoblasts|dxa bmd pcr measurement densitometry|osteoclasts|ntx serum became the first and only commercially available test in the united states that measures specific bone breakdown by entity using a blood sample .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|osteoclasts affect upon epithelial osteoblasts|macrophages platelets osteoclasts lymphocytes microglia|osteoclasts|the drug appears to be selectively toxic for activated entity , displaying a negligible effect on bone marrow stromal cells .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|monocytes stimulated macrophages leukocytes chemokines|macrophages monocytes lymphocytes neutrophils eosinophils|monocytes|csf-1r is expressed on the surface of specific immune cells known as macrophages and their precursor cells known as entity .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|monocytes stimulated macrophages leukocytes chemokines|cultures signals platelets fibroblasts exosomes|monocytes|this is an exclusive license to a stem cell technology in which adult pluripotent stem cells are derived from entity obtained from the patient  s own blood .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|monocytes stimulated macrophages leukocytes chemokines|transplant volunteer allograft marrow xenograft|monocytes|these mdsc can be derived from a patients entity , expanded ex vivo , and then administered to the same patient .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|monocytes stimulated macrophages leukocytes chemokines|monocytes macrophages lymphocytes neutrophils neurons|monocytes|targets the colony stimulating factor-1 receptor , or csf-1r , a cell surface protein thought to control the survival and function of entity and macrophages .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|monocytes stimulated macrophages leukocytes chemokines|precursors clones derivatives variants lineages|monocytes|researchers have been able to turn these dedifferentiated entity into several different types of cells including islet cells , nerve cells , liver cells , blood vessel cells and skin cells .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|monocytes stimulated macrophages leukocytes chemokines|neurons astrocytes macrophages lymphocytes microglia|monocytes|in january 2017 , we reported that targeting of mospd2 inhibits chemotaxis of entity and neuropils , and that unpublished vbl data also show mospd2 expression on certain tumor cells .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|monocytes stimulated macrophages leukocytes chemokines|monocytes microglia platelets neurons macrophages|monocytes|fpa008 ( cabiralizumab ) : an investigational antibody that inhibits csf1r and has been shown to block the activation and survival of entity and macrophages .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 1), ('DRUG', 1), ('DIS', 1)])|cell|monocytes stimulated macrophages leukocytes chemokines|macrophages lymphocytes monocytes fibroblasts neutrophils|monocytes|cells ; and  these proteins secondarily activate other innate immune cells such as natural killer cells and entity , which become able to recognize and kill some tumor cells .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|monocytes stimulated macrophages leukocytes chemokines|monocytes macrophages lymphocytes neutrophils platelets|monocytes|eascs exhibit broad immunomodulatory properties , including the regulation of immune cells such as b lymphocytes , t lymphocytes , natural killer cells , entity or macrophages and neutrophils .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|monocytes stimulated macrophages leukocytes chemokines|monocytes macrophages dcs neutrophils lymphocytes|monocytes|when applied to human immune cells such as entity , selective immunoproteasome inhibitors , like kzr-616 and onx 0914 , blocked the release of inflammatory cytokines following cell stimulation .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('BIO', 3), ('OTHER', 3)])|cell|monocytes stimulated macrophages leukocytes chemokines|vessels lymphocytes leukocytes donors monocytes|monocytes|the companys stem cell technology isolates novel multipotent stem cells derived from peripheral blood entity .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|monocytes stimulated macrophages leukocytes chemokines|macrophages lymphocytes monocytes macrophage neutrophils|monocytes|patients with various diseases , as well as established cell lines from immune and non-immune cell lineages , including t cell subsets , entity , macrophage subpopulations and cancer cell lines .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|monocytes stimulated macrophages leukocytes chemokines|monocytes macrophages neutrophils lymphocytes eosinophils|monocytes|fcgri is expressed in certain human immune cells including entity , macrophages and dendritic cells and may function to activate these immune cells .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('BIO', 3), ('OTHER', 3)])|cell|monocytes stimulated macrophages leukocytes chemokines|vessels lymphocytes leukocytes monocytes donors|monocytes|our stem cell technology isolates novel multipotent stem cells derived from peripheral blood entity .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('DIS', 2), ('OTHER', 1), ('DRUG', 1)])|cell|monocytes stimulated macrophages leukocytes chemokines|monocytes macrophages neutrophils lymphocytes granulocytes|monocytes|immune system cells , including cd4+ and cd8+ t effector cells , t regulatory cells , natural killer cells , granulocytes , mast cells and entity / macrophages .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|monocytes stimulated macrophages leukocytes chemokines|transplant volunteer allograft marrow xenograft|monocytes|these mdsc can be derived from a patients entity , expanded ex vivo , and then administered to the same patient .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|monocytes stimulated macrophages leukocytes chemokines|monocytes macrophages lymphocytes neutrophils eosinophils|monocytes|cells with the cd4 receptor are critical components of the immune system and include t lymphocytes , entity , macrophages and dendritic cells .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|monocytes stimulated macrophages leukocytes chemokines|monocytes microglia macrophages platelets neutrophils|monocytes|developments clinical pipeline : cabiralizumab ( fpa008 ) : an antibody that inhibits csf1r and has been shown to block the activation and survival of entity and macrophages .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|monocytes stimulated macrophages leukocytes chemokines|lymphocytes vessels marrow cultures monocytes|monocytes|our novel multi-potent stem cell is derived from peripheral blood entity which when cultured under defined conditions are able to further differentiate into several cellular lineages .
OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|monocytes stimulated macrophages leukocytes chemokines|lymphocytes vessels marrow cultures monocytes|monocytes|our multi-potent stem cell is derived from peripheral blood entity which when cultured under defined conditions are able to further differentiate into several cellular lineages .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|fibroblasts pigment fibroblast epithelial characterized|specimens collections solutions bags pellets|fibroblasts|the entity are then harvested , tested by quality control and released by quality assurance prior to shipment .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|fibroblasts pigment fibroblast epithelial characterized|embryos cultures lines embryo specimens|fibroblasts|of disease causing ability , was accomplished by making over 500 passages of the virus in chicken embryos or chick embryo entity which resulted in large genomic deletions .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|fibroblasts pigment fibroblast epithelial characterized|fibroblasts embryos extracts cultures eggs|fibroblasts|products and reagents like avian cell substrates have rt activity that does not represent adventitious infectious retroviruses ( e . g . chicken embryo entity , dermal cells and eggs ) .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|fibroblasts pigment fibroblast epithelial characterized|keratinocyte fibroblast keratinocytes fibroblasts adhesion|fibroblasts|method of enhancing wound healing by stimulating entity and keratinocyte growth in vivo , utilizing amphipathic peptides .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2)])|cell|fibroblasts pigment fibroblast epithelial characterized|fibroblasts lymphocytes platelets erythrocytes leukocytes|fibroblasts|the company has produced clonal populations of human entity which have been transfected to express factor viii in vitro , demonstrated that the protein is properly processed and achieved protein
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|cell|fibroblasts pigment fibroblast epithelial characterized|keratinocytes fibroblasts epidermis melanocytes lymphocytes|fibroblasts|hses are composed of both a dermal layer containing entity and an epidermal layer containing keratinocytes .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 3), ('DRUG', 1)])|cell|fibroblasts pigment fibroblast epithelial characterized|fibroblasts hepatocytes tumours adenocarcinoma islets|fibroblasts|cold selectively inhibits akt activation in human cancer cells compared to normal proliferating cells ( e . g . , human entity ) .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|fibroblasts pigment fibroblast epithelial characterized|damaged viable apoptotic necrotic transplanted|fibroblasts|used are fat injections and cell injections , which are mainly based on enriching the damaged tissue with external source of entity cells .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 3), ('DRUG', 1), ('DIS', 1)])|cell|fibroblasts pigment fibroblast epithelial characterized|fibroblasts keratinocytes macrophages epithelia epidermis|fibroblasts|furthermore , ccl24 is constitutively expressed by skin and dermal entity .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 3), ('DRUG', 2), ('DIS', 2), ('OTHER', 1)])|cell|fibroblasts pigment fibroblast epithelial characterized|fibroblasts macrophages leukocytes joints cytokines|fibroblasts|pierer m , brentano f , rethage j , et al . the tnf superfamily member light contributes to survival and activation of synovial entity in rheumatoid arthritis .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|fibroblasts pigment fibroblast epithelial characterized|macrophages neutrophils myofibroblasts monocytes fibroblasts|fibroblasts|● increase in apoptosis of inflammatory cells , including neutrophil and pro-fibrotic cells , including entity .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|fibroblasts pigment fibroblast epithelial characterized|colony suspension served embryo mixture|fibroblasts|product consisting of a cream vehicle blended with the conditioned media extract from the cell culture of a customers own entity .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2)])|cell|fibroblasts pigment fibroblast epithelial characterized|fibroblasts cardiomyocytes lymphocytes leukocytes platelets|fibroblasts|we isolated and cultured entity from lhon-nd4 patients .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|fibroblasts pigment fibroblast epithelial characterized|fibroblasts keratinocytes glands explants epidermis|fibroblasts|the rheumatic diseases 72 adenosine a2a receptor activation stimulates collagen production in sclerodermic dermal entity either directly and through a cross-talk with the cannabinoid system .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|fibroblasts pigment fibroblast epithelial characterized|experiments mutants observations assays investigations|fibroblasts|in these entity , we demonstrated that gs010 restores mitochondrial function , including complex i activity and atp production , to the level of normal entity .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 1), ('DRUG', 1), ('DIS', 1)])|cell|fibroblasts pigment fibroblast epithelial characterized|macrophages monocytes neutrophils lymphocytes fibroblasts|fibroblasts|in ssc patients , increased production of no is suggested by increased expression of inos in endothelial cells , entity , mononuclear cells infiltrating ssc skin and alveolar macrophages .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1), ('DRUG', 1)])|cell|fibroblasts pigment fibroblast epithelial characterized|mscs microarrays electroporation ipscs vectors|fibroblasts|much of tkt  s work has focused on gene therapy using entity , a cell type present in the skin ( and throughout the body ) that is readily obtained from patients and propagated in
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|fibroblasts pigment fibroblast epithelial characterized|they elastin collagens proteoglycans fibers|fibroblasts|entity are also found in the dermis and are responsible for creating collagen and elastin that provide strength and flexibility to
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|fibroblasts pigment fibroblast epithelial characterized|fibroblasts grafts substitutes keratinocytes allografts|fibroblasts|dermagraft dermagraft is a dermal substitute grown from human dermal entity and has received pma approval for the treatment of dfus .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3)])|cell|fibroblasts pigment fibroblast epithelial characterized|fibroblasts telomeres hepatocytes lymphocytes cardiomyocytes|fibroblasts|von zglinicki t , saretzki g , docke w , lotze c . mild hyperoxia shortens telomeres and inhibits proliferation of entity : a model for senescence? .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|cell|thymocytes sinusoidal immature labeled thymic|lymphocytes thymus erythrocytes thymocytes antibodies|thymocytes|description thymoglobulin* [ anti-thymocyte globulin ( rabbit ) ] is a purified , pasteurized , gamma immune globulin , obtained by immunization of rabbits with human entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|thymocytes sinusoidal immature labeled thymic|lymphocytes macrophages monocytes leukocytes dcs|thymocytes|under control conditions , lps kills entity , which are important immune system precursor cells , known as t cells , created in the thymus to fend off infection .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 1), ('DRUG', 1), ('DIS', 1)])|cell|thymocytes sinusoidal immature labeled thymic|lymphocytes macrophages leukocytes monocytes neutrophils|thymocytes|under control conditions , lps kills entity , which are important immune system precursor cells created in the thymus to fend off infection .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|cell|thymocytes sinusoidal immature labeled thymic|dp lymphocytes counts clones macrophages|thymocytes|implants in the haart and nanoviricide treatment groups exhibited 80-85% cd4+ , cd8+ dp cells while the vehicle control groups had only approximately 30% cd4+cd8+ entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3)])|cell|thymocytes sinusoidal immature labeled thymic|thymocytes lymphocytes antibodies thymocyte erythrocytes|thymocytes|description thymoglobulin® [ anti-thymocyte globulin ( rabbit ) ] is a purified , pasteurized , gamma immune globulin , obtained by immunization of rabbits with human entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 1), ('DRUG', 1), ('DIS', 1)])|cell|thymocytes sinusoidal immature labeled thymic|macrophages lymphocytes monocytes fibroblasts neutrophils|thymocytes|its cognate receptor , pd-1 , is a co-inhibitory transmembrane protein expressed on t cells , b cells , natural killer cells and entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|thymocytes sinusoidal immature labeled thymic|organisms cultures colonies organs embryos|thymocytes|senescos technology allowed for approximately 90% greater survival of these entity in the presence of lps .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|lymphocytes erythrocytes neurons rats platelets|neutrophils|the effect of the drug on the recovery of entity is slow .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|neutrophils macrophages leukocytes platelets erythrocytes|neutrophils|in preclinical studies , plinabulin increased the survival of entity , a type of white blood cell important in the prevention of bacterial infections .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DRUG', 1)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|phagocytosis apoptosis antibiotics necrosis cytotoxicity|neutrophils|factor in promoting bacterial invasion as well as rendering the bacteria resistant to attack from reactive oxygen species ( ros ) and entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 1), ('DRUG', 1)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|lymphocytes cytokines leukocytes platelets neutrophils|neutrophils|neulasta selectively stimulates the production of entity that are depleted by cytotoxic chemotherapy , a condition called neutropenia that makes it more difficult for the body to fight
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|pathogenesis diseases arthritis fibrosis hs|neutrophils|role of c5a and c5ar in hs entity are believed to play an important disease-promoting role , as well as certain cytokines and mediators commonly found in autoimmune diseases ,
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|viability engraftment grafts counts chimerism|neutrophils|patients treated with omidubicel recovered their entity ( 500 cells per microliter ) with a median recovery of 11 . 5 days after transplantation , which is significantly shorter than the 21
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|macrophages eosinophils neutrophils neurons nodes|neutrophils|in addition , 10150 decreased sm-induced increase in the numbers of bal entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 4), ('DRUG', 2), ('OTHER', 1), ('DIS', 1)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|macrophages lymphocytes monocytes cytokines neutrophils|neutrophils|immunomodulatory properties , including the regulation of immune cells such as b lymphocytes , t lymphocytes , natural killer cells , monocytes or macrophages and entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|macrophages monocytes lymphocytes eosinophils neutrophils|neutrophils|addition to its expression on b cells , cd32b is also expressed on other immune cells such as dendritic cells , macrophages , entity , and mast cells .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|platelets lymphocytes macrophages monocytes neutrophils|neutrophils|these cells are programmed to end up as blood cells of a specific type , such as entity , red blood cells and platelets .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|cd8 cd4 lymphocytes nk monocytes|neutrophils|blood versus the lymphoid tissues , you have a preferential depletion of cd4 , cd8 and b cells , much greater than nk , entity and plasma cells .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|doses neutropenia fever mortality morbidity|neutrophils|in addition , the treatment is associated with considerable adverse events like neutropenia ( low entity ) and neuropathy ( damage to the peripheral nervous system ) .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DIS', 1)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|neutrophils leukocytes platelets monocytes eosinophils|neutrophils|although these conditions have multiple causes , each involves neutrophil adhesion to the blood vessel wall and the subsequent migration of entity into the tissue .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|decreases eosinophils neutrophils macrophages necrosis|neutrophils|also treated with viprovex , did not develop the clinical symptoms of viral infection , which included increases in alveolar macrophages and entity in broncho-alveolar lavage fluid .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|engraftment neutrophils platelets neutrophil hscs|neutrophils|the studys primary endpoint was time to neutrophil engraftment , and was met based on recovery of entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|viability engraftment hematocrit wbc platelets|neutrophils|patients treated with nicord recovered their entity ( 500 cells per microliter ) with a median recovery of 11 . 5 days after transplantation , which is significantly shorter than the 21
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|mediators cytokines biomarkers molecules enzymes|neutrophils|animal studies to allow manipulation and control of oxidative biomarkers of protein and dna , nitric oxide , antioxidant enzymes and inflammatory entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|necrosis neutrophils macrophages apoptosis leukocytes|neutrophils|second , pep005 activates the bodys immune system , causing entity , a type of white blood cell , to infiltrate the treated site .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|chemotherapy relapse radiotherapy efficacy qol|neutrophils|companies such as amgen inc . have developed or are developing products to boost entity after chemotherapy .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|neutrophils neutrophil upon polymorphonuclear leukocytes|they toxins macrophages leukocytes lymphocytes|neutrophils|once in the tissue , entity release toxins which attack normal cells as well as the antigen .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|lymphocytes tumour leukocytes pigment labeled|specification rearrangements rearrangement lineages diversification|lymphocytes|approximately 80% of all all cases involve lineage entity in the bone marrow .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|lymphocytes tumour leukocytes pigment labeled|lymphocytes receptors genes antigens molecules|lymphocytes|were generated in the t cell transfer model which utilizes immunodeficient mice which are deficient in functional b and t entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|lymphocytes tumour leukocytes pigment labeled|diseases neoplasms significance heterogeneity categories|lymphocytes|there are two main categories of entity : b-entity , or b-cells , and t-entity , or t-cells .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|lymphocytes tumour leukocytes pigment labeled|entity helper lineage entities subset|lymphocytes|the immune system is composed of a network of immune cells that include t entity ( t cells ) and b entity ( b cells ) .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|cell|lymphocytes tumour leukocytes pigment labeled|macrophages apcs lymphocytes chemokines monocytes|lymphocytes|the most crucial types of cells are antigen-presenting cells , or apcs , and entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('DRUG', 3), ('DIS', 1)])|cell|lymphocytes tumour leukocytes pigment labeled|cytokines erythropoietin cortisol ige neopterin|lymphocytes|to the occurrence and severity of these adverse events due to its role in inducing lymphopenia , or low levels of entity in the blood , and enhanced car t cell activity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 2), ('DRUG', 2), ('OTHER', 2), ('DIS', 1)])|cell|lymphocytes tumour leukocytes pigment labeled|lymphocytes antibodies cytokines antigens macrophages|lymphocytes|or more diagnostic antigens for detection of tuberculosis infection by measuring g-ifn ( gamma-interferon ) ( or , in field b , other cytokine- ) secreting entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|lymphocytes tumour leukocytes pigment labeled|macrophages organs lymphocytes pathogens leukocytes|lymphocytes|allogeneic bone marrow transplant in which tissues of the host , most frequently the gut , liver , and skin , are attacked by entity in the donor ( graft ) marrow .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|lymphocytes tumour leukocytes pigment labeled|lymphoblast precursors platelets lymphocytes genes|lymphocytes|abnormally large numbers of immature , abnormal entity called lymphoblasts are produced and released into the bloodstream .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|cell|lymphocytes tumour leukocytes pigment labeled|lymphocytes lymphocyte ctl tregs macrophages|lymphocytes|as shown below , following gp2 immunotherapy , cd8+ cytotoxic t entity recognize and destroy her2 / neu-expressing cancer cells .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|lymphocytes tumour leukocytes pigment labeled|lymphocytes appear occur occurred occurs|lymphocytes|lymphokine any of a number of soluble physiologically active factors produced by t entity in response to specific antigens .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|lymphocytes tumour leukocytes pigment labeled|lymphocytes macrophages leukocytes erythrocytes organs|lymphocytes|ceplene is designed to protect entity responsible for immune-mediated destruction of residual leukemic cells .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|lymphocytes tumour leukocytes pigment labeled|lymphocytes antigens precursors macrophages monocytes|lymphocytes|white blood cells that have differentiated to produce a specific antibody are called b entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|lymphocytes tumour leukocytes pigment labeled|macrophages lymphocytes monocytes astrocytes neutrophils|lymphocytes|the type of immune response is characterized by the way the response was initiated through specialized cells known as entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|lymphocytes tumour leukocytes pigment labeled|lymphocytes lymphocyte leukocytes til macrophages|lymphocytes|as predefined in the clinical protocol , patient subgroups were evaluated for levels of tumor infiltrating entity ( til ) and for pd-l1 checkpoint protein expression on tumor cells .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|lymphocytes tumour leukocytes pigment labeled|persons individuals people leukocytes hours|lymphocytes|consequently , in each persons bloodstream , only a relatively few entity will recognize the same antigen .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|lymphocytes tumour leukocytes pigment labeled|lymphocytes til macrophages leukocytes monocytes|lymphocytes|til means tumor infiltrating entity that are collected from a tumor cell , including naturally-occurring t cells with specificity against such tumor .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|cell|lymphocytes tumour leukocytes pigment labeled|enzymes molecules genes receptors cytokines|lymphocytes|itk , an enzyme that functions in t‑cell signaling and differentiation , is expressed predominantly in t‑cells , which are entity that play a vital role in immune responses .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|lymphocytes tumour leukocytes pigment labeled|lymphocytes til lymphocyte leukocytes macrophages|lymphocytes|) – lion biotechnologies , inc . ( otcqb : lbio ) , a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating entity ( til )
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('DRUG', 1), ('BIO', 1)])|cell|lymphocytes tumour leukocytes pigment labeled|lymphocytes subsets molecules cytokines genes|lymphocytes|although the exact mechanism of action for alemtuzumab is unknown , it is presumed to deplete circulating t and b entity after each treatment course .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|platelets platelet aggregation thromboxane upon|vwf fibrinogen fviii prp thrombin|platelets|genetically linked by an amino acid linker , targeting the a1 domain of vwf and inhibiting the interaction between ulvwf and entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|platelets platelet aggregation thromboxane upon|platelets lymphocytes erythrocytes macrophages leukocytes|platelets|the ellipse in the upper left- hand corner contains the phrase " virally inactivated red blood cells and entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|platelets platelet aggregation thromboxane upon|fibrin fibrinogen platelets clot thrombus|platelets|against acutect® because fibrimage® binds to fibrin , which comprises 75-80% of an actively forming blood clot , whereas acutect® binds to entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('BIO', 2)])|cell|platelets platelet aggregation thromboxane upon|platelets epinephrine nutrients leukocytes vitamins|platelets|blood and immune systems , including : t cells and b cells to fight infections ; red blood cells to carry oxygen and entity to control bleeding .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|cell|platelets platelet aggregation thromboxane upon|coagulation platelets hemostasis secretion fibrin|platelets|immune thrombocytopenia ( itp ) - itp is an uncommon autoimmune bleeding disorder characterized by insufficient entity in the blood .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|platelets platelet aggregation thromboxane upon|platelets macrophages aggregates nanoparticles lymphocytes|platelets|these agents work by preventing the ability of entity to aggregate together .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|cell|platelets platelet aggregation thromboxane upon|pressures transfusion sugar cholesterol transfusions|platelets|we have contributed novel research and technologies for approved medicines that treat cancer , osteoporosis , fungal infections and low blood entity , among others .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|platelets platelet aggregation thromboxane upon|fibroblasts lymphocytes platelets macrophages erythrocytes|platelets|are overproduced in the bone marrow affecting the synthesis of normal blood cells , causing a decrease in red blood cells , entity and normal white blood cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|platelets platelet aggregation thromboxane upon|platelets substrates substances organisms molecules|platelets|glutamate release by a platelet acts to stimulate release of glutamate from other entity , potentially leading to aggregation and the formation of the thrombus .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 3), ('OTHER', 3)])|cell|platelets platelet aggregation thromboxane upon|platelets lymphocytes leukocytes lipids organs|platelets|banks or transfusion centers because the main objective of these banks and centers is to obtain the blood cells and entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1), ('DIS', 1)])|cell|platelets platelet aggregation thromboxane upon|neurons receptors platelets macrophages surfaces|platelets|released glutamate acts by binding cell surface glutamate receptors expressed on entity themselves .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|platelets platelet aggregation thromboxane upon|antigens antibodies autoantibodies receptors molecules|platelets|the affected individuals make antibodies against their own entity leading to the entity  destruction , which in turn leads to the abnormal bleeding .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|cell|platelets platelet aggregation thromboxane upon|humans catecholamines hypoxia acetylcholine platelets|platelets|the effects of integrilin are specific to entity , avoiding interference with other normal cardiovascular processes .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|platelets platelet aggregation thromboxane upon|platelets lymphocytes monocytes neutrophils macrophages|platelets|in many hematological disorders , there is abnormal proliferation and differentiation of the progenitor cells for red blood cells , entity and neutrophils .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 2), ('BIO', 2), ('DRUG', 1)])|cell|platelets platelet aggregation thromboxane upon|count counts lymphocytes leukocytes sugar|platelets|in addition to anemia , fatigue , hair-loss , reduction in blood entity and white and red blood cells , and bone pain , one of the most common side effects of chemotherapy is nausea
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3)])|cell|platelets platelet aggregation thromboxane upon|platelets itp neutrophils erythrocytes leukocytes|platelets|our laboratory personnel had previously developed a pre-clinical itp model with data showing that prtx-100 inhibits the phagocytosis ( ingestion ) of entity in vitro .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|platelets platelet aggregation thromboxane upon|platelets platelet fibrinogen vwf leukocytes|platelets|integrilin is a small synthetic peptide administered by injection that prevents the aggregation of entity by blocking the platelet receptor glycoprotein , or gp , iib-iiia .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 2), ('BIO', 1)])|cell|platelets platelet aggregation thromboxane upon|platelets adenosine adp thrombin aspirin|platelets|a2 ( blocked by aspirin ) and adenosine diphosphate ( blocked by plavix® ) , researchers have recently demonstrated the release of glutamate by entity during platelet activation .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|platelets platelet aggregation thromboxane upon|platelets erythrocytes lymphocytes monocytes neutrophils|platelets|plasma donation means that donors give only plasma but not the other blood components such as entity , red cells and infection-fighting white cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cell|platelets platelet aggregation thromboxane upon|proliferation apoptosis angiogenesis cytotoxicity leukemia|platelets|training he performed basic research at the royal prince of wales hospital to develop a new monoclonal antibody to inhibit entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|laminin fibronectin integrins integrin fibrinogen|leukocytes|integrins are subdivided into those on entity , and those that recognize rgd‑peptide , collagen and laminin ligands .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|technology services resources devices technologies|leukocytes|the costs and availability of entity are subject to fluctuation depending on a variety of factors beyond our control , including competitive factors , changes in technology , and
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 4), ('OTHER', 2)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|antibodies lymphocytes erythrocytes leukocytes fibroblasts|leukocytes|human entity produce millions of different types of antibodies , all with varying shapes that allow them to attach to and , as a
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|laminin fibronectin integrins integrin fibrinogen|leukocytes|integrins are subdivided into those on entity , and those that recognize rgd-peptide , collagen and laminin ligands .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 3), ('DRUG', 3), ('OTHER', 2), ('DIS', 1)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|monocytes interferon macrophages cytokines lymphocytes|leukocytes|manufacture of interferon human white blood cells , also known as entity , and a stimulating agent are needed to produce human leukocyte derived interferon .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|equipment operations steps materials resources|leukocytes|if we are unable to obtain the necessary entity , we may be required to scale back our operations or stop manufacturing multiferon® .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|rbc wbc rbcs pmns plt|leukocytes|in inflammation , white blood cells ( entity ) move out of the bloodstream into the inflamed tissue , for example , the cns in ms , and the lung airways in
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|residue distance turn residues molecule|leukocytes|comprising phosphosugar residues , that play a central role in the entry of is , sugar residues bearing at least one entity into inflammatory sites .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|integrins platelets surfaces receptors integrin|leukocytes|the next stage of development of integrins as drug targets has focused on integrin receptors on entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|beings resources donors homes milk|leukocytes|edinburgh , scotland , and has the physical and , with the company  s proprietary technology , the technical capacity to manufacture omniferon ( tm ) from human entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 5), ('DIS', 2), ('OTHER', 1), ('DRUG', 1)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|lymphocytes macrophages eosinophils neutrophils leukocytes|leukocytes|in addition , the bronchoalveolar lavage of anti-siglec-8 treated mice displayed reduced levels of infiltrating entity that were similar to sham treated animals .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|leukocytes platelets erythrocytes rbcs lymphocytes|leukocytes|revenue was derived from the commercial sales of its leukonet system , a medical device designed for the removal of contaminating entity from donated blood .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 5), ('DIS', 2), ('OTHER', 1), ('DRUG', 1)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|lymphocytes macrophages neutrophils eosinophils leukocytes|leukocytes|in addition , the bronchoalveolar lavage ( bal ) of anti-siglec-8 treated mice displayed reduced levels of infiltrating entity that were similar to sham treated animals .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 4), ('DRUG', 3), ('OTHER', 1), ('DIS', 1)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|cytokines chemokines macrophages monocytes leukocytes|leukocytes|chemokines are cytokines which regulate the trafficking patterns of entity , the effector cells of the human immune system .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|platelets macrophages antibodies erythrocytes monocytes|leukocytes|antibodies are made in the immune system by human white blood cells , called entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|donors collected bank banks donation|leukocytes|by the first quarter 2007 , we anticipate preparing new alferon n injection ( r ) lots from blood entity at our new jersey facility .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|vessels spots gases reactions donors|leukocytes|typically by extraction with vegetable oil and hydrophobic chromatography , and sterile filtering to remove bacteria , parasites and all undesirable blood entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 1), ('DRUG', 1), ('DIS', 1)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|monocytes leukocytes lymphocytes macrophages neutrophils|leukocytes|monocytes phagocytic blood entity , originating from the bone marrow .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|ligands molecules receptors platelets selectin|leukocytes|addition of sialyl lewis x ( " slex " ) carbohydrate side chains yielding scr1sle x . slex is a carbohydrate which mediates binding of entity including neutrophils to selectin proteins .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|leukocytes lymphocytes polymorphonuclear leukocyte pigment|hemoglobin albumin bilirubin creatinine fibrinogen|leukocytes|risk of poorer clinical outcomes as measured by atlas score , a tool for evaluating cdi in patients by age , temperature , entity and albumin levels , and use of systemic antibiotics .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('BIO', 2), ('DRUG', 2), ('OTHER', 2), ('DIS', 1)])|cell|macrophages macrophage secretion pigment foam|macrophages lymphocytes organs cytokines antigens|macrophages|abx-cbl the cbl antigen is selectively over-expressed on activated immune cells including t-cells , b-cells and certain entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|macrophages macrophage secretion pigment foam|microglia macrophages neutrophils monocytes platelets|macrophages|activated entity release a variety of mediators of inflammation that contribute to a broad range of diseases , such as rheumatoid arthritis , osteoarthritis ,
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|cell|macrophages macrophage secretion pigment foam|chemotherapy apoptosis radiotherapy irradiation cisplatin|macrophages|the targeting of cd47 to make cancer cells susceptible to entity , a component of the innate immune system , is analogous to the approach that has been applied with checkpoint inhibitors and
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 1), ('DRUG', 1), ('DIS', 1)])|cell|macrophages macrophage secretion pigment foam|macrophages lymphocytes neutrophils microglia monocytes|macrophages|beyond cancer , we have discovered that activated entity , a type of white blood cell found at sites of acute and chronic inflammation , also over-express the folate receptor .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|macrophages macrophage secretion pigment foam|monocytes macrophages lymphocytes neutrophils platelets|macrophages|this is carried out primarily by some specialized cells in the blood ( e . g . , monocytes and entity ) .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|macrophages macrophage secretion pigment foam|macrophages platelets lymphocytes leukocytes them|macrophages|these compounds , intended for use as immuno- pharmaceutical agents , activate entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('DIS', 3), ('OTHER', 2), ('DRUG', 1)])|cell|macrophages macrophage secretion pigment foam|macrophages monocytes eosinophils granulocytes neutrophils|macrophages|immune system cells , including cd4+ and cd8+ t effector cells , t regulatory cells , natural killer cells , granulocytes , mast cells and monocytes / entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|cell|macrophages macrophage secretion pigment foam|m2 m1 macrophages lymphocytes functions|macrophages|in patients with cancer , immuno-evasion occurs as a result of suppressor entity ( m2 ) and inhibitory myeloid suppressive cells and treg cells .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|macrophages macrophage secretion pigment foam|they lymphocytes macrophages there leukocytes|macrophages|entity are cells found in the blood which recognize and destroy malignant cells and invading microbes .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|macrophages macrophage secretion pigment foam|phenotypes genes neurons signals signaling|macrophages|the mt-2000 series is designed to modulate activated entity from a classically activated phenotype to the alternatively activated phenotype .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('BIO', 4), ('OTHER', 1), ('DRUG', 1), ('DIS', 1)])|cell|macrophages macrophage secretion pigment foam|keratinocytes fibroblasts lymphocytes macrophages neutrophils|macrophages|recent experiments have shown that complex polynucleotides administered topically are absorbed by cells such as keratinocytes and entity within the superficial skin .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|cell|macrophages macrophage secretion pigment foam|microglia caspases platelets astrocytes macrophages|macrophages|the mt-1000 series is designed to deplete activated entity via apoptosis and / or alter the phenotype of entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|macrophages macrophage secretion pigment foam|macrophages monocytes lymphocytes neutrophils platelets|macrophages|expressed by tumor cells and have been modified to more efficiently attract immune effector cells , such as nk cells and entity , to effectively kill tumor cells .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 1), ('DRUG', 1), ('DIS', 1)])|cell|macrophages macrophage secretion pigment foam|monocytes macrophages neutrophils lymphocytes leukocytes|macrophages|phagocytes are a class of white blood cells , which include monocytes , entity and neutrophils , found in abundant quantities in and around tumors and areas of infection .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|macrophages macrophage secretion pigment foam|macrophages monocytes neutrophils microglia platelets|macrophages|we believe that by inhibiting csf-1r activation on monocytes and entity , that axatilimab has the potential to be used to treat cgvhd .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4)])|cell|macrophages macrophage secretion pigment foam|neurons plaques erythrocytes lymphocytes axons|macrophages|entity affected by the disease become highly enlarged due to the accumulation of glccer and are referred to as “gaucher cells .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 2), ('BIO', 1)])|cell|macrophages macrophage secretion pigment foam|rct macrophages lrp ldl cd36|macrophages|our anti-mirs promotes reverse cholesterol transport , or rct , which is the efflux of cholesterol from specific cholesterol-laden inflammatory cells called entity in atherosclerotic plaques .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|macrophages macrophage secretion pigment foam|lysosomes macrophages astrocytes erythrocytes platelets|macrophages|absence of an active gcd enzyme leads to the accumulation of glccer in lysosomes of certain white blood cells called entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|macrophages macrophage secretion pigment foam|monocytes macrophages platelets lymphocytes granulocytes|macrophages|the surface of almost all nucleated cells , and mhc class ii , expressed constitutively on professional antigen presenting cells ( apc ) , including entity and dendritic cells .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 1), ('DRUG', 1), ('DIS', 1)])|cell|macrophages macrophage secretion pigment foam|macrophages monocytes lymphocytes neutrophils fibroblasts|macrophages|growth factor receptors known as her2 and her3 , as well as recruit immune killer cells , such as nk cells and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|concentrations glycoprotein vesicles membranes granules|proliferating adherent immature undifferentiated fresh|plasmablasts|promising approach for the treatment of rrmm patients due to the restriction of bcmas expression solely on the surface of entity and differentiated plasma cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|cell|concentrations glycoprotein vesicles membranes granules|they lymphocytes monocytes macrophages eosinophils|plasmablasts|entity are highly enriched for vaccine-specific b cells and , therefore , negligible in pre-vaccination , day 0 samples .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|concentrations glycoprotein vesicles membranes granules|monocytes lymphocytes spleen myeloid macrophages|plasmablasts|disease , and other conditions such as kidney transplant , are associated with autoantibodies secreted by a subset of b cells known as entity and plasma cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|concentrations glycoprotein vesicles membranes granules|lymphocytes monocytes spleen macrophages platelets|plasmablasts|cd19 is a cell surface molecule broadly expressed on b cells , including some antibody-secreting entity and plasma cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|concentrations glycoprotein vesicles membranes granules|numbers precursors subsets subtypes densities|plasmablasts|we presented data from the study demonstrating that our vaccine elicited a significant expansion of mucosal homing receptor entity to approximately 60% of all activated b cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|concentrations glycoprotein vesicles membranes granules|they analytes concentrations metabolites substrates|plasmablasts|if entity are elevated in a particular sample , we then employ a multi-step process to generate a potential product candidate .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|concentrations glycoprotein vesicles membranes granules|monocytes spleen lymphocytes macrophages myeloid|plasmablasts|other conditions such as kidney transplant desensitization , are associated with autoantibodies secreted by a subset of immune b cells known as entity and plasma cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|concentrations glycoprotein vesicles membranes granules|monocytes spleen myeloid lymphocytes macrophages|plasmablasts|in the autoantibody pathway , autoantibodies are secreted by a subset of immune system b cells known as entity and plasma cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|concentrations glycoprotein vesicles membranes granules|antigens antibodies alterations epitopes cytokines|plasmablasts|we believe these mucosal entity are a key indicator of a protective mucosal immune response and a unique feature of our vaccines .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|concentrations glycoprotein vesicles membranes granules|macrophages lymphocytes thymocytes dcs clones|plasmablasts|in in vitro studies using human immune cells , cpi-006 led to activation of b cells and differentiation into antibody producing entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|concentrations glycoprotein vesicles membranes granules|lymphocytes monocytes macrophages spleen platelets|plasmablasts|cd19 is a molecule broadly expressed on b cells , including some antibody-secreting entity and plasma cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 5), ('OTHER', 1), ('DRUG', 1), ('DIS', 1)])|cell|concentrations glycoprotein vesicles membranes granules|leukocytes monocytes macrophages lymphocytes neutrophils|plasmablasts|mechanism of action a number of autoimmune diseases , including nmosd , are associated with autoantibodies secreted by entity and some plasma cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|concentrations glycoprotein vesicles membranes granules|they vaccines antibodies dcs antigens|plasmablasts|we believe entity are a key indicator of a protective mucosal immune response and a unique feature of our vaccines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|concentrations glycoprotein vesicles membranes granules|igg iga antibodies igm immunoglobulin|plasmablasts|pbmcs were collected at day 0 and day 7 , enriched for entity and analyzed in elisas against either the prefusion or the postfusion version of the f protein antigen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|cell|concentrations glycoprotein vesicles membranes granules|antibodies lymphocytes antigens they eosinophils|plasmablasts|for those patients , we then examine their samples for rare antibody-producing b cells called entity that are elevated during an active immune response .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|concentrations glycoprotein vesicles membranes granules|genes antibodies copies clones transcripts|plasmablasts|we start by isolating single entity and determining the sequences of the co-expressed antibody genes using our proprietary immune repertoire capture® technology .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('DRUG', 2), ('DIS', 2), ('OTHER', 1)])|cell|endothelial pericytes endothelium pigment microvascular|adipocytes macrophages fibroblasts monocytes lymphocytes|pericytes|in contrast , svf is merely a heterogeneous fraction including preadipocytes , endothelial cells , smooth muscle cells , entity , macrophages , fibroblasts and adipose-derived stem cells .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|endothelial pericytes endothelium pigment microvascular|fibroblasts macrophages pericytes platelets endothelium|pericytes|in wet amd abnormal new blood vessels are predominantly made up of two cell types , endothelial cells and entity .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|endothelial pericytes endothelium pigment microvascular|they vessels capillaries them platelets|pericytes|entity then intimately cover the outside of these blood vessels .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|endothelial pericytes endothelium pigment microvascular|smooth endothelial fibroblasts macrophages endothelium|pericytes|these normal , blood vessel endothelial cells have matured , and have much greater supporting structures such as entity and smooth muscle cells .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|cell|endothelial pericytes endothelium pigment microvascular|they fibroblasts macrophages mscs platelets|pericytes|entity locally supply the endothelial cells with growth and survival factors , including vegf , and play a major role in endothelial cell survival .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cell|endothelial pericytes endothelium pigment microvascular|they tumours integrins antibodies gliomas|pericytes|entity are not targeted by vegf inhibitor therapies , but because they express endoglin , they are an additional target for anti-endoglin antibodies
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|endothelial pericytes endothelium pigment microvascular|vessels grafts capillaries tubes electrodes|pericytes|after the entity are stripped from the new blood vessels , endothelial cells located inside the newly formed blood vessels are left unprotected and
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|endothelial pericytes endothelium pigment microvascular|apoptosis proliferation osteoblasts proliferate cardiomyocytes|pericytes|the binding of pdgf provides an important cell survival signal to entity .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|endothelial pericytes endothelium pigment microvascular|rpe rgcs epcs hscs rgc|pericytes|function of multiple growth factors involved in blood vessel formation and angiogenesis in the retina while sparing key retinal cells ( entity ) .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|cell|endothelial pericytes endothelium pigment microvascular|they platelets vessels stents capillaries|pericytes|entity also physically support and stabilize the abnormal new blood vessels .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|endothelial pericytes endothelium pigment microvascular|epcs rgcs rpe hscs npcs|pericytes|of multiple growth factors involved in blood vessel formation and angiogenesis in the retina while sparing key retinal -21- cells ( entity ) .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|cell|endothelial pericytes endothelium pigment microvascular|vegf angiogenesis egfr hypoxia hgf|pericytes|this increased resistance to vegf inhibitors is thought to be related to the presence of entity as a result of cancers up-regulating other angiogenesis pathways including those involving pdgfrβ .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|endothelial pericytes endothelium pigment microvascular|platelets fibroblasts macrophages pericytes endothelium|pericytes|( va ) from baseline over time abnormal new blood vessels are predominantly made up of two cell types , endothelial cells and entity .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|cell|endothelial pericytes endothelium pigment microvascular|macrophages platelets astrocytes mscs pericytes|pericytes|pdgfrβ signaling is responsible for recruiting cells called entity which play a key role in the development and stabilization of blood vessels .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|endothelial pericytes endothelium pigment microvascular|platelets leukocytes fibroblasts macrophages them|pericytes|pdgf also recruits entity to the abnormal new blood vessel , where they mature and cover the endothelial cells .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cell|endothelial pericytes endothelium pigment microvascular|they tumours integrins gliomas sarcomas|pericytes|entity are not targeted by vegf inhibitor therapies , but because they express endoglin , they are an additional target for endoglin 13
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|endothelial pericytes endothelium pigment microvascular|vessels capillaries grafts tubes electrodes|pericytes|after the entity are stripped from the new blood vessels , endothelial cells lining the inside of the newly formed blood vessels are left
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('DRUG', 2), ('DIS', 2), ('OTHER', 1)])|cell|endothelial pericytes endothelium pigment microvascular|adipocytes macrophages fibroblasts monocytes lymphocytes|pericytes|in contrast , svf is merely a heterogeneous fraction including preadipocytes , endothelial cells , smooth muscle cells , entity , macrophages , fibroblasts , and adipose-derived stem cells .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 2), ('DIS', 1)])|cell|endothelial pericytes endothelium pigment microvascular|vegf epcs pericytes macrophages angiogenesis|pericytes|in addition , the impact of vegf inhibitors may be limited by the activity of entity , which are the cells that cover the outside of blood vessels and support and stabilize newly formed vessels .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|platelets lymphocytes blasts monocytes granulocytes|granulocytes|the enzyme tyrosine kinase in the bone marrow , which causes too many stem cells to develop into white blood cells ( entity or blasts ) .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|hscs progenitors lymphocytes them blasts|granulocytes| enables aml blast cells to differentiate into entity and may be applicable in a broad range of aml patients .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('BIO', 4), ('DRUG', 2), ('DIS', 1), ('OTHER', 1)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|platelets leukocytes cytokines neutrophils macrophages|granulocytes|oncology biosimilar udenyca™ stimulates production of entity ( a type of white blood cell ) in order to promote the bodys ability to fight infections .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|urine vivo adults humans saliva|granulocytes|for up to two years after treatment , as well as preliminary efficacy as measured by changes in cystine levels in entity .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|macrophages monocytes lymphocytes eosinophils neutrophils|granulocytes|of naive and activated immune system cells , including cd4+ and cd8+ t effector cells , t regulatory cells , natural killer cells , entity , mast cells and monocytes / macrophages .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|macrophages lymphocytes monocytes macrophage phagocytosis|granulocytes|responses detected in treated pts  klh carrier as immune stimulant  gm-csf stimulates entity and macrophages antigen binding site = idiotype ( id ) biovaxld : id-klh + gm-csf  first in a
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|precursors platelets granules progenitors lymphocytes|granulocytes|in apl , there is an abnormal accumulation of immature entity called promyelocytes .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|platelets erythrocytes fibrin fibrinogen hemoglobin|granulocytes|soluble fibrin and formed elements in the blood , maintains the deformability of red blood cells , non-adhesiveness of unactiviated platelets and entity and the normal viscosity of blood .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|macrophages monocytes lymphocytes neutrophils eosinophils|granulocytes|immune cells recruited by the antibody to kill the cancer include entity , macrophages and nk cells .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|lymphocytes precursors platelets eosinophils macrophages|granulocytes|cml is a clonal bone marrow stem cell disorder in which proliferation of mature entity ( neutrophils , eosinophils , and basophils ) and their precursors is the main finding .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('DIS', 3), ('OTHER', 1)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|lps antibiotics endotoxin lipopolysaccharide doxycycline|granulocytes|in an animal model of infection , the antibacterial activity of sivextro was reduced in the absence of entity .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|platelets monocytes lymphocytes neutrophils leukocytes|granulocytes|mg / kg alx377 in mouse models and measured red blood cell , or rbc , platelet and white blood cell ( lymphocyte , monocytes and entity ) counts .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|monocytes macrophages lymphocytes fibroblasts neurons|granulocytes|gm-csf stimulates the growth and differentiation of entity and macrophages .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|monocytes macrophages lymphocytes platelets granulocytes|granulocytes|however , cll-1 is also expressed on normal hematopoietic cells such as entity and monocytes .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 2)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|atra mscs differentiate hscs osteoblasts|granulocytes|aslan003 has demonstrated the ability to differentiate aml blast cells into entity in a variety of aml cell lines that do not respond to atra .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|macrophages fibroblasts oligodendrocytes astrocytes lymphocytes|granulocytes|evidence that normal cell maturation is returning , as noted by the increase in normal maturing cells ( promyeocytes , myeocytes , metamyelocytes and entity ) .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|aggregates macrophages eosinophils lymphocytes platelets|granulocytes|in aml , blast cells are unable to differentiate and form entity , such as neutrophils and eosinophils , causing depletion of white blood cells .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|lymphocytes monocytes neutrophils macrophages eosinophils|granulocytes|lymphocytes : the white blood cells ( leukocytes ) that include the b cells and t cells , but not the others ( such as entity and eosinophils ) .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|osteoblasts adipocytes hepatocytes cardiomyocytes hscs|granulocytes|the lead compound , lg7455 , activates the gcsf-gcsfr signaling pathway and induces the differentiation of human bone marrow cells into entity .
OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|cell|granulocytes polymorphonuclear leukocytes pigment lymphocytes|myeloid monocytes precursors macrophages lymphoid|granulocytes|clone 818-18 produces a murine igg1 monoclonal antibody which recognizes a nuclear antigen expressed in human entity and myeloid precursors and acute and chronic myeloid leukemia .
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('BIO', 3), ('DRUG', 3), ('DIS', 1), ('OTHER', 1)])|cell|eosinophils epithelial pigment mast epithelium|cytokines macrophages apoptosis neutrophils chemokines|eosinophils|it has also been shown to impact some diseases , such as asthma , that are driven by entity , another important class of immune cells .
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cell|eosinophils epithelial pigment mast epithelium|entity entities neoplasm neoplasms tumours|eosinophils|despite the knowledge that entity and mast cells drive many pathological conditions , there are no approved therapies that selectively target both entity and mast cells .
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('BIO', 4), ('DRUG', 2), ('DIS', 2), ('OTHER', 1)])|cell|eosinophils epithelial pigment mast epithelium|macrophages eosinophils fibroblasts neutrophils cytokines|eosinophils|believes that it is helpful to provide investors with an overview of the types of diseases that are affected by entity and / or mast cells .
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|eosinophils epithelial pigment mast epithelium|monocytes macrophages neutrophils lymphocytes eosinophils|eosinophils|ak002 binds to siglec-8 , an inhibitory receptor found on entity and mast cells , which represents a novel way to selectively deplete or inhibit these important immune cells and thereby resolve
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|eosinophils epithelial pigment mast epithelium|macrophages eosinophils mucosa mucus leukocytes|eosinophils|eg is a rare disease that is characterized by chronic inflammation due to patchy or diffuse infiltration of entity into layers of the stomach .
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 2)])|cell|eosinophils epithelial pigment mast epithelium|eosinophils monocytes neutrophils basophils platelets|eosinophils|cml is a clonal bone marrow stem cell disorder in which proliferation of mature granulocytes ( neutrophils , entity , and basophils ) and their precursors is the main finding .
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|eosinophils epithelial pigment mast epithelium|microglia macrophages monocytes neutrophils they|eosinophils|in ad , entity are important effector cells that promote inflammation and tissue damage .
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2), ('DRUG', 1)])|cell|eosinophils epithelial pigment mast epithelium|macrophages expressed upregulated monocytes eosinophils|eosinophils|eotaxin-1 is expressed on type 2 t helper ( “th2” ) cells and entity in bp lesions and an increasing body of data documents the role of these cells in both the innate and
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|eosinophils epithelial pigment mast epithelium|versus than among while between|eosinophils|** ** prs-060 48-hr 1 1006 ** * 0 total macrophages entity lymphocytes 48hr timepoint anticaln control *p 34 . 5 µm 60?
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 3)])|cell|eosinophils epithelial pigment mast epithelium|they platelets leukocytes lymphocytes there|eosinophils|entity are a type of white blood cell .
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DIS', 2)])|cell|eosinophils epithelial pigment mast epithelium|eosinophils neutrophils monocytes leukocytes basophils|eosinophils|bertilimumab may prevent eotaxin-1-induced chemotaxis of entity and neutralize eotaxin-1 in the circulation , preventing eosinophil migration .
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cell|eosinophils epithelial pigment mast epithelium|troponin suspicion ecg echocardiography bnp|eosinophils|cardiac screening should be considered in patients with hes / cel , and patients with mds / mpd with high level of entity ( echocardiogram , serum troponin level ) .
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|eosinophils epithelial pigment mast epithelium|eosinophils neutrophils lymphocytes macrophages treg|eosinophils|background on eoe and current treatments eoe results from a dysregulation of th2-mediated immunity that drives recruitment of entity to the esophagus .
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|eosinophils epithelial pigment mast epithelium|lymphocytes macrophages monocytes nk neutrophils|eosinophils|provided data on the mechanism of anticancer activity for il-17e , showing that il-17e activated the immune system , specifically acting on entity and b cells .
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|cell|eosinophils epithelial pigment mast epithelium|neutrophils macrophages platelets monocytes eosinophils|eosinophils|in aml , blast cells are unable to differentiate and form granulocytes , such as neutrophils and entity , causing depletion of white blood cells .
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|eosinophils epithelial pigment mast epithelium|eosinophils neutrophils macrophages monocytes lymphocytes|eosinophils|importantly , and in contrast to other agents , hgen005 appears to have an effect solely on entity , without impacting other populations , such as mast cells .
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|eosinophils epithelial pigment mast epithelium|chemistry leukocytes lipids cultures biochemistry|eosinophils|outcomes associated with asthma symptoms , as measured using the asthma control questionnaire 5 and biomarker levels as measured using blood entity .
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 1)])|cell|eosinophils epithelial pigment mast epithelium|leukocytes eosinophils neutrophils monocytes lymphocytes|eosinophils|eotaxin  a protein that attracts entity into tissues , where they degranulate and cause tissue damage .
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|eosinophils epithelial pigment mast epithelium|neutrophils monocytes macrophages eosinophils lymphocytes|eosinophils|in addition to the effects on neutrophils and cytokines , a trend towards reduction in other immune cells in sputum , namely entity and macrophages , was also observed .
OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 1), ('DRUG', 1)])|cell|eosinophils epithelial pigment mast epithelium|ige allergens eosinophils leukocytes neutrophils|eosinophils|wo 97 / 00960 also discloses methods of use of the eotaxin proteins in the recruitment of entity to a particular site or in the treatment of allergic conditions .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|erythrocytes pigment erythrocyte labelled possess|polypeptides enzymes peptides molecules genes|erythrocytes|we are aware of an issued patent outside the united states that is directed to entity that comprise exogeneous polypeptides .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 5), ('DRUG', 2), ('DIS', 2), ('OTHER', 2)])|cell|erythrocytes pigment erythrocyte labelled possess|macrophages adipocytes monocytes fibroblasts neurons|erythrocytes|shown that our imids ( r ) can interact with stem cells and modulate them in such a way that they differentiate into entity , or red blood cells .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|erythrocytes pigment erythrocyte labelled possess|organisms embryos fibroblasts neurons mitochondria|erythrocytes|dna , genes , and transcription factors dna is present in all cells , except mature entity , and encodes the inherited characteristics of all living organisms .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|erythrocytes pigment erythrocyte labelled possess|minimum reduces lowering reducing against|erythrocytes|ra101495 protects against complement-mediated hemolysis of type dose response iii pnh entity drug concentration no drug ra101495
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|erythrocytes pigment erythrocyte labelled possess|concentrations particles receptors carriers molecules|erythrocytes|bilirubin entity ( red blood cells ) circulating in the blood stream have a life expectancy of 120 days .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|erythrocytes pigment erythrocyte labelled possess|monocytes neutrophils platelets they macrophages|erythrocytes|these cells have a limited life span ; neutrophils live a few hours and entity or red blood cells survive for a few weeks .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2)])|cell|erythrocytes pigment erythrocyte labelled possess|lymphocytes monocytes leukocytes neutrophils platelets|erythrocytes|with an increased likelihood of sle . test method description results were obtained using flow cytometry for complement c4d fragment bound to entity ( ec4d ) and b-lymphocytes ( bc4d ) .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|erythrocytes pigment erythrocyte labelled possess|platelets leukocytes macrophages erythrocytes neutrophils|erythrocytes|and inflammations ( leukocytes ) and form the basis of the immune system ( lymphocytes ) ; red cells that carry oxygen through our bodies ( entity ) ; and platelets that help blood to clot .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|erythrocytes pigment erythrocyte labelled possess|molecules complexes erythrocytes platelets substances|erythrocytes|the entity are then separated from the other blood compounds and opened by osmotic hemolysis , thus releasing the hemoglobin molecules .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|cell|erythrocytes pigment erythrocyte labelled possess|hepatocytes macrophages monocytes hcv lymphocytes|erythrocytes|drugs like ribavirin to infected liver cells while reducing the amount of drug going to other cells and tissues , including entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|erythrocytes pigment erythrocyte labelled possess|platelets neutrophils leukocytes macrophages erythrocytes|erythrocytes|up to 20 percent of the eculizumab-treated population , is most commonly attributable to extravascular hemolysis driven by intense c3 deposition on entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|erythrocytes pigment erythrocyte labelled possess|platelets leukocytes macrophages erythrocytes neutrophils|erythrocytes|inflammations ( leukocytes ) and form the basis of the immune system ( lymphocytes ) ;  red cells that carry oxygen through our bodies ( entity ) ; and  platelets that help blood to clot .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|erythrocytes pigment erythrocyte labelled possess|stably transiently consistently percent uniformly|erythrocytes|the nine month post-infusion data point , with total hemoglobin levels of 11 . 9 g / dl , 10 . 1 g / dl fetal hemoglobin and 99 . 8 percent f-cells ( entity expressing fetal hemoglobin ) .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 3), ('DIS', 3), ('DRUG', 1), ('OTHER', 1)])|cell|erythrocytes pigment erythrocyte labelled possess|lymphocytes macrophages fibroblasts carcinomas melanoma|erythrocytes|( hsa ) , a glycoprotein expressed on the surface of many human cell types , including immature human hematopoietic cells , peripheral blood lymphocytes , entity , and many human carcinomas .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|erythrocytes pigment erythrocyte labelled possess|macrophages lymphocytes monocytes spleen hepatocytes|erythrocytes|strong cell mediated immunity ( e . g . th1 biased cd4+ ad cd8+ ) to reduce parasitemia by clearing infected cells ( liver cells or entity ) .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|erythrocytes pigment erythrocyte labelled possess|hemoglobin glutathione catalase peroxidase myoglobin|erythrocytes|blood : this test is based on the pseudo peroxidase action of hemoglobin and entity which catalyzes the reaction of 3 , 3 , 5 , 5-tetramethyl-benzidine and buffered organic peroxide .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|erythrocytes pigment erythrocyte labelled possess|who they where what than|erythrocytes|it provides vital oxygen supplies to places in the human body entity cannot reach for instance due to arterial sclerosis .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|erythrocytes pigment erythrocyte labelled possess|platelets leukocytes macrophages erythrocytes rbcs|erythrocytes|( leukocytes ) and form the basis of the immune system ( lymphocytes ) ;  red cells that carry oxygen through our bodies ( entity ) ; and  platelets that help blood to clot .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|erythrocytes pigment erythrocyte labelled possess|aggregate spontaneously irreversibly preferentially aggregates|erythrocytes|for example , the deposition of the c4d fragment to entity forms erythrocyte c4d , or ec4d .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|erythrocytes pigment erythrocyte labelled possess|igg erythrocytes sera lymphocytes antibodies|erythrocytes|unlike cd47-blocking antibodies , tti-622 bound minimally to human entity and did not induce hemagglutination in vitro .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|hepatocytes livers organs segments venules|hepatocytes|target of 10% enzyme replacement at all doses in otc-deficient mouse model lunar-otc treatment increases otc expression in mouse periportal entity ( main site of ureagenesis )
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('BIO', 3), ('DRUG', 2), ('DIS', 1)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|fibroblasts pbmc pbmcs lymphocytes mscs|hepatocytes|in the companys preclinical studies , transduction of primary human entity with aavs3 pseudotyped vectors was significantly higher as compared with the other vectors listed above .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|relation humans vivo genes turn|hepatocytes|our initial focus is on monogenic diseases with clear biology linking the missing activity of a gene in entity to a disease outcome .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|microsomes cytosol membranes characterized prepared|hepatocytes|the polymer is targeted to the asialoglycoprotein receptor on liver entity by the inclusion of a galnac moiety to one end of the polymer .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|clones lines clone cultures counterparts|hepatocytes|improvements in the function of our immortalized entity will open more markets and expand the usage in the current markets for our cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|accumulate humans occur rats concentrate|hepatocytes|mrt5201 , is designed to address the underlying cause of otc deficiency by delivering mrna encoding fully functional otc enzyme to entity through intravenous administration .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|hcc hepatocytes livers hccs individuals|hepatocytes|have shown that the rap receptor , lrp1 , is well expressed on human hcc and under-expressed on non-cancerous , but otherwise diseased , entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|biopsies metastases microsomes fibroblasts slices|hepatocytes|we recently demonstrated that liver entity show a rapid , primary nf-kb activation response following in vivo administration of cblb502 in mice and nhps .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|individuals treatments organisms rats agents|hepatocytes|however , combining multiple interventions , particularly multiple small molecules , places an additional burden of drug metabolism and clearance upon already stressed entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|hepatocytes livers fibroblasts pancreas intestine|hepatocytes|these cells have been shown to retain many key synthetic and metabolic processes of normal human entity , the primary functional cell of the liver .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|microsomes homogenates enzymes extracts homogenate|hepatocytes|pmx-30063 has been tested for stability in the presence of mouse and human liver entity to investigate the extent to which liver metabolism could be a factor upon compound administration .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|microsomes cirrhosis enzymes homogenate metastases|hepatocytes|pmx-30063 demonstrated high stability in the presence of liver entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|participants individuals dogs women males|hepatocytes|percentage of entity showing steatosis , or fatty change , mean ± sd ( n ) 54 . 8 ± 21 . 2 49 . 9 ± 24 . 3
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1), ('DIS', 1)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|macrophages autophagy adipogenesis hepatocytes mitochondria|hepatocytes|it has been previously demonstrated that impairment of entity by ethanol is associated with the production of free radical and oxidative stress .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|counterparts clones clone lines genome|hepatocytes|these efforts have been towards improving the functionality of our immortalized entity , introducing products utilizing these cells and expanding our intellectual property base .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|progenitor mscs progenitors lines precursors|hepatocytes|our liversafe 3d™bioassay system uses our stem cell-derived entity , or liver cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|vivo neurons mammals humans vertebrates|hepatocytes|for example , the asg receptor exists primarily in entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DRUG', 1), ('DIS', 1)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|aat lysosomes macrophages alternatively subsequently|hepatocytes|patient has a mutation in both copies of the serpina1 gene , which causes aat to aggregate inside liver cells , or entity , rather than being secreted from the liver .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4), ('DRUG', 1), ('DIS', 1)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|they macrophages mitochondria peroxisomes hepatocytes|hepatocytes|entity are the most biochemically complex cells in the human body and play an important role in the synthesis and metabolism
OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1), ('DIS', 1)])|cell|hepatocytes hepatic hepatocyte fatty sinusoidal|hepatocytes nash macrophages mitochondria hepatocyte|hepatocytes|apoptosis of entity manifests as ballooning of the cells , a characteristic microscopic feature of nash liver tissue .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|megakaryocytes platelet platelets characterized possess|platelets megakaryocytes macrophages vwf monocytes|megakaryocytes|lx-5431 has been demonstrated in ex vivo bone marrow culture to stimulate production of platelet forming cells called entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|cell|megakaryocytes platelet platelets characterized possess|hescs viable mscs pluripotent autologous|megakaryocytes|we have developed a manufacturing process for generating entity , proplatelet forming cells and ultimately platelets using either hescs or ipscs as the starting materials .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 3), ('DIS', 1)])|cell|megakaryocytes platelet platelets characterized possess|macrophages cytokines monocytes mscs hscs|megakaryocytes|in addition , bet proteins promote the generation of entity from hematopoietic stem cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|megakaryocytes platelet platelets characterized possess|viable platelets autologous nucleated adherent|megakaryocytes|we have developed a manufacturing process for generating entity , proplatelet forming cells and ultimately platelets using either hes or ips cells as the starting materials .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|megakaryocytes platelet platelets characterized possess|platelets megakaryocytes monocytes lymphocytes leukocytes|megakaryocytes|tpo-ras , like tpo , stimulate the activation , proliferation and maturation of entity , resulting in an increase in circulating platelet counts .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('DRUG', 1), ('DIS', 1), ('OTHER', 1)])|cell|megakaryocytes platelet platelets characterized possess|macrophages platelets microglia neutrophils lymphocytes|megakaryocytes|we believe that the blood cells most responsible for bone marrow scarring in mf are dysfunctional entity , which produce inflammatory molecules in part through elevated nf-kb signaling .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|megakaryocytes platelet platelets characterized possess|progenitors macrophages organs lymphocytes monocytes|megakaryocytes|the angiopoietins are in preclinical studies for their abilities to promote growth and mobilization of hemopoietic stem cells and entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cell|megakaryocytes platelet platelets characterized possess|leukemia proliferation tumorigenesis lymphoma apoptosis|megakaryocytes|an editorial entitled , myelodysplasia , entity , and methylation was also published in the same issue of leukemia research ( steensma , leuk .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|megakaryocytes platelet platelets characterized possess|macrophages platelets lymphocytes neutrophils monocytes|megakaryocytes|precursors of the red blood cells or of the granulocytes and macrophages , which are also of the immune system , and entity , which produces platelets .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2)])|cell|megakaryocytes platelet platelets characterized possess|platelets monocytes lymphocytes leukocytes neutrophils|megakaryocytes|tpo-ras , like tpo , stimulate the activation , proliferation and maturation of entity , resulting in an increase in circulating platelets .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|megakaryocytes platelet platelets characterized possess|platelets they leukocytes macrophages erythrocytes|megakaryocytes|entity normally function to produce platelets , which are small blood cells involved in blood clotting .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('DRUG', 1), ('DIS', 1), ('OTHER', 1)])|cell|megakaryocytes platelet platelets characterized possess|platelets leukocytes neutrophils macrophages lymphocytes|megakaryocytes|entity , which are large cells found in the bone marrow , are the source of platelets that are released into the bloodstream .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|megakaryocytes platelet platelets characterized possess|platelets monocytes macrophages megakaryocytes fibroblasts|megakaryocytes|these cells , known as entity , are found in the bone marrow and are the precursor cells to platelets .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1), ('DIS', 1)])|cell|megakaryocytes platelet platelets characterized possess|progenitors platelets megakaryocytes precursors macrophages|megakaryocytes|specifically , jak2 activation leads to proliferation of red blood cell progenitors and platelet progenitors , or entity , that fail to mature to platelets .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|cell|megakaryocytes platelet platelets characterized possess|fibroblasts macrophages mscs osteoblasts hscs|megakaryocytes|the inability of entity to fully differentiate leads to the release of pro-inflammatory and pro-fibrotic factors that results in scarring of the bone marrow ,
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|megakaryocytes platelet platelets characterized possess|there 16 they lymphocytes them|megakaryocytes|entity are the bone marrow cells that give rise to blood platelets . 13 about eltrombopag eltrombopag was given accelerated approval by the
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 3)])|cell|megakaryocytes platelet platelets characterized possess|platelets platelet leukocytes erythrocytes neutrophils|megakaryocytes|itp can also result in damage to entity , leading to impaired platelet production .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|megakaryocytes platelet platelets characterized possess|them differences individuals variations organisms|megakaryocytes|we could not readily identify entity in our conditions on morphological grounds despite some effort with mgdf and therefore do not know which of our sampled
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|cell|megakaryocytes platelet platelets characterized possess|fibroblasts macrophages mscs osteoblasts hscs|megakaryocytes|the inability of entity to fully differentiate leads to the release of pro-inflammatory and pro-fibrotic factors that results in scarring of the bone marrow , which further exacerbates the
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|podocytes epithelial renal within glomerular|podocyte podocytes glomeruli glomerular glomerul|podocytes|inhibition of calcineurin within the entity can prevent the dephosphorylation of synaptopodin which in turn inhibits the degradation of the actin cytoskeletion within the podocyte .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|podocytes epithelial renal within glomerular|genome chromosome prp molecule cytochrome|podocytes|these immunologic impacts recent data suggests that cnis have another subtle but important impact on the structural integrity of the entity : 931-8 .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|podocytes epithelial renal within glomerular|vasculature homeostasis microcirculation glomeruli transcriptome|podocytes|additionally , recent evidence suggests that inhibition of calcineurin has direct physical impacts on the entity within the kidney .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|podocytes epithelial renal within glomerular|enzymes activities molecules agents peptides|podocytes|voclosporin also potentially stabilizes disease modifying entity , which protects against proteinuria .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cell|podocytes epithelial renal within glomerular|podocytes proteinuria podocyte glomeruli gfr|podocytes|( a and b ) gl-3 reduction in entity was closely paralleled by a reduction in podocyte volume .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|podocytes epithelial renal within glomerular|genome molecule organism barrier chromosome|podocytes|immunologic impacts recent data suggests that cnis have another subtle but important impact on the structural integrity 8 of the entity : 931-8 .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('DIS', 3), ('BIO', 3), ('OTHER', 2)])|cell|podocytes epithelial renal within glomerular|podocytes platelets proteinuria neutrophils glomeruli|podocytes|voclosporin also potentially stabilizes entity , which can protect against proteinuria .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|podocytes epithelial renal within glomerular|25 cysteine urine glutathione proteinuria|podocytes|voclosporin also potentially stabilizes entity , s-12 table of contents which can protect against proteinuria .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|podocytes epithelial renal within glomerular|versus murine cns between within|podocytes|affinity of melanocortin peptides and distribution of receptor subtypes 29 mcr prevalent tissue / cells with receptor mc3r cns macrophages mc4r entity renal mesangial cells ( ? )
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|podocytes epithelial renal within glomerular|versus murine cns between within|podocytes|affinity of melanocortin peptides and distribution of receptor subtypes 30 mcr prevalent tissue / cells with receptor mc3r cns macrophages mc4r entity renal mesangial cells ( ? )
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|cell|podocytes epithelial renal within glomerular|urine albumin creatinine cholesterol urea|podocytes|there were statistical trends towards associations between 24-hr urine protein and % change in gl-3 inclusion content of entity .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|podocytes epithelial renal within glomerular|platelets molecules they leukocytes macrophages|podocytes|entity form part of the barrier that enable the glomerulus to filter the blood in a manner that retains large molecules
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|podocytes epithelial renal within glomerular|urine humans rats vivo platelets|podocytes|curr pharm des 21 overactive cannabinoid 1 receptor in entity drives type 2 diabetic nephropathy .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 4), ('DIS', 3), ('OTHER', 3), ('DRUG', 1)])|cell|podocytes epithelial renal within glomerular|podocytes macrophages glomeruli monocytes astrocytes|podocytes|gas6 is upregulated in either endothelial / mesangial cells or entity in igan dual involvement of growth arrest-specific
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DIS', 2), ('DRUG', 2)])|cell|podocytes epithelial renal within glomerular|kidneys hepatocytes macrophages fibroblasts podocytes|podocytes|combined with reduction of local hypoxia , plxdc2 can improve the health and homeostasis of renal epithelial cells and entity .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|podocytes epithelial renal within glomerular|versus murine cns between within|podocytes|affinity of melanocortin peptides and distribution of receptor subtypes 32 mcr prevalent tissue / cells with receptor mc3r cns macrophages mc4r entity renal mesangial cells ( ? )
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|cell|podocytes epithelial renal within glomerular|csf macrophages vivo erythrocytes balf|podocytes|( c ) volume fraction of gl-3 inclusions in entity did not change during the 6 months migalastat treatment .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 3), ('OTHER', 3)])|cell|podocytes epithelial renal within glomerular|lymphocytes cultures leukocytes erythrocytes organs|podocytes|endothelial cells , tubular epithelial cells , cns mc5r cns , exocrine glands , lymphocytes , entity adapted from gong 2011 , catania 2004 , schioth 1997
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|podocytes epithelial renal within glomerular|cns cytoskeleton intestine myocardium organism|podocytes|these immunologic impacts recent data suggests that cnis have another subtle but important impact on the structural integrity of the entity .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 3), ('DIS', 3), ('BIO', 3)])|cell|podocytes epithelial renal within glomerular|capillaries glomeruli podocytes endothelium glomerular|podocytes|fsgs is understood to start with damage to entity , cells that wrap around capillaries of the glomerulus .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 5), ('DIS', 3), ('OTHER', 2), ('DRUG', 1)])|cell|mast basophils eosinophils secretion basophil|eosinophils neutrophils macrophages monocytes granulocytes|basophils|neutrophils , eosinophils and entity , which are types of mature leukocytes , are normally formed only in the bone marrow and are stored there until they
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|mast basophils eosinophils secretion basophil|bind recognize express binds contain|basophils|high affinity anti-human ige- 12 / 31 / 87 s / n 140 , 036 u . s . monoclonal antibody which bind to igge-bearing b cells and not entity tnx87-12a change et al .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|cell|mast basophils eosinophils secretion basophil|macrophages monocytes eosinophils neutrophils platelets|basophils|cml is a clonal bone marrow stem cell disorder in which proliferation of mature granulocytes ( neutrophils , eosinophils , and entity ) and their precursors is the main finding .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|mast basophils eosinophils secretion basophil|monocytes macrophages dcs lymphocytes neutrophils|basophils|vista is an immunoregulatory receptor and is highly expressed on various immune system cells including neutrophils , monocytes , macrophages , entity and dcs .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|mast basophils eosinophils secretion basophil|cultures monocytes leukocytes lymphocytes macrophages|basophils|anb020 inhibits secretion of il-5 from primary entity purified from peripheral blood of healthy subjects with an ic 50 of approximately 1 . 5 nm , which is approximately 15-fold greater
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|mast basophils eosinophils secretion basophil|binds bind recognizes does against|basophils|high affinity anti-human ige- 7 / 29 / 88 s / n 226 , 421 u . s . monoclonal antibody which binds to ige-bearing b cells and not entity tnx87-12aa chang et al .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DIS', 3), ('DRUG', 1)])|cell|mast basophils eosinophils secretion basophil|eosinophils macrophages neutrophils basophils monocytes|basophils|e25 blocks ige from binding to mast cells and entity , thereby inhibiting the allergic response .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|mast basophils eosinophils secretion basophil|cultures monocytes leukocytes lymphocytes macrophages|basophils|anb020 inhibits secretion of il-5 from primary entity purified from peripheral blood of healthy subjects with an ic50 of approximately 1 . 5 nm , which is approximately 15-fold greater than
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|mast basophils eosinophils secretion basophil|eosinophils macrophages neutrophils lymphocytes monocytes|basophils|mast cells , entity , goblet cells and other cells also play a role .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|mast basophils eosinophils secretion basophil|indirectly migrate differentiate penetrate them|basophils|these ige molecules circulate in the blood stream and find their way to attach to the mast cells or entity through specific ige receptors on the cell surface .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DIS', 3), ('DRUG', 1)])|cell|mast basophils eosinophils secretion basophil|macrophages eosinophils neutrophils basophils monocytes|basophils|pci-32765 is a potent inhibitor of histamine release ( also known as degranulation ) from mast cells and entity , which are specific immune cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|mast basophils eosinophils secretion basophil|eosinophils macrophages neutrophils monocytes leukocytes|basophils|to the antigen , or allergen in this case , by producing ige . ige binds to the surface of mast cells and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|cell|mast basophils eosinophils secretion basophil|macrophages monocytes eosinophils fibroblasts platelets|basophils|these ige molecules attach to the surfaces of mast cells or entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DIS', 3), ('DRUG', 1)])|cell|mast basophils eosinophils secretion basophil|eosinophils macrophages basophils lymphocytes platelets|basophils|and masking the binding site for the ige receptor which prevents ige from binding to and arming mast cells and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DIS', 1)])|cell|mast basophils eosinophils secretion basophil|leukocytes lymphocytes eosinophils neutrophils receptors|basophils|similarly , calcium ions also play a central role in the activation and degranulation of tissue mast cells and circulating counterpart entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|mast basophils eosinophils secretion basophil|macrophages monocytes eosinophils leukocytes lymphocytes|basophils|these ige molecules circulate in the blood stream and find their way to attach to the mast cells or entity , thereby arming these cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 1), ('DRUG', 1), ('DIS', 1)])|cell|mast basophils eosinophils secretion basophil|macrophages monocytes neutrophils lymphocytes leukocytes|basophils|in animal models that ccr2 is important for host defense , inflammation and immunity mediated through hematopoietic cells including monocytes and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DIS', 3), ('DRUG', 1)])|cell|mast basophils eosinophils secretion basophil|eosinophils neutrophils monocytes macrophages basophils|basophils|siglec-8 is an inhibitory receptor located selectively on eosinophils , mast cells and , to a lesser extent , on entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 4), ('DRUG', 3), ('OTHER', 2), ('DIS', 2)])|cell|mast basophils eosinophils secretion basophil|macrophages eosinophils platelets chemokines cytokines|basophils|omalizumab works by binding to the immune mediator immunoglobulin e , or ige , and inhibiting ige-mediated activation of mast cells and entity , types of white blood cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 1), ('DRUG', 1), ('DIS', 1)])|cell|mast basophils eosinophils secretion basophil|macrophages monocytes lymphocytes neutrophils leukocytes|basophils|cd123 is also expressed by plasmacytoid dendritic cells , or pdcs , entity , endothelial cells and , to a lesser extent , monocytes and eosinophils .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|neurons ganglion dopamine dopaminergic labeled|neurons fibers fibres neurones afferents|neurons|in parallel , electrophysiology recordings of single ganglion entity that innervate the craniofacial muscles were performed ( 33 masticatory muscle mechanoreceptors ) .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neurons ganglion dopamine dopaminergic labeled|neurons them organisms membranes individuals|neurons|amyloid fibrils are believed to be neurotoxic and interfere with the normal communication between entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neurons ganglion dopamine dopaminergic labeled|neurons receptors signals pathways channels|neurons|these entity are responsible for producing dopamine , an essential brain signaling chemical , or neurotransmitter , that enables smooth , coordinated movements of both voluntary
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neurons ganglion dopamine dopaminergic labeled|rod photoreceptor photoreceptors cone inner|neurons|these results suggest that the photoreceptor entity and pigmented retinal epithelial cells  cell types that are both lost in ga  are sandwiched between deposits of
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|neurons ganglion dopamine dopaminergic labeled|neurons they astrocytes rats motoneurons|neurons|as a result , entity are unable to respond to normal stimuli and can become over-stimulated by a neurotransmitter or be unable to respond to
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neurons ganglion dopamine dopaminergic labeled|neurons plaques lysosomes aggregates synapses|neurons|in ad , tau protein is misfolded , becomes hyperphosphorylated and aggregates into neurotoxic oligomers that ultimately form neurofibrillary tangles within entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|neurons ganglion dopamine dopaminergic labeled|neurons fibers axons nuclei neuron|neurons|these symptoms are caused by the degeneration of dopaminergic entity in the substantia nigra and depletion of dopamine in the striatum .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|neurons ganglion dopamine dopaminergic labeled|neurons synapses axons dendrites fibers|neurons|can transition into mild , moderate and , finally , severe stages of alzheimers disease that are characterized by greater systemic loss of entity and synapses in the brain tissue .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neurons ganglion dopamine dopaminergic labeled|neurons receptors neurotransmission transporter transporters|neurons|parkinsons disease ( the “mptp model” ) showed that when administered orally , aeol 11207 crosses the blood brain barrier and protected dopamine entity in a dose-dependent manner .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neurons ganglion dopamine dopaminergic labeled|cns neurons intestine axons nerve|neurons|the dendrites and axons , or nerve endings , of the entity contain an elaborate series of thin tubes , or microtubules , which serve to support them and transport nutrients down to the
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|neurons ganglion dopamine dopaminergic labeled|neurons axons neuron fibers motoneurons|neurons|sma is caused by a genetic defect in the smn1 gene that codes smn , a protein necessary for survival of motor entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neurons ganglion dopamine dopaminergic labeled|neurons mitochondria myelin tau mrna|neurons|accumulation of mhtt protein causes progressive loss of entity in the brain .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|neurons ganglion dopamine dopaminergic labeled|microglia neurons astrocytes fibroblasts monocytes|neurons|cord in commercial quantities , and the ability to control the differentiation of these cells constitutively into mature , physiologically relevant human entity and glia .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neurons ganglion dopamine dopaminergic labeled|neurons humans rats plants mammals|neurons|neurotoxic peptiderefers to a small protein ( called a peptide ) that can be toxic to entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|neurons ganglion dopamine dopaminergic labeled|candidates scheduled threshold indications thresholds|neurons|· ep1937352 sub-threshold stimulation to precondition entity for supra-threshold stimulation – opposition hearing is scheduled for january 21 , 2015 in munich , germany .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|neurons ganglion dopamine dopaminergic labeled|neurons fibers functions pathways nerves|neurons|limitations of current therapies als is a neurodegenerative disorder that involves gradual breakdown of motor entity leading to muscle weakness , disability , and ultimately death .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|neurons ganglion dopamine dopaminergic labeled|neurons axons photoreceptors oligodendrocytes astrocytes|neurons|which leads to production of a mutant huntingtin protein that is thought to be neurotoxic and promote the degeneration of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|neurons ganglion dopamine dopaminergic labeled|hippocampus cns striatum cerebellum amygdala|neurons|to further demonstrate this , we utilized in vivo electrophysiology where cbn blocked the pain signals in the entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4)])|cell|neurons ganglion dopamine dopaminergic labeled|neurons axons fibroblasts astrocytes fail|neurons|loss of dopamine causes critical nerve cells , or entity , in the brain , to fire out of control , leaving patients unable to direct or control their movement in a normal
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neurons ganglion dopamine dopaminergic labeled|functions coordination skills ability neurons|neurons|about sma sma is a severe neuromuscular disease characterized by the loss of motor entity leading to progressive muscle weakness and paralysis .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|cell|cardiomyocytes characterized epithelial into kind|microrna fibroblasts micrornas rnas nanog|cardiomyocytes|we have derived human entity ( grncm1 ) from hescs for the potential treatment of heart disease .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|cardiomyocytes characterized epithelial into kind|diagnosed congestive malignant progressive hereditary|cardiomyocytes|cm1 – entity heart failure 6 million total patients in u . s . cells derived and characterization studies performed ( parameters analyzed showed normal cell functions
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|cardiomyocytes characterized epithelial into kind|neurons players driver store bodies|cardiomyocytes|product sales for both 2012 and 2013 is primarily attributable to an increase in unit volume sales of our icell entity and , in 2012 , to our icell neurons .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|cardiomyocytes characterized epithelial into kind|mediated driven caused diagnosed congenital|cardiomyocytes|cm1 - entity heart failure 6 million total patients in u . s . cells derived and fully characterized ( all normal cell functions verified in vitro ) .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|cell|cardiomyocytes characterized epithelial into kind|mscs msc therapeutics hesc candidates|cardiomyocytes|gerons grncm1 program is developing hesc-derived entity for the treatment of heart failure .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|cell|cardiomyocytes characterized epithelial into kind|hearts cardiomyocytes myocytes fibroblasts myocardium|cardiomyocytes|in human entity isolated from the left ventricle of patients with end-stage heart failure , serca2a levels were correlated with improved diastolic function .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|cell|cardiomyocytes characterized epithelial into kind|cardiomyocytes hearts myocardium myocytes fibroblasts|cardiomyocytes|isolated entity from aav-s100a1 treated pig heart showed superior systolic and diastolic performance .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|cardiomyocytes characterized epithelial into kind|vivo younger telomeres older old|cardiomyocytes|moreover , old g5terc-null mice exhibited shorter telomeres in entity than did younger counterparts , and this led to ventricular dilation , page .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|cardiomyocytes characterized epithelial into kind|agents therapies approaches peptides nanoparticles|cardiomyocytes|the targeted entity are expected to produce sustained therapeutic protein levels in the myocardium where it is needed .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2), ('BIO', 1)])|cell|cardiomyocytes characterized epithelial into kind|pancreatic pancreas spleen hepatic aorta|cardiomyocytes|such cells include entity or heart muscle cells , neural cells , hepatic cells and pancreatic ( logo ) islet cells .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|cardiomyocytes characterized epithelial into kind|hescs embryos fibroblasts hsc embryo|cardiomyocytes|the first product developed under the alliance , human entity derived from hescs , was launched in october 2010 by gehc .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|cell|cardiomyocytes characterized epithelial into kind|fibroblasts hepatocytes islets embryos cardiomyocytes|cardiomyocytes|specific precursor cells which , together with a specific combination of growth factors , develop full culture wells of functional , beating human entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|cardiomyocytes characterized epithelial into kind|myocytes segments fibers cardiomyocytes vesicles|cardiomyocytes|the product is predominantly composed of ventricular entity which have been shown to electrically and mechanically couple to the animal myocardium in which they are injected and contract
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|cardiomyocytes characterized epithelial into kind|hescs embryos hesc blastocysts lessons|cardiomyocytes|u . s . patent no . 7 , 425 , 448 was issued to geron with broad claims to entity derived from hescs .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|cell|cardiomyocytes characterized epithelial into kind|materials precursors mscs ascs grafts|cardiomyocytes|that asterias will reach an agreement for support in the manufacture of vac2 or the development of hes cell derived entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|cardiomyocytes characterized epithelial into kind|hf cardiomyocytes cms smc smcs|cardiomyocytes|heart muscle cells ( entity ) do not regenerate during adult life .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|cardiomyocytes characterized epithelial into kind|cardiomyocytes hepatocytes mitochondria fibroblasts macrophages|cardiomyocytes|dbcm is caused by metabolic derangements in entity that result in cell death and fibrosis .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DRUG', 2)])|cell|cardiomyocytes characterized epithelial into kind|molecules receptors exosomes chemokines mscs|cardiomyocytes|cm1 , hes cell-derived entity , have been extensively characterized in vitro and in vivo .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|cardiomyocytes characterized epithelial into kind|biomarker bioassay dataset panel nanoparticles|cardiomyocytes|we used our hpsc-derived entity ( human heart cells ) in cardiosafe 3d™ , our novel , customized in vitro bioassay system for predicting potential cardiotoxicity of drug rescue
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|cardiomyocytes characterized epithelial into kind|discovered reviewed now discussed characterized|cardiomyocytes|today we have entity , two types of neural cells -- dopaminergic neurons and oligodendrocytes -- and hematopoietic cells in animal models , and we hope
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|fibroblasts mscs macrophages cardiomyocytes osteoblasts|keratinocytes|these supported isolation , expansion and long-term culture of entity , fibroblasts , smooth muscle cells and mesenchymal stem cells .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|monocytes macrophages keratinocytes platelets leukocytes|keratinocytes|il-17 binding to il-17ra on entity stimulates and perpetuates the inflammation cascade of psoriasis .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|agents agent substances plaques materials|keratinocytes|believes that the therapeutic utility of 2-cdap in psoriasis would result from its ability to gain direct access to hyperproliferating entity in a form that would be rapidly effective .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|fibroblasts keratinocytes lymphocytes monocytes macrophages|keratinocytes|apligraf contains living human skin cells , entity and fibroblasts , organized in an epidermal and dermal layer .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('BIO', 1)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|egf keratinocytes egfr fibroblasts epidermis|keratinocytes|hyperproliferation of entity contributes to psoriasis , and work by sugen and others has demonstrated that egf tk signalling is required for the growth of entity .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 3)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|fibroblasts keratinocytes chondrocytes myofibroblasts epidermis|keratinocytes|hemidesmosome formation also occurs during normal differentiation of entity as they mature from the basal layer , not only in a wound-healing situation .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|typically been commonly warts rarely|keratinocytes|etiology – entity infected by human papillomavirus ( hpv ) ; manifests as common warts , plantar warts or genital warts virus spreads via direct contact or
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|fibroblasts keratinocytes fibroblast grafts explants|keratinocytes|revitix provides a more complete array of growth factors than those produced by dermal fibroblasts or epidermal entity alone , which helps to speed the healing process of skin .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|epidermis melanocytes dermis nucleus melanin|keratinocytes|tanning is mediated by melanocytes producing melanin , which is subsequently transferred to the entity .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|keratinocytes fibroblasts epidermis melanocytes keratinocyte|keratinocytes|in in vitro skin models , p529 was shown to inhibit keratinocyte proliferation ( growth of entity ) and induce apoptosis ( cause death of hyperproliferating entity ) .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|epidermis epithelium dermis keratinocytes endothelium|keratinocytes|in preclinical studies , xcur17 inhibited il-17ra in the entity of the skin .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|they keratinocytes fibroblasts melanocytes there|keratinocytes|entity are the most abundant cells in the epidermis and account for 80 to 90% of the total epidermal cellular population .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 1), ('DIS', 1)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|ak keratinocytes fibroblasts mda scc|keratinocytes|kx-01 inhibits the proliferation of entity and up-regulates p53 so its utility in clinically treating ak was of interest .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|keratinocytes epidermis fibroblasts they neurons|keratinocytes|the epidermis is comprised mainly of cells known as entity that are continually regenerated and move toward the skin surface where they flatten , lose their nucleus , and become the outermost
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|genes p53 chromosomes fibroblasts tumours|keratinocytes|this exposure can lead to oncogenic changes , such as inactivation of p53 , and consequential hyper-proliferation of mutated entity .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|they keratinocytes fibroblasts there epidermis|keratinocytes|entity are the predominant cell type in the epidermis , the outermost layer of the skin .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|keratinocytes langerhans fibroblasts epidermis mast|keratinocytes|first , il-8 is produced by a type of skin cell called entity , and is a potent growth factor for these skin cells .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|angiogenesis neovascularization proliferation atherosclerosis melanoma|keratinocytes|as p529 has been shown to inhibit neovascularization , together with its effect on entity , p529 is expected to show activity in psoriasis and atopic dermatitis .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|counted macrophages absent fibroblasts seen|keratinocytes|barrier function and inflammation in atopic dermatitis the most abundant cells in the epidermis are entity , shown in figure 16 below .
OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|cell|keratinocytes epidermal epithelial fibroblasts pigment|keratinocytes epidermis they fibroblasts melanocytes|keratinocytes|the epidermis is comprised mainly of cells known as entity which are continually regenerated and move toward the skin surface where they flatten , loose their nucleus and become the outermost
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|astrocytes labeled degeneration neurons express|microglia astrocytes macrophages glia neurons|astrocytes|the chronic activation of microglia and entity has been implicated as an important disease mechanism in huntingtons disease , progressive ms , and other neurodegenerative disorders .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 2)])|cell|astrocytes labeled degeneration neurons express|microglia macrophages tnf monocytes neutrophils|astrocytes|when innate immune dysfunction causes chronic inflammation , activated microglial cells produce soluble tnf that activates entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 4)])|cell|astrocytes labeled degeneration neurons express|neurons astrocytes oligodendrocytes glia interneurons|astrocytes|in addition , the target cells , motor neurons and entity , or cells supporting the neurons , reside within and surrounding the spinal cord and brain stem , which we believe can be
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|astrocytes labeled degeneration neurons express|neurons oligodendrocytes microglia astrocytes macrophages|astrocytes|when ipsc-derived hgpcs were transplanted into these mice , the cells spread widely throughout the brain , developing as entity and oligodendrocytes .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|astrocytes labeled degeneration neurons express|microglia astrocytes macrophages neurons glia|astrocytes|cells that repair damage to myelin and neurons and prevent chronic activation of inflammatory cells of the brain , microglia and entity , which is implicated in neurodegenerative diseases .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|astrocytes labeled degeneration neurons express|brains hippocampus microglia astrocytes neurons|astrocytes|jun ; 71 : 1500-4 ; modulation of interleukin-1beta mediated inflammatory response in human entity by flavonoids : implications in neuroprotection . brain res bull .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|astrocytes labeled degeneration neurons express|oligodendrocytes neurons astrocytes microglia macrophages|astrocytes|entity and oligodendrocytes , the other two principle types of central nervous system cells , are also generated from the human neural stem
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|astrocytes labeled degeneration neurons express|neurons receptors astrocytes microglia nmdar|astrocytes|av-101s ability to activate entity for focal delivery of an anti-epileptic principle , and its dual action as a nmdar glyb antagonist and quinolinic acid synthesis
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|astrocytes labeled degeneration neurons express|neurons oligodendrocytes astrocytes macrophages glia|astrocytes|together , these activities lead to a cascade of enhanced disease responses in neurons , oligodendrocytes , and entity , cell types that are most vulnerable to energetic deficiencies .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 3)])|cell|astrocytes labeled degeneration neurons express|them neurons axons fibroblasts leukocytes|astrocytes|spinal cord are damaged , guanosine , which is present normally in every cell , can be released in high concentrations to stimulate entity to produce these protective factors .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|astrocytes labeled degeneration neurons express|synapses neurons dendrites axons neurites|astrocytes|conditions anavex®3-71 demonstrated the formation of new synapses between neurons ( synaptogenesis ) without causing an abnormal increase in the number of entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|astrocytes labeled degeneration neurons express|macrophages microglia astrocytes monocytes neurons|astrocytes|pre-clinical data suggest that ccr2 , and mcp-1 , are upregulated in cells , such as macrophages , microglial cells and entity which play a central role in the origination of pain signals .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|astrocytes labeled degeneration neurons express|them surgeons resources researchers clinicians|astrocytes|customers frequently request entity to build a more complete human neurological model .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|astrocytes labeled degeneration neurons express|synapses neurons dendrites axons neurites|astrocytes|anavex 3-71 demonstrated the formation of new synapses between neurons ( synaptogenesis ) without causing an abnormal increase in the number of entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|astrocytes labeled degeneration neurons express|neurons astrocytes microglia macrophages oligodendrocytes|astrocytes|the effect of iw-6463 was studied in rat brain 3d microtissues , a 3d cell model containing a mix of neurons , entity , microglial cells and oligodendrocytes .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|astrocytes labeled degeneration neurons express|nscs nsc astrocytes npcs microglia|astrocytes|clr1501 uptake was visualized with confocal microscopy and compared to matched sergbm , normal human entity , and human nscs .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|cell|astrocytes labeled degeneration neurons express|glioblastoma gliomas astrocytes astrocytomas tumours|astrocytes|glioblastoma are tumors that arise from entity , which are star-shaped cells making up the supportive tissue of the brain .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|astrocytes labeled degeneration neurons express|neurons oligodendrocytes astrocytes microglia macrophages|astrocytes|q-cells produce entity and oligodendrocytes , the support cells that enable the normal function of neurons .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|astrocytes labeled degeneration neurons express|unlike among within while although|astrocytes|entity cells found in the brain that support neuronal function these cells are synergistic with icell neurons .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|astrocytes labeled degeneration neurons express|neurons astrocytes microglia macrophages oligodendrocytes|astrocytes|aß peptides are derived from the amyloid precursor protein , or app , an integral membrane protein , in neurons and entity in the brain .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|preadip adipocytes characterized proliferation adipogenesis|macrophages fibroblasts monocytes pericytes leukocytes|preadipocytes|in contrast , svf is merely a heterogeneous fraction including entity , endothelial cells , smooth muscle cells , pericytes , macrophages , fibroblasts , and adipose-derived stem cells .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|preadip adipocytes characterized proliferation adipogenesis|macrophages fibroblasts monocytes pericytes leukocytes|preadipocytes|in contrast , svf is merely a heterogeneous fraction including entity , endothelial cells , smooth muscle cells , pericytes , macrophages , fibroblasts and adipose-derived stem cells .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|cell|preadip adipocytes characterized proliferation adipogenesis|adipocytes preadip l1 3t3 myotubes|preadipocytes|a paper entitled “chromium picolinate depressed proliferation and differentiation of 3t3-l1 entity” was published in nutrition research .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2), ('DRUG', 1)])|cell|osteoblasts characterized upon epithelial oste|osteoclasts osteoblasts macrophages osteoclast osteoclastogenesis|osteoblasts|only a portion of the bone remodeling process : they either block bone breakdown by osteoclasts or stimulate bone formation by entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1), ('DIS', 1)])|cell|osteoblasts characterized upon epithelial oste|osteoclasts osteoblasts macrophages osteoclast osteoblast|osteoblasts|small areas of bone are constantly being broken down by special cells called osteoclasts , then made again by cells called entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|osteoblasts characterized upon epithelial oste|except now searching looking here|osteoblasts|entity for osteoporosis and non-union bone fractures we have made osteoblasts from hescs and are now conducting preclinical tests in animals .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|osteoblasts characterized upon epithelial oste|osteoclasts osteoblasts macrophages platelets monocytes|osteoblasts|n / a ( generic ) ​ in osteoporosis patients , who have normal basal levels of pth , therapeutic administration of pth activates osteoclasts and entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|osteoblasts characterized upon epithelial oste|bones osteoclasts complexes osteoblasts plates|osteoblasts|it has a potent anabolic effect on bone tissues , stimulating the formation and maturation of bone-forming entity which in turn causes significant increases in new bone formation .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|osteoblasts characterized upon epithelial oste|osteoclasts osteoblasts macrophages osteoclast platelets|osteoblasts|k , arris and its partner believe that a new drug may be able to re-balance the activity of osteoclasts and entity and arrest the bone-destroying effects of osteoporosis .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|cell|osteoblasts characterized upon epithelial oste|osteoblasts osteoclasts osteocalcin osteoblast osteoclastogenesis|osteoblasts|intravenously administered antibody that is designed to inhibit sclerostin , a protein that inhibits the activity of bone-forming cells , known as entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|osteoblasts characterized upon epithelial oste|they osteoblasts osteoclasts macrophages platelets|osteoblasts|while both types of cells are activated when pth is administered , entity are activated to a greater extent , increasing net bone formation and bone mass .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|osteoblasts characterized upon epithelial oste|biomarkers adjuvants biocompatibility scaffolds biomaterials|osteoblasts|current work focuses on confirming their characteristics as entity , improving cell yields , testing function in vitro and then testing the cells in animals .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|cell|osteoblasts characterized upon epithelial oste|hescs mscs msc embryos hesc|osteoblasts|we intend to infuse entity derived from hescs to treat osteoporosis .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|osteoblasts characterized upon epithelial oste|osteoclasts osteoclast osteoblasts osteoblast osteoblastic|osteoblasts|bone loss ( mediated by osteoclasts  cells which resorb bone ) that is incompletely compensated by new bone formation ( mediated by entity  cells which form new bone ) .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|osteoblasts characterized upon epithelial oste|adolescence childhood adulthood adults puberty|osteoblasts|because osteosarcoma usually develops from entity , it most commonly affects children and young adults experiencing their adolescent growth spurt .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|osteoblasts characterized upon epithelial oste|approximately nearly almost roughly fewer|osteoblasts|while both types of cells are activated when pth is administered , entity 92 table of contents are activated for a longer period , increasing bone formation and bone mass .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|osteoblasts characterized upon epithelial oste|osteoclasts resorption osteoclast osteoblasts osteoclastogenesis|osteoblasts|cells called entity cause new bone formation while other cells called osteoclasts remove old bone through a process called resorption .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|osteoblasts characterized upon epithelial oste|osteoclasts mscs osteoblasts bmc mcs|osteoblasts|the condition is the stimulation of a population of normal bone cells ( osteoclasts ) relative to another population of bone cells ( entity ) .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|osteoblasts characterized upon epithelial oste|adolescence childhood adulthood puberty adults|osteoblasts|because osteosarcoma usually develops from entity , it most commonly develops in teenagers who are experiencing their adolescent growth spurt .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|cell|osteoblasts characterized upon epithelial oste|osteoblasts osteoclasts macrophages mscs fibroblasts|osteoblasts|forteo ( marketed as forsteo in europe ) builds bone primarily by increasing the activity of entity ( cells that deposit bone ) .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|osteoblasts characterized upon epithelial oste|they osteoblasts osteoclasts hence thereby|osteoblasts|osteoclasts mediate destruction of bone and entity are responsible for bone growth and mineral production .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1), ('DIS', 1)])|cell|osteoblasts characterized upon epithelial oste|osteoclasts osteoblasts osteoclast macrophages osteoblast|osteoblasts|bone loss ( mediated by osteoclasts -- cells which resorb bone ) that is incompletely compensated by new bone formation ( mediated by entity -- cells which form new bone ) .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('BIO', 4), ('DRUG', 3), ('OTHER', 2), ('DIS', 1)])|cell|osteoblasts characterized upon epithelial oste|osteoclasts osteoblasts cytokines macrophages chemokines|osteoblasts|normal functioning of bone depends on osteoclasts and entity acting in concert .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|erythro leukemia fibroblasts chondrosarcoma cultures|than immature lymphocytes adults neurons|erythroblasts|b , which are more immature entity .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|erythro leukemia fibroblasts chondrosarcoma cultures|lymphocytes macrophages monocytes fibroblasts platelets|erythroblasts|it is well-known that fetal cells , including trophoblasts , lymphocytes and entity , circulate in the peripheral blood of pregnant women , in some cases as early as five weeks gestation .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4)])|cell|erythro leukemia fibroblasts chondrosarcoma cultures|ery erythrocytes rbc hepatocytes rbcs|erythroblasts|c , which is the population of mature entity , in comparison to ery .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 1)])|cell|erythro leukemia fibroblasts chondrosarcoma cultures|platelets rbcs erythrocytes lymphocytes granulocytes|erythroblasts|reactivation of hbf occurs in immature rbcs , known as entity and reticulocytes .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|erythro leukemia fibroblasts chondrosarcoma cultures|lymphocytes macrophages monocytes fibroblasts platelets|erythroblasts|it is well-known that fetal cells , including trophoblasts , lymphocytes , and entity , circulate in the peripheral blood of pregnant women , in some cases as early as five weeks gestation .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|adverse beneficial detrimental cytotoxic vaccine|transitional|the initial application of ifrs 9 at january 1 , 2018 has resulted in no significant entity effects for immunic .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|collection regulation cultivation policy marketing|transitional|after the expiry of any applicable entity period , only ivds that have been ce marked under the ivd regulation may be placed on the market in the
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|existing national private social public|transitional|as per the benefit arrangement contemplated by the entity services agreement , the existing stock shall be delivered to purchaser exw - incoterms 2010 , delivery in monheim or other sellers
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|cognitive hearing neuropsychological renal neurological|transitional|the provisions of sfas 142 require that a entity impairment test be performed as of the beginning of the year the statement is adopted .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|transitional squamous centre zone carcinoma|transitional spindle squamous renal giant|transitional|entity cell carcinoma of the bladder frequently occurs in adolescents with costello syndrome , a presentation that is rare in the general
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|median national summary international economic|transitional|“entity costs” shall mean all costs incurred by seller that are identified in exhibit “j” .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|uk see online australian randomized|transitional|entity small business disclosure format ( check one ) :
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|consumer pharmaceutical pharmacy market company|transitional|will also pay bms for any required product supply at a price approximating the product cost as well as negotiated entity service fees .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|mark original name final regular|transitional|( ii ) and section 2 . 2 , in no event shall aetna use or permit any affiliate to use any mark or the entity mark
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|usual least minimum original optimal|transitional|we elected to use the entity practical expedient allowing the standard to be applied only to contracts that were previously identified as leases under ias 17
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|legal federal statistical international national|transitional|retrospectively from january 1 , 2019 , but has not restated comparatives for the 2018 reporting period , as permitted under the specific entity provisions in the standard .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|shared service necessary transaction national|transitional|and the buyer are expected to enter into related transaction agreements at the closing of the proposed transaction , including a entity services agreement .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|financial publication profit legal funding|transitional|respect to any grant ( including the grant made on the effective date ) a-3 to secure the benefit of any applicable entity rule promulgated under section 409a of the code .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|entire national existing planning medicare|transitional|internal costs and out-of-pocket expenses shall not exceed the corresponding agreed to budget for such services set forth in the entity service plan .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|financial economic reimbursement educational legal|transitional|the entity requirements of sfas 148 are effective for all financial statements for fiscal years ending after december 15 , 2002 .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|decision guidance safety computer search|transitional|we elected the optional entity guidance under asc 842 that allowed the initial recognition of the operating right-of-use assets and the corresponding lease liabilities as
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|tax financial economic income highest|transitional|the entity impact was finalized during the fiscal year ended june 30 , 2019 , with no significant impact on income tax expense .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|organic special legal practical mental|transitional|acquisition by cytyc corporation , a diagnostic and medical device company , he served as a consultant to cytyc to assist with entity matters from 2001 to 2002 .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|uk see online australian randomized|transitional|entity small business disclosure format ( check one ) :
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|transitional squamous centre zone carcinoma|statistical decision into criteria simulation|transitional|we adopted these changes using the prospective application entity alternative in accordance with the entity provisions of cica handbook section 3870 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|oocytes matured fertilization fertilized cumulus|hscs rbcs ucb blastocysts oocytes|oocytes|we anticipate that in the unites states cryopreservation of entity will be regulated similarly to viacords family umbilical cord blood cryopreservation product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|oocytes matured fertilization fertilized cumulus|follicles oocytes organs eggs embryos|oocytes|if successful , the ovature treatment could reduce , or possibly eliminate , the need for hormonal hyperstimulation for the maturation of multiple entity prior to egg retrieval in the ivf process .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|oocytes matured fertilization fertilized cumulus|them fertility themselves consent women|oocytes|with a number of in vitro fertility clinics in the southern california region enrolling individuals who are willing to donate entity for research purposes in order to create new hpsc lines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|oocytes matured fertilization fertilized cumulus|oocytes embryos blastocysts spermatozoa hepatocytes|oocytes|media supplier will be required to obtain 510 ( k ) clearance for the technology we have licensed for use in the cryopreservation of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|oocytes matured fertilization fertilized cumulus|needs remains seems appear appears|oocytes|“raw material” means conforming rana pipiens entity to be supplied to spl by alfacell .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|oocytes matured fertilization fertilized cumulus|embryos embryo oocytes ovary organs|oocytes|cancer research technology limited rnai uses in mammalian entity , preimplantation embryos and somatic cells ( ep only : wherein the rnai compound is at least 25 base pairs ) 11 / 19 / 1999
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|oocytes matured fertilization fertilized cumulus|fibroblasts embryos embryo cdna technology|oocytes|which includes the production of human differentiated cells from stem cells and involves the use of nuclear transfer technology , human entity , and embryonic material .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|oocytes matured fertilization fertilized cumulus|ivf them consent oocytes fertility|oocytes|a number of in vitro fertility ( “ivf” ) clinics in the southern california region enrolling individuals who are willing to donate entity for research purposes in order to create new hpsc lines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|oocytes matured fertilization fertilized cumulus|embryos oocytes blastocysts eggs fibroblasts|oocytes|the first patent covers the use of fertilized human entity for the creation of human embryonic stem cell lines , and was issued in great britain .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|oocytes matured fertilization fertilized cumulus|fertility reproduction infertility fertilization longevity|oocytes|another opportunity in the use of cells for therapy relates to entity , which are female egg cells essential to reproduction .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|oocytes matured fertilization fertilized cumulus|leukocytes donors sera milk urine|oocytes|of health information we obtain from research collaborators or from providers who enroll patients and collect cord blood or human entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|oocytes matured fertilization fertilized cumulus|them ivf consent themselves candidates|oocytes|a number of in vitro fertility ( ivf ) clinics in the southern california region enrolling individuals who are willing to donate entity for research purposes in order to create new hpsc lines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|oocytes matured fertilization fertilized cumulus|eggs oocytes embryos females hens|oocytes|iscos core technology , parthenogenesis , results in the creation of pluripotent human stem cells from unfertilized entity ( eggs ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|cell|oocytes matured fertilization fertilized cumulus|transplantation fibroblasts mscs tumours transplants|oocytes|is focused on human cell therapy , which includes the production of human differentiated cells from stem cells and involves human entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|oocytes matured fertilization fertilized cumulus|eggs oocytes embryos ovaries testes|oocytes|viacyte , a product expected to offer women the ability to preserve or extend their fertility through the cryopreservation of their entity ( eggs ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|cell|oocytes matured fertilization fertilized cumulus|transplantation fibroblasts mscs tumours transplants|oocytes|are focused on human cell therapy , which includes the production of human differentiated cells from stem cells and involves human entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 3), ('OTHER', 3)])|cell|oocytes matured fertilization fertilized cumulus|beings embryos spermatozoa lymphocytes fibroblasts|oocytes|the second and third patents , both covering parthenogenetic activation of human entity , were 47 table of contents issued in japan and korea .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|cell|oocytes matured fertilization fertilized cumulus|ova oocytes blastocysts mscs dcs|oocytes|for ovature , ovascience was exploring different subculture systems that allow for even further maturation of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|oocytes matured fertilization fertilized cumulus|embryos oocytes eggs females follicles|oocytes|although our focus is on stem cells derived from unfertilized entity , certain aspects of that work may involve the use of nuclear transfer technology or material deemed to be embryonic material .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|oocytes matured fertilization fertilized cumulus|embryos oocytes eggs females gametes|oocytes|although our focus is on parthenogenetic stem cells derived from unfertilized entity , certain aspects of that work may involve the use of embryonic stem cells .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DRUG', 1)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|mscs fibroblasts platelets hscs epcs|chondrocytes|autologous cultured entity ( " carticel ( tm ) aucc " ) .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|suitable responsible reserved while whereas|chondrocytes|chnd1 : entity for cartilage disorders and degenerative disc disease articular cartilage is the shock absorber for joints .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DRUG', 1)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|cultured seeded grown fibroblasts mscs|chondrocytes|maci® ( autologous cultured entity on porcine collagen membrane ) is an autologous cellularized scaffold product indicated for the repair of symptomatic , single or multiple full-thickness
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|cartilage chondrocytes mscs chondrocyte osteoarthritis|chondrocytes|use of hystem® hydrogels with purestem™ progenitors resulting in a combined product that produces cartilage- producing cell masses known as entity .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|payment insurance costs issues claims|chondrocytes|some third party payers , however , do not cover carticel entity .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|registration makers workers sharing ups|chondrocytes|the commercial success of carticel-registered trademark- entity will depend on many factors , including the following : - positive results from post-marketing studies .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|grafts flaps allografts wounds devices|chondrocytes|compared to the same period a year ago due primarily to decreased shipments of both epicel skin grafts and carticel entity during the three months ended march 31 , 2002 .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|sharing cards spending orders outs|chondrocytes|some third-party payers , however , do not cover carticel-registered trademark- entity .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('BIO', 4), ('OTHER', 3)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|chondrocytes fibroblasts cartilage matrices proteoglycans|chondrocytes|preclinical studies have shown that entity embedded in bst-gel ( tm ) produce a matrix having the characteristics of normal cartilage tissue .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|registered registration cards records board|chondrocytes|genzyme biosurgery has developed a device to improve the procedure for implanting carticel-registered trademark- entity and has filed for marketing approval with the fda .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|fibroblasts mscs chondrocytes bmscs lymphocytes|chondrocytes|as reported in this article , 19 of 23 patients had restored or improved joint function after treatment with cultured autologous entity .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|approval medicines guidelines fda trial|chondrocytes|since the fda approved carticel entity , genzyme has seen a substantial increase in the number of third party payers who cover it .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|autologous mscs marrow cartilage grafts|chondrocytes|gtr is aware of at least one other company that is culturing autologous entity for cartilage repair in europe .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|anesthesia terminology category decomposition dai|chondrocytes|there are two type of entity , “articular” and “growth plate” .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|cartilage chondrocytes joints surfaces osteoclasts|chondrocytes|articular entity are responsible for cartilage that lines our joints , whereas growth plate entity are involved with new bone formation .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|workers physicians registered cards registration|chondrocytes|the increase in sales of carticel-registered trademark- entity was a result of continued increases in the numbers of patients treated and surgeons trained as well as an increase
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|hscs platelets mscs marrow progenitors|chondrocytes|the process used by gtr to grow autologous entity is not patentable , and gtr does not yet have significant patent protection covering the other methodologies used in providing carticel ( tm )
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|sharing sponsored board outs wide|chondrocytes|since the fda approved carticel-registered trademark- entity , genzyme has seen a substantial increase in the number of third-party payers who cover it .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DRUG', 2)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|mscs cytokines biomaterials materials chondrocytes|chondrocytes|solid tissue cell therapies one of the newest areas of cell therapy involves the production of entity for the restoration of cartilage .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('BIO', 3), ('OTHER', 3)])|cell|chondrocytes cartilage characterized synthesized fibroblasts|cartilage chondrocytes proteoglycan chondrocyte mrna|chondrocytes|chondrocyte therapy involves the surgical removal of a small amount of tissue from the patient  s knee and a therapeutic quantity of entity is produced from this surgical biopsy .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 2)])|cell|fibrosis epithelial myofibroblasts fibroblasts stellate|myofibroblasts macrophages fibroblasts adipocytes cardiomyocytes|myofibroblasts|tgf-b is a cytokine that is a key driver of fibrosis and acts by activating fibroblasts into entity , which in turn drives the production of fibrotic tissues .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|fibrosis epithelial myofibroblasts fibroblasts stellate|endothelial vessels macrophages endothelium fibroblasts|myofibroblasts|in a sampling of approximately 200 tumors , epha2 was found to be expressed in tumor cells , entity and / or tumor-associated blood vessels .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|fibrosis epithelial myofibroblasts fibroblasts stellate|macrophages fibroblasts keratinocytes myofibroblasts monocytes|myofibroblasts|fezagepras has been observed to regulate several cell types involved in the fibrotic pathway : macrophages , fibroblasts / entity and epithelial cells .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|fibrosis epithelial myofibroblasts fibroblasts stellate|hydroxyproline collagens elastin glycosaminoglycans collagenase|myofibroblasts|the number of entity and hydroxyproline ( i . e . , collagen ) content was also significantly reduced in both organs .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|cell|fibrosis epithelial myofibroblasts fibroblasts stellate|hscs mscs myofibroblasts macrophages fibroblasts|myofibroblasts|moreover , ehp-101 has been shown to inhibit the tgfβ-associated differentiation of cells ( called entity ) that are responsible for fibrosis .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 1), ('DRUG', 1), ('DIS', 1)])|cell|fibrosis epithelial myofibroblasts fibroblasts stellate|macrophages monocytes neutrophils lymphocytes fibroblasts|myofibroblasts|vla-1 is found on a variety of cells associated with tissue inflammation and fibrosis , including activated t-cells , macrophages and entity .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|fibrosis epithelial myofibroblasts fibroblasts stellate|ecm fibroblasts proteoglycans collagens fibronectin|myofibroblasts|ctgf increases the abundance of entity , a cell type that drives wound healing , and stimulates them to deposit ecm proteins such as collagen at the site of tissue injury .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 1)])|cell|fibrosis epithelial myofibroblasts fibroblasts stellate|lymphocytes leukocytes neutrophils fibroblasts fibrin|myofibroblasts|in the skin , it has been shown to reduce scar formation by reduction of infiltration of entity .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('DRUG', 2), ('OTHER', 2), ('DIS', 1)])|cell|fibrosis epithelial myofibroblasts fibroblasts stellate|mscs vsmcs fibroblasts macrophages chondrocytes|myofibroblasts| anti-fibrosiscysteamine blocks tgf-ß signaling and thereby inhibits the production and proliferation of entity .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 3), ('DRUG', 1)])|cell|fibrosis epithelial myofibroblasts fibroblasts stellate|ecm fibroblasts myofibroblasts mmps chondrocytes|myofibroblasts|constant myofiber breakdown results in persistent activation of entity and altered production of ecm resulting in extensive fibrosis in skeletal muscles of dmd patients .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|cell|fibrosis epithelial myofibroblasts fibroblasts stellate|ctgf ecm mmps myofibroblasts hscs|myofibroblasts|in fibrotic conditions , excess ctgf results in chronic activation of entity , which leads to chronic ecm deposition and fibrosis ( see figure above ) .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|cell|fibrosis epithelial myofibroblasts fibroblasts stellate|smooth adipocytes endothelial proliferating epithelial|myofibroblasts|anti-tshr antibodies also increase the proliferation of adipose or fat cells as well as entity , smooth muscle-like cells .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('DRUG', 2), ('DIS', 2), ('OTHER', 2)])|cell|fibrosis epithelial myofibroblasts fibroblasts stellate|myofibroblasts fibroblasts macrophages adipocytes hepatocytes|myofibroblasts|tgf-b is a cytokine that is a key driver of fibrosis and acts by activating fibroblasts into entity , which in turn drives the production of fibrotic connecting tissues .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('BIO', 1)])|cell|fibrosis epithelial myofibroblasts fibroblasts stellate|inhibitors cardiomyocytes enzymes catecholamines cholesterol|myofibroblasts|research programs involving cell-based approaches to restoring cardiac function and a research program involving a gene therapy approach to converting entity into cardiac muscle .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|cell|fibrosis epithelial myofibroblasts fibroblasts stellate|they fibroblasts wounds platelets neurons|myofibroblasts|in the case of normal healing of a limited tissue injury , entity eventually die by programmed cell death , or apoptosis , and the fibrous scarring process recedes .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 3), ('DRUG', 2), ('DIS', 1)])|cell|fibrosis epithelial myofibroblasts fibroblasts stellate|elastin fibroblasts proteoglycans macrophages mmps|myofibroblasts|fibrosis is the formation of excess connective tissue ( collagen and other proteins plus cellular elements such as entity ) in response to damage , inflammation or repair .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('BIO', 3), ('DRUG', 3), ('OTHER', 2), ('DIS', 1)])|cell|fibrosis epithelial myofibroblasts fibroblasts stellate|macrophages cytokines mmps hscs neutrophils|myofibroblasts|additionally supported by the anti-inflammatory effects , including downregulation of tnf and il-6 , that can reduce the proliferation and activation of entity in the liver .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DRUG', 2), ('DIS', 1)])|cell|upon adipocytes express characterized secrete|mscs ascs dcs lcs adipocytes|adipocytes|the ultrashape system targets and selectively destroys fat cells ( entity ) , leaving critical surrounding structures such as blood vessels , nerves and connective tissue unharmed .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|upon adipocytes express characterized secrete|endothelium capillaries capillary endothelial vessels|adipocytes|in addition , the fraction also contains blood cells from the capillaries supplying the entity and the extracellular matrix .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 4), ('DRUG', 2), ('DIS', 2), ('OTHER', 2)])|cell|upon adipocytes express characterized secrete|precursors hepatocytes adipocytes lymphocytes macrophages|adipocytes|in non-cancerous tissues , it is predominantly found at low levels on entity , or fat cells , and briefly on precursors to b-cells , or pre-b-cells , during normal b-cell maturation .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('DRUG', 3), ('BIO', 3), ('OTHER', 3)])|cell|upon adipocytes express characterized secrete|pancreatic adipocytes macrophages acinar adipose|adipocytes|vitro studies have shown that activation of the beta-3 adrenergic receptor in the colon causes the release of somatostatin from entity , or fat cells , which causes pain relief .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('DRUG', 1), ('DIS', 1), ('OTHER', 1)])|cell|upon adipocytes express characterized secrete|fibroblasts lymphocytes platelets chondrocytes macrophages|adipocytes|antibodies form against the thyroid-stimulating hormone receptor , or tshr , which is present in the thyroid and other cells such as entity and fibroblasts .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('DRUG', 1), ('DIS', 1), ('OTHER', 1)])|cell|upon adipocytes express characterized secrete|macrophages cartilage fibroblasts lymphocytes leukocytes|adipocytes|this attenuation by protein-rich tissue results in the preferential destruction of entity by atx-101 .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|upon adipocytes express characterized secrete|epithelial cartilage epidermal fibrous dermal|adipocytes|mechanism of action atx-101 is designed to be a locally-injected drug that causes proximal , preferential destruction of entity , or fat cells , with minimal effect on surrounding tissue .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|upon adipocytes express characterized secrete|vivo plants yeast humans hepatocytes|adipocytes|believe that rnai could potentially be a reliable method to selectively inhibit certain genes and their corresponding protein expression in entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('DRUG', 3), ('DIS', 2), ('OTHER', 2)])|cell|upon adipocytes express characterized secrete|adipocytes hepatocytes fibroblasts mscs macrophages|adipocytes|the research is focused on using cultured entity ( fat cells ) as a model system for studying the regulation of gene expression involved in adipocyte differentiation and function .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|upon adipocytes express characterized secrete|vivo rats humans neurons tumours|adipocytes|rnai delivery for therapeutic gene silencing in cells and animals ; and  inhibition of gene expression in entity using rnai .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 2), ('DIS', 2)])|cell|upon adipocytes express characterized secrete|progenitors precursors adipocytes fibroblasts macrophages|adipocytes|initial product development plans include : pluripotent stem cell-derived brown entity ( agex-bat1 ) ; vascular progenitors ( agex-vasc1 ) ; and induced tissue regeneration ( itr ) .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|upon adipocytes express characterized secrete|macrophages monocytes neutrophils leukocytes macrophage|adipocytes|the destruction of entity , or adipocytolysis , elicits a natural response in which macrophages are attracted to remove cellular debris and fat particles through the
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 2), ('BIO', 1)])|cell|upon adipocytes express characterized secrete|adipocytes pancreas pad nodules lean|adipocytes|in addition , msi-1436 was shown to reduce the size of entity , reduce body fat with no reduction of lean mass , and improve glucose tolerance via inhibition of a unique combination of
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|cell|upon adipocytes express characterized secrete|msc mscs wt pcs sat|adipocytes|cells obtained from the blood vessels in the lipoaspirate from the small volume of fat harvested , minus the fat cells ( entity ) and non-cellular material .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|upon adipocytes express characterized secrete|partly osteoblasts once neurons nuclei|adipocytes|by the presence and absence of particular biological markers , and the ability of the cell to differentiate into at least entity , osteocytes , endothelial cells and smooth muscle cells .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|upon adipocytes express characterized secrete|fibroblasts astrocytes chondrocytes macrophages neurons|adipocytes|these antibodies activate certain cell types , such as fibroblasts and entity , present in the extraocular space , which are known to highly express tshr .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('DRUG', 3), ('DIS', 2), ('OTHER', 2)])|cell|upon adipocytes express characterized secrete|adipocytes macrophages mscs hepatocytes fibroblasts|adipocytes|namodenoson was also shown to inhibit the proliferation of entity , further hampering the expansion of fat producing cells .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4)])|cell|upon adipocytes express characterized secrete|hepatocytes neurons myocytes cardiomyocytes fibroblasts|adipocytes|metabolic benefits of the lancl2 signaling axis are observed in hepatocytes , entity and myocytes through uptake and oxidation of glucose to improve the systemic glucose homeostasis .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|upon adipocytes express characterized secrete|sirna cardiomyocytes rats liposomes hepatocytes|adipocytes|pending delivery of sirna into entity for treatment of diabetes and obesity michael p . czech qiong l . zhou zhen y . jiang 12 / 11 / 2002 exclusive
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 2)])|cell|upon adipocytes express characterized secrete|liposarcoma lipoma tumours leiomyosarcoma neoplasm|adipocytes|liposarcomas arise by malignant transformation of entity , not necessarily entity from within a lipoma .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|hemangi carcinoma tumour malignant epithelioid|they hscs there mscs platelets|hemangioblasts|entity are a newly-characterized stem cell capable of differentiating into both hematopoietic , meaning blood cell-forming , and angiogenic , meaning blood vessel endothelium-forming ,
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DRUG', 1)])|cell|hemangi carcinoma tumour malignant epithelioid|mscs hscs they fibroblasts epcs|hemangioblasts|entity are a newly-characterized stem cell capable of differentiating into both hematopoietic ( blood cell forming ) and angiogenic ( blood vessel endothelium forming )
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|hemangi carcinoma tumour malignant epithelioid|precursors antigens embryos placenta fibroblasts|hemangioblasts|no . 6 , 338 , 942 selective expansion of target cell populations 5 / 19 / 2015 us patent no . 6 , 429 , 012 cell population containing non-fetal entity and method for producing same
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|cell|hemangi carcinoma tumour malignant epithelioid|platelets hscs mscs they macrophages|hemangioblasts|entity are a newly-characterized stem cell capable of differentiating into both hematopoietic , meaning blood cell forming , and angiogenic , meaning blood vessel
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|hemangi carcinoma tumour malignant epithelioid|placenta embryos precursors antigens fibroblasts|hemangioblasts|no . 6 , 338 , 942 selective expansion of target cell populations 10 / 7 / 2014 us patent no . 6 , 429 , 012 cell population containing non-fetal entity and method for producing same
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|hemangi carcinoma tumour malignant epithelioid|rpe retinal endothelial dermal fibroblasts|hemangioblasts|development of its rpe cells for conditions involving retinal degeneration · act is evaluating research and development programs for esc-derived entity and dermal regeneration .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|hemangi carcinoma tumour malignant epithelioid|embryos fibroblasts oocytes placenta fetuses|hemangioblasts|this patent broadly covers the derivation and growth of human entity from a non-fetal source .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|precursors erythro cultures immature cultured|platelets lymphocytes erythrocytes fibroblasts macrophages|myeloblasts|acute myeloid leukemia aml is a type of cancer in which the bone marrow makes abnormal entity ( a type of white blood cell ) , red blood cells or platelets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 2), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|cell|precursors erythro cultures immature cultured|cellularity lymphocytes dysplasia macrophages necrosis|myeloblasts|comprises normalizing peripheral blood counts , resolution of bone marrow dysplasia and reduction in the percentage of immature blood cells , or entity , to less than 5% .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 3), ('OTHER', 3)])|cell|precursors erythro cultures immature cultured|lymphocytes progenitors fibroblasts genes platelets|myeloblasts|leukemia aml is a rapidly progressing cancer of the blood and bone marrow characterized by the uncontrolled proliferation of dysfunctional entity that do not mature into healthy blood cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1), ('DIS', 1)])|cell|precursors erythro cultures immature cultured|mscs cscs progenitors oligodendrocytes astrocytes|myeloblasts|which both failure to differentiate and excessive proliferation in the stem cell compartment result in accumulation of non-functional cells termed entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|cell|precursors erythro cultures immature cultured|platelets megakaryocytes granulocytes blasts lymphocytes|myeloblasts|the myeloid cells are predominantly immature platelet cells called entity , or blasts , which are the leukemia cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cell|precursors erythro cultures immature cultured|aml hcc nsclc gbm crc|myeloblasts|this suggests that differentiation of entity  made possible by inhibition of mutated idh2  may drive the clinical efficacy of enasidenib .  targeting idh mutations is
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1), ('DIS', 1)])|cell|precursors erythro cultures immature cultured|monocytes myeloid hematopoietic macrophages endothelial|myeloblasts|the gm-csf receptor is expressed on entity and other progenitor cells , and binding results in differentiation and maturation into monocytes .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 3), ('OTHER', 3)])|cell|precursors erythro cultures immature cultured|lymphocytes fibroblasts progenitors platelets genes|myeloblasts|aml is a rapidly progressing cancer of the blood and bone marrow characterized by the uncontrolled proliferation of dysfunctional entity that do not mature into healthy blood cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|cell|precursors erythro cultures immature cultured|lymphocytes monocytes macrophages megakaryocytes blasts|myeloblasts|immature white blood cells known as entity , or blasts proliferate in the bone marrow rather than mature into normal blood cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|cell|precursors erythro cultures immature cultured|platelets lymphocytes blasts hematopoiesis macrophages|myeloblasts|acute myeloid leukemia market • bone marrow makes abnormal entity ( a type of white blood cell ) , red blood cells , or platelets • if left untreated , aml progresses rapidly to death
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('BIO', 2), ('OTHER', 2), ('DIS', 2)])|cell|precursors erythro cultures immature cultured|cytokines erythropoietin macrophages interferon chemokines|myeloblasts|acute leukemia or blood cancer that results from the improper maturation of myeloid stem cells leading to the production of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|cell|precursors erythro cultures immature cultured|blasts lymphocytes numbers progenitors nuclei|myeloblasts|blast ( % ) refers to the percentage of leukemic entity , or blood cells affected by disease , compared to all blood cells in the sample .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|cell|precursors erythro cultures immature cultured|lymphocytes leukocytes count counts coagulation|myeloblasts|from this trial show that patients with relapsed , refractory acute myeloid leukemia , or aml , experienced a decrease in peripheral blood entity , a measure of clinical activity .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 4), ('OTHER', 3)])|cell|precursors erythro cultures immature cultured|platelets lymphocytes erythrocytes hematopoiesis fibroblasts|myeloblasts|aml is a type of cancer in which the bone marrow makes abnormal entity , a type of white blood cell , red blood cells or platelets .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|erythro cultured membranes proliferation erythrocytes|necrosis apoptosis proliferation staining mitosis|proerythroblasts|on stained slides the cells had the features of entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|cell|erythro cultured membranes proliferation erythrocytes|erythroid progenitors granulocytes hscs precursors|proerythroblasts|increase in overall numbers of entity in mice the rapid expansion of the pro-e population also coincided with decreased numbers of erythroid burst-forming units and erythroid
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|interneurons pyramidal labeled gabaergic neurons|neurons interneurons synapses neurones terminals|interneurons|specifically , inhibitory gabaergic entity are susceptible to excessive excitatory amino acid release .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|interneurons pyramidal labeled gabaergic neurons|neurons nerves nerve interneurons terminals|interneurons|this loss of nav1 . 1 channels in inhibitory entity and other nerve cells results in dravet syndrome .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 3), ('BIO', 3)])|cell|myotubes express myoblasts upon synthesize|fibroblasts myotubes dystrophin myoblasts muscles|myotubes|in non-clinical studies with human entity grown from 35 different nmdmd patients , ataluren also exhibited a bell-shaped dose-response curve with maximal dystrophin staining observed at 10
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|myotubes express myoblasts upon synthesize|comparing along muscles mutants rats|myotubes|force increased exon skipping in human dmd entity with exon 51 mutation *** p < 0 . 001 in studies in the mdx mouse dmd model , a validated and
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|myotubes express myoblasts upon synthesize|mrna mrnas transcripts rnas cdna|myotubes|we used rna-sequence ( rna-seq ) analysis of the entity from dm1 patients to create a splice score for control human subjects cells treated with sidmpk . 19 or the inactive sirna , sidmpk . 29 .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|myotubes express myoblasts upon synthesize|mutants neurons brains embryos hearts|myotubes|mock treated dm1 entity ( open black diamonds ) show the full splice derangement .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|myotubes express myoblasts upon synthesize|records charts demographics histories files|myotubes|when patient entity were analyzed , there was a marked improvement in the splice score of the entity treated with the sidmpk . 19 compared to the inactive sidmpk . 29 ( see figure 11 below ) .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|myotubes express myoblasts upon synthesize|rats neurons embryos fibroblasts mutants|myotubes|as shown in the figure on the right below , we also observed reduced cell death , or apoptosis , in fshd entity , as measured by active caspase-3 .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 3)])|cell|myotubes express myoblasts upon synthesize|myotubes myoblasts myocytes fibroblasts muscles|myotubes|effect of ataluren on dystrophin staining scores in entity isolated from nmdmd mice myotubes from nmdmd patients .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 3), ('BIO', 3)])|cell|myotubes express myoblasts upon synthesize|fibroblasts myotubes myoblasts volunteers embryos|myotubes|able to sustain utrophin protein expression based on in vitro data generated in myoblast cells from dmd patients and human entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|myotubes express myoblasts upon synthesize|muscles fibres fibers myocytes neurons|myotubes|the proprietary compounds bio101 and bio103 on muscle cells in particular regarding protein syntheses and growth in the diameter of entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2)])|cell|myotubes express myoblasts upon synthesize|myotubes fibroblasts platelets myoblasts lymphocytes|myotubes|as depicted below , results from an in vitro study demonstrate that human entity are larger in muscle cells treated with sarconeos ( bio101 ) as compared to untreated control cells .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|myotubes express myoblasts upon synthesize|mrna transcripts genes mrnas transcript|myotubes|the splice signature approached that of control entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1), ('DIS', 1)])|cell|myotubes express myoblasts upon synthesize|fibroblasts xenografts mscs tumours hepatocytes|myotubes|the studies used gymnotic uptake , or no transfection reagents , in patient-derived entity ( in vitro ) .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|myotubes express myoblasts upon synthesize|rats neurons embryos fibroblasts cultures|myotubes|as shown in the figure on the right below , also observed reduced cell death , or apoptosis , in fshd entity , as measured by active caspase-3 .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 1), ('DRUG', 1)])|cell|myotubes express myoblasts upon synthesize|myotubes myoblasts adipocytes fibroblasts cardiomyocytes|myotubes|fgfs can also induce or inhibit differentiation in a variety of cell types ( e . g . of myoblasts into entity ) .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|myotubes express myoblasts upon synthesize|hcc crc vivo nsclc arabidopsis|myotubes|in the study , we demonstrated that mbd3l2 was representative of broader dux4-driven gene expression changes in entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|myotubes express myoblasts upon synthesize|sera cohorts specimens pbmcs cohort|myotubes|administration of our proprietary aso conjugated to a fab targeting tfr1 reduced expression of key dux4 biomarkers in fshd patient entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 3), ('BIO', 3)])|cell|myotubes express myoblasts upon synthesize|myoblasts fibroblasts myotubes myoblast cultured|myotubes|and 50% , respectively , based on our in vitro studies that were undertaken in myoblast cells from patients with dmd and entity from healthy individuals .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|myotubes express myoblasts upon synthesize|vivo macrophages fibroblasts hepatocytes astrocytes|myotubes|we used active caspase-3 to quantify cell death because it is a protein that has been shown to be an important regulator of the apoptosis pathway in entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|myotubes express myoblasts upon synthesize|sera pbmcs fibroblasts hepatocytes monocytes|myotubes|human entity when dosed with smt c1100 for 7 days demonstrated and increase of utrophin protein of around 50% when compared to
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cell|myotubes express myoblasts upon synthesize|myocardium ischemia infarct necrosis infarction|myotubes|the four hearts and in one heart diacrin noticed an increase in small vessel formation at the site of surviving entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('BIO', 1)])|cell|myoblasts express synthesize upon characterized|peptides albumin platelets cytokines radioactivity|myoblasts|we use a number of proprietary processes to create therapeutic quantities of entity from a patients thigh muscle biopsy .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('BIO', 3)])|cell|myoblasts express synthesize upon characterized|myoblasts they myotubes there fibroblasts|myoblasts|entity are precursors to muscle cells that have the capacity to fuse with other myoblasts or with damaged muscle fibers to regenerate skeletal muscle .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|myoblasts express synthesize upon characterized|muscles acids myoblasts fibroblasts bones|myoblasts|genvec , genzyme , and bioheart are all developing products consisting of skeletal entity isolated from muscle , expanded in culture , and injected into a patients heart to repair dead tissue .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 1)])|cell|myoblasts express synthesize upon characterized|platelets mscs leukocytes erythrocytes lymphocytes|myoblasts|bv , was previously awarded a manufacturing permit from the netherlands ministry of health for the in vitro culture of autologous entity for use as human medications .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|myoblasts express synthesize upon characterized|images recordings specimens sequences biopsies|myoblasts|by using entity obtained from a patients own body , we believe myocell is able to avoid certain challenges currently faced by other types
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|myoblasts express synthesize upon characterized|facilities them opportunities resources standards|myoblasts|in the capacity that we have at diacrin without stressing the facilities and continuing to also be able to produce entity for cardiac repair .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('BIO', 1)])|cell|myoblasts express synthesize upon characterized|peptides albumin platelets cytokines radioactivity|myoblasts|we use a number of proprietary processes to create therapeutic quantities of entity from a patients thigh muscle biopsy .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|myoblasts express synthesize upon characterized|actin them lipids polysaccharides toxin|myoblasts|at the cell culturing site , our proprietary techniques are used to isolate and remove entity from the muscle tissue .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|cell|myoblasts express synthesize upon characterized|mscs fibroblasts neurons macrophages bmscs|myoblasts|histopathology confirmed that entity expressing sdf-1a resulted in increased muscle and blood vessel formation in the damaged areas of the hearts , which was not
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|cell|myoblasts express synthesize upon characterized|they mscs fibroblasts platelets chondrocytes|myoblasts|when injected into scar tissue within the heart wall , entity have been shown to be capable of engrafting in the damaged tissue and differentiating into mature skeletal muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|myoblasts express synthesize upon characterized|devices catheters implants microspheres particles|myoblasts|after expansion , the entity are packaged and delivered to the clinical site for implantation into the injured heart tissue by a surgeon or interventional
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|myoblasts express synthesize upon characterized|muscles materials implants grafts substitutes|myoblasts|intellectual property in connection with products , processes or services developed or provided by genvec other than autologous and allogenic skeletal entity for cardiac therapy .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('BIO', 3)])|cell|myoblasts express synthesize upon characterized|myoblasts muscles genes fibroblasts myotubes|myoblasts|similarly , the fusion of entity with other entity is essential for the formation , growth , and regeneration of skeletal muscle .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 1)])|cell|myoblasts express synthesize upon characterized|fibroblasts mscs platelets neurons lymphocytes|myoblasts|for example , some of our competitors are exploring whether the use of cells , other than entity , is safer or more effective than myocell .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|cell|myoblasts express synthesize upon characterized|stents heparin implants sirolimus stent|myoblasts|implantation during coronary artery bypass graft ( cabg ) surgery may lead to similar effects , as do recent studies using percutaneous delivery of entity as a stand-alone procedure .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|myoblasts express synthesize upon characterized|myotubes myoblasts fibroblasts cardiomyocytes myocytes|myoblasts|ctgf treatment of entity induced their de-differentiation , or failure to become mature muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|myoblasts express synthesize upon characterized|images recordings specimens sequences biopsies|myoblasts|by using entity obtained from a patients own body , we believe myocell is able to avoid certain challenges currently faced by other types
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|cell|myoblasts express synthesize upon characterized|fibroblasts mscs myoblasts myotubes adipocytes|myoblasts| wve-n531 induced a dose-dependent increase in dystrophin production ( up to 71% ) in vitro in dmd patient-derived entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|cell|myoblasts express synthesize upon characterized|muscles myoblasts dysplasia fibroblasts cartilage|myoblasts|cellular based therapies such as skeletal entity and embryonic stem cells are being pursued by companies such as bioheart , mg biotherapeutics , a joint venture created by medtronic
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|myoblasts express synthesize upon characterized|scar biopsies scars flaps fibrosis|myoblasts|clinical therapy designed to improve cardiac function by populating regions of scar tissue within a 8 patients heart with entity derived from a biopsy of a patients thigh muscle .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|lymphoblastic myeloid promyelocytic myelogenous lymphocytic|lymphoblastic|we are developing marqibo for the treatment of acute entity leukemia and other blood cancers including lymphoma .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|myelogenous lymphocytic myeloid lymphoblastic promyelocytic|lymphoblastic|exclusive license agreement pursuant to which we licensed the patent rights to a specific gene mutation with respect to chronic entity leukemia .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|myeloid lymphoblastic promyelocytic myelogenous lymphocytic|lymphoblastic|achieve the primary endpoint of efficacy in the phase 2 clinical trial of blinatumomab in patients with acute entity leukemia 10 % 12 . 5 % 6 .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|lymphoblastic myeloid myelogenous promyelocytic lymphocytic|lymphoblastic|in the second quarter , we initiated a pharmacokinetic study in phase 2 for erwinaze for the treatment of acute entity leukemia in the young adult population .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|lymphoblastic myeloid lymphocytic myelogenous promyelocytic|lymphoblastic|all patients receiving autologous sb-modified t cells had non-hodgkin lymphoma , and most patients receiving allogeneic car+ t cells had acute entity leukemia .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|lymphoblastic myeloid myelogenous promyelocytic lymphocytic|lymphoblastic|of the most important potential uses of annamycin is in the treatment of children with either aml or all ( acute entity leukemia , which is more common in children ) .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|lymphoblastic myeloid myelogenous promyelocytic lymphocytic|lymphoblastic|nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute entity leukemia after at least two prior regimens .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|lymphoblastic myeloid myelogenous promyelocytic lymphocytic|lymphoblastic|candidate blinatumomab ( mt103 ) is currently the subject of a european pivotal trial in patients with minimal residual disease positive acute entity leukemia .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|lymphoblastic myeloid myelogenous promyelocytic lymphocytic|lymphoblastic|erwinaze , a biologic product , is used in conjunction with chemotherapy to treat patients with acute entity leukemia , or all , with hypersensitivity to e . coli-derived asparaginase .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|lymphoblastic myeloid lymphocytic myelogenous promyelocytic|lymphoblastic|pbcar0191 , is an allogeneic car t cell therapy targeting the well-validated tumor target cd19 and is being developed for acute entity leukemia , or all , and non-hodgkin lymphoma , or nhl .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|myeloid lymphoblastic myelogenous promyelocytic lymphocytic|lymphoblastic|oncaspar is a first-line biologic used as part of a chemotherapy regimen to treat patients with acute entity leukemia .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|myeloid lymphoblastic myelogenous lymphocytic promyelocytic|lymphoblastic|for iclusig is bcr-abl , an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia ( cml ) and philadelphia-chromosome positive acute entity leukemia ( ph+ all ) .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|lymphoblastic myeloid lymphocytic myelogenous promyelocytic|lymphoblastic|sar3419 targets cd19 and is a potential new treatment for cd19-expressing b-cell malignancies including nhl and b-cell acute entity leukemia , or b-all .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|lymphoblastic myeloid lymphocytic promyelocytic myelogenous|lymphoblastic|the fda approved kymriah ( tisagenlecleucel ) for the treatment of certain pediatric and young adult patients with a form of acute entity leukemia ( all ) .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|lymphoblastic myeloid lymphocytic myelogenous promyelocytic|lymphoblastic|it is in a phase 2 clinical trial for the treatment of patients with acute entity leukemia and a phase 1 clinical trial for the treatment of patients with non-hodgkin  s lymphoma .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|myeloid lymphoblastic myelogenous promyelocytic lymphocytic|lymphoblastic|patients , in august 2011 , we initiated a phase 1 clinical trial of quizartinib in pediatric patients with either relapsed acute entity leukemia , or all , or relapsed aml .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|lymphoblastic myeloid promyelocytic lymphocytic myelogenous|lymphoblastic|may 2005 , we commenced an open-label , multicenter phase i and ii study of talotrexin in the treatment of refractory adult entity leukemia or “all .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|lymphoblastic myeloid myelogenous promyelocytic lymphocytic|lymphoblastic|the company also acquired the u . s . and canadian marketing rights to oncaspar ( tm ) for use in the treatment of acute entity leukemia .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|lymphoblastic lymphocytic myeloid myelogenous promyelocytic|lymphoblastic|u . s . for advanced non-hodgkins lymphoma , and vincristine sulfate liposome injection ( marqibo® ) approved in the u . s . for advanced adult ph- acute entity leukemia ( all ) .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|leukemia lymphoblastic leukaemia lymphoma lymphomas|myeloid lymphoblastic myelogenous lymphocytic promyelocytic|lymphoblastic|two other sar3419 phase ii trials are ongoing in relapsed / refractory dlbcl and in acute entity leukemia .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 1), ('DRUG', 1), ('DIS', 1)])|cell|enterocytes epithelial colonic intestinal polyps|macrophages mucosa epithelium epithelia epithelial|enterocytes|fxr activation in intestinal entity results in the secretion of fibroblast growth factor 19 , or fgf19 , which has been associated with increased serum low-density lipoprotein ,
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|enterocytes epithelial colonic intestinal polyps|intestine stomach ileum jejunum gut|enterocytes|by inhibiting nhe3 on the apical surface of the entity , tenapanor reduces absorption of sodium from the small intestine and colon , resulting in an increase in water secretion into the
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|enterocytes epithelial colonic intestinal polyps|urine circulation csf dialysate bloodstream|enterocytes|we believe that kp201 is then completely hydrolyzed down to hydrocodone and the ligand in the entity , which then release the hydrocodone directly into the blood stream .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|cell|enterocytes epithelial colonic intestinal polyps|mucosa macrophages vesicles glands stores|enterocytes|it can thus inhibit iron absorption from the gi tract by interacting with duodenal entity and limit the release of iron in the bone marrow by interacting with macrophages .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('DRUG', 1), ('DIS', 1)])|cell|enterocytes epithelial colonic intestinal polyps|macrophages mucosa epithelium fibroblasts epithelial|enterocytes|fxr activation in intestinal entity results in the secretion of fibroblast growth factor 19 , or fgf19 , which has been associated with increased serum ldl cholesterol
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|cell|enterocytes epithelial colonic intestinal polyps|epithelium lumen mucosa cavity barrier|enterocytes|believe that due to kp201s low binding affinity to the µ-opioid receptors it is absorbed largely intact into the intestinal entity , which are the cells lining the small intestine .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|cell|enterocytes epithelial colonic intestinal polyps|mucosa glands enterocytes ulcer ulcers|enterocytes|the cellular trans-membrane protein ferroportin , which functions as an export channel for intracellular iron in macrophages , liver hepatocytes , and duodenal entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|enterocytes epithelial colonic intestinal polyps|hepatocytes vivo livers bile rats|enterocytes|this was observed in a preclinical study in mice in which kd026 caused fat accumulation in entity and prevented fat accumulation in the liver tissues .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|cell|enterocytes epithelial colonic intestinal polyps|vivo macrophages hepatocytes intestine bile|enterocytes|lomitapide also blocks mtp in entity ( cells lining the gastrointestinal tract ) , leading to an accumulation of fat in the intestinal mucosa .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|cell|spermatids spermatocytes spermatozoa nuclei tubules|testosterone androgens estradiol androstenedione lh|spermatids|hormone ) drives synthesis of testosterone in the leydig cells of the testes and fsh ( follicle stimulating hormone ) drives production of entity in the sertoli cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|cell|spermatids spermatocytes spermatozoa nuclei tubules|integrity tubules proliferation epithelium atrophy|spermatids|clinical dose on a mg / m2 basis ) in a 6-month iv study had bilateral degeneration of the seminiferous epithelium with retained entity and atrophy of interstitial cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|spermatids spermatocytes spermatozoa nuclei tubules|they males androgens testes testosterone|spermatids|entity mature over a 72 day cycle in the seminiferous tubules in the testes under the influence of endogenous testosterone produced
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 3)])|cell|spermatids spermatocytes spermatozoa nuclei tubules|lymphocytes fibroblasts erythrocytes hepatocytes spleen|spermatids|to be mutagenic in the in vivo mouse micronucleus assay and positive for the induction of chromosomal aberrations in mouse entity and murine lymphocytes .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|motility fertilization spermatozoa semen fertility|egg embryo oocyte needle follicle|sperm|taken from the womans ovarian follicles and fertilized in vitro with either standard insemination , or icsi , in which a single entity is injected by needle into the egg .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|motility fertilization spermatozoa semen fertility|bank national knee nhs commercial|sperm|the decrease is due to a smaller demand for the entity bank services .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|motility fertilization spermatozoa semen fertility|fetus mother embryo placenta egg|sperm|each parent , including recombination , or the exchange of dna within the parent chromosomes that occurs during the formation of the entity and the egg that become the fetus .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|motility fertilization spermatozoa semen fertility|bank national entire manual nhs|sperm|the company operates in two distinct reporting segments , one for the entity bank division and one for its stem-cell and skin care divisions as of december 31 , 2009 and 2008 and for
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cell|motility fertilization spermatozoa semen fertility|platelet testosterone testicular cd4 lymphocyte|sperm|this trial showed that androxal® was able to maintain entity counts in men being treated for their low testosterone levels , whereas testim® resulted in suppressed entity levels .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cell|motility fertilization spermatozoa semen fertility|embryo semen egg oocyte vesicle|sperm|the latter include , among other technologies , in vitro fertilization , or ivf , and intracytoplasmic entity injection , or icsi .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|motility fertilization spermatozoa semen fertility|semen spermatozoa volumes glands motility|sperm|lastly , semen samples that had fewer normal entity had slightly , but not significantly , higher sorp values .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|motility fertilization spermatozoa semen fertility|exception subgroup majority percentage proportion|sperm|of the protocol or for other unanticipated reasons , and we may be unable to achieve the same results with the entity of infertile donors that have been achieved with entity of fertile donors .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|cell|motility fertilization spermatozoa semen fertility|platelet fibrinogen cortisol hemoglobin bilirubin|sperm|those with an abnormally low entity concentration or overall total number , have significantly higher sorp values than those in the normal range .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|motility fertilization spermatozoa semen fertility|spermatozoa couples individuals eggs females|sperm|o application as an enhancement in human intercourse - for couples prone to male factor infertility from immotile or poorly motile entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|motility fertilization spermatozoa semen fertility|eggs embryos oocytes worms larvae|sperm|the university of pennsylvania safety and efficacy laboratory studies with atp ( the active ingredient in atpotent ) using human and animal entity as well as animal eggs and animal embryos .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|motility fertilization spermatozoa semen fertility|provide require keep supply save|sperm|the contractor must provide full service cryobiology program to include storage of embryos and entity all laboratory equipment and staffing as work load requires .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|motility fertilization spermatozoa semen fertility|mucus them eosinophils oocytes spermatozoa|sperm|conducted in 20 women and published in the journal of reproductive medicine® in 2009 , ovaprene demonstrated the ability to immobilize entity and prevent their progression into the cervical mucus .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|motility fertilization spermatozoa semen fertility|organisms rods spermatozoa motile vesicles|sperm|abnormally few motile entity or few entity with a progressive motility were also associated with significantly higher sorp values than those in the normal range .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|motility fertilization spermatozoa semen fertility|embryo egg fetus mother eggs|sperm|transgenic animal  shall mean a non-human animal , or an egg , entity or embryo of such animal , which bears in its germline a foreign gene derived from another animal species .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|motility fertilization spermatozoa semen fertility|bank original own next manual|sperm|continued to develop its pre-clinical-stage therapeutic agents and various treatments utilizing stem cell treatments while generating revenues and operating its entity bank division .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|cell|motility fertilization spermatozoa semen fertility|females testosterone androgens males estrogens|sperm|that plays a key role in masculine growth and development during puberty — or has an impaired ability to produce entity or both .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|motility fertilization spermatozoa semen fertility|eggs embryos oocytes larvae birds|sperm|not viable , the work prompted calls for a moratorium or other types of restrictions on gene editing of human eggs , entity , and embryos .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|motility fertilization spermatozoa semen fertility|sexual erectile reproductive testicular renal|sperm|program with androxal as a treatment for men being treated for low testosterone that want to maintain or improve their entity function during treatment .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|motility fertilization spermatozoa semen fertility|mucus them eosinophils spermatozoa oocytes|sperm|conducted in 21 women and published in the journal of reproductive medicine in 2009 , ovaprene® demonstrated the ability to immobilize entity and prevent their progression into the cervical mucus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gametes fertilization genome gamet fertility|embryos organs eggs embryo oocytes|gametes|( b ) donors of entity , embryos , somatic cells or human tissue did not receive valuable consideration .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|gametes fertilization genome gamet fertility|spermatozoa cryopreservation eggs them fertilization|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as assisted reproductive technology , or " art " , services .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|gametes fertilization genome gamet fertility|eggs embryos oocytes urine platelets|gametes|( e ) individuals who consented to donate stored entity , embryos , somatic cells , or human tissue were not reimbursed for the cost of storage prior to the decision to donate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gametes fertilization genome gamet fertility|bodies labels eggs lists organs|gametes|( c ) a person may not knowingly , for valuable consideration , purchase or sell entity , embryos , somatic cells , or human tissue for research purposes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|gametes fertilization genome gamet fertility|spermatozoa cryopreservation fertilization semen eggs|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as assisted reproductive technology , or art , services .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gametes fertilization genome gamet fertility|embryos organs oocytes eggs donors|gametes|ivf treatment while the procurement , processing and distribution of entity and embryos for use in ivf and other assisted reproduction treatments falls within the scope of the eu rules governing
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|gametes fertilization genome gamet fertility|embryos oocytes organs embryo fibroblasts|gametes|national stem cell oversight committee , or · been derived under the following conditions : ( a ) donors of entity , embryos , somatic cells , or human tissue gave voluntary and informed consent .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gametes fertilization genome gamet fertility|diploid haploid tetraploid embryo yeast|gametes|enactment of this act , that is derived by fertilization , parthenogenesis , cloning , or any other means from one or more human entity or human diploid cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|gametes fertilization genome gamet fertility|spermatozoa cryopreservation eggs them semen|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as art services .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gametes fertilization genome gamet fertility|embryos organs embryo eggs oocytes|gametes|( b ) donors of entity , embryos , somatic cells , or human tissue did not receive valuable consideration .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|gametes fertilization genome gamet fertility|spermatozoa eggs cryopreservation semen them|gametes|procedures that require entity ( sperm and eggs ) to be handled in 3 vitro ( outside the body ) are classified as assisted reproductive technology , or " art " ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|gametes fertilization genome gamet fertility|embryos oocytes organs embryo fibroblasts|gametes|national stem cell oversight committee , or ● been derived under the following conditions : ( a ) donors of entity , embryos , somatic cells or human tissue gave voluntary and informed consent .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gametes fertilization genome gamet fertility|embryos embryo eggs oocytes placenta|gametes|of a duly authorized institutional review board ( irb ) ; and prohibits the knowing purchase , sale or transfer of human embryos or entity for valuable consideration for research purposes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|gametes fertilization genome gamet fertility|spermatozoa eggs cryopreservation semen fertilization|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as assisted reproductive technology ( " art " ) services .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|gametes fertilization genome gamet fertility|embryos organs oocytes donors eggs|gametes|( d ) donation of entity , embryos , somatic cells , or human tissue was overseen by an irb ( or , in the case of foreign sources , an irb-equivalent ) .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|analysed secretion synthesized pituitary catecholamine|neurons parts portions muscles mitochondria|somatotrophs|gh is an anabolic hormone synthesized , stored in , and secreted from entity of the anterior pituitary gland in response to chemical modulators from the hypothalamus and stomach .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|glands chromaffin adrenal biosynthesis adenomas|vivo conclusion summary humans lymphocytes|corticotrophs|similarly , dipyridamole did not amplify prednisolone effects in entity , cells that mediate the hpa axis suppression of high-dose glucocorticoid treatment .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|cell|seb pigment follows epithelial mast|keratinocytes fibroblasts melanocytes lymphocytes mscs|sebocytes|because there are no preclinical models of acne , human entity , which are the cells that make up the sebaceous glands and secrete sebum , are a useful research tool for a
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|seb pigment follows epithelial mast|epidermis nucleus dermis intestine follicle|sebocytes|it has also been shown in a laboratory study that a chemical that blocks acetylcholine from reaching the entity reduces sebum production .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|cell|seb pigment follows epithelial mast|keratinocytes mast fibroblasts langerhans melanocytes|sebocytes|acetylcholine has been shown in laboratory studies to increase activity in the sebum-producing skin cells called entity , which form sebaceous glands .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('DRUG', 3), ('BIO', 2), ('OTHER', 2), ('DIS', 1)])|cell|synovi fibroblasts cartilage mast characterized|cytokines macrophages molecules mediators lymphocytes|synoviocytes|synoviocyte inhibitory moa : pro-inflammatory entity in the ra joint proliferate highly and secrete multiple cytokines involved in ra disease pathogenesis .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 4), ('DRUG', 3), ('DIS', 1)])|cell|synovi fibroblasts cartilage mast characterized|macrophages cytokines leukocytes lymphocytes chemokines|synoviocytes|rheumatoid arthritis results from interactions between immune cells and entity that leads to joint swelling , pannus formation and bone loss .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|cell|synovi fibroblasts cartilage mast characterized|macrophages fibroblasts vesicles aggregates debris|synoviocytes|the synovium is lined by cells , or entity , which produce a small amount of liquid called synovial fluid that nourishes and lubricates the joint .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|synovi fibroblasts cartilage mast characterized|macrophages platelets lungs fibroblasts intestine|synoviocytes|the entity , in turn , secrete a variety of chemicals that contribute to inflammation , tissue degradation and harmful new blood vessel formation .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|synovi fibroblasts cartilage mast characterized|macrophages osteoclasts osteoblasts chondrocytes here|synoviocytes|of articular joints and joint surfaces , characterized by the rapid , uncontrolled growth of the cells that line the joints , called entity .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|synovi fibroblasts cartilage mast characterized|macrophages fibroblasts granules lymphocytes monocytes|synoviocytes|of most individuals with rheumatoid arthritis , which drive the production of tnf and the recruitment of neutrophils and fibroblast like entity .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('DRUG', 3), ('BIO', 2), ('OTHER', 2), ('DIS', 1)])|cell|synovi fibroblasts cartilage mast characterized|cytokines macrophages mediators lymphocytes molecules|synoviocytes|synoviocyte inhibition : pro-inflammatory entity in the ra joint proliferate highly and secrete multiple cytokines involved in ra disease pathogenesis .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|synovi fibroblasts cartilage mast characterized|fibroblasts clones macrophages lines fibroblast|synoviocytes|data published today demonstrate that ppi-2458 potently inhibits the growth of both human fibroblast-like entity derived from rheumatoid arthritis patients and human endothelial cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|mechan receptors nerve sympathetic nerves|muscles fibers neurons specimens segments|mechanoreceptors|in parallel , electrophysiology recordings of single ganglion neurons that innervate the craniofacial muscles were performed ( 33 masticatory muscle entity ) .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|cell|angio chondrosarcoma hemangi carcinoma sarcoma|rats fibroblasts cardiomyocytes lymphocytes mscs|angioblasts|the young entity will be tested in preclinical mouse models of accelerated aging to assess the safety and efficacy of the cells in
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|cell|angio chondrosarcoma hemangi carcinoma sarcoma|progenitors vessels organs precursors lineages|angioblasts|recyte will also develop ips cells into primitive entity , which are cells believed to be capable of reconstituting and repairing age-related changes in the vascular system .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|cell|angio chondrosarcoma hemangi carcinoma sarcoma|rats fibroblasts cardiomyocytes lymphocytes mscs|angioblasts|the young entity will be tested in preclinical mouse models of accelerated aging to test the safety and efficacy of the cells in
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|phagocytic phagocytes phagocyt react leukocytes|leukocytes neutrophils monocytes macrophages sera|phagocytes|binding of ar-101 to p . aeruginosa bacteria facilitates human complement binding and improves immune recognition and destruction by circulating human entity .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|phagocytic phagocytes phagocyt react leukocytes|functions mediators organs constituents examples|phagocytes|important entity include macrophages , that rid the body of dead cells and other debris , and granulocytes , including neutrophils , that contain granules filled
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 2)])|cell|phagocytic phagocytes phagocyt react leukocytes|lps hypoxia h2o2 lipopolysaccharide irradiation|phagocytes|t cells have been shown to be sensitive to oxygen free radical-induced apoptosis when these immune cells were exposed to entity .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3), ('DRUG', 1)])|cell|phagocytic phagocytes phagocyt react leukocytes|hypoxia h2o2 lps irradiation superoxide|phagocytes|nk / t cells have been shown to be sensitive to oxygen free radical-induced apoptosis when these immune cells were exposed to entity .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|phagocytic phagocytes phagocyt react leukocytes|mutants enzymes organisms microorganisms particles|phagocytes|these defective entity cannot generate superoxide , leading to an inability to kill harmful microorganisms such as bacteria and fungi .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 1), ('DRUG', 1), ('DIS', 1)])|cell|phagocytic phagocytes phagocyt react leukocytes|macrophages monocytes lymphocytes rbcs neutrophils|phagocytes|one part of the innate immune system involves large white blood cells called entity ( literally , " cell-eaters " ) that can engulf and digest foreign microorganisms and other antigens .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|phagocytic phagocytes phagocyt react leukocytes|pathogens leukocytes erythrocytes macrophages lymphocytes|phagocytes|have been shown to induce antibodies that are protective in animal models and that facilitate killing of bacteria by human entity .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|phagocytic phagocytes phagocyt react leukocytes|neutrophils mitochondria leukocytes macrophages superoxide|phagocytes|laboratory research has demonstrated that ceplene reduces formation of oxygen radicals from entity , inhibiting nadph oxidase and protecting il-2-activated nk-cells and t-cells .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|phagocytic phagocytes phagocyt react leukocytes|rats oocytes they hepatocytes liposomes|phagocytes|entity were depleted using clodronate loaded liposomes through day 21 .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 1)])|cell|phagocytic phagocytes phagocyt react leukocytes|macrophages neutrophils pathogens monocytes phagocytes|phagocytes|and increasing anti-inflammatory mediators , the production of antimicrobial effectors and increased absorption of pathogens by specially adapted cells known as entity .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|phagocytic phagocytes phagocyt react leukocytes|dcs apcs exosomes tregs cscs|phagocytes|we observed that depletion of entity , including myeloid apcs , significantly reduced our bdc-1001 surrogate-mediated anti-tumor activity .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|phagocytic phagocytes phagocyt react leukocytes|cd4 cd8 cd3 treg th1|phagocytes|furthermore , significant increases in entity and cd8 t cells were measured in tumors following bdc-1001 surrogate treatment , further supporting a mechanism that bridges the innate
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|phagocytic phagocytes phagocyt react leukocytes|scid lethal murine subcutaneous recombinant|phagocytes|figure 4 : bdc-1001 surrogate activity dependent on presence of entity scid / beige were dosed systemically with 5 mg / kg on day 0 , 5 and 10 .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|phagocytic phagocytes phagocyt react leukocytes|contrary receptors nucleus endothelium cytosol|phagocytes|or other molecules in the class known as histamine type-2 ( h ) receptor agonists bind to the h receptor on the entity , the production and release of free radicals is temporarily prevented .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('DRUG', 2), ('OTHER', 2), ('DIS', 1)])|cell|phagocytic phagocytes phagocyt react leukocytes|macrophages neutrophils mitochondria monocytes phagocytes|phagocytes|the release of free radicals by entity results in apoptosis , or programmed cell death , of nk , t and nk / t cells , thereby destroying their cytotoxic capability and
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('DRUG', 2), ('OTHER', 2), ('DIS', 1)])|cell|phagocytic phagocytes phagocyt react leukocytes|macrophages neutrophils monocytes mitochondria phagocytes|phagocytes|the release of free radicals by entity results in apoptosis ( programmed cell death ) of nk cells and t cells , thereby destroying their cytotoxic capability and rendering the
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('DRUG', 2), ('OTHER', 2), ('DIS', 1)])|cell|phagocytic phagocytes phagocyt react leukocytes|macrophages neutrophils mitochondria monocytes phagocytes|phagocytes|the release of free radicals by entity results in apoptosis , or programmed cell death , of nk , t and nk / t cells , thereby destroying their cytotoxic capability and rendering
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('BIO', 4), ('DRUG', 1), ('DIS', 1), ('OTHER', 1)])|cell|phagocytic phagocytes phagocyt react leukocytes|lymphocytes they macrophages leukocytes neutrophils|phagocytes|entity are a class of white blood cells found in abundant quantities at the site of tumors and viral infections .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|cell|phagocytic phagocytes phagocyt react leukocytes|cytokines tnf glucocorticoids lps histamine|phagocytes|maxim  s researchers have shown , however , that nk cells and t cells are suppressed by entity , another component of the body  s immune system .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 1), ('DRUG', 1), ('DIS', 1)])|cell|phagocytic phagocytes phagocyt react leukocytes|macrophages leukocytes lymphocytes neutrophils monocytes|phagocytes|table of contents results in a dramatic increase in the production of cytokines that orchestrate the proliferation and recruitment of entity to the site of damage , resulting in inflammation .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|stimulated elicited splenocytes killed cultured|monocytes lymphocytes macrophages supernatants astrocytes|splenocytes|entity were analyzed by flow cytometry to confirm effector / memory phenotype , and cultured with anti-human cd3 antibodies at 2 . 5 mg / ml and anti-human
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|stimulated elicited splenocytes killed cultured|lymphocytes platelets supernatants macrophages neutrophils|splenocytes|entity were lysed and assayed for phospho- nuclear factor kappa b ( nfb ) p65 using an enzyme-linked immunosorbent assay .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|cell|stimulated elicited splenocytes killed cultured|macrophages splenocytes supernatants extracts monocytes|splenocytes|figure 11 : entity from eae mice treated with edp1815 produced an anti-inflammatory cytokine profile .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|stimulated elicited splenocytes killed cultured|recipient graft into recipients versus|splenocytes|svp 1 3 week week naïve recipient lmb-100 transfer entity lmb-100 + / -lmb-100 + / -
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|stimulated elicited splenocytes killed cultured|elisa monocytes facs macrophages lymphocytes|splenocytes|cell responses will be assessed by in vivo cd4 and cd8 cell depletion and measure cytotoxicity and gamma-ifn release by entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|stimulated elicited splenocytes killed cultured|lymphocytes macrophages leukocytes platelets hepatocytes|splenocytes|administration for 14 days ( 10 mg / kg , sid , ip ) : no effect on blood count , blood chemistry and cytokine secretion by isolated entity no herg inhibition observed ( in vitro )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|stimulated elicited splenocytes killed cultured|depletion into transplantation rescue depleted|splenocytes|svp prime challenge donor transfer entity day 0 14 aav8-hfix day 0 19 20 21 32 recipient anti-cd25 treg depletion day 0 1 28 anti-aav8 igg
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|stimulated elicited splenocytes killed cultured|macrophages monocytes hepatocytes lymphocytes chondrocytes|splenocytes|in vitro studies demonstrated that treatment of isolated entity with virulizin ( r ) result in increased il-17e mrna expression .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1), ('DIS', 1)])|cell|stimulated elicited splenocytes killed cultured|macrophages hepatocytes livers splenocytes monocytes|splenocytes|entity from either young or older atherosclerotic apoe ko mice were isolated from the spleen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|stimulated elicited splenocytes killed cultured|brains axons sera cns csf|splenocytes|to explore further the mechanisms of cns remyelination , we made a panel of monoclonal antibodies ( mabs ) derived from entity of sjl / j mice injected with homogenized spinal cord .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|cell|stimulated elicited splenocytes killed cultured|splenocytes spleen pbmc dcs lymphocytes|splenocytes|stimulation of entity harvested 7 days post last vaccination with respective peptides demonstrated strong induction of antigen specific t cells in elispot ( depicted in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|cell|stimulated elicited splenocytes killed cultured|spleen splenocytes lymphocytes dcs pbmc|splenocytes|stimulation of entity harvested 7 days post last vaccination with respective peptides demonstrated strong induction of antigen specific t cells in enzyme-linked immune absorbent
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|stimulated elicited splenocytes killed cultured|immunization incubation vaccination priming experiments|splenocytes|t cell responses were measured on day 15 by re-stimulating entity with either control ( medium ) or peptides corresponding to each antigen ( 1 , 2 , 6 , 9 , and 12 ) in the mrna vaccine
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|stimulated elicited splenocytes killed cultured|rats rabbits pigs calves monkeys|splenocytes|before transfer , immunized entity were separated or fractionated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 2), ('DRUG', 2), ('BIO', 2)])|cell|stimulated elicited splenocytes killed cultured|pbmcs vivo pbmc macrophages lymphocytes|splenocytes|robust and specific antigen specific cd8+ifng+ t cell responses were detected in entity after re-stimulation with kras mutation 1 peptide and kras mutation 2 peptide .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|stimulated elicited splenocytes killed cultured|macrophages monocytes splenocytes pbmcs neutrophils|splenocytes|cgen-25007 exhibited anti-inflammatory activity in both human pbmcs and murine entity challenged with various inflammatory stimuli as well as in an animal model of endotoxemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|cell|stimulated elicited splenocytes killed cultured|while subsequently lps antibodies macrophages|splenocytes|enumeral platform used for antibody discovery • mice were immunized with pd - 1 - his • entity activated with lps for 3 days •
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|stimulated elicited splenocytes killed cultured|embryos brains fibroblasts livers retinas|splenocytes|these methods were applied to analyze gene expression data from mouse entity exposed to either copaxone® or the purported generic ga .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 2), ('DRUG', 2), ('BIO', 2)])|cell|stimulated elicited splenocytes killed cultured|splenocytes lymphocytes pbmcs macrophages pbmc|splenocytes|cd4+ and cd8+ t cells from entity isolated from bnt162b2-immunized mice were strongly positive for ifn-ɣ and il-2 , producing high levels of the th1 cytokines but minute
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|stimulated elicited splenocytes killed cultured|endothelium platelets leukocytes macrophages monocytes|splenocytes|preincubation of the endothelial cells with blocking antibodies to eotaxin-2 was found to attenuate the adhesion of the entity to these cells ( fig . 15a ) .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|epithelium pigment epithelial characterized degeneration|materials scaffolds polymers fibers hydrogels|corneocytes|in addition , to providing most of the mechanical strength of the tissue , these entity provide a stabilizing scaffold for the mortar .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|epithelium pigment epithelial characterized degeneration|gloves tear alternatively sutures liquids|corneocytes|the bricks ,  or entity , provide a durable defense against the ordinary frictional wear and tear of life .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium pigment epithelial characterized degeneration|surfaces vesicles patches particles membranes|corneocytes|the stratum corneum , consisting of flattened and hardened non-living entity held together by a lipid matrix , acts as the main barrier to drug delivery .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|epithelium pigment epithelial characterized degeneration|membranes chains sheets spaces layers|corneocytes|the mortar is primarily made up of fats or lipids that are organized into broad sheets or membranes .  stacks of these membranes fill the spaces between the entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|epithelium pigment epithelial characterized degeneration|lipids aggregates keratinocytes fibroblasts plaques|corneocytes|keratinocytes , the most common cell type in the outer layer of skin , has been shown to increase the formation of entity and the production of lamellar lipids .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|hetero mosaic ordered hybrids clusters|transcripts hybridization cultures embryos rnas|heterokaryons|elegans to isolate innate immunity mutations , and implementing species specific primers to distinguish rat transcipts from mouse transcripts in rat-mouse entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 2), ('DIS', 2)])|cell|cholangi ducts duct epithelium stellate|hepatocytes macrophages fibroblasts lysosomes adipocytes|cholangiocytes|the licensed technology describes advanced methods for the production of mature hepatocytes and entity , the primary cell types of the liver .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|cholangi ducts duct epithelium stellate|hepatocytes macrophages epithelial hepg2 fibroblasts|cholangiocytes|specific and robust ccl24 staining was also shown in entity , the epithelial cells of the bile ducts .
OrderedDict([('BIO', 4), ('OTHER', 2)])|OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|pneum epithelium epithelial fibroblasts alveolar|macrophages viruses particles fibroblasts lymphocytes|pneumocytes|sars - cov - 2 infects type ii entity in lung alveoli 1 these cells also serve as progenitor cells for repairing damaged alveoli .
OrderedDict([('BIO', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|pneum epithelium epithelial fibroblasts alveolar|receptors molecules mutants particles integrins|pneumocytes|type it entity , known to be primary targets / reservoirs for flu , are plated in a transwell system , which essentially suspends the polarized cell monolayer
OrderedDict([('BIO', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|pneum epithelium epithelial fibroblasts alveolar|viruses pneum pneumonia streptococci rotavirus|pneumocytes|in covid - 19 , infection of type ii entity results in impaired gas exchange and fluid leakage into alveoli .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|they participants who respondents australia|oncocyte|as of december 31 , 2017 , entity had $2 . 1 million outstanding and payable to biotime and affiliates in connection with the costs incurred under the shared facilities
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|hospitals medicaid physicians participants medicare|oncocyte|entity incurred no royalty expenses to date as of december 31 , 2014 .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|fr microfluidic uf lb poc|oncocyte|importantly , entitys methods appear to be compliant with commercial manufacturing processes .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|our your every his her|oncocyte|the fact that certain of our executive officers and directors own shares of entity common stock should not be considered to mean that they constitute or are acting in concert as a “group” with
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|scientific safety market patent software|oncocyte|the patent is useful for biotimes subsidiary entity corporation for its cancer diagnostic product development .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|participants equipment people facilities residents|oncocyte|on july 2 , 2018 , entity entered into a lease schedule under the lease agreement no . 2 for certain equipment costing approximately $209 , 000 , requiring payments of
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|patent international called scientific european|oncocyte|another subsidiary , entity corporation , focuses on the therapeutic applications of stem cell technology in cancer , including using vascular progenitor cells engineered to destroy
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|esi proteomics oncology nanotechnology bioinformatics|oncocyte|additional information about biotime , recyte therapeutics , cell cure , orthocyte , entity , biotime asia , lifemap sciences , and esi can be found on the web at www . biotimeinc . com .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|proliferation epithelial onc characterized secretion|researchers there scientists she drosophila|oncocyte|in concert with the protocol development , entity has established a broad range of support assays to monitor and measure vascular progenitor cell differentiation processes .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|participants she they students people|oncocyte|on may 11 , 2017 , entity entered into another master lease line agreement ( “lease agreement no . 2” ) with the same finance company on terms similar to lease agreement no . 1 .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|our his own another her|oncocyte|to beneficially own the shares owned by broadwood , in the aggregate beneficially own approximately 18 . 9% of the outstanding shares of entity common stock as of april 22 , 2019 .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|they consideration attention feedback supervision|oncocyte|under the provisions of the contracts , entity may be required to incur severance obligations for matters relating to changes in control , as defined , and involuntary terminations .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|american louis british legal national|oncocyte|you should direct any requests to : entity corporation 15 cushing irvine , california 92618 409-7600 s-11 3 , 523 , 776 shares common stock january
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|they who users physicians clinicians|oncocyte|entity will reimburse sbmri for 25% of the costs incurred in filing , prosecuting , and maintaining patent protection , subject to entity&#8217 ; s approval of the costs .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|employment leadership she education nurses|oncocyte|entity has entered into employment contracts with certain executive officers .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|tc who di li au|oncocyte|references to “entity , ” “we , ” “us , ” and “our” are references to entity corporation .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|today canada master medicare society|oncocyte|of royalty bearing products commence , the annual fee will be credited towards entity  s royalty payment obligations for the applicable year .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|stock lineage tree former share|oncocyte|in note 3 , the asterias shares of common stock lineage held generated similar deferred tax liabilities to lineage as the entity shares discussed above .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|technology fda literature ngs researchers|oncocyte|entity has expanded and banked large numbers of vascular progenitor cells derived from multiple hes cell lines , including clinical-grade stem cells provided by us and our subsidiary esi .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation epithelial onc characterized secretion|law laws author court physicians|oncocyte|except as required by law , entity disclaims any intent or obligation to update these forward-looking statements .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|pigment epithelium epithelial characterized membranes|fibroblasts chromosomes cultures specimens substrates|amniocytes|fluorescence images demonstrating hybridization of the cep x / y and lsi 21 probes on uncultured entity .
OrderedDict([('BIO', 4), ('DIS', 4), ('DRUG', 2), ('OTHER', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|lymphocytes granulocytes mitogen macrophages eosinophils|monocytes lymphocytes platelets macrophages neutrophils|promonocytes|two leukine treated patients had progressive increase in circulating monocytes and entity and blasts in the marrow which reversed when leukine was discontinued .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|hemoglobin bilirubin albumin haemoglobin hematocrit|reticulocytes|to six months have shown a profound and durable reduction in hemolysis ( red blood cell destruction ) as assessed by hemoglobin , entity and / or bilirubin .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|antibiotics patents pharmaceuticals medications chemotherapy|reticulocytes|the streck patents relate to the addition of entity to hematology controls .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|them pharmaceuticals patents impurities standards|reticulocytes|is successful , after cancellation of the streck patents , the company may be issued a patent covering integrated hematology controls containing entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 3)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|there they platelets rbcs neutrophils|reticulocytes|ldh and bilirubin are released when rbcs undergo hemolysis , and entity are young rbcs that are released by the bone marrow in response to the ongoing hemolysis ; thus we believe that
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|rats infants neonates newborns urine|reticulocytes|mg / kg , *** ) , elevated hemoglobin concentrations in entity ( retic ch ) were observed on day 30 compared to pre-treatment ( pre-dose ) .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|bmd qol hba1c fmd bmi|reticulocytes|we observed an 18% reduction in entity in the 10 mg treatment arm relative to the placebo arm .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|nodules eyes explants colonies corneas|reticulocytes|then exposed to a defined media formulation to promote further expansion and differentiation until they differentiate and mature into enucleated entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|hemoglobin mortality haemoglobin hematocrit anemia|reticulocytes|improvement in the hemolytic anemia would be expected to result in a decrease in entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|platelets lymphocytes erythrocytes macrophages leukocytes|reticulocytes|products provide a means of assessing the linearity of hematology analyzers for white blood cells , red blood cells , platelets and entity ( immature red blood cells ) .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|there they platelets rbcs erythrocytes|reticulocytes|bilirubin and ldh are released when rbcs undergo hemolysis , and entity are young rbcs that are released by the bone marrow in response to the ongoing hemolysis ; thus we believe that
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 1)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|lymphocytes erythrocytes platelets leukocytes granulocytes|reticulocytes|these controls are designed for manual and automated counting of entity ( immature red blood cells ) .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|hemoglobin hematocrit haemoglobin platelets hb|reticulocytes|the increase in hemoglobin levels was preceded by an increase in entity showing that an increase in hemoglobin levels is a result of a physiologic increase in rbc production .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|include period indicate doses took|reticulocytes|dose ( mg / kg / day ) average bodyweight at end ofstudy hematology results at end of study entity ( x 103 / µl ) neutrophils ( x 103 / µl ) control - 603 m / 324 f
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|eyes retinas oocytes embryos retina|reticulocytes|at this stage , the enucleated entity are rcts that express one or more biotherapeutic proteins in the cytosol or on the cell surface .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|ldh hemoglobin crp creatinine albumin|reticulocytes|while gbt4 showed improvement in hemoglobin , entity and ldh levels in the first 15 days , these values worsened after day 15 .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|bilirubin hemoglobin albumin haemoglobin creatinine|reticulocytes|levels and improved clinical measures of hemolysis at 16 weeks , as evaluated by changes from baseline in hemoglobin , percent of entity , and percent of unconjugated bilirubin .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|hemoglobin hematocrit platelets haemoglobin creatinine|reticulocytes|robust and sustained increase in red blood cells , hemoglobin and entity , supporting monthly or less frequent dosing .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|hemoglobin creatinine hematocrit hba1c lipids|reticulocytes|receiving the 300 mg dose , measuring changes in parameters over the 14-day treatment and 7-day follow-up period including hemoglobin and entity , as well as tolerability and safety .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|erythrocytes chromosomes lymphocytes micronuclei nuclei|reticulocytes|standard in vivo genotoxicity studies in rodents , including a 2-day comet assay and a 28-day evaluation of micronucleated entity , revealed no test-article effects on genotoxicity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|cell|reticulocyte hemoglobin erythrocyte pigment erythrocytes|hemoglobin hba1c haemoglobin hematocrit creatinine|reticulocytes|( 700 mg ) 8 ( 900 mg ) 9 ( 3 per cohort ) akb-6548 was well tolerated , and dose responsive increases in entity and hemoglobin levels were demonstrated .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 3), ('DRUG', 1)])|cell|granulocytes consisted characterized follows fibroblasts|platelets apl granulocytes eosinophils macrophages|promyelocytes|in apl , there is an abnormal accumulation of immature granulocytes called entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|cell|granulocytes consisted characterized follows fibroblasts|platelets apl they mscs lymphocytes|promyelocytes|in apl , immature white blood cells called entity accumulate in the bone marrow .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|granulocytes consisted characterized follows fibroblasts|immature circulating fresh neutrophil peripheral|promyelocytes|in addition , the data showed that plinabulin has a superior immune profile compared to neulasta based on entity and immature neutrophil data from the clinical study .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2)])|cell|granulocytes consisted characterized follows fibroblasts|platelets fibroblasts leukocytes lymphocytes erythrocytes|promyelocytes|the overgrowth of entity leads to a shortage of normal white and red blood cells and platelets in the body , which causes many of
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|cell|granulocytes consisted characterized follows fibroblasts|blasts progenitors precursors lymphocytes leukemias|promyelocytes|differentiation therapy causes leukemic entity to mature and undergo cell death .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 4), ('DRUG', 2), ('OTHER', 2), ('DIS', 1)])|cell|granulocytes consisted characterized follows fibroblasts|platelets neutrophils iron macrophages leukocytes|promyelocytes|the accumulation of entity in the bone marrow results in a reduction in the production of normal red blood cells and platelets resulting in
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DRUG', 1), ('DIS', 1)])|cell|granulocytes consisted characterized follows fibroblasts|platelets macrophages rbcs erythrocytes hscs|promyelocytes|this fusion gene leads to the overproduction of immature white blood cells called entity and the underproduction of healthy blood cells .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('BIO', 5), ('DIS', 2), ('OTHER', 1), ('DRUG', 1)])|cell|degeneration neuropathy pigment diseases macular|macrophages granulocytes monocytes neutrophils lymphocytes|metamyelocytes|associated with evidence that normal cell maturation is returning , as noted by the increase in normal maturing cells ( promyeocytes , myeocytes , entity and granulocytes ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 2), ('BIO', 2)])|cell|gland glands pituitary hypophys rats|adipocytes islets pituitary hepatocytes oocytes|pituicytes|mechanism of action of lum-201 ghsr1a activation via lum-201 binding induces gh release , as demonstrated in vitro in rat entity ( lum-201 ec50 1 . 3 nm ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|cell|gland glands pituitary hypophys rats|rats adipocytes cardiomyocytes hepatocytes neurons|pituicytes|in addition , the treatment of entity with lum-201 augments the effect of ghrh on gh secretion , as the two compounds synergistically stimulated gh release from rat
OrderedDict([('BIO', 3), ('OTHER', 2), ('DIS', 2)])|OrderedDict([('BIO', 4), ('DIS', 2), ('DRUG', 1), ('OTHER', 1)])|cell|pigment kerat epithelial epithelium fibroblasts|corneas neutrophils macrophages fibroblasts microglia|keratocytes|activated entity have been associated with increased collagen deposition and collagen disorganization which correlate with corneal haze and regression of the correction
OrderedDict([('BIO', 3), ('OTHER', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cell|pigment kerat epithelial epithelium fibroblasts|neoplasms tumours entity entities neoplasm|keratocytes|the superficial entity initially undergo apoptosis , followed by proliferation and activation of the remaining entity .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DIS', 2)])|OrderedDict([('BIO', 5), ('DRUG', 2), ('OTHER', 2), ('DIS', 1)])|cell|pigment kerat epithelial epithelium fibroblasts|myofibroblasts fibroblasts macrophages neutrophils mscs|keratocytes|treatment resulted in a reduction of pro-fibrotic gene expression from day 7-14 post-injury , indicating that target engagement was achieved in entity and myofibroblasts in the corneal stroma .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DIS', 2), ('DRUG', 2)])|cell|fibro proliferation epithelial epithelium mast|fibroblasts adipocytes macrophages osteoblasts myofibroblasts|fibrocytes|igf-1r , the receptor for igf-1 , is highly expressed in entity , cells that are derived from the bone marrow and that have the potential to differentiate into either myofibroblasts or fat
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 2), ('BIO', 1)])|cell|fibro proliferation epithelial epithelium mast|chemokines receptors cytokines pathways functions|fibrocytes|inflammation and when chronically activated , drives the development of fibrosis via several pathways and several cell inflammatory cell types and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|cell|melanocytes pigment melanoma epidermal melan|melanocytes melanin they keratinocytes fibroblasts|melanocytes|entity produce melanin , the pigment that determines skin color and protects the body from ultraviolet radiation .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|cell|melanocytes pigment melanoma epidermal melan|melanin keratinocytes fibroblasts enzymes melanocytes|melanocytes|tanning is mediated by entity producing melanin , which is subsequently transferred to the keratinocytes .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cell|melanocytes pigment melanoma epidermal melan|melanin pigment melanocytes pigmentation pigments|melanocytes|vitiligo is an autoimmune condition in which the skin turns white due to the loss of entity , cells that produce the pigment melanin , which gives skin color .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|cell|melanocytes pigment melanoma epidermal melan|epidermis dermis stroma cytoplasm epithelium|melanocytes|melanoma melanoma is a type of cancer which originates in the entity , the cells responsible for pigmentation .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|cell|melanocytes pigment melanoma epidermal melan|melanin melanocytes hair fibroblasts pigment|melanocytes|melanin is produced by entity and is the pigment that gives human skin , hair and eyes their color .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|melanocytes pigment melanoma epidermal melan|melanocytes langerhans morphologically epidermis multipotent|melanocytes|the skin cells that produce the melanins are called entity and comprise 5 to 10% of the total cellular population in the epidermis .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|melanocytes pigment melanoma epidermal melan|childhood melanoma tongue langerhans choice|melanocytes|melanoma is a malignant tumor of entity , a potentially dangerous form of skin cancer .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|melanocytes pigment melanoma epidermal melan|layer epithelium glands zone neurons|melanocytes|cutaneous melanomamelanoma tumors originate in the pigment-producing entity in the basal layer of the epidermis .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|cell|melanocytes pigment melanoma epidermal melan|melanoma keratinocytes melanocytes epidermis fibroblasts|melanocytes|· melanoma : melanoma is a cancer that begins in specific skin cells called entity , and exposure to ultraviolet rays is a major risk factor for most melanomas .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|cell|melanocytes pigment melanoma epidermal melan|keratinocytes fibroblasts macrophages lymphocytes eosinophils|melanocytes|the epidermis is comprised of specialized cells such as keratinocytes and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|cell|melanocytes pigment melanoma epidermal melan|epithelial numerous endothelial melanoma stromal|melanocytes|melanoma begins in entity cells that make a pigment called melanin .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|cell|melanocytes pigment melanoma epidermal melan|dermis epidermis stroma epithelium penis|melanocytes|melanoma melanoma is a type of cancer which originates in the entity , the cells responsible for pigmentation of the skin .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 2), ('DRUG', 1)])|cell|melanocytes pigment melanoma epidermal melan|melanoma melanocytes fibroblasts melanomas macrophages|melanocytes|melanoma is a disease in which pigmented cells in the skin , called entity , turn into cancer cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3), ('BIO', 2), ('DRUG', 1)])|cell|melanocytes pigment melanoma epidermal melan|melanocytes fibroblasts they macrophages melanoma|melanocytes|melanoma occurs when entity ( pigment cells ) become malignant .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3)])|cell|melanocytes pigment melanoma epidermal melan|fibroblasts lymphocytes keratinocytes hepatocytes astrocytes|melanocytes|normal entity do not express mcam , but expression is turned on and continues to increase as the cells become more malignant .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|melanocytes pigment melanoma epidermal melan|organs cancers tumours neoplasms vessels|melanocytes|malignant melanoma - predominantly a skin cancer , malignant melanoma can also occur in entity found in the bowel and the eye .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|melanocytes pigment melanoma epidermal melan|breast prostate bladder tongue epidermis|melanocytes|melanoma is a cancer of the entity , the cells that produce pigment in the skin .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|melanocytes pigment melanoma epidermal melan|melanoma melanocytes epidermis melanomas keratinocytes|melanocytes|melanoma melanoma is a cancer that begins in specific skin cells called entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|melanocytes pigment melanoma epidermal melan|neck eyes periphery fundus dorsum|melanocytes|melanoma is primarily a skin tumor , although it may also occur less frequently in the entity of the eye .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|melanocytes pigment melanoma epidermal melan|breast prostate penis tongue extremities|melanocytes|melanoma is a malignant tumor of the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|endos particles pigment inclusion within|pathogens yeast bacterium pathogen organisms|endospores|proteins and cross-linking of unprotonated proteins thereby denaturing the proteins to corrupt and penetrate the bacterial walls to kill the entity and other microorganisms .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 3), ('DIS', 3), ('OTHER', 2), ('DRUG', 1)])|cell|proliferation neurons express neuroblast project|neuroblastoma astrocytes macrophages oligodendrocytes pheochromocytoma|neuroblasts|a neuroblastoma tumor develops from immature nerve cells called entity and arises predominantly in the adrenal glands and abdomen .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|proliferation neurons express neuroblast project|pesticides chemicals microorganisms metabolites pharmaceuticals|neuroblasts|the license also covers methods for the production and screening of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 1)])|cell|protoplasts pigment vegetative labeled fluorescent|electroporation mitochondria fibroblasts itself lymphocytes|protoplasts|electroporation is a method for increasing dna uptake by entity through prior exposure to a high voltage , which results in the temporary formation of small pores in the cell membrane .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|cell|pigment melan melanin possess pigments|they there photoreceptors fibroblasts melanocytes|melanophores|entity are pigment-bearing cells .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DRUG', 1)])|cell|pigment melan melanin possess pigments|they there leukocytes erythrocytes steroids|melanophores|for most types of lower animals , entity are the primary chromatophores responsible for skin color control .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|pigment melan melanin possess pigments|melanocytes photoreceptors rpe cones tyrosinase|melanophores|receptor targets melanophore technology melanophore technology is a unique screening technique based upon the use of pigment bearing cells called entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|pigment melan melanin possess pigments|there they mammals photoreceptors vertebrates|melanophores|entity are amphibian cells that are responsible for skin color .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|pigment melan melanin possess pigments|melanocytes photoreceptors rpe cones tyrosinase|melanophores|receptor targets melanophore technology melanophore technology is a unique screening technique based upon the use of pigment bearing cells called entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|pigment melan melanin possess pigments|plants they neurons rats individuals|melanophores|entity undergo a color change in response to light or stimulation by chemicals .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|pigment spher inclusions shows into|haptoglobin albumin hemolysis bilirubin hemoglobin|spherocytes|the laboratory evaluation of waiha begins with a peripheral blood analysis revealing evidence of extravascular hemolysis ( entity , low haptoglobin , elevated bilirubin and elevated ldh ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|sider iron pigment anemia erythropoiesis|thrombocytopenia anemia abnormalities neutropenia remission|sideroblasts|treatment of anemia failing an erythropoiesis stimulating agent in adult patients with very low- to intermediate-risk mds who have ring entity and require rbc transfusions .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cell|sider iron pigment anemia erythropoiesis|anemia aml mds leukemia thrombocytopenia|sideroblasts|patients to evaluate the efficacy and safety of luspatercept in patients with anemia due to lower-risk mds with ring entity who require regular rbc transfusions .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cell|sider iron pigment anemia erythropoiesis|mds aml leukemia criteria mutations|sideroblasts|the medalist trial , a global phase 3 study in patients with very low , low , or intermediate risk , mds with ring entity who require red blood cell transfusions , is currently enrolling .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|sider iron pigment anemia erythropoiesis|stained infected resistant deficient cultured|sideroblasts|when at least 15% of the cells in an mds patients bone marrow are ring entity , this patient is considered rs positive .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cell|sider iron pigment anemia erythropoiesis|chemotherapy mds mutations myeloma anemia|sideroblasts|new class of therapy , for the treatment of adult patients with very low- to intermediate-risk mds-associated anemia who have ring entity and require red blood cell ( rbc ) transfusions .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cell|sider iron pigment anemia erythropoiesis|mds aml criteria abnormalities defects|sideroblasts|the phase 3 mds medalist trial targets patients with very low , low or intermediate risk mds with ring entity who require rbc transfusions .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cell|sider iron pigment anemia erythropoiesis|mf blasts aml mutations mds|sideroblasts|patients with mf that has transformed into aml , known as blast-phase mf , and in patients with refractory anemia with ringed entity , or rars , a subpopulation of mds .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|sider iron pigment anemia erythropoiesis|mutations linkage rings repeats heterozygosity|sideroblasts|the majority of patients with mds that develop cytopenias lack ring entity or a single , defining splicing factor mutation and are termed non-rs .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cell|sider iron pigment anemia erythropoiesis|blasts mds anemia aml mutations|sideroblasts|clinical safety and efficacy data on imetelstat from patients with a form of mds known as refractory anemia with ringed entity ( mds-rars ) enrolled as part of the mayo clinic pilot study .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|cell|sider iron pigment anemia erythropoiesis|defects iii mitochondria channels iv|sideroblasts|of contents subgroup of patients with mds that show the presence of iron deposits around the mitochondria , known as ring entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cell|sider iron pigment anemia erythropoiesis|who dysfunction abnormalities anemia defects|sideroblasts|all patients presented with ring entity were rbc transfusion dependent and were either refractory or intolerant to prior erythropoiesis-stimulating agent ( esa ) therapy , or were esa naïve
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cell|sider iron pigment anemia erythropoiesis|mds anemia aml blasts thrombocytopenia|sideroblasts|and safety of luspatercept versus placebo in patients with anemia due to very low , low , or intermediate-risk mds with ring entity ( ≥ 15% ) who require red blood cell transfusions .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|sider iron pigment anemia erythropoiesis|defects mutations mutants syndromes rings|sideroblasts|these ring entity are associated with ineffective erythropoiesis and anemia .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 1)])|cell|sider iron pigment anemia erythropoiesis|ti rbc platelets rbcs mds|sideroblasts|in the overall trial population , the rate of ≥8-week rbc ti did not differ based on the presence of ringed entity , indicating activity of imetelstat across different subtypes of mds .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|trial university trials prospective centre|hematocrit wbc platelets rbc plt|retic|g / dl . this was thought to be not clinically possible for a hgb at this level in conjunction with markedly elevated entity and low rbc counts .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|trial university trials prospective centre|vas lympho hem uro macro|retic|mg / kg , *** ) , elevated hemoglobin concentrations in entityulocytes ( retic ch ) were observed on day 30 compared to pre-treatment ( pre-dose ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|trial university trials prospective centre|vas lympho pneum hem uro|retic|mg / kg ) , elevated hemoglobin concentrations in entityulocytes ( retic ch ) were observed on day 30 compared to pre-treatment ( pre-dose ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|trial university trials prospective centre|original pcr simplified protocol next|retic|the entity procedure , which is now implemented , measures the number of entityulocytes ( immature red blood cells produced in the bone marrow ) and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|trial university trials prospective centre|lympho vas hem pneum muco|retic|elevated hemoglobulin concentrations in entityulocytes ( retic ch ) as determined on day 30 ( ** : p < 0 . 005 , *
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|trial university trials prospective centre|lympho hem vas pneum muco|retic|elevated hemoglobulin concentrations in entityulocytes ( retic ch ) as determined on day 30 ( ** : p 2 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|trial university trials prospective centre|lympho supra vas microv leuk|retic|in may 1996 , the company received fda 510 ( k ) clearances for two additional commonly performed microscope procedures : entityulocyte count ( entity ) and anti-nuclear antibodies ( anas ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|cell|subcl analysed clones derivatives amplified|molecules rnas lymphocytes intestine peptides|subclones|progressive disease to elucidate whether these alterations were newly acquired following ibrutinib exposure or represent selective expansions of pre-existing small entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|subcl analysed clones derivatives amplified|cultures extracts fibroblasts lysates nuclei|subclones|evidence against the existence of mammalian tpe comes from a comparison of mrna levels for a telomeric neo gene in entity of sv40-transformed human fibroblasts with varying telomere lengths .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl analysed clones derivatives amplified|extracts mixtures lysates subsets aggregates|subclones|such non-limiting examples include : entity of unmodified cell lines , purified or fractionated subsets of materials provided by atcc , proteins expressed by dna / rna supplied by atcc ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl analysed clones derivatives amplified|extracts lysates preparations mixtures fractions|subclones|some examples include : entity of unmodified cell lines , purified or fractionated sub-sets of the original material , proteins expressed by dna / rna supplied by university , monoclonal
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl analysed clones derivatives amplified|extracts lysates preparations mixtures aggregates|subclones|some examples include : entity of unmodified or modified cell lines , purified or fractionated sub-sets of the original material , proteins expressed by dna / rna supplied by
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl analysed clones derivatives amplified|papers references moab authors patents|subclones|the term " moab 7e11 " includes all entity claimed in such patent .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl analysed clones derivatives amplified|subsets subpopulations mixtures subgroups cultures|subclones|some examples include : entity of cell lines ; purified or fractionated subsets of the original materials or progeny ; dna or rna ; genetic material ; secreted or
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl analysed clones derivatives amplified|extracts lysates preparations mixtures fractions|subclones|some examples include : entity of unmodified cell lines , purified or fractionated sub-sets of the original material , proteins expressed by dna / rna supplied by genencor or
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|subcl analysed clones derivatives amplified|insertions deletions substitutions duplications mutations|subclones|with information concerning the enzymes being used for ongoing subcloning to determine -9- 11 the absolute orientation and position of entity and deletions with respect to the original clone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl analysed clones derivatives amplified|progeny parental transformed unmodified original|subclones|( i ) licensed products means materials and all progeny , entity , and unmodified derivatives of the cell clones .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl analysed clones derivatives amplified|sequences sequencing bases fragments chips|subclones|concentrate samples and load curagen  s dna sequencing gels , allowing the integrated system to generate base called sequences directly from dna entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl analysed clones derivatives amplified|subsets extracts lysates subpopulations fractions|subclones|some examples include : entity of unmodified cell lines , purified or fractionated subsets of the material , proteins expressed by dna / rna supplied by m . i . t . , or monoclonal
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl analysed clones derivatives amplified|lines blocks seeds progeny clusters|subclones|with any refills of the material and any progeny and unmodified derivatives of the material ( including , without limitation , expression products , entity , sub-units or fractionations ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl analysed clones derivatives amplified|progeny derivatives precursors seeds hybrids|subclones|biological materials means the materials identified in appendix a together with any progeny , entity , or derivatives thereof provided by the foundation or created by licensee .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|subcl analysed clones derivatives amplified|clones mutants lymphocytes lines isolates|subclones|in the face of immune pressure , entity susceptible to t cell killing are eliminated , leaving behind resistant tumor clones that are mhc deficient , and hence no longer
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl analysed clones derivatives amplified|lines blocks seeds progeny clusters|subclones|with any refills of the material and any progeny and unmodified derivatives of the material ( including , without limitation , expression products , entity , sub-units or fractionations ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl analysed clones derivatives amplified|newly progeny get recently who|subclones|materials shall mean the tangible material specifically described in exhibit a and physically transferred to licensee and any unmodified copies , progeny and entity made therefrom .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|allo lymphocyte transplantation tolerance auto|allo allogeneic sct xen hla|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vaz tm ( “licensed products” ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|allo lymphocyte transplantation tolerance auto|allo allogeneic sct xen hla|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vaz tm ( &#147 ; licensed products&#148 ; ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|allo lymphocyte transplantation tolerance auto|allo allogeneic sct xen hla|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vaz tm ( &#8220 ; licensed products&#8221 ; ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|allo lymphocyte transplantation tolerance auto|allo allogeneic xen sct autologous|allostim|the license granted covered two experimental products for the treatment of cancer in clinical development called entity tm and allo vax tm ( &#147 ; licensed products&#148 ; ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|allo lymphocyte transplantation tolerance auto|allo allogeneic xen sct hla|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vax tm ( “licensed products” ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|cart clinic art cad il|median urinary log adjusted annual|carticel|the improvement in gross margin is primarily the result of an increase in entity [ r ] aucc sales and a reduction in labor and manufacturing expenses and decreased material expenses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 3), ('DIS', 1)])|cell|cart clinic art cad il|methadone methotrexate isoniazid methamphetamine platelet|carticel|through june 30 , 1997 , gtr had received approximately $5 . 1 million in revenues from u . s . sales of entity ( tm ) acc since its market introduction in march 1995 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|cart clinic art cad il|example adults comparison surgeons decades|carticel|efficacy data demonstrating durability of repair is now out to 20 years for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|cart clinic art cad il|hydroxyapatite atrial titanium ventricular chitosan|carticel|the following table summarizes the early results of the commercialization of entity ( tm ) acc in the u . s . :
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|cart clinic art cad il|marketing approval market safety trial|carticel|if gtr were prohibited from marketing entity ( tm ) aucc in the u . s . , its results of operations would be materially adversely affected .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|cell|cart clinic art cad il|doctor physician specialist nurse pharmacist|carticel|the company recognizes maci ( or entity ) kit revenue upon delivery of the biopsy kit at which time the customer ( the doctor ) is in control of the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cell|cart clinic art cad il|tm platelet idiopathic subcutaneous intravenous|carticel|in august 1997 , the fda approved gtr  s bla for entity ( tm ) aucc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|cart clinic art cad il|annual medicare bill tax consumer|carticel|for the first half of 2015 , total entity and epicel net product revenues increased approximately 17% over pro-forma net product revenues for the same period in 2014 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|cart clinic art cad il|articular autologous bovine rheumatoid synovial|carticel|the blue cross blue shield association has determined that its technology assessment committee does not believe that entity chondrocytes meets all of its published criteria for new treatments .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|cell|cart clinic art cad il|devices pharmaceuticals materials medicines biologics|carticel|the cambridge facility has been used for u . s . manufacturing and distribution of entity , worldwide manufacturing and distribution of epicel and production of maci for clinical testing .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|cart clinic art cad il|il al version 200 bio|carticel|orthopaedics gabi*  sepra  synvisc®  provisc® ( alcon )  entity  hylaform® ( inamed ) focused on treating disease and restoring health through local effects on biology
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|cart clinic art cad il|annual medicare bill price consumer|carticel|total entity and epicel net product revenues in the second quarter increased approximately 31% over pro-forma second-quarter net product revenues in 2014 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|cart clinic art cad il|platelet intravenous subcutaneous tenofovir platinum|carticel|the commercial success of entity ( tm ) aucc will also depend materially on the ability of gtr to increase the approval rate for reimbursement of the product
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|cart clinic art cad il|dental implant implants orthopedic cochlear|carticel|total revenues for the quarter ended june 30 , 2015 were $13 . 6 million and included $9 . 1 million in net sales of entity implants and surgical kits and $4 . 3 million in net sales of epicel .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|cell|cart clinic art cad il|services medicines service physicians healthcare|carticel|the increase is primarily due to higher demand for entity , offset , in part , by a decline in sales of epicel due to a decrease in patients requesting this service .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cell|cart clinic art cad il|articular hypertrophic cultured rheumatoid degenerative|carticel|genzyme believes that entity chondrocytes does in fact meet all of these criteria and are discussing the evaluation with the blue cross blue shield
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|cell|cart clinic art cad il|radiofrequency autologous metastatic inoperable subcutaneous|carticel|( 5% ) 16 ( 76% ) 1 ( 5% ) 4 ( 19% ) gtr has compiled safety data on 460 patients who have undergone treatment with entity ( tm ) acc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|cart clinic art cad il|caution arthroscopy consideration emphasis decompression|carticel|entity is indicated for the repair of symptomatic cartilage defects of the femoral condyle ( medial , lateral or trochlea ) caused by acute
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|cart clinic art cad il|surgeons osteoarthritis arthroscopy cartilage arthroplasty|carticel|market opportunity for entity in the u . s . annually , there are approximately 1 million arthroscopic procedures and more than 250 , 000 cartilage surgical procedures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|cart clinic art cad il|medline electrocardiogram tm tuberculosis pharmacokinetics|carticel|gtr is conducting additional research relating to entity ( tm ) aucc pursuant to a sponsored research agreement with the university of gotenburg in sweden and certain physicians , including the two
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|al pigment fur ru leaf|cel 200 iii 50 111|rivogenlecleucel|about rivo-cel ( bpx-501 ) rivo-celtm ( entity ) is an allogeneic polyclonal t-cell product designed to accelerate immune recovery after hsct and to reduce relapse of leukemia following
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|al pigment fur ru leaf|cel hscs bilirubin toxin platelets|rivogenlecleucel|rimiducid will be administered to inactivate entity ( rivo-cel ) in the event of gvhd not responsive to standard of care treatment updated 8 nov 2018 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|cell|al pigment fur ru leaf|cel eg curcumin formerly here|rivogenlecleucel| rivo-cel ( entity , formerly known as bpx-501 ) is a product candidate intended to improve hsct outcomes in the treatment of hematologic malignancies , including
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|al pigment fur ru leaf|cel 200 iii 50 90|rivogenlecleucel|about rivo-cel ( bpx-501 ) rivo-celtm ( entity ) is an allogeneic polyclonal t cell product designed to reduce the rate of relapse of leukemia following a stem cell
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|al ky university institute uk|contamination bias them relapse amplification|kymriah|– conserving the clinically validated cd19 car cell manufacturing process minimizes confounding risks penn process , not novartis process ; avoids entity release
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|al ky university institute uk|approved sponsored funded introduced recommended|kymriah|the fda has also approved two non-aav gene therapy products , entity by novartis international ag , for pediatric and young adult patients with a form of acute lymphoblastic leukemia and yescarta by
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|al ky university institute uk|commercial autologous donors allogeneic moab|kymriah|two such companies , novartis international ag ( entity® ) and kite pharma inc . / gilead sciences , inc . ( yescarta® ) , have now commercialized autologous car+ t cells against cd19 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|al ky university institute uk|she fda company there industry|kymriah|the company did not recognize royalty revenue in the comparative periods in the prior year given that entity was first approved for commercial sale in the second half of 2017 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cell|al ky university institute uk|crs vitiligo nar mrsa ibd|kymriah|only 20% of entity or yescarta patients treated with tocilizumab had resolution of signs and symptoms 6 days after onset of crs and ~50%
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|al ky university institute uk|tau p65 di just 5mg|kymriah|nomenclature ‘zuma-19 , may be the basis for the registration of lenzilumab , given the similar trial design to yescartas and novartiss entity® ( “entity” or “entity®” ) registration trials .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|al ky university institute uk|crs das cms hc experts|kymriah|both entity and yescarta carry “black box” warnings in their labels for nt and crs and are subject to a rems program ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|al ky university institute uk|aug requires foundation van during|kymriah|maintaining clear leadership in share of voice entity polivy xpovio yescarta share of voice aug sep oct monjuvi compared to >50% monjuvi monjuvi 50% 30% 0% hcp engagement
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|cell|al ky university institute uk|rituximab chemotherapy imatinib cyclophosphamide biologics|kymriah|the fda approved entity ( tisagenlecleucel ) for the treatment of certain pediatric and young adult patients with a form of acute lymphoblastic leukemia ( all ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|cell|al ky university institute uk|fda etanercept infliximab immunotherapy rituximab|kymriah|because of the risk of cytokine release syndrome and neurological events , entity is being approved with a rems .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|al ky university institute uk|china who library university academic|kymriah|september 2018 , we entered into a license and collaboration agreement with novartis to manufacture and supply their car-t cell therapy entity® in china .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|al ky university institute uk|another alternative trial funding placebo|kymriah|no head to head trials have been conducted that would enable a direct safety and efficacy comparison to yescarta or entity source : uspi unless otherwise noted a aacr , 2017 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|cell|al ky university institute uk|adalimumab ranibizumab bevacizumab psoriasis citrus|kymriah|in 2017 , three gene therapies were approved for the first time in the united states , namely , entity , yescarta , and luxturna .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|al ky university institute uk|namely australia italy france usa|kymriah|in 2017 , three gene therapies were approved for the first time in the united states , entity , yescarta , and luxturna .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|cell|al ky university institute uk|pharmaceuticals medicines physicians overdose fda|kymriah|in august 2017 , novartis received fda approval for entity and paid the company $2 . 5 million as a result of the achievement of a related milestone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|cell|al ky university institute uk|immunotherapy rituximab infliximab there psoriasis|kymriah|entity is a genetically-modified autologous t-cell immunotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|al ky university institute uk|usa eu uk era union|kymriah|there are currently two car-t therapies approved in the u . s . and eu , novartis entity ( tisagenlecleucel ) and gilead / kites yescarta ( axicabtagene ciloleucel ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|al ky university institute uk|namely whereas brazil germany france|kymriah|commenting on the results , joseph jimenez , ceo of novartis , said : “novartis became the first company to commercialize a car-t therapy , entity , in q3 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|al ky university institute uk|rituximab immunotherapy vaccine mesylate mab|kymriah|• entity ( tisagenlecleucel ) is a cd19-directed genetically modified autologous chimeric antigen receptor t-cell ( car-t ) therapy delivered as an intravenous infusion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|al ky university institute uk|approved licensed recently recommended now|kymriah|yescarta has been approved for the treatment of relapsed or refractory large b-cell lymphoma and entity for the treatment of relapsed or refractory b-cell precursor acute lymphoblastic leukemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|cell|island surg al med surgeons|rituximab everolimus imatinib bevacizumab chop|yescarta|in 2017 , the fda approved the first two car-t cell therapies , kymriah and entity , after these products demonstrated strong efficacy in select relapsed or refractory b cell malignancies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|cell|island surg al med surgeons|approval approved enrolled comprising imatinib|yescarta|one of these therapies , entity® obtained accelerated approval for treatment of refractory non-transplant-eligible dlbcl patients in october 2017 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|island surg al med surgeons|approved therapies trials respectively leading|yescarta|finally , two car-t cell therapies were just approved for the treatment of all – kymriah™ ( novartis ) and entity™ ( gilead ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|island surg al med surgeons|approved therapies biologics vaccines approval|yescarta|novartis kymriah™ and gileads entity™ , two gene-modified cell-based therapies , are approved in both the united states and europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|island surg al med surgeons|chemicals groundwater foods contaminants pharmaceuticals|yescarta|further , if contaminants are discovered in our supply of entity or in the manufacturing facilities , such manufacturing facilities may need to be closed for an extended period of time to
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|cell|island surg al med surgeons|fda approval approved medicines rituximab|yescarta|in october 2017 , kite obtained fda approval to commercialize entity for the treatment of adults with relapsed / refractory diffuse large b-cell lymphoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|cell|island surg al med surgeons|psoriasis tacrolimus propofol acupuncture morphine|yescarta|the primary objective of the study is to determine the effect of lenzilumab on the safety of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|island surg al med surgeons|placebo european national uk sham|yescarta|no head to head trials have been conducted that would enable a direct safety and efficacy comparison to entity or kymriah source : uspi unless otherwise noted a aacr , 2017 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|cell|island surg al med surgeons|tacrolimus mmf bevacizumab psoriasis morphine|yescarta|the objective of the phase 2 trial is to determine the effect of mavrilimumab on the safety of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|island surg al med surgeons|mortality epilepsy osteoporosis psoriasis asthma|yescarta|kite has published data on entity in all as well .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|island surg al med surgeons|pharmaceuticals station medicine 25 where|yescarta|arcalyst® is a registered trademark of regeneron pharmaceuticals , inc . and entity® is a registered trademark of gilead sciences , inc . , or its related companies . ​5 table of contentspart 
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|island surg al med surgeons|market canada sales activities award|yescarta|the royalties stem from sales and milestones related to the entity® product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|cell|island surg al med surgeons|rituximab nhl approval chemotherapy immunotherapy|yescarta|additionally , in october 2017 , kite received approval from the fda for entity ( axicabtagene ciloleucel ) , formerly known as kte-c19 , for treatment of patients with r / r nhl .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|island surg al med surgeons|criteria trials approved protocol arms|yescarta|both kymriah® and entity® were approved with a rems .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|island surg al med surgeons|now recently been therapies include|yescarta|two car-t therapies have been approved to treat large b-cell lymphoma , kymriah® and entity® , and others are being tested in clinical trials .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|island surg al med surgeons|review pipeline approved develop comprising|yescarta|pipeline , building on current marketed products and late-stage clinical candidates for patients with hematological malignancies at kite and gilead , including entity® , tecartus® and magrolimab .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|cell|island surg al med surgeons|psoriasis tacrolimus propofol acupuncture morphine|yescarta|the primary objective of the study is to determine the effect of lenzilumab on the safety of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|island surg al med surgeons|bt ts nac bd chop|yescarta|the initial results of axicabtagene ciloleucel ( entity ) , the prognosis of high-grade chemo refractory nhl , is dismal with a medium survival time of a few weeks .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 2)])|cell|island surg al med surgeons|rituximab methotrexate chemotherapy imatinib infliximab|yescarta|entity is a therapy for patients who have not responded to or who have relapsed after at least two other kinds
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|cell|island surg al med surgeons|relapse lymphoma remission relapsed chemotherapy|yescarta|this was notable given the patient had relapsed following treatment with entity® .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|tab fur al mol meta|allele genotype snps snp alleles|tabelecleucel|recent highlights and anticipated upcoming milestones tab-cel® ( entity ) • two phase 3 clinical studies are ongoing ( match and allele ) to evaluate tab-cel® for patients with ebv+ ptld
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|cell|tab fur al mol meta|ema fda rituximab infliximab immunotherapy|tabelecleucel|we believe that entity has the potential to be the first commercially available off-the-shelf t-cell immunotherapy and the first fda- and ema-approved therapy for
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|cell|tab fur al mol meta|ema fda cea rituximab infliximab|tabelecleucel|we believe that entity has the potential to be the first commercially available off-the-shelf t-cell immunotherapy and the first fda and ema approved therapy
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|tab fur al mol meta|our efforts them scientists knowledge|tabelecleucel|with entity poised to potentially become the first approved off-the-shelf t-cell therapy and a robust pipeline of high potential candidates , our ambition
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|tissue|tendon tendons tendin tear ruptures|peripheral lumbar spinal thoracic sciatic|tendon|and adcon-t / n to be marketed in the 19 european union countries which recognize ce marking for lumbar disc surgery and entity and peripheral nerve surgeries , respectively .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|tissue|tendon tendons tendin tear ruptures|tendon meniscal aneurysm premature ligament|tendon|warnings and precautions risk of tendinitis , entity rupture , peripheral neuropathy and central nervous system effects is increased with use of fluoroquinolones .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|tissue|tendon tendons tendin tear ruptures|ligament tendon cartilage meniscal meniscus|tendon|and / or product development for various treatments for or involving fracture repair , spine fusion surgery , cartilage defect repair and ligament and entity repair .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|tissue|tendon tendons tendin tear ruptures|tendon tendons ligament ligaments tears|tendon|graftjacket® maxforce extreme is a high strength form of graftjacket® matrix which provides maximum suture holding power for the most challenging of entity and ligament repairs .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|tissue|tendon tendons tendin tear ruptures|peripheral thoracic spinal renal abdominal|tendon|now being sold in all major countries in the eu , as well as australia and new zealand for use in entity and peripheral nerve surgeries .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|tendon tendons tendin tear ruptures|ligament tendon cartilage periodontal wound|tendon|therapeutic devices utilizing its nonthermal ultrasound technology ( " orthosound " ) for use in medical applications that relate to bone , cartilage , ligament or entity diagnostics and healing .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|tissue|tendon tendons tendin tear ruptures|cartilage ligament tendon gingiva ligaments|tendon|extent the gingiva functions as part of the apparatus holding the tooth to the jaw ) , ligament ( including the periodontal ligament ) , entity and / or cartilage .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|tendon tendons tendin tear ruptures|gastrointestinal neurological psychiatric mood mental|tendon|quinsair is contraindicated in patients with hypersensitivity to levofloxacin , a history of entity disorders related to fluoroquinolones , epilepsy , or who may be pregnant or breast feeding .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|tissue|tendon tendons tendin tear ruptures|mineral milk abdominal soft maxillofacial|tendon|bone & entity pill it consists of extracts of a variety of chinese medicinal herbs .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|tendon tendons tendin tear ruptures|gastrointestinal neurological psychiatric mood mental|tendon|quinsair is contraindicated in patients with hypersensitivity to levofloxacin , a history of entity disorders related to fluoroquinolones , epilepsy , or who may be pregnant or breast feeding .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|tissue|tendon tendons tendin tear ruptures|musculoskeletal skeletal neurological periodontal maxillofacial|tendon|the medicinal product is to be taken orally for the purpose of curing bone and entity disorders .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|tissue|tendon tendons tendin tear ruptures|antibiotic fluoroquinolones quinolone fluoroquinolone vancomycin|tendon|warnings regarding the risk of entity related adverse events were already included in the prescribing information , as part of a class labeling , for all fluoroquinolones .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|tissue|tendon tendons tendin tear ruptures|tendon tendons tears ligament ligaments|tendon|graftjacket® is a human-derived soft tissue graft designed for augmentation of entity and ligament repairs such as those of the rotator cuff in the shoulder and achilles entity in the ankle .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|tendon tendons tendin tear ruptures|wound tendon flap original meniscal|tendon|by augmenting the strength of the entity repair and incorporating biologically , graftjacket® regenerative tissue matrix increases surgeons confidence in the surgical outcome .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|tissue|tendon tendons tendin tear ruptures|tendon tendons tears ligament ligaments|tendon|graftjacket® matrix is a human-derived soft tissue graft designed for augmentation of entity and ligament repairs such as those of the rotator cuff in the shoulder and achilles entity in the ankle .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|tendon tendons tendin tear ruptures|septic tendin onych acne lacer|tendon|fluoroquinolones are 26 known for several undesirable effects such as entityitis , achilles entity rupture , c . difficile colitis , and hepatotoxicity and central nervous system side effects .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|tissue|tendon tendons tendin tear ruptures|peripheral lumbar spinal thoracic cervical|tendon|adcon-l and adcon-t / n to be marketed in the 19 european countries which recognize ce marking for lumbar disc surgery and entity and peripheral nerve surgeries , respectively .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|tissue|tendon tendons tendin tear ruptures|antibiotic quinolone fluoroquinolones vancomycin fluoroquinolone|tendon|currently , warnings regarding the risk of entity related adverse events are included in the prescribing information , as part of a class labeling , for all fluoroquinolones .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|tendon tendons tendin tear ruptures|ligament tendon ligaments soft cement|tendon|ligament and entity repair ligaments are the soft tissues that connect bone to bone .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|tissue|tendon tendons tendin tear ruptures|renal chromosomal genomic pulmonary chromosome|tendon|further , in july 2008 , the fda requested manufacturers of fluoroquinolones to include a black box warning for entity damage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macular macula retinal retina eyes|macular retinal choroidal optic foveal|macula|optina for diabetic entity edema on october 7 , 2013 , we received positive results from the interim analysis of optina trial for diabetic macular edema .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macular macula retinal retina eyes|american european vision british international|macula|company presented preclinical data at the association for research and vision in opthalmology conference in may 2012 , and at the entity society meeting in june 2012 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macular macula retinal retina eyes|ability tendency capacity inability barrier|macula|the leakage of fluid , solutes , proteins and immune cells cause the entity to swell and thicken .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|macular macula retinal retina eyes|nerve ganglion retina rod tendon|macula|described as a partial or total loss of visual field resulting from certain progressive disease or degeneration of the retina , entity or nerve fiber bundle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macular macula retinal retina eyes|retina choroid macula fovea iris|macula|in patients with dme , leakage from these abnormal blood vessels occurs in the central portion of the retina , called the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macular macula retinal retina eyes|retina macula rpe choroid globe|macula|introduction to amd amd is a progressive and irreversible disorder of the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|macular macula retinal retina eyes|retina pigment iris choroid macula|macula|the entity is the central portion of the retina in the eye and is responsible for both high acuity vision and color
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macular macula retinal retina eyes|national world vision retinal universal|macula|according to the entity vision research foundation , as many as 15 million people in the united states suffer from some form of amd , with more
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|macular macula retinal retina eyes|retina eyes vessels cornea endothelium|macula|these vessels can leak fluid and blood , which may lead to swelling and damage of the entity causing vision loss .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macular macula retinal retina eyes|retina fovea eyes vision rpe|macula|implies , usually affects older adults and results in a loss of vision in the center of the visual field ( the entity ) because of damage to the retina .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macular macula retinal retina eyes|amd rd macular melan vitre|macula|for age-related entityr degeneration , or amd , which is a disorder of the central portion of the retina , known as the entity , that may result in blindness .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macular macula retinal retina eyes|retina globe macula cornea fovea|macula|or neovascularization , causes vision loss due to blood and protein - 94 - table of contents leakage below the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macular macula retinal retina eyes|american european international national japanese|macula|the principal investigator of study 003 presented a case report from the first patient to complete the protocol at the entity society meeting on february 19 , 2014 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macular macula retinal retina eyes|retina dark rpe vitreous macula|macula|in the dry form , there is a breakdown of retinal pigment epithelial cells in the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|tissue|macular macula retinal retina eyes|retina choroid vasculature endothelium cornea|macula|the wet form is caused by growth of abnormal blood vessels ( cnv ) under the central part of the retina or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|macular macula retinal retina eyes|retina retinopathy pigment cataract macula|macula|an eye disease characterized by the growth of abnormal blood vessels under the central part of the retina , called the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macular macula retinal retina eyes|vas om rd br dme|macula|entityr edema is the build-up of fluid that can cause abnormal swelling of the macula , the portion of the retina responsible for central vision and color perception .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macular macula retinal retina eyes|retina largest smallest cerebellum fovea|macula|the central portion of the retina is the entity , which is the region responsible for seeing color and the acute central vision necessary for activities such as reading , face
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macular macula retinal retina eyes|fovea retina vision eyes rpe|macula|that usually affects older adults and results in a loss of vision in the center of the visual field ( the entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|macular macula retinal retina eyes|retina periphery stroma lumen vitreous|macula|this process , known as angiogenesis or neovascularization , results in fragile blood vessels that leak fluid and blood into the entity , the center portion of the retina .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|nerve nerves tendon dye ganglion|fibers tendon fibrils tendons graft|perineurium|the lamellar structure of the entity and a deficiency in collagen packing in the endoneurium was observed more frequently and to a larger extent in fibromyalgia
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|nerve dye neurotoxin endo nerves|dermis cortex synovium joints extremities|endoneurium|the lamellar structure of the perineurium and a deficiency in collagen packing in the entity was observed more frequently and to a larger extent in fibromyalgia patients than in controls .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|tissue|uroth bladder epithelial carcinoma epithelia|submucosa mucosa epithelium bladder prostate|urothelium| by three months post-implantation , the scaffold is replaced by native-like bladder tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|tissue|uroth bladder epithelial carcinoma epithelia|submucosa epithelium mucosa bladder crypts|urothelium|months post-implantation , the bioabsorbable scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 3), ('OTHER', 3)])|tissue|uroth bladder epithelial carcinoma epithelia|epithelial epithelium superficial basement mucosal|urothelium|bladder carcinoma is a specific form of bladder cancer resulting from the development and progression of cancerous tumors within the entity layer .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|uroth bladder epithelial carcinoma epithelia|bladder prostate pelvis ureter rectum|urothelium|eligible patients included those with transitional cell carcinoma of the entity , including renal pelvis , ureters , urinary bladder , and urethra .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|uroth bladder epithelial carcinoma epithelia|bladder intravesical transdermal urinary delivered|urothelium|not effectively permeating the entity  rtgel delivered treatment to the bladder as expected with dwell time of up to 10 hours
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|tissue|uroth bladder epithelial carcinoma epithelia|bladder urethra prostate detrusor ureter|urothelium|one theory of cpps pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|tissue|uroth bladder epithelial carcinoma epithelia|submucosa epithelium mucosa bladder crypts|urothelium|three months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DIS', 1)])|tissue|uroth bladder epithelial carcinoma epithelia|epithelium mucosa stroma bladder epithelia|urothelium|upper tract urothelial carcinoma ( utuc ) utuc refers to malignant changes of the entity ( the epithelial lining ) of the upper urinary tract of the calyces , renal pelvis and ureter .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 3), ('OTHER', 2), ('DIS', 1)])|tissue|uroth bladder epithelial carcinoma epithelia|submucosa epithelium mucosa bladder fibroblasts|urothelium|three months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like urinary tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|uroth bladder epithelial carcinoma epithelia|lamina mucosa submucosa epithelium propria|urothelium|beneath the entity , there is a layer called the lamina propria .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|tissue|uroth bladder epithelial carcinoma epithelia|formulation catheter medication agent toxin|urothelium|apollo trial did not meet the primary endpoint , believed to be the result of botox not effectively permeating the entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|tissue|uroth bladder epithelial carcinoma epithelia|bladder epithelium barrier prostate urethra|urothelium|one theory of pbss pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|tissue|uroth bladder epithelial carcinoma epithelia|bladder prostate epithelium mucosa urethra|urothelium|normally , the entity is covered with a mucus layer , the glycosaminoglycan , or gag , layer , which is thought to protect the bladder from urinary
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|tissue|uroth bladder epithelial carcinoma epithelia|bladder urethra prostate detrusor ureter|urothelium|one theory of cpps pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|uroth bladder epithelial carcinoma epithelia|tumour vasculature bbb microenvironment tube|urothelium|implantation of stray " floating " tumor cells in areas in which the entity has been disrupted may be followed by the growth of the implanted cells to form a new tumor .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|tissue|uroth bladder epithelial carcinoma epithelia|bladder urethra prostate detrusor epithelium|urothelium|one theory of bpss pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|tissue|uroth bladder epithelial carcinoma epithelia|transitional urothelial epithelial bladder tubular|urothelium|the innermost lining is comprised of cells called urothelial or transitional cells , and this inner layer is called the entity or transitional epithelium .
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|tissue|uroth bladder epithelial carcinoma epithelia|bladder prostate epithelium mucosa urethra|urothelium|normally , the entity is covered with a mucus layer , the glycosaminoglycan , or gag layer , which is thought to protect the bladder from urinary
OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|uroth bladder epithelial carcinoma epithelia|wall floor integrity neck sphincter|urothelium|be well positioned , as it will address both the acute pain the patient experiences and the dysfunctional aspect of the entity of the bladder wall .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|epithelium epithelial pigment epithelia squamous|mucosa submucosa stomach rectum ileum|epithelium|overview of ibd ulcerative colitis ( uc ) description uc is a chronic gi inflammatory disorder which involves the surface mucosa , the entity and the submucosa of the colon .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|tissue|epithelium epithelial pigment epithelia squamous|pigment retina pigmented iris epithelium|epithelium|key portions of the eye that were evaluated for levels of drug remaining were the sclera-choroid-retinal pigmented entity , or scr , the neural retina and the vitreous .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|tissue|epithelium epithelial pigment epithelia squamous|epithelium layer pigment gland glands|epithelium|in occult lesions , all of the blood vessels are below the retinal pigment entity , or rpe , and the areas on angiograms have a stippled appearance .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|tissue|epithelium epithelial pigment epithelia squamous|organs diseases destruction injuries defects|epithelium|this includes injuries to the hematopoietic and immune systems , the entity of the digestive tract and hair follicles .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|epithelium epithelial pigment epithelia squamous|fibroblasts epithelium epidermis keratinocytes dermis|epithelium|tamibarotene does not bind the rar-g receptor , the major retinoic acid receptor in the dermal entity .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|epithelium epithelial pigment epithelia squamous|dermis fibroblasts epidermis epithelium keratinocytes|epithelium|tamibarotene does not bind the rar-g receptor , the major retinoic acid receptor in the dermal entity , which should lessen the occurrence of ras .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|tissue|epithelium epithelial pigment epithelia squamous|epithelium epithelial layer gland glands|epithelium|by the much greater amount of the fluorescent protein expressed ) with aav8 as compared to aav2 in the retinal pigment entity ( rpe ) and to the photoreceptor ( pr ) layer .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|epithelium epithelial pigment epithelia squamous|lumen mucosa epithelium cavity epidermis|epithelium|of calcium and phosphate ions , which are hypothesized to exert their beneficial effects by diffusing into intracellular spaces in the entity and permeating the mucosal lesion in mucositis .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('BIO', 3), ('OTHER', 2)])|tissue|epithelium epithelial pigment epithelia squamous|epithelium endothelium graft cornea stroma|epithelium|these events are commonly observed following removal of the corneal entity and in the treatment group of our trials , occurred at a higher incidence than observed in control patients .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|epithelium epithelial pigment epithelia squamous|diameter thickness patency composition enlargement|epithelium|pathologic analysis showed marked effects on breast duct entity in ducts treated with either drug compared with untreated ducts .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|epithelium epithelial pigment epithelia squamous|mucosa epithelium lumen wall barrier|epithelium|blood causes a prolonged period of low blood flow to the intestines that can lead to damage to the intestinal entity .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|epithelium epithelial pigment epithelia squamous|mucosa epithelium lumen wall villi|epithelium|the expression of il-15 in the intestinal entity is necessary for villous atrophy in animal models of celiac disease and circumstantial evidence suggests this to be the case
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('BIO', 3), ('OTHER', 2)])|tissue|epithelium epithelial pigment epithelia squamous|stroma epithelium endothelium cornea iris|epithelium|the procedure involves the removal of " bowman  s layer , " an intermediate layer between the entity ( outer corneal layer ) and the stroma ( middle corneal layer ) .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|epithelium epithelial pigment epithelia squamous|epithelium layer proteoglycan sheath genome|epithelium|the hair matrix entity is one of the fastest growing cell populations in the human body .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|tissue|epithelium epithelial pigment epithelia squamous|mucus pathogens antigens debris cytokines|epithelium|the gi tract is highly sensitive due to the continuous need for crypt stem cells and production of mucosal entity .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|epithelium epithelial pigment epithelia squamous|epithelium layer layers stroma lumen|epithelium|loss of the functional oca2 protein results in a lack of pigment in the retinal pigment entity and the underlying choroid layers .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|tissue|epithelium epithelial pigment epithelia squamous|epithelium epithelial gland layer glands|epithelium|for lca2 , retinal function was restored by reconstituting gene function in the retinal pigment entity ( rpe ) .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|epithelium epithelial pigment epithelia squamous|cavity mucosa sinus circulation airway|epithelium|the nasal administration is intended to determine if physiologic measurement of cftr function can be obtained in the nasal entity .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|epithelium epithelial pigment epithelia squamous|cavity epithelium mucosa wall lumen|epithelium|our vaginal products adhere to the vaginal entity until discharged upon normal cell turnover , a physiological process that can take 72 hours , or longer , and provide sustained and
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|epithelium epithelial pigment epithelia squamous|mucosa epithelium cavity septum tip|epithelium|however , the nasal entity is the most accessible site for measuring cftr function in humans and provides a human model of epithelial cell uptake
OrderedDict([('OTHER', 3), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|tissue|epithelial ectoderm mesenchyme sensory epithelium|mesoderm endoderm ectoderm mesenchyme mesodermal|ectoderm|and the capability to differentiate into cells representing the three germ layers - endoderm ( gut epithelium ) , mesoderm ( striated muscle ) and entity ( neural epithelium ) .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|endoderm epithelial mesenchyme ectopic within|autologous pluripotent progenitor mesenchymal hematopoietic|endoderm|the third patent , granted in the united states , covers the method for deriving entity cells using stem cells .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|endoderm epithelial mesenchyme ectopic within|mesoderm endoderm mesodermal blast progenitor|endoderm|territory patent no . general subject matter expiration us 7 , 763 , 466 method to produce entity cells may 2025 us 7 , 955 , 849 method of enriching population of mesoderm cells may 2023 us
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|tissue|endoderm epithelial mesenchyme ectopic within|epithelial mast mesenchymal mesothelial somatic|endoderm|in particular , entity cells make cells of internal organs such as the lung , pancreas , and liver as well as other internal cell types .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|endoderm epithelial mesenchyme ectopic within|pluripotent germ progenitor primitive transformed|endoderm|by way of example , we are currently a party to an interference proceeding that involves patent filings for making entity cells from hescs .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|endoderm epithelial mesenchyme ectopic within|endoderm germ embryonic zyg progenitor|endoderm|that the derivation of any of the entityal lineage cells from embryonic stem cells would necessarily pass through the definitive entity stage .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|tissue|endoderm epithelial mesenchyme ectopic within|consent conclusions transplantation therapies decisions|endoderm|if we are not successful in the viacyte appeal , viacyte would retain its patent claims directed to definitive entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 4)])|tissue|endoderm epithelial mesenchyme ectopic within|transplantation pancreas pancreatectomy islet islets|endoderm|definitive entity is an early pre-cursor of numerous cell types including liver and β-cells of the pancreas that could potentially treat diabetes ,
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 2)])|tissue|endoderm epithelial mesenchyme ectopic within|epithelial mast mesenchymal endothelial acinar|endoderm|entity cells develop into the internal organs such as the heart , liver , pancreas and intestines , among other cell types .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|endoderm epithelial mesenchyme ectopic within|epithelial mononuclear few giant mammalian|endoderm|australia patent 2010200610 – the claims in this patent relate to cell cultures comprising entity cells , one of the three major lineages of cells that make up the human body .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|endoderm epithelial mesenchyme ectopic within|embryonic dorsal endoderm mesoderm called|endoderm|stem cells and pluripotency stem cell primative and thus unspecialized self-renewing can differentiate into cells with specific functions ectoderm mesoderm entity skin hair brain nerves etc .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|endoderm epithelial mesenchyme ectopic within|mesoderm ectoderm endoderm mesenchyme embryo|endoderm|mesentity cells are precursor cells that differentiate into mesoderm and entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|tissue|endoderm epithelial mesenchyme ectopic within|germ progenitor epithelial endothelial tumour|endoderm|these rulings related to interference proceedings involving patent filings relating to definitive entity cells .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|tube hippocampal synapse blastocyst colony|mesoderm|emt is essential for numerous developmental processes including entity formation and neural tube formation .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|mesenchymal epithelial endothelial schwann mast|mesoderm|entity cells develop into muscle , bone and blood , among other cell types .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|mammalian drosophila breast pharmaceutical eukaryotic|mesoderm|developing a drug-targeting platform based on the proprietary use of the human protein called receptor-associated protein , or rap , and the entity development protein , or mesd .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|embryonic hematopoiesis embryogenesis hematopoietic erythropoiesis|mesoderm|the libraries and screens will focus on genes important to entity and early hematopoietic development .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|endoderm mesoderm ectoderm embryo neural|mesoderm|produce such cells , and applications of such cells for es cell-derived immature pluripotent precursors of all the cells of the entity and endoderm lineages .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|breast called mammalian scaffold mammary|mesoderm|table of contents raptors entity development protein , or mesd , platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|breast embryo mammalian eukaryotic preclinical|mesoderm|our entity development protein ( mesd ) platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|stroma inner outer epithelium cytoplasm|mesoderm|in the early embryo , the middle layer of cells ( known as the entity ) and certain portions of the outer cell layers give rise to groups of cells that differentiate into bone marrow stroma ,
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|during inhibitor undergoing library kinase|mesoderm|promising novel drug-targeting platform , based on the proprietary use of a human protein called receptor-associated-protein , or rap and the protein entity development , or mesd .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|breast embryo tobacco fruit mammalian|mesoderm|- 38 - table of contents our entity development protein ( mesd ) platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|mammalian drosophila breast eukaryotic pharmaceutical|mesoderm|are developing drug-targeting platforms based on the proprietary use of the human protein called receptor-associated protein , or rap , and the entity development protein , or mesd .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|endoderm mesoderm ectoderm embryo mesenchyme|mesoderm|mesendoderm cells are precursor cells that differentiate into entity and endoderm .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|during undergoing inhibitor kinase called|mesoderm|and drug delivery platform , based on the proprietary use of a human protein called receptor-associated-protein , or rap and the protein entity development , or mesd .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|neural hematopoietic epithelial embryonic mesenchymal|mesoderm|the seven new cell lines have markers of diverse entity and neural crest cell types and are designated w11 , z2 , sk31 , sm35 , t36 , en51 , and en55 .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|eukaryotic mammalian pharmaceutical prostate lysosomal|mesoderm|is a promising novel drug-targeting platform , based on the proprietary use of a human protein called receptor-associated protein ( rap ) and entity development protein ( mesd ) .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|breast own preclinical newly recent|mesoderm|· our entity development protein , or mesd , platform consists of wnttide™ for the potential treatment of breast cancer .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|breast embryo mammalian eukaryotic preclinical|mesoderm|our entity development protein ( mesd ) platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|breast newly preclinical top naturally|mesoderm|• our entity development protein , or mesd , platform consists of wnttide™ for the potential treatment of breast cancer .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|breast mammalian preclinical wnt top|mesoderm| our entity development protein , or mesd , platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|tissue|mesoderm mesenchyme ectopic endoderm epithelial|world skeleton knee intestine jaws|mesoderm|mesenchymal stem cells ( mscs ) : embryonic-like cell capable of differentiating into multiple tissues of the entity , including cartilage , bone , tendon , ligament , muscle , stroma and fat .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|tissue|lamina epithelium ganglion ganglia epithelial|epidermal dorsal cervical adrenal intestinal|lamina|in-vitro experiments have shown that sirnas against factor 5a protected human entity cribrosa ( optic nerve ) and colon epithelial ( ht-29 ) cells from tnf alpha induced apoptosis .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|lamina epithelium ganglion ganglia epithelial|lamina muscularis corpus layer stratum|lamina|beneath the urothelium , there is a layer called the entity propria .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|lamina epithelium ganglion ganglia epithelial|lamina muscularis intestinal corpus mucosa|lamina|the adaptive response is mediated by gluten-reactive cd4+ t cells in the entity propria that recognize gluten-derived peptides when presented by the hla class ii molecules dq2 or dq8 .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|lamina epithelium ganglion ganglia epithelial|lamina muscularis intestinal corpus mucosa|lamina|gliadin fragments in celiac disease , they are able to pass thru the leaky paracellular pathway from the lumen to the entity propria , where the immune cells reside and are then activated .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|lamina epithelium ganglion ganglia epithelial|lamina muscularis layer corpus propria|lamina|targeted localization of amt-101 to the gi tissue entity propria is expected to translate into clinically meaningful reductions in inflammation and disease activity .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|lamina epithelium ganglion ganglia epithelial|lamina muscularis submucosal luminal mucosal|lamina|gi tissue or entering into systemic circulation : when designing our product candidates , we can target the therapeutic payload to the entity propria of the local gi tissue .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|lamina epithelium ganglion ganglia epithelial|lamina muscularis intestinal bowel luminal|lamina|in healthy bowel wall , bacteria cannot pass from the lumen to the entity propria because tight junctions are maintained between the epithelial cells ( intact barrier function of the bowel wall ) .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|lamina epithelium ganglion ganglia epithelial|guidelines experts colleagues manufacturers legislation|lamina|on february 25 , 2015 , the company entered into the license agreement with entity .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|lamina epithelium ganglion ganglia epithelial|lamina muscularis mucosa intestinal corpus|lamina|at any given time , over 70% of an individuals immune system resides in the entity propria , which is the target-rich tissue of the intestinal tract .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|lamina epithelium ganglion ganglia epithelial|neck implant prosthesis spine radius|lamina|in a decompressive laminectomy , the surgeon removes bone , known as the entity , from the back part of the symptomatic vertebrae over the spinal canal to create more space for , and relieve pressure
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|lamina epithelium ganglion ganglia epithelial|lamina muscularis corpus intestinal mucosa|lamina|cell-secreted gp96-ig-peptide complexes induce entity propria and intraepithelial cd8+ cytotoxic t lymphocytes in the intestinal mucosa .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|lamina epithelium ganglion ganglia epithelial|there india france italy germany|lamina|entity is a private corporation over which dr . raouf guirguis has sole control .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|lamina epithelium ganglion ganglia epithelial|international federal british nhs european|lamina|&#160 ; on february 25 , 2015 , the company entered into a license agreement with entity equities corporation ( &#8220 ; entity&#8221 ; ) .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|lamina epithelium ganglion ganglia epithelial|intestinal colonic peritoneal intestine epidermal|lamina|these data were collected in tests in human entity cribrosa cells grown from human optic nerve heads and from human intestinal epithelial cells .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|lamina epithelium ganglion ganglia epithelial|nerve disk herniation prosthesis hernia|lamina|of all or part of a damaged disc , and laminectomy , which is the removal of all or part of a entity .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|lamina epithelium ganglion ganglia epithelial|lamina muscularis intestinal corpus gut|lamina|in the gut antigens such as gluten are processed by resident dendritic cells in the entity propria which then migrate to the local mesenteric 31 lymph nodes .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|lamina epithelium ganglion ganglia epithelial|lamina muscularis corpus propria stratum|lamina|disease activity index , colonic leukocytic infiltration , entity propria neutrophils and colonic tnf expression were used as endpoints .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|lamina epithelium ganglion ganglia epithelial|epidermal lamina colonic intestinal corpus|lamina|in-vitro experiments have shown that sirnas against factor 5a protected human entity cribrosa ( optic nerve ) and colon epithelial cells from tnf alpha induced apoptosis .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|lamina epithelium ganglion ganglia epithelial|lamina muscularis corpus stratum layer|lamina|ta and cis are limited to the urothelial layer , and t1 is limited to the layer below , which is the entity propria .
OrderedDict([('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|lamina epithelium ganglion ganglia epithelial|cultured untreated a549 transfected murine|lamina|by inhibiting factor 5a , we were able to reduce tnf-a induced apoptosis by 80% in entity cribrosa cells .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|myocardial myocardium ultrastructure infarction ischemic|graft grafts flap regeneration scaffold|myocardium|finally , the cells could promote regeneration of viable new tissue , improving the functional capacity of the entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|myocardial myocardium ultrastructure infarction ischemic|myocardium circulation aorta hearts majority|myocardium|thus such a molecule should have desirable properties in experiments aimed at inducing collateral circulation in the entity of patients with coronary stenosis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|myocardial myocardium ultrastructure infarction ischemic|myocardium mitochondria ventricle cardiomyocytes myocytes|myocardium|may also provide information on cardiac mitochondrial membrane potential , enabling global and regional assessment of the electro-physiologic integrity of the entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|myocardial myocardium ultrastructure infarction ischemic|chest extremities lungs diaphragm breath|myocardium|characterized by thoracic pain and a feeling of suffocation , most often due to anoxia ( lack of oxygen supply ) to the entity precipitated by physical exertion or excitement .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|myocardial myocardium ultrastructure infarction ischemic|aorta ventricle limb hearts atrium|myocardium|the primary objectives of this trial are to evaluate the safety and efficacy of injecting 150 million mpcs into the native entity of lvad recipients .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|myocardial myocardium ultrastructure infarction ischemic|organism electrode wall epithelium epidermis|myocardium|cm1 has been shown to couple electrically and mechanically with the host entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|tissue|myocardial myocardium ultrastructure infarction ischemic|ischemia infarction myocardium infarct reperfusion|myocardium|the death of myocardial cells first occurs in the area of entity that is most distal to the arterial blood supply , the endocardium .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|myocardial myocardium ultrastructure infarction ischemic|wall myocardium septum myocytes walls|myocardium|potassium channels that control normal functioning of the middle layer of heart wall composed of cardiac muscle , or the ventricular entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|myocardial myocardium ultrastructure infarction ischemic|myocardium limb vessels vessel graft|myocardium|the hesc-cm treated heart ( right ) shows a large graft of human heart muscle ( green ) replacing the entity lost to infarction .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|myocardial myocardium ultrastructure infarction ischemic|myocardium wall myocytes septum atrium|myocardium|appear to target these channels which mediate atrial arrhythmia without disrupting potassium channels that control normal functioning of the ventricular entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|myocardial myocardium ultrastructure infarction ischemic|scar blue myocardium vessels gray|myocardium|the heart of an nhp by hesc-cm transplantation the saline-treated heart ( left ) shows infarct scar tissue ( blue ) replacing the entity lost to infarction .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myocardial myocardium ultrastructure infarction ischemic|myocardium hearts rats cortex vessels|myocardium|responsive relationship , with higher doses of bone marrow mononuclear cells resulting in reduced fibrosis and increased microvascular change in infarcted entity 60 days after treatment .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|myocardial myocardium ultrastructure infarction ischemic|setting myocardium future manner direction|myocardium|the targeted 24 table of contents cardiomyocytes are expected to produce sustained therapeutic protein levels in the entity where it is needed .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|myocardial myocardium ultrastructure infarction ischemic|arteries vessels myocardium rats veins|myocardium|when injected into ischemic entity , mlcs are very potent inducers of large caliber arteriogenesis compared to 104 table of contents index to financial statements
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|myocardial myocardium ultrastructure infarction ischemic|myocardium hearts lungs extremities aorta|myocardium|bfpet has been designed to effectively differentiate among those cells of the entity that are ischemic , infarcted and those that are healthy .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|myocardial myocardium ultrastructure infarction ischemic|viable candidates donors myocardium grafts|myocardium|physicians to screen for coronary artery disease , to assess flow rates and flow reserve , and to distinguish viable from nonviable entity for bypass and transplant candidates .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myocardial myocardium ultrastructure infarction ischemic|individuals hearts myocardium athletes muscles|myocardium|if blood flow can be restored to at-risk entity , more heart muscle can be saved from irreversible damage or death .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|myocardial myocardium ultrastructure infarction ischemic|myocardium apex ventricle septum endocard|myocardium|as the duration of the occlusion increases , the area of myocardial cell death enlarges , extending from the endocardium to the entity and ultimately to the epicardium .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|myocardial myocardium ultrastructure infarction ischemic|capillary circulation vessel capillaries venules|myocardium|this results in the solution entering the entity via post capillary venules .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myocardial myocardium ultrastructure infarction ischemic|myocardium hearts wall pericardium valve|myocardium|we believe that ik-5001 will work as a temporary structural support while the damaged entity heals by replacing the dead tissue that would normally support the wall of the heart .
OrderedDict([('OTHER', 3), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|epithelial carcinoma tumour mesothelioma mesothelial|licens code public every mist|mesothelium|the company will license entity mab from the nih and in return the agreement , requires the company to make a $75 , 000 non-refundable license issue payment
OrderedDict([('OTHER', 3), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|epithelial carcinoma tumour mesothelioma mesothelial|lungs pleura cavity peritoneum stomach|mesothelium|mesothelioma mesothelioma is a rare form of cancer in which malignant cells develop in the entity , a protective lining that covers most of the bodys internal organs .
OrderedDict([('OTHER', 3), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|epithelial carcinoma tumour mesothelioma mesothelial|monoclonal recombinant conjugate chimeric directed|mesothelium|of march 22 , 1999 , the company and nih entered into an exclusive worldwide licensing agreement to develop and commercialize a entity antigen therapy ( mesothelin mab ) .
OrderedDict([('OTHER', 3), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|epithelial carcinoma tumour mesothelioma mesothelial|licens code issue public mist|mesothelium|the company will license entity mab from the nih and in return , the agreement requires the company to make a $75 , 000 non-refundable license issue payment
OrderedDict([('OTHER', 3), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|epithelial carcinoma tumour mesothelioma mesothelial|lungs pleura mediastinum chest neck|mesothelium|malignant pleural mesothelioma is an aggressive form of cancer that occurs in the entity , the thin layer of tissue that covers the lungs .
OrderedDict([('OTHER', 3), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|epithelial carcinoma tumour mesothelioma mesothelial|sac peritoneum lumen lymph spleen|mesothelium|differentiating mesothelioma from adenocarcinoma mesothelioma is a cancer that develops in the entity - a protective sac that covers most of the bodys internal organs .
OrderedDict([('OTHER', 3), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|epithelial carcinoma tumour mesothelioma mesothelial|majority wall floor periphery lumen|mesothelium|when ovarian cancer spreads to the entity of the organs within the peritoneal cavity , it can result in encasement of these organs with significant pain and eventual
OrderedDict([('OTHER', 3), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|tissue|epithelial carcinoma tumour mesothelioma mesothelial|periphery parenchyma cytoplasm interior epithelium|mesothelium|about malignant mesothelioma malignant mesothelioma is a cancer that originates in the entity – the tissue that surrounds different organs in the body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|dentine enamel demineral dentin caries|enamel dentin teeth tooth dentine|dentine|the lactic acid erodes the mineral in enamel and entity , weakening the tooth and ultimately resulting in decay .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|enamel dentine caries fluoride demineral|extracellular injectable acellular alternative artificial|enamel|ongoing dental projects include : o an entity matrix protein-based product for endodontic therapy ( treatment of dental pulp ) - a phase i trial is underway .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|enamel dentine caries fluoride demineral|pulp tooth wall surfaces canal|enamel|fluorinex has developed a unique device that delivers fluoride ions directly to the tooth entity via a sophisticated electro-chemical technique .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|enamel dentine caries fluoride demineral|injectable extracellular acellular aqueous innovative|enamel|o an entity matrix protein-based product to reduce pain and discomfort following scaling and root planing of periodontal pockets - a phase ii
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel dentine caries fluoride demineral|market industry medicine sales paper|enamel|in nail entity , sally hansen® , the number one brand , increased its market share to 27 . 4% .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel dentine caries fluoride demineral|latex containing via rubber coated|enamel|toilet core walls shall receive 2 coats latex entity paint .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel dentine caries fluoride demineral|plate bonded crossed removable resin|enamel|d . exposed columns and ironwork at open ceiling areas shall be cleaned , primed painted with semi-gloss entity paint to cover .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel dentine caries fluoride demineral|dental special our periodontal preventive|enamel|entity care is the first toothpaste to combine the cleaning and whitening properties of baking soda with fluoride and patented liquid calcium to fill tooth surfaces and restore enamel luster .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('BIO', 1)])|tissue|enamel dentine caries fluoride demineral|extracellular enamel mineral dentin cartilage|enamel|the active ingredient is the entity matrix protein amelogenin and the product has been launched in north america , europe and japan for treatment of patients who
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|enamel dentine caries fluoride demineral|wall tooth pulp itself canal|enamel|derives its energy from carbohydrate metabolism as it converts dietary sugar to lactic acid which , in turn , erodes the tooth entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel dentine caries fluoride demineral|dental tooth mouth periodontal buccal|enamel|- more - early in the quarter , the company launched arm & hammer entity care toothpaste , its most important oral care initiative in several years .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel dentine caries fluoride demineral|polish hot regular clean dry|enamel|wash and polish all mirrors , powder shelves , bright work and entity surfaces , including flushometers , piping , toilet set hinges , and all metal .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel dentine caries fluoride demineral|shadow spots spot stick mold|enamel|will continue to market multiple nat robbins color cosmetics items including lipliner pencils , lipsticks , eyeliner pencils , eye shadow , mascara , nail entity and assorted accessories .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel dentine caries fluoride demineral|apple oil orange artificial elite|enamel|simply wow™ was compared to orange clean , fantastik and formula 409 for the ability to remove cooked-on grease from an entity stovetop .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel dentine caries fluoride demineral|nail market cover plate fill|enamel|number of its principal product categories in the u . s . mass-market distribution channel , including the lip , eye , face makeup and nail entity categories .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel dentine caries fluoride demineral|surfaces enamel matrices bones teeth|enamel|hap is naturally found in bone and tooth entity and is rapidly integrated into the human body .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel dentine caries fluoride demineral|services service facilities hygiene safety|enamel|remover and nail care products in certain countries outside the u . s . in 2003 , the company launched colorstay always on nail entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel dentine caries fluoride demineral|60 accessory 40 45 90|enamel|on net sales of a hair-off mitten that is a depilatory-product accessory , and nutra nail 60 , a fast- acting nail entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel dentine caries fluoride demineral|tooth teeth enamel dentition skeleton|enamel|as a person ages the adult teeth often become darker due to changes in the mineral structure of the tooth , as the entity becomes less porous and phosphate-deficient .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel dentine caries fluoride demineral|brush glass smooth buccal leaf|enamel|floors , hand brush corners and hand brush toilet edges with approved germicidal detergent solution . 2 . wash completely all partitions , tile walls and entity surfaces .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|enamel dentine caries fluoride demineral|enamel dentin teeth tooth dentine|enamel|tooth decay is characterized by the dissolution of entity and dentin , eventually resulting in the destruction of the entire tooth .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|cement mineral resin cements cup|ligament canal junction interface barrier|cementum|dental field  means the field of treatment , repair or replacement of the tooth , dentin , alveolar bone , tooth-root entity , gingiva and / or periodontal ligament .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|cement mineral resin cements cup|fibers canals fibres roots segments|cementum|by coating the surface of the exposed dental root with emdogaingel during periodontal surgery , new root entity , periodontal ligament fibers , and surrounding bone tissue can be formed .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cement mineral resin cements cup|canal canals wall layer apex|cementum|a healthy tooth attachment apparatus is made up of the root entity , the outer layer of the root ; the periodontal ligament , which both anchors the root to the jawbone and cushions the
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|cement mineral resin cements cup|canal wall crest ligament layer|cementum|a healthy tooth attachment apparatus is made up of the root entity , the outer layer of the root ; the periodontal ligament , which both anchors the root to the jaw bone and cushions
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|cement mineral resin cements cup|gingiva saliva enamel teeth cartilage|cementum|the extent , the gingiva functions as 6 7 part of the apparatus holding the tooth to the jaw ) , alveolar bone , entity , enamel and periodontal ligament .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|tissue|cement mineral resin cements cup|ligaments tendons cartilage nerves ligament|cementum|the periodontal setting , these agents do not directly stimulate the repair of other important tissues such as periodontal ligaments or entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|cement mineral resin cements cup|gingiva saliva enamel teeth cartilage|cementum|only to the extent , the gingiva functions as part of the apparatus holding the tooth to the jaw ) , alveolar bone , entity , enamel and periodontal ligament .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|tissue|cement mineral resin cements cup|ligament cartilage tendon ligaments nerve|cementum|are utilized even though these methods do not have the same capability as emdogain of regenerating the tissues - bone , entity and ligament - that make up the tooth-supporting structures .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|periodon periodontal alveolar gingival periodontitis|mouth elderly teeth people workers|periodontium|data indicate that the presence of streptococcus oralis and streptococcus uberis provide a good indication of the health of the entity ( gums ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|periodon periodontal alveolar gingival periodontitis|mouth elderly teeth people workers|periodontium|data indicate that the presence of streptococcus oralis and streptococcus uberis provides a good indication of the health of the entity ( gums ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|periodon periodontal alveolar gingival periodontitis|implants implant cartilage tendon prosthesis|periodontium|these patents relate to the biodegradable in situ forming implants and the biodegradable system for regenerating the entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|periodon periodontal alveolar gingival periodontitis|mouth mandible gingiva jaws foot|periodontium|dr . caton has conducted many studies evaluating various treatment modalities for periodontitis and other diseases involving the entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|endothelial endothelium oxide microvascular characterized|endothelium beds networks walls rings|endothelium|drug candidate indicates that consistent increases in gb3 levels were measured in cardiomyocytes ( as opposed to decreases measured in vascular entity ) .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|endothelial endothelium oxide microvascular characterized|board member meeting publication conference|endothelium|research articles , serves as an editorial board member to several biomedical journals and is the founder of the biomedical journal entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|endothelial endothelium oxide microvascular characterized|endothelium lumen periphery vessel stroma|endothelium|in the inflammatory component , white blood cells begin to roll along and then adhere to the entity , the thin layer of cells that lines the interior surface of blood vessels .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|tissue|endothelial endothelium oxide microvascular characterized|endothelium vasculature vessels veins vessel|endothelium|that the company believes may be important in identifying unique sites on the lining of the blood vessels or the entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|endothelial endothelium oxide microvascular characterized|vessel endothelium plaque wall vessels|endothelium|atherosclerotic plaque to 732 nanometer light delivered through a catheter resulted in elimination of the lesions without damage to the entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|tissue|endothelial endothelium oxide microvascular characterized|endothelium vasculature myocardium aorta periphery|endothelium|atherosclerotic apoe ko mice corresponding to initial steps of atherosclerosis that comprise cell to cell adhesion of monocytes / macrophages to the entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 3), ('BIO', 3)])|tissue|endothelial endothelium oxide microvascular characterized|leukocyte endothelium platelet leukocytes platelets|endothelium|the interaction between certain cell adhesion molecules on the surface of both the leukocyte and the entity facilitates these contacts .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|tissue|endothelial endothelium oxide microvascular characterized|platelets monocytes neutrophils macrophages leukocytes|endothelium|into inflamed areas because sle ( x ) present on the surface of white blood cells binds to selectin molecules present on activated entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|tissue|endothelial endothelium oxide microvascular characterized|platelets endothelium venom platelet thrombin|endothelium|nitric oxide produced by the entity also inhibits the clumping of platelets , which are cells in the blood that promote clotting , and the adhesion of platelets
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|tissue|endothelial endothelium oxide microvascular characterized|pad rca aaa smc lm|endothelium|initially , this new tissue consists of healthy cells from the lining of the arterial wall ( entity ) .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|endothelial endothelium oxide microvascular characterized|vascularization thickness majority diameter endothelium|endothelium|large caliber arteriogenesis compared to only small vessel angiogenesis obtained with hematopoietic stem cells which only give rise to the entity of capillaries .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|endothelial endothelium oxide microvascular characterized|thrombosis rupture thrombus necrosis clot|endothelium|clot is most often triggered when there is damage or disruption to the lining of the blood vessel wall , or entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|endothelial endothelium oxide microvascular characterized|thrombosis necrosis rupture thrombus perforation|endothelium|cascade is most often triggered when there is damage or disruption to the lining of the blood vessel wall , or entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('BIO', 3), ('OTHER', 3)])|tissue|endothelial endothelium oxide microvascular characterized|endothelium endothelial walls epithelium junctions|endothelium|these experiments used cells important in human disease and aging--retinal pigment epithelium , fibroblasts , and vascular entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|endothelial endothelium oxide microvascular characterized|surfaces endothelium beds walls wall|endothelium|white blood cells express carbohydrates on their surfaces that bind to e-selectin that is present on inflamed vascular entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|endothelial endothelium oxide microvascular characterized|endothelium cns retina filter cornea|endothelium|specifically , we believe that by inhibiting selectin-mediated adhesion of white blood cells to the entity , rivipansel prevents propagation of voc and promotes early resolution .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 4)])|tissue|endothelial endothelium oxide microvascular characterized|endothelium vasculature microcirculation microvasculature cytoskeleton|endothelium|the entity , a single-cell lining of the arteries that acts as an interface between the blood and arterial wall , is impaired in
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|tissue|endothelial endothelium oxide microvascular characterized|vessels vasculature vessel endothelium microvasculature|endothelium|protein markers , unique to the surface of the entity in specific organs and those markers that distinguish tumor blood vessels from those vessels in healthy tissue , are thought to
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|tissue|endothelial endothelium oxide microvascular characterized|vessel endothelium vasculature vessels arteries|endothelium|an overgrowth of the entity that forms capillaries and lines blood vessel interiors contributes to atherosclerosis .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|tissue|endothelial endothelium oxide microvascular characterized|platelets endothelium platelet circulation nucleus|endothelium|binding of all three types of selectins and inhibit the selectin-mediated recognition and binding of white blood cells to the entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|fibro tendon cartilage stromal ligament|cartilage sf bm acl ta|fibrocartilage|another type of cartilage ( entity ) serves a shock-absorbing function in the knee and in the spine between the vertebrae .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|tissue|fibro tendon cartilage stromal ligament|tears plaques folds defects scars|fibrocartilage|biopsies from 135 of 141 of these re-looks showed the development of meniscus-like entity , confirming the devices effectiveness as a surgical mesh .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|tissue|peric tail tendon cartilage vein|fibroblasts tibia osteoblasts mesoderm cultured|perichondrium|model was completed and bmp signaling was shown to be enhanced in the outermost cells of the growth plate , or entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 3)])|tissue|peric tail tendon cartilage vein|fibroblasts osteoblasts cultured chondrocytes respectively|perichondrium|by dr . yu yamaguchi , bmp signaling was shown to be enhanced in the outermost cells of the growth plate , or entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|renal glomerular glomerul glomerulonephritis mesang|tubules interstitium cortex glomeruli lumen|mesangium|igan is a nonsystemic renal disease that is characterized by predominant iga deposition in the glomerular entity , causing mesangial proliferation and fibrosis .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|renal glomerular glomerul glomerulonephritis mesang|cortex glomeruli tubules interstitium parenchyma|mesangium|iga nephropathy igan is a common glomerulopathy diagnosed by the predominant histologic presence of galactose-deficient iga1 deposits in the glomerular entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|renal glomerular glomerul glomerulonephritis mesang|lumen majority cytoplasm wall periphery|mesangium|these iga containing immune complexes deposit in the entity of glomeruli in the kidney and are proinflammatory .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1), ('DRUG', 1)])|tissue|renal glomerular glomerul glomerulonephritis mesang|glomeruli podocytes kidneys glomerular gfr|mesangium|chronic activation of inflammatory pathways also leads to long-term structural alterations in the entity , which results in reduced glomerular surface area and gfr .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|tissue|been neuroect express endocrine homolog|mast epithelial schwann mesenchymal progenitor|neuroectoderm|entity cells are committed to developing into cells of the skin and nervous systems .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4)])|tissue|been neuroect express endocrine homolog|endoderm mesoderm ectoderm epithelial embryonic|neuroectoderm|with the differentiation signals resulting from the physical attributes of the cell culture techniques , induce the epiblasts to differentiate into entity or mesendoderm cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|tissue|been neuroect express endocrine homolog|mast epithelial schwann mesenchymal endothelial|neuroectoderm|entity cells are committed to developing into cells of the skin and cells of the nervous system .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1), ('DRUG', 1)])|tissue|been neuroect express endocrine homolog|adipocytes proliferate endoderm hepatocytes mesoderm|neuroectoderm|van rooijen m , xu x , zweigerdt r , mummery c , passier r . insulin redirects differentiation from cardiogenic mesoderm and endoderm to entity in differentiating human embryonic stem cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4)])|tissue|been neuroect express endocrine homolog|endoderm mesoderm ectoderm epithelial embryonic|neuroectoderm|together with the differentiation signals resulting from the physical attributes of the culture techniques , induce the epiblasts to differentiate into entity or mesendoderm cells .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|tonsil carcinoma laryngeal tonsils squamous|collar house button cover stick|tonsil|the company introduced during fiscal 1995 a line of specialty sponges , including eye spears , dissecting , stick and entity sponges , all of which are
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|tonsil carcinoma laryngeal tonsils squamous|hollow polypropylene mesh silicone polyurethane|tonsil|( b ) entity sponges - a round , fiber filled gauze constructed with a strong abdominal tape string sewn into the sponge to anchor
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|tissue|tonsil carcinoma laryngeal tonsils squamous|bladder pancreas prostate kidneys pelvis|tonsil|tumor shrinkage was also seen in patients with renal cell cancer , liver cancer , sarcoma , and cancer of the entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|tissue|tonsil carcinoma laryngeal tonsils squamous|pancreatic splenic hepatitis peripheral lymphoid|tonsil|tjx7 has been shown to completely inhibit the migration of primary human entity b cells .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|tonsil carcinoma laryngeal tonsils squamous|button needle stick collar cutting|tonsil|the company has also introduced a line of specialty sponges , including eye spears , dissecting , stick and entity sponges , all of which are used in a variety of surgical procedures .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|tissue|tonsil carcinoma laryngeal tonsils squamous|bladder pancreas prostate kidneys pelvis|tonsil|tumor shrinkage also was seen in patients with renal cell cancer , liver cancer , sarcoma , and cancer of the entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|tonsil carcinoma laryngeal tonsils squamous|stick needle collar wound soft|tonsil|products used primarily in the operating room environment ; medical action introduces a line of specialty sponges , which include dissecting sponges , entity sponges , stick sponges and eye spears .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|bones functions organs joints extremities|cartilage|it has a dual method of action that could provide the unique benefit of protecting bones and preserving entity in patients with osteoarthritis and osteoporosis , all in one medication .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|explant cartilage fibroblast saline callus|cartilage|in comparison with tissue stiffness , streaming potentials measured showed almost identical behavior for the normal and degraded entity explant .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|cartilage tendon meniscal wound osteoarthritis|cartilage|developed and commercialized chondrocelect , the first cell-based medicinal product to receive marketing authorization from the ema , which was indicated for entity repair in the knee .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|acl meniscal knee graft successful|cartilage|the secondary endpoints were entity repair at 12 months by assessment of changes of the knee joint entitys volume measured with 3d spgr quantitative mri ,
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|bones osteoblasts implants osteoclasts defects|cartilage|these compounds induce the formation of entity and regenerates new bone .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|noise statistical specimen sleep electrical|cartilage|the handle ; o software for the acquisition of electrical signals and for the analysis and interpretation of data to quantify entity quality ; and o a computer system .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|voice specimen semen tooth sleep|cartilage|the simplicity of the technique for the assessment of entity quality was demonstrated .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|biomedical tendon scientific cartilage mineral|cartilage|in both of these prior positions dr . christgau worked in the area of bone and entity research .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 1)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|joints cartilage wall endothelium epithelium|cartilage|disease that affects almost 1% of the adult population worldwide and it ultimately results in irreversible damage of the joint entity and bone .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|cartilage joints chondrocytes wall meniscus|cartilage|oa background oa is a joint disorder involving the degeneration of the articular entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|cartilage joints wall discs ligament|cartilage|treatment of various injuries and degeneration of other tissue structures such as the intervertebral disc of the spine and articular entity of degenerated joints .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|breast bones pancreas skeletal marrow|cartilage|sarcomas are cancers of the bone , entity , fat , muscle , blood vessels , or other connective or supportive tissue .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|surfaces defects wounds cartilage plaques|cartilage|entity on any of these surfaces can be damaged due to disease or injury , leading to pain and inflammation requiring knee
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|itself fibrils cartilage dynamically mobility|cartilage|it assists in regained mobility as it refurbishes entity in the bone end of joints , consisting of the same cellular structure , collagen type ii .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|meniscal tendon cartilage knee acl|cartilage|a fully functional clinical version of the arthro-bst ( tm ) was presented at the third meeting of the international entity repair society ( icrs ) in sweden in april 2000 .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|cartilage joints synovium tendon marrow|cartilage|from a mouse with cia with no treatment showing severe inflammation in the joint with sever damage to bone and entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|fluids effusion fibroblasts cartilage fibrosis|cartilage|major teaching hospital and other institutions have demonstrated that the use of the company  s compounds inhibit the loss of synovial entity in the joint .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|cartilage joints surfaces chondrocytes wall|cartilage|this condition grows more severe over time and leads to progressive thinning of articular entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|spleen cartilage pancreas intestine adipose|cartilage|product development programs utilize adult bone marrow stem and progenitor cells for forming solid tissues such as bone , vascular tissue , entity , and blood and immune system cells .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cartilage chondrocytes proteoglycan articular regeneration|tumour hair successful histological final|cartilage|additional studies are being carried out to confirm the entity regrowth .
OrderedDict([('BIO', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|tissue|mesenchyme epithelial epithelium epithelia mammalian|anatomy architecture morphogenesis dysplasia biology|mesenchyme|the scientific publication demonstrates that 4d20 . 8 cells possess site-specific markers of craniofacial entity , in particular , markers of proximal mandibular entity .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|ependym ganglion neuronal neuroblastoma cysts|barrier ganglion parenchyma cortex glial|ependyma|filters toxins 1 cerebrospinal fluid ( csf ) – brain barrier / glymphatic system : extracts toxins from the brain 2 ventricle brain entity ( glial cells ) astrocytes ( glial cells )
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|umb anastomosis duct teg vein|hair scalp arms fingers forehead|umbilicus|it usually involves the face , digits , arms , inguinal area , anogenital area , entity and nipples , and can also affect the hair .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|umb anastomosis duct teg vein|start placebo trial endpoint treatments|umbilicus|reductions observed in the circumference at the entity and treatment area volume were the same in both the placebo and lipo-202 treatment groups .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|umb anastomosis duct teg vein|trial doses clinic experiment week|umbilicus|manual tape measure procedure , the 0 . 4 µg total weekly dose of lipo-202 produced significant reductions in abdominal circumference at the entity compared to placebo .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 3), ('OTHER', 2)])|tissue|epidermis epidermal pigment dermal hair|epidermis dermis epithelium mucosa stroma|epidermis|most common form of skin cancer , is an uncontrolled growth of abnormal cells arising from the squamous cells in the entity , the skins outermost layer .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|epidermis epidermal pigment dermal hair|sun wound wounds clothing scar|epidermis|skin in order to achieve enough heating at the required depth significantly increases the risk of damaging or burning the entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|epidermis epidermal pigment dermal hair|epidermis dermis mucosa epithelium tongue|epidermis|bcc develops in the basal , or lower , layer of the entity , and accounts for approximately 80% of all new cases of skin cancer annually .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|epidermis epidermal pigment dermal hair|epidermis dermis plaques plaque joints|epidermis|psoriasis , for example , which is characterized by inflammation and accelerated growth of the entity , can sometimes be triggered by a simple cut or abrasion to the skin .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|epidermis epidermal pigment dermal hair|follicles hair follicle epidermis organs|epidermis|removal is based upon the selective heating of hair follicles while cooling the surface of the skin to protect the entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|epidermis epidermal pigment dermal hair|neck dermis epidermis rectum stomach|epidermis|scc usually develops in the entity , the upper layer of the skin , and accounts for approximately 16% of all new cases of skin cancer annually .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|epidermis epidermal pigment dermal hair|dermis epidermis dermal layer submucosa|epidermis|autologous skin regeneration construct of its kind , which can regrow full-thickness and functional polarized skin , including all layers ( dermis & entity ) , hair , and skin appendages .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|epidermis epidermal pigment dermal hair|dermis epidermis mucosa epithelium prostate|epidermis|by precisely focusing ultrasound energy to cause permanent disruption , or ablation , of fat cells , or adipocytes , without damage to the entity , dermis or underlying tissues and organs .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|epidermis epidermal pigment dermal hair|dermis epidermis thickness mucosa corneum|epidermis|to effectively penetrate the skin barrier , reducing their ability to improve the health of the skin at the stratum corneum , entity and dermis level .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|epidermis epidermal pigment dermal hair|follicles follicle ovary oocytes epithelium|epidermis|the cold sapphire tip protects the entity while allowing the laser light to efficiently destroy the target follicles .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|epidermis epidermal pigment dermal hair|epidermis dermis plaque mucosa plaques|epidermis|plaque psoriasis is a disease marked by hyperproliferation of the entity , resulting in inflamed and scaly skin plaques .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|epidermis epidermal pigment dermal hair|dermis epidermis epithelium cortex corneum|epidermis|designed to penetrate below the skin  s surface to correct damage in all layers of the skin ( the stratum corneum , the entity and the dermis ) and accelerate cellular turnover .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|epidermis epidermal pigment dermal hair|epithelium mucosa cervix intestine breast|epidermis|topical interferon alpha-2b is intended to deliver interferon alpha-2b therapy to the viable entity , combating hpv infections where they would otherwise cause abnormal cellular proliferation .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|tissue|epidermis epidermal pigment dermal hair|dermis epidermis mucosa tendon epidermal|epidermis|the ability to effectively penetrate the skin barrier , reducing their ability to improve the health of the skin at the entity and dermis level .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|epidermis epidermal pigment dermal hair|dermis epidermis pad tumour peel|epidermis|these changes can visibly affect the shape of the entity and resemble an orange peel-like dimpling of the skin . 1 in the normal subcutaneous fat layer directly under the skin , there
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|tissue|epidermis epidermal pigment dermal hair|epidermis dermis epithelium epidermal outer|epidermis|keratinocytes are the predominant cell type in the entity , the outermost layer of the skin .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|epidermis epidermal pigment dermal hair|deeper superficial dermal hair dermis|epidermis|our products will be naturally infused into hair follicles , dermis and entity layers of the scalp through the direct application and use of all-natural products .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|epidermis epidermal pigment dermal hair|dermis epidermis epidermal dermal superficial|epidermis|vii collagen , or col7 , that forms anchoring fibrils that bind the dermis , or inner layer of the skin , to the entity , or outer layer of the skin .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|epidermis epidermal pigment dermal hair|epidermis dermis hair dark atmosphere|epidermis|concentration of hydroquinone , which is designed to correct skin pigmentation problems by normalizing the production of new melanin in the entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|tissue|epidermis epidermal pigment dermal hair|aureus epidermidis pneumoniae cerevisiae aeruginosa|epidermis|azitra inc . is developing azt-02 , a staphylococcus entity strain engineered to express lekti in preclinical development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|al university surg il anal|appendix table appendic duodenum appendicitis|anlage|thereof ; 4 . 1 . 3 all running expenses as defined in appendix 3 to section 27 , subsection 1 , of the second computation order ( entity 3 zu section 27 abs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|tissue|al university surg il anal|sch al uk law dsm|anlage|the business address for each of the persons listed below other than christopher k . norton is messeturm , friedrich-ebert- entity 49 , 60308 frankfurt am main , germany .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|al university surg il anal|entity question fact category figure|anlage|l . der verkaufer verkauft und ubertragt hiermit samtliche vertrags-erfindungen und vertrags-schutzrechte , die in den in entity 1 und entity 2 beigefugten schutzrechtskaufvertragen definiert sind .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|al university surg il anal|ist und das als il|anlage|des verschmelzungsplans ) wird die übernehmende gesellschaft die neue satzung , wie sie als entity 2 dem verschmelzungsplan beigefügt ist , beschließen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|al university surg il anal|und das sich der ist|anlage|zeitpunkt dieser lizenzerklärung im eigentum der sag stehen , darin insbesondere eingeschlossen die patente und patentanmeldungen gemäss entity 2 , die sich auf die substanz prostone
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|al university surg il anal|der und ist das od|anlage|verkauft und ubertragen werden daher insbesondere die in der entity 3 aufgefuhrten vermogensgegenstande und rechte ( insgesamt der , , kaufgegenstand " ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|al university surg il anal|und der her nach sind|anlage|schutzrechtsanmeldungen , die vom dkfz parallel dazu gemäß entity 2 vorgenommen worden sind .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|tissue|al university surg il anal|uk ga germany das dsm|anlage|the principal business address of each of gscp ii germany and gs ohg is messeturm friedrich-ebert- entity 49 , 60308 frankfurt am main , germany .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|al university surg il anal|der zu sich germany fact|anlage|belastungen des in entity 1 . 1 beschriebenen grundbesitzes in abteilung iii des grundbuchs werden vom käufer nicht übernommen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|al university surg il anal|und zu ist der sich|anlage|schutzrechtsanmeldungen gemäß entity 2 zugrundeliegenden erfindungen zu zahlen ist , steht den erfindern von asta pharma ein anteil von 20% zu .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|al university surg il anal|als ist und stages das|anlage|​ die satzung der übernehmenden gesellschaft , als aus der gesellschaft hervorgehende gesellschaft , ist als entity 1 zu diesem verschmelzungsplan beigefügt .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|al university surg il anal|germany ist und von das|anlage|dr . thomas drosdeck beiten burkhardt rechtsanwaltsgesellschaft mbh bockenheimer entity 15 mozartplatz 60322 frankfurt am main germany 30 . 13 execution by counterpart .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|al university surg il anal|od der bi mrt fact|anlage|rechten und ansprüchen gegen sie an pcof 1 llc ( der zessionar ) im wege der sicherungsabtretung abgetreten haben , einschließlich der in entity 1 genannten forderungen .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|osteoid oste chondrosarcoma carcinoma dysplasia|trabecular implant tumour alveolar volumetric|osteoid|the six patients had mean entity volume / bone volume decreases from 24 . 3 percent to 7 . 0 percent , representing a 71 percent improvement .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|osteoid oste chondrosarcoma carcinoma dysplasia|trabecular implant bm plaque tumour|osteoid|at 48 weeks , all ten patients with evaluable paired bone biopsies demonstrated meaningful improvements from baseline in mean entity volume / bone volume .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|osteoid oste chondrosarcoma carcinoma dysplasia|trabecular wall probing pocket cartilage|osteoid|the patients also demonstrated mean improvements of 32% and 26% in entity thickness and entity surface / bone surface parameters respectively .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|fascia cutaneous nerve tendon varicose|barrier mucosa nerve junction apparatus|fascia|this procedure may be done without disrupting the endopelvic entity and is especially valuable for women who have scarring from previous abdominal surgery and are not good candidates for a
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|fascia cutaneous nerve tendon varicose|forearm palmar finger wrist aspect|fascia|background dupuytrens disease is a slowly progressive fibroproliferative disease of the palmar entity in the hand .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|fascia cutaneous nerve tendon varicose|warning final decision ban original|fascia|any changes or additions to the entity sign shall be subject to landlords prior written approval , in landlords sole discretion , and shall be made at tenant  s sole cost and expense .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|fascia cutaneous nerve tendon varicose|cartilage dermis tendon veins fibrosis|fascia|plantar fibromatosis is a non-malignant thickening of the feets deep connective tissue or entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|fascia cutaneous nerve tendon varicose|final warning safety le master|fascia|for all purposes under the lease , the entity sign shall be deemed to be tenant  s off-premises equipment . 7 . brokerage .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|fascia cutaneous nerve tendon varicose|room blocks floor rubber building|fascia|tenant shall repair , paint , and / or replace the building entity surface to which its signs are attached upon vacation of the premises , or the removal or alteration of its signage ,
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|fascia cutaneous nerve tendon varicose|collapse detachment opening branching division|fascia|no alteration shall ( i ) affect the exterior walls , entity or fenestration of the building or the demising walls of the premises , ( ii ) affect any part of the project other than
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|fascia cutaneous nerve tendon varicose|dermis cartilage epidermis veins tendon|fascia|are you going to start accepting dermis , entity and pericardium recoveries?
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|fascia cutaneous nerve tendon varicose|commercial own respective european existing|fascia|the revenue increase was primarily due to an increase in the demand for our entity lata products to treat incontinence and urologic and gynecologic defects .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|fascia cutaneous nerve tendon varicose|joints cartilage muscles ligaments organs|fascia|muscoloskeletal conditions  means conditions of the muscles , bones , joints ( including the intervertebral discs ) , ligaments , tendons , cartilage and entity of the body .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|fascia cutaneous nerve tendon varicose|barrier mucosa nerve junction apparatus|fascia|this procedure may be done without disrupting the endopelvic entity and is especially valuable for women who have scarring from previous abdominal surgery .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|fascia cutaneous nerve tendon varicose|signs warning vital allow take|fascia|green  s dairy road a . all entity signs to be single faced cabinets , and shall be constructed of 100% aluminum with stencil cut aluminum backgrounds with white
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|fascia cutaneous nerve tendon varicose|dermis epidermis lungs intestine spleen|fascia|cutaneous eosinophilias are inflammatory diseases that manifest in dermal and subcutaneous layers including the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|fascia cutaneous nerve tendon varicose|plate tip warning name mark|fascia|signage no entity , sign , name plate , bill , notice , placard , advertisement or similar device shall be affixed to or displayed in or on any
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|fascia cutaneous nerve tendon varicose|fascia bovine corpora porcine staphylococcus|fascia|meanwhile , the company is offering alternative tissues such as entity lata and bovine pericardium to the market .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|fascia cutaneous nerve tendon varicose|signs materials radiographs injuries lines|fascia|kind and quality and having made good any material physical damage resulting from the removal of any tenant  s fixtures , fittings , entity or signs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|fascia cutaneous nerve tendon varicose|artery ankle nerve foot tendon|fascia|the plantar entity is the foots shock absorber .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|tissue|fascia cutaneous nerve tendon varicose|spleen cartilage nerves muscles mucosa|fascia|a therapeutic protein and / or bioactive rna for the treatment of autoimmune and non-infectious inflammatory disorders that manifest in cutaneous tissues , entity and / or muscle .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|fascia cutaneous nerve tendon varicose|our annual future economic pharmacy|fascia|entity inventories are higher than normal by $720 due to reduced demand and the anticipation of the launch of a new
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|tissue|fascia cutaneous nerve tendon varicose|spleen cartilage nerves mucosa muscles|fascia|therapeutic protein and / or bioactive ribonucleic acid for the treatment of autoimmune and non-infectious inflammatory disorders that manifest in cutaneous tissues , entity and / or muscle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|tissue|endo muco rhiz wall nid|cytoskeleton ecm endothelium myocardium vasculature|endomysium|- 5 - in muscle tissue , collagen serves as a major component of the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|tissue|endo muco rhiz wall nid|cytoskeleton ecm endothelium myocardium vasculature|endomysium|in muscle tissue , collagen serves as a major component of the entity .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|endocrine epithelium epithelial carcinoma epithelia|object odor question hypothesis stimulus|neuroepithelium|the entity is the tissue by which man detects the presence of odor .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|endocrine epithelium epithelial carcinoma epithelia|bulb epithelium mucosa nerve apparatus|neuroepithelium|smell ) can result from a number of causes , including mechanical obstruction of the nasal cavity and damage to the olfactory entity , the olfactory bulb , or the nerves between them .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|tissue|mole matter molar organic tris|carcinoma choriocarcinoma adenocarcinoma leiomyoma adenoma|mole|the major histologic entities for this disease include complete molar pregnancy , partial molar pregnancy , invasive entity , and choriocarcinoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mole matter molar organic tris|year month week century decade|mole|mm  shall mean one-thousandth of a entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|tissue|mole matter molar organic tris|choriocarcinoma adenoma carcinoma leiomyoma adenocarcinoma|mole|the term gestational trophoblastic neoplasia ( gtn ) is used when molar and non-molar pregnancies become malignant , and comprise the morphologic entities of invasive entity and choriocarcinoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|mole matter molar organic tris|entity entities macul category anatomy|mole|to 12-month period in order to detect new or changing entitys through total body photography , by monitoring a specific entity or entitys .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mole matter molar organic tris|colour colors texture appearance diameter|mole|cancer societys abcde criteria , which includes asymmetric , irregular border , variegated or dark color , diameter greater than 6 mm , or evolving entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|tissue|mole matter molar organic tris|entity entities category neoplasm macul|mole|to 12 month period in order to detect new or changing entitys through total body photography , by monitoring a specific entity or entitys .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mole matter molar organic tris|colour colors texture appearance diameter|mole|american cancer societys abcde criteria , which includes asymmetric , irregular border , variegated or dark color , diameter greater than 6 mm , or evolving entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mole matter molar organic tris|flat thin thick raised larger|mole|present in two forms , nodular bcc , which appears as a shiny bump or nodule that may be confused with a entity , and superficial bcc , which has a slightly raised , ulcerated or crusted surface .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mole matter molar organic tris|computer prototype person trial user|mole|we believe that their software , at present , cannot define whether a entity is a new one or not .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mole matter molar organic tris|ml mol microl min mole|mole|referred to antibodies excluded from the licence 1all antibodies to alpha tumour necrosis factor having an association constant greater than 106l / entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mole matter molar organic tris|pseudo endo subs phospho sub|mole|tks , tps , stks and related downstream signalling entitycules ( target identification ) and vali- dation of the role , if any , of those entity- cules in a given disease ( target valida- tion ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|tissue|mole matter molar organic tris|entity feature neoplasm anomaly phenomenon|mole|the abcd rule is defined as follows : a ● asymmetry , a benign entity that is not asymmetrical ; b ● border , a benign entity has smooth , even borders , unlike melanomas ; c ● color .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mole matter molar organic tris|phenomenon prognosis entity concept indicator|mole|one of the best early indicators of melanoma is a new or changing entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mole matter molar organic tris|colleagues johnson al hill martin|mole|/ s / weisberg , polansky , kulberg , einhorn & entity , llp carle place , new york july 30 , 1996 exhibit 23 . 8 consent of independent certified public accountants we consent to the
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|tissue|mole matter molar organic tris|mole cysts encephalopathy teratoma hydatid|mole|choriocarcinoma metastasizes hematogenously and can follow any type of pregnancy , but most commonly develops after complete hydatidiform entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mole matter molar organic tris|flat thin thick raised larger|mole|itself in two forms , nodular bcc , which appears as a shiny bump or nodule that may be confused with a entity , and superficial bcc , which has a slightly raised , ulcerated or crusted surface .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mole matter molar organic tris|colour colors texture appearance diameter|mole|american cancer societys abcde criteria , which includes asymmetric , irregular border , variegated or dark color , diameter greater than 6 mm , or evolving entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|mole matter molar organic tris|manner fashion situation variety few|mole|it may begin in a entity as skin melanoma , but can also begin in other pigmented tissues , such as in the eye or in the intestines .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2)])|tissue|dermis epidermis dermal epidermal cutaneous|elastin cartilage tendon ligament epithelium|dermis|the entity is comprised largely of connective tissue fibers made of collagen and elastin .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|dermis epidermis dermal epidermal cutaneous|lungs dermis intestine kidneys spleen|dermis|muscle cells , azx100 may inhibit the scarring that results from wound healing and may mitigate fibrotic disease states in the entity , blood vessels , lungs , liver and other organs .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|tissue|dermis epidermis dermal epidermal cutaneous|bones tendons muscles kidneys joints|dermis|type 1 collagen is the primary fibril-forming collagen in bone , entity , tendons and ligaments and is the most abundant protein in the human body .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|dermis epidermis dermal epidermal cutaneous|dermis epidermis mandible cheek forehead|dermis| hst-002 is a human-derived collagen and extracellular matrix dermal filler intended to be injected into the entity for the treatment of facial folds and wrinkles .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|dermis epidermis dermal epidermal cutaneous|dermal scaffold fibrin cartilage polymer|dermis|our acellular entity scaffolds are utilized in wound care and plastic and reconstructive procedures .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|dermis epidermis dermal epidermal cutaneous|capillaries dermis capillary bloodstream epidermis|dermis|temporarily permeable , allowing a drug to diffuse through the stratum corneum in the epientity , and then into and through the entity , where it can enter the bloodstream through the capillaries .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|dermis epidermis dermal epidermal cutaneous|marrow ear vein foot lungs|dermis|we believe that the fibroblasts created by our isolagen process and injected into the patient  s entity continue to multiply and lead to the production of collagen and elastin .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|dermis epidermis dermal epidermal cutaneous|safety welfare nutrition education industry|dermis|human entity initiatives training sales force product introduced in 2nd quarter to clinical sites product launched july 2007 markets currently a $50
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|dermis epidermis dermal epidermal cutaneous|dermal mos regenerated pcl derm|dermis|with the dermavac , entity mos are rapidly harvested under local anesthetic from just under the skin to provide unique tissue structures with long-term viability
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|dermis epidermis dermal epidermal cutaneous|dorsum neck hands gingiva dermis|dermis|( mos )  our proprietary device , the dermavac , is used to extract a small piece of tissue from the skins lower level , the entity of the patient .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|dermis epidermis dermal epidermal cutaneous|dermal cosmetic plaque sensory mucosal|dermis|penetrate the skin barrier , reducing their ability to improve the health of the skin at the stratum corneum , epientity and entity level .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|dermis epidermis dermal epidermal cutaneous|led implantation iii med creation|dermis|at ciba-geigy , novartis , prosanos , adventrx participated / led development and launch of voltaren , apligraf , femara and exjade 4 5 epientity dermis subcut .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|dermis epidermis dermal epidermal cutaneous|dermis epidermis thickness hence consequently|dermis|in undamaged skin , the epientity , or the surface layer of skin , and entity , the deeper layer , form a protective barrier against the external environment .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|dermis epidermis dermal epidermal cutaneous|routinely them experts together independently|dermis|in october 2001 , the company entered into a project with mentor for use of tutoplast ( r ) processed entity in urological and gynecological indications .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|dermis epidermis dermal epidermal cutaneous|layers layer dermis epidermis shell|dermis|due to the structure of the skin , its two main layers , the outer epientity and inner entity , effectively inhibit the transdermal delivery of most therapeutics .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|dermis epidermis dermal epidermal cutaneous|microcirculation intestine vasculature circulation dermis|dermis|small molecular weight sodium hyaluronate can penetrate into the entity where it combines with water to promote microcirculation , nutrient absorption , and metabolism .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|dermis epidermis dermal epidermal cutaneous|nails nail epidermis bones dermis|dermis|skin means that part of the human anatomy consisting of the entity , the epientity , and the appendages of the skin , to wit , the nails , the hair and hair follicles , the sudoriferous and
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|dermis epidermis dermal epidermal cutaneous|prosthesis mesh graft prostheses tendon|dermis|currently rely on single source suppliers for the silicone and fabric used in our male prostheses and for the porcine entity and mesh used in many of our female products .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|dermis epidermis dermal epidermal cutaneous|except while lumen just mucosa|dermis|small molecular weight sodium hyaluronate can penetrate into the 7 table of contents entity where it combines with water to promote microcirculation , nutrient absorption , and metabolism .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|dermis epidermis dermal epidermal cutaneous|electrodes electrode needle tip patch|dermis|the faces handpiece uses a vacuum to fold the skin between two electrodes , ensuring tight contact and positioning the entity in direct alignment with the path of radio frequency energy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|tissue|ventricular myocardial segments infarction myocardium|myocardium former aorta spleen pancreas|endocardium|of myocardial cells first occurs in the area of myocardium that is most distal to the arterial blood supply , the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|ventricular myocardial segments infarction myocardium|myocardium infarct ventricle apex septum|endocardium|as the duration of the occlusion increases , the area of myocardial cell death enlarges , extending from the entity to the myocardium and ultimately to the epicardium .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|gingiva gingival periodontal periodon teeth|ligament periodontal tooth pulp teeth|gingiva|dental field  means the field of treatment , repair or replacement of the tooth , dentin , alveolar bone , tooth-root cementum , entity and / or periodontal ligament .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|gingiva gingival periodontal periodon teeth|mouth gel enamel mucosa dentin|gingiva|exposure of the gel on the strips to the entity ( gums ) should be avoided since it can cause irritation to the tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gingiva gingival periodontal periodon teeth|gum ds sm lip bd|gingiva|in heart rate ; ( ii ) focal hyperpigmentation ( darkening of the skin on certain parts of the body ) , including the face , gums ( entity ) and breasts ; and ( iii ) nausea .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gingiva gingival periodontal periodon teeth|mouth own saliva teeth tongue|gingiva|in the case of the dental product , a 1mm biopsy is taken from the patient  s entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|gingiva gingival periodontal periodon teeth|neck extremities hands feet breasts|gingiva|focal hyperpigmentation : reported by 1% of patients who received up to 8 doses per month , including involvement of the face , entity and breasts .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|gingiva gingival periodontal periodon teeth|lungs esophagus kidneys organs larynx|gingiva|lesion , congenital plasminogen deficiency is a multi-systemic disease that can also affect the ears , sinuses , tracheobronchial tree , genitourinary tract , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|gingiva gingival periodontal periodon teeth|lungs esophagus kidneys larynx palate|gingiva|common lesion , congenital plasminogen deficiency is a multi-systemic disease that can also affect the ears , tracheobronchial tree , genitourinary tract , and entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|ligament tendon ligaments cartilage tendons|tendon ligament suture wound meniscal|ligament|a high strength form of graftjacket® matrix which provides maximum suture holding power for the most challenging of tendon and entity repairs .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2), ('DRUG', 1)])|tissue|ligament tendon ligaments cartilage tendons|tendon tendons cartilage kidneys fibroblasts|ligament|begun to earn royalties on a portion of the estimated 2005 $800 million to $1 billion u . s . tissue market , which includes entity , tendon and bone allografts .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|tissue|ligament tendon ligaments cartilage tendons|tendon injuries repairs defects fractures|ligament|first albany annual growth conference page 15 entity and tendon repairs , we mentioned , is still in preclinical work .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|tissue|ligament tendon ligaments cartilage tendons|tendon ligament tendons cartilage nerve|ligament|group ; and  use our glucan technology to develop product candidates for intra-operative and injection applications in tendon , entity and bone surgeries and injuries .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|ligament tendon ligaments cartilage tendons|ligament ligaments tunnel allograft abscess|ligament|the impact of fortetropin® on reducing muscle atrophy in dogs after tibial-plateau-leveling osteotomy ( tplo ) surgery to repair the cranial cruciate entity ( ccl ) .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|ligament tendon ligaments cartilage tendons|tendon meniscal musculoskeletal nerve ligament|ligament|svf is a regenerative treatment for a number of conditions including osteoarthritis , tendon repair , entity injuries and other traumatic and degenerative diseases .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|ligament tendon ligaments cartilage tendons|ligament graft reconstruction tunnel allograft|ligament|announced receipt of the technical section complete letter for effectiveness for nocita to provide local post-operative analgesia for cranial cruciate entity surgery in dogs .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|ligament tendon ligaments cartilage tendons|implant cement prosthetic cartilage graft|ligament|continues to develop a collagen based tissue patch , a collagen and calcium phosphate based bone cement , and a collagen based entity prosthesis .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|ligament tendon ligaments cartilage tendons|pockets ligament calculus pocket plaque|ligament|of periodontal pockets ( spaces between the gum and tooth ) resulting from loss of the tooth  s supporting structure ( bone and periodontal entity ) .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|ligament tendon ligaments cartilage tendons|tendon nerve nail ankle foot|ligament|for the technology include pressure ulcer ( bed sore ) prevention , chronic wounds , burns , dermatology , and product testing and superficial tendon and entity pathology .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|ligament tendon ligaments cartilage tendons|tear anterior conjunctival arthroscopic corneal|ligament|college of veterinary medicine at kansas state university&#160 ; to study the impact of fortetropin on reducing muscle atrophy in dogs after entity tear repair surgery .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|tissue|ligament tendon ligaments cartilage tendons|tendon cartilage nerve ligament nerves|ligament|stimulation of growth factors and the potential use of ultrasound technology in diagnostic and therapeutic applications relating to bone , cartilage , entity or tendon .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|ligament tendon ligaments cartilage tendons|ligament ligaments grafts injuries acl|ligament|for example , attempts to replicate mouse anterior cruciate entity , or acl , transection findings using different animal models of osteoarthritis , or oa , have proven to be challenging , as it is
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|tissue|ligament tendon ligaments cartilage tendons|meniscus knee cartilage meniscal ligaments|ligament|there are over 1 . 2 million arthroscopic procedures for repair of the knee , including procedures involving articular cartilage , meniscus and entity performed annually in the united states .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|ligament tendon ligaments cartilage tendons|cartilage bones ligaments tendon tibia|ligament|studies with engineered cartilage and bone for reconstructive applications and have constructed an entire joint consisting of bone , cartilage and entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|ligament tendon ligaments cartilage tendons|ligament reconstruction ligaments allograft acl|ligament|the agreement covers such products as , bone-tendon-bone ( btb ) implants used for acl ( anterior cruciate entity ) procedures .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|ligament tendon ligaments cartilage tendons|tendon ligament cartilage nerve wound|ligament|to extend its worldwide license for chrysalin to include the rights for orthopedic " soft tissue " indications , including cartilage , tendon and entity repair .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|ligament tendon ligaments cartilage tendons|bones tendons muscles cartilage joints|ligament|of protein synthesis at a particular site in the body and can be used in soft tissue such as skin , entity , tendons and cartilage , as well as hard tissue such as bone .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|ligament tendon ligaments cartilage tendons|pathways junction routes canals junctions|ligament|the spacer is placed between the spinous processes through the interspinous entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|tissue|ligament tendon ligaments cartilage tendons|cartilage meniscus ligament ligaments knee|ligament|there are over 1 . 2 million arthroscopic procedures for repair of the knee , including procedures involving articular cartilage , meniscus and entity , performed annually in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|nerve sheath myelin axonal axon|myelin|we refer to the axon and its surrounding entity sheath as a nerve fiber .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|myelin nerve axonal sensory tendon|myelin|the disease is believed to be caused by the destruction of entity sheaths by the body  s own immune system .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|axonal retrograde afferent axon nerve|myelin|loss of entity insulation in surviving axons can cause nerve impulses to be delayed or lost entirely , resulting in impaired neurological function .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|myelin nerve axonal myelinated spinal|myelin|we believe a therapy that could repair entity sheaths has the potential to restore neurological function to those affected by deentityating conditions .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|sheath nerve myelin capillary axonal|myelin|the entity sheath that surrounds axons in the brain and spinal cord provides insulation that facilitates the transmission of nerve impulses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|myelin nerve sheath axonal tendon|myelin|ms attacks the covering surrounding nerve cells , or entity sheaths , leading to loss of entity ( deentityation ) and nerve damage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|capillary myelin fibrous outer optic|myelin|the entity sheath is composed of multiple layers of tightly packed cell membrane and is vulnerable to damage in conditions like ms
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|layer barrier thin dense capillary|myelin|by neurons as well as remove compounds that are toxic to them ; and  form the insulating entity layer around the axons of neurons , enabling their normal function for signal transmission .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|myelin nerve sheath capillary axonal|myelin|multiple sclerosis , or ms , is an autoimmune disease in which immune cells attack and destroy the entity sheath , which insulates neurons in the brain and spinal cord .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|nerve sheath tendon axonal sensory|myelin|when the entity sheath is destroyed , nerve messages are sent more slowly and less efficiently .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|axons nerves myelin consciousness conduction|myelin|the loss of entity disrupts the conduction of nerve impulses , producing the symptoms of multiple sclerosis including vision loss , incontinence , short-term memory loss , fatigue ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|myelin axonal neural oligodendrocyte fibrous|myelin|reentityation reentityation is the process propagating oligodendrocyte precursor cells to form oligodendrocytes to create new entity sheaths on deentityated axons in the cns .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|adipose there cholesterol glycogen fatty|myelin|entity is the fatty tissue that surrounds and protects the nerve fibers of the central nervous system and facilitates the flow of nerve impulses to and from the brain .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|myelin barrier cns neuronal nerve|myelin|clene also has state of matter claims for entity protection , remyelination , neuroprotection that will last until 2032 and manufacturing device and process patents that will last beyond 2030 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|nerve fibers m1 untreated thin|myelin|in laboratory studies , dalfampridine has been found to improve impulse conduction in nerve fibers in which the insulating layer , called entity , has been damaged .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|connective lymphoid peripheral adipose neural|myelin|the identified autoimmune mechanisms directed at entity tissue of the cns may play an important role in the pathogenesis of ms .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|cartilage tendons tears defects tendon|myelin|currently , there is no available therapy indicated to repair entity that has been destroyed in ms or other deentityating diseases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|neuronal oxidative axonal hippocampal neurological|myelin|to evaluate the effect of ehp-101 on entity damage in a cuprizone-induced deentityation murine model , brain coronal sections from animals after 6 weeks of cpz 0 . 2% diet and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|acetylcholine glycogen glycerol finally moreover|myelin|entity , a fatty tissue , surrounds and protects the nerve fibers of the cns and helps those nerve fibers to conduct electrical impulses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin glycoprotein sensory lysosomal oligodendrocyte|recombinant soluble chimeric purified synthetic|myelin|to formulate tovaxin t cell vaccine , the patient  s own entity peptide-specific activated t cell lines are harvested and attenuated on the day of vaccine administration .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|tissue|steroids pigment organs endocrine prostan|they there mscs platelets hscs|organoids|as a stem cell derived system , entity are a renewable model permitting repeat testing from a single patients biopsy .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|steroids pigment organs endocrine prostan|cohort registry enrolled participation bank|organoids|out of the hubrecht institute , knaw and university medical center utrecht in the netherlands to evaluate the nonsense-bearing cf patient entity in its biobank .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DIS', 2), ('DRUG', 1)])|tissue|steroids pigment organs endocrine prostan|lungs fibroblasts neutrophils eosinophils macrophages|organoids|entity derived from nonsense mutation cf patients lack apparent swelling in this system due to their lack of functional cftr .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|steroids pigment organs endocrine prostan|sera urine sputum lungs biopsies|organoids|in a poster titled : “cftr protein detection in entity from healthy and cf patients with nonsense mutations support using organoid model to test elx-02 mediated cftr read-through restoration” , we
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|steroids pigment organs endocrine prostan|mutations mutants alleles genotypes carriers|organoids|significant restoration of cftr protein expression as measured via a capillary-based immunoassay approach in multiple g542x or w1282x nonsense carrying entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|steroids pigment organs endocrine prostan|mutants cultures mutant plants monolayers|organoids|·g542x entity treated with elx-02 demonstrate proper cell surface cftr localization on the apical surface , which is consistent with increased cftr , mrna ,
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|tissue|steroids pigment organs endocrine prostan|mscs xenografts dcs msc antibodies|organoids|the ex vivo portion of the study will quantify the functional response of patient-derived entity to pti investigational agents dirocaftor , posenacaftor and nesolicaftor .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|steroids pigment organs endocrine prostan|sera specimens biopsies cultures swabs|organoids|entity from over 100 individuals bearing rare nonsense mutations in the cftr have been collected and are being tested for responsiveness to elx-02 in the laboratory .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|steroids pigment organs endocrine prostan|datasets specimens cancers cohorts biomarkers|organoids|the first dataset evaluated elx-02 in 31 patient-derived entity and demonstrated activity in the majority of them .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|steroids pigment organs endocrine prostan|organs nodes supply visceral pancreas|organoids|to change the classic model of drug discovery using 3d bioprinted human tissues and other 3d models ( sometimes known as “entity” or “organs on a chip” ) .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|steroids pigment organs endocrine prostan|specimens lines biopsies xenografts cancers|organoids|high content imaging to identify mcla-158 after screening hundreds of bispecific antibodies for activity in more than 20 patient-derived colorectal cancer entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|steroids pigment organs endocrine prostan|foundation market counterpart industry rights|organoids|going concern the company has a history of operating losses as it has developed its human entity for drug toxicity and efficacy testing .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|steroids pigment organs endocrine prostan|neurons retinas retina segments photoreceptors|organoids|we also plan to test the editor for editing efficiency in human retinal entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|steroids pigment organs endocrine prostan|consent recommendations criteria conclusions references|organoids|the internal position was subject to change upon review of additional clinical and ex vivo data from the patient derived entity when such data were made available .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|steroids pigment organs endocrine prostan|specimens biopsies lines xenografts sera|organoids|content imaging to identify mcla-158 after screening more than 500 bispecific antibodies for activity in more than 20 patient-derived colorectal cancer entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|steroids pigment organs endocrine prostan|examples here they there applications|organoids|entity are cell cultures based on cancer cells from patients that mimic the physiology of tumor growth and depend on the
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|steroids pigment organs endocrine prostan|hot cold melting temperatures warm|organoids|of cancers . 1 they may include : smarca4 , arid1a , and smarcb4 swi / snf complex mutations sensitize to lsd1 immunomodulatory effects , turning cold tumor entity hot .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|tissue|steroids pigment organs endocrine prostan|epilepsy uc melanoma crc acromegaly|organoids|the intent of the program is to use these positive results to enroll patients with responsive entity in a prospective trial with elx-02 .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|steroids pigment organs endocrine prostan|biopsies sera specimens urine sputum|organoids|hit-cf recently announced completion of the first phase of the program with the collection of entity from patients at 47 of the biggest cystic fibrosis centers in 16 countries throughout europe .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|tissue|steroids pigment organs endocrine prostan|fibroblasts metastases xenografts macrophages biopsies|organoids|humanized anrp2-10 decreased viability , inhibited formation of mammospheres and anchorage-independent growth in cells or entity from tnbc patients .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|tissue|chondrosarcoma cartilage regenerate perioste mineral|cartilage chondrocytes mscs implants grafts|periosteum|graftjacketò regenerative tissue matrix is an onlay for repair or replacement of entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|tissue|chondrosarcoma cartilage regenerate perioste mineral|cartilage chondrocytes mscs implants grafts|periosteum|graftjacket® regenerative tissue matrix is an onlay for repair or replacement of entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|chondrosarcoma cartilage regenerate perioste mineral|lumen outer largest interior inner|periosteum|● the pericranium is the entity ( a membrane that lines the outer surface of all bones ) of the skull bones and provides nutrition to the bone
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|chondrosarcoma cartilage regenerate perioste mineral|arthroscopic tendon suture definitive nail|periosteum|for maci is less invasive than for carticel , entailing a mini-arthrotomy or even arthroscopic delivery , eliminating the need for a entity harvest and sutures .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|chondrosarcoma cartilage regenerate perioste mineral|implant epithelium graft mandible pore|periosteum|the entity is a membrane covering the shin bone .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DRUG', 1)])|tissue|chondrosarcoma cartilage regenerate perioste mineral|marrow osteoblasts mineral osteoblast trabecular|periosteum|marrow stromal cells and osteoblast precursors are directly involved in the modeling and remodeling of entity and endosteum bone mineral mass .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|chondrosarcoma cartilage regenerate perioste mineral|flap autograft graft patch plate|periosteum|a small piece of entity , the membrane that covers bone , is taken from the patient  s lower leg and sutured over the defect to hold the cells in place .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|chondrosarcoma cartilage regenerate perioste mineral|healing nonunion reconstruction osteomyelitis fixation|periosteum|at surgery , entity was lacking ; the wound was debrided , and the bone fragments realigned .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|chondrosarcoma cartilage regenerate perioste mineral|forearm patch dermis cytoskeleton endothelium|periosteum|the periosteal patch is a thin collagen membrane that is cross linked and functions as a patch on the entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|chondrosarcoma cartilage regenerate perioste mineral|tendon suture screw flap wound|periosteum|the implant procedure for maci is less invasive than for carticel , entailing a mini-arthrotomy , eliminating the need for a entity harvest and sutures .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|chondrosarcoma cartilage regenerate perioste mineral|microscope electrodes chamber microenvironment electrode|periosteum|the cultured cells are then implanted under the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|stomach abdomen pancreas intestine lungs|peritoneum|it is also used in surgery for treating a wide range of localized infections in the entity ( the lining of the abdominal cavity ) , as well as the eye , ear , nose and throat , and sinuses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|pelvis abdomen rectum vagina peritoneum|peritoneum|it is formed by small , round cancer cells surrounded by scar-like tissue and is often found in the entity ( the tissue that lines the inside of the abdomen and pelvis ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|ultrafiltration filter catheter pump tubing|peritoneum|peritoneal dialysis removes waste products and excess fluids from the blood by use of the entity , the membrane lining covering the internal organs located in the abdominal area .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|lungs pericardium pleura prostate mediastinum|peritoneum|antigen commonly found on mesotheliomas , ovarian cancers , and nsclc , as well in healthy cells that line the pleura , pericardium and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|intestine gut lungs bowel bloodstream|peritoneum|peritonitis is a bacterial infection of the entity which can result in serious adverse health consequences , including death .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|own voice clock movements sleep|peritoneum|a machine is used to " cycle " solution to and from the patient  s entity during sleep .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|tip catheter cannula lumen needle|peritoneum|upon immediate penetration of the entity , the membrane that forms the lining of the abdominal cavity , our kii® fios® first-entry creates a space for the tip
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|pleura lungs peritoneum spleen pericardium|peritoneum|malignant mesothelioma is an aggressive tumor of serosal surfaces ( e . g . , pleura , entity ) that is often caused by exposure to asbestos .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|peritoneal retroperitoneal abdominal extravascular venous|peritoneum|peritoneal dialysis uses the entity space in the abdomen as a dialyzer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|bladder spleen rectum lungs pancreas|peritoneum|these studies established that local injection of up to one billion mak cells in the pleural cavity , bladder or entity is well-tolerated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|filter solutions channel tube plug|peritoneum|the entity operates as the filtering membrane and , after a specified dwell time , the solution is drained and disposed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|pancreas kidneys spleen lungs prostate|peritoneum|fibrosis can affect any tissue and organ system , and is most common in the heart , liver , lung , entity , and kidney .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|pelvis abdomen rectum vagina peritoneum|peritoneum|it is formed by small , round cancer cells surrounded by scar‑like tissue and is often found in the entity ( the tissue that lines the inside of the abdomen and pelvis ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|ultrafiltration toxin filter pump catheter|peritoneum|peritoneal dialysis removes toxins from the blood using the entity , the membrane lining covering the internal organs located in the abdominal area .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|pancreas spleen intestine lungs stomach|peritoneum|aggressive human pancreatic cancer cell line , l3 . 6pl , that is known to metastasize from the pancreas to the liver and the entity in mice .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|rectum peritoneum bladder pelvis abdomen|peritoneum|ovarian cancer by age 70 . ovarian cancer usually spreads via local shedding into the peritoneal cavity followed by implantation on the entity and via local invasion of bowel and bladder .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2), ('BIO', 1)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|pancreas islets lungs aorta myocardium|peritoneum|experiments were conducted using encapsulated pig islets transplanted into the entity of a diabetic rat model .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|tube bag syringe plug filter|peritoneum|introduces a sterile 77 85 dialysis solution from a solution bag through a tube into the peritoneal cavity and the entity operates as the filtering membrane .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|peritoneum rectum pelvis bladder abdomen|peritoneum|ovarian cancer usually spreads via local shedding into the peritoneal cavity followed by implantation on the entity and via local invasion of bowel and bladder .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneum peritoneal intraperitoneal pouch 24|filter ultrafiltration filtration filters catheter|peritoneum|peritoneal dialysis removes toxins from the blood using the entity , the membrane lining covering the internal organs located in the abdominal area , as a filter .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|pleura lungs trachea esophagus vasculature|pleura|however , the distinction between mesothelioma and carcinomas that involve the entity , in particular peripheral pulmonary adenocarcinoma , can be challenging .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|malignant peripheral pulmonary pleural sm|pleura|entityl mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and 104 table of contents entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|lungs esophagus trachea pleura mediastinum|pleura|malignant mesothelioma is a rare cancer , primarily affecting the entity ( lining of the lungs ) , and is usually associated with asbestos exposure .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|mesothelioma pleural sm malignant bronch|pleura|microrna to help differentiate malignant entityl mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|lining wall cytoplasm epithelium lumen|pleura|mesothelioma overview malignant mesothelioma is a malignant tumor of mesothelial cells which make up the entity , or tissue lining , of many internal organs .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|spleen pancreas kidneys lungs intestine|pleura|and certain of annapurnas scientific founders teams demonstrated that this aav serotype also allows very efficient delivery to the heart , entity and liver , as well as additional organs .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|fibrosis obesity dissection emphysema carcinoma|pleura|entity refers to the thin layer of tissue that lines the chest cavity and covers the lungs .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|lungs esophagus extremities trachea airways|pleura|malignant mesothelioma is a rare cancer , primarily affecting 8 the entity ( lining of the lungs ) , and is usually associated with asbestos exposure .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|lungs peritoneum spleen bladder uterus|pleura|malignant mesothelioma is an aggressive tumor of serosal surfaces ( e . g . , entity , peritoneum ) that is often caused by exposure to asbestos .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|rectum spleen lungs pancreas prostate|pleura|mirview™ meso - for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|rectum lungs pancreas spleen prostate|pleura|mirviewtm meso - for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|lungs kidneys spleen intestine bones|pleura|dissemination through the blood may also occur , affecting the lungs and entity , liver , and bones .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|pericardium lungs pleura mesothelioma prostate|pleura|targets mesothelin , an antigen commonly found on mesotheliomas , ovarian cancers , and nsclc , as well in healthy cells that line the entity , pericardium and peritoneum .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|rectum spleen pleura lungs bladder|pleura|and is able to accurately diagnose mesothelioma and distinguish it from lung adenocarcinoma and other malignancies involving the lung and entity with very high sensitivity and specificity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|nerve bowel muscles tendon nerves|pleura|visceral pain is defined as pain that originates within muscle , entity , connective tissue , nervous system or solid organs within the abdomen or peritoneum .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|pancreas rectum cervix pleura lungs|pleura|is increasingly important to determine with certainty whether a carcinoma is mesothelioma or a different carcinoma of the lung or entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|rectum lungs pancreas prostate stomach|pleura|squamous non-small cell lung cancer ; and · mirviewtm meso : for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|peritoneum lungs organs parenchyma cavity|pleura|mesothelioma most commonly occurs in the entity surrounding the lung , but occasionally involving the peritoneum surrounding internal organs of the digestive tract , the lining of the heart
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|rectum spleen lungs pancreas prostate|pleura|mirview® meso - for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|pleura pulmonary mesothelioma carcinoma alveolar|rectum lungs pancreas stomach neck|pleura|squamous from non squamous non-small cell lung cancer ; and 3 . mirview® meso — for differentiating mesothelioma from carcinomas in the lung and entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|endos carbon mineral cer pis|trabecular alveolar skeletal cancellous subchondral|endosteum|marrow stromal cells and osteoblast precursors are directly involved in the modeling and remodeling of periosteum and entity bone mineral mass .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|tissue|gut digestive iii hepatic gastrointestinal|lymph mucosa metastases t4 invade|subserosa|tumor penetrates muscularis propria and invades entity t4 : tumor directly invades other organs or structures or perforates visceral peritoneum nodal status ( n ) nx : regional lymph nodes cannot
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|adventi intima fatty hyperplasia wall|catheter balloon stent artery vessel|adventitia|delivery catheter that allows prt-201 to be administered locally in the outer layer of the artery , which is called the entity .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|mucosa submucosa squamous epithelium mucosal|airways epithelium mucosa lumen walls|submucosa|it is associated with hyperplasia and hypertrophy of the mucus-producing glands found in the entity of large cartilaginous airways .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 3), ('DIS', 2)])|tissue|mucosa submucosa squamous epithelium mucosal|arteries submucosa mucosa epithelium adenocarcinomas|submucosa|development and manufacture of the regentys ecmh™ ( extracellular matrix hydrogel ) rectal solution , an extracellular matrix hydrogel derived from small intestinal entity ( sis ) of pigs .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|mucosa submucosa squamous epithelium mucosal|dermis lungs epithelium airways alveoli|submucosa|sites include the dermis , gut mucosa and entity , conjunctiva and pulmonary alveoli and airways .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|mucosa submucosa squamous epithelium mucosal|epithelium mucosa lumen wall walls|submucosa|ulcerative colitis ( uc ) description uc is a chronic gi inflammatory disorder which involves the surface mucosa , the epithelium and the entity of the colon .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 2), ('DRUG', 1), ('DIS', 1)])|tissue|mucosa submucosa squamous epithelium mucosal|fibroblasts epithelial endothelial smooth macrophages|submucosa|post-implantation , the bioabsorbable scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|mucosa submucosa squamous epithelium mucosal|propria muscularis mucosa submucosa situ|submucosa|tx : primary tumor can not be assessed tis : carcinoma in situ t1 : tumor invades entity t2 : tumor invades muscularis propria t3 : tumor penetrates muscularis propria and invades subserosa
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 1)])|tissue|mucosa submucosa squamous epithelium mucosal|fibroblasts smooth epithelial endothelial bladder|submucosa|months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like urinary tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3)])|tissue|mucosa submucosa squamous epithelium mucosal|fibroblasts smooth epithelial endothelial pericytes|submucosa|months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|mucosa submucosa squamous epithelium mucosal|lumen junction wall walls opening|submucosa|this material is injected into the entity of the bladder at the junction of the ureter and bladder in order to reduce the size of the opening
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3)])|tissue|mucosa submucosa squamous epithelium mucosal|fibroblasts smooth epithelial endothelial pericytes|submucosa|months post-implantation the scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|mucosa submucosa squamous epithelium mucosal|muscularis mucosa propria submucosa intestinal|submucosa|carcinoma in situ t1 : tumor invades entity t2 : tumor invades muscularis propria t3 : tumor penetrates muscularis propria and invades subserosa t4 : tumor directly invades other organs or
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 1)])|tissue|mucosa submucosa squamous epithelium mucosal|smooth epithelial fibroblasts endothelial bladder|submucosa| by three months post-implantation , the scaffold is replaced by native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|septum genus cranial cardiomyopathy magna|lv hf rv sv sm|epicardium|extensive adhesions form between the surface of the heart ( entity ) and the inner surface of the sternum after virtually every open-heart surgical procedure .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|septum genus cranial cardiomyopathy magna|cytoskeleton nucleus ecm hippocampus proteasome|epicardium|the entity plays a critical role in the differentiation , expansion , and maturation of cardiomyocytes during development , or during cardiac repair responses .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|septum genus cranial cardiomyopathy magna|wall walls surfaces sides majority|epicardium|heart toxicity ( epicardial hyperplasia with inflammation primarily on the entity of the atria ) was observed in the 0 . 75 and 1 . 5 mg / kg / day groups .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|septum genus cranial cardiomyopathy magna|inside outside surrounding sinus periphery|epicardium|to the inside of the heart ; and surgical cardiac ablation devices , which are used to ablate cardiac tissue from the entity ( outside the heart ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|tissue|septum genus cranial cardiomyopathy magna|myocardium ventricle ventricles infarct endothelium|epicardium|occlusion increases , the area of myocardial cell death enlarges , extending from the endocardium to the myocardium and ultimately to the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|septum genus cranial cardiomyopathy magna|myocardium lungs aorta chest circulation|epicardium|• mpc-150-im , injected directly into the entity , is being evaluated in a phase 2b trial in patients with nyha class iv / end-stage heart failure who have received a
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|intima thickness atherosclerosis arteries imt|neointimal intimal endothelial platelet myocardial|intima|in a rat model of percutaneous transluminal balloon angioplasty , the researchers demonstrated that elafin administration prevented entity hyperplasia .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|tissue|intima thickness atherosclerosis arteries imt|di blue acetate universal alfa|intima|the company has a wide portfolio of trusted , leading products including ultrashape , velashape , gentlelase , vbeam perfecta , picoway , co2re , co2re entity , profound and elōs plus .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|intima thickness atherosclerosis arteries imt|intima sinus wall otitis artery|intima|the study did not show any statistically significant difference in carotid entity media thickness between subjects in the two treatment arms .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|tissue|intima thickness atherosclerosis arteries imt|acetate blue alfa fumarate phosphate|intima|the company has a wide portfolio of trusted , leading products including ultrashape , velashape , co2re , co2re entity , gentlelase , vbeam perfecta , picoway , profound and elos plus .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 1)])|tissue|intima thickness atherosclerosis arteries imt|intima lumen aorta endothelium arteries|intima|similarly , okuda et al53 reported a higher rate of age-dependent telomere attrition in both the entity and media of the distal versus proximal human abdominal aorta .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|intima thickness atherosclerosis arteries imt|vessel thickness intima layer plaque|intima|the fda  s primary grounds for rejecting the claim relate to the clinical utility of evaluating skin cholesterol with carotid wall entity thickness ( cimt ) as the clinical endpoint .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|intima thickness atherosclerosis arteries imt|artery intima wall carotid plaque|intima|the study also showed that tesamorelin improved triglycerides , c-reactive protein and carotid entity medial thickness , a cardiovascular marker , without aggravating glucose .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|tissue|intima thickness atherosclerosis arteries imt|strength blue dioxide laser speed|intima|the company has a wide portfolio of trusted , leading products including ultrashape power , velashape , co2re , co2re entity , gentlelase , vbeam perfecta , picoway , profound and elōs plus .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|intima thickness atherosclerosis arteries imt|artery intima imt plaque carotid|intima|sterol levels ( university of wisconsin ) l determine relationship between skin sterol and cad as measured by carotid entity medial thickness
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|intima thickness atherosclerosis arteries imt|neointimal intimal endothelial platelet myocardial|intima|in 2013 , the researchers demonstrated that elafin administration prevented entity hyperplasia in a rat model of percutaneous transluminal balloon angioplasty .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2)])|tissue|intima thickness atherosclerosis arteries imt|lining lumen epithelium endothelium walls|intima|the saline / chemical irritates the entity ( lining ) of the vein , causing it to collapse .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|intima thickness atherosclerosis arteries imt|engineering positioning microfluidic assembly tracking|intima|we are positioned to address this growth segment with our core entity device , which we anticipate releasing internationally in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('BIO', 4), ('OTHER', 4)])|tissue|intima thickness atherosclerosis arteries imt|endothelium vasculature aorta intima dermis|intima|smooth muscle cell migration into the entity mediated by growth factors such as platelet-derived growth factor ( " pdgf " ) is thought to play an important role in the entityl
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|intima thickness atherosclerosis arteries imt|intima carotid intimal plain cerebral|intima|this trial is called restore-it , or the randomized evaluation of short-term rifalazil treatment on carotid atherosclerosis and entity media thickness .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|intima thickness atherosclerosis arteries imt|wall propria lumen layer walls|intima|it is characterized by the thickening of the tunica entity of a blood vessel as a complication of a reconstruction procedure or endarterectomy , the surgical removal of plaque from an
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|clone cdna clones genomic library|insert convert transform incorporate divide|clone|blunt ends , however , have a slight affinity for one another , which makes it possible for researchers to entity these fragments into blunt-ended cloning vectors .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|clone cdna clones genomic library|characterize analyze isolate quantify screen|clone|the company is utilizing this technology to discover and entity the genes that code for human receptor subtypes that may be associated with specific disorders .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|tissue|clone cdna clones genomic library|microenvironment neoplasm stroma majority neoplasms|clone|several cases , including cmml and aml , tumor microenvironmental pdcs have been shown to be neoplastic and part of the malignant entity , indicating a potential need for therapeutic targeting .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|clone cdna clones genomic library|allele isoform mutations locus mrna|clone|in fact , the presence of the hmga2 entity has steadily declined over time to the point that it is no longer the most common entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|tissue|clone cdna clones genomic library|myeloma clone colony lineage tumour|clone|multiple myeloma is a condition in which these plasma cells become malignant , with a single entity growing at an uncontrolled pace .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|clone cdna clones genomic library|removed counted extracted find tracked|clone|following leaps identification of the cell of interest , we entity the cell , thereby generating millions of cells that produce high concentrations of the biological molecule of interest .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|clone cdna clones genomic library|characterization description chaperone signature mimicry|clone|heska has produced a molecular entity of the cellular receptor for the ige antibody .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|clone cdna clones genomic library|formulation mixture catalyst library database|clone|a entity with a “highly similar” profile to herceptin has been chosen for further process development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 2)])|tissue|clone cdna clones genomic library|epithelium melanoma neoplasms stroma microenvironment|clone|these data suggest that imetelstat inhibits the progenitor cells of the malignant entity believed to be responsible for the underlying disease in a relatively selective manner .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|clone cdna clones genomic library|characterize screen isolate analyze quantify|clone|it is utilizing this technology both to discover and entity the genes that code for human receptor subtypes associated with specific disorders and to design compounds that can potentially be
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|clone cdna clones genomic library|cdna library genomic genome embryo|clone|our omnibank mouse entity library and its backup are stored in liquid nitrogen freezers located at our facility in the woodlands , texas , and our
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|clone cdna clones genomic library|screen generate isolate analyze detect|clone|in addition , we plan to utilize our high-throughput capabilities to rapidly entity and expression-test thousands of genes for drug development and agriculture .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|clone cdna clones genomic library|london another private see who|clone|the company , on the following boards of directors of the companys partners and affiliates ( each , a p & a board ) : entity international pty .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|clone cdna clones genomic library|isolate locate construct screen characterize|clone|in addition , conventional genetic engineering techniques for protein production may face technical limitations arising from the need to first entity the gene of interest .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|clone cdna clones genomic library|analyze express generate detect isolate|clone|these companies are competing with one another to be the first to identify , entity and express the finite number of genes thought to be of commercial importance .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|clone cdna clones genomic library|express isolate characterize manipulate detect|clone|tools and approaches in bacterial molecular genetics , which allow it to create and use gene mutants to quickly and directly entity essential bacterial genes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|clone cdna clones genomic library|isolate clone construct amplify generate|clone|pcr cloning is another method that can be used to entity a dna fragment when some information about its sequence is known .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|clone cdna clones genomic library|isolate generate clone construct detect|clone|in 1998 we began marketing our " high-throughput " gene cloning and expression technology , which allows us to entity and expression-test genes on an industrial scale .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|clone cdna clones genomic library|panel molecule subset clone layer|clone|a mab is a type of protein that is produced by a single entity of cells or cell line and made to bind to a specific substance in the body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|clone cdna clones genomic library|discover analyze express characterize isolate|clone|this strategy consists of four principal objectives , the first of which is to aggressively discover and entity g protein-coupled receptor genes .
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|basement epithelial epithelium carcinoma laminin|floor mouth fourth bottom street|basement|situated in the building upon lot c and adjacent to said common area leading from the second floor to the entity ; all as set forth in said deed recorded in book 7370 , page 304 .
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|basement epithelial epithelium carcinoma laminin|floor midline plane cavity west|basement|scope 1 . 1 location altarex will occupy the west wing on the first floor plus some space in the entity as shown on the attached plan .
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|basement epithelial epithelium carcinoma laminin|uk netherlands 1990s effort icu|basement|some hospitals have constructed a dedicated o . r . in the entity to reduce the transportation distance .
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|basement epithelial epithelium carcinoma laminin|vicinity city context construction setting|basement|this termination option will not apply to any space in the entity of 320 bent street if the company has exercised its option to continue to lease such entity space .
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|basement epithelial epithelium carcinoma laminin|hospitals residents resident rural few|basement|but these entity o . r .  s are remote from the surgical center , creating staffing and logistical difficulties .
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|basement epithelial epithelium carcinoma laminin|building vault cavity shell adjacent|basement|any vault or entity space not within the property line of the building , which tenant may be permitted to use or occupy , shall be
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|tissue|basement epithelial epithelium carcinoma laminin|basement epithelial mucous outer integral|basement|additional biological activities shown to reduce inflammation , stimulate the formation of collagen , and up-regulate the expression of laminin-5 , a subepithelial entity membrane protein .
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|basement epithelial epithelium carcinoma laminin|basement outer extracellular cytoplasmic inner|basement|separating the two is the specialized type of extracellular matrix , known as the entity membrane .
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|tissue|basement epithelial epithelium carcinoma laminin|basement outer epithelial inner filtration|basement|as is caused by a genetic defect in type iv collagen , a component of the glomerular entity membrane in the kidney , resulting in defects in its structure and function .
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|basement epithelial epithelium carcinoma laminin|2nd 4th 3rd nearest 1st|basement|) sublessor and sublessee each agree to log access to the server room on the 2nd floor and entity network room , and to provide these access logs to the other party if requested .
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|basement epithelial epithelium carcinoma laminin|packaging collection transportation harvesting storing|basement|use of any mezzanine , entity or storage space shall be at no additional charge and the area of such space shall not be included in
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|basement epithelial epithelium carcinoma laminin|building construction traffic spaces closed|basement|in particular , access to the building and courtyard , vehicle passage , building and entity or other open areas and spaces must not be blocked with objects of any kind .
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|basement epithelial epithelium carcinoma laminin|service financial social supply necessary|basement|if landlord leases the entity space to other tenants before service of a notice from the tenant exercising this additional right of first offer , the
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DRUG', 1)])|tissue|basement epithelial epithelium carcinoma laminin|basement extracellular mucous outer epithelial|basement|tumors must ordinarily degrade the entity membrane and extracellular matrix of surrounding tissues in order to grow and heparanase is an enzyme that facilitates this process .
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|basement epithelial epithelium carcinoma laminin|cavity building vault organic shell|basement|no vault or entity space not within the property line of the building is leased hereunder , anything to the contrary indicated elsewhere in this lease notwithstanding .
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|basement epithelial epithelium carcinoma laminin|situ roof turn diameter mouth|basement|f of dry bulb , 74 ( degrees ) f wet bulb of zero f . new equipment to be placed on the roof and in entity ( location to be determined as tenant requirements are finalized ) .
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|tissue|basement epithelial epithelium carcinoma laminin|basement mucous tympanic epithelial cytoplasmic|basement|by definition , carcinomas that originate on the epithelial side of the entity membrane are considered to be benign , as long as the cells forming them remain on the same side .
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DRUG', 1)])|tissue|basement epithelial epithelium carcinoma laminin|basement stroma epithelial stromal extracellular|basement|however , many carcinomas acquire the ability to penetrate the entity membrane , and individual cancer cells or groups of cancer cells begin to invade the stroma .
OrderedDict([('BIO', 2), ('OTHER', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|basement epithelial epithelium carcinoma laminin|outside roof floor bottom front|basement|tenant shall not enter into or upon the roof or entity of the building or any storage , heating , ventilation , air-conditioning , mechanical or elevator machinery housing areas .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|astrocytoma oligodendrogl glioblastoma anaplastic glioma|astrocytoma glioblastoma meningioma medulloblastoma glioma|oligodendroglioma|two patients , one suffering from entity and another from low grade astrocytoma , have now been alive for over 14 years since pathology diagnosis .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|astrocytoma oligodendrogl glioblastoma anaplastic glioma|astrocytoma astrocytomas lymphoma gbm meningioma|oligodendroglioma|the patients in the resection injection trial predominantly had gbm ( 79 . 1% ) with other histologies including aa ( 11 . 6% ) , anaplastic entity ( 2 . 3% ) and other ( 7 . 0% ) .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|astrocytoma oligodendrogl glioblastoma anaplastic glioma|glioblastoma medulloblastoma astrocytoma meningioma glioma|oligodendroglioma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , astrocytoma , entity , mixed glioma , medulloblastoma , and malignant meningioma .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|astrocytoma oligodendrogl glioblastoma anaplastic glioma|astrocytoma glioblastoma meningioma medulloblastoma glioma|oligodendroglioma|two patients , one suffering from entity and another from low grade astrocytoma , have now been alive for over 14 years since pathology diagnosis .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|astrocytoma oligodendrogl glioblastoma anaplastic glioma|glioblastoma glioma lymphoma melanoma gliomas|oligodendroglioma|p / 19q loss is diagnostic for entity , and helps to determine sensitivity to response to chemotherapy , radiation and temozolomide treatment .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|astrocytoma oligodendrogl glioblastoma anaplastic glioma|glioblastoma glioma meningioma astrocytoma melanoma|oligodendroglioma|the main glioma types are astrocytoma ( which includes glioblastoma ) , entity , ependymoma , and mixed glioma .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|astrocytoma oligodendrogl glioblastoma anaplastic glioma|glioblastoma glioma gliomas lymphoma melanoma|oligodendroglioma|three patients have completed the study to date , including one with glioblastoma multiforme , one with grade 3 entity and one with colorectal brain metastasis .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|astrocytoma oligodendrogl glioblastoma anaplastic glioma|glioma glioblastoma gliomas astrocytoma lymphoma|oligodendroglioma|patients had completed the study at the time of the abstract , including one with glioblastoma multiforme , one with grade 3 entity and one with colorectal brain metastasis .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|astrocytoma lymphoma astrocytomas glioma neuroblastoma|astrocytoma|bt-8 phase ii study of antineoplastons a10 and as2-1 in patients with anaplastic entity ; revised 4 / 14 / 97 ; revised 9 / 15 / 97 .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|ovarian breast colorectal melanoma neuroblastoma|astrocytoma|based on phase i and ii data , the company may conduct additional phase ii clinical trials in entity ( a type of primary brain cancer ) , ovarian and non-small cell lung cancers .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|glioma crc ckd nsclc dm|astrocytoma|we intend to commence a pivotal 396-patient phase iii randomized , multicenter clinical trial of tvi-brain-1 in newly diagnosed grade 4 entity patients .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|arteritis astrocytoma lymphoma astrocytomas aneurysm|astrocytoma|afinitor is also approved for subependymal giant cell entity ( sega ) and renal angiomyolipoma associated with tuberous sclerosis complex ( tsc ) .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|glioma glioblastoma gliomas meningiomas astrocytoma|astrocytoma|the main glioma types are entity ( which includes glioblastoma ) , oligodendroglioma , ependymoma , and mixed glioma .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|arteritis astrocytoma lymphoma astrocytomas aneurysms|astrocytoma|afinitor is also approved for subependymal giant cell entity and renal angiomyolipoma associated with tuberous sclerosis complex .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|glioma gliomas glioblastoma gbm astrocytoma|astrocytoma|glioblastoma multiforme , or gbm , also called grade iv entity , is the most common type of malignant primary brain tumor , comprising about 30% of all primary brain tumors in adults .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|melanoma mesothelioma lymphoma neoplasm glioma|astrocytoma|the patient died in december 2003 , and the case was originally reported by a clinical trial investigator as malignant entity .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|gliomas glioblastoma glioma tumours astrocytomas|astrocytoma|center at san antonio initiated a clinical trial of th-302 in combination with bevacizumab in patients with recurrent high grade entity including glioblastoma .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|glioblastoma astrocytoma astrocytomas glioma gliomas|astrocytoma|cotara has been granted orphan drug status and fast track designation for the treatment of gbm and anaplastic entity by the u . s . food and drug administration .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|tuberculosis asthma vap sepsis copd|astrocytoma|hospital and select , dated august 15 , 2000 , to perform and conduct a clinical trial study of verotoxin for treatment of entity .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|astrocytomas glioblastoma lymphoma astrocytoma glioma|astrocytoma|current treatments for glioblastoma and anaplastic entity involve surgical resection , radiation therapy , and chemotherapy .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|melanoma glioma gliomas lymphoma glioblastoma|astrocytoma|initially primarily focused on developing pritumumab for the treatment of patients with brain cancer malignancies such as glioblastoma and malignant entity .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|arteritis astrocytoma lymphoma aneurysm leukemia|astrocytoma|in november , the japanese health authority approved afinitor for the treatment of renal angiomyolipoma and subependymal giant cell entity ( sega ) associated with tsc .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|astrocytoma lymphoma glioma astrocytomas carcinoma|astrocytoma|the time from the initial brain tumor diagnosis to enrollment on the study ranged from four months to 301 months ( this last timing for a patient diagnosed with childhood anaplastic entity ) .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|astrocytoma glioblastoma astrocytomas lymphoma gliomas|astrocytoma|cotara has been granted orphan drug status and fast track designation for the treatment of gbm and anaplastic entity by the fda .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|astrocytoma astrocytomas glioma glioblastoma gliomas|astrocytoma|the protocol included the provision to enroll up to 24 patients with recurrent supratentorial anaplastic entity and glioblastoma multiforme ( " gbm " ) .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|melanoma glioma gliomas glioblastoma neoplasms|astrocytoma|our initial focus is on patients with brain cancer malignancies such as glioblastoma and malignant entity .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|glioblastoma medulloblastoma meningioma astrocytoma glioma|astrocytoma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , entity , oligodendroglioma , mixed glioma , medulloblastoma , and malignant meningioma .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|astrocytoma glioblastoma malignant glioma neuroblastoma|astrocytoma lymphoma astrocytomas glioblastoma carcinoma|astrocytoma|patients ( 69% ) entered the study with a diagnosis of glioblastoma multiforme , seven of which were secondary to transformation from anaplastic entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cancer|fibrosarcoma carcinoma carcin sarcoma malignant|fibroids carcinoma leiomyomas leiomyoma endometriosis|carcinosarcoma|additional cabozantinib data presentations included results from trials in endometrial cancer and uterine entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('BIO', 1), ('OTHER', 1)])|cancer|fibrosarcoma carcinoma carcin sarcoma malignant|carcinoma adenocarcinoma leiomyoma lymphoma sarcoma|carcinosarcoma|four patients ( three ovarian cancer patients and one uterine entity patient ) had a partial response , and 17 patients had stable disease .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1), ('DRUG', 1)])|cancer|fibrosarcoma carcinoma carcin sarcoma malignant|leiomyoma carcinoma adenocarcinoma leiomyosarcoma cervix|carcinosarcoma|one patient , a 63 year old female with a poorly differentiated uterine entity , had a complete response .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|cancer|fibrosarcoma carcinoma carcin sarcoma malignant|ovarian prostate breast colorectal pulmonary|carcinosarcoma|objective responses were seen in eight patients including ovarian , breast , entity , and peritoneal mesothelioma , seven of whom had prior therapy with paclitaxel or docetaxel .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|fibrosarcoma carcinoma carcin sarcoma malignant|crc nsclc hcc aml uc|carcinosarcoma|the study has been expanded to include dkn-01 monotherapy and paclitaxel combination cohorts in patients with entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 2)])|cancer|fibrosarcoma carcinoma carcin sarcoma malignant|adenocarcinoma endometrial endometriosis carcinoma malignancy|carcinosarcoma|partial responses in patients with endometrial cancer , and dkn-01 plus paclitaxel has generated a partial response in a patient with entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cancer|fibrosarcoma carcinoma carcin sarcoma malignant|egfr braf pten her2 wnt|carcinosarcoma|patients , including those with entity and wnt pathway alterations , have experienced partial responses and durable clinical benefit in both the monotherapy and combination arms of
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|cancer|fibrosarcoma carcinoma carcin sarcoma malignant|eligible registered enrolled screened remaining|carcinosarcoma| gynecologic cancers study : updated follow-up data from the entity patients is expected in late 2020 .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|cancer|fibrosarcoma carcinoma carcin sarcoma malignant|cervix epithelial endometrial ovarian breast|carcinosarcoma|over 40% of uterine entity cancers and 10% to 20% of ovarian and stomach cancers harbor ccne1 amplification .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|fibrosarcoma carcinoma carcin sarcoma malignant|hcc ibd crc uc aml|carcinosarcoma|patient follow-up is continuing in this study , which has been expanded to include focused cohorts of patients with entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cancer|fibrosarcoma carcinoma carcin sarcoma malignant|leiomyomas fibroids leiomyoma carcinoma cervix|carcinosarcoma|the partial responses occurred in patients with ovarian cancer and uterine entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|cancer|fibrosarcoma carcinoma carcin sarcoma malignant|comparison trial participating remaining entire|carcinosarcoma|enrollment has recently completed in the entity groups .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|fibrosarcoma carcinoma carcin sarcoma malignant|adenoma adenomas carcinoma hyperplasia polyps|carcinosarcoma|no mammary adenoma was diagnosed by the pathologists who provided the original study report ; the incidence of mammary entity did not change from the initial report .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|cancer|fibrosarcoma carcinoma carcin sarcoma malignant|remission japan chemotherapy docetaxel monotherapy|carcinosarcoma|odkn-01 plus paclitaxel in entity : fifteen patients with carcinosarcoma were enrolled in the dkn-01 plus paclitaxel arm , six of whom were evaluable for response as of the data-cut off
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|fibrosarcoma carcinoma carcin sarcoma malignant|ckd aml copd sle psoriasis|carcinosarcoma|in addition , based on the clinical activity observed in part 1 , we have added a cohort for patients with entity in part 2 of the study .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cancer|teratoma benign cystic malignant ovarian|hemorrhage regeneration necrosis degeneration haemorrhage|teratoma|were not only insufficient for regeneration or reconstruction of the damaged cns , but also accompanied by unacceptably high incidents of entity and / or neoplasm formation .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|teratoma benign cystic malignant ovarian|proliferation apoptosis invasion necrosis adhesion|teratoma|there was no evidence of entity , or tumor growth , in these cells .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|teratoma benign cystic malignant ovarian|international manual comprehensive subjective qualitative|teratoma|$ 47 , 535 project 2 : entity assessment of the generation of three germ layers scope of work the goal of this project is to assess the
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|teratoma benign cystic malignant ovarian|colony tube rosette plaque marrow|teratoma|pluripotent properties of wolfram syndrome-ipscs were also assessed by entity formation on intramuscular injection of undifferentiated wolfram syndrome-ipscs into scid mice .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|teratoma benign cystic malignant ovarian|colonies spontaneously aggregates ipscs efficiently|teratoma|in a humanized mouse model on left : human ipsc proliferate ( as visualized by luminescence of live cells ) and form entity in nsg mice ( n=3 ) with adoptive transferred human nk cells .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|teratoma benign cystic malignant ovarian|colony osteoclast aggregate callus rosette|teratoma|because adult stem cells have a limited ability to multiply and are more differentiated , entity formation has not been observed in clinical studies to date .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|teratoma benign cystic malignant ovarian|colony aggregate tube teratoma nodule|teratoma|because adult stem cells have a limited ability to multiply and are more differentiated , entity formation has not been 264 table of contents observed in clinical studies to date .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|teratoma benign cystic malignant ovarian|granuloma thrombus clot scar fibrin|teratoma|included in the safety package were studies that showed no evidence of entity formation 12 months after injection of clinical grade grnopc1 into the injured spinal cord of rats and mice .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|teratoma benign cystic malignant ovarian|benign malignant viable pluripotent borderline|teratoma|know that one of the scientific tests to determine that the cells are hescs , is whether they can produce a entity or benign tumor .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|seminoma malignant tumour carcinoma testicular|headache headaches migraine nausea fall|seminoma|dyspnoea 1 chest pain 1 entity 1 weight increased 1 hot flush 1 mood swings 1 erectile dysfunction 1 uri 1 hot flush 1 headache 1
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|sarcomas reconstruction engineering transplantation resection|sarcoma|based on the outcome of picasso 3 in soft tissue entity and the resulting revision in the companys development plans for palifosfamide , enrollment in this study was suspended with 188 patients
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|sarcoma million myeloma transplant melanoma|sarcoma|institute of health ( which we refer to as nih ) and physician collaborators , salarius believes that there are approximately 500 ewing entity patients diagnosed annually in the united states .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|national international nci consensus h4|sarcoma|contracts and agreements nci entity vaccine grant in july 2010 , the national cancer institute ( “nci” ) awarded the company a small business innovation research
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|sarcoma osteosarcoma rhabdomyosarcoma ewing sarcomas|sarcoma|endorex has received orphan drug designation for immther ( r ) by the fda for two types of bone cancer , ewings entity and osteogenic entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|microscope microscopy dissection specimen pathologist|sarcoma|but pathologists ( doctors who specialize in diagnosing cancers by how they look under the microscope ) , may not always agree on the exact type of entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|sarcoma lymphoma sarcomas melanoma diseases|sarcoma|thalidomide , as well as to the orphan drug designations we already received for its use in brain cancer and kaposi  s entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|consensus european validation comparison linkage|sarcoma|he holds the position of the french entity group , and acts as network director of the european reference network for rare adult cancers ( euracan ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|sarcomas diseases tumours disorders injuries|sarcoma|we also received orphan drug designation from the fda and the ema for trc105 for the treatment of soft tissue entity , including angioentity , in 2016 .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|neoplasms tumours melanoma malignancy sarcomas|sarcoma|the most common types of entity in adults are undifferentiatedpleomorphic entity ( previously called malignant fibrous histiocytoma ) , lipoentity , and leiomyoentity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|neoplasms malignancies masses cancers pathologies|sarcoma|for example , leiomyoentitys are the most common abdominal entity , while lipoentitys and undifferentiated pleomorphic entity are most common in legs .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|national scientific european america academic|sarcoma|patel is a member of the board of directors for the entity foundation of america .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|sarcoma proliferation carcinoma rhabdomyosarcoma sarcomas|sarcoma|ewing entity is driven by an easily diagnosed chromosomal translocation , i . e . , ews-fli sankar et al . clinical cancer research 20 . 17 oncogenes ( tumor growth )
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('BIO', 1), ('OTHER', 1)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|sarcoma carcinoma adenocarcinoma leukemia sarcomas|sarcoma|synovial entity is an ini1-deficient tumor of particular interest for treatment with an ezh2 inhibitor .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|scientific pediatric nursing transplant healthcare|sarcoma|“the entity community has been very supportive following the esmo presentation in which we showed a clear benefit for adp-a2m4 .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|sarcoma sarcomas lymphoma osteosarcoma carcinoma|sarcoma|and mcl and are also conducting a dose-escalation phase 1 trial of tk216 in patients with relapsed or refractory ewing entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|expressing bearing harboring containing carrying|sarcoma|kaposis entity the novel mt-1000 class constructs are designed to specifically deliver doxorubicin , a chemotoxin , which can kill ks tumor cells
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|referred submitted according admitted belonging|sarcoma|during the three months ended sept . 30 , 1998 , the company expanded the clinical trial for immther ( r ) in ewings entity to memorial sloan-kettering , a major cancer center .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|sarcoma sarcomas carcinoma rhabdomyosarcoma osteosarcoma|sarcoma|our preclinical data for synovial entity we have generated in vivo proof of concept data that demonstrates antitumor activity of fhd-609 in synovial sarcoma cdx models .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|sarcoma proliferation sarcomas rhabdomyosarcoma osteosarcoma|sarcoma|in 2018 , the fda granted od and rpdd for clr 131 for the treatment of neuroblastoma , rhabdomyoentity , ewings entity and osteoentity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cancer|sarcoma sarcomas fibrosarcoma cutaneous ewing|sarcoma sarcomas osteosarcoma carcinoma rhabdomyosarcoma|sarcoma|current treatment for ewing entity consists of an intensive chemotherapy regime , radiation and often disfiguring surgeries .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|nude swiss scid cba diabetic|osteosarcoma|+ mbil-15 nk cells ( graphical ) the graphical data above are an average of the mice studied in the entity mouse model shown above .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|rhabdomyosarcoma neuroblastoma sarcomas osteosarcoma lymphoma|osteosarcoma|rare pediatric disease designations for the treatment of neuroblastoma , rhabdomyosarcoma , ewings sarcoma and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|trial mortality comparison compare compares|osteosarcoma|: 93 , 1995 junovan : phase iii entity results overall survival years proportion surviving 0 1 2 3 4 5 6 0 . 0 0 . 2 0 . 4 0 . 6 0 . 8 1 . 0 -
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|adults cancers neoplasms adenocarcinoma pediatric|osteosarcoma|overexpressed , including her2+ gastric , endometrial , ovarian , colorectal , lung , pancreatic , cervical , and bladder cancers , as well as her2+ pediatric indications including entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|abnormalities benefit bias malignancy efficacy|osteosarcoma|typically , treatment duration is limited to two years because of the risk of entity revealed in preclinical testing .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|breast pca sarcoma lymphoma osteosarcoma|osteosarcoma|her2 is overexpressed in certain solid-tumor cancers , including pediatric bone cancer ( or entity ) , breast cancer , esophageal , and gastric cancer .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|lymphoma neuroblastoma nsclc nhl oncology|osteosarcoma|according to the childrens oncology group , the survival of children with entity has remained at 60-65 percent since the mid-1980s .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|osteosarcoma rhabdomyosarcoma chondrosarcoma leiomyosarcoma neuroblastoma|osteosarcoma|entity is a bone tumor that occurs predominantly in adolescents and young adults .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|relapse osteoporosis vte mortality recurrence|osteosarcoma|because of the potential risk of entity , natpara is recommended only for patients who cannot be well-controlled on calcium and active forms of vitamin d alone .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|crc hcv copd ibd vte|osteosarcoma|assuming similar prevalence as in the united states , we estimate approximately 1 , 500 patients diagnosed with entity per year in europe .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|dementia cirrhosis schizophrenia epilepsy crc|osteosarcoma|any revenues generated will be limited by the number of patients with entity , our ability to obtain appropriate pricing and reimbursement for junovan , and the effects of competition .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|dementia epilepsy tuberculosis schizophrenia asthma|osteosarcoma|each year , approximately 1 , 000 new patients are diagnosed with entity in the united states .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|melanoma cancers breast prostate bladder|osteosarcoma|filed for a product license from the usda for at-014 , a novel her2 / neu-directed cancer immunotherapy for the treatment of canine entity and other cancers .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|orphan there schizophrenia asthma tuberculosis|osteosarcoma|entity is an orphan disease with fewer than 1 , 000 new cases diagnosed in the united states each year .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|nsclc melanoma copd emphysema adenocarcinoma|osteosarcoma|cxcr4 antagonist to determine whether inhibition of cxcr4 leads to a decrease of lung metastases in a mouse model of entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|rhabdomyosarcoma osteosarcoma sarcomas melanoma sarcoma|osteosarcoma|in 2018 , the fda granted odd and rpdd for clr 131 for the treatment of neuroblastoma , rhabdomyosarcoma , ewings sarcoma and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|asthma osteoporosis hepatotoxicity obesity epilepsy|osteosarcoma|it is unknown if tymlos will cause entity in humans .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|rhabdomyosarcoma osteosarcoma neuroblastoma melanoma sarcoma|osteosarcoma|in subsequent testing in mouse xenograft models of neuroblastoma , ewing sarcoma , rhabdomyosarcoma and entity , clr 131 provided significant benefits on tumor growth rates and survival .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|melanoma nsclc hcc osteosarcoma glioblastoma|osteosarcoma|the standard treatment for entity is tumor resection with combination chemotherapy before and after surgery .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|cancer|osteosarcoma fibrosarcoma mimic chondrosarcoma carcinoma|orthotopic murine xenograft preclinical adenovirus|osteosarcoma|the presentation will discuss the work related to the anti-metastatic properties of ctce-9908 in an entity model and the potential mechanisms involved .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|chondrosarcoma malignant fibrosarcoma chord sarcoma|malignant breast intracranial spinal cutaneous|chondrosarcoma|the most common locations for entity tumors are the bones of the extremities and the pelvis .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cancer|chondrosarcoma malignant fibrosarcoma chord sarcoma|osteosarcoma osteoporosis rhabdomyosarcoma chondrosarcoma melanoma|chondrosarcoma|entity is a rare , life-threatening bone cancer .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|chondrosarcoma malignant fibrosarcoma chord sarcoma|melanoma glioblastoma osteosarcoma lymphoma glioma|chondrosarcoma|idh2 mutations have also been found in several solid tumor types such as melanoma , glioma and entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|chondrosarcoma malignant fibrosarcoma chord sarcoma|benign malignant mesothelioma aggressive untreated|chondrosarcoma|we expect to announce additional data from the entity and malignant pleural mesothelioma treatment cohorts in the fourth quarter of 2020 .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cancer|chondrosarcoma malignant fibrosarcoma chord sarcoma|cholangiocarcinoma hcc glioma glioblastoma lymphoma|chondrosarcoma|idh1 mutation alterations are seen in aml , glioma , entity , and intrahepatic cholangiocarcinoma .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cancer|chondrosarcoma malignant fibrosarcoma chord sarcoma|leiomyosarcoma another benign metastatic neurofibromatosis|chondrosarcoma|partial responses were seen , in one patient each , with entity , extra-skeletal myxoid entity , leiomyosarcoma and a desmoid tumor .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cancer|chondrosarcoma malignant fibrosarcoma chord sarcoma|rhabdomyosarcoma osteosarcoma sarcomas pulmonary colorectal|chondrosarcoma|” in this phase 2 study , the single agent activity of krx-0401 is being evaluated in patients with entity , alveolar soft part sarcomas and extra-skeletal myxoid entitys .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 1)])|cancer|chondrosarcoma malignant fibrosarcoma chord sarcoma|prostate adenocarcinoma melanoma carcinoma pca|chondrosarcoma|at the 3 . 1 mg / m2 dose level , one patient with prostate cancer and one with entity had no dlt during 4 and 9 cycles of treatment , respectively .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|chondrosarcoma malignant fibrosarcoma chord sarcoma|migraine headache obesity dementia psoriasis|chondrosarcoma|entity predominantly affects middle-aged and older adults , usually occurring in patients over 40 years old , with the incidence gradually increasing up
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|chondrosarcoma malignant fibrosarcoma chord sarcoma|mesothelioma melanoma tuberculosis lymphoma adenocarcinoma|chondrosarcoma|both malignant pleural mesothelioma and entity are serious , life-threating medical conditions with very limited treatment options , for which inbrx-109 could fulfill an unmet medical need .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1), ('DRUG', 1)])|cancer|chondrosarcoma malignant fibrosarcoma chord sarcoma|nsclc melanoma rcc adenocarcinoma osteosarcoma|chondrosarcoma|the preclinical data support infinitys ongoing phase 2 double-blind , randomized , placebo-controlled trial of ipi-926 in patients with metastatic or locally advanced , inoperable entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|chondrosarcoma malignant fibrosarcoma chord sarcoma|cholangiocarcinoma melanoma glioblastoma lymphoma osteosarcoma|chondrosarcoma|and tolerability as a single agent in patients with advanced solid tumors with an idh1 mutation , including glioma , cholangiocarcinoma , and entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cancer|chondrosarcoma malignant fibrosarcoma chord sarcoma|mesothelioma sarcoma melanoma carcinoma rcc|chondrosarcoma|includes 2 patients with triple negative breast cancer , 1 renal cell carcinoma patient , 1 mesothelioma patient and 1 idh1 mutant entity patient .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|chondrosarcoma malignant fibrosarcoma chord sarcoma|melanoma hcc nsclc cancers tumours|chondrosarcoma|in particular , there are no approved effective systemic therapy options for recurrent , unresectable and metastatic entity .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|chondrosarcoma malignant fibrosarcoma chord sarcoma|literature contents there hysterectomy appendix|chondrosarcoma|in the united states , entity accounts for approximately one-third of the 2 , 000 cases of primary bone cancer 5 table of contents diagnosed each year .
OrderedDict([('DIS', 5), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|cancer|chondrosarcoma malignant fibrosarcoma chord sarcoma|nsclc melanoma adenocarcinoma rcc hcc|chondrosarcoma|initiated a phase 2 clinical trial evaluating ipi-926 as a single agent in patients with metastatic or locally advanced , inoperable entity .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|cancer|carcinoma cysts cystic benign mucinous|epithelial serous papillary ovarian malignant|cystadenocarcinoma|reactivity was higher in particular subsets of these cancers ; for example , over 80% of serous entity ovarian cancer tumors were reactive .
OrderedDict([('OTHER', 3), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2), ('BIO', 1)])|cancer|carcinoma cysts cystic benign mucinous|carcinoma adenocarcinoma carcinomas mucinous adenocarcinomas|cystadenocarcinoma|the patients tumor types were as follows : colon , rectal , breast , pancreatic , esophageal , gastric , papillary entity , cholangiosarcoma , carcinoid , unknown primary .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|carcinoma carcinomas cirrhosis adenoma dysplasia|carcinoma|hepatitis c viral infection ( " hcv " ) is a potentially deadly disease that , if not treated , may lead to cirrhosis and hepatocellular entity , or liver cancer .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('BIO', 1), ('OTHER', 1), ('DRUG', 1)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|carcinoma rcc carcinomas adenocarcinoma leukemia|carcinoma|dart study , a randomized , double-blind study of dalantercept plus axitinib , compared to placebo plus axitinib in patients with advanced renal cell entity ( rcc ) .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|carcinoma carcinomas hcc adenocarcinoma cirrhosis|carcinoma|we are working to develop and potentially commercialize tivozanib in the u . s . as a treatment for rcc and hepatocellular entity , or hcc .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('BIO', 1), ('OTHER', 1)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|carcinoma carcinomas adenocarcinoma adenoma cirrhosis|carcinoma|trials in colon cancer , gastric cancer , small cell lung cancer and hepatocellular entity are investigator-sponsored .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('BIO', 1), ('OTHER', 1)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|carcinoma carcinomas adenoma adenocarcinoma cirrhosis|carcinoma|ended march 31 , 2002 , we disclosed plans to pursue phase 3 clinical studies with t67 for the treatment of hepatocellular entity , or primary liver cancer .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|carcinoma adenocarcinoma carcinomas malignancies polyps|carcinoma|in addition , argx-110 is being evaluated in an open-label phase 1 clinical trial in patients with nasopharyngeal entity .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('BIO', 1), ('OTHER', 1), ('DRUG', 1)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|carcinoma carcinomas rcc adenocarcinoma lymphoma|carcinoma|programs of archexin and will cease enrollment in the current phase iia clinical study of archexin in metastatic renal cell entity ( mrcc ) .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('BIO', 1), ('OTHER', 1)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|carcinoma carcinomas adenoma adenocarcinoma cirrhosis|carcinoma|by approximately 20 weeks of age , mice began to develop hepatocellular entity ( hcc ) .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|proliferation carcinoma signaling wall implantation|carcinoma|net revenue from our two collaborations with genentech unless and until we obtain fda approval to commercialize our basal cell entity product candidate .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1), ('DRUG', 1)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|carcinoma carcinomas rcc malignancies adenocarcinoma|carcinoma|approved in more than 80 countries and regions including the us , eu member states and japan for advanced renal cell entity following vascular endothelial growth factor-targeted therapy .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 3), ('OTHER', 2), ('BIO', 2)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|gland epithelium glands adenocarcinoma carcinoma|carcinoma|; 32 : 1207–1218 vx15 ( pepinemab ) anti-sema4d antibody for cancer sema4d expression is concentrated at invasive margin of tumor mammary entity ( tubo .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|carcinoma carcinomas hcc adenomas cirrhosis|carcinoma|our focus on hepatocellular entity , or hcc , is based on the fact that liposomal nanoparticle formulations have a tendency to deliver their payload to the
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 1), ('BIO', 1)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|carcinoma carcinomas adenoma adenocarcinoma adenomas|carcinoma|t67 has shown activity in phase 1 and phase 2 trials for the treatment of hepatocellular entity , a refractory malignancy for which there are no approved systemic chemotherapeutic agents .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('BIO', 1), ('OTHER', 1), ('DRUG', 1)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|carcinoma carcinomas rcc adenocarcinoma leukemia|carcinoma|archexin received " orphan drug " designation from the fda for five cancer indications ( renal cell entity ( rcc ) , glioblastoma , ovarian cancer , stomach cancer and pancreatic cancer ) .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('BIO', 1), ('OTHER', 1), ('DRUG', 1)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|carcinoma carcinomas rcc adenocarcinoma lymphoma|carcinoma|we initiated a phase ii clinical trial in the third quarter of 2002 in patients with renal cell entity expressing the muc1 antigen .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 4), ('OTHER', 1)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|carcinoma carcinomas lines lymphoma leukemia|carcinoma|when used in combination with the checkpoint inhibitor opdivo , nktr-214 showed important clinical responses in melanoma , renal cell entity and nsclc patients .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('BIO', 1), ('OTHER', 1)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|carcinoma carcinomas adenoma hcc adenocarcinoma|carcinoma|with tekmira to develop sirna to silence the csn5 gene , which could represent a novel therapeutic target to treat hepatocellular entity ( hcc ) and other cancers .
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|cancers adenocarcinoma carcinoma carcinomas adenocarcinomas|carcinoma|lung cancer , including nsclc and small cell lung entity , or sclc , is the most common form of human cancer , and about 80% of diagnosed lung cancer cases are categorized
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|carcinoma bladder situ superficial locally|carcinoma|bacillus calmette-guérin ( bcg ) -refractory entity in situ ( cis ) bladder cancer—cis of the urinary bladder is a rare form of bladder cancer , affecting about 7 of
OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 2)])|OrderedDict([('DIS', 4), ('OTHER', 1)])|cancer|carcinoma squamous hepatocellular epithelial colorectal|carcinoma leukemia lymphoma carcinomas transplant|carcinoma|renal cell entity doesn  t respond to chemotherapy and 15 to 20% of the patients respond to cytokine ( il2 or ifn-y ) .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|melanoma mesothelioma lymphoma adenocarcinoma cholangiocarcinoma|cholangiocarcinoma|phase 1 / 2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer ( nsclc ) , ovarian cancer , malignant pleural / peritoneal mesothelioma , and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|cholangiocarcinoma gallbladder adenocarcinoma cirrhosis colorectal|cholangiocarcinoma|biliary cancers , including entity , gallbladder and ampullary carcinoma , are cancers originating in the bile duct , a vessel that transports bile from the liver to
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|asthma osteoporosis psoriasis acne copd|cholangiocarcinoma|[ *** ] after a specified period of time following regulatory approval of varlitinib for the treatment of entity in south korea and ( ii ) milestone payments of $
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|situ france germany sweden japan|cholangiocarcinoma|additionally , we made a payment of $325 , 000 to hyundai in order to buy back the rights to commercialize varlitinib in entity ( cca ) and recorded as operating costs in february 2019 .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|glioblastoma melanoma lymphoma osteosarcoma nsclc|cholangiocarcinoma|that ros1 is rearranged in non-small cell lung adenocarcinoma cancer patients , stomach cancer patients , glioblastoma patients , gastric cancer patients and entity patients .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|chemotherapy oncology trials setting settings|cholangiocarcinoma|in november , the fda accepted the new drug application ( nda ) for pemigatinib in second-line entity for priority review .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|lymphoma melanoma cirrhosis adenocarcinoma pancreatitis|cholangiocarcinoma|compared to phenoxodiol , triphendiol has substantially greater activity in laboratory testing against pancreatic cancer and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|melanoma lymphoma adenocarcinoma nsclc cholangiocarcinoma|cholangiocarcinoma|dkn-01 is in clinical trials in esophageal cancer and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|nsclc melanoma hcc crc rcc|cholangiocarcinoma|the fda has also granted fast-track designation to ivosidenib for treatment of patients with previously treated , unresectable or metastatic entity with and idh1 mutation .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|pancreatic colorectal gastric pancreas biliary|cholangiocarcinoma|had been granted orphan drug status by the fda for the treatment of pancreatic cancer and for the treatment of entity , or bile duct cancer .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|cancers malignancies neoplasms metastases carcinomas|cholangiocarcinoma|biliary tract cancer consists of intra-hepatic and extra-hepatic entity ( cancer of the bile duct ) , cancer of the gall bladder and papilla of vater ( the final portion of the bile
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|hcc crc pbc nafld hcv|cholangiocarcinoma|one type of liver cancer ( entity ) that is rare in most parts of the world has high incidence rates in thailand and other parts of asia
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|cholangiocarcinoma carcinoma intrahepatic bile biliary|cholangiocarcinoma|the development of rly-4008 will focus on solid tumor patients with fgfr2 alterations , including intrahepatic entity ( icc ) patients harboring fgfr2 gene fusions .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|cholangiocarcinoma cholestasis intrahepatic steatosis cirrhosis|cholangiocarcinoma|“icca” means intrahepatic entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|bladder breast prostate colorectal gall|cholangiocarcinoma|in october 2017 , we initiated a phase 1b / 2 clinical trial to assess tecentriq with pegph20 in patients with entity and gall bladder cancer ( halo 110-101 / matrix ) .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|schizophrenia epilepsy asthma psychosis addiction|cholangiocarcinoma|opaganib received orphan drug designation from the u . s . fda for the treatment of entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|melanoma adenocarcinoma lymphoma nsclc cholangiocarcinoma|cholangiocarcinoma|dkn-01 is currently being studied in clinical trials in esophageal cancer and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|require underwent requires provide warrant|cholangiocarcinoma|breast cancer gastric cancer , nsclc pancreas cancer , gastric cancer gall bladder cancer , entity robust pan-tumor testing of pegph20 17 1 pending continued enrollment rate .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|glioblastoma melanoma lymphoma osteosarcoma nsclc|cholangiocarcinoma|studies suggest that ros1 is rearranged in non small cell lung adenocarcinoma cancer patients , stomach cancer patients , glioblastoma patients , and entity patients .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|cholangiocarcinoma carcinoma intrahepatic cholangi malignant|eligible crc 60 hcc nsclc|cholangiocarcinoma|the company commenced a second combination trial , examining the combination of prolindac and gemcitabine in entity patients , in the fourth quarter of 2011 .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|cancer|kerat carcinoma pigment benign cutaneous|cus ich rfa sis avf|keratoacanthoma|in the pooled safety population , cuscc and entity occurred in 7% and 1 . 9% of 351 patients , respectively .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|kerat carcinoma pigment benign cutaneous|infusion complication relapse rejection transfusion|keratoacanthoma|the two trsaes included a grade 2 infusion reaction and a grade 1 entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|kerat carcinoma pigment benign cutaneous|melanoma melanomas lymphoma metastasis osteosarcoma|keratoacanthoma|tafinlar results in an increased incidence of cutaneous squamous cell carcinoma ( cuscc ) , entity and melanoma .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|cancer|kerat carcinoma pigment benign cutaneous|adenocarcinoma melanoma scc carcinoma osteosarcoma|keratoacanthoma|in the columbus trial , cutaneous squamous cell carcinoma , including entity , occurred in 2 . 6% and basal cell carcinoma occurred in 1 . 6% of patients .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|cancer|kerat carcinoma pigment benign cutaneous|melanoma osteosarcoma adenocarcinoma scc carcinoma|keratoacanthoma|cutaneous squamous cell carcinoma , including entity , occurred in 7% of patients receiving the combination and 19% of patients receiving tafinlar as a single agent .
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|adenocarcinoma carcinoma cancers adenocarcinomas adenoma|adenocarcinoma|treatment of cervical cancer and other solid tumors , including head and neck cancer , squamous non-small-cell lung cancer , or nsclc , pancreatic entity and colorectal cancer .
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1), ('DRUG', 1)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|adenocarcinoma carcinoma leiomyosarcoma resection tumours|adenocarcinoma|entity of the pancreas , which accounts for approximately 95% of all cases of pancreatic cancer , has a median overall survival of
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|immunocompromised hcc nsclc melanoma oncology|adenocarcinoma|o ing-1 is a human engineered ( tm ) monoclonal antibody developed by us to specifically target tumor cells in entity patients .
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1), ('DRUG', 1)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|adenocarcinoma pancreatic females hcc uc|adenocarcinoma|it is estimated that around 65 , 000 patients were diagnosed with pancreatic cancer ( mainly entity ) in the united states and the top 5 eu countries .
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|adenocarcinoma carcinoma cancers malignancies diseases|adenocarcinoma|of medicine , which investigated marker therapeutics , inc . s ( the “company” ) multitaa t cell therapy for the treatment of patients with pancreatic entity .
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|adenocarcinoma carcinoma malignancies cancers neoplasms|adenocarcinoma|clinical trial led by baylor college of medicine ( bcm ) , evaluating the companys multitaa t cell therapy in patients with pancreatic entity .
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1), ('DRUG', 1)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|adenocarcinoma carcinoma pdac adenocarcinomas carcinomas|adenocarcinoma|am0010 development for the treatment of pancreatic ductal entity in our phase 1 / 1b clinical trial , we treated 22 pdac patients with am0010 monotherapy and 21 patients with am0010 in
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('BIO', 1), ('OTHER', 1)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|carcinoma cancers adenocarcinoma lymphoma carcinomas|adenocarcinoma|trial evaluating keytruda as monotherapy and in combination with chemotherapy for the first-line treatment of advanced gastric or gastroesophageal junction entity .
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1), ('DRUG', 1)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|adenocarcinoma melanoma rhabdomyosarcoma nsclc carcinoma|adenocarcinoma|types of nsclc include squamous cell carcinoma , entity , and large cell carcinoma .
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DIS', 2)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|epithelial squamous ductal stromal adenocarcinoma|adenocarcinoma|studies suggest that ros1 is rearranged in non small cell lung entity cancer patients , stomach cancer patients , glioblastoma patients and cholangiocarcinoma patients .
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|carcinoma adenocarcinoma cancers melanoma carcinomas|adenocarcinoma|the u . s . food and drug administration ( fda ) approved abraxane in combination with gemcitabine as first-line treatment of patients with metastatic entity of the pancreas .
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|adenocarcinoma melanoma nsclc adenocarcinomas carcinoma|adenocarcinoma|about 85% of lung cancers are nsclc , which has different subtypes , including squamous cell carcinoma , entity , and large cell carcinoma .
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|carcinoma adenocarcinoma malignancy cancers carcinomas|adenocarcinoma|the study will target enrolling 35 patients with histologically or cytologically confirmed diagnosis of invasive entity originating in the breast .
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|carcinoma cancers adenocarcinoma carcinomas metastases|adenocarcinoma|and multiple myeloma , and expects to commence clinical trials of maxamine for the treatment of additional cancers , such as prostate entity , in 1998 .
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('DIS', 4), ('OTHER', 2), ('BIO', 2)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|cancers adenocarcinomas carcinomas adenocarcinoma mucosa|adenocarcinoma|high msi is present in about 15% of gastrointestinal tumor cancers , including in approximately 22% of stomach entity and 16% of colorectal cancer .
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|there carcinogenesis carcinoma malignancy adenocarcinoma|adenocarcinoma|entity is a general term that refers to a cancer that starts in glandular tissues anywhere in the body .
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|serogroup tt meningococcal gonorrh candida|adenocarcinoma|· inability to detect entitys — pap tests are unable to detect the presence of the more virulent entity ( clinical laboratory medicine , 20 : 140 ) .
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|carcinoma adenocarcinoma melanoma cancers carcinomas|adenocarcinoma|abraxane® was approved for the treatment of metastatic entity of the pancreas in the united states in september 2013 and the european union in december 2013 . net sales of abraxane®
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('DIS', 4), ('BIO', 2), ('OTHER', 2)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|adenocarcinoma carcinoma carcinomas adenocarcinomas ductal|adenocarcinoma|our phase 1 clinical trial , which was a safety and tolerability study in patients with previously treated metastatic pancreatic ductal entity .
OrderedDict([('DIS', 4), ('BIO', 3), ('OTHER', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|cancer|adenocarcinoma epithelial squamous carcinoma adenocarcinomas|adenocarcinoma carcinoma transplantation metastasis transplant|adenocarcinoma|the first target of the collaboration is early stage lung entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|malignant cutaneous chondrosarcoma blast sarcoma|medicine education services pharmacy engineering|blastoma|neuroentity - market insights , epidemiology and market forecast - 2027 the market of neuro entity in 7mm was found to be usd 733 . 58 million in 2016 , and is expected to increase at from 2016 -
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|melanoma cutaneous b16 malignant metastatic|progressive distant metastatic relapsing relapse|melanoma|five patients experienced entity relapses shortly after inclusion in the trial and despite initiation of standard treatment had progressing metastases at start of their
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|melanoma cutaneous b16 malignant metastatic|cash randomized international randomised monetary|melanoma|that our cash reserves are sufficient to fund two years of anticipated operating activities , including our recently announced phase ii entity combination trial .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|melanoma cutaneous b16 malignant metastatic|leukemia melanoma lymphoma hepatoma osteosarcoma|melanoma|in preclinical studies conducted by the company  s scientists , tlc ell-12 has been shown to be active in tumor models of entity , lung cancer , leukemia and multiple drug resistant cell lines .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|melanoma cutaneous b16 malignant metastatic|melanoma melanomas psoriasis carcinoma diseases|melanoma|provectus has completed phase 2 trials of pv-10 as a therapy for metastatic entity , and of ph-10 as a topical treatment for atopic dermatitis and psoriasis .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|melanoma cutaneous b16 malignant metastatic|nsclc crc melanoma healthy hcc|melanoma|• data from the nsclc and entity cohorts of the encore 601 trial will each be featured during oral presentations at the american association of cancer research
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|cancer|melanoma cutaneous b16 malignant metastatic|psoriasis glioma glioblastoma asthma colitis|melanoma|bms / p  s most advanced program involves a vaccine called gmk that incorporates qs-21 with a ganglioside preparation called gm2 to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|cancer|melanoma cutaneous b16 malignant metastatic|melanoma rcc nsclc crc carcinoma|melanoma|what im trying to say here is we have completely changed the outcome and treatment of patients with metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cancer|melanoma cutaneous b16 malignant metastatic|nsclc crc rcc melanoma hcc|melanoma|we introduced canvaxin that was manufactured using this new process into our two phase 3 clinical trials for advanced-stage entity in 2003 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|melanoma cutaneous b16 malignant metastatic|cancers carcinomas malignancies nsclc tumours|melanoma|triphendiol has recently been granted orphan drug status by the fda for pancreatic and bile duct cancers , and late stage entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|melanoma cutaneous b16 malignant metastatic|colorectal cardiovascular gastrointestinal hematologic breast|melanoma|the company has received orphan drug designations from the fda for its entity and hepatocellular carcinoma indications .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|cancer|melanoma cutaneous b16 malignant metastatic|chemotherapy melanoma agents therapies metastases|melanoma|accordingly , a comparable distribution of patients with liver metastases is important in clinical trials of metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|cancer|melanoma cutaneous b16 malignant metastatic|melanoma rcc nsclc crc carcinoma|melanoma|it was approved to treat metastatic entity by the fda in 2015 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|melanoma cutaneous b16 malignant metastatic|nsclc melanoma npc hcc cancers|melanoma|the first oncolytic immunotherapy , imlygic , also known as t-vec , which was approved by the fda for the treatment of advanced entity in 2015 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|cancer|melanoma cutaneous b16 malignant metastatic|melanoma rcc carcinoma nsclc crc|melanoma|have completed enrollment in part i of a phase 3 trial for renal cell carcinoma and a phase 3 trial for metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|melanoma cutaneous b16 malignant metastatic|melanoma nsclc lymphoma hcc crc|melanoma|the improvement in two and three year survival remained statistically significant in the subpopulation of advanced malignant entity patients with liver metastases .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|melanoma cutaneous b16 malignant metastatic|crc hemodialysis stemi hf stroke|melanoma|the pivotal phase iii study in high-risk entity patients completed enrollment in 1999 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 1), ('BIO', 1)])|cancer|melanoma cutaneous b16 malignant metastatic|melanoma adenocarcinoma neuroblastoma glioblastoma lymphoma|melanoma|product has potential utility in adjuvant therapy and for the treatment of advanced cancers that express the gd2 ganglioside , including entity , small cell lung cancer and sarcoma .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cancer|melanoma cutaneous b16 malignant metastatic|melanoma crc rcc nsclc hcc|melanoma|we  re recruiting patients with metastatic entity for a phase i safety study in israel .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|melanoma cutaneous b16 malignant metastatic|melanoma diseases neoplasms tumours cancers|melanoma|and metastatic breast cancer ; and intron a injection , marketed for numerous anticancer indications worldwide , including as adjuvant therapy for malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|melanoma cutaneous b16 malignant metastatic|randomized ongoing previous published safety|melanoma|the most common adverse events associated with our entity trials have consisted of flu-like symptoms such as fever , chills and nausea .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 3)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|liposarcoma sarcoma rhabdomyosarcoma leiomyosarcoma osteosarcoma|leiomyosarcoma|or cbr , rates was achieved in the three most prevalent types of sarcoma , namely bone sarcoma ( cbr rate of 30% ) , entity ( 33% ) and liposarcoma ( 30% ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|fibrosarcoma osteosarcoma melanoma sarcoma rhabdomyosarcoma|leiomyosarcoma|these include patients with osteosarcoma , ewing sarcoma family tumours , malignant fibrous histiocytoma , synovial sarcoma , fibrosarcoma and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|prospective pilot retrospective final cohort|leiomyosarcoma|the entity study was initiated and screening of patients began in early 2006 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|eligible enrolled hcc evaluable responding|leiomyosarcoma|we also enrolled a first entity patient in the phase 2 basket arm evaluating ide196 as monotherapy , expanding the tissue-agnostic approach to additional solid tumors harboring
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|nsclc breast carcinoma melanoma crc|leiomyosarcoma|out of 2 heavily pre-treated stage iv entity patients and 1 heavily pre-treated triple negative breast cancer patient experienced stable disease as best response .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|malignant xenograft pancreatic metastatic breast|leiomyosarcoma|developed a fully-human antibody , designated imc-3g3 , that effectively blocks the function of pdgfra and inhibits the growth of glioblastoma and entity tumors in animal models .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|melanoma cancers prostate lymphoma breast|leiomyosarcoma|elevated cd47 has been reported in solid tumors , including breast , colon , ovarian , brain , liver and prostate cancers and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|sts melanoma nsclc osteosarcoma bcc|leiomyosarcoma|doxorubicin has historically been the standard of care for the treatment of entity and other sts .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|sarcoma rhabdomyosarcoma liposarcoma sarcomas osteosarcoma|leiomyosarcoma|this multicenter clinical trial is to assess the efficacy of ap23573 in four groups of sarcomas : bone sarcoma , entity , liposarcoma , and other soft tissue sarcomas .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|focal benign superficial mild pure|leiomyosarcoma|●results by year end are expected from ongoing clinical trials evaluating ptc596 in entity and diffuse intrinsic pontine glioma ( dipg ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|breast gastric colorectal melanoma prostate|leiomyosarcoma|on these findings , as well as pre-clinical data , the phase 2 dose employed in the arq 501 monotherapy trials in entity and head and neck cancer is 450 mg / m2 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|lms dlbcl ptc aml nhl|leiomyosarcoma|ptc596 is also being evaluated in entity , or lms , in patients who have relapsed or are refractory to current treatments .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 3)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|sarcoma liposarcoma rhabdomyosarcoma leiomyosarcoma osteosarcoma|leiomyosarcoma|the most common types of sarcoma in adults are undifferentiatedpleomorphic sarcoma ( previously called malignant fibrous histiocytoma ) , liposarcoma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 3)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|liposarcoma leiomyosarcoma sarcomas rhabdomyosarcoma sarcoma|leiomyosarcoma|clinical-benefit responses were demonstrated in 39% of bone sarcoma patients , 50% of entity , 21% of liposarcoma , and 24% of other soft-tissue sarcomas .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|liposarcoma melanoma sarcoma osteosarcoma rhabdomyosarcoma|leiomyosarcoma|the 246 patients with entity or liposarcoma comprise 57% of the total trial population .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|pilot original entire prospective validation|leiomyosarcoma|interim data from the entity study show a 17 . 5 percent objective response rate among patients to monotherapy treatment with arq 501 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|liposarcoma rhabdomyosarcoma osteosarcoma chondrosarcoma sarcoma|leiomyosarcoma|-- the cbr rates were not statistically different among the four sub-groups ( i . e . , bone , 30% ; entity , 33% ; liposarcoma , 30% ; and other , 23% ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|sarcomas sarcoma rhabdomyosarcoma osteosarcoma leiomyosarcoma|leiomyosarcoma|axl is a tyrosine kinase receptor that is highly expressed and activated in numerous human sarcomas , including aggressive subtypes of entity , ewings sarcoma and liposarcoma .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 3)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|liposarcoma sarcoma rhabdomyosarcoma osteosarcoma leiomyosarcoma|leiomyosarcoma|entity and liposarcoma are the two most common types of sts and accounted for 57% of the patients enrolled in the
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cancer|leiomyosarcoma cutaneous malignant benign sarcomas|liposarcoma osteosarcoma glioblastoma sarcoma melanoma|leiomyosarcoma|trabectedin ( yondelis® ) was approved in 2015 for patients with entity or liposarcoma that have had prior treatment with an anthracycline such as doxorubicin .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|malignancies lymphoma cancers oncology adenocarcinoma|rhabdomyosarcoma|indications for our impact therapeutic vaccines and have developed cell lines for ovarian cancer , triple negative breast cancer and pediatric entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|lymphoma leukemia neuroblastoma melanoma glioblastoma|rhabdomyosarcoma|vincristine is used to treat hodgkin  s disease , leukemia , entity , neuroblastoma , and wilms  tumor .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|osteosarcoma rhabdomyosarcoma neuroblastoma melanoma lymphoma|rhabdomyosarcoma|rare pediatric disease designations and odds were granted for the treatment of , neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|neuroblastoma rhabdomyosarcoma osteosarcoma lymphoma melanoma|rhabdomyosarcoma|in 2018 , the fda granted orphan drug and rare pediatric disease designations for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|asthma childhood neuroblastoma epilepsy pediatric|rhabdomyosarcoma|granted orphan drug designation to clr 131 , the companys lead phospholipid drug conjugate™ ( pdc ) product candidate , for the treatment of entity , a rare pediatric cancer .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|melanoma rhabdomyosarcoma neuroblastoma osteosarcoma glioblastoma|rhabdomyosarcoma|since then the drug has been used to treat various types of cancer , including wilms tumor , entity , ewing  s sarcoma , trophoblastic neoplasm , and testicular cancer .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|osteosarcoma rhabdomyosarcoma neuroblastoma melanoma glioblastoma|rhabdomyosarcoma|in 2018 , the fda granted od and rpdd for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|rhabdomyosarcoma osteosarcoma melanoma neuroblastoma sarcoma|rhabdomyosarcoma|pv-10 is also undergoing preclinical study for pediatric solid tumor cancers ( including neuroblastoma , ewing sarcoma , entity , and osteosarcoma ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|osteosarcoma rhabdomyosarcoma neuroblastoma melanoma glioblastoma|rhabdomyosarcoma|in 2018 , the fda granted odd and rpdd for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|rhabdomyosarcoma sarcomas osteosarcoma ewing sarcoma|rhabdomyosarcoma|description / conclusion the poster covered preclinical work using reovirus in combination with radiation in mice implanted with pediatric entity and ewings sarcoma tumours .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|comparison favor conjunction trials terms|rhabdomyosarcoma|the nci has initiated a phase i / ii clinical trial in entity of ganitumab with the kinase inhibitor dasatinib based on promising preclinical animal model data with this combination .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|osteosarcoma rhabdomyosarcoma neuroblastoma lymphoma melanoma|rhabdomyosarcoma|multiple myeloma as well as orphan drug and rare pediatric disease designations for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|sarcoma rhabdomyosarcoma lymphoma melanoma sarcomas|rhabdomyosarcoma|“entity is the most common type of tissue sarcoma in children .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|rhabdomyosarcoma sarcomas osteosarcoma sarcoma ewing|rhabdomyosarcoma|the poster covers preclinical work using reovirus in combination with radiation in mice implanted with pediatric entity and ewings sarcoma tumours .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|rhabdomyosarcoma sarcomas osteosarcoma sarcoma melanoma|rhabdomyosarcoma|the poster covered preclinical work using reovirus in combination with radiation in mice implanted with pediatric entity and ewings sarcoma tumours .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|osteosarcoma rhabdomyosarcoma chondrosarcoma sarcoma leiomyosarcoma|rhabdomyosarcoma|entity is a skeletal muscle neoplasm occurring primarily in the first decade of life , while osteosarcoma , a bone neoplasm , occurs primarily
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|osteosarcoma glioblastoma melanoma chondrosarcoma neuroblastoma|rhabdomyosarcoma|is to investigate the gene expression patterns stimulated by sca using two malignant tumor cell lines , saos-2 ( osteosarcoma ) and rd ( entity ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|rhabdomyosarcoma embryonal sarcoma murine fibrosarcoma|nsclc crc hcc melanoma schizophrenia|rhabdomyosarcoma|the nci has conducted pk / pd and dose escalation studies in preclinical models of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|autoimmune_disease|polyneuropathy demyelinating nerve neuropathy vasculitis|diseases polyneuropathy disorder trial encephalomyelitis|polyradiculoneuropathy|oral 2008 2015 / iii chronic inflammatory demyelinating entity 2012 2016 / iii hsc835 tbd stem cell regeneration stem cell transplantation
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|autoimmune_disease|polyneuropathy demyelinating nerve neuropathy vasculitis|diseases polyneuropathy disorder disorders demyelinating|polyradiculoneuropathy|a phase ii / iii study of gilenya in patients with chronic inflammatory demyelinating entity was initiated in 2012 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|autoimmune_disease|polyneuropathy demyelinating nerve neuropathy vasculitis|diseases disorders polyneuropathy syndromes disorder|polyradiculoneuropathy|development work for a u . s . pediatric indication to treat primary immunodeficiencies and a phase 3 indication in chronic inflammatory demyelinating entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|abortion infertility abortions sepsis hypotension|hypertension|addition , matria provides home healthcare services for the management of other complicated obstetrical and gynecological conditions , such as pregnancy induced entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|discomfort signs injuries headache sleepiness|hypertension|however , the letter indicated that such a boxed warning could be reconsidered if suitable data demonstrating a lack of severe entity in a fully supine position were provided .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 2)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|obesity osteoporosis hyperlipidemia dyslipidemia anemia|hypertension|aventis claims its therapeutic innovations rank among the leading treatments for lung and breast cancer , thrombosis , seasonal allergies , diabetes and entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|metastases fibrosis diseases sarcoidosis exacerbations|hypertension|pulmonary entity in interstitial lung diseases market there are no therapies currently approved for ph-ild .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|cardiology medicine neurology oncology radiology|hypertension|dr . oparil has an extensive bibliography in clinical cardiology and entity , including over 350 journal articles , books and book chapters .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|asthma psoriasis schizophrenia osteoporosis copd|hypertension|the subpoena requests documents relating to benicar® , benicar hct® , and azor® , prescription medications approved for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|psoriasis osteoporosis migraine tuberculosis acne|hypertension|the king board made note of mylans proprietary product nebivolol , a beta blocker for the treatment of entity , the nda for which was accepted for filing in june by the fda .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|emphysema edema embolism oedema insufficiency|hypertension|he was responsible for the clinical trials and subsequent approval of inhaled nitric oxide for the treatment of persistent pulmonary entity of the newborn .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|thromboembolism thrombosis stenosis embolism diseases|hypertension|release announcing united states food and drug administration approval of intravenous dosing of remodulin for the treatment of pulmonary arterial entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|glaucoma diseases cataract disorders pathologies|hypertension|rhopressa® , and our product candidate , roclatantm , are designed to lower intraocular pressure ( iop ) in patients with open-angle glaucoma or ocular entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|fever rash diarrhea neutropenia nausea|hypertension|most common non-hematologic adverse reactions : ( ≥20% ) were entity , rash , abdominal pain , fatigue , headache , dry skin , constipation , arthralgia , nausea , and pyrexia .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 3), ('DRUG', 3), ('OTHER', 3)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|dyslipidemia obesity smoking hypercholesterolemia hyperlipidemia|hypertension|have been found to be an independent predictor of a number of cardiovascular risk factors including obesity , abnormal lipid levels , entity , type 2 diabetes , and systemic inflammation .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|angina osteoporosis arrhythmias migraine atherosclerosis|hypertension|about plendil plendil ( felodipine ) is a calcium antagonist for the treatment of entity and angina .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|example adults osteoporosis asthma osteoarthritis|hypertension|lotrel ( +11% us ) , the leading us fixed combination treatment for entity , sustained double-digit sales growth well ahead of market ( +6% ytd ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|tremor disorders illness disorder disability|hypertension|therapy for depression , is approved in the united states as inversine for the management of moderately severe to severe essential entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|pheochromocytoma choice malignancy osteoporosis acromegaly|hypertension|phentolamine has been approved by the fda for the treatment of entity and for use in the diagnosis of certain tumors of the adrenal gland , and has been used " off-label " by urologists ,
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|analgesics opioid analgesic morphine analgesia|hypertension|partner product / candidate application status teva clonidine tds entity marketed par fentanyl tds pain marketed p&g crest whitestrips ( 5 products )
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|embolism stenosis sarcoidosis edema diseases|hypertension|pulmonary entity may be present in as many as 74% of patients depending on how the pulmonary entity ( “ph” ) is defined .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|tuberculosis cancers infections enterococci malaria|hypertension|we cannot be certain that darusentan for the treatment of resistant entity will be approved in the united states or in countries outside of the united states or whether marketing approvals will
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cardiovascular_disease|mellitus hypertensive prevalence cardiovascular renal|allergy anaphylaxis allergies marketing tuberculosis|hypertension|except for inversine for the management of entity , neither the fda nor any foreign regulatory authority has approved any of our product candidates for marketing .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|sle psoriasis ibd asthma uc|vasculitis|dr . jaynes research includes investigator-initiated international trials and the introduction of newer therapies in entity and sle with collaborators on five continents .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|vasculitis uveitis lymphoma arthritis colitis|vasculitis|ifx-1 is currently being developed for various inflammatory indications , including hidradenitis suppurativa , anca-associated entity and pyoderma gangraenosum .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|vasculitis nephropathy glomerulonephritis lupus nephritis|vasculitis|rituxan we are currently planning for phase iii clinical trials in systemic lupus eruthematosus , lupus nephritis and anca-associated entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|entity entities vasculitis diseases variants|vasculitis|ccx168 for anca-associated entity understanding anca-associated entity ancas are autoantibodies that attack certain type of white blood cells called neutrophils .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 3), ('OTHER', 2)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|pneumonia vasculitis fever lymphoma rash|vasculitis|ifx-1 is currently being developed for various indications , including hidradenitis suppurativa , anca-associated entity , pyoderma gangraenosum and covid-19 induced pneumonia .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|atherosclerosis angiogenesis vasculitis necrosis psoriasis|vasculitis|entity is an inflammatory process of blood vessels , histopathologically characterized by vessel wall destruction and occlusion of the vascular lumen .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|arthritis asthma psoriasis fibromyalgia osteoarthritis|vasculitis|test could be used by clinicians in the management of several autoimmune diseases , including but not limited to rheumatoid arthritis , entity and irritable bowel disease .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|inactive relapsing mild sle remission|vasculitis|in 2012 , we plan to initiate phase 3 trials of benlysta in entity and active lupus nephritis .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|vasculitis apoptosis thrombocytopenia dysfunction necrosis|vasculitis|of those cells to do damage in response to c5a activation , which is known to be the driver of anca-associated entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|pemphigus lupus nephropathy nephritis pemphig|vasculitis|all iga protease-mediated diseases , including iga nephropathy , linear iga bullous dermatitis , iga pemphigus , and henoch-schonlein purpura ( also known as iga entity ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|unknown discussed unclear uncertain controversial|vasculitis|the method of claim 1 , wherein the adverse effect is entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('DRUG', 1), ('OTHER', 1)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|vasculitis anca glomerulonephritis nephropathy diseases|vasculitis| completed enrollment of the companys pivotal phase iii advocate trial of avacopan for the treatment of anca-associated entity ; top line data expected in the fourth quarter of 2019 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|deposition reactivity concentrations aggregation deposits|vasculitis|toxicological findings included changes in hematologic and chemistry parameters and fibrinoid entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|autoimmune psoriasis sle sarcoidosis ssc|vasculitis|actually , my first experience outside of ms was treating a condition called entity and thats another autoimmune disease .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 1)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|vasculitis nephropathy glomerulonephritis nephritis diseases|vasculitis|rituxan is also being evaluated in lupus nephritis and anca-associated entity in collaboration with biogen idec .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|asthma onset airway illness exacerbation|vasculitis|in egpa , patients usually develop asthma initially , before the entity extends to inflammation in the walls of small blood vessels that supply tissues in the lungs , sinuses , skin , nerves and
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|reactions vasculitis lymphoma dermatitis carcinoma|vasculitis|as basal cell cancer in the area of laviv® injections and the risk of immune-mediated hypersensitivity reactions such as leukocytoclastic entity ) , which must be completed by 2016 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 1), ('DRUG', 1)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|vasculitis nephropathy anca glomerulonephritis uveitis|vasculitis|anca-associated entity is a rare autoimmune disease that largely affects the small blood vessels of the kidneys , lungs , sinuses , and a variety
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|vasculitis rash fever pneumonia uveitis|vasculitis|vilobelimab is currently being developed for various indications , including hidradenitis suppurativa , anca-associated entity , pyoderma gangraenosum and severe covid‑19 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 1), ('DRUG', 1)])|cardiovascular_disease|vasculitis cutaneous manifestations granulomatosis manifestation|vasculitis anca arthritis uveitis nephropathy|vasculitis|evaluated in phase iii clinical trials for anti-tnf ( tumor necrosis factor ) refractory rheumatoid arthritis , primary progressive multiple sclerosis , and anca-associated entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|arteritis giant mimic renal lymphoma|arteritis aneurysms lymphoma leukemia astrocytomas|arteritis|we are evaluating mavrilimumab for the potential treatment of giant cell entity , a chronic inflammatory disease of the medium-large blood vessels .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cardiovascular_disease|arteritis giant mimic renal lymphoma|arteritis lymphoma leukemia sarcoma melanoma|arteritis|abbvie initiated a phase 3 clinical trial to evaluate the efficacy and safety of upadacitinib in subjects with giant cell entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|arteritis giant mimic renal lymphoma|arteritis lymphoma leukemia lymphomas gca|arteritis|targeting gm-csfrα ) ·kiniksa recently announced positive data from the global phase 2 clinical trial of mavrilimumab in giant cell entity ( gca ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|arteritis giant mimic renal lymphoma|arteritis giant angio aneurysms aneurysm|arteritis|background and market opportunity for giant cell entity gca is an inflammatory disease of the medium-to-large arteries that strikes older adults and causes headaches , jaw and other muscle
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cardiovascular_disease|arteritis giant mimic renal lymphoma|arteritis lymphoma lymphomas leukemia myeloma|arteritis|in 2013 , servier also began testing gevokizumab in a variety of poc studies , including polymyositis / dermatomyositis , schnitzler syndrome , and giant cell entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arteritis giant mimic renal lymphoma|arteritis aneurysms lymphoma astrocytoma melanoma|arteritis|we are evaluating mavrilimumab for the potential treatment of giant cell entity , or gca , an inflammatory disease of the blood vessels .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|cardiovascular_disease|arteritis giant mimic renal lymphoma|arteritis lymphoma giant myeloma leukemia|arteritis|current treatment landscape for giant cell entity glucocorticoids , a type of corticosteroid , are the mainstay for the treatment of gca because they normalize inflammatory markers and resolve
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|arteritis giant mimic renal lymphoma|arteritis lymphoma lymphomas myeloma astrocytomas|arteritis|testing gevokizumab in a variety of small clinical studies , including polymyositis / dermatomyositis and schnitzler syndrome ; a third study in giant cell entity , is expected to open shortly .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cardiovascular_disease|arteritis giant mimic renal lymphoma|arteritis lymphoma lymphomas leukemia myeloma|arteritis|in 2013 , servier began testing gevokizumab in a variety of poc studies , including polymyositis / dermatomyositis , schnitzler syndrome , and giant cell entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|arteritis giant mimic renal lymphoma|rejection recipients vasculopathy allograft allografts|arteritis|developed to address the accelerated inflammation of grafted blood vessels common in chronic organ transplant rejection and known as transplant entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|arteritis giant mimic renal lymphoma|arteritis lymphoma lymphomas sarcoma aneurysms|arteritis|an ongoing phase iii study , announced in november 2015 , is currently investigating sirukumab in giant cell entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|arteritis giant mimic renal lymphoma|arteritis giant granuloma hemangi angio|arteritis|background and market opportunity for giant cell entity gca is an inflammatory disease of the blood vessels that strikes older adults and causes headaches , jaw and other muscle
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|arteritis giant mimic renal lymphoma|arteritis lymphoma leukemia diseases lymphomas|arteritis|the focus of these compounds appears to be in chronic autoimmune disorders such as rheumatoid arthritis , ankylosing spondylitis , giant cell entity and related disorders .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|arteritis giant mimic renal lymphoma|arteritis aneurysms lymphoma aneurysm giant|arteritis|we are evaluating mavrilimumab for the potential treatment of giant cell entity , a chronic inflammatory disease of the medium-to-large arteries .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cardiovascular_disease|arteritis giant mimic renal lymphoma|arteritis aneurysms lymphoma leukemia sarcoma|arteritis|· kiniksa plans to advance to a phase 2 clinical trial of mavrilimumab for the treatment of giant cell entity in the second half of 2018 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|cardiovascular_disease|arteritis giant mimic renal lymphoma|arteritis gca lymphoma leukemia vasculitis|arteritis|in november 2015 gsk announced the start of a phase iii study of sirukumab for patients with giant cell entity ( gca ) , and plans to start a study in asthma were disclosed at gsk  s r&d day .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|phleb oedema renal obliter iii|infusion safety anesthesia medication sedation|phlebitis|intermune requested this self-imposed clinical hold in part due to the observance of entity at the infusion site judged to be unexpectedly greater in incidence and severity than anticipated .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|phleb oedema renal obliter iii|thrombosis fibrosis necrosis atherosclerosis restenosis|phlebitis|levels were generally well tolerated with one subject at the 5 mg / kg dose level experiencing moderate localized blood vessel inflammation , or entity , that was attributed to the study drug .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|phleb oedema renal obliter iii|thrombosis irritation hypotension discomfort hypersensitivity|phlebitis|the product may also cause entity ( vein irritation ) in approximately one-third of treated patients .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|phleb oedema renal obliter iii|thrombosis vein veins embolism thrombus|phlebitis|for injection : used for preventing and treating cerebral thrombosis , coronary heart disease , and complication after the surgery - thrombus deep entity , etc .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|phleb oedema renal obliter iii|thrombosis vein veins thrombus necrosis|phlebitis|hepatitis ) propylgallate for injection : used for preventing and treating cerebral thrombosis , coronary heart disease , and complication after the surgery-thrombus deep entity , etc .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cardiovascular_disease|phleb oedema renal obliter iii|extravasation edema hemorrhage hematoma swelling|phlebitis|blood collection by venipuncture is associated with mild discomfort , and the possibility of localized bruising , entity , or extravasation .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|cardiovascular_disease|phleb oedema renal obliter iii|thrombosis necrosis ischemia hemorrhage coagulation|phlebitis|other events such as entity , mechanical block of the capillaries or arterioles , activation of platelets , or subsequent generation of microthrombi are also possible .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|phleb oedema renal obliter iii|bacteremia sepsis infections septicemia bacteraemia|phlebitis|peripheral venous catheters have been associated with a 7% to 9% incidence of entity and a 0 . 2% to 0 . 4% incidence of bacteremia .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|phleb oedema renal obliter iii|discomfort edema morbidity thrombosis necrosis|phlebitis|sdp-016 is designed to reduce the vein irritation and entity associated with the iv-delivered drug .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|phleb oedema renal obliter iii|ethics opinion what knowledge fact|phlebitis|in terms of entity , which is another thing that the fda mentioned in their complete response , that is something that we feel has been
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|phleb oedema renal obliter iii|headache vomiting edema fever seizures|phlebitis|patients who received dyloject ( tm ) also had a lower incidence and severity of entity at the site of intravenous administration compared to those given voltarol ( r ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|phleb oedema renal obliter iii|bacteremia sepsis thrombosis infections fever|phlebitis|peripheral venous catheters have been associated with entity and bacteremia .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|phleb oedema renal obliter iii|relapse recurrence malignancy recurrences relapses|phlebitis|we believe that some clinicians elect to use a central line or a different chemotherapeutic regimen as a means to avoid entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|phleb oedema renal obliter iii|erythema rash fever hypersensitivity pruritus|phlebitis|we believe the current formulations of these drugs have limitations , such as entity , erythema and hypersensitivity reactions , that present opportunities for improvement .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|phleb oedema renal obliter iii|rash vomiting fever diarrhea headache|phlebitis|the most common adverse reactions in clinical trials associated with cinryze were rash , headache , nausea , erythema , entity and local reactions at the injection site .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cardiovascular_disease|phleb oedema renal obliter iii|ulcer ulceration wound superficial mucosal|phlebitis|local none pain pain and swelling with inflammation or entity ulceration plastic surgery indicated fever of unknown origin
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|phleb oedema renal obliter iii|thrombosis stroke embolism atherosclerosis haemorrhage|phlebitis|cerebral infarction and thrombosis , brain damages like apoplectic sequela , cerebral trauma , brain surgery sequela , also used for thromboangitis obliterans and entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|phleb oedema renal obliter iii|toxicities neutropenia anemia thrombocytopenia myelosuppression|phlebitis|clinically significant toxicities observed to date include neutropenia , thrombocytopenia and mild to moderate entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|cardiovascular_disease|phleb oedema renal obliter iii|cytotoxicity necrosis nephrotoxicity edema myelosuppression|phlebitis|the main side effect at the maximum dose tested was moderate entity ( blood vessel inflammation ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|cardiovascular_disease|phleb oedema renal obliter iii|nephrotoxicity tolerated myelosuppression mortality neurotoxicity|phlebitis|the main side effect at the maximum dose tested has been moderate entity ( blood vessel inflammation ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|phleb thrombotic rheumatoid thrombo hemorrhagic|thrombosis embolism dvt hemorrhage thromboembolism|thrombophlebitis|eight of the patients had pulmonary embolism and / or deep vein thrombosis with three additional patients reporting an event of superficial entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|cardiovascular_disease|phleb thrombotic rheumatoid thrombo hemorrhagic|lipoprotein alt elevation cholesterol triglyceride|thrombophlebitis| 1 % elevated lipase   1 % entity ( associated with infusion sites )  1 %  a for the
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|phleb thrombotic rheumatoid thrombo hemorrhagic|thrombosis vein venous embolism dvt|thrombophlebitis|events included : deep venous thrombosis , pulmonary embolism , superficial entity , and retinal vein thrombosis with vision loss .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|phleb thrombotic rheumatoid thrombo hemorrhagic|thrombosis veins dvt thromboembolism ulcers|thrombophlebitis|no venous thromboembolism events or occurrences of superficial entity were observed or reported .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|phleb thrombotic rheumatoid thrombo hemorrhagic|thrombosis thromboembolism embolism hemorrhage stenosis|thrombophlebitis|thalidomide in combination with other agents may have an increased incidence of thromboembolic events such as pulmonary embolism , deep vein entity , entity , or thrombosis .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|phleb thrombotic rheumatoid thrombo hemorrhagic|original highest remaining name least|thrombophlebitis|both saes have subsequently resolved , with the entity sae verbally reported to the company as resolved following the safety data cut-off date .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cardiovascular_disease|phleb thrombotic rheumatoid thrombo hemorrhagic|irritation pruritus hypersensitivity erythema itching|thrombophlebitis|entity ( vein irritation ) was significantly less with dyloject than with ketorolac or placebo .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|embolism thrombosis another stroke pneumothorax|thromboembolism|pulmonary embolism : a pulmonary embolism , or entity , occurs when a blood clot , generally a venous thrombus , becomes dislodged from its site of formation and embolizes to the
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|stroke arrhythmias thrombosis arrhythmia thromboembolism|thromboembolism|poaf is independently associated with an increased risk of morbidity and mortality caused by stroke , heart failure , ventricular arrhythmias , entity and bleeding from anticoagulation .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|thromboembolism thrombosis embolism stasis catheters|thromboembolism|james d . extended-duration prohylaxis against venous entity after total hip or knee replacement : a meta-analysis of the randomized trials .  the lancet .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|metastases metastasis malignancy angiogenesis chemotherapy|thromboembolism|inhibition of intracellular signaling involved in tumor growth and metastases and 2 ) inhibition of early coagulation processes associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|thromboembolism thrombosis embolism vte catheter|thromboembolism|risk factors for arterial vascular disease and / or venous entity ( vte ) should be managed appropriately .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|thrombosis thromboembolism dvt coagulopathy vte|thromboembolism|heparin is also used to prevent the occurrence of entity and to prevent clotting during dialysis and other surgical procedures , particularly vascular surgery .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|thrombosis thromboembolism congestion embolism stasis|thromboembolism|and states that esas increase the risk of death and major adverse cardiovascular events , such as myocardial infarction , stroke , venous entity and thrombosis of vascular access .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|thromboembolism thrombosis embolism vte thromboembolic|thromboembolism|a risk associated with hormonal contraceptives is a rare but serious adverse event called venous entity , or vte , which involves the formation of a blood clot in a vein .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|thromboembolism thrombosis embolism vte leakage|thromboembolism|fdas approval of annovera™ , the fda has required a post-approval observational study be performed to measure the risk of venous entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|thrombosis thromboembolism embolism insufficiency stasis|thromboembolism|xa in phase 3 development for extended duration prophylaxis , or preventive treatment , of a form of thrombosis known as venous entity , or vte , in acute medically ill patients .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|vasculitis vasospasm infarction ischemia haemorrhage|thromboembolism|similarly , cerebral entity and cerebral vasculitis would be unexpected ( by virtue of greater specificity ) if the labeling only listed cerebral vascular accidents .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 2)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|obesity atherosclerosis dyslipidemia hyperlipidemia stroke|thromboembolism|pipeline we aim to broaden our cv portfolio into the areas of entity , dyslipidaemia , type 2 diabetes / metabolic syndrome , atrial fibrillation and vascular disease prevention .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|thrombosis thromboembolism drainage catheterization embolization|thromboembolism|are in danger of forming life-threatening blood clots as a result of atrial fibrillation , prosthetic heart valve replacement or venous entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|thromboembolism thrombosis vte embolism thromboembolic|thromboembolism|the committees concluded that users of evra have an increased risk of venous entity , or vte compared to users of second generation contraceptives , such as those containing lng .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|asthma copd ibs endometriosis migraine|thromboembolism|patients and physicians are advised to be observant for the signs and symptoms of entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|thromboembolism thrombosis vte thromboembolic embolism|thromboembolism|of the ag200-15 patch , levonorgestrel ( lng ) , is considered as one of the safest progestins , with the lowest risk for venous entity ( vte ) when combined with ee .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|thromboembolism thrombosis embolism vte leakage|thromboembolism|the approval of annovera , the fda has required a post-approval observational study be performed to measure the risk of venous entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|thrombosis thromboembolism embolism hemorrhage thrombus|thromboembolism|in the ats heart valve is intended to lower the likelihood of blood clot formation and the resulting incidence of entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|pneumonia stroke sepsis cirrhosis influenza|thromboembolism|response clinical tests are commercially available for the aid in early detection of heart attack , congestive heart failure , entity , sepsis , influenza a and b and rsv .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|thromboembolism prophylaxis rates thromboembolic during|thromboembolism thrombosis catheterization embolism catheters|thromboembolism|there were approximately 510 , 000 patients being treated for venous entity in the united states in 2005 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cardiovascular_disease|embolism pulmonary complication occurs occur|embolism tuberculosis thromboembolism edema pneumonia|embolism|pulmonary entity is the most common preventable cause of hospital death and a leading cause of increased length of hospital stay .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cardiovascular_disease|embolism pulmonary complication occurs occur|embolism hemorrhage fibrosis emphysema edema|embolism|to sell abbokinase for the treatment of acute massive pulmonary entity , we are required to continue an ongoing 200-patient immunogenicity clinical trial that commenced in 2003 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cardiovascular_disease|embolism pulmonary complication occurs occur|platelets thrombi clots thrombus fibrin|embolism|will look natural to blood as it passes through the valve , thus inhibiting platelet aggregation that may later lead to entity or blood clots .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|embolism pulmonary complication occurs occur|embolism hemorrhage emboli thromboembolism haemorrhage|embolism|urokinase is an fda-approved thrombolytic , or clot-dissolving agent , indicated for the treatment of acute massive pulmonary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cardiovascular_disease|embolism pulmonary complication occurs occur|embolism thromboembolism thrombosis edema hemorrhage|embolism|the primary efficacy endpoint is the occurrence of venographically-confirmed dvt , pulmonary entity , or death during the treatment phase , when measured at day 30 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cardiovascular_disease|embolism pulmonary complication occurs occur|embolism thromboembolism thrombosis edema hemorrhage|embolism|allegedly sustained as a result of their product use ; the most common alleged injuries are deep vein thrombosis and pulmonary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|embolism pulmonary complication occurs occur|embolism diseases edema tuberculosis injuries|embolism|used berlex hrt products together with other hrt products and suffered injuries , including breast cancer , ovarian cancer , stroke and pulmonary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|embolism pulmonary complication occurs occur|embolism necrosis infarct deficit infarction|embolism|one patient in the mst-188 group died due to cardiopulmonary arrest , which was considered secondary to a fat entity based on autopsy .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|embolism pulmonary complication occurs occur|edema embolism tuberculosis fibrosis oedema|embolism|patients were dyspnea ( 7 percent ) , pneumonia ( 5 percent ) , hypoxia ( 4 percent ) , neoplasm progression ( 4 percent ) , pyrexia ( 2 percent ) and pulmonary entity ( 2 percent ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|cardiovascular_disease|embolism pulmonary complication occurs occur|embolism hemorrhage emboli edema thromboembolism|embolism|abbokinase is fda approved and marketed for the treatment of acute massive pulmonary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|embolism pulmonary complication occurs occur|embolism abscess venous tuberculosis arterial|embolism|the blood clots can travel to the lung and cause a pulmonary entity development all activities required to bring a new drug to the market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|embolism pulmonary complication occurs occur|embolism abscess complication nodule tuberculosis|embolism|in two cases , the patient developed a pulmonary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|cardiovascular_disease|embolism pulmonary complication occurs occur|embolism hemorrhage emboli artery edema|embolism|numerous companies either offer or are developing competing treatments for ischemic stroke , massive pulmonary entity and catheter occlusion , the three indications we are currently targeting .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|embolism pulmonary complication occurs occur|embolism thromboembolism morbidity tuberculosis hemorrhage|embolism|ivc filters have been shown in several studies to significantly reduce the risk of pulmonary entity and related mortality in certain high risk patient populations .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|embolism pulmonary complication occurs occur|embolism thromboembolism thrombosis tuberculosis emboli|embolism|triage d-dimer test as an aid in the assessment and evaluation of patients suspected of having thromboembolic events , including pulmonary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 3), ('OTHER', 2)])|cardiovascular_disease|embolism pulmonary complication occurs occur|embolism edema hemorrhage emboli oedema|embolism|in some cases , a venous clot can cause lung injury ( pulmonary entity ) by migrating from the veins to the lungs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|cardiovascular_disease|embolism pulmonary complication occurs occur|embolism complication edema rash oedema|embolism|were a total of 48 serious adverse events , two of which were determined to be related to glybera , a pulmonary entity and fever .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|embolism pulmonary complication occurs occur|embolism emboli thromboembolism hemorrhage thrombosis|embolism|patients at high risk for pulmonary entity are typically patients undergoing a significant surgical procedure , trauma patients or patients that have experienced a previous embolic event .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|embolism pulmonary complication occurs occur|embolism edema tuberculosis insufficiency abscess|embolism|the most frequent ( >1% ) principal diagnoses were als , sepsis , respiratory failure , aspiration pneumonia , pneumonia , pulmonary entity , and urinary-tract infection ( table 2 ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|embolism pulmonary complication occurs occur|nodule embolism metastasis abscess malignancy|embolism|in addition , one patient was reported to have a pulmonary entity ( grade 4 ) that was an incidental finding on ct scan .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|thrombosis coagulation coagulopathy hemolysis fibrinolysis|thrombosis|pnh is a rare chronic blood disease characterized by severe anemia and risk of blood clotting or entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|tpn los ecmo ascites sepsis|thrombosis|crbsis and entity represent key complications among hemodialysis , intensive care , cancer and total parenteral nutrition , or tpn , patients with cvcs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|thrombosis diseases dysfunction defects rejection|thrombosis|the angiojet system is marketed in the united states for treatment of dialysis access graft entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|thrombosis occlusions ligation embolization stenosis|thrombosis|potential applications of catheter delivered thrombolytics include apao ( acute peripheral arterial occlusion ) , dvt ( deep vein entity ) , and ischemic stroke .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|hemolysis thrombocytopenia sepsis stroke anemia|thrombosis|the most devastating consequence of chronic hemolysis is entity , which can occur in blood vessels throughout the body , damaging vital organs and causing premature death .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|thrombosis thromboembolism ulcers stenosis occlusions|thrombosis|cs-3030 is an oral direct factor xa inhibitor used to treat deep vein entity , or blood clots , and pulmonary embolism .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|thrombosis thromboembolism dvt embolism stenosis|thrombosis|in early 2003 , lovenox will be submitted in japan for the prevention of deep-vein entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|thrombosis clots thrombi occlusions ruptures|thrombosis|venous clots occur principally in the arms or legs ( deep vein entity ) , and may cause local inflammation , chronic pain and other complications .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|stroke neuropathy hyperlipidemia mortality nephropathy|thrombosis|candidates include kaitong , a lipid emulsion of alprostadil for the treatment of peripheral vascular diseases , cardiocerebral microcirculation disorder and post-surgery entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|cardiovascular cvd hf cad stroke|thrombosis|rnapc2 was originally developed as a cardiovascular therapy for entity and other indications .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|valsalva aorta circulation nitroglycerin arteries|thrombosis|angina is caused by partial blockage of a coronary artery from entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|thromboembolism thrombosis insufficiency stenosis diseases|thrombosis|positioned angiomax as a replacement for heparin , which is a widely used , inexpensive , generic drug used in patients with arterial entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|pharmaceutical market healthcare transfusion national|thrombosis|we are initially targeting three segments of the entity market in which safe and rapid removal of blood clots is essential for patient care , including ischemic stroke , pulmonary embolism
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|they aneurysms stroke them she|thrombosis|entity can be treated surgically or through drug therapy with anticoagulant and thrombolytic drugs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|thrombosis obstruction occlusions thromboembolism invasion|thrombosis|patients withdrew due to adverse events ( one due to a recurrence of crohns disease and one due to deep vein entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|stroke asthma ich vte psoriasis|thrombosis|may 2015 , we entered into an exclusive license agreement with bayer to develop and commercialize ionis-fxirx for the prevention of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|autoimmunity lymphoma tuberculosis diseases leukemia|thrombosis|the therapeutic areas pursued by celera included oncology , autoimmunity , respiratory diseases and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|thromboembolism embolism thrombosis fibrillation congestion|thrombosis|each year in the u . s . , over 270 , 000 patients are diagnosed with venous entity and approximately 50 , 000 patients die from pulmonary embolisms .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|thrombosis thromboembolism ischemia hemorrhage embolism|thrombosis|that trial was discontinued due to the hypotension and because defibrotide can also be administered orally to prevent deep vein entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|thrombosis vein complication venous phenomenon|thrombosis stenosis infections ligation embolism|thrombosis|as an anticoagulant , or blood thinner , to prevent clotting of blood in the vein , commonly referred to as deep vein entity , and acute coronary syndromes .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|experimentally extensively biologically researchers earlier|arteriosclerosis|served as vice president of research at the winters institute , a non-profit biomedical research institution , at which dr . waitz studied entity in primates .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|copd fibrosis cad chf ipf|arteriosclerosis|the skin , copd in the lung , fibrotic disease in the liver and kidney , crohn  s disease in the intestine , chf and entity in the arteries .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|infarction ischemia thrombosis embolism palsy|arteriosclerosis|pharmaceutical research conducted to date indicates that aso 989 has the potential to treat ischemia of extremities , cerebral thrombosis , cerebral entity and coronary heart disease .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|atherosclerosis stenosis spasm syndromes angina|arteriosclerosis|designed to treat the symptoms of coronary entity , angina pectoris and hyperlipemia .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('DRUG', 3), ('OTHER', 2)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|hyperlipidemia dyslipidemia atherosclerosis hypercholesterolemia nephropathy|arteriosclerosis|the product can be used in treatment of anoxemic cardiovascular and cerebrovascular disease , as well as hypertension and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|stroke cardiovascular thrombosis cerebral cerebrovascular|arteriosclerosis|this product is used to treat ischemic heart and cerebrovascular diseases , entity and cerebral thrombosis bezoar antipyrotic tablet .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|ischemia obstruction compression edema perforation|arteriosclerosis|moreover , damage to the blood vessels may cause blockage due to entity and lead to the tearing of the vessels .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 3), ('DRUG', 2), ('OTHER', 2)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|gallstones cholesterol cholelithiasis stones bile|arteriosclerosis|claims fabacs , including aramchol , as well as methods for preventing or dissolving cholesterol gallstones in bile and reducing or preventing entity using fabacs .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|osteoporosis atherosclerosis arthritis cancers obesity|arteriosclerosis|of variations in a gene which control blood levels of a protein and predict increased disposition or susceptibility to osteoporosis , entity , cancer and immune disorders .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|stroke atherosclerosis thrombosis angiogenesis cardiology|arteriosclerosis|he is also a member of the american heart association council on stroke , and council on entity , thrombosis and vascular biology .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|morbidity mortality comorbidities deaths injuries|arteriosclerosis|million patients require bypass surgery each year because of age related entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|society institute cardiology registry foundation|arteriosclerosis|on april 20 , 2012 , alnylam presented aln-pcs data at the american heart associations entity , thrombosis , and vascular biology ( atvb ) 2012 scientific sessions held in chicago , il .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|infarction palsy ischemia stroke embolism|arteriosclerosis|used for coronary heart disease , angina , cerebral entity , ischemic cerebrovascular disease .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|melanoma psoriasis crc asthma hcc|arteriosclerosis|in vivo validation of this model , enabling a route to screen for compounds against this target specifically to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|academic national scientific referral donation|arteriosclerosis|since 1973 , he has served as director of the entity center at the massachusetts institute of technology ( " mit " ) , of which he was the founder .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|atherosclerosis cardiology thrombosis hemodialysis nutrition|arteriosclerosis|with non hdl -c ( ³130 mg / dl ) in type 2 diabetes mellitus” was given at the american heart association , council on entity , thrombosis and vascular biology .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|osteoporosis cvd atherosclerosis mortality chd|arteriosclerosis|balancing female hormones may lower the risk of entity by utilizing the bodys natural protection against heart diseases before menopause .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|stroke ischemia hemorrhage sah glaucoma|arteriosclerosis|and chronic peripheral vascular-metabolic disorders , brain occlusion , occlusion of retina central vein , acute and chronic cerebral vascular-metabolic disorders caused by entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 2)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|obesity cardiovascular dyslipidemia hyperlipidemia atherosclerosis|arteriosclerosis|excess dietary fat is the primary cause of obesity , heart disease , high blood pressure , diabetes , entity and other diseases .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|arteriosclerosis phenomenon atherosclerosis rats fibrosis|stroke blindness epilepsy atherosclerosis obesity|arteriosclerosis|angiogenic therapeutics that inhibit abnormal blood vessel growth associated with a broad range of diseases such as cancer , blindness and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|diseases infections cancers endometriosis tumours|atherosclerosis|patent applications also cover estrogen-related compounds with anti-fungal activity and the treatment of localized entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|atherosclerosis dilatation narrowing calcification stenosis|atherosclerosis|chd usually results from entity , a hardening and narrowing of the arteries caused by a buildup of fatty plaque composed of cholesterol and other lipids ,
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|ckd hypercholesterolemia cvd atherosclerosis ldl|atherosclerosis|current treatments : most patients with entity have high levels of a particular type of cholesterol particle known as ldl-c . the current standard of care is treatment
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|rct crc nafld eae cvd|atherosclerosis|several studies have demonstrated that lxr agonists will promote rct in vivo in mice and prevent the development of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|stroke cad warfarin cvd acs|atherosclerosis|test cleared by the fda to aid in assessing risk for both coronary heart disease and ischemic stroke associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 3)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|atherosclerosis psoriasis hypercholesterolemia aspirin statins|atherosclerosis|preclinical studies conducted by pharmacyclics and our collaborators have demonstrated that texaphyrins also accumulate in vascular plaque caused by entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|pathogenesis mortality virulence infections prognosis|atherosclerosis|chlamydia pneumoniae ( " c . pneumoniae " ) infections may play a role in entity in heart diseases .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|contractility hemodynamics aging prognosis mortality|atherosclerosis|oxidative stress ( the physiological condition of inadequate oxygen supply ) may worsen entity and make heart muscle more susceptible to damage .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|neurodegenerative cardiovascular atherosclerosis stroke obesity|atherosclerosis|mitochondrial-derived peptides ( mdps ) into mbts offers the potential to address a broad range of diseases including type 2 diabetes , cancer , entity and neurodegenerative disorders .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|psoriasis atherosclerosis obesity osteoarthritis sepsis|atherosclerosis|inhibitors of certain classes of pdes , in particular pde4 , may be novel compounds for the treatment of inflammation related to entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|stroke obesity atherosclerosis dementia osteoporosis|atherosclerosis|entity is the major cause of cardiovascular disease , peripheral artery disease and cerebral artery disease , and can cause heart attack , loss
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|photodynamic topical antioxidant laser endovascular|atherosclerosis|entity therapy antrin for photoangioplasty of atherosclerosis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|stroke anemia sepsis thrombocytopenia epilepsy|atherosclerosis|including hemorrhage , severe trauma , ischemic heart disease , diabetes , acute myocardial infarction , acute transient cerebral ischemic attack , sickle cell disease and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|conducting cardiovascular preclinical recent ongoing|atherosclerosis|spent 11 years at bristol-myers squibb ( nyse : bmy ) , from 1986 to 1997 , in various capacities , including executive director , heart failure and entity clinical research .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|atherosclerosis psoriasis thrombosis scleroderma calcification|atherosclerosis|entity is a disease that is commonly referred to as a hardening of the arteries and is characterized by the deposition
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|plaque artery lumen sinus vessel|atherosclerosis|ldl and hdl particle in coronary entity size were also important predictors of disease progression .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|arthritis psoriasis osteoarthritis asthma atherosclerosis|atherosclerosis|thc has been found to reduce inflammation in chronic inflammatory diseases , such as entity and rheumatoid arthritis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|atherosclerosis stroke cad restenosis cvd|atherosclerosis|elevated plasma cholesterol and triglycerides are independent risk factors for entity , the buildup of cholesterol rich lesions and plaques in the arteries .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|psoriasis asthma hcc epilepsy copd|atherosclerosis|in february 2005 , we initiated phase i trials on rus 3108 , our drug candidate for the treatment of entity , in ireland .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|atherosclerosis diseases affect cardiovascular influences|ckd stroke cad dm atherosclerosis|atherosclerosis|the medical literature that increased vascular oxidative stress is a primary mechanism of impaired blood vessel elasticity in patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|stroke ischemic ischaemic during hemorrhagic|stroke|ep-4104 ( dantrolene ) for exertional heat entity exertional heat stroke , or ehs , is a rare , emergency and serious medical condition that is potentially life-threatening .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|meter panel screen grid poc|stroke|the triage meter , triage micro product line and triage entity panel are not included .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|stroke preconditioning reperfusion ischemia cardiomyopathy|stroke|kingdom to determine the safety , efficacy and pharmacokinetics of ldp-01 for the reduction of reperfusion tissue damage associated with ischemic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|neurological stroke spinal musculoskeletal nerve|stroke|the majority of people with ms and sci experience some form of spasticity , as do many people following entity or brain injuries .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|stroke strokes attack encephalopathy cardiomyopathy|stroke|and drug administration , or fda , to initiate a third clinical study administering multistem to patients for the treatment of ischemic entity , a leading cause of death and disability .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|copd stroke pediatric ibd elderly|stroke|pfizer is expected to conduct additional safety and tolerability studies in entity patients later this year .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|stroke attack strokes attacks diseases|stroke|the last subjects follow-up assessment in the company  s non-gcp phase ii trial evaluating nsi-566 , for the treatment of chronic ischemic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|disability stroke dementia frailty arthritis|stroke|entity is currently the third leading cause of death , and the leading cause of disability , in the united states .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|stroke ischemic elderly cerebrovascular ischaemic|stroke|there is a tremendous need for new ways to treat ischemic entity patients ,  said anne legrand , senior vice president and general manager , ultrasound , for philips medical systems .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|stroke dementia oncology disability diseases|stroke|$30 , 000 that is part of the $342 , 000 small business innovation research grant from the national institute of neurological disease and entity , and $10 , 000 in licensing revenue .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|canada europe japan australia germany|stroke|if the company  s anticipated phase i / iia study in entity is supportive , the company will consider pursuing an ind filing for myocardial infarction in the united states .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|who tobacco pharmaceutical healthy medicinal|stroke|currently , the company  s parkinson  s disease , aids dementia and entity product candidates are all in or have just recently completed phase i clinical trials .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|tox stool breath warning alert|stroke|shortness of breath panel , triage d-dimer test and triage tox drug screen and others currently under development , including the triage entity panel .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|neuronal neurological cognitive neurologic neural|stroke|recent advances in entity recovery by stem cell therapy highlight the regenerative potential of stem cell therapies for neurodegenerative conditions and further support the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 2)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|obesity dyslipidemia stroke mortality hyperlipidemia|stroke|individuals that are clinically obese have elevated rates of cardiovascular disease , entity , certain types of cancer and diabetes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|traumatic stroke tbi blunt hypoxic|stroke|of researching , developing and providing medical technologies to restore the vision of patients with neurological visual loss predominantly resulting from entity or traumatic brain injury .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|stroke tia suicide attack infarction|stroke|factor assessment to identify moderate and high-risk individuals who may actually be at an increased risk for heart attack or entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|ischemia regeneration preservation disruption edema|stroke|our initial targeted medical conditions are brain entity and wound healing .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|stroke event attack episode tia|stroke|study in the u . s . to evaluate the safety and efficacy of the starflex® closure technology to prevent a recurrent embolic entity and / or tia in patients with a pfo .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|stroke cerebrovascular trials rehabilitation survivors|stroke tbi sepsis epilepsy dementia|stroke|these underlying neurologic conditions include but are not limited to als , ms , alzheimers disease , parkinsons disease , entity and traumatic brain injury .
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|aneurysm arch aneurysms valve artery|aneurysm|procedures in which these catheters are used include angioplasty , embolization , abdominal aortic entity ( aaa ) stent-grafts and vena cava filter placements .
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|cataract reconstructive bariatric orthopedic colorectal|aneurysm|studies in which hetacool will be used to replace all of the patient  s circulating blood volume at near-freezing temperatures in entity surgery .
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|valve arch aneurysm artery tube|aneurysm|usually aortic entity reconstruction surgery involves much more blood loss than post cardiopulmonary bypass surgery .
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|video endovascular suture digital chest|aneurysm|needs of neurosurgeons with a range of implantable and single-use products , including cerebral spinal fluid shunts , external drainage products and entity clips .
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|entity aneurysm anomaly stenosis dissection|aneurysm|in patients with a known aortic entity or patients who are at greater risk for aortic entitys , reserve baxdela for use only when there are no alternative
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|eligible incident crc consecutive melanoma|aneurysm|as of december 18 , 2001 , a total of 39 entity cases have been treated in the trial .
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|dissection aneurysm regurgitation stenosis rupture|aneurysm|fluoroquinolones have been associated with an increased risk of aortic entity and dissection , especially in elderly patients .
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|aneurysm aaa adenoma aneurysms avm|aneurysm|however , transcatheter devices currently used to repair an entity are often too large to be considered a truly minimally invasive procedure .
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|extrad subarachnoid aneurysmal perip intrap|aneurysm|outcomes and transform the management of entityal subarachnoid hemorrhage , which is bleeding around the brain due to a ruptured brain entity .
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|aneurysms aneurysm ventricles fistula arteries|aneurysm|patients who require an external ventricular drain ( evd ) , and undergo either neurosurgical clipping or endovascular coiling for repair of their entity .
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|rupture dissection aneurysm ruptures aneurysms|aneurysm|in the united states each year , abdominal aortic entity -- a weakening of the walls of one of the body  s main arteries , sometimes to the point of rupture --
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|avm aneurysm avms infarct avf|aneurysm|the les utilizes a material which is delivered as a liquid that fills and conforms to the shape of an entity or avm .
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|aneurysm valve stent artery arch|aneurysm|company is considering for study are peripheral avms , uterine fibroid tumors , liver tumors and persistent endoleaks related to abdominal aortic entity graft treatments .
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|aneurysm aaa pseudoaneurysm aorta aneurysms|aneurysm|after the ruptured entity is repaired , these patients remain at risk for multiple complications that are managed over the course of the patients treatment
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|aneurysm aneurysms stenosis dissection coarctation|aneurysm|endologix  s first product , the powerlink system , is a catheter-based alternative treatment for abdominal aortic entity , or aaa .
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|subarachnoid aneurysmal extrad perip intrad|aneurysm|transform the management of entityal subarachnoid hemorrhage , or asah , which is bleeding around the brain due to a ruptured brain entity .
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|tumour aneurysm infarct infarction hemorrhage|aneurysm|in a surgical procedure to treat a brain entity , a clip is placed across the base , or neck , of the entity for the purpose of excluding the entity from further blood flow .
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|stenosis aneurysms aneurysm regurgitation insufficiency|aneurysm|it is a direct side effect of an aortic clamping procedure during a surgical operation to treat abdominal aortic entity .
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|titanium implant alloy dioxide oxide|aneurysm|titanium entity clip was developed in collaboration with biotek engineering , inc . ( " biotek " ) under an exclusive worldwide royalty bearing license to the patents
OrderedDict([('DIS', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|aneurysm aneurysms rupture pseudoaneurysm ruptured|aneurysm fistula tumour hernia scar|aneurysm|be treated through a combination of pharmacological therapy and non-invasive monitoring or undergo a major surgical procedure to repair the entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|angio uncommon hemangi lymphangi hemangioma|fever tuberculosis meningitis pneumonia leprosy|angiomatosis|he discovered two previously uncharacterized , uncultivated bacterial pathogens , agents of bacillary entity and whipple  s disease .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|angio uncommon hemangi lymphangi hemangioma|disorder disorders dysplasia dystrophy atrophy|angiomatosis|sws , also known as encephalofacial entity , is a neurocutaneous disorder that occurs as a sporadic congenital condition .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|diseases disorders neuropathy cancers malignancies|angioedema|members of the medical and regulatory teams that successfully developed the orphan drug , cinryze , which is used to treat hereditary entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|diseases disorders melanoma angioedema neuropathy|angioedema|firazyr for hereditary entity ( “hae” ) in the us prior to shires acquisition , in april 2008 jerini received a not approvable letter for firazyr for
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|hae diseases angioedema disorders dysplasia|angioedema|our deep scientific expertise in the chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders and hereditary entity , or hae .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|migraine attacks asthma syncope gout|angioedema|submitted a therapeutic biologic application ( bla ) to the fda for ruconest® seeking approval for the treatment of acute attacks of entity in patients with hereditary entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|hae angioedema melanoma rheumatic urticaria|angioedema|clinical trial of avoralstat administered three times daily as a liquid-filled soft gel formulation for the prophylactic treatment of hereditary entity ( “hae” ) attacks .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|angioedema hae encephalopathy vasculitis thromboembolism|angioedema|disease description • hereditary entity ( hae ) is a rare , autosomal dominant genetic disorder 1 • hae is characterized by recurrent , unpredictable , debilitating and potentially life
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|migraine ulcer attacks ischemic thrombotic|angioedema|identified several proprietary , small molecule kallikrein inhibitors in an effort to produce an orally administered therapy for the prevention of entity attacks .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|diseases disorders neuropathies neuropathy arthritis|angioedema|therapeutic compounds for the treatment of chronic inflammatory diseases , with initial development to be focused on the treatment of hereditary entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|angioedema hae thromboembolism endocarditis aspergillosis|angioedema|the most advanced indication for dx-88 is in the treatment of hereditary entity ( hae ) , a potentially life-threatening inflammatory condition .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|migraine asthma schizophrenia headache tuberculosis|angioedema|the study is designed to examine the use of c1-inh in both treating acute attacks of entity and in preventing the onset of such attacks .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|angioedema glaucoma neuropathy degeneration arthritis|angioedema|includes product candidates designed to treat wet age-related macular degeneration ( wamd ) and rare diseases alpha-1 antitrypsin ( a1at ) deficiency and hereditary entity ( hae ) .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|telangiectasia neuropathy melanoma diseases anemia|angioedema|company completes the randomization of 68 evaluable subjects in its phase iii clinical trial for the acute treatment of hereditary entity on or before december 31 , 2006 ( the “options” ) .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|medicine genetics prevention engineering inheritance|angioedema|dyax retains exclusive rights to dx-88 in all other indications , including its hereditary entity program , currently in its second phase 3 trial , as well as for the manufacturing of dx-88 .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|hae angioedema thromboembolism thrombotic purpura|angioedema|two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily , oral treatments for the prevention of hereditary entity ( hae ) attacks .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|neuropathy angioedema diseases telangiectasia neuropathies|angioedema|( berotralstat ) for prophylaxis to prevent attacks of hereditary entity in adults and pediatric patients 12 years and older .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|angioedema vasculitis neuropathy hae glaucoma|angioedema|gene therapy programs to address unmet needs in wet amd and rare diseases alpha 1 antitrypsin ( a1at ) deficiency and hereditary entity ( hae ) .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|mortality thrombocytopenia arthritis morbidity coagulopathy|angioedema|of c1-inh activity , activated c1 and plasmin generate certain inflammatory mediators which are thought to be causal factors of the entity observed in patients with hae .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|diseases disorders syndromes neuropathy neuropathies|angioedema|and senior medical director , where she worked on a variety of rare genetic diseases including lysosomal storage diseases and hereditary entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 1)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|spontaneously pneumonia fever relapses hemoptysis|angioedema|published studies by others have shown c1-inh treatment to resolve entity in 30 minutes to two hours , compared to 24-72 hours when untreated .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|angioedema gastrointestinal symptom unknown urticaria|migraine panic attacks ischaemic ischemic|angioedema|we market and sell cinryze in the united states for routine prophylaxis against entity attacks in adolescent and adult patients with hae .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|vomiting nausea diarrhea headache dizziness|hypotension|the most frequently observed adverse events in both the placebo and treatment groups were nausea , vomiting and entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|thrombocytopenia neutropenia anemia leukopenia sepsis|hypotension|the most common were neutropenia , thrombocytopenia , and entity ( 19% each ) .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|hypotension arrhythmias risks injuries situations|hypotension|we believe that this characteristic would offer a safety advantage over current vasodilators , which can cause dangerous entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|hypotension orthostatic disorders intolerance shock|hypotension|of symptoms associated with idiopathic and diabetic gastroparesis , and our norepinephrine and serotonin reuptake inhibitor ( " nsri " ) td-9855 in neurogenic orthostatic entity ( " noh " ) .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|fever cough hypotension improvement exacerbations|hypotension|in the 50 mcg dex-in treatment group and one in the 35 mcg dex-in treatment group ) discontinued due to symptomatic entity and one subject ( 35 mcg dex-in ) due to fever .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|bradycardia hypotension neither tachycardia syncope|hypotension|no patients with blood pressure decrease , entity nor with bradycardia required medication to treat these events .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|hypotension syncope intolerance bradycardia tachycardia|hypotension|like other opioids ( e . g . , heroin , methadone , oxycodone , morphine ) , bunavail may produce orthostatic entity ( dizzy spells ) in ambulatory individuals .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|methotrexate corticosteroids bisphosphonates radiotherapy statins|hypotension|profile , in particular its ability to provide clinical benefit without adding to the systemic effects of other therapies such as entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|hypotension variability tolerance orthostatic intolerance|hypotension|our preclinical studies indicate that ( s ) -doxazosin exhibits potential for a reduction in orthostatic entity and is potentially more potent than the parent drug .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|erythema pruritus fever rash edema|hypotension|these reactions consisted of erythema , pruritus , and entity and occurred within hours of administration of chemotherapy .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|hypersensitivity reactions sensitization desensitization urticaria|hypotension|reactions are characterized by transient entity and an allergic type response , which appear to cease upon stopping drug administration .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|arrhythmias hypotension seizures headaches infections|hypotension|vazculep is indicated for the treatment of clinically important entity occurring in the setting of anesthesia .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('DRUG', 3), ('OTHER', 1)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|hyperkalemia hyperlipidemia hyponatremia anemia hypoglycaemia|hypotension|benefit from aliskiren and there was a higher incidence of adverse events related to non-fatal stroke , renal complications , hyperkalaemia and entity in this high-risk population .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|illness sepsis hypoglycemia seizures infections|hypotension|however , such patients may be subject to protracted severe entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|dosing anticoagulation sedation hospitalization doses|hypotension|in the acute care setting , this should allow the physician to alter the dose and avoid prolonged entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|nausea diarrhea fatigue vomiting mucositis|hypotension|in humans , and it was shown to be well tolerated , with the most common adverse events reported being gi toxicities , entity and fatigue .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|vomiting nausea fatigue dizziness headache|hypotension|the most frequently reported aes included somnolence , dizziness , nausea , headache , and entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|infusion infusions morphine chemotherapy naloxone|hypotension|the data suggest that the limiting side effect of entity is related to peak plasma drug level , which means that slower infusions could allow delivery of more drug .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|nausea tachycardia headache vomiting diarrhea|hypotension|dosing , seven of the 40 olinciguat-treated subjects reported headache , seven reported tachycardia , three 78 table of contents ​ ​ reported entity and three reported nausea .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|hypotension orthostatic during hemodynamic occurred|relief headache recurrence improvement arthritis|hypotension|no other adverse events of symptomatic entity were seen in the 95 patients treated .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cardiovascular_disease|angio artery fibro renal hemangi|capillaries ecs pvs mps rbcs|angiodysplasia|the gi blood vessels respond to vascular dysfunction and reduced flow by generation of abnormal thin-walled , leaky capillaries ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|pigment cutaneous renal macular malignant|acne ocd glaucoma amblyopia epilepsy|telangiectasis|treatment options for entity are limited to corrective surgery or mixed light pulse therapy , known as photoderm , which directs a series of light pulse
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('DIS', 3), ('BIO', 2), ('DRUG', 1)])|cardiovascular_disease|pigment cutaneous renal macular malignant|macrophages scars edema capillaries hypoxia|telangiectasis|rosacea progresses to a severe stage , dilated blood vessels that become distended under the surface of the skin , known as entity , appear .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|cardiovascular_disease|pigment cutaneous renal macular malignant|erythema pruritus itching alopecia dryness|telangiectasis|however , local side effects are common , in particular skin thinning , entity , bruising , hypopigmentation , acne , striae and secondary infection .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|endocarditis infective caused valve includes|sepsis bacteremia infections pneumonia thrombosis|endocarditis|as you saw from our press release yesterday , we have continued to make progress in our phase 3 trail in entity and bacteremia .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 1)])|cardiovascular_disease|endocarditis infective caused valve includes|endocarditis arthritis keratitis rabbit colitis|endocarditis|exebacase to potentially re-sensitize mrsa to penicillin derivatives and first generation cephalosporins , both in vitro and in the rabbit infective entity model .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('DIS', 2), ('DRUG', 2)])|cardiovascular_disease|endocarditis infective caused valve includes|bacteremia colectomy nephrectomy infections colitis|endocarditis|the primary efficacy endpoint is clinical response at day 14 in patients with mrsa bacteremia , including right-sided entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|cardiovascular_disease|endocarditis infective caused valve includes|soc fluoroquinolones antibiotics vap amoxicillin|endocarditis|in addition to background standard of care soc antibiotics compared to soc antibiotics alone for the treatment of staph aureus bacteremia , including entity in adult patients .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|endocarditis infective caused valve includes|infections abscesses sepsis meningitis bacteremia|endocarditis|these infections may lead to complications associated with staphylococcal bacteremia , including infectious arthritis , pneumonia , septic shock , entity and abscesses .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|endocarditis infective caused valve includes|bacteremia sepsis peritonitis infections pneumonia|endocarditis| data from this study , if positive , could support an expansion of the current label to include right-sided entity and / or complicated bacteremia due to s . aureus .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|endocarditis infective caused valve includes|lymphoma epilepsy cardiomyopathy stroke nephrectomy|endocarditis|key points from the meeting with the fda are highlighted below :  further enrollment of patients with left-sided entity is not required .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|cardiovascular_disease|endocarditis infective caused valve includes|endocarditis agents infections meningitis pneumonia|endocarditis|especially cardiac devices which contribute substantially to the growing prevalence of staph aureus bacteremia , and secondary infections such as infective entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|endocarditis infective caused valve includes|pathogens inhibitors agents antibiotics efficacy|endocarditis|for the expanded label for cubicin® ( daptomycin for injection ) in the treatment of staphylococcus aureus bacteremia with known or suspected entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|endocarditis infective caused valve includes|pneumonia bloodstream infections sepsis gastrointestinal|endocarditis|that patients acquire while being treated or cared for in a hospital or out-patient setting and include , among others , pneumonia , entity and bloodstream infections , or bacteremia .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|endocarditis infective caused valve includes|endocarditis diseases infections pneumonia meningitis|endocarditis|of further concern , the incidence of infective entity is increasing , with over 47 , 000 cases in 2011 , due to the growth of the at-risk populations , such as adults with
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|endocarditis infective caused valve includes|septicemia sepsis meningitis infections pneumonia|endocarditis|gentamicin is an antibiotic used to treat entity , septicemia and bacterial , bone , respiratory tract , soft tissue , urinary tract and other infections .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|cardiovascular_disease|endocarditis infective caused valve includes|meningitis infections pneumonia endocarditis peritonitis|endocarditis|taken either drug has any invasive procedure for which antibiotic prophylactic treatment is recommended to prevent the development of bacterial entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|endocarditis infective caused valve includes|ethical informed alternative own excellent|endocarditis|to get just what  hopefully get what youre looking for or do you feel like youre at loggerheads on an entity indication?
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|endocarditis infective caused valve includes|thrombosis endocarditis thromboembolism restenosis vap|endocarditis|the silzone® coating was intended to reduce the risk of entity , a bacterial infection affecting heart tissue , which is associated with replacement heart valves .
#Masked F1-score:0.91|CLS F1-score:0.92|Masked Confusion matrix:{'matrix': OrderedDict([('DRUG', OrderedDict([('DRUG', 857), ('OTHER', 383), ('DIS', 53), ('BIO', 2)])), ('OTHER', OrderedDict([('DRUG', 0), ('OTHER', 0), ('DIS', 0), ('BIO', 0)])), ('DIS', OrderedDict([('DRUG', 56), ('OTHER', 235), ('DIS', 1434), ('BIO', 10)])), ('BIO', OrderedDict([('DRUG', 102), ('OTHER', 431), ('DIS', 275), ('BIO', 712)]))]), 'precision': OrderedDict([('DRUG', 1.0), ('OTHER', 0), ('DIS', 1.0), ('BIO', 1.0)]), 'recall': OrderedDict([('DRUG', 0.66), ('OTHER', 0), ('DIS', 0.83), ('BIO', 0.47)]), 'f1_score': OrderedDict([('DRUG', 0.8), ('OTHER', 0), ('DIS', 0.91), ('BIO', 0.64)]), 'max_f1': 0.91}|CLS confusion matrix:{'matrix': OrderedDict([('DRUG', OrderedDict([('DRUG', 817), ('OTHER', 416), ('DIS', 62), ('BIO', 0)])), ('OTHER', OrderedDict([('DRUG', 0), ('OTHER', 0), ('DIS', 0), ('BIO', 0)])), ('DIS', OrderedDict([('DRUG', 52), ('OTHER', 211), ('DIS', 1472), ('BIO', 0)])), ('BIO', OrderedDict([('DRUG', 75), ('OTHER', 296), ('DIS', 337), ('BIO', 812)]))]), 'precision': OrderedDict([('DRUG', 1.0), ('OTHER', 0), ('DIS', 1.0), ('BIO', 1.0)]), 'recall': OrderedDict([('DRUG', 0.63), ('OTHER', 0), ('DIS', 0.85), ('BIO', 0.53)]), 'f1_score': OrderedDict([('DRUG', 0.77), ('OTHER', 0), ('DIS', 0.92), ('BIO', 0.69)]), 'max_f1': 0.92}
